I/II 78.-

Archivexemplar

RAETTIG · POLIOMYELITIS IMMUNITÄT
TEIL I

DOCUMENTATION OF LITERATURE

Series 2

Poliomyelitis Immunity

By

DR. MED. HANSJÜRGEN RAETTIG

Wissenschaftlicher Rat und Professor beim Bundesgesundheitsamt
Robert Koch-Institut
apl. Professor an der Freien Universität Berlin

PART I

Introduction
Index of subjects
Index of authors
Reference word index

GUSTAV FISCHER VERLAG · STUTTGART
1963

LITERATUR-DOKUMENTATION

Reihe 2

Poliomyelitis Immunität

Von

DR. MED. HANSJÜRGEN RAETTIG

Wissenschaftlicher Rat und Professor beim Bundesgesundheitsamt
Robert Koch-Institut
apl. Professor an der Freien Universität Berlin

TEIL I

Einführung
Sachregister
Autoren-Index
Stichwort-Index

GUSTAV FISCHER VERLAG · STUTTGART
1963

©
Gustav Fischer Verlag Stuttgart 1963
Alle Rechte vorbehalten
Satz und Druck: Universitätsdruckerei Mainz GmbH
Einband: Sigloch, Künzelsau/Württ.
Printed in Germany

GELEITWORT

Vor Jahrzehnten war es für die Wissenschaftler bei der Erforschung der Infektionskrankheiten, der Epidemiologie und Seuchenbekämpfung leicht, die Fachliteratur zu übersehen. Heute wird eine «Dokumentation» benötigt, d. h. eine weitausholende, umfangreiche Organisation für das Sammeln, Auswerten und Ordnen des Schrifttums. Diese Aufgaben können nicht von Zentralen mit anonymen Angestellten erfüllt werden, sondern nur Fachexperten sind in der Lage, die Literatur des von ihnen bearbeiteten Forschungsgebietes zu erfassen, zu verschlüsseln und nutzbar zu machen. Dieses Verfahren allein ist ökonomisch tragbar.

In privater Initiative und als organisatorisch-literarische Leistung hat H. RAETTIG in der Dokumentation der «Bakteriophagie» (Gustav Fischer Verlag, Stuttgart) eine Lösung des Problems vorgeschlagen, die nach den bisherigen Erfahrungen als optimal gelten kann. Eine Bibliographie über ein definiertes Gebiet ist durch ein Sachregister, dem eine bis ins einzelne gehende Disposition zugrunde liegt, und durch ein Autorenregister so geordnet, daß der Suchende leicht und schnell durch das Schrifttum geführt wird.

Mit den Literaturzusammenstellungen über die «Bakteriophagie» und die «Poliomyelitis-Immunität» beginnt eine Reihe von Übersichten von Mitarbeitern aus dem Robert Koch-Institut. Es ist zu hoffen, daß die Art der Darstellung unseren Kollegen gefällt und ihnen so vorteilhaft und nützlich ist, daß sich weitere Mitarbeiter finden werden, die ihre über ein Spezialthema gesammelten Referate der Allgemeinheit zur Verfügung stellen. Die Empfehlung, den Textteil auch in englischer Übersetzung zu bringen, wird den Kreis der Nutznießer vergrößern.

PROF. DR. G. HENNEBERG
Vizepräsident des Bundesgesundheitsamtes
und Leiter des Robert Koch-Institutes

PREFATORY WORD

For decades, it was no difficulty for scientists to survey the special literature on the investigation of infectious diseases, epidemiology and control of epidemics. Today, we need «documentation», that is a far-reaching, large organization for the collection, evaluation and classification of the literature. These tasks cannot be undertaken by central offices with anonymous employees. Only experienced specialists are able to grasp, code and make useful the literature of their own special field. Only this approach is economically justifiable.

As a private enterprise and as a feat in the field of literary organization, H. RAETTIG, in the documentation of «Bakteriophagie» (Gustav Fischer Verlag, Stuttgart), suggested a solution of this problem which, according to experience hitherto gained, can be described as optimal. A bibliography on a well-defined area has been elaborated (by means of a subject index based on a detailed arrangement and by an authors index) so that the searcher is rapidly and easily guided through the literature.

With the compilations of «Bakteriophagie» and «Poliomyelitis-Immunität» we have the beginnings of a series of reviews by collaborators of the Robert Koch Institute. It is hoped that the manner of presentation will meet the approval of our colleagues and that they will find it so convenient and useful that other collaborators will be found, who are willing to put their collected references on a special subject at the general disposal. The fact that the text will also be presented in English translation will increase the number of those who benefit.

PROF. DR. G. HENNEBERG
Vice-President of the Federal Health Office
and Head of the Robert Koch Institute

VORWORT

Im Beginn unseres Jahrhunderts entwickelte sich die Poliomyelitis, die bis dahin nur sporadisch oder in kleinen Gruppenerkrankungen aufgetreten war, in den zivilisierten Ländern zu einer epidemischen Erkrankung. Unter dem Eindruck der ersten schweren Epidemien in Skandinavien und den USA begannen ab 1908 Epidemiologen, Infektiologen und Mikrobiologen die Ätiologie aufzuklären und eine Immunprophylaxe zu entwickeln. In dem seither vergangenen halben Jahrhundert ist eine Fülle von Erfahrungen im internationalen Schrifttum veröffentlicht worden. Die sehr umfangreiche und über viele spezielle Fachzeitschriften verstreute Literatur zur Poliomyelitis-Immunität zu sammeln und zu sichten, erschien wegen der weltweiten Aktualität dieses Themas notwendig und zweckmäßig. Der Leser, der über den Sinn und das Ziel der vorliegenden Bibliographie, über die Technik der Sammlung und Sichtung des Schrifttums und über die Anordnung des Stoffes in den zwei Bänden ausführlicher unterrichtet werden möchte, findet darüber Auskunft in der «Einführung».

An dieser Stelle möchte ich allen denen danken, die durch ihre Hilfe und Mitarbeit Durchführung und Abschluß meiner Arbeit ermöglichten. An erster Stelle habe ich Frau SIGRID PETERS und Fräulein ELFRIEDE CRONENBERG für ihre unermüdliche und zuverlässige Hilfe zu danken. Frau Peters hat die erste Hälfte des Weges mit der Materialsammlung, Fräulein Cronenberg den Abschluß der Materialsammlung und die umfangreichen Arbeiten an der Drucklegung betreut. Weiter gebührt mein Dank der Leiterin der Bibliothek des Robert-Koch-Institutes, Frau Dr. phil. LOTTE ROUDOLF, und ihren Mitarbeiterinnen, ohne deren jahrelange Unterstützung eine so vollständige Sammlung oft schwer zugänglicher Literatur nicht möglich gewesen wäre. Nicht zuletzt aber möchte ich besonders herzlich dem VERLAG GUSTAV FISCHER, Stuttgart, danken,

der alle meine Wünsche für Druck und Ausstattung des Buches in vorbildlicher Weise erfüllt hat.

Die Durchführung der vorliegenden Arbeit wurde durch eine Sachbeihilfe des Präsidenten des Bundesgesundheitsamtes, Herrn Professor Dr. LIESE, ermöglicht, wofür ich auch an dieser Stelle verbindlichst danken darf.

Weihnachten 1962

HANSJÜRGEN RAETTIG

PREFACE

During the early years of our century poliomyelitis, which had previously occurred only sporadically or in small groups of cases, became an epidemic disease in the civilized countries. Impressed by the first severe epidemics in the Scandinavian countries and in the USA, epidemiologists, infectiologists and microbiologists in 1908 started projects to clear up its aetiology and to develop immunological prophylaxis. In the half-century which has since passed, an enormous volume of observations has been published in the international literature. The collection and arrangement of this body of material on poliomyelitis immunity – voluminous and scattered over many special technical journals – seemed both useful and necessary in view of the worldwide topical interest of this subject. The reader who wishes to be more fully informed about the significance and aim of this bibliography, the technique of collection and arrangement of data, and the classification of the subject matter in the two volumes, can find this information in the «Introduction».

Here I would like to express my thanks to all those who, by their assistance and cooperation, enabled me to carry out and to complete this work. First I must thank Mrs. SIGRID PETERS and Miss ELFRIEDE CRONENBERG for their tireless and reliable assistance. Mrs. Peters helped me the first half of the way, collecting the material. Miss Cronenberg helped me conclude the collection of material and assisted in the considerable task of getting the book printed. My thanks are also due to the Chief Librarian of the Library of the Robert Koch Institute, Mrs. LOTTE ROUDOLF (Dr. phil.) and her assistants, without whose support for many years so complete a collection of often not readily accessible literature could not have been obtained. Certainly not less is my indebtedness to the GUSTAV FISCHER VERLAG, Stuttgart, who have fulfilled all my wishes concerning the printing and finish of the book in an admirable way.

This work was made possible by the grant made by the President of the Federal Health Office, Professor Dr. LIESE for which I express my warmest thanks.

Christmas 1962

HANSJÜRGEN RAETTIG

INHALTSVERZEICHNIS
TABLE OF CONTENTS

Einführung 1
Begründung des Vorhabens 1
Zunahme der wissenschaftlichen Veröffentlichungen 1
Das Handbuch 3
Heutige Formen der Literatur-Information 3
Das Problem der Vollständigkeit 4
Rationalisierungsversuche in der Literatur-Dokumentation 7
Die Materialsammlung 8
Benutzte Literaturquellen 8
Vollständigkeit der Erfassung 10
Stichworte und ihre Erfassung auf Randlochkarten 11
Anordnung des Stoffes 14
Sachregister 14
Autoren-Index 15
Stichwort-Index 16
Bibliographie 16
Literatur-Statistik 17
Vorschläge für die weitere Entwicklung 21

Introduction 24
Author's warrant 24
Increase in scientific publications 24
The manual 25
Current forms of literature information 26
The problem of comprehensiveness 27
Attempts at rationalization in literature documentation 28
The collection of material 29
Sources of literature used 30
Completeness of coverage 30
Reference words and their registration on punched cards 31
Arrangement of subject matter 32
Index of subjects 32
Index of authors 34
Reference word index 34
Bibliography 34
Literature statistic 35
Suggestions for further development 37

Sachregister / Index of subjects 41
Antigenität / Antigenicity 41
Allgemeines / General 42

Nach Inaktivierung / After inactivation 43
Typisierung / Typing 44
Antikörper / Antibody 44/45
Allgemeines / General 46
Altersverteilung / Age distribution 47
Booster-Effekt / Booster effect 48
Diaplazentare Übertragung / Diaplacental transmission 49
Entstehung / Origin 50
Globulin / Globuline 50
Geographische Verteilung / Geographical distribution 50
Haltbarkeit des Titers / Duration of titres 52
Immunität und Antikörper / Immunity and antibodies 53
Nach Impfung / After vaccination 53
Nach natürlicher Exposition / After natural exposure 59
Nachweismethoden / Methods 63
Allgemeines / General 63
Hämagglutination / Haemagglutination 64
Komplementbindungsreaktion / Complement fixation test . . . 64
Neutralisationstest / Neutralization test 65
Präzipitation / Precipitation 66
Tierversuche / Animal experiments 67
Immunität / Immunity 69/70
Allgemeines / General 71
Altersverteilung / Age distribution 72
Celluläre Immunität / Cellular immunity 73
Nach natürlicher Exposition / After natural exposure 73
Allgemeines / General 73
Antikörper / Antibody 73
Epidemiologisch-statistischer Nachweis / Epidemiological statistical evidence 77
Spezifität des Virustyps / Specifity of types 77
Zweiterkrankung / Reinfection 77
Nach Schutzimpfung / After vaccination 78
Allgemeines / General 78
Antikörper / Antibody 79
Epidemiologisch-statistischer Nachweis / Epidemiological statistical evidence 83
Lähmungsrate / Paralysis rate 86
Letalität / Lethality 87
Morbidität / Morbidity 87
Tierversuche / Animal experiments 88
Typabhängigkeit / Type dependence 90
Unspezifität / Nonspecifity 90
Impfmethoden / Methods of vaccination 91/92
Allgemeines / General 92
Intrakutane Injektion / Intracutaneous injection 92
Intramuskuläre Injektion / Intramuscular injection 93
Orale Anwendung / Oral application 93
Subkutane Injektion / Subcutaneous injection 93
Impfstoffe / Vaccines 93/94
Allgemeines / General 95

Abgeschwächtes, lebendes Virus / Attenuated live virus 96
Adsorbat-Impfstoffe / Adsorbat vaccines 100
Inaktiviertes Virus / Inactivated virus 101
Allgemeines / General 101
Formaldehyd / Formaldehyde 101
Immunserum / Immune serum 106
Kombinierte Methoden / Combined methods 106
UV-Strahlen / UV-radiation 106
Wärme / Heat 106
Haltbarkeit und Konservierung / Keeping capacity and preservation 107
Mehrfach-Impfstoffe / Combined vaccines 107
Produktionsverfahren / Production 108
Prüfung / Examination 108
Stammauswahl / Selection of strains 111
Standards / Standards 111
Unschädlichkeit / Safety 111
Wirksamkeit / Potency 114
Inaktivierung des Virus / Inactivation of virus 117/118
Allgemeines / General 118
Fehlerquellen / Sources of error 119
Formaldehyd / Formaldehyde 119
Immunserum / Immune serum 119
Kinetik / Kinetics 120
UV-Strahlen / UV-radiation 120
Wärme / Heat 120
Monographien / Monographs 121
Provokation / Provocation 121/122
Allgemeines / General 123
Infektionskrankheiten / Infectious diseases 123
Heterologe Impfungen / Heterologeous vaccinations 123
Homologe Impfungen / Homologous vaccinations 125
Tierversuche / Animal experiments 125
Tonsillektomie / Tonsillectomy 126
Stress-Situation / Stress situation 127
Reinfektion / Reinfection 128/129
Resistenz / Resistance 130/131
Allgemeines / General 131
Altersverteilung / Age distribution 132
Ernährung / Nutrition 132
Geschlechtsverteilung / Sex distribution 132
Herabsetzung / Reduction 133
Hormone / Hormones 137
Konstitution und Vererbung / Constitution and heredity 138
Neugeborene / Newborn infants 138
Rasse / Race 138
Schwangerschaft / Pregnancy 139
Soziologie / Sociology 139
Tierversuche / Animal experiments 140
Tonsillen / Tonsils 143
Vitamine / Vitamine 143
Wetter / Weather 144

Schutzimpfung / Vaccination 144/146
Allgemeines / General 147
Aktive Impfung / Active vaccination 147
Allgemeines / General 147
Allergische Reaktionen / Allergic reactions 149
Altersabhängigkeit / Dependence of age 149
Epidemie-Impfung / Intraepidemic vaccination 149
Erfolgsstatistik / Statistical evaluation of effectiveness 150
Impfplanung / Vaccination programme 152
Impfschäden / Untoward reactions to vaccination 155
Inaktivierte Impfstoffe / Inactivated vaccines 156
Indikation / Indication 162
Lebend-Impfstoffe / Live vaccines 163
Tierversuche / Animal experiments 167
Wiederholungsimpfungen / Revaccinations 170
Passive Impfung / Passive vaccination 170
Allgemeines / General 170
Gammaglobulin / Gamma globuline 171
Rekonvaleszentenserum / Convalescent serum 172
Spezifische Immunseren / Specific immune sera 174
Tierversuche / Animal experiments 176
Kombinierte Verfahren / Combined methods 177
Kosten / Costs 177

Serologie / Serology 177/178
Allgemeines / General 178
Antigen-Antikörper-Reaktion / Antigen-antibody-reaction 179
Antigenität / Antigenicity 179
Blutbild / Blood count 180
Blutgruppen / Blood groups 181
Differenzierung der Typen / Differentiation of types 181
Eiweißverteilung im Serum / Distribution of serum proteins . . . 181
Laboratoriumsdiagnostik / Laboratory diagnosis 182

Serologische Methodik / Serological methods 183
Allgemeines / General 184
Hämagglutination / Haemagglutination 184
Komplementbindung / Complement fixation 185
Neutralisation / Neutralization 186
Präzipitation / Precipitation 187

Serumprophylaxe und -therapie / Serum prophylaxis and treatment 187/188

Tierversuche / Animal experiments 192/193
Allgemeines / General 193
Immunisierung / Immunization 194
Impfstoffprüfung / Testing of vaccines 197
Infektionsversuche / Infection experiments 198
Resistenzversuche / Experiments on resistance 205
Virulenztest bei nach Lebendimpfung ausgeschiedenen Stämmen / Virulence test of strains excreted after live vaccination 206

Übersichtsarbeiten / Reviews 207
Allgemeines / General 207

Immunität / Immunity 207
Schutzimpfung / Vaccination 208
Vaccinetherapie / Vaccine therapy 211
Versuchstiere / Experimental animals 212
Allgemeines / General 213
Affen / Monkeys 214
Goldhamster / Syrian hamster 221
Kaninchen / Rabbits 222
Mäuse / Mice 222
Meerschweinchen / Guineapigs 224
Ratten / Rats 225
Autoren-Index / Index of authors 226
Stichwort-Index / Reference word index 276

EINFÜHRUNG

Begründung des Vorhabens

Im Jahre 1958 erschien im Verlag Gustav Fischer, Stuttgart, die «Bakteriophagie», in der insgesamt 5655 Veröffentlichungen auf dem Gebiete der Phagenforschung für die Zeit von 1917 bis 1956 gesichtet worden waren und die zugleich als Vorschlag zur Methodik der Dokumentation wissenschaftlicher Literatur gedacht war. Die freundliche Aufnahme, die die «Bakteriophagie» gefunden hat, zeigte uns, daß der eingeschlagene Weg richtig war und daß für die Publikation von Bibliographien bestimmter, begrenzter Fachgebiete in der vorgeschlagenen Form ein echter Bedarf besteht. Eine Fortsetzung des Vorhabens und eine Erweiterung der Thematik erschien danach berechtigt und zweckmäßig zu sein. Ausgangspunkt für die vorliegende Sammlung war die Gutachtentätigkeit des Bundesgesundheitsamtes auf dem Gebiet der Schutzimpfung gegen Poliomyelitis, die eine möglichst vollständige Sammlung und ein gründliches Studium der wissenschaftlichen Literatur erforderte. Bei dieser Arbeit wurde sehr bald klar, daß wichtige epidemiologische wie experimentelle Erfahrungen auf dem Gebiete der Poliomyelitis-Immunität in Vergessenheit geraten waren, weil es auf diesem Gebiete keine schnell orientierenden Literaturübersichten gibt. Es lag also nahe, als nächstes Thema die Poliomyelitis-Immunität zu bearbeiten und daran die vorgeschlagene Form der Literatur-Dokumentation zu bewähren, zumal die hohe Aktualität, die die Bekämpfung der Poliomyelitis durch aktive Schutzimpfungen in den letzten Jahren gewonnen hat, eine gründliche Durchdringung der Grundlagen besonders wichtig erscheinen ließ. Im nachfolgenden soll das Vorhaben ausführlich erläutert und seine Ergebnisse analysiert werden.

Zunahme der wissenschaftlichen Veröffentlichungen

Jedem Wissenschaftler ist bekannt, daß die Zahl der jährlich erscheinenden Veröffentlichungen auf seinem Fachgebiet ständig zunimmt und daß die Bewältigung des anfallenden Materials in beängstigendem Maße zeitraubender und schwieriger wird. In Abb. 1 habe ich die Veröffentlichungen auf dem Gebiete der Poliomyelitis-Immunität, die ich für die Zeit von 1908 bis 1961 gesammelt und im nachfolgenden aufgearbeitet habe, für jedes Jahr und in absoluten Zahlen graphisch dargestellt. Nach den ersten großen Poliomyelitis-Epidemien im Beginn unseres Jahrhunderts begannen Forscher mehrerer Länder mit den eben entdeckten Methoden der Virusforschung Ätiologie und Immunität der Poliomyelitis aufzuklären. Durch diese ersten Arbeiten und ihre Nachprüfungen entstand der erste kleine Gipfel von Publikationen zwischen 1910 und 1918. Als Folge des I. Weltkrieges und der relativen Harmlosigkeit der Poliomyelitis in

den folgenden Jahren bleibt die Kurve bis 1927 gleichbleibend niedrig, um dann laufend, nur durch den II. Weltkrieg unterbrochen, ständig anzusteigen. Die Ursachen dieses Kurvenverlaufes sollen in dem Absatz über Literatur-Statistik ausführlicher analysiert werden. Hier soll vor allem der in den letzten zehn Jahren rapide ansteigende Trend der Kurve interessieren, der gebieterisch moderne Dokumentationsmethoden zur Bewältigung der Veröffentlichungsflut fordert. Übrigens zeigt der Wert des Jahres 1961 in Abb. 1 keine beginnende Stabilisierung der Verhältnisse an, weil dieser Wert noch unvollständig ist; bei dem Abschluß der Arbeiten im Juni 1962 hatten noch nicht alle Veröffentlichungen des Jahres 1961 zur Verwertung vorliegen können. Die in Abb. 1 aufgezeichnete Entwicklung des Schrifttums auf dem Gebiete der Poliomyelitis-Immunität verläuft ähnlich der der Phagenforschung (s. «Bakteriophagie» I, S. 2, Abb. 1) und dürfte auch für andere Wissensgebiete typisch sein.

Abbildung 1



Die jährliche Verteilung der Veröffentlichungen auf dem Gebiet der Poliomyelitis-Immunität von 1908 bis 1961 in absoluten Zahlen

Annual distribution of publications on poliomyelitis immunity over the period 1908 through 1961, in absolute values

Gelegentlich hört man die Ansicht, man sollte geeignete Maßnahmen ergreifen, um die Veröffentlichungsflut zu drosseln. Bemühungen, die Zahl der wissenschaftlichen Arbeiten durch schärfere Auslese durch die Herausgeber der Fachzeitschriften zu beschränken, sind gefährlich, weil dabei zu leicht bestimmte Forschungsrichtungen und Schulen bevorzugt werden und weil ein Dirigismus erfahrungsgemäß der wissenschaftlichen Arbeit schadet und gegen das Grundrecht der freien Meinungsäußerung verstößt.

Die Beschränkung des Umfanges der einzelnen Veröffentlichung hat dazu geführt, daß eine größere Arbeit in Form zahlreicher «Mitteilungen» herausgegeben wird und daß damit das Mitteilungsunwesen entstand, dem sich heute kaum ein Wissenschaftler entziehen kann. Die langen Druckzeiten der meisten Fachzeitschriften haben in vielen Fällen den Autor veranlaßt, eine Kurzfassung in einer schnell abdruckenden Zeitschrift vorauszuschicken, so daß heute ein Tatbestand oft doppelt veröffentlicht wird. Beides hat zur zusätzlichen Belastung des Publikationsvolumens geführt. Es soll zunächst untersucht werden, ob die herkömmlichen Formen der Literatur-Information noch zur Bewältigung dieser Entwicklung ausreichen.

Das Handbuch

Die klassische Form der Literatur-Dokumentation war das Handbuch. Von ihm erwartete man, daß es erschöpfend, objektiv und mit vollständigem Literaturverzeichnis über das Fachgebiet berichtete. Diese Aufgabe hat das Handbuch bis etwa zum Beginn des II. Weltkrieges allerdings mit zunehmenden Schwierigkeiten erfüllen können. Am Beispiel des Handbuches der pathogenen Mikroorganismen (KOLLE, KRAUS, UHLENHUTH) hatte ich in der «Bakteriophagie» nachgewiesen, welchen Umfang Handbücher heute haben müßten, wenn sie der ursprünglichen Forderung nach objektiver und erschöpfender Darstellung und nach Vollständigkeit der Literatur entsprechen sollen. Die letzte und dritte Auflage des Handbuches der pathogenen Mikroorganismen (1929–1931) umfaßte ohne den Indexband fast 14000 Textseiten. Bei einer Extrapolation des Publikationsvolumens hatte sich ergeben, daß eine Neuauflage dieses Handbuches im Jahre 1956 etwa 100000 Druckseiten mit schätzungsweise einer Million Literaturzitaten bringen müßte. Ein solches Werk wäre für den Benutzer unübersehbar und unhandlich, es wäre organisatorisch und wirtschaftlich nicht mehr realisierbar, und es würde nicht zuletzt die Arbeitskraft der Forscher eines Fachgebietes für mehrere Jahre beanspruchen und von produktiver Arbeit abziehen. Der Versuch, ein Handbuch alten Stils zu verwirklichen, wäre also unrationell.

Wenn dennoch vor allem in Deutschland auf anderen Teilgebieten der Medizin Handbücher herausgegeben werden, so erfüllen sie nicht mehr die Bedingungen des Handbuches im klassischen Sinne. Die Autoren sind zu einer subjektiven Auswahl des Stoffes gezwungen, wobei meist nur die jüngsten Ergebnisse und die Ansichten bestimmter Schulen berücksichtigt werden. Die Teilstücke des Handbuches folgen einander so langsam, daß die ersten Bände veraltet sind, wenn die letzten erscheinen. In dieser Situation hat man Zuflucht zu der Form der Ergänzungsbände genommen, in denen besonders aktuelle Themen des Fachgebietes nachgeholt werden und die im Grunde nur Übersichtsarbeiten über ein kleines Teilgebiet sind. Endergebnis ist dann nicht mehr ein geschlossenes, allgemein und vollständig orientierendes Handbuch.

Heutige Formen der Literatur-Information

Um die Lücke, die durch den Ausfall des Handbuches entstand, zu schließen, sind in zunehmendem Maße Zeitschriften und Veröffentlichungs-

reihen erschienen, in denen umfangreichere *Übersichtsarbeiten* veröffentlicht werden können («Archive», «Ergebnisse», «Fortschritte», «Reviews»). Obwohl hier genügend Raum zur Verfügung steht, um große Literaturverzeichnisse mit Angabe der Überschrift der Veröffentlichungen abzudrucken – diese sind für eine ausreichende Literatur-Dokumentation unbedingt erforderlich –, reicht der Platz nur dazu aus, Spezialthemen abzuhandeln, die meist auf eigene experimentelle Arbeiten und auf die Literatur der letzten Jahre beschränkt sind.

Wer sich heute erschöpfend orientieren will, muß zu den *Referaten-Zeitschriften* greifen, auf denen heute die Hauptlast der Information liegt. Obwohl ohne sie eine wissenschaftliche Arbeit heute kaum vorstellbar ist und keinesfalls auf sie verzichtet werden kann, reichen sie allein nicht zur Information aus. Die Referaten-Zeitschriften haben zwei kaum vermeidbare Nachteile. Erstens können die Referate nur unter einem Stichwort, also nur «eindimensional» eingeordnet werden. Zum anderen ist es in zunehmendem Maße unmöglich, alle Publikationen durch Fachreferenten zu erfassen, so daß keine Vollständigkeit mehr erreicht werden kann.

Unter einer «*eindimensionalen*» *Ordnung* versteht man in der Literatur-Dokumentation heute Systeme, die jede Arbeit nur nach einem Stichwort einzuordnen vermögen. Wenn beispielweise eine Arbeit über den Einfluß von Schutzimpfungen auf die epidemiologische Lage eines Landes einzuordnen ist, so muß der Redakteur von sich aus entscheiden, ob das Referat unter dem Kapitel «Poliomyelitis», «Schutzimpfung» oder «Seuchenbekämpfung» einzuordnen ist. Einen gewissen Ausgleich dieser Gefahr kann das jeder Referaten-Zeitschrift beigefügte Stichwortverzeichnis bringen. Doch werden diese Register nicht von Fachwissenschaftlern hergestellt, sondern es werden bestenfalls alle im Titel der Arbeit erscheinenden Stichworte registriert. Alle Begriffsinhalte einer Arbeit, die nicht im Titel erscheinen, gehen in den Referatenblättern unweigerlich verloren. Es ist jedoch unmöglich, die Register der Referaten-Zeitschriften durch eine Vielzahl von Fachspezialisten bearbeiten zu lassen, um alle wichtigen Sachverhalte, die im Text einer Originalarbeit angesprochen werden, im Register zu bringen.

Die *Unvollständigkeit* der Erfassung wird zwangsläufig durch das zunehmende Publikationsvolumen verschärft. Das zeigen einige Zahlen, die an dem vorliegenden Material erarbeitet wurden. Das Zentralblatt für Bakteriologie (I. Referate) hat von den Originalarbeiten auf dem Gebiete der Poliomyelitis-Immunität in den Jahren 1910 bis 1915 durchschnittlich 60,5 % aller Arbeiten referiert, von 1926 bis 1941 42,6 % und von 1949 bis 1960 nur noch 19,2 %. Die entsprechenden Zahlen für das Kongreßzentralblatt für die gesamte innere Medizin lauten: 42,0 %, 21,5 % und 13,6 %. Die Vollständigkeit der Erfassung sinkt also bei gleichbleibender Abgrenzung des Aufgabengebietes mit der Zunahme der Veröffentlichungen, weil die anfallende Arbeit immer schwerer zu bewältigen ist. Diese statistische Aussage zwingt zu einer Diskussion der Frage, ob eine vollständige Erfassung der Literatur heute überhaupt noch notwendig ist.

Das Problem der Vollständigkeit

Es wird auch heute noch darüber gestritten, ob es notwendig oder möglich ist, die Literatur eines Wissensgebietes vollständig zu sammeln. Im Handbuch alten Typs war es selbstverständlich, daß die Literatur an-

nähernd vollständig zitiert wurde. In der «Bakteriophagie» hatte ich gezeigt, daß bei «*Handbüchern*», «*Monographien*» und «*Übersichtsarbeiten*» die Literaturzitate immer mehr hinter der Gesamtzahl der erschienenen Arbeiten zurückblieben (s. dort: Einführung, Abb. 2 und 3). Waren 1926 in dem der Phagenforschung gewidmeten Kapitel des Handbuches der pathogenen Mikroorganismen noch über 80 % der Weltliteratur zitiert, so wurden nach 1945 in Monographien und Übersichtsarbeiten kaum mehr als 5 % des Schrifttums berücksichtigt. Denselben Trend fand ich bei der Durchsicht der Publikationen über die Poliomyelitis-Immunität. Selbst in der sonst ausgezeichneten Bibliographie über die Poliomyelitis von FISHBEIN, in der die Literatur bis 1944 gesammelt worden war, finden sich nur knapp ein Drittel der bis dahin erschienenen Arbeiten über die Poliomyelitis-Immunität.

Abbildung 2



Die relative Intensität der Literatur-Erfassung von 5 Referaten-Zeitschriften von 1910–1960

Relative intensity of the literature coverage by five abstract journals over the period 1910–1960

Wie bereits oben erwähnt, ist dieselbe Tendenz bei den *Referaten-Organen* zu beobachten. Um diesen Eindruck zu objektivieren, habe ich für fünf der systematisch durchgesehenen Referaten-Zeitschriften die Frage der Vollständigkeit der Erfassung statistisch geprüft. In Abb. 2 habe ich von 1910 bis 1960 für jedes Jahr und jede Zeitschrift eingetragen, wieviel Prozent der Literatur durch Referate erfaßt wurden. Dabei wurde die Gesamtzahl der erschienenen Arbeiten in jedem Jahr nach der vorliegenden Bibliographie, wie sie in Abb. 1 dargestellt ist, gleich hundert gesetzt. Da auch meine Erfassung des Materials nicht absolut vollständig ist (vgl.

S. 10), sind die in Abb. 2 eingezeichneten Werte etwas günstiger als in Wirklichkeit. Das Zbl. f. Bakt. I. Ref. erfaßt vor dem I. Weltkrieg ziemlich gleichmäßig etwa zwei Drittel der Literatur zur Poliomyelitis-Immunität, während das Kongr. Zbl. ges. inn. Med. entsprechend seiner thematischen Beschränkung auf das klinisch Wichtige nur knapp die Hälfte berücksichtigt. Abb. 2 zeigt nun, wie verheerend sich die beiden Weltkriege ausgewirkt haben. Das Kongr. Zbl. ges. inn. Med. stellt während des I. Weltkrieges sein Erscheinen ganz ein (vgl. Abb. 3, S. 9), die Erfassungsintensität des Zbl. f. Bakt. I. Ref. fällt fast zu null ab. Beide Zeitschriften und die nach dem Kriege neu gegründete Zeitschrift für die gesamte Hygiene benötigen mehr als zehn Jahre, um sich in auffallend ähnlichen Kurven langsam zu erholen. Die Erfassungsintensität der Vorkriegszeit wird von keiner der drei Referaten-Zeitschriften mehr erreicht. Das Kongr. Zbl. ges. inn. Med. beginnt bereits nach 1930, offenbar unter dem Druck des lawinenartigen Ansteigens der Literatur der gesamten internen Medizin, immer mehr unter den einschlägigen Veröffentlichungen auszuwählen, während die beiden anderen Zeitschriften nicht mehr als etwa 40 % Vollständigkeit erreichen. Mit dem II. Weltkrieg fällt die Erfassungsintensität zunächst allgemein ab, bis die deutschen Referaten-Organe dem totalen Krieg zum Opfer fallen. Das Bulletin of Hygiene kann während des II. Weltkrieges offenbar infolge der kriegsbedingten Schwierigkeiten in der Literaturbeschaffung auch nur begrenzt referieren. Erst Jahre nach dem II. Weltkrieg nehmen zwei deutsche Zeitschriften und die neu gegründete Excerpta Medica ziemlich gleichzeitig ihr Erscheinen auf. Die Erfassungsintensität knüpft etwa an die letzten Werte im II. Weltkrieg an. Die Exc. Med. IV gewinnt langsam die Spitze, kommt aber trotz ihrer weltweiten Mitarbeiterorganisation kaum über die 40 %-Grenze hinaus. Das Bull. of Hyg. und das Kongr. Zbl. ges. inn. Med. wählen offenbar immer stärker die wichtig erscheinenden Arbeiten aus, so daß ihre Kurven ziemlich gleichmäßig abfallen. Daß die Erfassungsintensität bewußt eingeschränkt wird, geht auch daraus hervor, daß einige Referaten-Organe trotz des ständig steigenden Publikationsvolumens seit Jahren den Umfang ihrer Zeitschrift nicht vergrößert haben.

Aus dieser Statistik ergibt sich der allgemeine Trend, die Literatur sowohl in Übersichtsarbeiten und Monographien wie in den Referaten-Organen immer stärker auszuwählen. In den Diskussionen über dieses Problem wird oft diese Entwicklung mit der Begründung gutgeheißen, daß es gar nicht notwendig sei, das Schrifttum vollständig zu zitieren. Die alte Literatur sei zum größten Teil überholt, unmodern und nicht mehr lesenswert, in der neuen Literatur aber sei vieles nicht wertvoll genug, um zitiert zu werden. Beide Argumente führen zu einer durchaus subjektiven und willkürlichen *Auswahl der Literatur*, die ich für gefährlich halte. Das Auswählen bestimmter Arbeiten aus der modernen Literatur hat zur Folge, daß wissenschaftliche Gegner totgeschwiegen werden und nur die eigene Schule zitiert wird. Und wer will sich heute in einer Zeit höchster Spezialisierung ein verbindliches Werturteil über die wissenschaftlichen Arbeiten seiner Zeitgenossen anmaßen? Was aber die ältere Literatur anbetrifft, so muß immer wieder betont werden, daß das Studium älterer Arbeiten auf dem Gebiete der Poliomyelitis-Immunität sehr wertvoll gewesen wäre und viele Doppelarbeiten und unnötige Diskussionen erspart hätte. In den Legenden des Sachregisters zu den einzelnen Hauptthemen wird deutlich werden, wieviele epidemiologische und experimen-

telle Erfahrungen und Ergebnisse bereits im älteren Schrifttum mitgeteilt worden sind, die eine Neubearbeitung unnötig gemacht hätten. Aus der Erfahrung dieser Zusammenhänge hat der pflichtbewußte Wissenschaftler schon immer versucht, sich auf seine Weise möglichst vollständig über die erscheinende Literatur zu orientieren.

Rationalisierungsversuche in der Literatur-Dokumentation

Den meisten alten Ordnungsprinzipien lag in vielen Modifikationen die «*Zettelkartei*» zugrunde. Es wurde für jede erfaßte Veröffentlichung eine Karte angelegt, auf der der Name des Autors, Titel und Fundstelle der Arbeit und ein kurzes Referat oder eine Inhaltsnotiz verzeichnet wurden; diese Kartei wurde nach bestimmten Themen und innerhalb dieser Themen alphabetisch nach dem Autor abgestellt. Auch die Zettelkartei hat den Nachteil, daß sie «eindimensional» ist. Man versuchte dem abzuhelfen, indem man mehrere Exemplare der Karte herstellte und sie bei mehreren Themen abstellte oder indem man Stichwortverzeichnisse oder Karteien anlegte, über die man die Karten wiederfinden konnte.

In dem letzten Jahrzehnt wurde das Einordnen der einzelnen Belege nach diesen Verfahren infolge der Zunahme des Publikationsvolumens so umständlich, schwerfällig und zeitraubend, daß man nach *rationelleren Dokumentationsmethoden* Ausschau hielt. Es boten sich hier verschiedene Möglichkeiten an: das Hollerith-Verfahren, die verschiedenen Randlochkarten-Muster, die Cordonnier-Methode u. a. Ihr Gemeinsames ist das Rationalisieren, das Vermeiden des Nachteiles der «eindimensionalen» Einordnung und das Intensivieren der Arbeit. Die Ersparnis von Zeit und Arbeit durch die Möglichkeit der technischen Sortierung der Belege bei den genannten Verfahren liegt auf der Hand. Dadurch, daß man eine Mehrzahl von Begriffen auf jeder Karteikarte vereinigen und die Begriffsinhalte speziell für den eigenen wissenschaftlichen Bedarf festlegen kann, wird die wissenschaftliche Arbeit entscheidend intensiviert.

Mit diesen Methoden sind in den letzten Jahren viele Literaturkarteien bei einzelnen Wissenschaftlern oder in Instituten entstanden. Um den wissenschaftlichen Machtfaktor, den die Ausnutzung einer «mehrdimensionalen» und mechanisierten Kartei darstellt, für sich ausnutzen zu können, findet man heute gelegentlich das Bestreben, das Bestehen, den Inhalt und die Methode einer solchen Kartei geheimzuhalten. Andererseits gibt es Dokumentalisten mit der fatalen Neigung zum Theoretisieren und übertriebenen Systematisieren, die nicht früher mit der praktischen Arbeit anfangen wollen, bis nicht alle Begriffe bis ins letzte geklärt sind und ein international gültiger Schlüssel erarbeitet worden ist. Sowohl das Geheimhalten funktionsfähiger Methoden und Karteien wie das übertriebene Theoretisieren verstoßen gegen die Prinzipien der Rationalisierung. Die Theoretiker sparen keine Zeit, sondern verbrauchen sie unnötig, weil sie nicht den Absprung zur Verwirklichung ihrer Theorien finden und weil sie eine Hilfsmethode zum Selbstzweck machen. Das Geheimhalten aber ist unrationell, weil der Arbeitsertrag nur einem oder wenigen zugute kommt und nicht der allgemeinen wissenschaftlichen Arbeit dient.

Diesen Erfahrungen und Überlegungen folgend hatte ich vor etwa zehn Jahren begonnen, die Literatur auf dem Gebiet der Phagenforschung, die ich im Verlauf eigener experimenteller Arbeiten gesammelt hatte, mit

Randlochkarten zu vervollständigen, um das Schrifttum in möglichst vollständiger und rationeller Form zu veröffentlichen. Die 1958 erschienene «Bakteriophagie» hatte mir gezeigt, daß das gesteckte Ziel erreicht werden kann. Es war gelungen, einen umfangreichen Stoff auf engstem Raum zusammenzufassen und in einer Form zu veröffentlichen, in der die Vorteile der «mehrdimensionalen» Kartei und der Buchform verbunden sind und die den Leser schnell und vollständig orientieren kann. Dieser Erfolg ermutigte mich, auch das Schrifttum zur Poliomyelitis-Immunität in ähnlicher Weise aufzuarbeiten, wobei einige Verbesserungen vorgenommen werden konnten, die sich aus den Erfahrungen an der «Bakteriophagie» ergaben und die im nachfolgenden zu besprechen sind.

Die Materialsammlung

Am Beginn der Materialsammlung steht naturgemäß die *Begrenzung des gestellten Themas*. Bei der «Bakteriophagie» war diese recht einfach, denn der Begriff «Phage» war international eindeutig definiert, und alle einschlägigen Arbeiten waren zu erfassen. Bei dem Thema «Poliomyelitis-Immunität» war die Abgrenzung schwieriger, weil viele Arbeiten auf der Grenze zur Epidemiologie, Klinik und Virologie der Poliomyelitis auch immunologische Fragen behandeln. Grundsätzlich wurden alle Veröffentlichungen einbezogen, die über Immunität und Resistenz gegen Poliomyelitis, über aktive und passive Schutzimpfungen und über die Antigenität und Serologie des Poliomyelitisvirus handelten. Darüber hinaus wurden epidemiologische und pathogenetische Untersuchungen, Tierversuche und Arbeitsmethoden bearbeitet, die zur Immunität oder Resistenz in Beziehung standen. Der Rahmen wurde also thematisch so weit wie möglich gespannt. Die Auswahl der Publikationen war somit durchaus subjektiv; sie wird auch bei anderen Dokumentationsverfahren notwendigerweise immer subjektiv sein. So ist es unvermeidlich, daß man sich streiten kann, ob eine Veröffentlichung einschlägig ist oder nicht. In Zweifelsfällen habe ich mich gefragt, ob ich es wünschen würde, daß ein mit dem Thema betrauter Doktorand die betreffende Arbeit lesen sollte oder nicht. Jede einschlägige Arbeit wurde auf einer Autorenkarte und einer Randlochkarte erfaßt. Die Autorenkarten (DIN A 6) enthalten die Namen der Autoren, den Titel der Arbeit, die Originalfundstelle und die aufgefundenen Referate; sie werden alphabetisch nach dem Namen des ersten Autoren abgestellt. Mit der Autorenkartei wird geprüft, ob eine Veröffentlichung bereits erfaßt ist oder nicht. Die Randlochkarte (DIN A 5) nimmt die bei der Durcharbeit der Publikation festgestellten Sachverhalte auf (s. S. 11).

Benutzte Literaturquellen

Zuerst wurden die Originalarbeiten auf dem Gebiet der Poliomyelitis-Immunität aus den periodisch erscheinenden Zeitschriften erfaßt, die mir in großer Vollständigkeit in der Bibliothek des Robert Koch-Institutes zur Verfügung standen. Von hier wurden über die Literaturverzeichnisse ältere Originalarbeiten gefunden, die ihrerseits wieder älteres Schrifttum zitierten. Auf diese Weise verbreiterte und vervollständigte sich ständig die Erfassung. Darüber hinaus sah ich laufend die erreichbaren Referate

und die in einigen Wochenzeitschriften erscheinenden Literaturlisten auf geeignete Veröffentlichungen durch. Zum Abschluß der Sammlung habe ich die Literaturverzeichnisse von größeren Übersichtsarbeiten und von sechs Referaten-Organen zur Feststellung der Vollständigkeit systematisch durchgearbeitet. Die benutzten Referaten-Zeitschriften und ihre Erscheinungszeiten sind in Abb. 3 graphisch dargestellt. Die in der Kartei noch nicht erfaßten Arbeiten wurden auf die Karteikarten übernommen, die Originalarbeiten wurden, soweit sie nicht in der Bibliothek des Robert Koch-Institutes vorhanden waren, von anderen Bibliotheken besorgt.

Abbildung 3



Die Erscheinungszeit von 6 Referaten-Zeitschriften zwischen 1910 und 1962 (Der schraffierte Teil des Bull. of Hyg. konnte nicht systematisch durchgesehen werden, weil die Bände nicht vor dem Abschluß der Arbeit beschafft werden konnten)

Time of publication of six abstract journals between 1910 and 1962 (the hatched part of the Bull. of Hyg. could not be systematically studied because the volumes were not available before conclusion of the work)

Nach der Durcharbeit des Originals legte ich die Stichworte fest. Nur gelegentlich mußte ich die Stichworte aus dem Referat herauslesen, wenn die Originalarbeit nicht beschafft werden konnte. Gerade bei der Durchsicht der Referaten-Organe kann nur derjenige, der jahrelang selber auf dem Arbeitsgebiet und in der Fachliteratur Erfahrungen gesammelt hat, die Eigentümlichkeiten der Register und die Terminologie in ihren fremdsprachlichen Abwandlungen beherrschen. Man muß erfahren, daß die eine Zeitschrift Arbeiten über Poliomyelitis-Immunität nur unter dem Stichwort «Virus» bringt, eine andere nur unter «Vakzination». Das Register jedes Bandes der Referaten-Zeitschrift wurde deshalb mindestens unter folgenden Stichworten durchgesehen: Antigenität, Antikörper, Immunität, Poliomyelitis, Resistenz, Schutzimpfung und Virus. Diese Arbeitsgänge der Erfassung ergänzten sich gegenseitig. Damit nahm die Vollständigkeit der Sammlung in einem bestimmten Rhythmus zu.

Vollständigkeit der Erfassung

Jeder erfahrene Dokumentalist weiß, daß eine absolut vollständige Erfassung des internationalen Schrifttums nicht möglich ist. Es ist also zu untersuchen, bis zu welchem Grad der Vollständigkeit man praktisch vordringen und wie man diesen Grad bestimmen kann. Zu diesem Zweck habe ich in den letzten Monaten der Bearbeitung, nachdem ich die meisten Referaten-Zeitschriften bereits durchgearbeitet hatte, die Literaturver-

Abbildung 4



Die mit fortschreitender Bearbeitungszeit zunehmende Vollständigkeit der Materialsammlung (Die punktierte Linie markiert die 5%-Grenze der Erfassung, die ausgezogene Linie den errechneten Trend)

The increasing comprehensiveness of material collecting with advancing time. (The dotted line marks the 5% limit of coverage; the full line indicates the trend calculated)

zeichnisse von Originalarbeiten, die mehr als fünfzig Literaturzitate enthielten, und von Referaten-Bänden durchgesehen. Für jede Einheit habe ich festgestellt, wie viele der Literaturangaben in meiner Kartei noch nicht erfaßt waren. Diesen Wert habe ich jeweils in Prozenten berechnet und in Abb. 4 graphisch dargestellt. Jeder Balken repräsentiert eine dieser Arbeiten. Abb. 4 zeigt, in welchem Tempo die Vollständigkeit der Erfassung zunimmt. Da man den Nullpunkt praktisch in absehbarer Zeit nicht erreicht und eines Tages den Mut aufbringen muß, die Literatur-

sammlung abzuschließen, fragt es sich, wann dieser Zeitpunkt erreicht ist. Ich habe schon in der «Bakteriophagie» zwei Kriterien für den Abschluß der Arbeit festgelegt, die sich auch hier bewährt haben. Wenn sich die durchschnittliche Fehlerquote für eine Zeit auf 5 % und darunter eingestellt hat und wenn der aus den Prozentzahlen errechnete Trend (ausgezogene Linie in Abb. 4) die Null-Linie erreicht hat, kann man und sollte man aufhören. Man darf dann aussagen, daß man mehr als 95 % der Weltliteratur erfaßt hat. Für die «Bakteriophagie» habe ich nach der Drucklegung, also in den vergangenen sechs Jahren, jede Gelegenheit benutzt, um noch fehlende Arbeiten für den bald fälligen Ergänzungsband zu erfassen. Ich darf heute sagen, daß ich erstaunt war, wie selten ich noch fehlende Arbeiten fand. Die Vollständigkeit war hier höher als erwartet; die «Bakteriophagie» bestätigte damit, daß die in Abb. 4 dargestellte statistische Methode eine zuverlässige Aussage über die Vollständigkeit der Literaturerfassung erlaubt.

Stichworte und ihre Erfassung auf Randlochkarten

Was die *Zahl der festgelegten Begriffe* anbetrifft, so habe ich mich, wie in der «Bakteriophagie», bemüht, einen Mittelweg einzuhalten. Um das Material nicht unübersichtlich werden zu lassen und den Rahmen meines Vorhabens nicht zu sprengen, bin ich von dem Grundsatz ausgegangen, soviel wie notwendig und so wenig wie möglich Stichworte festzulegen. Da in Monographien und Übersichten die Zahl der angesprochenen Begriffe sehr groß ist, habe ich hier in der Regel nicht alle Einzelstichworte verzeichnet, sondern diese Arbeiten unter dem Stichwort «Monographien» und «Übersichten» gesondert aufgeführt. Abb. 5 stellt graphisch die Verteilung der Zahl der Begriffe dar, die für jede der 5500 verarbeiteten Veröffentlichungen festgelegt worden sind. Am häufigsten sind zwei und drei Begriffe ausreichend gewesen, um den Inhalt einer Arbeit zu beschreiben. Durchschnittlich wurden für jede Veröffentlichung 3,81 Begriffe eingetragen. In dem Sachregister sind demnach insgesamt 20976 Begriffe geordnet (vgl. die entsprechenden Zahlen in der «Bakteriophagie», Teil I, S. 13 und 14).

Bei der *Auswahl der Begriffe* war ich bemüht, mich in die Lage eines Wissenschaftlers zu versetzen, der über eine bestimmte Frage der Poliomyelitis-Immunität ausreichend informiert werden will. Die Begriffe ergaben sich während der Bearbeitung von selbst. Ihre Ordnung geht am besten aus dem Inhaltsverzeichnis des Sachregisters hervor. Ich legte einerseits nicht ohne weiteres jeden Begriff fest, der expressis verbis in einer Arbeit vorkam, sondern ich berücksichtigte ihn nur dann, wenn über ihn etwas Neues oder Lesenswertes mitgeteilt wurde. Andererseits habe ich gelegentlich Arbeiten unter Stichworten aufgeführt, die nicht ausdrücklich vorkamen, die aber sinngemäß angesprochen und für den Leser wichtig waren. Es liegt somit in dem Material begründet, daß die Stichworte trotz allen Bemühens um Objektivität subjektiv ausgewählt wurden. Hier ist die Grenze, an der alle Bemühungen der mechanischen Dokumentation aufhören und die auswählende, fachlich geübte und notwendigerweise subjektive Arbeit des Wissenschaftlers anfängt.

Die Stichworte wurden auf einer *zweireihigen Randlochkarte* (Kerbkarte) abgelocht. Ich benutzte hierfür den Kartentyp 020196 (DIN A 5) der

Firma Edler & Krische, Hannover. Die Verwendung der Karte und ihre Einteilung und Vorteile sowie die Schlüsselaufstellung habe ich an anderem Orte («Wie kann der einzelne Wissenschaftler seine Literaturarbeit intensivieren?» Zbl. f. Bakt. I. Ref. **153**, 209 [1954]) ausführlicher beschrieben, so daß ich hier nur auf einige wichtige Punkte hinzuweisen brauche. Auf jeder Karte können fünf Stichworte gekennzeichnet werden. Sind mehr Begriffe festgelegt, so wird eine zweite Karte angefertigt.

Abbildung 5



Die prozentuale Verteilung der für jede Publikation festgelegten Begriffe

The percentual distribution of conceptions laid down for each paper

Durch die Randlochmarkierung ist es möglich, mechanisch mit Sortiernadeln oder mit einem Sortiergerät jedes gewünschte Stichwort in kürzester Zeit zu selektieren. Damit erfüllt die Randlochkarte die Forderung nach einer «mehrdimensionalen» Einordnung. Da außerdem auf der Randlochkarte noch das Erscheinungsjahr und die Zahl der gekennzeichneten Begriffe abgelocht werden, können Auszählungen für die Literatur-Statistik, wie sie für Abb. 1 und 5 notwendig waren, in wenigen Stunden bewältigt werden, während eine Zerlegung und Rückordnung einer gewöhnlichen Kartei tagelange Arbeit beanspruchen würde; über diesen Vorteil wird im Abschnitt über «Literatur-Statistik» noch ausführlicher gesprochen werden.

Die Möglichkeit, die 5500 Randlochkarten gleichzeitig nach dem Erscheinungsjahr und der Zahl der festgelegten Begriffe zu sortieren, habe ich für eine Statistik über die *Intensität der Erfassung* ausgenutzt. In Abb. 6 ist die durchschnittliche Zahl der festgelegten Begriffe für jedes Jahr der absoluten Zahl der erfaßten Publikationen gegenübergestellt. Zwei inter-

Abbildung 6



Die durchschnittliche Zahl der für jede Publikation festgelegten Begriffe als Ausdruck der Erfassungsintensität im Vergleich zu der in jedem Jahr erschienenen Zahl von Publikationen

The average number of conceptions laid down per publication as a manifestation of the intensity of coverage, compared with the annual number of publications

essante Tatbestände können aus dem Diagramm abgelesen werden. Erstens steigt der Trend der Erfassung an. Das bedeutet, daß ich unbewußt die Arbeiten der jüngeren Zeit entsprechend ihrer Aktualität intensiver ausgewertet habe. Zum anderen ist eine unerwartete Parallele zwischen beiden Kurven zu beobachten. Wenn die Zahl der Publikationen einen Gipfel bildet, zeigt auch die Intensität der Erfassung ein Maximum. Das kann nur folgendermaßen interpretiert werden: Immer dann, wenn neue Forschungsimpulse einen Anstieg der Publikationen mit sich bringen, werden zahlreichere neue Tatbestände veröffentlicht, die sich in einer vermehrten Zahl von festzulegenden Begriffen widerspiegeln. In den Zwischenzeiten nimmt die Zahl der nur bestätigenden Originalarbeiten und

Übersichten zu, bei denen ich mit einer durchschnittlich geringeren Zahl von Begriffen auskam. Diese Darlegung soll nebenbei zeigen, wie sehr eine Lochkartei mit geringem, zusätzlichem Arbeitsaufwand den Einblick in die Struktur des bearbeiteten Materials vertiefen kann.

Anordnung des Stoffes

Der Teil I der in zwei Bänden vorliegenden Studie enthält Geleitwort, Vorwort, Inhaltsverzeichnis, Einführung, Sachregister, Autoren-Index und Stichwort-Index. Teil II bringt die von 1 bis 5500 durchnumerierte Bibliographie, in der alle Publikationen mit Autorennamen, Titel der Arbeit, Originalfundstelle und Referaten aufgeführt sind. Die Trennung der beiden Teile in zwei Einbände soll die Benutzung erleichtern. Für den Leser wäre das gleichzeitige Aufschlagen der Stichworte im Sachregister und der Namen im Autoren-Index einerseits und das Aufsuchen der entsprechenden Literaturstellen in der Bibliographie andererseits in einem Band lästig. Jetzt können beide Bände nebeneinander gelegt und gleichzeitig benutzt werden.

Sachregister

Das Sachregister bedarf einer eingehenderen Erläuterung, weil hier ein neuer Weg der Stoffbewältigung versucht wird. Es ist meine Absicht, den Stoff im Sachregister so anzuordnen, daß der Leser möglichst einfach und schnell an die Literaturquellen eines Sachverhaltes herangeführt wird. Die Sachverhalte habe ich in Hauptbegriffe (Fettdruck), Begriffe erster Ordnung (Groteskdruck) und zweiter Ordnung (Kursivdruck) unterteilt. Alle Begriffe sind innerhalb dieser Gliederung alphabetisch geordnet. Die Begriffe sind zweisprachig mit Seitenzahl im Inhaltsverzeichnis aufgeführt, damit sich der Leser schnell über die Stoffanordnung orientieren kann.

Zu jedem Hauptbegriff gehört eine Legende, in der ich eine kurze Übersicht über historische Entwicklung, Gliederung des Stoffes, derzeitigen Stand der Forschung, Begriffsdefinitionen und ähnliches gebracht habe. Damit habe ich versucht, den Leser möglichst knapp über den jeweiligen Hauptbegriff zu informieren. Der Legende folgen in Kursivschrift Stichworthinweise auf andere benachbarte Gebiete, in denen das Thema des Hauptbegriffes auch berührt wird und die der Leser tunlichst nachschlagen wird, wenn er sich weiter und allgemeiner informieren will.

Es folgen nun die Literaturhinweise. Zunächst steht eine vierstellige Zahl, die auf die entsprechende Nummer in der Bibliographie (Teil II) hinweist. In der darauffolgenden Klammer gibt die zweistellige Zahl das Erscheinungsjahr der Veröffentlichung und der nachfolgende Buchstabe die Sprache an, in der die Arbeit geschrieben wurde. Für die Sprachhinweise gelten folgende Abkürzungen:

Balkan-Sprachen	= b
deutsche Sprache	= d
englische Sprache	= e
französische Sprache	= f
holländische Sprache	= h

hebräische Sprache	=	he
italienische Sprache	=	i
japanische Sprache	=	j
nordische Sprachen	=	n
orientalische Sprachen	=	o
portugiesische Sprache	=	p
polnische Sprache	=	pl
russische Sprache	=	r
spanische Sprache	=	s
tschechische Sprache	=	t
ungarische Sprache	=	u

In der «Bakteriophagie» hatte ich gelegentlich zwei Buchstaben hinter die Jahreszahl gestellt; dann bedeutete der erste Buchstabe die Sprache der Originalarbeit und der zweite die der beigefügten fremdsprachigen Zusammenfassung. In der Zwischenzeit haben aber zahlreiche Zeitschriften Zusammenfassungen in mehreren Fremdsprachen für alle Publikationen eingeführt, so daß sich der Hinweis auf anderssprachige Referate oder Zusammenfassungen erübrigt und nur noch die Originalsprache gekennzeichnet wird. Die vierstelligen Ziffern der Publikationen sind innerhalb eines jeden Stichwortes nach dem Erscheinungsjahr der Arbeit und innerhalb dessen nach der fortlaufenden Nummer geordnet. Auf diese Weise ist es dem Leser einerseits leicht möglich, sich über einen bestimmten Zeitabschnitt der Forschung auf dem Gebiete der Poliomyelitis-Immunität zu informieren, und andererseits kann er, wenn ihm der Autor und die Fundstelle einer Veröffentlichung bekannt sind, über den Autoren-Index die Nummer und das Erscheinungsjahr in der Bibliographie heraussuchen und schnell feststellen, ob die Arbeit unter einem bestimmten Sachverhalt aufgeführt ist.

In der Regel sind hinter jedem Hauptbegriff oder jedem Begriff erster Ordnung, sofern ihm Begriffe zweiter Ordnung folgen, zunächst Literaturhinweise aufgeführt, die sich allgemein mit dem Thema beschäftigen oder spezielle Fragen bearbeiten, die so selten vorkommen, daß sich die Abtrennung unter einem besonderen Stichwort nicht lohnte. Dieser Abschnitt wurde mit «Allgemeines» überschrieben.

Eine «mehrdimensionale» Einordnung ist in dieser Form der Darstellung dadurch möglich, daß jede Arbeit unter mehreren einschlägigen Stichworten aufgeführt wird. Darüber hinaus habe ich durch Anhängen von Stichworten auf Querverbindungen hingewiesen und dadurch die Übersicht erleichtert, wobei der Doppelpunkt soviel wie «Verhältnis zu» bedeutet. So findet der Leser beispielsweise unter dem Hauptbegriff «Antikörper» den Begriff erster Ordnung «Geographische Verteilung». Hier sind also die Arbeiten aufgeführt, die über die Antikörperverteilung in einem bestimmten Areal berichten; hinter dem Sprachhinweis steht in der Regel das Land, in dem die Antikörpermessung durchgeführt wurde; ist kein angehängtes Stichwort vorhanden, so handelt es sich um eine Arbeit vergleichenden oder allgemeinen Inhaltes.

Autoren-Index

In der «Bakteriophagie» konnte auf einen Autoren-Index verzichtet werden, weil die Bibliographie (dort noch Autorenregister genannt)

alphabetisch nach dem ersten Autor geordnet war. Aus Gründen, die später näher zu erläutern sind, habe ich die Bibliographie der Poliomyelitis-Immunität nicht mehr alphabetisch sortiert. Deshalb wurde ein Autoren-Index notwendig. Das hat den Nachteil, daß man eine Arbeit, die man über den Namen des Autors sucht, erst auf dem Umweg über den Autoren-Index findet; doch dürfte diese Fragestellung relativ selten sein. Andererseits aber hat diese Stoffanordnung den Vorteil, daß man alle Arbeiten eines bestimmten Autors im Autoren-Index findet, denn alle Autoren einer Arbeit wurden berücksichtigt. In der «Bakteriophagie» hingegen konnte man bei der alphabetischen Ordnung der Bibliographie nur diejenigen Arbeiten eines Autors finden, bei denen er an erster Stelle aufgeführt worden war. Die vierstellige Ziffer im Autoren-Index hinter dem Namen verweist auf die laufende Numerierung in der Bibliographie.

Stichwort-Index

Schließlich wurde ein Stichwort-Index angefügt, um auch wichtige querverbindende Stichworte in den Klammern des Sachregisters, Synonyme der im Sachregister benutzten Begriffe und spezielle Fachausdrücke in englischer und deutscher Sprache leicht und schnell finden zu können. Ich hoffe, durch diesen Index die Suche nach sehr speziellen Fragen zu erleichtern und zu intensivieren. Hinter jedem Stichwort sind die Seitenzahlen angegeben, auf denen es vorkommt. Wenn das Stichwort im Sachregister als gesonderter Abschnitt geführt wird, ist die Seitenzahl dieser Hauptfundstelle in halbfettem Druck gesetzt.

Bibliographie

Zunächst habe ich die *Umbenennung* dieses Teiles zu begründen. In den Besprechungen zur «Bakteriophagie» war wiederholt angeregt worden, den Teil II nach der bibliothekarischen Üblichkeit Bibliographie zu nennen, weil diese Literaturzusammenstellung inhaltlich über ein Autorenregister hinausgeht. Ich bin dieser Anregung gefolgt, zumal durch die nichtalphabetische Anordnung der Bibliographie ein Autorenregister im üblichen Sinne im Teil I erforderlich wurde. Zum anderen muß der *Verzicht auf die alphabetische Ordnung* in der Bibliographie begründet werden. Entweder man sammelt zunächst die gesamte Literatur, ordnet sie dann alphabetisch und legt erst anschließend die Begriffe für das Sachregister fest; dieser Weg benötigt im nicht vollautomatisierten Einmannbetrieb zuviel Zeit bis zum Druck. Oder man muß bei der jahrelangen Durcharbeit des Materials für jede Veröffentlichung eine vorläufige laufende Nummer festlegen und muß nach Abschluß der Literatursammlung über einen Schlüssel etwa 20000 vierstellige Ziffern umschlüsseln; dieser Weg, den ich bei der «Bakteriophagie» eingeschlagen hatte, ist außerordentlich aufwendig, unrationell und mit einer unvermeidlichen, zusätzlichen Fehlerquote belastet. Ein weiteres Argument erleichterte den Entschluß, die alphabetische Ordnung in der Bibliographie aufzugeben. Die geplanten Ergänzungen würden in zunehmendem Maße die alphabetische Ordnung auflösen. Wenn man auf die alphabetische Anordnung der Bibliographie verzichtet, kann man unverzüglich noch während der Drucklegung der ersten Ausgabe mit der weiteren Materialsammlung für eine spätere Ergänzung beginnen.

Die Überschriften der Veröffentlichungen sind in der Bibliographie soweit wie möglich in der Originalsprache eingesetzt. Nur gelegentlich sind sie in der Sprache des Referates angegeben oder ganz fortgelassen, wenn das Original nicht erreichbar war oder die Veröffentlichung im Original in kyrillischen Buchstaben oder in einer Bilderschrift erschienen ist. Es folgt der Ort der Veröffentlichung mit abgekürzter Angabe der Zeitschrift, halbfettgedruckter Angabe der Bandnummer, normalgedruckter Seitenzahl und dem Erscheinungsjahr in Klammern. Der Fundstelle der Originalarbeit sind in Klammern die Referate beigefügt. Um dem Leser das Nachschlagen in den erreichbaren Referaten-Zeitschriften zu erleichtern, habe ich alle Referate gebracht, auf die ich gestoßen bin. Vollständig sind die Angaben über Referate nicht, weil ich nur einige Zeitschriften (vgl. Abb. 3, S. 9) systematisch durchgesehen habe.

Literatur-Statistik

Die mechanische Dokumentation des Schrifttums macht mit wenig Zeitaufwand einige wichtige Aussagen statistischer Art über Struktur und Entwicklung eines Wissensgebietes möglich. So soll das Wort «Literatur-Statistik» verstanden werden, das diesem Kapitel voransteht. Die in den vorangehenden Kapiteln gezeigten Abbildungen gehören schon zur Literatur-Statistik im weiteren Sinne. In den drei folgenden Abbildungen möchte ich über die Veränderungen der wissenschaftlichen Schwerpunkte in der Forschung über die Poliomyelitis-Immunität berichten. Diese Strukturanalyse wurde technisch so angelegt, daß jede Veröffentlichung einem Hauptthema zugeordnet wurde, das auf der Randlochkarte gekennzeichnet werden kann. Da es nur darauf ankommt, Entwicklungstendenzen aufzuspüren und aus ihnen auf den Strukturwandel eines Wissensgebietes zu schließen, ist die eindimensionale Einordnung der Veröffentlichungen hier durchaus ausreichend und geeignet.

Die beiden wichtigsten, praktischen Anliegen der *Forschung über die Poliomyelitis-Immunität*, die aktive Immunisierung und die Serumprophylaxe und -therapie, habe ich analysiert, indem ich die absolute Zahl der Publikationen für jedes Jahr von 1909 bis 1960 in den Abb. 7 und 8 graphisch dargestellt habe. Im oberen Teil der Diagramme sind die Verhältnisse für das gesamte Material abgebildet, in den darunter liegenden Kurven ist das Forschungsgebiet jeweils in drei Teilgebiete unterteilt worden.

Das Stichwort «*aktive Immunisierung*» vereinigt alle Arbeiten, die sich mit der spezifischen aktiven Schutzimpfung gegen Poliomyelitis bei Mensch und Tier beschäftigen. Die Kurve aller Publikationen zeigt drei Gipfel: einen kleinen um 1910, einen größeren in den dreißiger Jahren und einen steilen Anstieg seit 1950. Die Unterteilungen in Abb. 7 klären die Struktur dieses Kurvenverlaufes. Der Gipfel um 1910 wird allein durch tierexperimentelle Arbeiten verursacht; in dieser Zeit wird zwar bewiesen, daß man Affen mit virushaltigem Material immunisieren kann, aber es fehlen noch die technischen Voraussetzungen, um einen beim Menschen anwendbaren Impfstoff zu entwickeln. Erst um 1930 versucht man erneut, durch Tierexperimente die Voraussetzungen für eine aktive Immunisierung des Menschen zu schaffen. Der Erfolg dieser Bemühungen sind der inaktivierte Impfstoff von BRODIE und der virulenzabgeschwächte Impfstoff von KOLMER, die beide um 1935 gleichzeitig in Feldversuchen beim Men-

schen eingesetzt werden. Beide Impfverfahren kamen vor allem aus folgenden Gründen über das Versuchsstadium nicht hinaus: die aus Hirnmaterial des Affen hergestellte Vakzine von BRODIE eignete sich nicht zur

Abbildung 7



Die jährlichen Veröffentlichungen auf dem Gebiete der aktiven Immunisierung gegen Poliomyelitis

The annual publications on active immunization against poliomyelitis

Massenherstellung, und die chemisch abgeschwächte Vakzine von KOLMER erwies sich als zu virulent und verursachte Erkrankungen an Poliomyelitis. Erst nach dem II. Weltkriege begannen unter dem Eindruck der immer bedrohlicher werdenden epidemiologischen Situation intensive tierexperimentelle Vorarbeiten für eine aktive Schutzimpfung. Nach 1950 beginnen Versuche am Menschen wiederum gleichzeitig mit inaktivierten

und lebenden Vakzinen. Es ist bekannt, daß die SALK-Vakzine nach dem großen Feldversuch in den USA im Jahre 1954 einen zeitlichen Vorsprung gewinnt, der sich in dem steilen Anstieg der Veröffentlichungen im Jahre 1955 dokumentiert. Langsamer entwickelt sich die Anwendung der Lebendvakzine aus vermehrungsfähigen, pathogenitätsabgeschwächten

Abbildung 8



Die jährlichen Veröffentlichungen auf dem Gebiete der passiven Immunisierung gegen Poliomyelitis

The annual publications on passive immunization against poliomyelitis

Virusstämmen nach KOPROWSKI, SABIN und COX; im Jahre 1960 überholt aber die Zahl der Arbeiten zu diesem Thema alle anderen Teilthemen.

Ebenso sind die Bemühungen um die «*passive Immunisierung*» gegen Poliomyelitis in Abb. 8 analysiert. Das Stichwort umfaßt gemeinsam «Serumprophylaxe und -therapie», weil Prophylaxe und Therapie in der Praxis kaum gegeneinander abgegrenzt werden können und weil dementsprechend in der Regel beide Anwendungsformen in der Literatur auch

gemeinsam beschrieben werden. Auch diese Kurve zeigt drei Gipfel; aber das erste Maximum liegt später als das in Abb. 7, die beiden folgenden dagegen früher. Die drei wichtigsten Möglichkeiten einer passiven Immunisierung, die spezifischen Immunsera, das Rekonvaleszentenserum und das Gammaglobulin, sind zur Analyse dieser Kurve getrennt wiedergegeben. Nachdem um 1910 erste tastende Versuche gezeigt hatten, daß man große Säugetiere zwecks Herstellung von Immunseren aktiv immunisieren kann und daß man Affen mit Rekonvaleszentenserum des Menschen passiv schützen kann, begannen nach dem I. Weltkrieg praktische

Abbildung 9



Die Verschiebung der Hauptthemen in der Forschung über die Poliomyelitis-Immunität aufgezeigt an der relativen Beteiligung an dem jährlichen Publikationsvolumen

The displacement of main subjects in research on poliomyelitis as indicated by the relative representation in the annual volume of publications

Versuche mit beiden Methoden. Unter dem Einfluß der langsam ansteigenden Poliomyelitis-Morbidität nimmt die Anwendung von spezifischen Immunseren und Rekonvaleszentenserum Ende der zwanziger Jahre wieder erneut zu; das Rekonvaleszentenserum wird mehr angewendet, weil es leichter zu beschaffen ist. Unter dem Eindruck der relativen Wirkungslosigkeit beider Formen der passiven Immunisierung fallen beide Kurven zu 1940 ziemlich gleichzeitig ab. Nach dem II. Weltkrieg wird ein kurzer, erneut erfolgloser Versuch der Rekonvaleszentenserum-Anwendung durch das Aufkommen der Gammaglobulin-Prophylaxe nach 1950 abgelöst. Dieser dritte Gipfel fällt bald wieder ab, weil auch diese Form der passiven Immunisierung enttäuschte, vor allem wohl wegen der Schwierigkeit, das Gammaglobulin zum richtigen Zeitpunkt anzuwenden.

Wie sich die Bemühungen um die aktive und passive Immunisierung ablösen und wie sie sich zur Bearbeitung anderer Themen zeitlich verhalten, läßt sich sinnfällig machen, wenn man den prozentualen Anteil an dem Publikationsvolumen eines jeden Jahres additiv darstellt, wie dies in Abb. 9 geschehen ist. Um das Diagramm nicht unübersichtlich zu machen, habe ich der aktiven und passiven Immunisierung nur noch das große Thema der «Resistenz» gegenübergestellt und habe die übrigen Themen unter der Bezeichnung «Varia» zusammengefaßt. Unter dem Begriff der Resistenz sind alle Veröffentlichungen vereinigt, die sich mit unspezifischen Abwehrmechanismen und mit den Schwankungen der Disposition nach Geschlecht und Konstitution, sowie ihrer Beeinflussung durch Hormone, Vitamine, Ernährung und anderes beschäftigen. Nach den tierexperimentellen Bemühungen um die aktive Immunisierung um 1910, die noch zu keiner praktischen Verwertung führte, gewinnt die passive Immunisierung für lange Zeit den ersten Platz. Um 1935 ist der neue Anlauf der aktiven Immunisierung deutlich erkennbar. Beide Verfahren enttäuschen, und ihre Kurven fallen ziemlich gleichzeitig ab. Wie schon um 1920 angedeutet, stößt die Forschung über die Resistenz in dieses Vakuum vor. Weil die Verfahren der spezifischen Immunprophylaxe nicht vorankommen, werden die Bemühungen um die Expositions- und Dispositionsprophylaxe verstärkt. Man versucht, die konstitutionell besonders Gefährdeten zu erforschen, um sie vor der Ansteckung zu schützen, man bemüht sich um eine Anhebung der Resistenz durch geeignete Diät, Vitamine und Hormone und um die Vermeidung von Resistenzdepressionen durch übermäßige körperliche Belastungen und andere Stress-Situationen. Die relative Vorherrschaft der Veröffentlichungen über die Resistenz geht langsam zurück, während zunächst die Gammaglobulin-Prophylaxe kurz zunimmt und dann die neuen Verfahren der aktiven Immunisierung die Vorrangstellung gewinnen. Kurz zusammengefaßt zeigt also Abb. 9, daß die passive Immunisierung über zehn Jahre, etwa von 1922–1934, fast 60 % des Veröffentlichungsvolumens für sich in Anspruch nahm, daß die Forschung über die Resistenz um 1945, die spezifische Immunprophylaxe ablösend, ebenfalls fast 60 % erreichte und daß heute mehr als 60 % des Schrifttums die aktive Schutzimpfung behandeln.

Vorschläge für die weitere Entwicklung

Mein Versuch, eine neue Form der Literatur-Dokumentation zu entwickeln, kann sich nur erfolgreich weiterentwickeln, wenn Ergänzungen oder Neuauflagen in regelmäßigen Zeitabständen folgen und wenn diese Form der Veröffentlichung von anderen Fachgebieten übernommen wird. Einiges zur Rationalisierung des weiteren Weges möchte ich hier noch diskutieren und vorschlagen.

Die möglichen Formen einer *Fortsetzung der Literatur-Dokumentation* innerhalb eines bestimmten Fachgebietes wurden nach dem Erscheinen der «Bakteriophagie» mit Fachkollegen und vor der Veröffentlichung der «Poliomyelitis-Immunität» mit dem Verlag Gustav Fischer eingehend diskutiert. Neben Ergänzungsbänden in mehrjährigen Abständen oder gelegentlichen, zusammenfassenden Neuauflagen wurde von verschiedenen Seiten die laufende Herausgabe von etwa jährlich erscheinenden Ergänzungen in der Loseblatt-Form vorgeschlagen, die sich für Gesetzblatt-

Sammlungen, Atlanten und topographische Handbücher bewährt hat. Die Einordnung von einzelnen, gelochten Nachtragsblättern in entsprechend groß geplante Einbände mit einem Schnappmechanismus hat neben den offensichtlichen Vorteilen auch einige schwerwiegende, praktische Nachteile, die dafür entscheidend waren, daß wir diese Form für die «Poliomyelitis-Immunität» nicht wählten. Bei der starken Benutzung in den Bibliotheken können einzelne Blätter leicht in der Lochung ausreißen und dann verlorengehen. Weiter würde die Einordnung der Nachträge erfahrungsgemäß sowohl in den Bibliotheken als auch bei dem einzelnen Wissenschaftler auf Schwierigkeiten stoßen. Bei der Bibliographie wäre diese Gefahr noch nicht so groß, weil die Ergänzungsteile nur hinten angefügt zu werden brauchen. Beim Sachregister hingegen müßten die Blätter einzeln eingefügt oder gegen veraltete ausgetauscht werden, wofür erfahrungsgemäß selten genug Zeit und Sorgfalt erübrigt werden. Weiter müßte schon in der ersten Ausgabe jedes Stichwort auf ein gesondertes Blatt gedruckt werden, damit die Ergänzungsseiten sinnvoll bei jedem Stichwort eingefügt werden können. Die «Poliomyelitis-Immunität» hat immerhin 144 Stichworte. Auch die Ergänzungen müßten für jedes Stichwort ein gesondertes Blatt bringen unabhängig davon, ob in der Zwischenzeit zwei oder zweihundert Publikationen zu dem Thema erschienen sind. Schließlich würden also der größere Umfang und der erhöhte technische Aufwand die Herstellungskosten nicht unwesentlich erhöhen. Deshalb wollen wir sowohl bei der Herausgabe von Literatur-Dokumentationen auf anderen Fachgebieten, als auch bei den Ergänzungsbänden an der gebundenen Form der Veröffentlichung festhalten.

Der Autor einer Literatur-Dokumentation, wie ich sie hier vorgeschlagen habe, wird sich in Zukunft auf die *aktive Mitarbeit des fachlich interessierten Benutzerkreises* stützen müssen, um die verschiedenen Fehlerquellen eines solchen Vorhabens einzuschränken. Es können Erfassungs-, Übertragungs-, Einordnungs- und Druckfehler unterlaufen, die auch bei sorgfältigster Kontrolle nicht alle beseitigt werden können. Bei der «Bakteriophagie» hatte ich nach genauer Überprüfung einer größeren Stichprobe eine Fehlerquote von 1,85 % gefunden. Nach meiner Erfahrung wird man diesen Prozentsatz kaum unterschreiten können. Daher möchte ich mich mit einigen konkreten Bitten an den Leser wenden: Scheuen Sie bitte nicht die Mühe, mich auf Druckfehler, auf Fehler der sachlichen Einordnung oder auf fehlende Veröffentlichungen hinzuweisen. Sind Arbeiten, die Sie selber veröffentlicht haben, nicht berücksichtigt, so schicken Sie mir möglichst einen Sonderdruck. Senden Sie mir bitte Sonderdrucke von Arbeiten über die Poliomyelitis-Immunität, die Sie in Zukunft veröffentlichen werden. Wenn Sie Wert darauf legen, daß bestimmte Stichworte im Sachregister erscheinen, so streichen Sie sie im Sonderdruck an. Wenn Sie meinen, daß das Literaturregister noch sinnvoller eingerichtet werden kann, dann wäre ich Ihnen für praktische Vorschläge dankbar.

Zum Abschluß möchte ich noch auf weitere Entwicklungsmöglichkeiten hinweisen. Wirklich sinnvoll wären die Bemühungen um eine *einheitliche Literatur-Dokumentation* erst *auf internationaler Basis*. Wenn sich Wissenschaftler verschiedener Länder bereitfinden würden, die Fachliteratur auf anderen Gebieten mit dem vorgeschlagenen System zusammenzustellen, so würden sich weitere Vorteile dieser Informationsform abzeichnen. Jeder Autor einer wissenschaftlichen Arbeit würde wissen, welcher Forscher auf seinem Arbeitsgebiet die Literatur-Dokumentation übernommen hat.

Er würde unaufgefordert einen Separatdruck seiner Arbeit an diesen Forscher schicken und in der Arbeit die Stichworte markieren, die er für die Aufnahme in das Sachregister für zweckmäßig hält. Diese Handhabe wäre sowohl eine fachliche Intensivierung der Literatur-Dokumentation, als auch eine große Arbeitserleichterung für den Herausgeber.

Weiter könnten die Autoren wissenschaftlicher Arbeiten *auf umfangreiche Literaturverzeichnisse verzichten*. Es würde genügen, wenn an Stelle der Zitierung einer Publikation im Text eine Zahl in Klammern erschiene, die auf die einschlägige Bibliographie verwiese. Damit würde das Volumen des internationalen Schrifttums um den Anteil der Literaturverzeichnisse verkleinert werden, und den Autoren würde die zeitraubende Arbeit für die Zusammenstellung und das Schreiben der Literaturverzeichnisse erspart werden. Für den Leser fällt das lästige Suchen innerhalb des Bandes fort; wenn er ein Zitat im Literaturverzeichnis nachsehen will, kann er die einschlägige Bibliographie wie ein Lexikon neben sich legen.

INTRODUCTION

Author's warrant

In 1958, Gustav Fischer Verlag, Stuttgart, published «Bakteriophagie» – an arrangement of 5,655 publications on the subject of phage research over the period 1917–1956, and at the same time a suggestion for a method of documentation of scientific literature. The welcome which «Bakteriophagie» received, showed us that the road chosen was the right one, and that there was a real need for the publication of bibliographies of well-defined special areas in the form suggested. Continuation of the project and expansion of the subjects therefore seemed justified and useful. The startingpoint for the present collection was the consulting activity of the Federal Health Office in the field of vaccination against poliomyelitis, which required the completest possible coverage and thorough study of the scientific literature. In the course of this work it soon became apparent that important epidemiological and experimental work in the field of immunity against poliomyelitis had been forgotten because there are no rapidly orienting surveys of the literature in this field. Poliomyelitis immunity was therefore the obvious choice for the next subject, in the elaboration of which the suggestions regarding literature documentation could be verified. The great topical interest acquired by the control of poliomyelitis with the aid of active vaccination in recent years emphasized the importance of a thorough study of the principles. The following is a detailed explanation of the project and an analysis of its results.

Increase in scientific publications

Every scientist knows that the annual number of publications on his special subject is gradually increasing, and that it is becoming alarmingly time-consuming and difficult to master the increasing body of data. Fig. 1 (s. p. 2) shows a graph in which the publications on poliomyelitis immunity, collected for the period 1908–1961 and elaborated in later parts, are presented for every year and in absolute figures. Following the first great poliomyelitis epidemics at the beginning of this century, research workers in several countries started to clarify the aetiology and immunity of poliomyelitis, using the just developed methods of virus investigation. These first investigations and their follow-ups led to the first small peak of publications between 1910 and 1918. As a result of World War I and the relative harmlessness of poliomyelitis in the postwar years, the curve remains at a low level until 1927; subsequently there is a steady increase, interrupted only by the period of World War II. The causes of this course of the curve are to be analysed in detail in the section

of literature statistics. At this time we are chiefly interested in the rapidly increasing trend in the curve for the past ten years, which makes it imperative that modern methods of documentation be introduced to cope with the torrent of publications. The value given for 1961 in fig. 1 does not indicate a stabilization, because this value is still incomplete; when the work was concluded in June 1962, not all publications of 1961 had been evaluated. The development of the literature on poliomyelitis immunity shown in fig. 1 has a similar course to that of phage research (cf. «Bakteriophagie» I, p. 2, fig. 1) and might be typical also of other areas of knowledge.

It is occasionally contended that suitable measures should be taken to stem the flood of publications. Efforts to limit the number of scientific publications by means of more rigorous selection (by the publishers of technical journals) are dangerous, because such a selection might readily give preference to some lines of research or some schools, and because excessive gubernation, as experience has shown, has an unfavourable effect on scientific work and is incompatible with the right of free expression. Restrictions regarding the length of single publications have led to a situation in which larger publications are presented in the form of several separate «communications»; hardly any scientist today can escape this institution of piecemeal communications. The long time taken in printing the various technical publications have often caused authors to have a summary printed in a journal with shorter printing time; this has led to duplication of publications, which has achieved nothing except an additional strain on the publication volume. An attempt must be made to establish whether the current forms of information in the literature can adequately cope with this development.

The manual

The classic form of literature documentation was the manual. This was expected to report on the special technical field exhaustively, objectively and with a comprehensive bibliography. Until the outbreak of World War II, the manual has met these requirements, although with increasing difficulty. Using the example of the manual of pathogenic micro-organisms (Kolle, Kraus, Uhlenhuth), I demonstrated in «Bakteriophagie» the size which manuals today should have if they are to meet the original demands for objective and exhaustive presentation and a comprehensive bibliography. The last (third) edition of the manual of pathogenic micro-organisms (1929–1931), had almost 14,000 pages text, apart from the index. An extrapolation of the volume of publication showed that a new edition of this manual in 1956 would have had to present some 100,000 pages text, with an estimated one million references to the literature. Such a manual would be too big and clumsy; its publication would be impracticable from a point of view of organization and economy. Also, it would take up the working time of the investigators in a special field for several years and during that time keep them from doing productive work. Any attempt to produce a manual in the old style, therefore, would serve no good purpose.

Yet manuals are being published, especially in Germany, in other areas of medicine; but these no longer meet the requirements of a manual in the

classic sense. The authors are forced to resort to a subjective selection of their subject matter, and usually recount only the most recent findings and the views of certain schools. The parts of the manuals are published in such slow succession that the first volumes have become obsolete by the time the last volume appears. To meet this situation, the system of insertion of supplementary pages was introduced, in which particularly topical subjects of the field are brought up to date; these supplements are essentially merely surveys of a small subordinate area. The ultimate result is not a complete, general and well-oriented manual.

Current forms of literature information

The gap resulting from the disappearance of the manual has been filled by the increasing publication of journals and series of publications in which more voluminous *surveys* could be published (e. g. «Archives», «Recent acquisitions», «Recent advances», «Reviews»). Although these publications afford sufficient space to print large lists of references with the titles of the publications – which is indispensable for adequate literature documentation – the space is only sufficient for treatises on special subjects, usually limited to personal experimental work and to the literature of the past few years.

Today, anyone who whishes to be thoroughly informed must resort to *abstract journals*, which give the gist of what is known on the subject. Although scientific work without these journals is hardly conceivable today, and although they are quite indispensable, they are not in themselves an adequate source of information. Abstract journals have two disadvantages that are hardly avoidable. First, abstracts can be classified only under one reference word (i. e. in a unidimensional system). Second, it is becoming increasingly impossible to have all publications abstracted by experts; «comprehensively» is therefore becoming a meaningless word.

In the current literature documentation, the term *«unidimensional» classification* refers to systems in which every publication is classified only under a reference word. For example, when a publication on the influence of vaccination on the epidemiological situation in a country is to be classified, the editor must decide whether the abstract must be presented under the heading «poliomyelitis», under «vaccination» or under «control of epidemics». This difficulty can be overcome to some extent by the reference word index being added to all abstract journals. These indices, however, are not composed by expert scientists; at best, all reference words which appear in the title of a given paper are registered. All conceptions in a publication, not included in the title, are inevitably lost in the abstract journals. On the other hand it is impossible to have a number of specialists elaborate the registers of abstract journals in order to index all important facts brought up in the text of the original paper.

The *incompleteness* of coverage is of course aggravated by the increasing volume of papers published. This is demonstrated by some figures based on the material available. The «Zentralblatt für Bakteriologie (I. Referate)» presented abstracts from about 60.5 % of all publications on poliomyelitis immunity during 1910–1915; the percentage covered over the period 1926–1941 was 42.6 %, and that over 1949–1960 only 19.2 %. Correspond-

ing figures for the «Kongreßzentralblatt für die gesamte innere Medizin» are 42.0, 21.5 and 13.6 %. The special area of interest remaining constant, therefore, the completeness of coverage diminishes with increasing numbers of publications, and it is increasingly difficult to do the work required for this coverage. This statistical result forces us to discuss the question whether complete coverage of the literature is at all necessary today.

The problem of comprehensiveness

Today it is still a subject of discussion whether it is necessary or possible to collect the complete literature on an area of knowledge. In the old-type manual it was a matter of course that the literature was almost completely reviewed. In «Bakteriophagie», I demonstrated that the bibliographies presented in «*Manuals*», «*Monographs*» and «*Reviews*» increasingly fall short of the actual number of pertinent publications (cf. Introduction, figs. 2 and 3). While in 1926, in the chapter on phage research in the Manual of Pathogenic Micro-organism, 80 % of the world's literature was referred to, monographs and reviews after 1945 have mentioned hardly 5 % of the literature. A similar trend was found in this study of publications on poliomyelitis immunity. Even in the otherwise exemplary poliomyelitis bibliography by FISHBEIN, which presents a survey of the literature up to 1944, we found barely one-third of the publications which appeared on this subject until that date.

As mentioned, a similar trend is discernible in the case of the *abstract journals*. To find out whether there was objective support for this impression, five abstract journals were systematically scrutinized and statistically tested as to completeness of coverage. Fig. 2 (s. p. 5), which covers the period 1910–1960, shows for every year and every journal the percentage of publications covered by the abstracts. The total number of publications per year, according to the available bibliography as shown in fig. 1, was accepted as 100 %. Since my own coverage of the material is not absolutely complete either (cf. page 30) the values presented in fig. 2 are slightly more favourable than reality. The «Zbl. f. Bakt. I. Ref.» fairly constantly covered some two-thirds of the literature on poliomyelitis immunity prior to World War I; the «Kongr. Zbl. ges. inn. Med.», in accordance with its thematic limitation to subjects of clinical importance, covered hardly 50 %. Fig. 2 shows the influence of the two World Wars. During World War I, the «Kongr. Zbl. ges. inn. Med.» was not published at all (cf. fig. 3, page 9), while the coverage of the «Zbl. f. Bakt. I. Ref.» diminished to almost zero. Both journals, and the «Zeitschrift für die gesamte Hygiene» established after the war, require almost ten years to complete their restoration to pre-war levels, as shown by strikingly similar curves. None of the three abstract journals returned to the degree of coverage shown in pre-war years. Already after 1930 the «Kongr. Zbl. ges. inn. Med.» begins to select from similar publications, apparently under pressure from the avalanche-like increase in the literature on internal medicine; the other two journals reach a coverage not exceeding 40 %. With World War II the degree of coverage first showed a general decrease, until the German abstract journals completely fell victim to total war. The «Bulletin of Hygiene», obviously due to wartime difficulties in the collection of material, also presented only a limited selection of

abstracts during World War II. It was not until several years after World War II that two German journals, and the newly established Excerpta Medica, more or less simultaneously made their appearance. The degree of coverage was about comparable with the last pre-war values. Excerpta Medica IV is steadily making for the top position but, despite its worldwide organization of collaborators, hardly exceeds the 40 % limit. The «Bulletin of Hygiene» and the «Kongr. Zbl. ges. inn. Med.» obviously make ever more rigorous selections from the apparently important publications, so that their curves show a gradual decline. The fact that the degree of coverage is intentionally reduced is also manifested by the circumstances that some abstract journals, despite a steady increase in the volume of publications, have for years kept the volume of their journal constant.

These statistics indicate the general trend towards more rigorous selection of the literature mentioned in reviews and monographs as well as in abstract journals. In discussions of these developments, it is often contended that complete lists of references are not at all necessary. The older literature, it is maintained, is for the most part obsolete, out of touch with modern thought and no longer worth reading; in the newer literature, on the other hand, much is not worth repeating. Both arguments lead to *selection of literature*, that is always subjective, which I consider dangerous. The selecting of certain papers from the modern literature has resulted in a situation in which scientific opponents are ignored, while citations are limited to the authors' own schools. And who, in these days of superspecialization, could pretend to be able to present a definite appraisal of the scientific work of contemporaries? As regards the older literature, it must be stressed again and again that study of older papers in the field of poliomyelitis immunity would have been very valuable, and could have saved many duplications and unnecessary discussions. In the legends of the subject indices it will become apparent just how many epidemiological and experimental experiences and findings have already been reported in the older literature; this would have made renewed elaboration unnecessary. From his experience in these matters the conscientious scientist has always attempted in his own way to keep abreast of the literature as well as possible.

Attempts at rationalization in literature documentation

The majority of the older principles of classification were based on various modifications of the *card index system*. For every publication covered a card was made on which the author's name, the publication in which his paper was found and the title, and a brief abstract or note on its contents were written; the system was arranged according to subjects and, within each subject, alphabetically according to authors' names. The card index system also had the disadvantage of being «unidimensional». An attempt was made to get over this difficulty by making several copies of each card, filing cards under several headings, or by making reference word indices or card indices by means of which the cards could be traced.

In the past decade, registration of separate publications according to this system was so cumbersome, time-consuming and complex that a search for more *rational methods of documentation* was instituted. Various possibilities, viz.: the Hollerith system, various punch card systems, the

Cordonnier method, etc. They have in common rationalization, avoidance of the disadvantage of «unidimensional» classification, and an intensification of the work. The saving of time and work through technical sorting is obvious. Since several conceptions can be combined on a single card, and because the conceptual contents are fixed especially for the scientific requirements considered, scientific work is decisively intensified.

In the past few years, many scientists or institutions have used these methods in card indexing the literature. In order to utilize the scientific gain from the use of multidimensional mechanized card indices, there is at present a tendency to be secretive about the existence, contents and method of such card indices. On the other hand there are documentalists with the fatal tendency to theorize and to over-systematize and who do not wish to start practical work until all conceptions have been fully clarified, and an internationally valid key has been worked out. Both the secrecy about functionally sound methods and card indices, and the exaggerated theorizing, are against the principles of rationalization. The theorists, instead of saving time, waste time because they cannot find the starting point for realization of their theories, and because they confuse means with ends. Secrecy is irrational because the gain is to benefit of only one or a few persons instead of serving scientific work in general.

On the basis of this experience and these considerations I started, some ten years ago, to make punch cards for the literature on phage research which I had collected in the course of my experimental work, in order to publish my references in the completest and most rational form possible. «Bakteriophagie», which was published in 1958, demonstrated to me that this goal could be reached. We had succeeded in summarizing a great mass of subject matter in a limited space, and in publishing it in a form combining the advantage of a «multidimensional» card index system with the book form, thus enabling the reader to find his way rapidly and completely. Encouraged by this success, I decided to elaborate the literature on poliomyelitis immunity in a similar way, making a few further improvements as a result of our experience with «Bakteriophagie», which will be discussed later.

The collection of material

The beginning of any collection of material is of course a *definition of the subject*. In the case of «Bakteriophagie» this was very simple, because the conception «phage» had been internationally defined, and all pertinent publications had to be covered. In the case of «poliomyelitis immunity» the definition was more difficult, because many publications on the borderlines of epidemiology, clinical medicine and virology also deal with immunological questions. In principle, all publications were included which dealt with immunity and resistance to poliomyelitis, active and passive vaccination, antigens and serology of the poliomyelitis virus. In addition, we considered epidemiological and pathogenic studies, animal experiments and methods in some way related to immunity and/or resistance. The scope of the subject was therefore kept as wide as possible. The selection of publications was of course subjective, as it is necessarily subjective regardless of the method of documentation. Of course it is always debatable whether a publication is or is not pertinent. In dubious

cases I asked myself whether I would require that a candidate for the degree of doctor who was interested in the subject should be obliged to read the publication in question, or not. Every pertinent publication was covered by an authors' card and by a punched card. The authors cards (DIN A 6) bore the name of the author(s), the title of the paper, the original source and the abstracts found; they were arranged alphabetically according to the first author's name. The authors card is used to test whether a publication has or has not yet been covered. The punched card (DIN A5) contains the notes on subjects made while the publication was being studied (cf. page 32).

Sources of literature used

First, we covered the original papers on poliomyelitis immunity from the periodicals, a complete collection of which was available in the library of the Robert Koch Institute. Via the bibliographies of these papers we found older original papers which, in turn, contained references to still older literature. In this way we steadily expanded and completed the coverage. In addition, I continually ran through the accessible abstracts and the lists of literature appearing in some weekly journals, for suitable publications. To conclude the collection I systematically worked through the bibliographies of larger surveys and those of six abstract journals, to establish their degree of coverage. The abstract journals used and their times of publications are shown in the graph of fig. 3 (s. p. 9). The publications not yet covered by the card system were registered, and the original papers not available in the library of the Robert Koch Institute were obtained from other libraries. After reading the original, I composed the reference words. Only in some cases did I have to take the reference words form the abstract, when the original was not to be obtained. Particularly in the going through abstract journals, only those who have years of experience in this special field and in the study of technical literature, can hope to master the peculiarities of the register and the terminology in its strange ramifications. One finds that one journal arranges papers on poliomyelitis immunity only under the reference word «virus», and the other only under «vaccination». The index of every volume of an abstract journal was therefore studied at least for the reference words antigens, antibodies, immunity, poliomyelitis, resistance, vaccination and virus. In this way, the comprehensiveness of the collection increased in a certain rhythm.

Completeness of coverage

Every experienced documentalist knows that an absolutely complete coverage of the international literature is an impossibility. It remains to be established to what degree of completeness it is possible to go in practice, and how this degree is to be determined. The last few months of my investigation were given up to this task as I had already worked through most of the abstract journals; I then read through the bibliographies of original papers containing more than 50 references, and those of abstract journals. For each unit I determined the number or references to the

literature not yet included in my bibliography. This value was converted into percents and is shown in the graph of fig. 4, in which each column represents one of these publications. This fig. 4 (s. p. 10) shows the rate at which the completeness of coverage increases. Since zero point is not reached in practice within a measurable period of time, and because one day one must have the courage to conclude the collection, the question arises as to when this time has come. In «Bakteriophagie» I established two criteria for the conclusion of work, which have also been used in the present study. When the average error for a given period is constant at 5 % or lower, and when the trend calculated from the percentages has reached zero (full line in fig. 4), one can and must conclude the work. It can then be stated that one has covered over 95 % of the world's literature. Regarding «Bakteriophagie» I have, since its printing (i. e. in the past 6 years), availed myself of every opportunity to collect papers still missing for the supplement which is to be published shortly. Today I can say that I was astonished to see how seldom I came upon papers not yet included. The completeness in this case was greater than had been expected; «Bakteriophagie» thus confirmed that the statistical method indicated in fig. 4 permits a reliable estimate of the completeness of coverage.

Reference words and their registration on punched cards

As to the *number of conceptions laid down* I have attempted, as in «Bakteriophagie» to keep to the middle of the road. In order not to make the material too difficult to sort out and also to avoid trespassing beyond my limits, I have acted on the principle of using as many words as are really necessary but keeping them as few as possible.

Because monographs and reviews contain a very large number of conceptions, I have not as a rule registered all reference words for these publications; instead. I have presented these publications separately under the reference words «monographs» and «reviews». Fig. 5 (s. p. 12) is a graph which showed the distribution of the number of conceptions laid down for each of the 5,500 publications covered. In the majority of cases two or three conceptions were sufficient to describe the contents of a paper. The average number of conceptions used to describe a publication was 3.81. The subject index consequently lists 20,976 conceptions (cf. corresponding figures in «Bakteriophagie», Vol. I, page 13–14).

In the *selection of conceptions* I tried to place myself in the position of a scientist who wishes to inform himself about a given question concerning poliomyelitis immunity. The conceptions emerged automatically as the work advanced. Their arrangement is best studied in the table of contents of the subject index. On the one hand, I did not lay down every conception which occurred in a paper «expressis verbis», but included it only if it gave information about something new or interesting. On the other hand, I sometimes registered papers under reference words which did not occur as such in the papers but which were significant and important to the reader. The material therefore led to a subjective selection of titles, despite all efforts at objectivity. Here we reach the boundary of all efforts at mechanical documentation; here begins the necessarily subjective work of the scientist.

The reference words were inserted on *double-row punched card.* I used cards type 020 196 (DIN A 5) of the firm of Edler & Krische, Hannover. The use and arrangement of these cards, their advantages and keying have been discussed elsewhere «How can a scientist intensify his literature work?» Zbl. f. Bakt. I. Ref. **153,** 209 (1954), and here I need mention only a few important points. On every card, five reference words can be inscribed; whenever more conceptions are laid down, a second card is added. The punchings make it possible to select any reference word desired within the shortest possible time, using sorting needles or some other mechanical sorting device. Consequently the punched cards meet the requirements of «multidimensional» arrangement. The cards, moreover, also bear markings indicating the year of publication and the number of conceptions laid down; counts for literature statistics, as required for figs. 1 and 5, can therefore be made within a few hours, whereas a count and rearrangement of an ordinary card index system would take days; this advantage will be discussed in detail in the section of «literature statistics».

The possibility of simultaneously sorting the 5,500 punched cards for year of publication and number of conceptions laid down, was used for a statistic of the *degree of coverage.* Fig. 6 (s. p. 13) compares the average number of conceptions laid down for each year with the absolute number of publications numbered. The diagram reveals two interesting facts. First, the coverage shows an increasing trend. This means that, unconsciously, I more intensively studied the more recent publications, in accordance with their topical interest. On the other hand, an unexpected parallel can be seen between the two curves. When the number of publications shows a peak, the intensity of coverage also shows a maximum. This can only be interpreted to mean that, whenever new research impulses cause an increase in publications, more numerous new facts are presented – which is reflected in an increased number of conceptions to be laid down. In the intervals, the number of merely corroborating original publications and reviews increases, in which a smaller average number of conceptions sufficed. This explanation shows, in addition, how a punched card index system can improve our understanding of the structure of the material considered, with only a slight additional effort.

Arrangement of subject matter

Part I of this study in two volumes includes a prefatory word, preface, table of contents, introduction, index of subjects, index of authors, and reference word index. Part II presents a bibliography numbered 1 through 5,500, indicating all publications with authors' names, title of paper, original source and abstracts. The separation into two volumes will facilitate the use of this book. The reader would find it difficult or tiresome to look up reference words in the subject index, authors' names in the authors index and corresponding references in the bibliography, all in one volume. Now the two volumes can be placed side by side and used simultaneously.

Index of subjects

The subject index requires a more detailed explanation, because in this we made an attempt at a new approach to the problem. It is my intention

to arrange the subject matter in the index of subjects in such a way that the reader is led to the sources of the literature on a given subject in the simplest and quickest way possible. The subjects were divided into main conceptions (bold print), conceptions of the first order (sanserif) and those of the second order (italics). Within this division, all conceptions were alphabetically arranged. The conceptions were included in two languages with the page number of the table of contents (page IX), so that the reader can easily grasp the arrangement of subject matter.

Every main conception is accompanied by a legend, in which I present a brief review of historical development, disposal of the subject matter, present state of research, concept definitions and so forth. In this way I have tried to give the reader succinct information on the main conception concerned. Legends are followed by reference words (italics) referring to neighbouring fields in which the subject of the main conception is touched upon, and which the reader will wish to see, if possible, for further and more general information.

Now come the references to the literature. First there is a four-figure number referring to the corresponding number in the bibliography (Vol. II). The next, in brackets, is a two figure number denoting the year of publication of the paper, with the subsequent letter indicating its language. The following abbreviations are used for the language indications.

Balkan languages	= b	Nordic languages	= n
German	= d	Oriental languages	= o
English	= e	Portuguese	= p
French	= f	Polish	= pl
Dutch	= h	Russian	= r
Hebrew	= he	Spanish	= s
Italian	= i	Czechoslovakian	= t
Japanese	= j	Hungarian	= u

In «Bakteriophagie», I sometimes affixed two letters to the year; the first letter denoted the language of the original paper, and the second that of the attached summary in a foreign language. Meanwhile, however, numerous journals have introduced summaries in several foreign languages for all publications; this obviates reference to other-language summaries or abstracts; only the original language need be indicated. The four-figure numbers of the publications, within the section of each reference word, are arranged according to the year of publication and, within this, according to a continuous numeration. This makes it possible for the reader to inform himself about a certain period in the research into poliomyelitis immunity; on the other hand, when he knows the author and the source of a publication, he can find the number and the year of publication via the authors index and the bibliography, and then rapidly establish whether the paper in question has been included under a given subject heading.

After each main conception or conception of the first order, in so far as it is followed by conceptions of the second order, I have first added references to the literature which concern the subject in general, or special questions of such rarity that they cannot reasonably be separated under a special reference word. This section is headed: «general».

In this presentation, «multidimensional» classification is possible because every paper is presented under several pertinent titles. Apart from

this I have attached reference words to indicate cross references, which facilitates a survey; the colon signifies «relation to». For example, under the main conception «antibodies» the reader encounters the conception of the first order «geographical distribution». This indicates papers reporting on the antibody distribution in a given area; the language indication is as a rule followed by the country in which the antibody determination was made; if no additional reference word is found, the paper concerned has a comparative or general content.

Index of authors

In «Bakteriophagie» it was possible to do without an authors index because the bibliography (then still called authors register) was alphabetically arranged according to the first author's name. For reasons to be discussed later, I did not alphabetically arrange the bibliography on poliomyelitis immunity. An index of authors was therefore required. This has the disadvantage that a paper looked up via the author's name if found via the detour of the authors index; but this event may be rather rare. On the other hand, this arrangement has the advantage that all papers by a given author can be found in the index of authors, for all authors of a given paper are listed. In «Bakteriophagie», on the contrary, with its alphabetically arranged bibliography, it was only possible to find those works of an author who had been mentioned in the first place. The four-figure numbers in the authors index after the names refer to the continuous numeration in the bibliography.

Reference word index

A reference word index was added to facilitate finding the important cross reference in brackets in the subject index, synonyms of conceptions used in the subject index and special technical expressions in English and German. I hope to facilitate the search for very special questions by means of this index, and to intensify this work. After each reference word is given the number of the page on which it occurs. When the reference word has been included in the subject index as a special section, the page number of this main source has been printed in semi-bold type.

Bibliography

First I must explain the *re-naming* of this part. In the discussions for «Bakteriophagie» it was repeatedly urged that part II be called Bibliography, according to library usage, because the contents of this collection exceeded those of an authors index. I have followed these suggestions because the non-alphabetical arrangement of the bibliography made it necessary to include an authors index in the usual sense of the word, in part I. On the other hand, we must give reasons for *abandoning the alphabetical order* in the bibliography. Either one first collects the entire literature, arranges it alphabetically, and then lays down the conceptions for the subject index (in a not fully automatic one-man project this method is too time-consuming), or in the years of sorting the material, one gives every publication a provisional continuous number; at the end of collecting, a key must then be used to convert some 20,000 four-figure numbers. This

way, which I used in «Bakteriophagie», is extraordinarily tiresome, irrational and burdened with an inevitable additional load of errors. There is another argument in favour of abandoning the alphabetical order of the bibliography; the planned supplements will increasingly interfere with the alphabetical order. Abandoning this order for the bibliography, we can unhesitatingly start collecting further material for subsequent supplements even while the first edition is being printed.

In the bibliography, the titles of the papers were included in the original language whenever possible. Only occasionally are they given in the language of the abstract or left out altogether because the original was inaccessible, or because the original title was printed in cyrillic letters or in some pictography. Follows the place of publication with abbreviated name of the journal, semibold indication of the volume number, normal-type number of pages and the year of publication in brackets. The source of the original paper is added in brackets to the abstracts. To facilitate the search in the accessible abstract journals, I mentioned all abstracts which I encountered. The references to abstracts are not complete because I systematically scrutinized only a few journals (cf. fig. 3, p. 9).

Literature statistic

Mechanical literature documentation makes it possible, in a short time, to reach important statistical conclusions regarding the structure and development of an area of knowledge. This is the meaning of the term «literature statistic» heading this section. The graphs shown in previous sections are part of literature statistic in the widest sense. In the following three graphs, I report on changes in scientific emphasis in research on poliomyelitis immunity. This structural analysis was technically arranged in such a way that every publication was filed under a main subject heading which can be marked on the punched card. Since the object was only to trace developmental tendencies in order to reach conclusions regarding the structural change in an area of knowledge, unidimensional arrangement of the publications was suitable and adequate for the purpose.

I analysed the two most important practical aspects of *research on poliomyelitis immunity* – active immunization and serum prophylaxis and -therapy. The absolute number of publications for every year from 1909 to 1960 was graphically demonstrated in figs. 7 and 8 (s. p. 18 and 19). The upper part of the diagram shows the overall material, while the lower curves indicate three subdivisions of the areas of research.

The reference word «*active immunization*» covers all publications concerning specific active vaccination against poliomyelitis in man and animals. The curve of all publications shows three peaks – a small one in 1910, a larger one in the thirties and a steep rise after 1950. The subdivisions in fig. 7 explain the structure of this course. The peak in 1910 was exclusively caused by reports on animal experiments; at this time, it was demonstrated that monkeys can be immunized with material containing virus; technical facilities to develop a vaccine for human use, however, were still lacking. Only about 1930 were new attempts made to create conditions for active immunization of human subjects by means of animal experiments. The results of these efforts were the inactivated vaccine of BRODIE and the attenuated vaccine of KOLMER; field trials with both were simultaneously started about 1935; both methods of vaccination

did not exceed the experimental stage, for the following reasons. BRODIE's vaccine, obtained from simian cerebral material, was not suited to mass production, and KOLMER's chemically attenuated vaccine proved to be virulent and caused poliomyelitis in the patients treated. It was only after World War II that – under pressure from the ever more menacing epidemiological situation – intensive animal experiments were started preparatory to active immunization. After 1950 experiments in human subjects were started, again simultaneously with inactivated and live vaccines. The SALK vaccine is known to have made a temporary gain after the great field trial in the USA in 1954; this is reflected in the steep rise in the curve of publications in 1955. Gradually there developed the use of live vaccine from virus strains of attenuated pathogenicity and capable of multiplication, according to KOPROWSKI, SABIN and COX; in 1960, the number of publications on this subject exceeds that on any other subject.

In a similar way, fig. 8 analyses the efforts in «*passive immunization*» against poliomyelitis. The reference word covers serum prophylaxis as well as serum therapy, because prophylaxis and treatment can be hardly separated in practice, so that as a rule both modes of application are simultaneously discussed in the literature. This curve, too, shows three peaks, but the first maximum lies later than that in fig. 7, while the next two maxima occur earlier. The three chief possibilities of passive immunization – specific immune sera, convalescent serum and gamma-globulin – are separately presented for analysis of this curve. Around 1910, the first tentative experiments showed that large mammals can be actively immunized to obtain immune serum, and that monkeys can be passively immunized with human convalescent serum. After World War I, practical trials with both methods started. As a result of the gradually increasing poliomyelitis morbidity, the use of specific immune sera and convalescent serum showed a renewed increase by the end of the twenties; convalescent serum is used more frequently because it is more readily obtained. Owing to the relative inefficacy of both forms of passive immunization, both curves show a more or less simultaneous decline around 1940. After World War II, another brief, again unsuccessful attempt at using convalescent serum was thwarted by the rise of gamma-globulin prophylaxis after 1950. The third peak soon deteriorated because this form of passive immunization is also disappointing, particularly because of the difficulty of applying the gamma-globulin at the correct time.

The manner in which the efforts at active and passive immunization alternate, and their chronological correlations with other subjects, can be demonstrated by adding the percentual part of the volume published for every year, as seen in fig. 9 (s. p. 20). In order to keep the diagram clear, I merely compared active and passive immunization with the large subject of «resistance», summarizing all other subjects under the heading «miscellaneous». The term resistance covers all publications concerning the unspecific defence mechanisms and the fluctuations in disposition according to sex and constitution, as well as their response to hormones, vitamins, nutrition, etc. After the animal experiments on active immunization around 1910, which had no practical consequences, passive immunization comes to the fore during a considerable period. By 1935 there is a clearly recognizable renewed interest in active immunization. Both methods are disappointing, and both curves show a simultaneous

decline. As indicated in 1920, research into resistance aimed at filling the gap. Because the methods of specific immune prophylaxis make no progress, there is an increase in the efforts at prophylaxis of exposure and disposition. An attempt is made to screen those with a constitutional predisposition in order to protect them from infection; attempts are also made to increase resistance by suitable diets, vitamin and hormone administration, and to avoid lowering resistance by excessive physical efforts and other stress situations. The relative prevalence of publications on resistance gradually diminishes, while those on gamma-globulin prophylaxis briefly increase, after which the new methods of active immunization take the lead. Summarizing, therefore, fig. 9 shows that passive immunization required almost 60 % of the total volume of publications during ten years (1922–1934); by 1945 papers on resistance, replacing those on specific immune prophylaxis, also made up about 60 % of the total volume; today, over 60 % of all publications are concerned with active vaccination.

Suggestions for further development

My attempt to develop a new form of literature documentation can only successfully develop further when supplements or new editions are published at regular intervals, and when this form of documentation is accepted in other special fields also. A few suggestions remain to be made for rationalization of the subsequent efforts.

The possible forms of a *continuation of literature documentation* within a given specialty were discussed in detail with colleagues after the publication of «Bakteriophagie», and with the Gustav Fischer Verlag before the publication of «Poliomyelitis-Immunität». In addition to supplemental volumes at intervals of a few years, or occasional summarizing new editions, several suggestions were in favour of the continual publication of, say, annual loose-leaf supplements, as have been successfully used for lawbooks, atlas publications and topographic manuals. The arrangement of single perforated supplement leaflets in bindings of suitable size, by means of a clip-on mechanism has obvious advantages and some rather important practical disadvantages; these disadvantages were sufficiently important to guide our decision against this form of supplementation. With the intensive use in libraries, the leaves can easily tear and be lost. Also, the inclusion of supplements, as experience indicates, would give rise to difficulties both in libraries and in private collections. In the case of the bibliography this would not be very difficult because the supplements could simply be added at the end. In the case of the subject index, however, the leaves would have to be separately inserted or exchanged against obsolete leaves; we know that few care to spend the time and effort to do this carefully. Also, even in the first edition every reference word would have to be printed on a separate leaf, so that supplemental leaves could be added per reference word. Poliomyelitis immunity has so far 144 reference words. The supplements would have to supply a separate leaf for each reference word, regardless of whether two or 200 publications on the subject have been published in the meantime. Finally, the larger volume and greater technical difficulties would increase the cost to a not inconsiderable extent. It is for these reasons that,

both in publishing the literature documentation in other special field, and in supplements, the bound form will be preferred.

The author of a literature documentation as I have suggested, must find support in future in the *active cooperation of the professionally interested users* in order to reduce the sources of error of such a project. Even the most scrupulous checking cannot be expected to control all errors of coverage, transfer, classification and printing. In the case of «Bakteriophagie» I carefully checked a large random sample and found a margin of error of 1.85 %. According to my experience it will hardly be possible to reduce this percentage. I would therefore address myself to the reader with a number of concrete requests. Please do not hesitate to bring to my attention any printing errors, errors in subject arrangement or missing publications. If papers published by yourself have not been included, please send me a copy if possible; the same holds true for copies of papers which you intend to publish on poliomyelitis immunity in future. If you attach value to the inclusion of certain reference words in the subject index, please underline them in the copy in question. If you believe that the arrangement of the references to the literature could be improved, I would welcome your practical suggestions.

In conclusion I should like to point out a few possible developments. Efforts to come to a *uniform literature documentation* can only be really meaningful when placed on an *international basis*. If scientists in different countries were prepared to index the literature on other subjects by the system suggested, further advantages of this mode of information would become apparent. Any author of a scientific paper would know which investigators in his field had undertaken literature documentation. He would send a copy of his paper to these investigators, and mark in his paper the reference words which he thinks should be included in the subject index. This would be both an intensification of professional literature documentation and a considerable aid to the publisher.

Also the authors of scientific publications could cease *presenting long lists of references*. It would be sufficient to replace a quotation in the text by a figure in brackets referring to the pertinent bibliography. This would reduce the volume of the international literature and of the references to the literature, and the authors would be saved the time and effort otherwise required to compose and write their bibliographies. The reader would no longer have to go on searching about in a single volume; if he wished to look up a quotation, he could use the pertinent bibliography in the manner of a lexicon.

Erläuterung zum Sachregister

Die vierstellige Ziffer weist auf die laufende Nummer der Veröffentlichung in der Bibliographie [Teil II] hin. In der Klammer bezeichnet die zweistellige Ziffer das Erscheinungsjahr und der Buchstabe die Sprache, in der die Arbeit erschienen ist. Für die Sprachen gelten folgende Abkürzungen: b = Balkan-Sprachen, d = deutsch, e = englisch, f = französisch, h = holländisch, he = hebräisch, i = italienisch, j = japanisch, n = nordische Sprachen, o = orientalische Sprachen, p = portugiesisch, pl = polnisch, r = russisch, s = spanisch, t = tschechisch, u = ungarisch.

Explanation of subject index

The four-figure number refers to the consecutive numeration of the bibliography (part II). The two-figure number in the brackets refers to the year of publication and the letter indicates the language in which the paper was written. The following abbreviations are used: *b* = Balkan languages; d = German; e = English; f = French; h = Dutch; he = Hebrew; i = Italian; j = Japanese; n = Nordic languages; o = Oriental languages; p = Portuguese; pl = Polish; r = Russian; s = Spanish; t = Czechoslovakian; u = Hungarian.

SACHREGISTER / INDEX OF SUBJECTS

Antigenität / Antigenicity

Schon bald nach den ersten erfolgreichen Übertragungen des Poliomyelitiserregers auf den Affen begann man spezifische serologische Methoden zu entwickeln, von denen hier nur diejenigen Arbeiten zitiert werden, die die Antigengewinnung beschreiben. In den zwanziger Jahren wurden von einigen Forschern (vor allem ROSENOW) polymorphe Streptokokken als ätiologischer Faktor angesprochen; von den Arbeiten dieses Irrweges, die sich mit der Antigenität (A.) befassen, sind nur einzelne als Beispiel angeführt. Erst in den dreißiger Jahren baut man die serologische Methodik aus, um verschiedene serologische Typen des Poliomyelitisvirus differenzieren und verwandte und pathogenetisch ähnliche Erkrankungen und ihre Erreger abtrennen zu können. In den letzten Jahren wird dann versucht, innerhalb der drei Antigentypen des Poliomyelitisvirus Antigendifferenzen herauszuarbeiten, das Antigen mit modernen, biochemischen Methoden in Fraktionen zu zerlegen und Antigenvariationen und ihre genetischen Grundlagen zu erforschen. Seit 1950 erscheinen zahlreiche Arbeiten, die das für die Impfstoffentwicklung so wichtige Thema der Veränderung der A. durch physikalische und chemische Inaktivierung behandeln.

s. a. Antikörper, Nachweismethoden.
Impfstoffe, Wirksamkeit.
Inaktivierung des Virus, Formaldehyd.
Serologie, Antigen-Antikörper-Reaktion.
Serologie, Antigenität.
Serologie, Differenzierung der Typen.
Serologische Methodik.

Soon after the first successful transmissions of the poliomyelitis pathogen to monkeys, a start was made with the development of specific serological methods; of the publications in this respect, only those can be mentioned that describe the acquisition of antigens. In the twenties some investigators, notably ROSENOW, indicated polymorphous streptococci as the aetiological factor; of the publications on this erroneous line, which are concerned with antigenicity (A.), only a few are presented as examples. Only in the course of the thirties were serological methods further developed, by which the various serological types of the poliomyelitis virus could be differentiated and the disease distinguished from related and pathogenically similar diseases and their pathogens. In recent years an attempt has been made at elaboration of antigen differences between the three antigen types of the

poliomyelitis virus, at fractionation of the antigens by modern biochemical methods, and at the study of the genetic principles of antigen variations. Since 1950, numerous publications have appeared which discuss the changes in A. produced by physical and chemical inactivation – a subject very important with a view to vaccine development.

cf. Antibody, methods
Inactivation of virus, formaldehyde
Serological methods
Serology, antigen-antibody-reaction
Serology, antigenicity
Serology, differentiation of types
Vaccines, potency

Allgemeines / General

0272 (17e: CFT); 1268 (17e: globoid bodies); 0347 (18e: streptococci); 1357 (18e: monkey: CFT); 0137 (28e: streptococci); 0408 (31e); 0737 (31e); 1098 (31e); 2237 (31e); 0435 (32e); 1078 (32e: purification); 0707 (33e: purification: skin test); 0881 (33e); 0892 (33e); 3701 (34f: PETTIT serum); 0704 (35e: serological diagnosis); 0474 (37e: fortified antigen); 3582 (37e); 0362 (39e: variation); 2793 (39e: CFT and precipitation); 3848 (43e); 3699 (44e: THEILER-virus); 2722 (47e: CFT); 4420 (48e: mouse adapted LANSING-strain); 0876 (49e); 4428 (49e: LANSING C (M) variant); 1497 (50e: CFT: mouse); 0063 (51e: titer of infectious activity); 1581 (51e: monkeys: differences in infectiousness); 1582 (51e: CFT: cotton rat); 1634 (51e: differentiation of types); 1686 (51e: CFT: mouse); 1703 (51e); 2716 (51e: CFT); 3083 (51e: CFT: newborn mice); 4440 (51e: cellular pathogenicity); 4445 (51e: classification); 2701 (52e: antigen: tissue culture); 2889 (52e: CFT); 4482 (52s: classification); 4483 (52f); 1974 (53s: CFT: mouse); 4465 (53e: CFT); 4470 (53e: CFT); 4475 (53f: conglutination); 4492 (53e: AK-strain); 5142 (53e); 2244 (54e: phenol red-color test); 2725 (54e: thermostability); 2726 (54e: multiple antigens: CFT); 4518 (54f: strains in France); 4565 (54e: LANSING-: Col. SK-virus); 1552 (55e: SALK-vaccine: Rh-antigen); 1893 (55e: quantity: neutralizationtest); 2740 (55e); 5178 (55f); 1665 (56e: flocculation); 1687 (56e: CFT: tissue culture); 1851 (56e: seven different type 1 strains); 1919 (56e: different commercial SALK-vaccines); 1929 (56e: homogenicity of type 1); 2423 (56e: MEF_1: soluble antigen: CFT); 2424 (56r: type 4); 4770 (56d: after adaptation to mice); 4773 (56i: CFT); 5440 (56e: relationship to canine hepatitis); 0115 (57b: LANSING: herpes); 0518 (57e: CFT); 0520 (57i: fluorescent antibody); 0539 (57f: intracellular development); 0961 (57e: CFT: tissue culture); 0972 (57e); 1112 (57f: 1956 Roumania); 1113 (57f: 1956 Roumania); 2014 (57e: after purification); 2689 (57d: concentration); 3398 (57e: fluorescent antibody); 0400 (58e: CFT: tissue culture); 0501 (58e: rapid slide precipitin microreaction); 0502 (58e: CFT); 0759 (58e: C- and D-antigen: tissue culture); 0761 (58e: chicken test); 0958 (58d: CFT); 0990 (58f: Belgish SALK-vaccine); 1138 (58e: alteration); 1172 (58e: combined vaccine); 1218 (58e: hemaggregation test); 1584 (58e: different types); 2453 (58e: sedi-

mentation); 2454 (58e: precipitin test in gel); 0186 (59d: testing of vaccines); 0392 (59e: stability: temperature); 0488 (59e: specifity); 0988 (59e); 0989 (59e: multiple antigen); 1021 (59d: tetravaccine); 1056 (59d: purification); 1134 (59d: adsorbed vaccine: uninterrupted antigen stimulus); 1135 (59d: titration of inactivated virus); 1141 (59b: specifity of type 2 and 3); 1227 (59e: CFT: mouseadapted virus); 1281 (59e: virulence); 1368 (59e: combined antigens); 1372 (59f: strains: Roumania); 1374 (59e: C- and D-antigen: precipitation); 1378 (59he: different SALK-vaccines); 1411 (59e); 1627 (59e: D-C-antigen); 1717 (59e: preparation); 2581 (59f); 1351 (60d: virus titration: hemaggregation test); 2350 (60d: combined vaccines); 2351 (60d: combined vaccines); 2352 (60e: after concentration); 2355 (60e: within type 1); 2370 (60e: concentration: bivalent cations); 2378 (60e: antibody-combining test); 2385 (60e: CFT: attenuated strains); 2386 (60d: CFT: HeLa cell cultures); 2394 (60d: combined antigens); 2440 (60e: serodifferentiation within the same type); 2446 (60e: CFT); 2525 (60e: attenuated strains); 2527 (60e: CFT); 2567 (60e: fluorocarbon-treated); 2575 (60u: room temperature); 2782 (60e: N- and H-antigen); 2878 (60f: CFT); 3059 (60r: precipitation); 3459 (60e: immunogenic potency); 4302 (60e: interference test); 4600 (60e: color test); 3484 (61e: microprecipitin test); 3495 (61e: CFT: purified antigen); 4144 (61e: tissue culture: fluorescent antibody); 4204 (61e: purified and concentrated vaccine); 4219 (61d: concentration: $Al(OH)_3$); 4691 (61r: non-infectious antigen); 5145 (61d: «Konkurrenz der Antigene»); 5152 (61e: CFT); 5163 (61e: serodifferentiation); 5370 (61e: D-antigen: potency of vaccine); 5438 (61r: intratype differences); 5465 (61r: fluorescent antibodies); 5489 (61f: modification: tissue cultures); 5452 (62e: C- and D-antigen: measurement).

Nach Inaktivierung / After inactivation

0146 (33e: serum); 0904 (33e: heat inactivated virus: skin test); 0818 (35e: formaldehyde); 1541 (51e: chemical inactivation); 1542 (51e: physical inactivation); 2030 (52e: formaldehyde); 3353 (52e: formaldehyde); 1769 (53e: formaldehyde); 1755 (54e: UV-radiation); 2459 (54e: formaldehyde); 1606 (55e: CFT: formaldehyde: type specifity); 1771 (55e: formaldehyde); 1779 (55d: formaldehyde); 1810 (55e: heat and UV-radiation); 1456 (56i: β-propiolactone); 1569 (56e: formaldehyde); 1828 (56e: merthiolate); 1882 (56e: UV-radiation); 1886 (56i: β-propiolactone); 1888 (56i: formaldehyde); 1890 (56e: heat: CFT: specifity); 2425 (56d); 2064 (57e: guinea pig test); 2070 (57e: UV-radiation and heat); 2193 (57f: formaldehyde and β-propiolactone); 2312 (57e: ionizing radiation and heat); 0389 (58e: heat: CFT); 0391 (58e: formaldehyde: CFT); 0556 (58d: hemaggregation test); 0846 (58e: CFT); 0849 (58e: guinea pig test); 0850 (58e: guinea pig test); 0951 (58f: chicken test); 1206 (58i: CFT); 2111 (58e: guinea pig test); 0525 (59e: UV-radiation and heat: specifity); 0559 (59e: vaccine: CFT); 0966 (59e: flocculation); 1032 (59e: guinea pig test); 1033 (59e); 1086 (59e: neutralizing antibody-combining test = NAC); 1267 (59e: rat test); 1279 (59f: chicken test); 2281 (59e: chick method for testing); 2283 (59e: antibody

combining test); 2301 (59r); 2374 (60f: chicken test); 2386 (60d: heat: CFT); 2976 (60e: formaldehyde); 3454 (60i: guinea pig test: chick test: antigen antibody combining test); 4668 (61e: gamma irradiation); 5367 (61e: CFT).

Typisierung / Typing

0144 (31e); 0379 (33e); 0822 (34e); 4789 (36e: monkey); 0813 (37e); 2690 (38e); 0803 (39e); 0624 (42e); 5138 (45e); 0072 (49e); 0179 (49e); 0180 (49e); 2661 (49e: flocculation test); 2710 (49e); 4223 (49e); 0031 (50e); 3147 (50e); 5329 (50e); 0037 (51e); 0045 (51e); 0046 (51e); 0047 (51e); 0048 (51e); 0049 (51e); 0050 (51e); 0051 (51e); 0052 (51e); 0053 (51e); 0119 (52e); 2129 (52e); 2877 (52e) 3180 (52e: in tissue culture); 0299 (53e: MACK-virus); 1440 (53e); 2963 (53e); 2964 (53e); 3361 (53e); 3404 (53e); 4561 (53pl: Poland); 0082 (54e: Canada); 2658 (54d: Germany); 2682 (54d: Germany); 2853 (54f); 4022 (54f); 0696 (55e); 1615 (55e: specifity); 1784 (55e: recombination: type 1 and 2); 1666 (56f: France); 4067 (57e: CFT); 4269 (57j: Japan); 0188 (58e: CFT); 0889 (58e: recombination: CFT); 1138 (58e: alteration: physical activity) 1203 (59e: antigenic variation: type 1); 1204 (59e: antigenic variation: type 3); 1300 (59e: variability and virulence); 2379 (60e: base composition of RNA); 2408 (60e: CFT); 2944 (60e: antigenic variation); 4201 (61e); 4229 (61e: common antigens); 4246 (61f); 4247 (61f); 4250 (61e: fluorescent antibody).

Antikörper / Antibody

Schon in der ersten Forschungsperiode von 1908 bis 1918 erarbeitete man die Erkenntnis, daß die belastbare Immunität nach natürlicher Infektion oder aktiver Immunisierung bei Mensch und Tier mit Antikörpern (A.) im Serum zusammenhängt. Die künstliche Infektion im Tierversuch, die eine Immunität hervorrufen soll, und die dabei entstehenden A. bilden den ersten Schwerpunkt auf diesem Arbeitsgebiet. Zu dieser Zeit werden auch die bereits bekannten Methoden der Komplementbindungsreaktion und des Neutralisationstestes zum serologischen Nachweis der A. angewendet; erst später werden die Präzipitation und die Hämagglutination versucht. Ab 1930 wird die Erforschung von speziellen Fragen begonnen, die mit den A. zusammenhängen. Vor allem beginnt die Bestimmung der A. als ein Beweis für die Wirksamkeit einer aktiven Immunisierung; nach Vorversuchen am Tier werden auf diese Weise von 1934 bis 1936 die BRODIE- und KOLMER-Vakzine geprüft, bis 1952 folgen wieder vor allem Tierversuche, und danach erscheinen die zahlreichen Veröffentlichungen, die die A.-Bildung nach den modernen aktiven Impfverfahren beschreiben. Nach einigen Infektionsversuchen am Tier wird ab 1953 der erneute Anstieg der A. nach Wiederholung der aktiven Immunisierung, die «Booster-Wirkung» als spezielle Frage bearbeitet. Zur gleichen Zeit wird die damit eng zusammenhängende Frage nach der Haltbarkeit der A. behandelt; vor allem interessiert, wie lange die A. nach Infektion, nach aktiver Immunisierung oder nach diaplazentarer Übertragung auf den Säugling im Blute nachweisbar bleiben. Die diaplazentare Übertragung der A. von der Mutter wurde zunächst in Blickrichtung auf die eigenartigen Immunitätsverhält-

nisse bei Neugeborenen und Säuglingen geprüft; später versuchte man durch aktive Immunisierung der Mutter dem Kind einen höheren Vorrat an A. in das Leben mitzugeben. Nach 1930 wurde auch der Anstieg der A. nach natürlicher Exposition und Infektion weiter erforscht. Dabei zielten diese Untersuchungen zunächst auf die Anwendung des Rekonvaleszentenserums ab; man wollte wissen, wie groß der Gehalt an A. in den prophylaktisch und therapeutisch angewendeten Seren war. Diese Frage nach dem Titer von spezifischen A. wiederholte sich 1951 bis 1955 für das Gammaglobulin. Nach 1950 verstärkte sich das Interesse, als man versuchte, durch die Bestimmung der geographischen und altersbedingten Verteilung von A. in größeren Populationen die Immunitätslage als Grundlage für epidemiologische Durchseuchung und Prognosen sowie für Impfindikationen zu bestimmen. An den Ergebnissen dieser beiden Themengruppen entzündete sich immer wieder die auch heute noch nicht beendete Diskussion über die Bedeutung der A. für die Immunität; sicher ist bisher, daß die spezifischen A. nach Infektion und aktiver Immunisierung in der Regel ansteigen und somit ein guter Indikator für die Immunreaktion des Makroorganismus sind; ebenso sicher ist, daß es auch ohne A. im strömenden Blute eine Immunität gegenüber Poliomyelitis gibt. Umstritten ist noch die Frage, ob auch A. nur infolge einer unspezifischen Reifung und ohne einen spezifischen Antigenstimulus entstehen können. Um so erstaunlicher ist es, daß die grundlegende Frage nach Ort und Mechanismus der Entstehung der A. speziell bei der Poliomyelitis nur gelegentlich gestellt und bearbeitet wurde.

s. a. Antigenität.
Immunität, nach natürlicher Exposition, Antikörper.
Immunität, nach Schutzimpfung, Antikörper.
Serologie, Antigen-Antikörper-Reaktion.
Serologische Methodik.

Even during the first research period from 1908 to 1918, it was found that the useful immunity following natural infection or active immunization in man and animals, correlates with antibodies (A.) in the serum. The artificial infection in animal experiments, which should provoke immunity, and the A. formed in the process, form the first focal point in this field of work. At this time, the established methods of the complement fixation test and the neutralization test were also used in the serological demonstration of A.; it was not until later that precipitation and haemagglutination tests were used for this purpose. Research into special questions correlated with the A. was started in 1930; a special project was the determination of A. as evidence of the efficacy of active immunization. After preliminary animal experiments, the BRODIE and KOLMER vaccines were tested in this way between 1934 and 1936; until 1952 the accent was again on animal experiments, and after this the numerous papers were published in which the A. formation following modern active vaccinations was described.
After a number of animal experiments on infection, a start was made in 1953 with the investigation of the special subject of the renewed increase in A. following repetition of active immunization (booster effect). At the same time the closely correlated question of the durability of A. was studied; the most interesting point was the question how long A. remain demonstrable in the blood after infection, active immunization or diaplacental

transmission to the foetus. The diaplacental transmission of maternal A. was first investigated with a view to the peculiar immunity conditions in neonates and infants; later, attempts were made to give the child a larger stock of A. for life by active immunization of the mother. After 1930, further studies were also made of the increase in A. following natural exposure and infection. These investigations were primarily aimed at the use of convalescent serum; investigators wanted to know the A. concentration in the sera used prophylactically and therapeutically.

The question of the titre of specific A. arose again, with regard to γ-globulin, during the period 1951–1955. After 1950 the interest increased when attempts were made at determining the general immunity as a basis of epidemiological and prognostic conclusions, and in indications for vaccination, by determining the geographical and age-linked distribution of A. in larger groups of the population. The results obtained in these two broad areas again and again started the discussion, which is still going on, about the significance of A. for immunity; so far it has been established with certainty that the specific A. as a rule increase following infection and active immunization, and therefore constitute a good indicator of the immune reaction of the macro-organism. It is also certain that immunity against poliomyelitis is also possible without A. in the circulating blood. A persistent controversial question is whether A. can also be formed as a result of unspecific maturation and without a specific antigen stimulus. It is all the more surprising, therefore, that the fundamental question of localization and mechanism of production of A., especially in poliomyelitis, is only occasionally raised and considered.

cf. Antigenicity
Immunity, after natural exposure, antibody
Immunity, after vaccination, antibody
Serological methods
Serology, antigen-antibody-reaction

Allgemeines / General

0107 (10e); 4862 (11e); 4863 (11e); 5022 (15d); 0278 (17e: cerebrospinal fluid); 0250 (18e: antipoliomyelitic serum of ROSENOW); 0737 (31e: antitoxic properties); 3797 (33d); 0735 (34e: inactivation: heat); 0722 (35e: serumtreatment); 0746 (35e: specifity); 0756 (35e: purification by adsorbtion); 0758 (35e: prophylaxis); 2272 (35e: prophylactic value of specific immune serum); 0667 (40e: absorption and elution with aluminagel); 0797 (50e: nasal secret: seasonal distribution); 1675 (53e); 4062 (54e); 1629 (55e: human serum: tissue culture); 2241 (55s: passive immunization); 4019 (55e); 0530 (57e: neonatal immunity); 1129 (57e: masked infections in tissue culture); 3009 (57e); 0393 (58e: human amniotic fluids); 0506 (58i: tonsil); 0971 (58e: normal bovine sera); 1297 (58e: cerebrospinal fluid); 1339 (58d: avidity); 1477 (58e: model); 1478 (58e: model); 2781 (58i: tonsil extracts); 4011 (58e); 0984 (59e: British standard antisera); 1193 (59e: molecular equivalents); 1208 (59e: stability of antigen-antibody complexes); 1298 (59e: in faeces); 2381 (60f); 4861 (60e); 4864 (60e); 5358 (60i: anticell-fraction-sera); 5452 (62e: C- and D-antigen).

Altersverteilung / Age distribution

0089 (30e: mother: newborn); 0340 (30e); 0717 (32e); 0900 (33e: Tennessee); 0382 (35e); 0725 (35e: vaccination); 0817 (35e); 0077 (36e); 0358 (39e); 3558 (39e: diphtheria antitoxin); 0327 (40e); 1835 (40e: USA); 0622 (45e: LANSING strain); 1259 (46e); 4837 (46e: West Africa natives); 1269 (48e); 0706 (49e); 5335 (49f: France); 0721 (50e); 0796 (50e: Chicago); 2649 (50e: Alaskan Eskimos); 2650 (50e: Baltimore); 0054 (51e: North Alaskan Eskimos); 2775 (51f: St. Augustin/Canada); 2817 (51e); 3219 (51e: Bantu: Europeans in South Africa); 3965 (51e); 4557 (51f); 1682 (52e: Cairo: CFT); 1950 (52e); 2029 (52e); 2040 (52e: Eskimos); 2746 (52f); 4021 (52e); 4448 (52e: Egypt); 4456 (52f: Quebec/Canada); 0296 (53e: Tahiti); 1947 (53d); 2002 (53e); 2734 (53f: Canada); 2965 (53e: during epidemic); 3030 (53e: San Francisco, Mexico City, Guam); 3384 (53e: Szeged/Hungary); 4503 (53pl: Poland); 0259 (54e: Eskimos: Canada); 2798 (54e: Georgia); 4028 (54i); 4034 (54n: Sweden); 4052 (54f: Brazzaville: CFT); 5038 (54f: Belgium); 0497 (55i: Italy); 0692 (55e); 0693 (55e: under-developed areas); 0697 (55e); 1496 (55e: Uruguay); 1576 (55e: Uruguay); 1632 (55e: New Zealand); 1651 (55f: Uruguay); 1765 (55e: Israel); 1821 (55e: South Australia); 1836 (55e: Tahiti); 1837 (55e: French Morocco); 1838 (55e: aborigines: North Australia); 1840 (55e: Charleston/USA); 1872 (55f); 2071 (55e: Helsinki); 2239 (55s); 2597 (55e: Melbourne); 2636 (55f: Uruguay); 2983 (55e: England); 2984 (55e); 2985 (55f: Italy); 2987 (55f: Belgium); 2988 (55f: Bucarest: type 2); 3461 (55i); 4037 (55e); 4056 (55e); 4605 (55f: Belgium); 4617 (55s: Chile); 5045 (55n: Finland); 5204 (55e: Aaland Islands); 1657 (56e: French Oceania); 1832 (56e: England); 1844 (56e: Northern Ireland); 1845 (56e: South Louisiana); 1852 (56d: CFT); 1860 (56d: Germany); 1870 (56f: Geneva); 1885 56i: Palermo/Italy); 1896 (56f: Belgish Congo); 1906 (56e: Island); 1918 (56d: Germany); 1932 (56e: Turkey); 1965 (56e: Middle America); 2034 (56d: Geneva); 2061 (56e: immunity); 2098 (56e: Liberia); 2106 (56e: New Zealand); 2113 (56e: New Zealand); 2187 (56b: Bucarest); 2425 (56d: morbidity); 2426 (56d: CFT: neutralization); 2443 (56f: Savona/Ligurien); 2479 (56i: Naples); 2553 (56d: Hamburg); 3084 (56e: Sweden); 3134 (56f: Paris); 3969 (56e: Finland); 4767 (56e: Aaland Islands); 5205 (56e: New Zealand); 5207 (56e: Aaland Islands); 0192 (57h: Belgium); 0310 (57d); 0530 (57e: mother: newborn); 0573 (57f: France); 0578 (57e: Japan); 0602 (57i: Italy); 0942 (57e); 1524 (57e: Alaska); 1528 (57e: Louisiana); 1530 (57f: Louisiana); 1966 (57d: Northern Germany); 1967 (57e: Scotland); 1969 (57e: Sweden); 1973 (57f: Switzerland); 2046 (57e: Manitoba); 2056 (57d: Switzerland); 2059 (57e: London); 2066 (57e: Louisiana); 2074 (57i: newborn: Genua); 2079 (57d: Bayern); 2081 (57e: Eastern Saudi Arabia); 2083 (57i: Sardinian); 2104 (57e: Cairo: USA); 2116 (57e: Northern Ireland); 2128 (57e: Israel); 2333 57d: Bern/Switzerland); 2335 (57e: Charleston and Phoenix/USA); 2428 (57f: Congo); 2484 (57p: South Africa); 2491 (57f: Belgium); 2493 (57n: Sweden); 2507 (57e: Peru and Colombia); 2511 (57e: Japan); 2542 (57d: Niedersachsen/Germany); 2651 (57e: Sweden); 4269 (57j: Tokyo); 5194 (57d: New Orleans); 5198 (57i: Bologna);

5296 (57f: Leopoldville); 0114 (58f); 0161 (58e); 0187 (58e: Stockholm); 0193 (58e: Scotland); 0202 (58f: Belgish Congo); 0203 (58e: British Guiana); 0230 (58f: France); 0244 (58d: Germany); 0312 (58d), 0390 (58d: Germany); 0394 (58e: indication); 0499 (58d: Germany); 0500 (58f: Belgish Congo); 0576 (58i: Italy); 0619 (58e); 0628 (58d); 0678 (58i: Italy); 0679 (58e: New Zealand); 0680 (58f: France); 0682 (58i: Italy); 0685 (58f: Belgium); 0843 (58e: ČSR); 0845 (58e: Slowenia); 0890 (58d: Westfalen); 0963 (58i: Bologna); 1004 (58e: Africa); 1025 (58f: Bucarest); 1139 (58f: France); 1140 (58i: Naples); 1213 (58f: SW-France); 1232 (58d: Germany); 1233 (58d: Germany/Würzburg); 1457 (58d: Germany); 1458 (58d: Germany: social structure); 2259 (58s: Ribeirão Prêto/Brazil); 2262 (58f: France: Vietnam); 2648 (58e: Japan); 2697 (58f: Greece); 2888 (58e: Japan: after birth); 4272 (58e: Ireland); 4282 (58j: Japan); 5374 (58f: Port Gentil/Gabon); 0524 (59e: USA/Montana); 0544 (59f: Dakar); 0870 (59d: Germany); 0962 (59e: upper Amazon basin); 1029 (59e: Nebraska/USA); 1130 (59e: young infants); 1131 (59h: Netherlands); 1225 (59e: young infants); 1226 (59e: Colombia); 1294 (59e: Netherlands); 1317 (59h: Netherlands); 1410 (59d: Wien); 1415 (59f: France); 1426 (59f: France); 1516 (59e); 1624 (59f: Dakar); 1625 (59f: Madagascar); 1933 (59f: France); 2266 (59e: St. Lucia); 2288 (59b: Bucarest); 2302 (59r: Armenian S. S. R.); 2448 (59j: Okayama/Japan); 2451 (59e: Caribbean Islands, British Guiana and Ecuador); 2522 (59s: Cuba); 2577 (59f: France); 2961 (59e: Matsumoto/Japan); 3167 (59e: Netherlands); 3172 (59e: Medellin/Colombia); 3174 (59e: Mexico); 3181 (59e: Costa Rica); 3184 (59e: Montevideo, Uruguay); 3220 (59e: Mexico City); 3231 (59e: Leopoldville/Congo); 3234 (59e: Esthonian and Lithuanian S. S. R.); 4900 (59e: India); 1395 (60e: Washington, D. C.); 1959 (60d: Niedersachsen); 1995 (60e: Congo); 2273 (60d: Germany); 2295 (60b: Roumania); 2357 (60e: Israel); 2383 (60f: Cape Verde Islands); 2388 (60e: Guatemala); 2393 (60e: natural decline in the infant); 2409 (60e: Nicaragua); 2513 (60e: Mexico); 2556 (60e: Guatemala); 2902 (60e); 2924 (60 0: Turkey); 2954 (60e: Alaska); 2955 (60e: Alaska/Bering Sea); 2956 (60e: Philadelphia); 2958 (60b: Roumania); 3021 (60e: Papuans: New Guinea); 3096 (60d: Wien); 3099 (60d: Nieder-Österreich); 3338 (60e: USSR); 3395 (60i); 3429 (60h: Netherlands: Curaçao); 3452 (60b: Roumania); 3464 (60e: Northern Rhodesia); 3477 (60r: USSR); 3971 (60i: Bologna); 3973 (60pl: Poland); 3980 (60s: Valencia); 4072 (60e: Roumania); 4078 (60e: Indonesia); 4114 (60e: Taipei area); 4207 (60e: Serbia 1954); 4405 (60e: Philadelphia); 4874 (60e: ČSR); 4920 (60e: Mexico); 5026 (60e: Southern Africa); 5040 (60e: Sottunga Island/Finland); 5063 (60e: India); 5445 (60e: Serbia); 3334 (61e: USSR); 4245 (61f: Valencia); 4301 (61e: Yonago/Japan); 4638 (61f: SW-France); 4642 (61e: Szeged); 4644 (61e: St. Vincent Island/West Indies); 5151 (61e: Greenland: India: USA); 5315 (61s: Spain).

Booster-Effekt / Booster effect

0003 (31e: monkey); 0738 (36e: reinfection: monkey); 4171 (43e: horse); 2619 (50e: monkeys); 1670 (53e); 1769 (53e); 0069 (54e);

1565 (54e); 2246 (54e: chimpanzees: second homotypic challenge); 4530 (54e: SALK-vaccine); 0024 (55e); 1610 (55e); 1775 (55e); 1776 (55e); 1820 (55e); 2012 (55e); 2103 (55e: hyperreactivity); 1569 (56e); 1879 (56e); 1882 (56e: UV-vaccine); 1892 (56e); 2053 (56e: SALK-vaccine); 2227 (56e: SALK-vaccine); 5423 (56e: SALK-vaccine); 0937 (57e); 1943 (57e: chimpanzees); 2048 (57e); 2067 (57e: reinfection); 2105 (57e: SALK-vaccine); 2139 (57e: SALK-vaccine); 3012 (57e: SALK-vaccine); 0191 (58e: SALK-vaccine); 0588 (58e: SALK-vaccine); 0603 (58e: British vaccine); 0646 (58e: British vaccine); 0652 (58e); 0684 (58e: intradermal or oral administration); 0951 (58f: chicken test); 1236 (58f); 1339 (58d); 1343 (58e); 1935 (58e); 0385 (59e: live vaccine); 0430 (59e); 0597 (59e); 0985 (59e); 0987 (59e); 0989 (59e: multiple antigen); 0996 (59e: 4. injection: SALK-vaccine); 1008 (59e); 1009 (59e); 1022 (59d); 1092 (59e); 1134 (59d); 1170 (59e: 3. dose); 1214 (59e); 1222 (59e: quadruple antigen); 1284 (59e: SALK-vaccine: natural immunity); 1320 (59f); 1330 (59i); 1368 (59e: combined antigens); 1426 (59f); 1940 (59i: pregnancy); 4287 (59i: quadruple vaccine); 5256 (59d: SALK-vaccine: 4. injection); 1346 (60d: SALK-vaccine); 1990 (60e: 4. injection SALK-vaccine); 2486 (60s); 2561 (60f: SALK-vaccine); 2587 (60e: SALK-vaccine: persistence of antibody); 2802 (60f); 2887 (60e: SALK-vaccine); 2902 (60e); 2960 (60e: SALK-vaccine); 4306 (60f); 4882 (60e: SALK-vaccine); 4913 (60e: live vaccine); 2939 (61e); 3988 (61i); 4357 (61f); 4625 (61e: DPTP-vaccine and live vaccine); 4640 (61i).

Diaplazentare Übertragung / Diaplacental transmission

0089 (30e); 3016 (32e); 0032 (48e: cotton rat); 0701 (48e: animal experiments); 1269 (48e); 0774 (49e: mice); 0065 (50e: mice); 2706 (50e: mice: milk); 2817 (51e); 0693 (55e); 1574 (55e: infection of newborn); 3963 (56e); 0530 (57e); 0531 (57e); 0548 (57e: after active vaccination of mother); 0582 (57e); 2074 (57i: newborn: Genua); 2808 (57e); 4273 (57s: SALK-vaccination); 0114 (58f); 0185 (58e: after active vaccination of mother); 0201 (58s: after active vaccination of mother); 0386 (58e: after active vaccination of mother); 0393 (58e: human amniotic fluids); 0647 (58i); 1152 (58d: duration); 1240 (58e: SALK-vaccination); 1248 (58e: interference: SALK-vaccination); 1457 (58d); 2514 (58e); 2888 (58e); 5425 (58e: SALK-vaccine); 0986 (59e: live vaccine); 1225 (59e: SALK-vaccination); 1940 (59i: after vaccination of mother); 3314 (59i); 2393 (60e); 2582 (60d); 2698 (60d); 2937 (60i: SALK-vaccination); 2948 (60e: DPT-Polio vaccine); 3395 (60i: persistence: half life time); 4575 (60e: live vaccination); 4903 (60e: live vaccination); 4911 (60e: live vaccination); 5063 (60e: India); 5347 (60e: twins); 2939 (61e: SALK-vaccination); 3191 (61f: SALK-vaccination); 3483 (61e: SALK-vaccine); 3493 (61e: live vaccination); 4080 (61e: SABIN-vaccine); 4236 (61e: SALK-vaccination); 4357 (61f: SALK-vaccination); 4959 (61f: live vaccine); 4976 (61e: SALK-vaccine); 5059 (61d: COX-vaccination of newborn).

Entstehung / Origin

0737 (31e); 0716 (32e); 0717 (32e); 0795 (32e: maturation?); 0742 (35e: maturation); 0746 (35e); 0817 (35e); 0020 (36e); 0731 (36e); 0753 (36e); 0226 (39e: infection); 1168 (59e).

Globulin / Globuline

1353 (31e); 4015 (43e: horse serum); 0286 (45e); 0434 (46e: β-globuline); 0072 (49e); 3970 (49e); 0132 (51e: monkey: tonsillectomy); 1642 (52e: protection tests); 1986 (52s); 2728 (52e); 2880 (52e); 2892 (52e); 4092 (52e); 2001 (53e); 2816 (53d); 4513 (53i: Italian gamma-globulins); 2535 (54d); 4030 (54i); 4534 (54e); 0111 (55f: tonsils); 0131 (55f: tonsils); 0699 (55e); 1628 (55e); 1804 (55d); 1805 (55f: immunsera from donkey); 0393 (58e: amniotic fluids); 0306 (59u); 1011 (59e); 1221 (59e: inhibitor in horse sera); 4275 (59e: in stools); 2557 (60r); 5347 (60e: twins).

Geographische Verteilung / Geographical distribution

0354 (30e: Atlanta, Georgia); 0456 (31e: Porto Rico); 0807 (32e: China); 2202 (32e: Liberia); 3685 (33e: Liberia); 3599 (35e: Philippines); 0167 (38e: tropical areas); 1835 (40e: USA); 4837 (46e: West African natives); 0036 (47e: USA: Japan); 3004 (48e: Southern Africa); 4419 (48t: ČSR); 5335 (49f: France); 0721 (50e); 2649 (50e: Alaskan Eskimos); 2650 (50e: Baltimore); 0054 (51e: North Alaska); 2230 (51e: Eskimos); 2633 (51e: animal sera: Japan); 2775 (51f: St. Augustin/Canada); 3127 (51e: Japan); 3219 (51e: Bantu: Europeans in South Africa); 3965 (51e); 0120 (52e); 1682 (52e: Cairo: CFT); 2029 (52e: type II); 2040 (52e: Eskimos); 3363 (52e: North Carolina); 4021 (52e); 4448 (52e: Egypt); 4456 (52f: Quebec/Canada); 4480 (52e: Bombay); 0296 (53e: Tahiti); 2002 (53e); 2734 (53f: St. Augustin/Canada); 2965 (53e: during epidemic: Winston-Salem, N. C.); 3030 (53e: San Francisco, Mexico City, Guam); 3126 (53e: North Australia); 3384 (53e: Szeged/Hungary); 4503 (53pl: Poland); 4523 (53i: Italy); 0259 (54e: Eskimos in Canada); 1512 (54i: Italy); 2798 (54e: Georgia); 4034 (54n: Sweden); 4052 (54f: Brazzaville: CFT); 4534 (54e: Great Britain: USA); 4589 (54e: India); 5038 (54f: Belgium); 5259 (54i: Italy); 0497 (55i: Italy); 0693 (55e: underdeveloped areas); 0697 (55e); 1496 (55e: Uruguay); 1518 (55e: NW-Mexico); 1576 (55e: Uruguay); 1579 (55e: Western Australia); 1632 (55e: New Zealand); 1651 (55f: Uruguay); 1765 (55e: Israel); 1821 (55e: Southern Australia); 1836 (55e: Tahiti); 1837 (55e: French Morocco); 1838 (55e: aborigines: Northern Australia); 1840 (55e: Charleston/USA); 2071 (55e: Helsinki); 2224 (55s: under-developed areas); 2253 (55e: Louisiana); 2254 (55e: Michigan); 2597 (55e: Melbourne); 2636 (55f: Uruguay); 2983 (55e: England); 2985 (55f: Italy); 2987 (55f: Belgium); 2988 (55f: Bucarest: type 2); 4056 (55e); 4605 (55f: Belgium); 4611 (55e: sanitation); 4617 (55s: Chile); 5045 (55n: Finland); 5204 (55e: Aaland Islands); 1340 (56e: Hungary); 1657 (56e: French Oceania); 1832 (56e: England); 1844 (56e: Northern Ireland); 1845 (56e: Louisiana); 1870 (56f: Geneva-Switzer-

land); 1885 (56i: Palermo/Italy); 1896 (56f: Belgish Congo); 1902 (56e: Rio de Janeiro); 1906 (56e: Island); 1918 (56e: Germany/type II); 1932 (56e: Turkey); 1965 (56e: Middle America); 2034 (56d: Geneva); 2073 (56e: Australia and New Zealand); 2098 (56e: Liberia); 2106 (56e: New Zealand); 2113 (56e: New Zealand); 2187 (56b: Bucarest); 2443 (56f: Savona/Ligurien); 2479 (56i: Naples); 2482 (56i: Italy: vaccination); 2498 (56s: Brazil); 2553 (56d: Hamburg); 3084 (56e: Sweden); 3134 (56f: Paris); 3969 (56e: Finland); 4767 (56e: Aaland Islands); 4771 (56e: Glasgow); 4772 (56d: Switzerland); 5205 (56e: New Zealand); 5207 (56e: Aaland Islands); 0396 (57e: Andaman Islands); 0531 (57e); 0573 (57f: France); 0578 (57e: Japan); 0582 (57e: Jamaica); 0998 (57f: Centralafrica); 1487 (57f: Tunis); 1524 (57e: Alaska); 1528 (57e: Louisiana); 1530 (57f: Louisiana); 1966 (57d: Northern Germany); 1967 (57e: Scotland); 1969 (57e: Sweden); 1973 (57f: Switzerland); 2046 (57e: Manitoba); 2056 (57d: Switzerland); 2059 (57e: London); 2066 (57e: Louisiana); 2074 (57i: newborn: Genua); 2077 (57e: Nebraska); 2079 (57d: Bayern); 2081 (57e: East Saudi Arabia); 2083 (57i: Sardinian); 2085 (57i: Savona/Italy); 2091 (57i: Italy); 2104 (57e: Cairo: USA); 2116 (57e: North Ireland); 2128 (57e: Israel); 2333 (57d: Bern/Switzerland); 2335 (57e: Charleston and Phoenix/USA); 2428 (57f: Congo); 2484 (57p: South Africa); 2491 (57f: Belgium); 2493 (57n: Sweden); 2507 (57e: Peru and Colombia); 2511 (57e: Japan); 2542 (57d: Niedersachsen/Germany); 2651 (57e: Sweden); 3067 (57e: New Zealand); 4269 (57j: Japan); 4278 (57e: India); 5194 (57d: New Orleans); 5198 (57i: Bologna); 5296 (57f: Leopoldville); 5299 (57e: India); 0202 (58f: Belgish Congo); 0203 (58e: British Guiana); 0230 (58f: France); 0231 (58f: France); 0312 (58d); 0499 (58d: Germany); 0500 (58f: Belgish Congo); 0576 (58i: Italy); 0580 (58d: Switzerland); 0678 (58i: Bologna); 0679 (58e: New Zealand); 0680 (58f: France); 0682 (58i: Italy); 0685 (58f: Belgium); 0843 (58e: CSR); 0845 (58e: Slowenia); 0963 (58i: Bologna); 1003 (58f: Belgish Congo); 1004 (58e: Africa); 1006 (58f: France); 1020 (58e: Maori: Europeans); 1025 (58f: Bucarest); 1139 (58f: France); 1140 (58i: Naples); 1143 (58i: Turin); 1213 (58f: SW-France); 1232 (58d: Germany); 1233 (58d: Germany/Würzburg); 1457 (58d: Germany); 2259 (58s: Ribeirão Prêto/Brazil); 2262 (58f: France: Vietnam); 2648 (58e: Japan); 2697 (58f: Greece); 4272 (58e: Ireland); 4282 (58j: Japan); 5374 (58f: Port Gentil/Gabon); 0524 (59e: USA/Montana); 0544 (59f: Dakar); 0841 (59e: Sudan); 0962 (59e: Amazon basin); 1029 (59e: Nebraska/USA); 1118 (59e: Eskimos); 1217 (59e: Norway); 1226 (59e: Colombia); 1294 (59e: Netherlands); 1317 (59h: Netherlands); 1382 (59f: France); 1383 (59f: Paris); 1410 (59d: Wien); 1415 (59f: France); 1516 (59e); 1622 (59f: Paris); 1624 (59f: Dakar); 1625 (59f: Madagascar); 1933 (59f: France); 1958 (59e: Hungary); 2266 (59e: St. Lucia); 2288 (59b: Bucarest); 2302 (59r: Armenian S. S. R.); 2415 (59n: Norway); 2448 (59j: Okayama/Japan); 2451 (59e: Caribbean Islands, British Guiana and Ecuador); 2522 (59s: Cuba); 2577 (59f: France); 2764 (59i: Italy); 2961 (59e: Matsumoto/Japan); 3060 (59i: Italy); 3167 (59e: Netherlands); 3172 (59e: Medellin/Colombia); 3174 (59e: Mexico); 3181 (59e: Costa Rica); 3184 (59e: Montevideo/Uruguay); 3220 (59e: Mexico City); 3231 (59e: Leopoldville/Congo);

3234 (59e: Esthonian and Lithuanian S. S. R.); 1959 (60d: Niedersachsen); 1995 (60e: Congo); 2273 (60d: Germany); 2295 (60b: Roumania); 2357 (60e: Israel); 2383 (60f: Cape Verde Islands); 2388 (60e: Guatemala); 2392 (60e: after SALK-vaccine); 2409 (60e: Nicaragua); 2513 (60e: Mexico); 2556 (60e: Guatemala); 2557 (60r: USSR); 2783 (60i: Messina); 2907 (60f: Paris); 2924 (60 o: Turkey); 2954 (60e: Alaska); 2955 (60e: Alaska/Bering Sea); 2958 (60b: Roumania); 2973 (60e: New Haven/Conn.); 3021 (60e: Papuans: New Guinea); 3096 (60d: Wien); 3099 (60d: Nieder-Oesterreich); 3316 (60r: USSR); 3338 (60e: USSR); 3429 (60h: Netherlands: Curaçao); 3452 (60b: Roumania); 3464 (60e: Northern Rhodesia); 3477 (60r: USSR); 3971 (60i: Bologna); 3973 (60pl: Poland); 3980 (60s: Valencia); 4072 (60e: Roumania); 4078 (60e: Indonesia); 4114 (60e: Taipei area); 4138 (60f: Congo: wild monkey); 4207 (60e: Serbia 1954); 4405 (60e: Philadelphia); 4874 (60e: ČSR); 4920 (60e: Mexico); 5026 (60e: Southern Africa); 5040 (60e: Sottunga Island/Finland); 5063 (60e: India); 5445 (60e: Serbia); 3334 (61e: USSR); 4198 (61e: Andaman Islands); 4245 (61f: Valencia); 4301 (61e: Yonago/Japan); 4381 (61d: Koeln/Germany); 4638 (61f: SW-France); 4642 (61e: Szeged); 4643 (61e: Newfoundland); 4644 (61e: St. Vincent Island, West Indies); 5123 (61e: Finland); 5151 (61e: Greenland: India: USA); 5315 (61s: Spain); 5494 (61s: Rosario/Argentine).

Haltbarkeit des Titers / Duration of titres

0723 (35e); 0725 (35e); 0751 (35e: KOLMER-vaccine); 0077 (36e: BRODIE-vaccine); 0078 (36e: KOLMER-vaccine); 0029 (50e: chimpanzees); 2619 (50e: monkeys); 3375 (50e: in vitro storage at 4° C); 3457 (51e); in horse); 1680 (52e: CFT); 1692 (52e: heterotypic antibodies); 1693 (52e: homotypic neutralizing antibody); 3367 (52e: monkey); 0069 (54e: inactivated vaccine); 1847 (54e: after infection); 2246 (54e: chimpanzees); 3964 (54e: live vaccination); 0698 (55e: live vaccination); 1610 (55e: SALK-vaccine); 1807 (55e); 1848 (55e: CFT after infection); 0673 (56e: live vaccine); 1927 (56e); 2053 (56e: SALK-vaccine); 2097 (56e: after live vaccine); 0548 (57e: maternal antibodies in newborns); 0605 (57e); 0859 (57e: after infection); 0937 (57e: SALK-vaccine); 2048 (57e: SALK-vaccine); 2105 (57e: SALK-vaccine); 0185 (58e: maternal antibodies in newborns); 0357 (58e: one year after vaccination); 0554 (58f); 0588 (58e: SALK-vaccine); 0603 (58e); 0610 (58e); 0653 (58f: SALK-vaccine); 1240 (58e: SALK-vaccine); 1343 (58e: SALK-vaccine); 0597 (59e: SALK-vaccine); 0840 (59e: after vaccination); 0965 (59e: SALK-vaccine); 0985 (59e: uv-inactivated vaccine); 0986 (59e: live vaccine); 0987 (59e: SALK-vaccine); 0989 (59e: multiple antigen); 0996 (59e: SALK-vaccine); 3213 (59e: CHAT-strain-vaccination); 1990 (60e: SALK-vaccine); 2375 (60d: SALK-vaccine); 2393 (60e: maternal antibody in infant); 2587 (60e: after third dose of SALK-vaccine); 2791 (60e: four years after field trial: SALK-vaccine); 2951 (60d: SALK-vaccine); 2960 (60e: SALK-vaccine); 3066(60e: SALK-vaccine); 3456 (60e: SALK-vaccine); 4575 (60e: live vaccine); 4882 (60e: SALK-vaccine); 4885 (60e: SALK-vaccine); 4911 (60e: live vaccine); 4989 (60e: SABIN-strain type 3); 4998 (60e: live vaccine: full-term infants); 2953 (61e: SALK-

vaccine); 3988 (61i: SALK-vaccine: Pisa); 4194 (61f: SALK-vaccine: Denmark); 4650 (61e: KOPROWSKI-vaccine); 5255 (61e: live vaccine); 5486 (61i: SABIN-vaccine).

Immunität und Antikörper / Immunity and antibodies

0103 (11e); 3018 (22f); 0141 (27e); 0089 (30e); 0288 (30e); 0304 (30e); 0340 (30e); 0459 (30e); 0007 (31e); 0455 (31e); 0456 (31e); 3008 (31e); 0716 (32e); 0717 (32e); 0727 (33e); 0751 (35e); 0817 (35e); 1023 (35e); 2272 (35e); 0020 (36e); 0085 (36e); 0463 (36e); 0471 (36e); 0731 (36e); 0738 (36e); 0753 (36e); 0830 (36e); 0879 (36e); 0883 (36e); 0912 (36e); 0932 (36e); 3420 (36e); 0482 (37e); 0872 (37e); 3585 (37e); 4797 (37e); 0337 (38e: second attacks); 3322 (38e); 3580 (38e); 4802 (38f); 0226 (39e); 2669 (39e); 0327 (40e); 3627 (40f); 2065 (41e); 3602 (41e); 4107 (41e); 0624 (42e); 2711 (42e); 0138 (43e); 0121 (45e); 0042 (47e: monkeys); 0043 (47e: monkeys); 0372 (47e); 0884 (47e); 1064 (47e); 1269 (48e); 0021 (49e); 0334 (49e); 4222 (49e); 4368 (49e); 0029 (50e: chimpanzees); 0195 (50e); 2222 (50i); 2650 (50e); 2739 (50e); 2863 (50e); 3397 (50e); 0044 (51e: second attacks); 1580 (51e); 1685 (51e); 2628 (51f); 0120 (52e); 2880 (52e); 2882 (52e); 2892 (52e); 0009 (53e); 0297 (53e); 1740 (53e); 1769 (53e); 2899 (53d); 0069 (54e); 1467 (54e); 1683 (54e); 1825 (54i); 2246 (54e); 2247 (54e); 2459 (54e); 0697 (55e); 0698 (55e); 1575 (55e); 1610 (55e); 1647 (55e); 1766 (55d); 1775 (55e); 1894 (55e); 2103 (55e); 2153 (55e); 2157 (55e;) 2239 (55s); 2240 (55s); 2256 (55e); 2537 (55d); 2539 (55d); 1819 (56d); 1844 (56e); 1927 (56e); 2053 (56e); 2061 (56e); 2180 (56e); 2330 (56f); 2425 (56d); 3101 (56e); 4759 (56f); 0310 (57d); 0943 (57e); 2051 (57f); 2058 (57e); 2067 (57e); 2319 (57e); 2335 (57e); 2336 (57e); 2651 (57e); 2741 (57e); 3015 (57e); 3377 (57e); 3380 (57e); 0161 (58e: type 1 epidemic); 0187 (58e); 0191 (58e); 0230 (58f); 0390 (58d); 0499 (58d: specifity); 0507 (58d); 0554 (58f); 0580 (58d); 0588 (58e); 0627 (58d); 0650 (58e); 0843 (58e); 0844 (58e); 1339 (58d); 1540 (58e); 2126 (58d); 2320 (58e); 2434 (58f); 0431 (59e); 0461 (59d: CFT); 0840 (59e); 0866 (59e); 0991 (59e); 1121 (59f); 1165 (59e); 1285 (59e); 2132 (59e); 2133 (59e); 2291 (59e); 3205 (59e); 3220 (59e); 3227 (59e); 5403 (59d); 1346 (60d); 2396 (60e); 2401 (60d); 2778 (60r); 2944 (60e); 2957 (60d); 4995 (60e); 4998 (60e); 5001 (60e); 3493 (61e); 3499 (61e); 3989 (61d); 4080 (61e); 4632 (61e: live vaccination); 4637 (61d); 4959 (61f); 4991 (61pl); 4992 (61pl).

Nach Impfung / After vaccination

0106 (10e: monkeys); 1380 (10d); 0374 (16e: monkeys); 0260 (17e: horse antisera: pleomorphic streptococcus); 0590 (18e: monkeys: heat-inactivated vaccine); 0888 (24e: monkeys); 0141 (27e: monkeys); 0887 (29e: monkeys); 0142 (30e: rabbit); 0831 (30e: monkeys: adsorbed vaccine); 1079 (30e: monkeys: intradermal); 0004 (31e: monkeys: aluminumhydroxide-vaccine); 0007 (31e: monkeys); 0198 (32e: antisera: goats and sheep); 0791 (32e); 0146 (33e: monkeys: virus and serum); 0145 (34e: monkeys: virus and serum); 2855 (34e: BRODIE-

vaccine); 3005 (34e: KOLMER-vaccine); 0703 (35e: KOLMER-vaccine: skin reactions); 0704 (35e: KOLMER-vaccine: colloidal gold-, CF and precipitation tests); 0723 (35e: BRODIE-vaccine); 0724 (35e: KOLMER-vaccine); 0725 (35e: KOLMER-vaccine); 0751 (35e: KOLMER-vaccine); 0768 (35e: BRODIE-vaccine); 0818 (35e: BRODIE-vaccine); 0913 (35e: BRODIE-vaccine); 1085 (35e: sheep); 3526 (35e: BRODIE-vaccine); 3594 (35e: BRODIE-vaccine); 3896 (35f: KOLMER-vaccine); 4318 (35d: KOLMER-vaccine); 4719 (35e: formaldehyd-inactivated vaccine); 0017 (36e: monkey and children: formalized virus); 0020 (36e); 0077 (36e: BRODIE-vaccine); 0078 (36e: KOLMER-vaccine); 0427 (36e: BRODIE- and KOLMER-vaccine); 0471 (36e: monkeys); 0731 (36e); 0932 (36e: monkeys); 4776 (36f: KOLMER-vaccine: monkey); 0482 (37e: monkeys: nasal and humoral substances); 4797 (37e); 2745 (38e: monkey: intranasal immunization); 5271 (44e: UV-vaccine: mice); 0042 (47e: monkeys: intracerebral immunity); 0043 (47e: monkeys: distribution of antibody); 0891 (47e: man and animals); 0032 (48e: cotton rat); 0021 (49e: monkeys); 4368 (49e: monkey: distribution of antibody); 0029 (50e: chimpanzees); 0034 (50e: monkeys: injected with virus and adjuvants); 0065 (50e: mice: passive transfer to young mice); 1531 (50e: monkey: faeces); 4416 (51s: LANSING antibody: rabies vaccination); 0173 (52e: chimpanzees: passive immunization); 1645 (52e: passive immunization with gammaglobuline); 2030 (52e); 2918 (52e: live vaccine); 1670 (53e); 1740 (53e); 1769 (53e); 2631 (53e: TN-strain: KOPROWSKI); 3136 (53e: SALK-vaccine); 3962 (53e: SALK-vaccine); 0069 (54e: SALK-vaccine); 1464 (54e: CFT); 1561 (54e); 1565 (54e); 1755 (54e: UV-vaccine); 2246 (54e: chimpanzees); 2459 (54e: SALK-vaccine); 2724 (54e: live vaccine); 2893 (54e); 3028 (54e: monkey: standard-antiserum); 3037 (54e); 3964 (54e: persistence of antibodies after live vaccination); 4530 (54e: SALK-vaccine); 4585 (54e: live vaccine: chimpanzees); 0024 (55e: children: SALK-vaccine); 0697 (55e); 0698 (55e: live vaccine); 0839 (55e: Denmark 1955); 1552 (55e: SALK-vaccine: Rh sensitivity); 1610 (55e); 1766 (55d: German vaccine); 1768 (55d); 1771 (55e); 1773 (55d: Behringwerk-vaccine); 1775 (55e); 1776 (55e); 1778 (55e: live vaccine); 1793 (55d); 1807 (55e: FRANCIS-report); 1810 (55e: heat- and uv-inactivated antigen); 1814 (55e: live vaccine); 1820 (55e: booster effect); 1868 (55i: adjuvants); 1876 (55e: CFT: neutralization); 1881 (55e: live vaccine); 1905 (55f: monkey: Central Africa); 1908 (55d); 1924 (55e: live vaccine); 2082 (55e: Swedish vaccine); 2103 (55e); 2239 (55s); 2240 (55s: live vaccine); 2257 (55e: live vaccine); 2475 (55e); 2600 (55e); 2813 (55d: Behringwerk-vaccine); 2981 (55e); 2982 (55e: SALK-vaccine: Denmark); 2984 (55e: Behringwerk-vaccine); 4038 (55e: SALK-vaccine); 4588 (55e: SALK-vaccine); 0673 (56e: live vaccine); 1465 (56i: Behringwerk-vaccine); 1521 (56e: South Africa vaccine); 1527 (56i); 1569 (56e); 1667 (56e); 1824 (56d); 1851 (56e: type I-vaccine); 1879 (56e); 1882 (56e: UV-vaccine); 1892 (56e: simultaneous vaccination); 1910 (56d: unspecific anamnestic serumreaction); 1913 (56d: German vaccine); 1927 (56e); 1954 (56e: live vaccine); 1965 (56e); 1979 (56e: live vaccine: young infants); 1996 (56d); 2033 (56d); 2047 (56e: live vaccine); 2053 (56e: SALK-vaccine: dose); 2097 (56e: live vaccine); 2109 (56e: electrophoresis); 2175 (56e: live vaccine: type specifity); 2180 (56e: live vaccine); 2227 (56e); 2306

(56d); 2307 (56d: monkeys: cortisone); 2442 (56d); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 3101 (56e: SALK vaccine); 4025 (56e: SALK-vaccine); 5243 (56f: SALK-vaccine: young infants); 5448 (56d: monkey: perivenoese encephalomyelitis); 0387 (57e: live vaccine); 0531 (57e); 0548 (57e: maternal antibodies in newborns); 0605 (57e: young infants); 0634 (57i: rabbit: treatment of spleen with ultrasound); 0763 (57e: formalin and uv-irradiation); 0857 (57e); 0937 (57e: SALK-vaccine); 0940 (57e: live vaccine); 0945 (57e: SALK-vaccine); 0947 (57e: SALK-vaccine: CFT and neutralization); 0972 (57e: antigenicity); 1513 (57d: Switzerland); 1528 (57e); 1943 (57e: chimpanzees); 1945 (57e); 1964 (57e: live vaccine); 1972 (57e: British vaccine); 2048 (57e); 2058 (57e); 2094 (57e: delayed second inoculation: SALK-vaccine); 2105 (57e); 2124 (57f: Belgium); 2139 (57e); 2304 (57e: live vaccine: SM type I); 2305 (57e: live vaccine: SM type I and TN type II); 2319 (57e); 2321 (57f); 2333 (57d: Bern/Switzerland); 2431 (57d: Switzerland); 2487 (57e: British vaccine); 2493 (57e: Sweden: SALK-vaccine); 2741 (57e: live vaccine); 2808 (57e: SALK-vaccine: pregnant women); 3012 (57e: SALK-vaccine); 3013 (57e: SALK-vaccine); 3014 (57e: SABIN-vaccine); 3015 (57e); 3163 (57e: FRANCIS-report); 3368 (57e: live vaccine); 3380 (57e: naturally acquired antibody); 4266 (57i); 4273 (57s: pregnant women); 0185 (58e: pregnancy); 0191 (58e: SALK-vaccine); 0201 (58s: live vaccine: neonatal period and early infancy); 0227 (58e: SALK-vaccine); 0228 (58e: SALK-vaccine); 0229 (58f: French vaccine); 0232 (58f: French vaccine); 0244 (58d: Germany); 0246 (58d: SALK-vaccine: live vaccine); 0357 (58e: live vaccine); 0384 (58e); 0386 (58e: pregnant women: young infants); 0389 (58e: CFT); 0390 (58d); 0393 (58e: amniotic fluids); 0394 (58e); 0507 (58d: SALK-vaccine); 0508 (58d: SALK-vaccine: neutralization and CFT); 0521 (58e: young infants: live vaccine); 0537 (58e: live vaccine); 0553 (58s: SALK-vaccine: Mexico); 0554 (58f); 0579 (58d: SALK-vaccine); 0588 (58e: SALK-vaccine); 0589 (58d: SALK-vaccine); 0603 (58e: British vaccine); 0604 (58e: British vaccine); 0610 (58e); 0619 (58e: children: multiple antigen); 0631 (58e: guinea pigs); 0635 (58e: CFT); 0638 (58h: live vaccine); 0646 (58e); 0651 (58e); 0652 (58e); 0653 (58f); 0654 (58e: British SALK-vaccine); 0660 (58f: Italian vaccine); 0684 (58e); 0686 (58s: live vaccine); 0691 (58e); 0844 (58e: ČSR 1957); 0850 (58e: SALK-vaccine: potency); 0860 (58d: Switzerland 1957); 0890 (58d: Westfalen); 0951 (58f: chicken test); 0959 (58e: animal experiments: CFT); 0990 (58f: Belgish SALK-vaccine); 1031 (58d: adsorbens); 1127 (58f); 1143 (58i); 1148 (58f: LEPINE-vaccine); 1172 (58e: multiple antigen); 1238 (58i); 1240 (58e: SALK-vaccine); 1248 (58e: early infancy); 1339 (58d); 1343 (58e: SALK-vaccine); 1519 (58e: multiple antigen); 1540 (58e); 1584 (58e); 1935 (58e: UV-formalin-vaccine); 2126 (58d: pathogenesis); 2322 (58e: jet injection); 2928 (58i); 3383 (58e); 4271 (58d: SALK-vaccine); 4288 (58i: SALK-vaccine); 5420 (58e: SALK-vaccine); 5424 (58n: intracutaneous: subcutaneous injection); 5425 (58e: infants: combined antigens); 0035 (59e: agamma globulinemia); 0186 (59d: potency-test); 0258 (59e: live vaccine); 0361 (59e: SALK-vaccine: infants); 0385 (59e: live vaccine); 0430 (59e: booster-dose); 0490 (59d: SALK-vaccine); 0568 (59e: type I); 0569 (59e: type I); 0572 (59e); 0597 (59e: SALK-vaccine); 0600 (59e:

multiple antigen); 0840 (59e: live vaccine); 0853 (59e); 0866 (59e: monkey: virus excretion); 0905 (59e: rapid immunization with one dose); 0965 (59e: persistence); 0976 (59e: live vaccine); 0985 (59e: uv-inactivated vaccine); 0986 (59e: live vaccine); 0987 (59e: SALK-vaccine); 0989 (59e: multiple antigen); 0991 (59e: live vaccine); 0992 (59e: live vaccine); 0996 (59e: SALK-vaccine: 4. dose); 1007 (59t: CSR: intracutaneous); 1008 (59e: booster-dose); 1009 (59e: booster-dose); 1087 (59e: live vaccine); 1092 (59e: SALK-vaccine); 1121 (59f: French SALK-vaccine); 1123 (59i: multiple antigens: animal experiments); 1130 (59e: SALK-vaccine: 6- and 9-months old infants); 1134 (59d: adsorbed vaccine); 1163 (59e: live vaccine); 1164 (59e: live vaccine); 1165 (59e: live vaccine); 1168 (59e: children under age of six months); 1169 (59f); 1170 (59e); 1199 (59e: live vaccine); 1202 (59e: live vaccine); 1205 (59e: trivalent live vaccine); 1214 (59e: SALK-vaccine: different ages); 1216 (59e: intradermal SALK-vaccine: Norway); 1222 (59e: quadruple antigen); 1223 (59d: multiple antigens); 1225 (59e: live vaccine: newborns); 1226 (59e: live vaccine); 1278 (59e: live vaccine: early infancy); 1284 (59e); 1292 (59d); 1313 (59e: COX-vaccine); 1314 (59r: live vaccine); 1318 (59d: multiple antigen); 1324 (59i: St. Gallen); 1330 (59i: SALK-vaccine); 1344 (59f: live vaccine); 1350 (59f: live vaccine); 1368 (59e: multiple antigen); 1369 (59e: flocculation test); 1370 (59t: SALK-: SABIN-vaccination); 1371 (59i: intradermal vaccination); 1381 (59f); 1382 (59f); 1383 (59f: Paris); 1414 (59f); 1415 (59f); 1426 (59f); 1431 (59e: live vaccine); 1621 (59e: multiple antigen); 1658 (59i); 1843 (59e: in cell cultures); 1940 (59i: pregnancy); 1988 (59i: after Di-vaccination); 2132 (59e: SALK-: live vaccine); 2133 (59e: live vaccine); 2269 (59i: cutaneous reaction); 2292 (59s: Andes/Colombia: live vaccine); 2293 (59s: Managua/Nicaragua: live vaccine); 2414 (59e: CFT: neutralization); 2415 (59n: SALK-vaccine); 2522 (59s: Cuba); 2562 (59d: combined vaccine); 2905 (59r: cortisone); 2930 (59i: DPT-Polio); 3082 (59e: live vaccine); 3158 (59e: COX-vaccine); 3159 (59e: pregnant women: COX-vaccine); 3164 (59e: resistance to infection and duration of excretion); 3167 (59e: SABIN-vaccine: Netherlands); 3172 (59e: Medellin/Colombia); 3174 (59e: SABIN-vaccine: Mexico); 3177 (59e: CHAT-strain: Poland); 3182 (59e: COX-vaccine: Finland); 3205 (59e: live vaccine); 3213 (59e: CHAT-strain); 3218 (59e: COX-vaccine: infants under six months); 3220 (59e: SABIN-vaccine); 3223 (59e: SABIN-vaccine); 3227 (59e: SABIN type 3); 3231 (59e: CHAT-strain: Leopoldville/Congo); 3234 (59e: SABIN-vaccine: USSR); 3235 (59e: SABIN-vaccine: CSR); 4274 (59f); 4276 (59e: increased amounts of SALK-vaccine); 4284 (59e: quadruple antigen); 4287 (59i: quadruple antigen); 4289 (59e: SALK-vaccine); 5376 (59i: cutaneous reactivity); 5467 (59d: SALK-vaccine); 1346 (60d: SALK-vaccine); 1352 (60d: SALK-vaccine); 1362 (60e: live vaccination); 1367 (60d: live vaccination); 1377 (60d); 1397 (60d: quadruple antigen); 1433 (60e: live vaccine); 1959 (60d); 1989 (60e: Cynomolgus-monkey); 1990 (60e: 4. injection: SALK-vaccine); 1991 (60e: CHAT-strain); 1995 (60e: Congo: CHAT-strain); 2308 (60d: monkeys: adsorbed vaccines); 2316 (60f: neutralization: immuno-inactivation [GARD]); 2350 (60d: combined vaccines); 2352 (60e: concentrated SALK-vaccine); 2353 (60e: live vaccine); 2357 (60e: Israel); 2358

(60e: trivalent live vaccine); 2359 (60e: live vaccine); 2375 (60d: SALK-vaccine); 2392 (60e; SALK-vaccine); 2394 (60d: combined vaccine); 2401 (60d: attenuated type I [CHAT-strain]); 2409 (60e: live vaccine); 2439 (60e: SALK-vaccine: increased amounts); 2486 (60s: live vaccine); 2513 (60e: live vaccine: interference); 2558 (60e); 2559 (60e: live vaccine); 2560 (60s: live vaccine: Central America); 2561 (60f: SALK-vaccine); 2565 (60i: SABIN's live vaccine); 2569 (60f: micro-flocculation-test); 2571 (60e: SABIN type III); 2572 (60e: Cox-vaccine); 2586 (60e: Cox-vaccine); 2587 (60e: persistence of antibody after 3 dose of SALK-vaccine); 2591 (60e: combined vaccine); 2592 (60e: Cox-vaccine: Florida); 2700 (60i: SALK-vaccine); 2774 (60i: SALK-vaccine: CFT); 2788 (60e: CHAT-strain); 2791 (60e: four years after field trial: SALK-vaccine); 2792 (60pl: CHAT-strain: Poland); 2802 (60f: SALK-vaccine); 2869 (60e: Compligen); 2887 (60e: SALK-vaccine); 2902 (60e: SALK-vaccine); 2903 (60e: early life: live vaccine); 2907 (60f); 2927 (60i: intradermic reaction); 2934 (60i: DPT-Polio); 2937 (60i: SALK-vaccine); 2940 (60i: DPT-Polio); 2943 (60f: DPT-Polio); 2948 (60e: DPT-Polio); 2951 (60d: Canada: SALK-vaccine); 2955 (60e: Alaska/Bering Sea); 2956 (60e: live vaccine); 2960 (60e: SALK-vaccine); 2973 (60e: New Haven/Conn.); 2977 (60e: Czechoslovakia: SABIN-vaccine); 3050 (60f: SALK-vaccine); 3058 (60i: SALK-vaccine); 3066 (60e: SALK-vaccine); 3088 (60f: combined vaccine); 3099 (60d: SALK-vaccine); 3196 (60e: SALK-vaccine: newborns); 3198 (60f: ČSR); 3239 (60f: combined vaccination); 3248 (60e: Cox-vaccine); 3319 (60t: combined vaccine); 3328 (60i: SALK-vaccine: flocculation); 3331 (60he: SALK-vaccine: Israel); 3338 (60e: live vaccine: USSR); 3343 (60e: trivalent Cox-vaccine); 3391 (60e: ČSR); 3393 (60i: SALK-vaccine); 3394 (60i); 3450 (60e: ČSR: SALK- and SABIN-vaccine); 3451 (60i: Cox-vaccine); 3452 (60b: Roumania: SALK-vaccine); 3453 (60r: Pertussis-Polio-vaccine); 3456 (60e: SALK-vaccine); 3480 (60r: trivalent live vaccine); 3984 (60f: trivalent Cox-vaccine); 3985 (60e: SABIN-vaccine: newborn infants); 3999 (60d); 4121 (60e: SABIN-vaccine); 4189 (60i: SALK-vaccine: tuberculosis); 4197 (60s: Cox-vaccine: Cuba); 4253 (60r: Riga); 4258 (60r: live vaccine); 4306 (60f: inapparent infections); 4332 (60e: SALK-vaccine); 4405 (60e: CHAT-strain: Philadelphia); 4570 (60e: live vaccine); 4575 (60e: KOPROWSKI-vaccine); 4578 (60d: live vaccine and DPT-Adsorbat); 4734 (60f: SABIN-vaccine: Mexico); 4874 (60e: SALK-vaccine: ČSR); 4877 (60e: SALK-vaccine: Israel); 4881 (60i: SALK-vaccine: Italy); 4882 (60e: SALK-vaccine: duration); 4885 (60e: SALK-vaccine: duration); 4887 (60e: SALK-vaccine: standardization); 4889 (60e: DPT-Polio-vaccine); 4893 (60e: live vaccine: USSR); 4908 (60e: trivalent live vaccine); 4911 (60e: live vaccine); 4913 (60e: live vaccine); 4916 (60e: live vaccine: dosage); 4920 (60e: SABIN-vaccine: Mexico); 4922 (60e: live vaccine); 4925 (60e: live vaccine: virus excretion); 4927 (60e: live vaccine: virus excretion); 4964 (60r); 4965 (60e: Cox-vaccine: Costa Rica); 4974 (60e: live vaccine: Southern Louisiana); 4984 (60e: live vaccine: Japan); 4985 (60e: Cox-vaccine: pregnant women and young infants); 4989 (60e: SABIN-strain type 3); 4990 (60e: trivalent SABIN-vaccine); 4994 (60e: Cox-vaccine: Israel); 4995 (60e: CHAT-strain: premature neonatals infants); 4998 (60e: live vaccine: fullterm infants); 5001 (60e: live vaccine: newborn infants);

5006 (60e: Cox-vaccine); 5032 (60e: ČSR); 5036 (60e: KOPROWSKI-vaccine: Poland); 5040 (60e: Cox-vaccine: Finland); 5043 (60e: live vaccine: Nicaragua); 5295 (60e: live vaccine); 5298 (60e: live vaccine); 5009 (50e: trivalent live vaccine); 5011 (60e: Cox-vaccine: Minnesota); 5014 (60e: live vaccine: Cuba); 5018 (60e: SABIN-vaccine: Mexico); 5021 (60e: SABIN-vaccine: USSR); 2771 (61d: Trivirelon); 2786 (61d: Cox-vaccine: Berlin); 2787 (61s: live vaccine: Philadelphia); 2883 (61d: Cox-vaccine: Switzerland); 2890 (61b: SABIN-vaccine); 2929 (61u: live vaccine: DPT); 2939 (61e: SALK-vaccine: early infancy); 2953 (61e: SALK-vaccine: persistence); 3019 (61d: Cox-vaccine: Berlin); 3020 (61d: Quatro-virelon); 3191 (61f: SALK-vaccine: pregnancy); 3303 (61d: Cox-vaccine: West Berlin 1960); 3305 (61d: CHAT-strain: Switzerland); 3334 (61e: live vaccine: USSR); 3341 (61d); 3355 (61e: N-Ireland); 3390 (61e: live vaccine); 3483 (61e: triple antigen: neonatal immunization); 3485 (61e: microprecipitin test); 3493 (61e: live vaccine: young infants); 3498 (61e: flocculating and nonflocculating); 3988 (61i: duration of antibody response: SALK-vaccine); 3989 (61d: SALK- and SABIN-vaccine); 4080 (61e: SABIN-vaccine); 4112 (61b: ČSR: SABIN-vaccine); 4116 (61d: SABIN-vaccine); 4117 (61e: SABIN-vaccine); 4127 (61d: trivalent Cox-vaccine: Berlin 1960); 4179 (61d: Cox-vaccine: Berlin 1960); 4180 (61d: SABIN-vaccine); 4183 (61d: SALK-vaccine); 4193 (61d: live vaccine: newborn and young infants); 4194 (61f: SALK-vaccine: duration: Denmark); 4203 (61e: SALK-vaccine: Massachusetts); 4204 (61e: purified SALK-vaccine); 4225 (61f: SALK-vaccine); 4227 (61f: trivalent Cox-vaccine); 4233 (61d: SABIN-vaccine); 4236 (61e: SALK-vaccine: young infants); 4241 (61h: combined vaccine DPTP); 4252 (61e: live vaccine); 4257 (61e: SALK-vaccination: prevalence of virus in pharyngeal secretions); 4303 (61e: newborns: trivalent live vaccine); 4322 (61e: SABIN-vaccine: adults in Britain); 4345 (61s: Cox-vaccine: Uruguay); 4357 (61f: SALK-vaccine: young infants); 4359 (61d: live vaccine: Germany); 4362 (61e: ČSR); 4625 (61e: DPTP-vaccine: live vaccine); 4629 (61e: spread of Cox-vaccine); 4640 (61e: SALK-vaccine); 4649 (61e: live vaccine and DPT-vaccine); 4650 (61e: KOPROWSKI-vaccine: Switzerland); 4651 (61e: SABIN-vaccine: ČSR); 4652 (61e: SABIN-vaccine: newborn infants); 4653 (61s: Cox-vaccine: Florida); 4654 (61s: Costa Rica); 4660 (61e: SABIN-vaccine: Cincinnati); 4661 (61i: Rome); 4662 (61e: CHAT-strain: Congo); 4711 (61o: live vaccine); 4731 (61r: live vaccine and DPT); 4736 (61e; trivalent Cox-vaccine); 4740 (61d: trivalent Cox-vaccine: Berlin); 4742 (61d: SABIN-vaccine: Germany); 4744 (61d: SABIN-vaccine: Germany); 4748 (61d: Cox-vaccine: Berlin); 4856 (61e: ČSR: SALK-vaccine); 4858 (61d: SABIN-vaccine); 4859 (61u: DPT- and live vaccine); 4894 (61i: Di-toxoid and SALK-vaccine); 4902 (61e: SALK-vaccine: cutaneous reaction); 4968 (61e: live vaccine: Poland); 4976 (61e: live vaccine: neonates); 4987 (61f: Cox-vaccine); 4988 (61f: Cox-vaccine); 4993 (61pl: KOPROWSKI-vaccine: Poland); 5059 (61d: Cox-vaccine: newborn); 5123 (61e: SALK-vaccine: Finland); 5145 (61d: combined antigens); 5175 (61e: SALK-vaccine: Taiwan); 5253 (61d: SABIN-vaccine); 5255 (61e: live vaccine: duration); 5258 (61e: live vaccine: newborn); 5277 (61e: SABIN-vaccine: Hungary); 5314 (61e: Cox-vaccine: Switzerland); 5351 (61d: Trivirelon); 5372 (61e:

Cox-vaccine); 5451 (61r: SABIN-vaccine: newborn); 5482 (61pl: KOPROWSKI-vaccine: Poland); 5484 (61e: live vaccine: interference); 5485 (61i: live vaccine: heterotypic reaction); 5486 (61i: live vaccine: heterotypic reaction); 5487 (61i: SABIN-vaccine: revaccination); 5020 (62d: Cox-vaccine: Berlin 1960: specifity).

Nach natürlicher Exposition / After natural exposure

1058 (08e); 0100 (10f: abortive cases); 0104 (10d: monkeys); 0106 (10e); 3572 (10f); 3574 (10e: abortive cases); 0090 (11e: abortive cases); 0103 (11e: abortive cases); 1019 (11d); 1057 (11d); 0613 (12e); 1548 (12d: monkeys); 4395 (12e); 4871 (12d); 0324 (13f); 0443 (13e); 4387 (13f); 4921 (13f); 1045 (14e); 4929 (14d); 0402 (15f); 0374 (16e); 2142 (16e); 0364 (18e: opsonic action); 0134 (19e: monkeys); 3584 (19e: opsonins for streptococcus); 4933 (19e: streptococcal agglutinins); 3581 (21e: epidemic encephalitis); 1041 (29e); 1071 (29e: convalescent-serum therapy); 1095 (29e: convalescent-serum therapy); 0288 (30e); 0304 (30e); 0340 (30e); 0341 (30e); 0354 (30e: subtropical areas); 0459 (30e); 2038 (30e); 4525 (30d); 0381 (31e); 0448 (31e); 0455 (31e: abortive cases); 0456 (31e: Porto Rico); 0737 (31e); 0739 (31e: serum therapy); 3008 (31e); 0028 (32e); 0143 (32e); 0702 (32e: blood groups); 0716 (32e); 0717 (32e); 0793 (32e: serum therapy); 0795 (32e); 0807 (32e: Chinese of Peiping); 0819 (32e: streptococcus); 0882 (32e: serum therapy); 1200 (32e); 2202 (32e: Liberia); 4682 (32d); 4686 (32e: coli-agglutinins); 0380 (33e: abortive cases); 0726 (33e: blood groups); 0727 (33e: menstruation and pregnancy); 0881 (33e); 0900 (33e: Tennessee); 0955 (33e); 3561 (33e: louping ill); 3570 (33f); 3573 (33e: abortive cases); 3681 (33f: spinal fluid); 3685 (33e: Liberia); 0153 (34e); 0735 (34e); 0741 (34e: monkeys); 3564 (34e: agglutinin titer for enteric organisms); 3679 (34f: spinal fluid); 0382 (35e); 0704 (35e: colloidal gold-, CFT- and precipitation tests); 0723 (35e); 0746 (35e); 0756 (35e: purification: neutralizing fraction); 0814 (35e); 0817 (35e); 0820 (35e: pregnancy); 2744 (35e: monkey); 3599 (35e: Philippines); 4775 (35n); 5132 (35e: tears, saliva and cerebrospinal fluid); 0020 (36e); 0427 (36e); 0463 (36e); 0468 (36e); 0731 (36e); 0738 (36e: monkeys: reinfection); 0825 (36e: serum therapy); 0830 (36e: immunity); 0877 (36e); 0912 (36e); 0482 (37e); 0483 (37e); 0872 (37e); 3585 (37e: nasal washings); 4295 (37d); 0167 (38e: tropical areas); 0337 (38e: second attacks); 3204 (38e); 3322 (38e); 4802 (38f); 0226 (39e); 0358 (39e); 2836 (39d: convalescent serum); 3558 (39e: heterologous antibodies); 0327 (40e); 0667 (40e); 1835 (40e: USA); 3642 (40t); 0895 (42e); 2711 (42e: immunity); 0138 (43e); 0714 (43e: Cynomolgus-monkeys); 0709 (44e: chimpanzees); 3604 (44e); 0487 (45e: dog serum); 0622 (45e: LANSING-strain); 1259 (46e); 4837 (46e: West Africa); 0039 (47e: symptomless children); 0711 (47e: chimpanzees); 0884 (47e); 0891 (47e: animals); 0071 (48e: human nasopharyngeal secretions); 0160 (48e: monkeys: oral infection); 0338 (48e: neutralizing antibodies to the infecting strain); 0649 (48e); 1269 (48e); 3004 (48e: Southern Africa); 3357 (48e); 4337 (48f); 4419 (48t: CSR); 4845 (48e); 0072 (49e: gammaglobuline: three immunological types); 0334 (49e: infecting strain); 0706 (49e); 2796 (49e: local formation: CNS);

4222 (49e); 4366 (49d: convalescent serum); 4368 (49e: monkey: distribution of antibody); 4428 (49e: LANSING C (M) variant); 5335 (49f: France); 0029 (50e: chimpanzees); 0195 (50e: Canada); 0721 (50e); 0796 (50e: subclinical infection); 2649 (50e: Alaskan Eskimos); 2650 (50e: seasonal development); 2707 (50e: polio and COXSACKIE); 2739 (50e: chimpanzees); 3397 (50e: antibodies to Col. SK- and Y-SK-virus); 4055 (50e: monkey); 0044 (51e: second attacks); 0054 (51e: Eskimos: North Alaska); 0064 (51e: human gammaglobuline); 1620 (51e: hemagglutination of Columbia-SK-virus); 1685 (51e: subclinical infections); 1686 (51e: CFT); 1691 (51e: COXSACKIE-infection); 2230 (51e: Eskimos); 2621 (51e: social serology: epidemic at North Carolina); 2628 (51f: immunity); 2685 (51e); 2775 (51f: St. Augustin/Canada); 3127 (51e: Japan); 3219 (51e: South Africa); 3965 (51e); 4412 (51e: LANSING); 4557 (51f); 0173 (52e: chimpanzees); 1680 (52e: CFT); 1681 (52e: monkeys: CFT); 1682 (52e: Cairo: CFT: neutralizationtest); 1692 (52e: type specifity); 1693 (52e: three years after infection); 1950 (52e); 2005 (52f); 2029 (52e: type II); 2040 (52e: Eskimos); 2667 (52d: parapoliomyelitis); 2704 (52e: CFT); 2746 (52f); 2882 (52e: chimpanzees); 3034 (52e); 3363 (52e: North Carolina); 4021 (52e: geography); 4448 (52e: Egypt); 4449 (52e); 4456 (52e: Quebec: Canada); 4480 (52e: Bombay); 4483 (52f); 0009 (53e: chimpanzees); 0293 (53e: viremia); 0296 (53e: Tahiti); 0297 (53e: monkey: repeated ingestions of minute amounts of virus); 1613 (53e: CFT); 1740 (53e); 2002 (53e); 2734 (53f: after epidemic in St. Augustin/Canada); 2899 (53d); 2965 (53e: during epidemic); 3030 (53e: San Francisco, Mexico City, Guam); 3126 (53e: North Australia); 3136 (53e); 3384 (53e: colostrum); 3402 (53e: COXSACKIE-virus); 4466 (53pl: Teschen disease); 4503 (53pl: Poland); 4523 (53i); 0259 (54e: Eskimos: Canada); 1464 (54e: CFT); 1512 (54i); 1825 (54i); 1847 (54e); 2232 (54e: contacts); 2246 (54e: chimpanzees); 2465 (54e: epidemiology); 2605 (54e: streptococcal thermal antibody); 2798 (54e: Georgia); 2894 (54e); 3961 (54e); 4028 (54i); 4030 (54i: gammaglobuline); 4034 (54n); 4052 (54f: Brazzaville: CFT); 4174 (54e: viremia); 4534 (54e: Great Britain: USA); 4537 (54e: Epidemic in Winston-Salem, N. C.); 4589 (54e: India); 5023 (54e: Col.-SK-virus: Mexico); 5038 (54f: Belgium); 5230 (54n); 5259 (54i: Italy); 0497 (55i: Italy); 0692 (55e); 0693 (55e: under-developed areas); 0697 (55e); 0699 (55e: gammaglobuline prophylaxis); 1495 (55e); 1496 (55e: Uruguay); 1518 (55e: NW-Mexico); 1576 (55e: Uruguay); 1577 (55e: gammaglobuline); 1579 (55e: Western Australia); 1630 (55e: neutralization); 1632 (55e: New Zealand); 1647 (55e: chimpanzees); 1651 (55f: Uruguay); 1663 (55e); 1765 (55e: Israel); 1776 (55e); 1791 (55i: Italy: type II – epidemic); 1794 (55e: CFT); 1806 (55e); 1821 (55e: South Australia); 1836 (55e: Tahiti); 1837 (55e: Morocco); 1838 (55e: North Australia); 1840 (55e: Charleston/USA); 1848 (55e: CFT); 1872 (55f); 1876 (55e: CFT); 1883 (55i); 1869 (55f: CFT); 2012 (55e); 2037 (55e: contacts); 2071 (55e: Helsinki); 2157 (55e: monkeys); 2239 (55s); 2253 (55e: contacts within households); 2254 (55e: Michigan); 2255 (55e: neutralization: CFT); 2536 (55d: micro-CFT); 2540 (55d: micro-CFT); 2597 (55e: Melbourne); 2636 (55f); 2980 (55f); 2983 (55e: England); 2984 (55e); 2985 (55f: Italy); 2987 (55f: Belgium);

2988 (55f: Bucarest: type 2); 3461 (55i); 4032 (55s); 4056 (55e); 4605 (55f: Belgium); 4609 (55n: CFT); 4611 (55e: sanitation); 4617 (55s: Chile); 4623 (55e: Connecticut [USA]); 5045 (55n: Finland); 5204 (55e: Aaland Islands); 5446 (55s); 1340 (56e: Hungary); 1650 (56e: hospital personnel); 1657 (56e: French Oceania); 1808 (56d: CFT); 1830 (56d); 1832 (56e: England); 1834 (56e: CFT: neutralization test); 1844 (56e: North Ireland); 1845 (56e: South Louisiana); 1849 (56e: contacts); 1852 (56d: CFT); 1855 (56d: CFT); 1860 (56d: Germany); 1870 (56f: Geneva); 1885 (56i: Palermo/Italy); 1896 (56f: Belgish Congo); 1898 (56e); 1902 (56e: Brazil); 1906 (56e: Island); 1918 (56d: Germany: type 2); 1923 (56e: heterotypic antibody response); 1927 (56e: type specifity); 1932 (56e: Turkey); 1965 (56e: Middle America); 2034 (56d: Geneva); 2061 (56e: immunity); 2098 (56e: Liberia); 2106 (56e: New Zealand); 2113 (56e: New Zealand); 2175 (56e: type specifity); 2187 (56b: Bucarest); 2425 (56d); 2443 (56f: Savona/Ligurien); 2445 (56i); 2479 (56i: Naples); 2498 (56s: Brazil); 2550 (56d: micro-CFT); 2553 (56d: Hamburg); 3084 (56e: Sweden); 3121 (56f); 3134 (56f: Paris); 3969 (56e: Finland); 4753 (56i); 4755 (56e); 4759 (56f); 4762 (56d); 4765 (56e); 4767 (56e: epidemic in the Aaland Islands); 4771 (56e: Glasgow); 4772 (56d: Switzerland); 4773 (56i: CFT); 4905 (56e); 5205 (56e: New Zealand); 5207 (56e: Aaland Islands); 5238 (56d: CFT); 0115 (57b: abortive cases); 0192 (57h); 0310 (57d); 0387 (57e: live vaccine); 0396 (57e); 0498 (57d: neutralization test: CFT); 0531 (57e); 0573 (57f: France); 0574 (57f: children and contacts); 0575 (57f: hospital personnel); 0577 (57i: neutralization: CFT); 0578 (57e: Japan); 0582 (57e); 0593 (57e: pediatricians and preclinical faculty members); 0602 (57i: Italy); 0633 (57i: paralytic cases); 0859 (57e: CFT: neutralization test); 0943 (57e); 0944 (57e); 0946 (57e: precipitin test); 0948 (57e: CFT: precipitin test); 0979 (57s: Colombia); 0998 (57f: Central Africa); 1487 (57f: Tunis); 1528 (57e: Louisiana); 1530 (57f: Louisiana); 1943 (57e: chimpanzees); 1966 (57d: North Germany); 1967 (57e: Scotland); 1969 (57e: Sweden); 1973 (57f: Switzerland); 2046 (57e: Manitoba); 2051 (57f); 2056 (57d: Switzerland); 2059 (57e: London); 2066 (57e: Louisiana); 2067 (57e: Louisiana); 2077 (57e: Nebraska); 2079 (57d: Bayern); 2081 (57e: East Saudi Arabia); 2083 (57i: Sardinia); 2085 (57i: Savona/Italy); 2091 (57i); 2104 (57e: USA: Cairo); 2110 (57e: type II antibodies: type I infection); 2116 (57e: North Ireland); 2128 (57e: Israel); 2192 (57i); 2319 (57e); 2321 (57f); 2327 (57d: micro-CFT); 2333 (57d: Bern/Switzerland); 2335 (57e: Charleston and Phoenix/USA); 2336 (57e: virus-excretion); 2428 (57f: Congo); 2484 (57p: South Africa); 2491 (57f: Belgium); 2493 (57n: Sweden); 2507 (57e: Peru and Colombia); 2511 (57e: Japan); 2542 (57d: Niedersachsen/Germany); 2651 (57e: Sweden); 3067 (57e: New Zealand); 3380 (57e: vaccine-acquired antibody); 4027 (57e); 4269 (57j: Tokyo); 4270 (57e); 4278 (57e: India); 4774 (57d: CFT); 4942 (57i: Italy); 4950 (57i: young children); 5194 (57d: New Orleans); 5198 (57i: Bologna); 5208 (57h: CFT); 5296 (57f: Leopoldville); 5299 (57e: India); 0161 (58e: type 1-epidemic); 0171 (58d: children: inapparent cases: CFT); 0182 (58d: CFT); 0187 (58e: Stockholm); 0188 (58e: CFT); 0191 (58e); 0193 (58e: Scotland); 0201 (58s: early infancy: attenuated virus); 0202 (58f: Belgish Congo); 0203 (58e:

British Guiana); 0207 (58e: Scotland); 0230 (58f: France); 0231 (58f: France); 0244 (58d: Germany); 0312 (58d); 0314 (58d); 0386 (58e: pregnancy); 0388 (58d: CFT); 0389 (58e: CFT); 0390 (58d: age distribution); 0393 (58e: human amniotic fluids); 0489 (58d: CFT); 0492 (58d); 0499 (58d); 0500 (58f: Belgish Congo); 0507 (58d); 0508 (58d: neutralization test: CFT); 0576 (58i: Italy); 0579 (58d: Switzerland); 0580 (58d: Switzerland); 0589 (58d); 0599 (58e: pediatricians and preclinical faculty members); 0627 (58d: immunity); 0628 (58d); 0635 (58e: CFT); 0643 (58e: Canada); 0647 (58i: mother: newborn); 0678 (58i: Italy); 0679 (58e: New Zealand); 0680 (58f: France); 0682 (58i: Italy); 0685 (58f: Belgium); 0843 (58e: ČSR); 0845 (58e: Slowenia); 0890 (58e: Westfalen); 0963 (58i: Bologna); 1003 (58f: Belgish Congo); 1006 (58f: France); 1020 (58e: Maori: Europeans); 1025 (58f: Bucarest); 1139 (58f: France); 1140 (58i: Naples); 1143 (58i: Turin); 1213 (58f: SW-France); 1315 (58b); 1339 (58d); 1457 (58d: Germany); 1458 (58d: Germany: sociological structure); 2121 (58d: Switzerland); 2259 (58s: Ribeirão Prêto/Brazil); 2262 (58f: France: Vietnam); 2434 (58f: immunity); 2514 (58e: family outbreak); 2648 (58e: Japan); 2697 (58f: Greece); 2888 (58e: Japan: early infancy); 4051 (58e: muscle weakness); 4271 (58d); 4272 (58e: Ireland); 4282 (58j: Japan); 4283 (58j: polyradiculoneuritis); 5312 (58e: COXSACKIE- and ECHO-virus); 5374 (58f: Port Gentil/Gabon); 0035 (59e: agammaglobulinemia); 0461 (59d: CFT); 0524 (59e); 0541 (59f); 0542 (59f); 0543 (59f); 0544 (59f: Dakar); 0592 (59d: CFT: hospital personnel); 0841 (59e: Sudan); 0869 (59d); 0870 (59d: «Siedlungsklassen»); 0962 (59e: upper Amazon bazin); 0982 (59e: CFT); 0983 (59e: Manitoba 1958); 1001 (59d); 1002 (59i: children epidemic: Italy); 1029 (59e: Nebraska/USA); 1118 (59e: Eskimos); 1131 (59h: Netherlands); 1169 (59f); 1202 (59e: South Arizona); 1208 (59e); 1217 (59e: Norway); 1226 (59e: Colombia); 1284 (59e: SALK-vaccine); 1285 (59e); 1294 (59e: Netherlands); 1298 (59e: faeces); 1316 (59f: tuberculosis); 1317 (59h: Netherlands); 1330 (59i: Italy); 1369 (59e: flocculation reaction); 1382 (59f); 1383 (59f: Paris); 1410 (59d: Wien); 1415 (59f: France); 1426 (59f); 1429 (59e: flocculation reaction); 1516 (59e); 1622 (59f: Paris); 1624 (59f: Dakar); 1625 (59f: Madagascar); 1933 (59f: France: season); 1934 (59f); 1958 (59e: Hungary); 2132 (59e); 2265 (59i: Terranegra/Padua); 2266 (59e: St. Lucia); 2269 (59i: cutaneous reaction); 2288 (59l: Bucarest); 2302 (59r: Armenian S. S. R.); 2415 (59n: Norway); 2438 (59e: Cynomolgus monkey: alimentary infection); 2448 (59j: Okayama/Japan); 2451 (59e: Caribbean Islands, British Guiana and Ecuador); 2522 (59s: Cuba); 2577 (59f: France); 2961 (59e: Matsumoto/Japan); 3025 (59h: family contacts); 3060 (59i); 3087 (59d); 3174 (59e: Mexico); 3181 (59e: Costa Rica); 3184 (59e: Montevideo/Uruguay); 3220 (59e: Mexico-City); 3231 (59e: Leopoldville/Congo); 3234 (59e: Esthonian and Lithuanian S. S. R.); 3314 (59i: mother: newborn); 4274 (59f); 4275 (59e: serum: faeces); 4289 (59e); 5364 (59e); 5376 (59i: cutaneous reactivity); 1352 (60d: Germany); 1377 (60d: Berlin); 1395 (60e: Washington, D. C.); 1959 (60d: Niedersachsen); 1993 (60e); 1995 (60e: Congo); 2273 (60d: Germany); 2295 (60b: Roumania); 2357 (60e: Israel); 2363 (60e: Detroit epidemic); 2383 (60f: Cape Verde Islands); 2388 (60e: Guatemala); 2393

(60e: maternal: umbilical cord: infantal antibody); 2396 (60e: families contacts); 2409 (60e: Nicaragua); 2411 (60u: Hungary); 2513 (60e: Mexico); 2527 (60e: CFT); 2531 (60d: CFT); 2556 (60e: Guatemala); 2557 (60r: USSR); 2568 (60f: micro-flocculation-test); 2569 (60f: micro-flocculation-test); 2582 (60d: diaplacental transfer); 2783 (60i: Messina); 2802 (60f); 2891 (60d: Germany); 2907 (60f: Paris); 2908 (60i: neutralizing antibodies: intradermoreaction); 2924 (60 o: Turkey); 2927 (60i: intradermic reaction); 2942 (60i: intradermic reaction); 2954 (60e: Alaska); 2955 (60e: Alaska/Bering Sea); 2957 (60d); 2958 (60b: Roumania); 2973 (60e: New Haven/Conn.); 3021 (60e: Papuans: New Guinea); 3096 (60d: Wien); 3099 (60d: Nieder-Oesterreich); 3194 (60i: virus-neutralizing activity in stools); 3315 (60t); 3316 (60r); 3338 (60e: USSR); 3395 (60i: antibodies of maternal origin); 3429 (60h: Netherlands: Curaçao); 3452 (60b: Roumania); 3464 (60e: Northern Rhodesia); 3477 (60r: USSR); 3489 (60e: Belfast 1957); 3971 (60i: Bologna); 3973 (60pl: Poland); 3980 (60s: Valencia); 4072 (60e: Roumania); 4078 (60e: Indonesia); 4114 (60e: Taipei area); 4138 (60f: wild monkey: Congo); 4188 (60r); 4207 (60e: Serbia 1954); 4234 (60r: contact with subjects inoculated with live vaccine); 4658 (60e); 4730 (60i); 4874 (60e: ČSR); 4883 (60i: auto-antibody); 4903 (60e); 4908 (60e); 4920 (60e: Mexico); 5026 (60e: Southern Africa); 5040 (60e: Sottunga Island/Finland); 5063 (60e: India); 5441 (60i); 5445 (60e: Serbia); 3334 (61e: USSR); 3485 (61e: microprecipitin test); 3495 (61d: CFT); 3498 (61e: flocculating and nonflocculating antibody); 4198 (61e: Andaman Islands); 4203 (61e: Massachusetts); 4243 (61f: CFT); 4245 (61f: Valencia); 4249 (61e: in human urine); 4301 (61e: Yonago/Japan); 4381 (61d); 4637 (61d); 4638 (61f: SW-France); 4642 (61e: Szeged); 4643 (61e: Newfoundland); 4644 (61e: St. Vincent Island, West Indies); 4878 (61d: latent infection: type of virus); 4891 (61u); 4991 (61pl: Poland); 5057 (61f); 5123 (61e: Finland); 5151 (61e: Greenland: India: USA); 5315 (61s: Spain); 5353 (61b: Croatia); 5494 (61e: Rosario/Argentine).

Nachweismethoden / Methods

Allgemeines / General

4397 (12d: syphilis reaction); 0347 (18e: agglutination of pleomorphic streptococcus); 3678 (18e: opsonic action); 1712 (26e: skin reaction); 0137 (28e: streptococci); 2204 (30e: colloidal gold test); 3560 (30e: colloidal gold test); 1101 (31e: allergic skin reaction); 2039 (31e: colloidal gold test); 2072 (31e: colloidal gold test); 3559 (31e: colloidal gold test); 0819 (32e: streptococci); 0707 (33e: skin test); 0904 (33e: skin reaction); 0224 (34e: colloidal gold test EBERSON); 0935 (34e); 0703 (35e: skin test); 0704 (35e: colloidal gold test); 0748 (35e: colloidal gold test); 4135 (40e); 2728 (52e); 1615 (55e: type specifity); 2255 (55e: neutralization: CFT); 1665 (56e: flocculation); 1827 (56e: fluorescent antibodies); 1841 (56e: neutralization: disposable plastic panels); 2181 (56f); 0520 (57i: fluorescent antibodies); 0540 (57e: immuno-inactivation); 2059 (57e: CFT: neutralization); 2062 (57e: filter paper disc test); 2092 (57e: filter paper disc test); 0183 (58e: virus antibody and host cells: tissue culture); 0314 (58d); 0556 (58d:

hemaggregation); 0761 (58e: chicken test); 0966 (59e: flocculation); 0968 (59e: disc-plate assay); 1308 (59i: intracutaneous reaction); 1368 (59e: micromethod of FARRELL); 1369 (59e: flocculation); 1429 (59e: flocculation); 2412 (59i: intradermal test); 2581 (59f); 2378 (60e: antibody combining test); 2382 (60f); 2440 (60e: serodifferentiation within the same type); 2910 (60e: antibody combining power test); 3328 (60i: flocculation test: other methods); 3498 (61e: flocculating and nonflocculating antibodies); 5465 (61r: flourescent antibodies).

Hämagglutination / Haemagglutination

4424 (48f: sheep erythrocytes); 2713 (49f); 4369 (49f); 1620 (51e: Columbia-SK-virus); 2759 (51f); 2666 (52d: Col. SK-strain); 2667 (52d: parapoliomyelitis); 3960 (52d); 4475 (53f: conglutination); 5268 (54e); 4766 (56e: flocculation by micro method); 4769 (56e); 2318 (58e: neutralization); 4271 (58d).

Komplementbindungsreaktion / Complement fixation test

1058 (08e); 0260 (17e: streptococcal serum of ROSENOW); 0272 (17e); 0283 (17e); 1357 (18e); 3644 (18e); 0737 (31e); 3645 (32f); 0704 (35e); 0748 (35e); 0933 (35e); 2793 (39e); 5138 (45e: specifity); 2722 (47e); 1497 (50e: nervous tissue: newborn mice); 2598 (50d); 0056 (51e: neutralization test); 1582 (51e: animal experiments); 1686 (51e); 2716 (51e); 1680 (52e); 1681 (52e: monkeys); 1682 (52e: neutralizing antibodies); 1692 (52e: type specifity); 2601 (52e); 2701 (52e: antigen: tissue culture); 2704 (52e); 2876 (52e); 2889 (52e); 1613 (53e: nervous tissue: adult mice); 1974 (53s); 4465 (53e); 4470 (53e); 4511 (53e); 1464 (54e); 1560 (54e); 3961 (54e); 4029 (54i); 4052 (54f); 4569 (54e); 5149 (54f: micromethod); 5230 (54n); 0696 (55e); 1606 (55e: type specifity: inactivation); 1794 (55e); 1836 (55e);1837 (55e); 1840 (55e); 1848 (55e); 1869 (55f: micromethod); 1876 (55e); 2536 (55d: micro-CFT); 4609 (55n); 1527 (56i: after vaccination); 1808 (56d); 1830 (56d); 1834 (56e); 1852 (56d); 1855 (56d); 1890 (56e: heat inactivated antigen: specifity); 1914 (56d: monkeys: neutralizationtests); 1932 (56e); 2306 (56d: vaccination); 2423 (56e: MEF_1 : soluble antigen); 2442 (56d: neutralization); 2445 (56i: neutralization); 2550 (56d: micro-CFT); 3042 (56e); 4773 (56i); 4905 (56e); 5238 (56d); 0498 (57d); 0518 (57e: antigen); 0577 (57i: neutralizationtest); 0859 (57e: neutralizationtest); 0944 (57e); 0947 (57e: neutralizationtest); 0948 (57e: precipitation); 0961 (57e: antigen: tissue culture); 2327 (57d: micro-CFT); 4774 (57d); 5208 (57b); 0171 (58e: inapparent infection); 0182 (58d: with inactivated antigen); 0184 (58e: noninfectious particles in HeLa cells); 0188 (58e: neutralizationtest); 0203 (58e); 0388 (58d); 0389 (58e); 0391 (58e: different antigens); 0400 (58e: particles: tissue culture); 0489 (58d); 0502 (58e: antigen); 0508 (58d: neutralizationtest); 0635 (58e: neutralizationtest); 0846 (58e); 0985 (58d); 0959 (58e: vaccination); 1119 (58r); 1206 (58i: inactivated antigen); 2121 (58d); 0461 (59d: age); 0559 (59e: inactivated vaccine); 0592 (59d: hospital personnel); 0869 (59d); 0982 (59e: specifity); 1063 (59d: fluorescent antibodies); 1292 (59d: after SALK-vaccination); 1411 (59e); 2414 (59e: neutralization); 3085 (59e); 2385 (60e: virus-strains); 2527 (60e); 2531 (60d); 2774

(60i: during SALK-vaccination); 2782 (60e: anti-N- and anti-H-antibody); 2878 (60f); 3979 (60i); 3313 (61d: purified antigen); 3495 (61d: purified antigen); 4243 (61f); 4634 (61f: CTI-test); 4657 (61e: unspecifity: enteroviruses); 5353 (61b); 5367 (61e: formalin treated antigen); 5488 (61i).

Neutralisationstest / Neutralization test

0095 (10d); 0099 (10f: monkeys); 0100 (10f: monkeys); 0106 (10e; monkeys); 0090 (11e: monkeys); 0103 (11e: monkeys); 0613 (12e); 4387 (13f); 0260 (17e: streptococcal serum of ROSENOW); 0101 (18e: monkeys); 0102 (18f: horse serum); 0378 (18e); 0397 (18e: NUZUM's antiserum); 0136 (28e: sera of ROSENOW and PETTIT); 0887 (29e); 0154 (30e: horse immune serum); 0175 (30e: horse immune serum); 0288 (30e); 0340 (30e: monkeys); 0341 (30e: monkeys); 0354 (30e: monkeys); 2038 (30e); 0002 (31e: horse immune serum); 0003 (31e: convalescent serum: immune serum); 0004 (31e); 0006 (31e: horse immune serum); 0007 (31e); 0144 (31e: different types); 0737 (31e); 0739 (31e: immune serum); 2237 (31e: antigenicity); 0028 (32e: monkey-infection); 0198 (32e: immune sera from goats and sheeps); 0702 (32e: blood groups); 0716 (32e); 0793 (32e: immune serum); 0882 (32e); 0896 (32e: herpes antiviral substances); 1948 (32e: monkeys); 0379 (33e: specifity); 0380 (33e); 0726 (33e); 0881 (33e); 0955 (33e: monkeys); 0200 (34e: horse serum); 0735 (34e); 0935 (34e); 0382 (35e: different antigens); 0723 (35e: monkeys); 0746 (35e); 0748 (35e); 0820 (35e: pregnancy); 0933 (35e); 0016 (36e); 0427 (36e); 0877 (36e); 0163 (37e: convalescent serum); 0483 (37e); 0872 (37e); 0170 (38e: sheep serum: typing); 0251 (38d: convalescent serum); 5130 (38e: monkey test); 0226 (39e: infection); 0528 (39e: intraocular inoculation: monkey); 0358 (39e); 0156 (40e: typing); 1835 (40e: animal experiments); 2884 (40e: mouse test); 3682 (40e); 3680 (41e: cotton rat strain); 5168 (41e: mouse protection test); 0624 (42e: specifity of strain); 0885 (42e: mouse test: standardization); 0895 (42e); 5076 (42e: mouse test); 0070 (43e: mouse protection test); 0128 (43e: mice); 0138 (43e: mice); 0125 (45e: mice); 0622 (45e: mouse protection test); 5137 (45d); 5138 (45e: specifity); 1259 (46e: mouse protection test); 4837 (46e: mouse protection test); 0039 (47e); 0041 (47e: mice); 0884 (47e: mouse protection test); 0033 (48e: infection of mice); 0071 (48e: mice); 0174 (48e: temperature); 0338 (48e: infecting strain); 1269 (48e: mouse protection test); 4420 (48e); 0021 (49e: infection of mice); 0334 (49e: infecting strain); 0031 (50e: type differentiation); 0037 (51e: monkey: differentiation); 0045 (51e: monkey: differentiation); 0048 (51e: monkey: differentiation); 0049 (51e: monkey: differentiation); 0050 (51e: monkey: differentiation); 0051 (51e: monkey: differentiation); 0052 (51e: monkey: differentiation); 0053 (51e); 0055 (51e: tissue culture); 0056 (51e: CFT); 0064 (61e: mice); 1582 (51e: animal experiments); 1682 (52e: CFT); 1692 (52e: type specifity); 1693 (52e); 2666 (52d: Col. SK-strain); 2667 (52d: parapoliomyelitis); 3029 (52e: monkey testicular tissue); 3180 (52e: tissue culture); 5333 (52e); 2816 (53d: gammaglobuline); 2966 (53e: tissue culture test); 2967 (53e: mouse protection test with small amount of blood); 4466 (53pl: mouse-

test); 1560 (54e); 1847 (54e); 2244 (54e: phenol red-color-test); 2798 (54e: mouse test); 3028 (54e: standard antiserum); 3961 (54e); 4023 (54e: mouse test); 4537 (54e: tissue culture methods); 4565 (54e: LANSING-: Col. SK-strain); 4586 (54f: micro method); 0696 (55e: monkeys and mice); 1630 (55e: virustitration); 1676 (55e: colortest); 1677 (55e: colortest); 1765 (55e); 1836 (55e: CFT); 1837 (55e: CFT); 1838 (55e); 1840 (55e: CFT); 1872 (55f); 1884 (55i: serum of guinea pigs); 1893 (55e); 2719 (55e: colortest); 4032 (55s); 1527 (56i: after vaccination); 1664 (56e); 1830 (56d); 1834 (56e); 1860 (56d); 1864 (56d: concentration of antigen); 1914 (56d: CFT: monkeys); 1929 (56e: type 2: antigenic differences); 1930 (56f: plastic panels); 1932 (56e: CFT); 2306 (56d: vaccination); 2442 (56d: CFT); 2445 (56i: CFT); 3042 (56e); 4755 (56e); 4763 (56e: micro method); 4905 (56e: CFT); 0115 (57b); 0242 (57d: micro color test); 0498 (57d); 0540 (57e: immuno-inactivation); 0577 (57i: CFT); 0593 (57e: pediatricians and preclinical faculty members); 0859 (57e: CFT); 0944 (57e); 0945 (57e: SALK-vaccination); 0946 (57e: precipitation); 0947 (57e: CFT after SALK-vaccination); 2064 (57e: guinea pig test); 2688 (57d); 0181 (58e: micro test); 0188 (58e: CFT); 0194 (58e); 0244 (58d); 0395 (58e); 0508 (58d: CFT); 0599 (58e: pediatricians and preclinical faculty members); 0635 (58e: CFT); 0845 (58e); 0860 (58d: HeLa cell culture); 1218 (58e: hemaggregation); 1307 (58e: standardization); 1478 (58e: critical comparison of hypotheses); 2121 (58d); 2318 (58e: hemagglutination); 0306 (59u: gammaglobuline); 0490 (59d: micro color test); 0541 (59f); 0542 (59f); 0853 (59e); 0869 (59d); 0984 (59e: British standard antisera); 1169 (59f); 1217 (59e); 1230 (59e: blocking by noninfective virus); 1375 (59e: plaque-test); 1411 (59e); 1418 (59i); 1843 (59e: tissue culture); 1934 (59f); 2414 (59e: CFT); 2448 (59j: intraspinal mouse test: HeLa cell tissue culture); 2528 (59f); 3085 (59e); 3087 (59d); 1421 (60f); 1990 (60e); 2316 (60f: immuno-inactivation [GARD]); 2382 (60f); 2529 (60f); 2904 (60i: quantity of virus); 2908 (60i: intradermoreaction); 2925 (60r: comparative study); 2927 (60i: intradermic reaction); 2942 (60i: intradermic reaction); 2972 (60e: micro method); 3315 (60t); 3978 (60i); 4186 (60b: peritoneal test in mice); 4231 (60e: kinetic); 5346 (60e: paper disc method); 5441 (60i); 3312 (61d: «Zonenphänomen»); 4208 (61e: modified color test); 4215 (61d: standardization); 4218 (61d: serum avidity: virus aggregation); 4663 (61e: different methods); 4668 (61e: modified color test); 4728 (61i); 4888 (61e: gel diffusion method); 5163 (61e: serodifferentiation of epidemic strains); 5488 (61i); 5499 (52e: guinea pigs); 5500 (62e: normal cattle sera).

Präzipitation / Precipitation

3677 (24e); 3676 (25e); 1713 (26e: horse immune serum); 0002 (31e: horse immune serum); 0737 (31e); 0704 (35e); 0748 (35e); 0933 (35e); 3557 (37e: streptococcal antigen); 2793 (39e); 2661 (49e: flocculation-test); 0670 (57e: agar diffusion test); 0946 (57e: neutralization); 0948 (57e: CFT); 5281 (57e); 0501 (58e: agar diffusion test); 1411 (59e); 2568 (60f: micro-flocculation-test); 2569 (60f: micro-flocculation-test); 3059 (60r); 3241 (60f); 3484 (61e: microprecipitin test); 3485 (61e: microprecipitin test); 4229 (61e: common antigens).

Tierversuche / Animal experiments

0095 (10d: monkey: infection); 0104 (10d: monkeys); 0377 (10d: monkeys); 1060 (10e: monkeys); 1062 (10d); 3200 (10e: monkey); 0096 (11d: sheep serum: passive immunization); 1548 (12d: monkeys); 0374 (16e: monkeys); 0278 (17e: monkeys: passage into cerebrospinal fluid); 0101 (18e: monkeys); 0102 (18f: horse serum); 0250 (18e: monkeys: antiserum of ROSENOW); 0344 (18e: horse serum); 0378 (18e: passage from blood into cerebrospinal fluid); 0590 (18e: monkeys: heat inactivated vaccine); 1036 (18e: rabbit); 3584 (19e: monkey: opsonins for streptococcus); 0551 (24f: PETTIT's horse serum); 0141 (27e: monkeys: intracutaneous vaccination); 0136 (28e: sera of ROSENOW and PETTIT); 0887 (29e: monkeys: vaccination); 3146 (29e: monkey: antipoliomyelitis serum); 0142 (30e: rabbit); 0175 (30e: horse); 0831 (30e: monkeys: adsorbed vaccine); 1079 (30e); 1265 (30e: horse); 2205 (30e); 0001 (31e: monkey: vaccination with mixtures of virus and convalescent serum); 0002 (31e: horse); 0004 (31e: monkey: aluminum hydroxide vaccine); 0006 (31e: horse); 0007 (31e: monkey: vaccination with mixtures of virus and convalescent serum); 0408 (31e: monkey: injection into the spleen); 0477 (31e: horse); 0737 (31e: monkeys); 0780 (31e: sheep and goats); 1353 (31e: horse); 2206 (31e: monkeys: nasale infection); 0148 (32e: horse); 0558 (32e: monkeys); 0791 (32e: monkeys); 0896 (32e: monkeys: herpes antiviral substances); 1948 (32e: monkeys); 2201 (32e: normal antibodies); 0146 (33e: monkey: vaccination with mixtures of virus and convalescent serum); 0379 (33e: type specifity); 0810 (33e: monkeys); 0812 (33e: monkeys); 0881 (33e: sheep immune serum); 0145 (34e: monkey: vaccination with mixtures of virus and convalescent serum); 0152 (34e: monkey: active virus); 0200 (34e: serum production: refractory animals); 0741 (34e: monkey: hormonal factors); 0742 (34e: monkey: hormonal factors); 2008 (34e: horse); 0768 (35e: monkey: BRODIE-vaccine); 0815 (35e: monkey: adsorbed vaccine); 0816 (35e: monkey: infection through isolated intestinal loops); 0817 (35e: monkeys); 1023 (35e: horse serum); 1085 (35e: sheep: adsorbed vaccine); 2744 (35e: monkey); 3555 (35e: sheep); 3571 (35e: monkey: adrenalectomy); 0016 (36e: monkey: vaccination with mixtures of virus and convalescent serum); 0017 (36e: monkeys); 0019 (36e: monkey: vaccination with mixtures of virus and convalescent serum); 0077 (36e: Rhesus monkey: BRODIE vaccine); 0731 (36e); 0738 (36e: monkey: reinfection); 0753 (36e); 0805 (36e: monkey: infection through isolated intestinal loops); 0883 (36e: monkey: immunity); 0912 (36e: monkey); 0932 (36e: monkey); 4776 (36f: monkey: KOLMER-vaccine); 4782 (36f: serum production); 4789 (36e: monkey); 5119 (36e: monkey); 0482 (37e: monkey); 1043 (37e: ricinoleated vaccine); 2659 (38e: monkey); 2690 (38e: monkey); 2745 (38e: monkey); 3551 (38e: horse); 2669 (39e: monkeys and sheep); 2793 (39e: CFT and precipitation); 2858 (39e: monkey); 1835 (40e); 3579 (40e: THEILER-virus); 3627 (40f: resistance of laboratory animals); 4135 (40e); 2065 (41e: monkey: immunity); 3620 (41e: cotton rat); 0897 (42e: Syrian hamster); 0070 (43e: mice: protection test); 0714 (43e: Cynomolgus-monkey: subclinical infection); 4015 (43e: horse serum: globuline fraction); 4171 (43e: horse); 0709 (44e:

chimpanzees: accidental contagion); 5271 (44e: UV-vaccine: mice); 0121 (45e: chimpanzees: passive immunization); 4574 (45e: mice: uv-inactivated vaccine); 0041 (47e: mouse neutralization test); 0042 (47e: monkeys: intracerebral immunity); 0043 (47e: monkeys: distribution of antibody); 0711 (47e: chimpanzees: subclinical infection); 0891 (47e: animals); 2673 (47e: cotton rat); 2722 (47e: CFT); 3155 (47e: cotton rats); 0032 (48e: cotton rats); 0059 (48e: Cynomolgus-monkey: oral inoculation); 0160 (48e: monkey: oral infection); 4105 (48f: rabbit); 4310 (48e: rats: intracerebral inoculation); 4420 (48e: rabbit); 0021 (49e: monkey); 0774 (49e: Swiss mice: congenital immunity); 2796 (49e: local formation: CNS); 4222 (49e: monkey); 4368 (49e: distribution of antibody); 4431 (49e: golden hamster); 0029 (50e: chimpanzees); 0034 (50e: monkeys); 0065 (50e: mice: passive transfer of immunity by milk); 1531 (50e: faeces: monkeys); 1951 (50f: rabbit); 2619 (50e: monkeys); 2739 (50e: chimpanzees); 4055 (50e: monkey); 0037 (51e: monkey: immunologic classification of virus); 0045 (51e: monkey: immunologic classification of virus); 0046 (51e: monkey: immunologic classification of virus); 0047 (51e: monkey: immunologic classification of virus); 0048 (51e: monkey: immunologic classification of virus); 0049 (51e: monkey: immunologic classification of virus); 0050 (51e: monkey: immunologic classification of virus); 0051 (51e: monkey: immunologic classification of virus); 0052 (51e: monkey: immunologic classification of virus); 0054 (51e); 1580 (51e: monkey: oral inoculation); 1581 (51e: monkey: oral inoculation: differences of two related strains); 1582 (51e: CFT: neutralization test); 1602 (51e: monkey: active and passive immunization); 1686 (51e: CFT after immunization); 2633 (51e: animal sera: Japan); 2685 (51e); 3457 (51e: horse); 0173 (52e: chimpanzees); 1681 (52e: monkey: CFT after infection); 2004 (52e: passive immunization); 2030 (52e: chimpanzees); 2213 (52e: poliomyelitis: rabies); 2601 (52e); 2704 (52e: monkey: CFT); 2797 (52e: monkey: COXSACKIE- and polio-virus); 2880 (52e: monkey); 2882 (52e: chimpanzees); 2892 (52e: immunity); 3141 (52e: monkey: SALK-vaccine); 3367 (52e: monkey); 0009 (53e: chimpanzees); 0297 (53e: monkey: repeated ingestion of minute amounts of virus); 1613 (53e: mice: CFT); 1749 (53e: monkey: Newcastle-virus); 2632 (53e); 2732 (53e: after passive immunization); 2804 (53e: mice: cross-immunity: rabies); 2962 (53e: normal monkey); 5142 (53e); 2245 (54e: Cynomolgus monkeys: viremia); 2246 (54e: chimpanzees: vaccination or infection); 2247 (54e: chimpanzees); 2460 (54e: live vaccine: monkeys); 2718 (54e: rabbit); 2894 (54e: monkey); 3028 (54e: standard antiserum); 4045 (54e: avirulent variant: monkey); 4585 (54e: chimpanzees: live vaccine); 0697 (55e); 0839 (55e: monkeys and guinea pigs: testing of vaccine); 1605 (55e: animals); 1610 (55e: monkeys); 1631 (55e: rabbit: production of type specific antisera); 1771 (55e); 1773 (55d: rabbit); 1775 (55e: monkeys); 1805 (55f: donkey); 1810 (55e); 1815 (55i: skin reaction); 1881 (55e: chimpanzees: live vaccine); 1884 (55i: guinea pigs); 1905 (55f: monkeys: Central Africa); 2082 (55e: Swedish vaccine: guinea pigs); 2157 (55e: immunity: monkeys); 2256 (55e: chimpanzees); 2340 (55i: rabbit); 1871 (56h: monkeys: live vaccine); 1875 (56e: cotton rat); 1887 (56i: guinea pigs); 1914 (56d: monkeys); 1919 (56e: guinea

pigs: testing of vaccine); 1929 (56e: homogenicity of type 2); 2119 (56e: chimpanzees); 2306 (56d); 2307 (56d: monkeys: cortisone); 0634 (57i: rabbit: treatment of spleen with ultrasound); 0763 (57e: monkeys: formalin-UV-vaccine); 1252 (57e: combined antigen); 1520 (57r: rabbit); 1943 (57e: chimpanzees); 2068 (57e: Cynomolgus-monkey after infection); 2069 (57e: hamster: nonspecific reaction: Col. SK-virus and poliovirus type II); 2087 (57e: mice); 2090 (57e: guinea pigs: combined antigen); 2338 (57e: guinea pigs and mice: combined antigen); 2595 (57e: attenuated strain: guinea pigs); 3012 (57e); 0503 (58e: guinea pigs: immunogenic potency of live and inactivated virus); 0553 (58s: SALK-vaccine: Mexico); 0557 (58e: monkeys: contact transmission); 0631 (58e: guinea pigs); 0849 (58e: guinea pigs: testing of vaccine); 0865 (58e: mice: interference: Polio- and COXSACKIE-virus); 0951 (58f: chicken test); 0959 (58e: CFT); 1004 (58e: animals: Africa); 1031 (58d: guinea pigs); 2111 (58e: guinea pigs); 3310 (58i); 3311 (58i: cattle); 0186 (59d: testing of vaccine); 0866 (59e: monkeys: virus excretion); 1032 (59e: guinea pig test); 1056 (59d: guinea pig); 1089 (59d: guinea pig: testing of vaccine); 1123 (59i: combined antigen); 1141 (59b: standard serum 1150 (59f: testing of vaccine); 1170 (59e: monkeys); 1221 (59e: inhibitor in certain horse sera against type 1); 1279 (59f: chicken test); 1281 (59e: monkeys); 1303 (59e: chicken test); 1304 (59f: testing of vaccine); 1309 (59d: chicken test); 2438 (59e: Cynomolgus-monkeys: alimentary infection); 2910 (59e: Taiwan-monkey); 1989 (60e: SALK-vaccine: Cynomolgus-monkeys); 2296 (60e: monkeys: subcutaneous inoculation); 2308 (60d: monkeys: adsorbed vaccines); 2355 (60e: guinea pig: specifity within type I); 2374 (60f: chicken); 2392 (60e: SALK-vaccine: results in man); 2456 (60e: roosters); 2529 (60f: chicken); 2941 (60i: skin test); 2944 (60e: monkey); 2971 (60e: chimpanzees: passive antibody); 3241 (60f: rabbit); 4138 (60f: wild monkey: Congo); 4211 (60e: rabbit and rooster: antisera); 4966 (60r: DT-Polio-vaccine); 3020 (61d: Quatro-Virelon); 3475 (61f: obsistin); 4147 (61e: monkey: viremia); 4733 (61r: antigenic activity); 4897 (61e: monkey: subcutaneous injection); 5145 (61e: combined antigens); 5493 (61r: production of diagnostic sera); 5499 (62e: guinea pigs); 5500 (62e: cattle sera).

Immunität / Immunity

Unter Immunität (I.) wird hier die im Laufe des Lebens erworbene Abwehrkraft gegenüber der Poliomyelitis verstanden, sofern sie durch die Einwirkung von spezifischen und unspezifischen, natürlichen oder künstlichen Antigenreizen entsteht. Demgegenüber werden unter dem Hauptbegriff «Resistenz» alle jene vorwiegend unspezifischen Vorgänge beschrieben, die die genetisch determinierte Empfänglichkeit des Makroorganismus gegenüber dem Poliomyelitisvirus erhöhen oder herabsetzen können (s. S. 130). Die I. der verschiedenen Lebensalter gegenüber der Poliomyelitis ist nur dann unter dem Stichwort «Altersverteilung» gebracht, wenn es sich um epidemiologische oder vergleichende Rückschlüsse auf die Altersabhängigkeit der I. handelt; alle serologischen Untersuchungen zu dieser Frage sind unter dem entsprechenden Stichwort

beim Hauptbegriff «Antikörper» zitiert. Der Begriff der zellulären I. ist nur selten in seinem Verhältnis zur Unspezifität, zur humoralen I. und zur aktiven Schutzimpfung diskutiert oder gar bearbeitet worden, weil die humorale I. als besser überschaubare und meßbare Eigenschaft von Anfang an mehr interessierte. Etwas häufiger wurde nach unspezifischen Immunitätsreaktionen gefragt; zunächst wird geprüft, ob unspezifische Infekte die I. gegen Poliomyelitis erhöhen können, später interessiert das Problem, ob man mit verwandten oder für verwandt gehaltenen Virusantigenen aktiv immunisieren kann oder ob man die bereits erworbene I. mit unspezifischen Reizen prophylaktisch oder therapeutisch im Sinne einer anamnestischen Serumreaktion stimulieren kann. Die meisten Arbeiten beschäftigen sich mit den beiden Hauptthemen: der Entstehung der I. nach natürlicher Exposition und der künstlichen Erhöhung der I. durch Schutzimpfungen. Unter natürlicher Exposition seien hier alle Arten des Kontaktes mit dem Virus von der schweren Infektion mit Lähmungen bis zur latenten oder temporären, subklinischen Infektion verstanden, die zu einer natürlichen, immunologischen Auseinandersetzung zwischen Wirtsorganismus und Virus führen. In beiden Themengruppen überwiegen entsprechend der schon erwähnten Überbetonung der humoralen I. die Arbeiten über das Verhalten der Antikörpertiter, während die Nachweismethoden aus den epidemiologisch-statistischen Erhebungen und die meist indirekten Rückschlüsse aus ihnen als erfahrungsgemäß unsicher gemieden werden. Bei der I. nach natürlicher Exposition habe ich noch den negativen, bereits seit dem vorigen Jahrhundert bekannten Spezialfall abgetrennt, daß die I. durch eine zweite Infektion durchbrochen wird und zur echten Zweiterkrankung führt. Bei der I. nach Schutzimpfung habe ich diejenigen Veröffentlichungen gesondert gebracht, in denen der Impferfolg speziell an der Lähmungsrate, an der Letalität und an der Morbidität geprüft wird, während ich alle übrigen Arbeiten zu diesem Thema allgemeinen oder vergleichenden Inhaltes unter dem Stichwort «Epidemiologisch-statistischer Nachweis» gesammelt habe. Weil mit Ausnahme der Primaten nur Menschen für die natürliche Poliomyelitisinfektion empfänglich sind, kann eine I. nach natürlicher Exposition in Tierversuchen kaum geprüft werden; hingegen sind diese bei der Prüfung der I. nach Schutzimpfung möglich und häufig schon seit 1910 angewendet worden; deshalb habe ich die Tierversuche hier gesondert aufgeführt.

s. a. Antikörper.
Reinfektion.
Resistenz.
Schutzimpfung.
Serumprophylaxe und -therapie.
Tierversuche, Immunisierung.
Übersichtsarbeiten, Immunität.

The term immunity (I.) is used here to describe the defence against poliomyelitis acquired in the course of life, in so far as it is acquired from specific and unspecific, natural or artificial antigen stimuli. On the other hand, the main concept «resistance» is the heading under which all these chiefly unspecific processes are described which can increase or reduce the genetically determined susceptibility of the macro-organism to the poliomyelitis virus (cf. page 131). The I. to poliomyelitis at various ages is

discussed under the heading «age distribution» only when epidemiological or comparative conclusions regarding the age-dependence of I. are concerned; all serological investigations into these questions are presented with the appropriate title under the main heading «antibody». The conception of cellular immunity has seldom been discussed or considered in its relation to unspecificity, humoral I. and active vaccination, because humoral I. has from the start been more interesting as a more surveyable and measurable characteristic. The question of unspecific immunity reactions arose somewhat more frequently; initially, attempts were made to establish whether unspecific infections could increase I. to poliomyelitis; the problem subsequently drawing attention was whether related and apparenlty related virus antigens could be used for active immunization, or whether already acquired I. can be stimulated with unspecific stimuli, prophylactically or therapeutically, in the sense of an anamnestic serum reaction. The majority of papers are concerned with the two main subjects, viz: the development of immunity after natural exposure, and the artificial improvement of I. by vaccination. The term natural exposure here refers to all kinds of contact with the virus, from severe infection with pareses to latent or temporary, subclinical infection, which lead to a natural immunological struggle between the host organism and the virus. Both main divisions show a predominance, in accordance with the abovementioned accentuation of the humoral I., of papers on the behaviour of the antibody titre; methods of demonstration based on epidemiological-statistical findings, and even the most indirect conclusions from them, are avoided because experience has shown them to be unreliable. In the case of I. after natural exposure I have separated the special negative case, known since the previous century, of I. being broken by a second infection, leading to a secondary illness. In the case of I. following vaccination I have separated the publications in which the vaccination results are especially verified against the rate of paralysis, lethality and morbidity; all other publications of general or comparative contents in this field were collected under the title «epidemiological statistical evidence». Because, with the exception of the primates, only man is susceptible to natural poliomyelitis infection, I. after natural exposure can hardly be tested in animal experiments; such experiments, however, are possible in the testing of I. following vaccination; they have been frequently carried out since 1910; animal experiments, therefore, were separately collected and presented.

cf. Animal experiments, immunization
Antibody
Reinfection
Resistance
Serum prophylaxis and -treatment
Reviews, immunity
Vaccination

Allgemeines / General

0107 (10e); 1380 (10d); 1435 (11d); 5398 (13e); 0280 (17e); 3598 (17e); 3018 (22f); 0381 (31e); 1102 (31e); 0435 (32e); 1949 (32e: exposition); 4675 (32i: neonatal period); 0707 (33e: skin test); 2026

(33e); 0725 (35e: maturation of immunity); 0934 (35e); 3608 (35d: hormonal dysfunction); 4723 (36d); 4786 (36i); 0481 (37e); 2766 (39d); 2837 (40d); 3438 (41e); 2711 (42e); 5439 (49f); 0797 (50e: season); 3225 (50f); 0248 (51e: twins family); 3434 (51f); 1728 (52e); 1950 (52e); 2805 (52d); 1740 (53e); 1947 (53d); 4511 (53e); 2853 (54f); 2893 (54e); 2894 (54e: immune barriers); 5037 (54s); 5286 (54e); 0697 (55e); 1856 (55d); 1894 (55e); 2158 (55f); 5232 (55d); 1833 (56d); 1877 (56d); 1898 (56e: pathogenesis); 1901 (56e); 4764 (56e); 5181 (56d); 3382 (57d); 0627 (58d); 0641 (58f: epidemiology); 2115 (58f); 2126 (58d: pathogenesis); 4011 (58e); 0555 (59e: newborns); 0991 (59e: local immunity); 3991 (60d: pathogenesis).

Altersverteilung / Age distribution

1707 (17e); 1549 (24d: Sweden); 0127 (28e: USA); 4004 (28d); 1042 (29d); 0089 (30e: newborns); 0335 (31e); 0381 (31e); 0455 (31e); 0717 (32e); 4005 (32d); 4123 (33d); 0328 (39e: rural: urban areas); 0327 (40e); 0923 (41e: epidemic: New South Wales); 0975 (41e); 1210 (42d); 2898 (45d: Switzerland); 0036 (47e: USA: Japan); 0429 (47e); 0062 (48e: USA: 1920–1944); 4338 (48d); 4429 (48e); 4845 (48e); 0436 (49e: Eskimos/Canada); 0926 (49e); 0220 (50e); 0236 (50e: Cleveland); 0237 (50e); 0796 (50e: Chicago); 2650 (50e: neutralizing antibodies); 3147 (50e); 3997 (50e); 0054 (51e: Eskimos: North Alaska); 1727 (51e); 2819 (51e: Buffalo); 4557 (51f); 4484 (52h: Netherlands); 0296 (53e: Tahiti); 1732 (53e: children under 6 months); 2002 (53e); 4558 (53e: neonatal period); 0259 (54e: Eskimos/Canada); 1744 (54e: season); 4589 (54e: India); 5044 (54n: Sweden); 0693 (55e: tropical areas); 0694 (55e); 0697 (55e); 1495 (55e); 1638 (55i); 1641 (55e: Scotland); 1655 (55e: Greenland); 1656 (55e); 1926 (55e: USA); 2985 (55f: Italy); 3461 (55i); 4037 (55e); 4039 (55e); 5047 (55s: Brazil); 5056 (55s); 1845 (56e: South Louisiana); 2061 (56e); 2113 (56e: New Zealand); 2425 (56d); 5065 (56i); 0192 (57h: Belgium); 0310 (57d); 0517 (57i: season); 0530 (57e: mother: newborn); 0578 (57e: Japan); 0582 (57e: Jamaica); 1207 (57i: Verona); 1277 (57e: Latvia); 1487 (57f: Tunis); 2067 (57e); 2651 (57e: Sweden); 2664 (57d: Germany); 4027 (57e); 0114 (58f); 0161 (58e: type 1 – epidemic); 0182 (58d: CFT); 0187 (58e: Stockholm); 0193 (58e: Scotland); 0203 (58e: British Guiana); 0230 (58f: France); 0231 (58f: France); 0312 (58d: Germany); 0519 (58e: Hungary); 0533 (58e: tropical areas); 0534 (58e: tropical areas); 0580 (58d: Switzerland); 0679 (58e: New Zealand); 0681 (58f: France); 1035 (58i: Italy); 1232 (58d: antibody distribution: Germany); 1233 (58d: antibody distribution: Germany: Würzburg); 1457 (58d: Germany); 2648 (58e: Japan); 0461 (59d: CFT); 0835 (59e: Winnipeg); 0867 (59e: Detroit 1958); 1131 (59h: Netherlands); 1169 (59f); 1188 (59d); 1198 (59f: Angola); 1275 (59i: Italy); 1294 (59e: Netherlands); 1299 (59e: Haifa: under 1 year of age); 1334 (59e: Libanon); 1335 (59i: Italy); 1623 (59b: Roumania); 2764 (59i: Italy); 2574 (60i: Genua); 2913 (60b: Roumania); 2931 (60e: Alaska); 4199 (61s: Spain).

Celluläre Immunität / Cellular immunity

0768 (35e: monkeys: BRODIE-vaccine); 0731 (36e); 0912 (36e); 0482 (37e); 4295 (37d); 2858 (39e: humoral immunity); 3602 (41e); 0369 (47e); 4342 (48d); 1740 (53e); 3969 (56e); 1129 (57e: masked infection in tissue culture); 2051 (57f); 3380 (57e); 0865 (58e: mice: nonspecific immunization with COXSACKIE-virus); 1243 (58e: SALK-vaccination); 2434 (58f); 0991 (59e: after live vaccination); 1228 (59i: nonspecifity); 1843 (59e: cell culture); 2778 (60r: leucaemic cell line); 3991 (60e).

Nach natürlicher Exposition / After natural exposure

Allgemeines / General

0675 (10e); 1019 (11d); 0734 (13f); 0266 (16e: micrococcus); 2142 (16e); 4004 (28d); 1042 (29d); 2140 (30e); 5336 (30e: urban and rural communities); 0381 (31e); 0448 (31e); 2207 (31e: local reaction); 5442 (31e: intracutaneous test); 0717 (32e); 0795 (32e); 4005 (32d); 0726 (33e); 0904 (33e: intracutaneous test); 3573 (33e: after abortive infection); 4123 (33d); 2744 (35e: monkey); 3529 (35d); 0731 (36e); 0830 (36e); 3516 (36e: diphtheria); 3575 (37e); 4295 (37d); 3515 (39e: SCHICK-test); 4886 (40f); 3602 (41e); 1210 (42d); 5118 (44d: drinking water); 0409 (46e); 1064 (47e); 0649 (48e); 2859 (48e: Macaca mulatta); 4845 (48e); 0706 (49e); 0929 (49e); 4384 (49e); 0220 (50e); 2685 (51e); 4410 (51f: South Africa); 4557 (51f); 2882 (52e: latency); 3034 (52e); 1982 (53d); 2148 (54f); 2605 (54e: cutan test with streptococcal antigen); 5031 (54i: hyperreactivity); 0693 (55e: under-developed areas); 1655 (55e: Greenland); 1853 (55e); 1970 (55d); 2239 (55s); 2980 (55f); 1863 (56d); 2073 (56e: Australia and New Zealand); 2496 (56s); 0630 (57e); 2321 (57f); 2664 (57d); 4262 (57e); 0627 (58d); 0642 (58e); 0643 (58e); 0681 (58f: type of virus: virulence); 1004 (58e: Africa); 1035 (58i: Italy); 3383 (58e); 1295 (59d); 1623 (59b: Roumania); 1661 (59f); 2132 (59e); 2133 (59e); 2412 (59i: intradermal test); 5376 (59i: cutaneous reactivity); 2580 (60e: Northern Israel); 2950 (60e); 4188 (60r: subclinical inapparent forms); 4575 (60e: live vaccination); 4658 (60e); 4217 (61e); 5337 (62d).

Antikörper / Antibody

0099 (10f); 0100 (10f: abortive cases); 0104 (10d: monkeys); 0106 (10e); 3572 (10f); 3574 (10e: abortive cases); 0103 (11e: abortive cases); 1057 (11d); 4863 (11e); 4395 (12e); 4871 (12d); 0324 (13f: contacts); 4387 (13f); 4921 (13f); 4929 (14d); 0374 (16e); 0364 (18e: opsonic action against streptococci); 3584 (19e: opsonins for streptococcus); 3581 (21e: epidemic encephalitis); 0288 (30e); 0304 (30e); 0340 (30e); 0341 (30e); 0354 (30e: Atlanta/Georgia); 0459 (30e); 4525 (30d); 0090 (31e: after abortive infection); 0448 (31e); 0455 (31e); 0456 (31e: Porto Rico); 0737 (31e); 3008 (31e); 0028 (32e); 0143 (32e); 0716 (32e); 0807 (32e: China); 1200 (32e); 2202 (32e: Liberia); 4682 (32d); 4686 (32e: coli-agglutinin); 0380 (33e: abortive infection); 0726 (33e: menstruation and pregnancy); 3570 (33f);

3573 (33e: abortive cases); 3681 (33f: spinal fluid); 3685 (33e: Liberia); 0153 (34e); 0735 (34e); 3679 (34f: spinal fluid); 0382 (35e); 0703 (35e: skin test); 0704 (35e); 0723 (35e); 0814 (35e); 0817 (35e); 0820 (35e: pregnancy); 3599 (35e: Philippines); 4775 (35n); 5132 (35e: tears, saliva and cerebrospinal fluid); 0020 (36e); 0427 (36e); 0463 (36e); 0468 (36e); 0877 (36e); 0912 (36e); 1965 (36e: Middle America); 5119 (36e: monkey); 0872 (37e); 3585 (37e); 0167 (38e: tropical areas); 0337 (38e: second attacks); 3322 (38e); 3580 (38e); 4802 (38f); 0358 (39e); 3558 (39e: heterologous antibodies); 0327 (40e); 1835 (40e); 3642 (40t); 4107 (41e); 0624 (42e: type specifity); 2711 (42e: immunity); 3604 (44e); 0622 (45e: mouseadapted LANSING-strain); 4837 (46e: West Africa); 0039 (47e); 0884 (47e); 0071 (48e: antiviral substances of nasopharyngeal secretions); 0338 (48e: infecting strain); 1269 (48e); 3004 (48e: Southern Africa); 3357 (48e); 4337 (48f); 4419 (48t: CSR); 0072 (49e: human gammaglobuline: 3 types of virus); 0334 (49e: specifity); 2796 (49e: monkeys: local antibody formation: CNS); 4222 (49e); 4366 (49d: convalescent serum); 4428 (49e: LANSING C (M) variant); 5335 (49f: France); 0195 (50e: Canada); 0721 (50e); 2649 (50e: Alaskan Eskimos); 1650 (50e: Baltimore); 2707 (50e: Polio and COXSACKIE); 3397 (50e: antibodies against Col. SK- and YSK-virus); 0044 (51e: second attacks); 0054 (51e: Eskimos: North Alaska); 1685 (51e: contacts); 2230 (51e Eskimos); 2621 (51e: social serology); 2628 (51f); 2633 (51e: animal sera: Japan); 2775 (51f: St. Augustin/Canada); 2817 (51e); 3127 (51e: Japan); 3219 (51e: South Africa); 3965 (51e); 4412 (51e: LANSING antibody); 4416 (51s: LANSING antibody: rabies vaccination); 1680 (52e: CFT); 1682 (52e: CFT: neutralizing antibodies); 1692 (52e: type specifity); 1693 (52e: duration of homotypic antibodies); 2029 (52e: type 2); 2040 (52e: Eskimos); 2704 (52e: CFT); 2746 (52f); 2882 (52e: chimpanzees); 2892 (52e: immunity); 3363 (52e: North Carolina); 4021 (52e: geography); 4448 (52e: Egypt); 4449 (52e); 4456 (52e: Quebec/Canada); 4480 (52e: Bombay); 4483 (52e); 0293 (53e: abortive infection); 0296 (53e: Tahiti); 1740 (53e; 2002 (53e); 2734 (53f: epidemic: St. Augustin/Canada); 2899 (53d); 2962 (53e: monkey); 2965 (53e: during epidemic); 3030 (53e: San Francisco, Mexico City, Guam); 3126 (53e: North Australia); 3136 (53e); 3384 (53e: Szeged/Hungary); 4503 (53pl: Poland); 4523 (53i: Italy); 0259 (54e: three types: Canada: Eskimos); 1512 (54i: Italy); 1825 (54i); 1847 (54e); 2232 (54e: contacts); 2465 (54e); 2798 (54e: Georgia); 4028 (54i); 4034 (54n: Sweden); 4052 (54f: Brazzaville: CFT); 4174 (54e: viremia); 4534 (54e: Great Britain: USA); 4537 (54e: epidemic in Winston-Salem, N. C.); 4589 (54e: India); 5023 (54e: Col.-SK-virus: Mexico); 5038 (54f: Belgium); 5230 (54n); 5259 (54i: Italy); 0692 (55e); 0693 (55e); 0697 (55e); 1496 (55e: Uruguay); 1518 (55e: NW-Mexico); 1575 (55e: immunity); 1576 (55e: Uruguay); 1579 (55e: Western Australia: epidemic); 1630 (55e); 1632 (55e: New Zealand); 1651 (55f: Uruguay); 1663 (55e); 1765 (55e: Israel); 1776 (55e); 1791 (55i: Italy: type 2 – epidemic); 1794 (55e: CFT); 1806 (55e); 1821 (55e: South Australia); 1836 (55e: Tahiti); 1837 (55e: Morocco); 1838 (55e: North Australia); 1840 (55e: Charleston/USA); 1848 (55e: CFT); 1872 (55f); 1876 (55e: CFT); 1883 (55i); 2037 (55e: contacts); 2253 (55e: contacts

within households); 2254 (55e: Michigan); 2255 (55e: neutralization: CFT); 2536 (55d: micro-CFT); 2539 (55d); 2540 (55d: micro-CFT); 2597 (55e: Melbourne); 2636 (55f); 2983 (55e: England); 2985 (55f: Italy); 2987 (55f: Belgium); 2988 (55f: Bucarest: type 2); 4032 (55s); 4056 (55e); 4605 (55f: Belgium); 4609 (55n: CFT); 4611 (55e); 4617 (55s: Chile); 4623 (55e: Connecticut/USA); 5045 (55n: Finland); 5204 (55e: Aaland Islands); 1340 (56e: Hungary); 1650 (56e: hospital personnel); 1657 (56e: French Oceania); 1830 (56d); 1832 (56e: England); 1834 (56e: epidemic: New York); 1844 (56e: North Ireland); 1845 (56e: South Louisiana); 1849 (56e: contacts); 1852 (56d: CFT: neutralization); 1855 (56d: CFT); 1860 (56d); 1870 (56f: Geneva); 1885 (56i: Palermo/Italy); 1896 (56f: Belgish Congo); 1902 (56e: Brasilia); 1906 (56e: Island); 1918 (56d: Germany: type 2); 1923 (56e: heterotypic antibodies); 1927 (56e); 1932 (56e: Turkey); 2034 (56d: Geneva); 2061 (56e: immunity); 2073 (56e: Australia and New Zealand); 2098 (56e: Liberia); 2106 (56e: New Zealand); 2113 (56e: New Zealand); 2175 (56e: type specifity); 2187 (56b: Bucarest); 2425 (56d); 2443 (56f: Savona/Ligurien); 2479 (56i: Naples); 2482 (56i: Italy: vaccination); 2498 (56s: Brazil); 2550 (56d: micro-CFT); 2553 (56d: Hamburg); 3084 (56e: Sweden); 3121 (56f); 3134 (56f: Paris); 3969 (56e: Finland); 4753 (56i); 4755 (56e); 4759 (56f); 4762 (56d); 4765 (56e); 4767 (56e: epidemic on the Aaland Islands); 4771 (56e: Glasgow); 4772 (56d: Switzerland); 4773 (56i: CFT); 4905 (56e); 5205 (56e: New Zealand); 5207 (56e: Aaland Islands); 0115 (57b: specifity?); 0573 (57f: France); 0575 (57f); 0578 (57e: Japan); 0582 (57e: Jamaica); 0593 (57e: pediatricians); 0859 (57e: CFT: neutralization test); 0943 (57e); 0998 (57f: Central Africa); 1524 (57e: Alaska); 1528 (57e: Louisiana); 1530 (57f: Louisiana); 1966 (57d: North Germany); 1967 (57e: Scotland); 1969 (57e: Sweden); 1973 (57f: Switzerland); 2046 (57e: Manitoba); 2056 (57d: Switzerland); 2059 (57e: London); 2066 (57e: Louisiana); 2067 (57e: reinfection); 2071 (57e: Helsinki); 2074 (57i: newborns in Genua); 2077 (57e: Nebraska); 2079 (57d: Bayern); 2081 (57e: East Saudi Arabia); 2083 (57i: Sardinia); 2085 (57i: Savona/Italy); 2091 (57i: Italy); 2104 (57e: USA: Cairo); 2116 (57e: North Ireland: social structure); 2128 (57e: Israel); 2192 (57i: young children: virus excretion); 2319 (57e); 2327 (57d: micro-CFT); 2333 (57d: Bern/Switzerland); 2335 (57e: Charleston and Phoenix/USA); 2336 (57e: virus-excretion); 2428 (57f: Congo); 2484 (57p: South Africa); 2491 (57f: Belgium); 2493 (57n: Sweden); 2507 (57e: Peru and Colombia); 2511 (57e: Japan); 2542 (57d: Niedersachsen/Germany); 2651 (57e: Sweden); 3067 (57e: New Zealand); 3380 (57e: avidity); 3419 (57e: avidity); 4027 (57e); 4269 (57j: Tokyo); 4270 (57e); 4774 (57d: CFT); 4942 (57i: Italy); 4950 (57i: young children); 5194 (57d: New Orleans); 5198 (57i: Bologna); 5208 (57h: CFT); 5296 (57f: Leopoldville); 5299 (57e: India); 0161 (58e: before and after type 1 – epidemic); 0182 (58d: CFT); 0187 (58e: Stockholm); 0202 (58f: Belgish Congo); 0203 (58e: British Guiana); 0230 (58f: France); 0231 (58f: France); 0232 (58f: France); 0244 (58d: Germany); 0386 (58e: pregnancy); 0389 (58e: CFT); 0390 (58d); 0576 (58i: Italy); 0580 (58d: Switzerland); 0599 (58e: pediatricians); 0628 (58d); 0635 (58e); 0643 (58e); 0647 (58i: mother: newborn); 0678 (58i: Italy); 0679

(58e: New Zealand); 0680 (58f: France); 0682 (58i: Italy); 0685 (58f: Belgium: indication for vaccination); 1003 (58f: Belgish Congo); 1006 (58f: France); 1020 (58e: Maori: Europeans); 1025 (58f: Bucarest); 1139 (58f: France); 1140 (58i: Naples); 1143 (58i: Turin); 1213 (58f: SW-France); 1232 (58d: young children: Germany); 1233 (58d: young children: Germany: Würzburg); 1339 (58d); 1457 (58d: Germany); 1458 (58d: Germany: social structure); 2121 (58d: Switzerland); 2259 (58s: Ribeirão Prêto/Brazil); 2262 (58f: France: Vietnam); 2434 (58f); 2514 (58e); 2648 (58e: Japan); 2697 (58f: Greece); 2888 (58e: Japan: early infancy); 3310 (58i: animals); 3311 (58i: cattle); 4051 (58e: muscle weakness); 4271 (58d); 4272 (58e: Ireland); 4282 (58j: Japan); 4283 (58j: polyradiculoneuritis); 5312 (58e: COXSACKIE- and ECHO-viruses); 5374 (58f: Port Gentil/Gabon); 0461 (59d: CFT); 0524 (59e); 0543 (59f); 0544 (59f: Dakar); 1029 (59e: Nebraska/USA); 1118 (59e: Eskimos); 1131 (59h: children: Amsterdam); 1169 (59f); 1217 (59e: Norway); 1285 (59e); 1294 (59e: Netherlands); 1308 (59i: intracutaneous test); 1316 (59f: tuberculosis); 1317 (59h: Netherlands); 1318 (59d: combined antigens); 1319 (59f: combined antigens); 1382 (59f: France); 1410 (59d: Wien); 1415 (59f: France); 1426 (59f: France); 1516 (59e); 1622 (59f: Paris); 1624 (59f: Dakar); 1625 (59f: Madagascar); 1933 (59f: France: season); 1934 (59f); 1958 (59e: Hungary); 2265 (59i: Terranegra/Padua); 2266 (59e: St. Lucia); 2269 (59i: cutaneous reaction); 2288 (59b: Bucarest); 2302 (59r: Armenian S. S. R.); 2414 (59e: CFT); 2415 (59e: Norway); 2448 (59j: Okayama/Japan); 2451 (59e: Caribbean Islands, British Guiana and Ecuador); 2522 (59s: Cuba); 2577 (59f: France); 2764 (59i: Italy); 2961 (59e: Matsumoto/Japan); 3025 (59h: family contacts); 3060 (59i); 3167 (59e: Netherlands); 3172 (59e: Medellin/Colombia); 3174 (59e: Mexico); 3181 (59e: Costa Rica); 3184 (59e: Uruguay); 3220 (59e: Mexico City); 3231 (59e: Leopoldville/Congo); 3234 (59e: Esthonian and Lithuanian S. S. R.); 3314 (59i: mother: newborn); 4274 (59f); 4275 (59e: serum: faeces); 4289 (59e); 5364 (59e); 5403 (59d); 1377 (60d: Berlin); 1959 (60d: Niedersachsen); 1993 (60e: after SALK-vaccination); 1995 (60e: Congo); 2295 (60b: Roumania); 2357 (60e: Israel); 2381 (60f); 2383 (60f: Cape Verde Islands); 2388 (60e: Guatemala); 2393 (60e: maternal: umbilical cord: infantal antibodies); 2396 (60e: families contacts); 2409 (60e: Nicaragua); 2411 (60u: Hungary); 2513 (60e: Mexico); 2531 (60d: CFT); 2556 (60e: Guatemala); 2557 (60r: USSR); 2568 (60f: micro-flocculation-test); 2569 (60f: micro-flocculation-test); 2582 (60d: diaplacental transfer); 2783 (60i: Messina); 2802 (60f); 2891 (60d: Germany); 2907 (60f: Paris); 2908 (60i: intradermoreaction); 2924 (60 0: Turkey); 2927 (60i: intradermoreaction); 2954 (60e: Alaska); 2955 (60e: Alaska/Bering Sea); 2957 (60d); 2958 (60b: Roumania); 2973 (60e: New Haven/Conn.); 3021 (60e: Papuans: New Guinea); 3096 (60d: Wien); 3099 (60d: Nieder-Oesterreich); 3315 (60t); 3316 (60r); 3338 (60e: USSR); 3395 (60i: persistence of antibodies of maternal origin); 3429 (60h: Netherlands: Curaçao); 3452 (60b: Roumania); 3464 (60e: Northern Rhodesia); 3477 (60r: USSR); 3489 (60e: Belfast 1960); 3971 (60i: Bologna); 3973 (60pl: Poland); 3980 (60s: Valencia); 4072 (60e: Roumania); 4078 (60e: Indonesia); 4114 (60e: Taipei area); 4138 (60f: Congo:

wild monkey); 4207 (60e: Serbia); 4405 (60e: Philadelphia); 4658 (60e); 4730 (60i); 4861 (60e); 4874 (60e: ČSR); 4883 (60i: auto-antibody); 4903 (60e); 4908 (60e); 4920 (60e: Mexico); 5026 (60e: Southern Africa); 5040 (60e: Sottunga Island/Finland); 5063 (60e: India); 5347 (60e: newborn twins); 5358 (60i: anticell-fraction sera); 5441 (60i); 5445 (60e: Serbia); 3334 (61e: USSR); 3485 (61e: micro-precipitin test); 4198 (61e: Andaman Islands); 4203 (61e: Massachusetts); 4243 (61f: CFT); 4245 (61f: Valencia); 4249 (61e: in human urine); 4301 (61e: Yonago/Japan); 4381 (61d); 4632 (61e: live vaccination); 4634 (61f: CFT); 4637 (61d); 4638 (61f: SW-France); 4642 (61e: Szeged); 4643 (61e: Newfoundland); 4644 (61e: St. Vincent Island/West Indies); 4878 (61d: latent infection); 4891 (61u); 4991 (61pl: Poland); 5057 (61f); 5123 (61e: Finland); 5151 (61e: Greenland: India: USA); 5315 (61s: Spain); 5353 (61b: Croatia).

Epidemiologisch-statistischer Nachweis / Epidemiological statistical evidence

1549 (24d: Sweden); 2140 (30e: distribution of age and season); 3601 (37f: Sweden); 4338 (48d); 4429 (48e: New York); 2222 (50i); 5044 (54n: Sweden); 0694 (55e); 2224 (55s: under-developed areas); 2113 (56e: New Zealand); 0630 (57e); 4262 (57e: South Africa); 0191 (58e); 0393 (58e: human amniotic fluids); 0679 (58e: New Zealand); 0835 (59e: Winnipeg); 1334 (59e: Libanon); 2931 (60e: Alaska); 4199 (61s: Spain); 5494 (61s: Rosario/Argentine).

Spezifität des Virustyps / Specifity of types

0379 (33e); 0382 (35e); 0705 (38e: monkeys); 0803 (39e: monkeys); 0338 (48e); 0179 (49e: monkeys: reinfection); 0180 (49e: monkeys); 0334 (49e: antibody against infecting strain); 4904 (57s: hamster: Col SK); 0312 (58d); 1192 (59e: type 3: type 1); 2527 (60e: CFT).

Zweiterkrankung / Reinfection

3567 (86i); 0104 (10d); 0105 (10e); 0108 (10e: monkeys); 0109 (10e: monkeys); 0666 (10e); 4849 (10f: monkey); 0333 (11d); 4854 (11e: monkey); 0664 (12e); 0332 (13e: virus excretion); 0768 (15s); 3649 (15s); 0374 (16e); 0596 (16e); 3654 (16e); 3646 (17e); 3653 (18e); 0665 (19e); 0611 (23f); 0552 (30e); 0005 (31e: monkeys); 0285 (34e); 0907 (34e); 2229 (34e); 3647 (34n); 3652 (34d); 0718 (35e); 3651 (35s); 0738 (36e: monkeys); 0829 (36e: monkeys: heterologic strain); 0883 (36e: monkeys: antibody); 3568 (36f); 3650 (36i); 4602 (36d); 0452 (37e); 0728 (37e: monkeys); 4294 (37d); 0166 (38e); 0337 (38e: antibody); 0705 (38e); 2874 (38e: monkey); 3648 (38n); 3600 (39e: monkey); 3267 (40e); 0712 (41e: Rhesus-monkeys); 2065 (41e: monkeys); 0624 (42e: type specifity); 0140 (43e: *Macaca mulatta*); 0126 (45e: chimpanzees); 5213 (45d); 5289 (45e); 0409 (46e); 0197 (47e); 0369 (47e); 0711 (47e: chimpanzees); 3297 (47e); 2859 (48e: *Macaca mulatta*); 4834 (48e); 0179 (49e: monkeys: type of virus); 0706 (49e); 0195 (50e); 0236 (50e); 2863 (50e); 0044 (51e: type of virus); 0110 (51n); 2670 (51e); 2995 (51e); 3460 (51t); 4417 (51e); 2129 (52e: type of virus); 3165 (52d); 1740 (53e); 2006 (54d); 2286 (54d); 3122 (54e); 1853 (55e); 2239 (55s); 4019 (55e); 2108 (56e);

4759 (56f: antibody titre); 2336 (57e); 4904 (57s: hamster: Col.-SK-virus); 0191 (58e); 1192 (59e: type 3: type 1); 2302 (59r); 1293 (60d).

Nach Schutzimpfung / After vaccination

Allgemeines / General

1019 (11d); 1023 (35e); 2280 (35e); 0076 (36e: BRODIE-vaccine); 0084 (36e: North Carolina 1935: BRODIE- and KOLMER-vaccine); 0085 (36e); 0731 (36e); 3270 (36f); 3666 (38e: against diphtheria); 0649 (48e); 0929 (49e); 0353 (51e); 4493 (52i: transmission of immunity); 1740 (53e); 1750 (53e); 1952 (53e); 0854 (54e); 1748 (54e); 2459 (54e); 2622 (54e); 2623 (54e); 2626 (54s); 2630 (54e); 2814 (54d); 4504 (54e); 5265 (54e); 0697 (55e); 1814 (55e: live vaccine); 1817 (55i); 1818 (55f); 1846 (55e); 1880 (55s); 1889 (55s); 1928 (55s); 1978 (55e); 2012 (55e); 2036 (55d); 2103 (55e); 2151 (55h); 2152 (55f); 2153 (55e); 2239 (55s); 2421 (55e); 2627 (55s); 2635 (55n); 2980 (55f); 3952 (55p); 4142 (55e); 4595 (55e); 1819 (56d); 1831 (56d); 1839 (56d: small pox vaccination); 1857 (56d); 1997 (56d); 2061 (56e); 2159 (56e); 2183 (56e); 2309 (56u); 2310 (56e); 2330 (56f); 2426 (56d); 2496 (56s); 2498 (56s); 2549 (56d); 2970 (56e: SALK-vaccine); 3017 (56n: SALK-vaccine); 3963 (56e); 0310 (57d: SALK-vaccine); 0942 (57e); 0995 (57e); 1971 (57f); 2088 (57i); 2112 (57f); 2117 (57d); 2138 (57e); 2184 (57e); 2321 (57f); 2416 (57e: 4. internat. Conf. Geneva); 2417 (57r: 4. internat. Conf. Geneva); 2418 (57s: 4. internat. Conf. Geneva); 2419 (57e: 4. internat. Conf. Geneva); 2430 (57f: 4. internat. Conf. Geneva); 2500 (57f); 3257 (57e: SALK-vaccine); 0201 (58s: early infancy: live vaccine); 0243 (58f: Belgium); 0356 (58e: live vaccine); 0413 (58r: SALK-vaccine: USSR); 0554 (58f); 0586 (58d); 0677 (58e); 0848 (58e); 1034 (58i: combination: live and inactivated vaccine); 1142 (58d); 1145 (58f); 1146 (58f); 1238 (58i: number of injections); 1243 (58e: SALK- and live vaccine); 1315 (58b: protection against herpes infection); 1540 (58e); 3383 (58e); 0262 (59e: live vaccine); 0431 (59e); 0432 (59e); 0462 (59e: USA); 0571 (59e); 0868 (59d); 0991 (59e: live vaccine); 0994 (59d); 1000 (59d: live vaccine); 1022 (59d: revaccinations); 1054 (59d); 1144 (59e); 1147 (59f); 1168 (59e: under 6 months of age); 1195 (59e: live vaccine); 1202 (59e: live vaccine); 1290 (59f); 1301 (59f); 1661 (59f); 2132 (59e); 2133 (59e); 2369 (59r: live vaccine); 2848 (59i: VI. europ. Symposium); 5376 (59i: cutaneous reactivity); 1984 (60d: live vaccine); 2356 (60d: live vaccine); 2366 (60e: live: killed vaccine); 2371 (60e: live vaccine); 2396 (60e); 2571 (60e: SABIN-type 3: contact infections); 2611 (60i); 2776 (60e: 5th Conf. Copenhagen); 2947 (60e); 3033 (60d); 3985 (60e: newborn infants: SABIN-vaccine); 4125 (60d); 4230 (60r: live vaccination); 4255 (60d); 4300 (60e: quadruple antigen: young infants); 5469 (60d); 4732 (60e: live vaccine); 2919 (61d); 2932 (61d); 3341 (61d); 4140 (61d); 4217 (61e); 4240 (61d); 4260 (61e: SALK-vaccination: virus excretion after oral vaccination); 4639 (61d: live vaccine); 4641 (61d: dose and application); 4645 (61e); 4648 (61e: live vaccine).

Antikörper / Antibody

0106 (10e: monkeys); 0154 (30e: horse: immune sera); 0006 (31e: horse: immune sera); 0144 (31e: monkeys: types of virus); 0408 (31e: monkeys); 2855 (34e: BRODIE-vaccine); 3005 (34e: KOLMER-vaccine); 0470 (35e: BRODIE-vaccine); 0703 (35e: skin test); 0704 (35e: KOLMER-vaccine); 0723 (35e: BRODIE-vaccine); 0724 (35e: KOLMER-vaccine); 0725 (35e: KOLMER-vaccine); 0751 (35e: KOLMER-vaccine); 0818 (35e: BRODIE-vaccine); 0913 (35e: BRODIE-vaccine); 3526 (35e: BRODIE-vaccine); 3594 (35e: BRODIE-vaccine); 3896 (35f: KOLMER-vaccine); 4318 (35d: KOLMER-vaccine); 4719 (35e: formaldehyde-inactivated vaccine); 0016 (36e: monkeys); 0017 (36e: children: formaldehyde-inactivated vaccine); 0020 (36e); 0077 (36e: BRODIE-vaccine); 0078 (36e: KOLMER-vaccine); 0427 (36e: BRODIE- and KOLMER-vaccine); 0471 (36e: monkeys); 4776 (36f: KOLMER-vaccine); 4574 (45e: mice: uv-inactivated vaccine); 0042 (47e: monkeys); 0043 (47e: monkeys: distribution of antibodies); 0021 (49e: monkeys); 0034 (50e: monkeys: stimulation by adjuvants); 2030 (52e); 2892 (52e: immunity); 2918 (52e: live vaccine); 1670 (53e); 1769(53e); 2631 (53e: TN-strain: KOPROWSKI); 3136 (53e: SALK-vaccine); 3962 (53e: SALK-vaccine); 0069 (54e); 1565 (54e); 1755 (54e: UV-vaccine); 2724 (54e: live vaccine); 2893 (54e); 3037 (54e); 3964 (54e: persistence of antibodies after live vaccination); 4530 (54e: SALK-vaccine); 0024 (55e: children: formaldehyde-inactivated vaccine); 0698 (55e: live vaccine); 0839 (55e: Denmark 1955); 1495 (55e); 1610 (55e); 1766 (55d); 1768 (55d); 1771 (55e); 1773 (55d); 1775 (55e); 1776 (55e); 1778 (55e: live vaccine); 1793 (55d); 1807 (55e); 1820 (55e: booster effect); 1876 (55e: CFT: neutralization); 1881 (55e: live vaccine); 1908 (55d); 1924 (55e: live vaccine); 2082 (55e: Swedish vaccine); 2103 (55e); 2240 (55s: live vaccine); 2257 (55e: live vaccine); 2475 (55e: live vaccine); 2813 (55d: Behringwerk-vaccine); 2981 (55e); 2982 (55e: SALK-vaccine: Denmark); 2984 (55e: German vaccine); 4038 (55e: SALK-vaccine); 4588 (55e: SALK-vaccine); 0673 (56e: live vaccine); 1465 (56i); 1521 (56e: South Africa-vaccine); 1569 (56e); 1824 (56d); 1851 (56e: type 1); 1879 (56e); 1882 (56e: UV-vaccine); 1892 (56e: simultaneous vaccination); 1913 (56d: German vaccine); 1927 (56e); 1954 (56e: live vaccine); 1965 (56e: Middle America); 1979 (56e: live vaccine: young infants); 1996 (56d: German vaccine); 2033 (56d); 2047 (56e: live vaccine); 2053 (56e: SALK-vaccine); 2097 (56e: live vaccine); 2180 (56e: live vaccine); 2227 (56e); 2306 (56d); 2442 (56d; SALK-vaccine); 2445 (56i: neutralization: CFT); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 3101 (56e); 4025 (56e: SALK-vaccine); 5243 (56f: SALK-vaccine: young infants); 0387 (57e: live vaccine: SALK-vaccine); 0548 (57e); 0605 (57e: young infants); 0857 (57e); 0937 (57e: SALK-vaccine); 0940 (57e: live vaccine); 0972 (57e: antigenicity); 1513 (57d: Switzerland); 1528 (57e); 1945 (57e); 1964 (57e: live vaccine); 1972 (57e: British vaccine); 2048 (57e); 2094 (57e: second injection: SALK-vaccine); 2105 (57e); 2124 (57f: Belgium); 2139 (57e); 2304 (57e: live vaccine: SM type 1); 2305 (57e: live vaccine: SM type 1 and TN type 2); 2319 (57e); 2333 (57d); 2431 (57d: Switzerland); 2487 (57e: British vaccine); 2493 (57n: Sweden); 2741 (57e: live vaccine); 2808 (57e: pregnant women); 3012 (57e: SALK-vaccine); 3013 (57e:

SALK-vaccine); 3014 (57e: SABIN-vaccine); 3015 (57e); 3163 (57e: FRANCIS-report); 3368 (57e: live vaccine); 3377 (57e: infection with live vaccine); 3380 (57e: avidity); 4266 (57i); 4273 (57s: SALK-vaccine: pregnant women); 0185 (58e: pregnant women); 0191 (58e: SALK-vaccine); 0201 (58s: live vaccination: neonatal period and early infancy); 0227 (58e: SALK-vaccine: Idaho 1955); 0228 (58e: children: SALK-vaccine); 0229 (58f: French vaccine); 0232 (58f: French vaccine); 0244 (58d: Germany); 0246 (58d: SALK-vaccine: live vaccine); 0357 (58e: live vaccine); 0384 (58e); 0386 (58e: pregnant women and young infants); 0389 (58e: animal experiments: CFT); 0390 (58d: SALK-vaccine); 0393 (58e: human amniotic fluids); 0507 (58d: SALK-vaccine); 0508 (58d: neutralizationtest: CFT); 0521 (58e: young infants: live vaccine); 0553 (58s); 0579 (58d: SALK-vaccine); 0589 (58d: SALK-vaccine); 0603 (58e: revaccination); 0604 (58e: British vaccine); 0610 (58e); 0638 (58h: live vaccine); 0646 (58e); 0651 (58e); 0652 (58e); 0653 (58f); 0654 (58e); 0660 (58f: Italian vaccine); 0684 (58e: application); 0686 (58s: live vaccine); 0691 (58e); 0844 (58e: CSR 1957); 0850 (58e: potency of inactivated vaccines); 0860 (58d: Switzerland 1957); 0890 (58d: Westfalen); 0990 (58f: Belgish SALK-vaccine); 1127 (58f); 1148 (58f: LEPINE-vaccine); 1236 (58f: booster-injection); 1240 (58e: SALK-vaccine); 1248 (58e: infants: SALK-vaccination); 1339 (58d); 1343 (58e); 1519 (58e: multiple antigen); 1584 (58e); 1935 (58e: UV-formalin-vaccine); 2322 (58e: jet injection); 2928 (58i); 4271 (58d: SALK-vaccine); 4288 (58i: SALK-vaccine); 5420 (58e: SALK-vaccine); 5424 (58n: intracutaneous: subcutaneous injection); 0258 (59e: live vaccine); 0361 (59e: formaldehyde vaccine: early infancy); 0385 (59e: live vaccine); 0430 (59e); 0490 (59d: SALK-vaccine); 0568 (59e); 0569 (59e); 0600 (59e: multiple antigens); 0840 (59e: live vaccine); 0853 (59e); 0905 (59e: rapid immunization with one dose); 0965 (59e: duration); 0976 (59e: live vaccine); 0985 (59e: uv-inactivated vaccine); 0986 (59e: live vaccine); 0987 (59e: SALK-vaccine); 0989 (59e: multiple antigen); 0992 (59e: live vaccine); 0996 (59e: SALK-vaccine: 4. injection); 1007 (59t: intracutaneous application); 1008 (59e: booster-dose); 1009 (59e: booster-dose); 1087 (59e: live vaccine); 1092 (59e: SALK-vaccine); 1121 (59f: French SALK-vaccine); 1130 (59e: young infants); 1163 (59e: live vaccine); 1164 (59e: live vaccine); 1165 (59e: live vaccine); 1169 (59f); 1170 (59e: 3. dose); 1202 (59e: live vaccine); 1205 (59e: trivalent live vaccine); 1214 (59e); 1216 (59e: intracutaneous SALK-vaccination); 1222 (59e: quadruple antigen); 1223 (59d: multiple antigens); 1225 (59e: live vaccine: early infancy); 1226 (59e: live vaccine); 1229 (59e: SALK-vaccination: infection); 1278 (59e: live vaccine: young infants); 1284 (59e); 1292 (59d); 1308 (59i: skin test); 1313 (59e: live COX-vaccine); 1314 (59r: live vaccine); 1324 (59i); 1330 (59i: Italy); 1344 (59f: live vaccine); 1350 (59f: live vaccine); 1368 (59e: multiple antigen); 1370 (59t: SALK-: SABIN-vaccination); 1371 (59i: intracutaneous injection); 1381 (59f); 1382 (59f); 1414 (59f); 1415 (59f); 1426 (59f); 1431 (59e: live vaccine); 1658 (59i); 1843 (59e: in cell cultures); 1940 (59i: pregnancy); 2269 (59i: cutaneous reaction); 2292 (59s: live vaccine); 2293 (59s: live vaccine); 2398 (59e: quadruple antigen); 2415 (59n: Norway: SALK-vaccine); 2522 (59s: Cuba: live vaccine); 2562 (59d: combined vaccine); 2930

(59i: DPT-Polio); 3082 (59e: live vaccine); 3158 (59e: Cox-vaccine); 3159 (59e: pregnant women: Cox-vaccine); 3164 (59e: resistance to infection and duration of excretion); 3167 (59e: Netherlands: SABIN-vaccine: virus excretion); 3172 (59e: Medellin/Colombia: live vaccine); 3174 (59e: SABIN-vaccine: Mexico); 3177 (59e: CHAT-strain: Poland); 3182 (59e: Cox-vaccine: Finland); 3213 (59e: CHAT-strain); 3218 (59e: Cox-vaccine: infants under six month); 3220 (59e: Mexico City: SABIN-vaccine); 3223 (59e: USSR: SABIN-vaccine); 3227 (59e: SABIN type 3); 3231 (59e: CHAT-strain: Leopoldville/Congo); 3234 (59e: SABIN-vaccine: USSR); 3235 (59e: SABIN-vaccine: ČSR); 4274 (59f); 4276 (59e: increased amounts of SALK-vaccine); 4284 (59e: quadruple antigen); 4287 (59i: quadruple antigen); 5467 (59d: SALK-vaccine); 1346 (60d); 1352 (60d: Germany); 1362 (60e: live vaccine); 1367 (60d: live vaccine); 1377 (60d: SALK-vaccine); 1397 (60d: quadruple antigen); 1433 (60e: live vaccine); 1959 (60d); 1990 (60e: 4. dose of SALK-vaccine); 1991 (60e: CHAT-strain); 1995 (60e: CHAT-strain: Congo); 2316 (60f: neutralization: immuno-inactivation [GARD]); 2350 (60d: combined vaccines); 2352 (60e: concentrated SALK-vaccine); 2353 (60e: live vaccine); 2357 (60e: Israel: SALK-vaccine); 2358 (60e: trivalent live vaccine); 2359 (60e: live vaccine); 2375 (60d: SALK-vaccine); 2381 (60f); 2392 (60e: SALK-vaccine); 2394 (60d: combined antigens); 2401 (60d: CHAT-strain); 2409 (60e: live vaccine); 2439 (60e: SALK-vaccine: increased amounts); 2486 (60s: live vaccine); 2513 (60e: live vaccine: interference); 2558 (60e); 2559 (60e: live vaccine); 2560 (60s: live vaccine); 2561 (60f: SALK-vaccine); 2565 (60i: SABIN's live vaccine); 2571 (60e: SABIN-type 3); 2572 (60e: Cuba: Cox-vaccine); 2586 (60e: Miami: Cox-vaccine); 2587 (60e: persistence of antibody after 3. dose of SALK-vaccine); 2591 (60e: DPT-Polio); 2592 (60e: Cox-vaccine: Florida); 2700 (60i); 2774 (60i: CFT: SALK-vaccine); 2788 (60e: CHAT-strain: Congo); 2791 (60e: SALK-vaccine: four years after field trial); 2792 (60pl: CHAT-strain: Poland); 2802 (60f); 2869 (60e: Compligen); 2887 (60e: SALK-vaccine); 2902 (60e: SALK-vaccine); 2903 (60e: live vaccine: early life); 2907 (60f); 2934 (60i: DPT-Polio); 2937 (60i: early infancy); 2940 (60i: DPT-Polio); 2943 (60f: DPT-Polio); 2948 (60e: DPT-Polio); 2951 (60d: SALK-vaccine); 2955 (60e: Alaska/Bering Sea); 2956 (60e: live vaccine); 2960 (60e: SALK-vaccine); 2973 (60e: New Haven/Conn.); 3050 (60f); 3058 (60i); 3066 (60e: SALK-vaccine); 3099 (60d: SALK-vaccine); 3196 (60e: SALK-vaccine: newborns); 3198 (60f: ČSR); 3239 (60f: combined vaccination); 3248 (60e: Cox-vaccine); 3319 (60t: combined vaccine); 3328 (60i: SALK-vaccine: flocculation test); 3331 (60he: SALK-vaccine: Israel); 3338 (60e: live vaccine: USSR); 3343 (60e: trivalent Cox-vaccine); 3391 (60e: ČSR); 3393 (60i: SALK-vaccine); 3394 (60i); 3450 (60e: ČSR: SALK- and SABIN-vaccine); 3451 (60i: Cox-vaccine); 3452 (60b: Roumanina: SALK-vaccine); 3453 (60r: Pertussis-Polio-vaccine); 3456 (60e: Hungary: SALK-vaccine); 3480 (60e: trivalent live vaccine); 3984 (60f: trivalent Cox-vaccine); 3999 (60d: live vaccine: Switzerland); 4121 (60e: SABIN-vaccine); 4189 (60i: SALK-vaccine: tuberculosis); 4197 (60s: Cox-vaccine: Cuba); 4211 (60e: rabbit and rooster: antisera); 4253 (60r: Riga); 4258 (60r: live vaccine); 4306 (60f: inapparent infections); 4332 (60e: SALK-vaccine); 4405 (60e: CHAT-

and Fox-strain: Philadelphia); 4570 (60e: live vaccine); 4575 (60e: live vaccine); 4578 (60d: live vaccine: DPT-adsorbat); 4734 (60f: SABIN-vaccine: Mexico); 4874 (60e: SALK-vaccine: ČSR); 4877 (60e: SALK-vaccine: Israel); 4881 (60i: SALK-vaccine: Italy); 4882 (60e: SALK-vaccine: duration); 4885 (60e: SALK-vaccine: duration); 4887 (60e: SALK-vaccine: standardization); 4889 (60e: DPT-Polio-vaccine); 4893 (60e: live vaccine: USSR); 4908 (60e: trivalent live vaccine); 4911 (60e: live vaccine); 4913 (60e: live vaccine: dose and schedule); 4916 (60e: live vaccine: dose and schedule); 4920 (60e: SABIN-vaccine: Mexico); 4922 (60e: live vaccine: type 2); 4925 (60e: live vaccine: virus excretion); 4927 (60e: live vaccine: virus excretion); 4964 (60r); 4965 (60e: Cox-vaccine: Costa Rica); 4966 (60r: DT-Polio-vaccine); 4974 (60e: live vaccine: Southern Louisiana); 4984 (60e: live vaccine: Japan); 4985 (60e: Cox-vaccine: pregnant women and young infants); 4989 (60e: SABIN-strain type 3: persistence of antibodies); 4990 (60e: trivalent SABIN-vaccine); 4994 (60e: Cox-vaccine: Israel); 4995 (60e: CHAT-strain: neonatal premature infants); 4998 (60e: CHAT-strain: full term infants); 5001 (60e: SABIN-strain type 1: newborn infants); 5006 (60e: Cox-vaccine: Cuba); 5009 (60e: trivalent live vaccine: Minnesota); 5011 (60e: Cox-vaccine: Minnesota); 5014 (60e: live vaccine: Cuba); 5018 (60e: SABIN-vaccine: Mexico); 5021 (60e: SABIN-vaccine: USSR); 5032 (60e: ČSR); 5036 (60e: KOPROWSKI-vaccine: Poland); 5040 (60e: Cox-vaccine: Finland); 5043 (60e: live vaccine: Nicaragua); 5295 (60e: live vaccine); 5298 (60e: live vaccine); 2771 (61d: Trivirelon); 2786 (61d: Cox-vaccine: Berlin); 2787 (61s: live vaccine: Philadelphia); 2883 (61d: Cox-vaccine: NE-Switzerland); 2890 (61h: SABIN-vaccine); 2929 (61u: live vaccine and DPT); 2939 (61e: early infancy: SALK-vaccine); 2953 (61e: SALK-vaccine: persistence); 3019 (61d: Cox-vaccine: Berlin); 3191 (61f: SALK-vaccine: pregnancy); 3289 (61e: life vaccine); 3303 (61e: Cox-vaccine: West Berlin 1960); 3305 (61d: CHAT-strain: Switzerland); 3334 (61e: live vaccine: USSR); 3355 (61e: North Ireland); 3390 (61e: live vaccine); 3483 (61e: triple antigen: neonatal immunization); 3485 (61e: microprecipitin test); 3493 (61e: live vaccine: young infants); 3988 (61i: duration of antibody after SALK-vaccination); 3989 (61d: SALK- and SABIN-vaccine); 4080 (61e: SABIN-vaccine); 4112 (61b: ČSR: SABIN-vaccine); 4117 (61e: SABIN-vaccine); 4127 (61d: trivalent Cox-vaccine: Berlin 1960); 4179 (61d: Cox-vaccine: Berlin 1960); 4180 (61d: SABIN-vaccine); 4183 (61d: SALK-vaccine); 4193 (61d: live vaccine: newborn and young infants); 4194 (61f: SALK-vaccination: duration); 4204 (61e: purified SALK-vaccine); 4225 (61f: SALK-vaccine); 4227 (61f: trivalent Cox-vaccine); 4233 (61d: SABIN-vaccine); 4236 (61e: SALK-vaccine: young infants); 4241 (61h: combined vaccine DPTP); 4252 (61e: live vaccine); 4257 (61e: SALK-vaccination: prevalence of virus in pharyngeal secretions); 4303 (61e: newborns: trivalent live vaccine); 4322 (61e: SABIN-vaccine: adults in Britain); 4345 (61s: Cox-vaccine: Uruguay); 4357 (61f: SALK-vaccine: young infants); 4359 (61d: live vaccine: Germany); 4362 (61e: ČSR); 4625 (61e: DPTP-vaccine and live vaccine); 4629 (61e: spread of Cox-vaccine); 4632 (61e: live vaccination); 4640 (61i: SALK-vaccine); 4649 (61e: DPT- and live vaccine); 4650 (61e: KOPROWSKI-vaccine: Switzerland); 4651 (61e: SABIN-vaccine: ČSR);

4652 (61e: SABIN-vaccine: newborn infants); 4653 (61s: Cox-vaccine: Florida); 4654 (61s: Costa Rica); 4660 (61e: SABIN-vaccine: Cincinnati); 4661 (61i: Rome); 4662 (61e: CHAT-strain: Congo); 4711 (61o: live vaccine); 4731 (61r: live vaccine and DPT); 4736 (61e: trivalent Cox-vaccine); 4740 (61d: trivalent Cox-vaccine: Berlin); 4742 (61d: SABIN-vaccine: Germany); 4744 (61d: SABIN-vaccine: Germany); 4748 (61d: Cox-vaccine: Berlin); 4856 (61e: ČSR: SALK-vaccine); 4858 (61d: Germany: SABIN-vaccine); 4859 (61u: DPT- and live vaccine); 4894 (61i: Di-toxoid and SALK-vaccine); 4902 (61e: SALK-vaccine: cutaneous reaction); 4968 (61e: live vaccine: Poland); 4976 (61e: live vaccine: neonates); 4987 (61f: Cox-vaccine); 4988 (61f: Cox-vaccine); 4993 (61pl: KOPROWSKI-vaccine: Poland); 5059 (61d: Cox-vaccine: newborn); 5123 (61e: SALK-vaccine: Finland); 5175 (61e: SALK-vaccine: Taiwan); 5253 (61d: SABIN-vaccine); 5255 (61e: live vaccine: duration of antibodies); 5258 (61e: live vaccine: newborn); 5277 (61e: live vaccine: Hungary); 5314 (61e: Cox-vaccine: Switzerland); 5351 (61d: Trivirelon); 5372 (61e: Cox-vaccine); 5451 (61r: SABIN-vaccine: newborn); 5482 (61pl: KOPROWSKI-vaccine); 5485 (61i: SABIN-vaccine: heterotypic reaction); 5486 (61i: SABIN-vaccine); 5487 (61i: SABIN-vaccine: revaccination); 5020 (62d: Cox-vaccine: Berlin 1960).

Epidemiologisch-statistischer Nachweis / Epidemiological statistical evidence

0076 (36e: USA: BRODIE-vaccine); 0077 (36e: BRODIE-vaccine); 0078 (36e: KOLMER-vaccine); 3379 (36e: BRODIE-vaccine); 4096 (36e); 3295 (38e: KOLMER-vaccine); 1563 (54e: USA: gammaglobuline); 0839 (55e: Denmark 1955); 1646 (55e); 1705 (55d: USA); 1782 (55e: USA 1954); 1802 (55e: USA/North Carolina); 1807 (55e: USA-FRANCIS-report); 1816 (55e: USA); 1977 (55e: USA 1954); 2155 (55i: USA); 2600 (55e: FRANCIS-report); 3072 (55e: field trials: USA); 3079 (55e: FRANCIS-report); 3166 (55e); 4588 (55e: FRANCIS-report); 5061 (55e: Southern Alameda County); 5237 (55e: SALK-vaccine); 5261 (55n: FRANCIS-report); 5279 (55s: FRANCIS-report); 1470 (56h: USA 1954); 1521 (56e: South Africa); 1527 (56i); 1551 (56e: USA); 1570 (56e: USA); 1667 (56e); 1699 (56d); 1702 (56d); 1826 (56e: Massachusetts 1955); 1859 (56d); 1862 (56h); 1874 (56e: USA); 1877 (56d); 1917 (56e: epidemic Hawaii 1955); 1953 (56d: USA 1954); 1956 (56e: Canada 1955); 1961 (56e: British Colombia); 2035 (56d: FRANCIS-report); 2093 (56e: Massachusetts 1955); 2099 (56e: New York); 2100 (56d: FRANCIS-report); 2167 (56e: Missouri); 2170 (56f); 2178 (56e: SALK-vaccine: USA); 2471 (56e: Louisiana); 2551 (56d); 2637 (56d: FRANCIS-report); 5211 (56e: SALK-vaccine: USA); 5235 (56f: SALK-vaccine); 5275 (56e: SALK-vaccine: Connecticut); 5293 (56s: SALK-vaccine: Puerto Rico); 0639 (57e); 0939 (57e: USA); 0941 (57e: live vaccine); 0942 (57e: SALK-vaccine); 1114 (57e: age distribution: USA); 1116 (57e: age distribution: Canada 1956); 1447 (57e: USA 1956); 1513 (57d: Switzerland); 1529 (57e: laboratory studies); 1537 (57e: USA); 1586 (57e: USA); 2049 (57e: North Carolina); 2057 (57e: England); 2060 (57e: FRANCIS-report); 2075 (57e: USA 1956); 2095 (57e: Canada); 2096 (57e: South Africa); 2123 (57e: Chicago 1956); 2125 (57e: Canada); 2127 (57d: Coburg

1957); 2137 (57e: SALK-vaccine: USA); 2196 (57e: Minnesota); 2315 (57e: Nebraska 1956); 2331 (57e: British Colombia); 2431 (57d: Switzerland); 2493 (57n: Sweden); 2499 (57f); 2505 (57t); 2506 (57e: United Kingdom); 2545 (57d); 2547 (57d: FRANCIS-report); 275 (57e); 3013 (57e: FRANCIS-report); 3163 (57e: FRANCIS-report); 4264 (57e: SALK-vaccine: England); 5327 (57e: FRANCIS-report); 5422 (57d: USA); 0191 (58e); 0204 (58e: Hungary: SALK-vaccine); 0235 (58e); 0249 (58d: Hungary); 0313 (58d: Germany/Niedersachsen); 0494 (58e: South Rhodesia); 0507 (58d: Germany); 0553 (58s: Mexico); 0581 (58d: SALK-vaccine: Switzerland); 0583 (58e); 0589 (58d: Switzerland); 0610 (58e); 0654 (58e: England); 0655 (58f: Belgium); 0656 (58f: Luxemburg); 0658 (58e: ČSR); 0659 (58e: Hungary: decline of epidemic curves); 0686 (58s: Belgish Congo: live vaccine); 0688 (58f: Switzerland); 0847 (58e: ČSR 1957); 0848 (58e: ČSR 1957); 0862 (58u: Hungary 1957); 0890 (58d: Westfalen); 1503 (58f: Switzerland); 1588 (58e: Ontario); 2121 (58d: Switzerland); 2320 (58e: household contacts); 2323 (58e: Minnesota 1955/56); 3465 (58he: Israel: SALK-vaccine); 4277 (58he: Israel: SALK-vaccine); 0027 (59d: USA); 0462 (59e: USA); 0663 (59e); 0835 (59e: Winnipeg); 0867 (59e: Detroit 1958); 0868 (59d); 0960 (59d); 0964 (59e: SALK-vaccine); 0973 (59e: live vaccine); 0974 (59e: live vaccine); 0976 (59e: live vaccine); 0981 (59d: Switzerland); 0983 (59e: Manitoba 1958); 0987 (59e: USA); 0993 (59e: USA); 0997 (59d: Switzerland 1958); 1027 (59d: Germany); 1133 (59e: Canada 1958); 1136 (59d: Germany 1958); 1155 (59f: Belgium); 1156 (59f: France); 1157 (59e: England); 1158 (59e: Hungary); 1159 (59f: Italy); 1160 (59e: Norway); 1161 (59d: Germany); 1165 (59e: USSR: live vaccine); 1166 (59e: Singapore: live vaccine); 1167 (59e: ČSR: live vaccine); 1199 (59e: live vaccine); 1226 (59e: live vaccine: Colombia); 1274 (59e: Canada); 1291 (59e: epidemic Chicago 1956); 1296 (59e: New Jersey 1958); 1323 (59e: Netherlands); 1328 (59e: USA); 1331 (59f: Belgium); 1332 (59r: SALK-vaccine: USSR); 1370 (59t: ČSR); 1388 (59d: Denmark); 1390 (59d: Switzerland); 1396 (59d: intracutaneous SALK-vaccination); 1407 (59e: epidemic); 1623 (59b: Roumania); 1637 (59r: Cheliabinsk/USSR); 1937 (59n); 2134 (59e: contacts: SALK- and live vaccine); 2260 (59i); 2261 (59f: Canada); 2263 (59e: statistical calculation); 2268 (59f: Belgium); 2289 (59s: Buenos Aires); 2292 (59s: Andes/Colombia: live vaccine); 2293 (59s: Managua/Nicaragua: live vaccine); 2362 (59i: Rome); 2391 (59e: USA); 2555 (59e: Southern Rhodesia); 2933 (59i); 3081 (59d: Austria); 3184 (59e: COX-vaccine: Montevideo/Uruguay); 3213 (59e: CHAT-strain: reinfection); 3231 (59e: CHAT-strain: Leopoldville/Congo); 3234 (59e: SABIN-vaccine: Esthonian and Lithuanian S. S. R.); 3235 (59e: SABIN-vaccine: ČSR); 4068 (59e); 4286 (59e: Canada); 4970 (59e: SALK-vaccine: Switzerland); 1362 (60e: USSR: live vaccination); 1367 (60d: USSR: live vaccination); 1395 (60e: epidemic type 3: Washington, D. C.); 1401 (60u: live vaccine); 1984 (60d: COX-vaccine: Switzerland); 1993 (60e: SALK-vaccine: virus dissemination); 1995 (60e: CHAT-strain: Congo); 2273 (60d: Germany); 2329 (60d: live vaccine); 2341 (60e); 2342 (60e); 2357 (60e: Israel); 2359 (60e: Mexico: live vaccine); 2363 (60e: Detroit 1958); 2387 (60e: New Jersey); 2397 (60u: Hungary); 2401 (60d: Switzerland: live vaccine);

2402 (60d: Switzerland); 2450 (60e: Kenya: live vaccine); 2523 (60f: Belgium); 2524 (60i: Genua); 2532 (60d: Cox-vaccination/Berlin); 2559 (60e: live vaccine: USSR); 2610 (60d: München); 2699 (60d); 2872 (60e: Nairushire 1958); 2879 (60e: Southampton 1958/59); 2914 (60e: England and Wales 1958); 2945 (60e: Mauritius); 2951 (60d: Canada); 2956 (60e: live vaccine: Philadelphia); 2957 (60d: SALK-vaccine: Basel); 2974 (60e: SALK-vaccine: Detroit 1958); 2977 (60e: ČSR: SABIN-vaccine); 3023 (60e: England and Wales); 3062 (60f); 3065 (60d: Florida 1960); 3086 (60i: Rom); 3233 (60e: SALK-vaccine: Alberta); 3243 (60e: live vaccine); 3317 (60t: SABIN-vaccine); 3318 (60t: SABIN-vaccine: ČSR); 3331 (60he: Israel); 3337 (60e: live vaccine); 3338 (60e: SABIN-vaccine: USSR); 3387 (60e: Canada); 3430 (60i: SALK-vaccine: Italy); 3431 (60e: SALK-vaccine: Tennessee); 3450 (60e: ČSR: SABIN-vaccine); 3469 (60r: Latvian S. S. R.: live vaccine); 3974 (60pl: SALK-vaccine: Poland); 3981 (60e: SALK-vaccine: Hungary); 3983 (60i: live vaccine); 3993 (60d: SALK-vaccine: Germany); 4074 (60u: Hungary); 4075 (60u: SALK-vaccine: Hungary); 4076 (60r: live vaccine); 4184 (60u: SALK-vaccine: Hungary 1959); 4196 (60i); 4226 (60r: live vaccine: Moldavian S. S. R.); 4228 (60r); 4235 (60r: live vaccine: USSR); 4237 (60r: live vaccine: Byelorussian S. S. R.); 4256 (60r: live vaccine: Latvian S. S. R.); 4867 (60e: SALK-vaccine: Canada); 4870 (60e: SALK-vaccine: Denmark); 4874 (60e: SALK-vaccine: ČSR); 4877 (60e: SALK-vaccine: Israel); 4880 (60e: SALK-vaccine: Norway); 4890 (60e: live vaccine: Latin America and USA); 4893 (60e: live vaccine: USSR); 4895 (60e: live vaccine); 4920 (60e: SABIN-vaccine: Mexico); 4963 (60r: live vaccine: USSR); 4969 (60e: live vaccine: Netherlands); 5021 (60e: SABIN-vaccine: USSR); 5032 (60e: SABIN-vaccine: ČSR); 5043 (60e: live vaccine: Nicaragua); 5051 (60e: SABIN-vaccine: USSR); 5068 (60e: live vaccine: Dade County); 5077 (60e: live vaccine); 5282 (60e: SABIN-vaccine: USSR); 5285 (60e: SABIN-vaccine: ČSR); 5292 (60e: Hungary: enterovirus isolation); 1850 (61f: Belgium); 2786 (61d: Cox-vaccine: Berlin); 2883 (61d: Cox-vaccine: NE-Switzerland); 3075 (61t: ČSR); 3192 (61e: SALK-vaccine: Seattle-King County); 3195 (61e: Cox-type 3: reinfection); 3333 (61e: SABIN-type 2: Singapore); 3334 (61e: live vaccine: USSR); 3335 (61d: SALK-vaccine: Hamburg); 3471 (61e: USSR: live vaccine); 3478 (61d: West-Berlin: COX-vaccine); 3496 (61d: Germany); 3499 (61e: spread of virus); 4001 (61e: SALK-vaccine: Arkansas 1959); 4002 (61e: SALK-vaccine: Iowa 1959); 4003 (61e: SALK-vaccine: Kansas City and Des Moines 1959); 4063 (61e: Mauritius 1959); 4103 (61d: Europe); 4112 (61b: ČSR: SABIN-vaccine); 4116 (61d: Germany); 4139 (61d: SALK-vaccine); 4145 (61e: SALK-vaccine: Houston area); 4150 (61e: SALK-vaccine: Kansas City); 4182 (61d: SALK-vaccine: Neunkirchen); 4191 (61e: N. Y. State 1959); 4203 (61e: SALK-vaccine: Massachusetts); 4213 (61d: Duesseldorf 1961); 4224 (61e: USA); 4238 (61d: SALK-vaccine: Hungary); 4345 (61s: Cox-vaccine: Uruguay); 4359 (61d: Germany); 4360 (61d: Switzerland); 4361 (61e: SALK-vaccine: Canada); 4362 (61e: ČSR); 4363 (61e: USSR); 4598 (61e: SABIN-vaccine: USSR); 4626 (61i: live vaccine); 4633 (61e: SALK-vaccine: North Carolina 1959); 4646 (61f: SALK-vaccination: Belgium); 4647 (61e: Hungary); 4651 (61e:

SABIN-vaccine: ČSR); 4655 (61s: live vaccine: Costa Rica); 4659 (61b: SABIN-vaccine: USSR); 4660 (61e: SABIN-vaccine: Cincinnati); 4662 (61e: KOPROWSKI-vaccine: Congo); 4692 (61e: SALK-vaccine); 4695 (61e: SALK-vaccine: New Jersey); 4741 (61d: Cox-vaccine: Berlin); 4742 (61d: SABIN-vaccine: Germany); 4745 (61d: SABIN-vaccine: Germany); 4858 (61d: SABIN-vaccine: Germany); 4899 (61e: SALK-vaccine: Rhode Island); 4901 (61e: SALK-vaccine: USA); 4975 (61e: SABIN-vaccine: USSR); 4986 (61e: SALK-vaccine: Brescia); 5277 (61e: Hungary: virus isolation); 5314 (61e: Cox-vaccine: Switzerland); 5316 (61e: SALK-vaccine: Ireland); 5338 (61e: SALK-vaccine: Connecticut); 5341 (61d: live vaccination); 5352 (61e: SALK-vaccine: Netherlands); 5355 (61e: SABIN-vaccine); 5359 (61e: SALK-vaccine: England and Wales); 5480 (61pl: Poland); 4738 (62d: SALK-vaccine: Middle Europe); 5496 (62d: Berlin 1960: Cox-vaccine).

Lähmungsrate / Paralysis rate

0024 (55e); 1782 (55e: USA 1954); 1807 (55e: FRANCIS-report); 1816 (55e: USA); 1977 (55e: USA 1954); 4588 (55e: FRANCIS-report); 5061 (55e: Southern Alameda County); 5237 (55e: SALK-vaccine); 1570 (56e: USA); 1667 (56e); 1826 (56e: Massachusetts 1955); 1874 (56e: USA); 1953 (56d: USA 1954); 1956 (56e: Canada 1955); 1961 (56e: British Colombia); 2093 (56e: Massachusetts 1955); 2227 (56e); 2471 (56e: Louisiana); 0639 (57e); 0939 (57e: USA); 1114 (57e: age distribution: USA); 1116 (57e: age distribution: Canada 1956); 1447 (57e: USA 1956); 1586 (57e: USA); 2049 (57e: North Carolina); 2057 (57e: England); 2075 (57e: USA 1956); 2095 (57e: Canada); 2123 (57e: Chicago 1956); 2125 (57e: Canada); 2196 (57e: Minnesota); 2313 (57e); 2331 (57e: British Colombia); 2506 (57e: United Kingdom); 2512 (57e); 2753 (57e); 3163 (57e: FRANCIS-report); 5192 (57e: severity of paralysis); 0204 (58e: Hungary: SALK-vaccine); 0581 (58d: Switzerland: SALK-vaccine); 0583 (58e: USA); 0589 (58d: Switzerland); 0610 (58e: USA); 0629 (58d); 0658 (58e: ČSR); 0659 (58e: Hungary); 0688 (58f: Switzerland); 0691 (58e: Ontario); 0847 (58e: ČSR); 0852 (58d); 1503 (58f: Switzerland); 2323 (58e: Minnesota 1955/56); 2420 (58e: Connecticut); 0835 (59e: Winnipeg); 0867 (59e: Detroit 1958); 0960 (59d); 0981 (59d: Switzerland); 0983 (59e: Manitoba 1958); 0993 (59e: USA 1957); 0997 (59d: Switzerland 1958); 1133 (59e: Canada 1958); 1147 (59f); 1189 (59d: Steiermark); 1312 (59i); 1320 (59f: revaccination); 5249 (59r: SALK-vaccine: USSR); 1395 (60e: Washington, D. C.); 2387 (60e: New Jersey); 2402 (60d: Switzerland: SALK-vaccine); 2566 (60e: epidemic Iowa 1959); 2700 (60i); 3023 (60e: England and Wales); 3431 (60e: Tennessee); 4126 (60e: Denmark: SALK-vaccine); 4867 (60e: SALK-vaccine: Canada); 4880 (60e: SALK-vaccine: Norway); 4002 (61e: SALK-vaccine: Iowa 1959); 4003 (61e: SALK-vaccine: Kansas City and Des Moines 1959); 4191 (61e: N. Y. State 1959); 4203 (61e: SALK-vaccine: Massachusetts 1959); 4238 (61d: SALK-vaccine: Hungary); 4646 (61f: SALK-vaccine: Belgium); 4899 (61e: SALK-vaccine: Rhode Island).

Letalität / Lethality

2125 (57e: Canada); 2315 (57c: Nebraska 1956); 5192 (57e); 0583 (58e: USA); 0867 (59e: Detroit 1958); 1133 (59e: Canada 1958); 2914 (60e: England and Wales 1958); 3981 (60e: SALK-vaccine: Hungary); 4075 (60u: SALK-vaccine: Hungary); 4184 (60u: SALK-vaccine: Hungary 1959); 4196 (60i); 3349 (61e: USA); 4001 (61e: SALK-vaccine: Arkansas 1959); 4182 (61d: SALK-vaccine: Neunkirchen); 4238 (61d: SALK-vaccine: Hungary); 4646 (61f: SALK-vaccine: Belgium).

Morbidität / Morbidity

0076 (36e: USA: BRODIE-vaccine); 4585 (54e: chimpanzees: live vaccine); 1782 (55e: USA 1954); 1807 (55e: FRANCIS-report); 3079 (55e: FRANCIS-report); 1953 (56d: USA 1954); 2471 (56e: Louisiana); 5293 (56s: SALK-vaccine: Puerto Rico); 0536 (57e: live vaccine); 0640 (57b); 0939 (57e: USA); 0942 (57e: USA: SALK-vaccine); 2058 (57e); 3163 (57e: FRANCIS-report); 0191 (58e); 0204 (58e: Hungary: SALK-vaccine); 0249 (58d: Hungary); 0494 (58e: South Rhodesia); 0507 (58d: Germany); 0538 (58e: live vaccine: Belgish Congo); 0553 (58s: Mexico); 0610 (58e: USA); 0650 (58e); 0654 (58e); 0655 (58f: Belgium); 0659 (58e: Hungary); 0686 (58s: Belgish Congo: live vaccine); 2320 (58e); 2420 (58e: Connecticut); 3465 (58he: Israel: SALK-vaccine); 4277 (58he: SALK-vaccine: Israel); 0027 (59d: USA); 0258 (59e); 0663 (59e: Israel); 0840 (59e); 0964 (59e: Connecticut 1958: SALK-vaccine); 0983 (59e: Manitoba 1958); 0987 (59e: USA); 0993 (59e: USA 1957); 0997 (59d: Switzerland 1958); 1027 (59d: Germany); 1133 (59e: Canada 1958); 1136 (59d: Germany 1958); 1159 (59f: Italy 1958); 1160 (59e: Norway 1958); 1165 (59e: USSR: live vaccine); 1274 (59e: Canada: age distribution); 2134 (59e: contacts); 2291 (59e: live vaccination); 2292 (59s: Andes/Colombia: live vaccine); 2293 (59s: Managua/Nicaragua: live vaccine); 3172 (59e: Medellin/Colombia: live vaccine); 3174 (59e: SABIN-vaccine: Mexico); 3234 (59e: SABIN-vaccine: Esthonian and Lithuanian S. S. R.); 4289 (59e: SALK-vaccine); 5249 (59r: SALK-vaccine: USSR); 1362 (60e: USSR: live vaccine); 1367 (60d: USSR: live vaccine); 2273 (60d: Germany); 2523 (60f: Belgium); 2558 (60e: virus excretion); 2872 (60e: Nairushire 1958); 2914 (60e: England and Wales 1958); 2945 (60e: Mauritius); 2951 (60d: Canada); 2956 (60e: Philadelphia: live vaccine); 2977 (60e: ČSR: SABIN-vaccine); 3450 (60e: ČSR: SABIN-vaccine); 3469 (60r: Latvian S. S. R.: live vaccine); 3974 (60pl: SALK-vaccine: Poland); 4074 (60u: Hungary); 4121 (60e: Germany); 4874 (60e: ČSR: SALK-vaccine); 4877 (60e: Israel: SALK-vaccine); 4920 (60e: Mexico: SABIN-vaccine); 4963 (60r: USSR: SABIN-vaccine); 4969 (60e: live vaccine: Netherlands); 5021 (60e: SABIN-vaccine: USSR); 5051 (60e: SABIN-vaccine: USSR); 1850 (61f: Belgium); 2786 (61d: Cox-vaccine: Berlin); 2883 (61d: Cox-vaccine: NE-Switzerland); 3075 (61t: live vaccine: ČSR); 3302 (61d: ČSR); 3334 (61e: live vaccine: USSR); 3471 (61e: USSR: live vaccine); 3478 (61d: West-Berlin: Cox-vaccine); 3493 (61e); 3993 (61d: SALK-vaccine: Germany); 4001 (61e: SALK-vaccine: Arkansas 1959);

4063 (61e: Mauritius 1959); 4103 (61d: Europe); 4116 (61d: Germany); 4117 (61e: Germany); 4119 (61d: Germany); 4150 (61e: SALK-vaccine: Kansas City 1959); 4345 (61s: Cox-vaccine: Uruguay); 4359 (61d: Germany); 4363 (61e: live vaccine: USSR); 4626 (61i: live vaccine: USSR); 4655 (61s: live vaccine: Costa Rica); 4662 (61e: KOPROWSKI-vaccine: Congo); 4741 (61d: Cox-vaccine: Berlin); 4742 (61d: SABIN-vaccine: Germany); 4745 (61d: SABIN-vaccine: Germany); 4858 (61d: SABIN-vaccine: Germany); 4968 (61e: Poland: live vaccine); 4986 (61i: SALK-vaccine: Brescia); 5078 (61e: live vaccine: eradication); 5314 (61e: Cox-vaccine: Switzerland); 5480 (61pl: Poland).

Tierversuche / Animal experiments

0093 (10d: monkeys: reinfection); 0094 (10d: monkeys: reinfection); 0095 (10d: monkeys: reinfection); 0098 (10f: monkeys); 0109 (10e: (10e: monkeys: heat inactivated vaccine); 0373 (10f: monkeys); 0377 (10d: monkeys); 0419 (10d: monkeys); 0421 (10d: monkeys); 0422 (10d: monkeys); 0466 (10f: monkeys); 0467 (10f: monkeys); 1060 (10e: monkeys); 1062 (10d: monkeys); 3200 (10e: monkey); 0096 (11d: monkeys: vaccination with carbol inactivated vaccine); 0359 (11f); 4862 (11e: immunsera); 4863 (11e: monkey); 0097 (12d); 1548 (12d: monkeys); 4395 (12e: horse); 0374 (16e: monkeys); 0273 (17e: sheep and rabbit: production of antisera); 0101 (18e: monkeys); 0102(18f: horse serum); 0590 (18e:monkeys: heat inactivated vaccine); 3895 (18e: monkey); 5278 (18e: monkey); 0888 (24e: monkey); 4373 (26f: horse: immune sera); 0141 (27e: monkeys); 4541 (27e. monkey: sodium ricinoleate virus); 0136 (28e: sheep, horse); 0887 (29e: monkey); 3300 (29f: monkey); 5005 (29f: monkey: immune sera); 0142 (30e: monkey and rabbit); 0154 (30e: horse immune serum); 0339 (30e: monkey: heat inactivated virus); 0447 (30e: monkey); 0831 (30e: monkey: adsorbed vaccine); 1079 (30e: monkey); 1185 (30e); 1265 (30e: horse); 2205 (30e: production of immune sera); 4550 (30s: monkey); 0001 (31e: monkey: virus and antiserum); 0004 (31e: monkeys: aluminum-hydroxyd-vaccine); 0007 (31e: monkeys: virus and antiserum); 1038 (31d: monkeys: phenol-vaccine); 1353 (31e: horse); 2206 (31e: monkeys: nasal infection); 3247 (31f); 4190 (31e: monkey: encephalomyelitis virus in horses); 0015 (32e: monkeys: virus and antiserum); 0558 (32e); 0791 (32e: monkeys); 0146 (33e: monkeys: neutralized mixtures of virus and serum); 2812 (33e: monkey); 3504 (33e: monkey); 3596 (33e: monkey); 0152 (34e: monkeys: active virus); 0225 (34e: monkeys: different vaccines); 0735 (34e: monkeys: nonspecifity); 0741 (34e: monkeys: hormone); 2008 (34e: horses); 3891 (34e: monkey: KOLMER-vaccine); 4111 (34e: monkey); 0470 (35e: monkeys: BRODIE-vaccine); 0768 (35e: monkeys: BRODIE-vaccine); 0815 (35e: monkeys: adsorbed vaccine); 1085 (35e: sheeps: immune serum); 2744 (35e: monkey); 2856 (35e: monkey); 2857 (35e: monkey: living virus); 3555 (35e: sheep); 3586 (35f: monkey: endocrine gland); 3896 (35f: monkey: KOLMER-vaccine); 4318 (35d: monkey: KOLMER-vaccine); 4719 (35e: monkey); 4777 (35f: monkey); 0016 (36e: monkeys: antibodies and infection); 0017 (36e: monkeys: antibodies);

0018 (36e: monkeys: antibodies and infection); 0019 (36e: monkeys: antibodies and infection); 0086 (36e: monkeys: KOLMER-vaccine: infection); 0471 (36e: monkeys); 0883 (36e: monkeys: antibodies); 0932 (36e: monkeys); 3270 (36f); 4776 (36f: monkey: KOLMER-vaccine); 4789 (36e); 1043 (37e: ricinoleat-vaccine); 2754 (37e: monkey: nasal route); 4797 (37e: monkey); 0342 (38e: monkey: intranasal infection); 2659 (38e: monkeys); 2745 (38e: monkey: nasal route); 2760 (38e: monkey: interference canine distemper-polio); 3204 (38e); 3322 (38e: monkey); 3551 (38e: horse); 2620 (39d: monkeys); 2669 (39e: monkey); 2858 (39e: monkey); 0157 (40e: monkeys: intracutaneous route of vaccination); 2752 (40e: monkey: intracutaneous route); 2884 (40e: monkey: murine virus); 3503 (41e: guinea pigs); 3286 (42f: mice); 4066 (42f: mice); 0038 (43j: monkeys: sonic vaccine); 4015 (43e: horse: globuline fraction: immune serum); 4171 (43e: horse); 3890 (44e: mice: uv-inactivated vaccine); 5271 (44e: UV-vaccine: mice); 0125 (45e: mice); 4571 (45e: Swiss mice); 4574 (45e: mice: uv-inactivated vaccine); 5384 (46f: mice: LANSING strain); 0042 (47e: monkeys); 0043 (47e: monkeys: distribution of antibody); 0372 (47e: formaldehyde-vaccine: mice); 0891 (47e); 2673 (47e: cotton rat); 2722 (47e: CFT); 3155 (47e: cotton rats); 4308 (47e: mice); 5074 (47e: isoimmunization to CNS tissue: monkey); 5075 (47e: isoimmunization to CNS tissue: monkey); 0032 (48e: mice and cotton rats); 0701 (48e); 2656 (48e: monkeys); 2749 (48e: monkey: oral route); 4105 (48f: rabbit); 4310 (48e: rabbit); 4420 (48e: mice and rabbit); 4720 (48e: mice: Col. SK- and THEILER-virus); 0021 (49e: monkeys: antibody and infection); 0774 (49e: mice: vaccination of mother); 4222 (49e: monkey); 4368 (49e: monkey); 4369 (49f: rabbit: immune sera); 4431 (49e: golden hamster); 5070 (49e: chimpanzee: alimentary carriage); 0029 (50e: chimpanzees); 1531 (50e: antibodies: faeces from monkeys); 2619 (50e: monkeys); 2706 (50e: mice: gestation); 4055 (50e: monkey: antibody response); 4438 (50e: monkey); 5329 (50e); 0046 (51e: monkeys: immunologic classification of types); 0047 (51e: monkeys: immunologic classification of types); 0048 (51e: monkeys: immunologic classification of types); 0049 (51e: monkeys: immunologic classification of types); 0050 (51e: monkeys: immunologic classification of types); 0051 (51e: monkeys: immunologic classification of types); 0052 (51e: monkeys: immunologic classification of types); 1541 (51e: cotton rat); 1542 (51e: cotton rat); 1580 (51e: monkeys: oral vaccination); 1581 (51e: monkeys: oral vaccination); 1582 (51e: CFT: neutralizationtest); 1602 (51e: monkey: activ: passiv vaccination); 1686 (51e: CFT); 2817 (51e: monkey); 3475 (51e: horse); 1603 (52e: mice: typespecifity); 2004 (52e: monkey: passiv vaccination); 2030 (52e: chimpanzees); 2213 (52e: mice: rabies: poliomyelitis); 2601 (52e); 2701 (52e: CFT: monkey); 2704 (52e: CFT: monkey); 2729 (52e: monkey: testicular tissue); 2880 (52e: monkey: antibodies and immunity); 2882 (52e: chimpanzees); 3140 (52e: chimpanzees); 3141 (52e: monkey); 3367 (52e: monk ey); 4460 (52e); 4464 (52e: monkey); 4493 (52i: mice: transmission of immunity); 0297 (53e: monkey: repeated ingestion of minute amounts of virus); 1740 (53e); 2732 (53e: monkey: passiv immunization); 2804 (53e: mice: cross-immunity: rabies); 2963 (53e: monkey: typing

of unknown strains); 2964 (53e: monkey: typing of unknown strains); 4492 (53e: monkey: AK-strain); 4561 (53pl: monkey: typing of strains); 2246 (54e: chimpanzees); 2247 (54e: chimpanzees: vaccines of marginal antigenic potency); 2460 (54e: monkeys: live vaccine); 2718 (54e: rabbit: immunserum); 2894 (54e: monkey); 3028 (54e: monkey: standard antiserum); 4045 (54e: monkey: avirulent variant); 0697 (55e); 1767 (55e: mice); 1775 (55e: monkeys); 1805 (55f: donkey); 1881 (55e: chimpanzees: live vaccine); 1905 (55f: monkeys: Central Africa); 2157 (55e: monkeys: antibody: immunity); 2256 (55e: chimpanzees); 2340 (55i: rabbit: neutralizing sera); 1871 (56h: monkey: live vaccine); 1875 (56e: cotton rat); 1919 (56e: guinea pig); 2306 (56d); 2307 (56d: monkeys: cortisone: antibodies); 4012 (56e: guinea pigs); 4025 (56e: mice and monkeys); 4770 (56d: mice); 5448 (56d: monkey: perivenoese encephalomyelitis); 1943 (57e: chimpanzees); 2069 (57e: hamster: Columbia SK-virus: Poliovirus type 2); 2070 (57e: uv- and heat-inactivated vaccine); 2087 (57e: mice: testing of vaccine); 2090 (57e: guinea pigs: diphtheria-toxoid- and Polio-antigen); 2338 (57i: combined antigen); 2595 (57e: attenuated strain: guinea pigs); 3012 (57e: SALK-vaccine); 3368 (57e: live vaccine); 0865 (58e: mice: nonspecific immunization with COXSACKIE virus); 0959 (58e: CFT); 3311 (58i: cattle); 0866 (59e: monkeys: antibody: excretion of virus); 1056 (59d: amounts of antigen: antibody response); 1141 (59b: standard sera); 1281 (59e: monkeys); 1303 (59e: antibody: chicken); 1304 (59e: potency test of vaccine); 1309 (59d: antibody: chicken); 1660 (59r: rats); 2905 (59r: antibody: cortisone); 2910 (59e: antibody response: Taiwan monkeys); 2978 (59d: poliomyelitis suum); 1989 (60e: Cynomolgus-monkeys); 2308 (60d: monkeys: adsorbed vaccines); 2456 (60e: antibody response of roosters); 2529 (60f: chicken); 2567 (60e: guinea pigs); 2971 (60e: chimpanzees); 2782 (60e: guinea pigs: type specific anti-N- and anti-H-indicator sera); 2941 (60i: skin test); 2944 (60e: monkey); 3241 (60f: rabbit: precipitins); 4187 (60i: cutaneous reactivity); 4211 (60e: rabbit and rooster: antisera production); 4958 (60e: monkey); 3475 (61f: Polio- and TAB-vaccine); 4147 (61e: monkey: viremia); 4733 (61r: SALK-vaccine: antigenic activity); 4897 (61e: monkey: subcutaneous injection); 5177 (61e: potency test: SALK-vaccine); 5493 (61r: production of diagnostic sera); 5499 (62e: guinea pigs).

Typabhängigkeit / Type dependence

0624 (42e); 0029 (50e: chimpanzees); 0031 (50e: monkeys); 2739 (50e: chimpanzees); 2175 (56e); 2425 (56d); 2110 (57e: type 2 antibody: type 1 – infection); 0627 (58d); 1192 (59e: type 3: type 1).

Unspezifität / Nonspecifity

0359 (11f: rabies); 4933 (19e: streptococcal agglutinins); 3581 (21e: epidemic encephalitis); 3906 (27d: malaria); 3907 (28f: malaria); 4190 (31e: encephalomyelitis in horses); 0896 (32e: herpes); 4686 (32e: coli-agglutinin); 3561 (33e: louping ill); 3587 (33e: immunization with heterologous antigens); 3689 (33e: recovery after malarial

paroxysm); 0735 (34e: immunization of monkey); 3564 (34e: agglutinin titers for enteric organisms); 4704 (34u: therapy: antirabic vaccine); 0472 (35d: rabies-vaccination); 3516 (36e: diphtheria); 3905 (36d: malarial therapy); 3154 (37e: dog distemper); 3904 (37i: malarial therapy); 2760 (38e: canine distemper: poliomyelitis); 2860 (38e: SCHICK-test); 3666 (38e: immunization against diphtheria); 4802 (38f); 2866 (39e: herpes antibody); 3515 (39e: SCHICK-test); 3558 (39e: antibodies after infection); 3903 (39i: malarial therapy); 2837 (40d); 3579 (40e: THEILER-virus); 3698 (40e: sparing effect: lymphocytic choriomeningitis); 3696 (43e: monkey: TAB-vaccination); 4170 (43e); 3699 (44e: THEILER-virus); 2738 (45e: interference); 2871 (48e: murine polio-virus); 3397 (50e: antibodies of Col. SK- and YSK-virus); 4438 (50e: cross protection test in monkey: Japanese B-encephalitis); 1620 (51e: Columbia SK-virus); 1690 (51e: COXSACKIE-virus); 1691 (51e: antibody: COXSACKIE-infection); 2621 (51e: COXSACKIE antibody: polio-epidemic North Carolina); 2628 (51f); 4416 (51s: LANSING antibody after rabies vaccination); 2213 (52e: polio: rabies); 2797 (52e: COXSACKIE); 2882 (52e: antibody stimulation with unrelated antigens); 0299 (53e: Polio-: MACK-virus); 1749 (53e: Newcastle-virus); 2804 (53e: cross immunity: rabies); 3402 (53e: COXSACKIE-virus); 4108 (53e: mice: aged DP-vaccine); 4466 (53pl: Teschen-disease); 2605 (54e: streptococcus-etiology); 4584 (54e: monkey: Naja flava neurotoxoid); 5023 (54e: Col. SK-virus); 1794 (55e: CFT); 1839 (56d: smallpox vaccination); 1897 (56e: smallpox vaccination); 1910 (56d: nonspecific anamnestic serumreaction); 2175 (56e: typespecifity); 4100 (56e: smallpox vaccination); 5440 (56e: canine hepatitis); 0396 (57e: smallpox vaccination); 2069 (57e: hamster: Columbia SK-virus: poliovirus type 2); 2110 (57e: type 2 antibody: type 1-infection); 4904 (57s: Col. SK-virus); 0245 (58d: polio-: COXSACKIE-infection); 0384 (58e: antibody response: Akureyri-fever); 0865 (58e: mice: COXSACKIE-infection); 1231 (58i: SCHICK-test); 1315 (58b: herpes); 4283 (58j: antibody: polyradiculoneuritis); 5312 (58e: COXSACKIE- and ECHO-viruses); 0982 (59e: CFT); 1228 (59i: Tbc-vaccination); 1716 (59e: COXSACKIE-infection); 1988 (59i: anamnestic serumreaction after Di-vaccination); 2380 (60d: COXSACKIE); 2458 (60e: COXSACKIE); 3489 (60e: smallpox vaccination); 5358 (60i: anticell-fraction-sera).

Impfmethoden / Methods of vaccination

Hier sind nur diejenigen Veröffentlichungen über die aktive Immunisierung gesammelt, die speziell über die Methodik der Applikationsart von Impfstoffen berichten und ausdrücklich verschiedene Anwendungsweisen vergleichen. Eine vollständige Aufführung aller einschlägigen Arbeiten hätte dieses Wort durch Doppelzitate unnötig aufgebläht: deshalb muß beispielsweise die «orale Anwendung» durch das Nachschlagen der entsprechenden Stichworte unter «Impfstoffe aus abgeschwächtem, lebenden Virus» und unter «Aktive Schutzimpfung mit Lebendimpfstoffen» ergänzt werden. Die intrakutane, intramuskuläre und subkutane Injektion und die orale Anwendung der Impfstoffe sind besonders aufgeführt. Arbeiten allgemeinen und vergleichenden Inhaltes und selten bearbeitete Themen,

die nicht unter die speziellen Stichworte fallen, habe ich unter «Allgemeines» aufgeführt.

s. a. Impfstoffe, abgeschwächtes lebendes Virus.
Impfstoffe, inaktiviertes Virus.
Schutzimpfung, aktive Impfung, inaktivierte Impfstoffe.
Schutzimpfung, aktive Impfung, Lebendimpfstoffe.

Under this heading we collected only those publications on active immunization which especially report on the method of application of vaccines, and explicitly compare different modes of application. Complete presentation of all pertinent papers would have unnecessarily enlarged this presentation with double references. For example, therefore, «oral application» must be supplemented by looking up corresponding titles under «vaccines from attenuated live virus» and under «active vaccination with live vaccines». Special mention has been made of papers concerned with intracutaneous, intramuscular and subcutaneous injection, as distinct from the oral use of vaccines. Papers of general and comparative contents and concerning subjects seldom considered, which do not come under special titles, were collected under «general».

cf. Vaccination, active vaccination, inactivated vaccines
Vaccination, active vaccination, live vaccines
Vaccines, attenuated live virus
Vaccines, inactivated virus

Allgemeines / General

0447 (30e: monkeys); 0001 (31e: monkeys: intranasal); 0408 (31e: monkeys: spleen vaccination); 2206 (31e: monkeys: intranasal); 0225 (34e: monkeys: comparative studies); 1043 (37e: monkeys: ricinoleat-vaccine); 2754 (37e: monkey: nasal route); 2745 (38e: monkey: intranasal route); 0042 (47e: monkey: comparative studies); 0032 (48e: mice and cotton rats); 1740 (53e); 3962 (53e: SALK-vaccine); 0069 (54e); 4034 (54n: SALK-vaccine); 1610 (55e: SALK-vaccine); 1776 (55e: antibody response); 1881 (55e: chimpanzees: avirulent strains); 1905 (55f: monkey: comparative studies); 2082 (55e: comparative studies with Swedish vaccine); 2227 (56e: antibody); 0586 (58d); 0631 (58e: guinea pigs: comparative studies); 2322 (58e: jet injection); 0853 (59e); 0905 (59e: rapid vaccination with one dose); 1370 (59t: comparative studies: ČSR).

Intrakutane Injektion / Intracutaneous injection

0141 (27e: monkeys); 0887 (29e: monkeys: subcutaneous); 1079 (30e: monkeys); 0007 (31e: monkeys); 0015 (32e: monkeys: subinfectious dose of live virus); 0152 (34e: monkeys: activ virus); 0818 (35e: BRODIE-vaccine); 2857 (35e: monkey: living virus); 0157 (40e: monkeys: active virus); 2752 (40e: monkey); 0839 (55e: Denmark 1955); 2470 (55e: Denmark); 2480 (56e: Denmark); 0548 (57e:

pregnancy); 0201 (58s: subcutaneous injection: pregnant women); 0204 (58e: Hungary: SALK-vaccine); 0234 (58f: animal experiments: sensibilization); 0249 (58d: SALK-vaccine: Hungary); 0585 (58d: Germany); 0651 (58e: subcutaneous); 0658 (58e: Canadian vaccine: ČSR); 0659 (58e: Hungary); 0684 (58e: formaldehyde-vaccine); 0842 (58e: ČSR 1957); 0862 (58u: Hungary 1957); 5424 (58n: subcutaneous injection); 0853 (59e: subcutaneous); 1007 (59t: ČSR); 1161 (59d: Germany); 1216 (59e: Norway); 1370 (59t: ČSR); 1371 (59i: antibody response); 1396 (59d); 3048 (59u); 4126 (60e: Denmark).

Intramuskuläre Injektion / Intramuscular injection

0145 (34e: monkeys: virus and serum); 2656 (48e: monkey); 0021 (49e: monkeys: active virus); 2619 (50e: monkeys); 4467 (52f: rabbit-adapted live virus); 0185 (58e: pregnancy); 0228 (58e: children: SALK-vaccine); 0361 (59e: formaldehyde-vaccine: early infancy); 0905 (59e: rapid immunization with one dose); 0987 (59e: SALK-vaccine); 1281 (59e: oral).

Orale Anwendung / Oral application

0225 (34e: monkeys); 0160 (48e: monkeys: antibody response); 2749 (48e: monkey); 0297 (53e: monkeys: repeated ingestion of minute amounts of virus); 2041 (53f: rabbit adapted virus); 2631 (53e: TN-strain: KOPROWSKI); 0698 (55e: live vaccine); 0536 (57e: live vaccine); 0684 (58e: antibody response: formalinised vaccine); 1281 (59e: intramuscular route); 2978 (59d: poliomyelitis suum).

Subkutane Injektion / Subcutaneous injection

0096 (11d: monkeys: carbol-vaccine); 0359 (11f: monkeys); 0101 (18e: monkeys: formalinised and heat inactivated vaccine); 0887 (29e: monkeys: intracutaneous); 0004 (31e: monkeys: aluminum-hydroxyd-vaccine); 0145 (34e: monkeys: virus and serum); 0724 (35e: KOLMER-vaccine); 0815 (35e: monkeys: adsorbed vaccine); 0818 (35e: BRODIE-vaccine); 0018 (36e: monkeys: ricinoleat-vaccine); 0019 (36e: monkeys: aluminum-hydroxyd-vaccine); 0078 (36e: KOLMER-vaccine); 0086 (36e: KOLMER-vaccine); 0548 (57e: pregnancy); 0201 (58s: intracutaneous injection: pregnancy); 0386 (58e: intracutaneous injection: pregnancy); 0229 (58f: French vaccine); 0313 (58d: Germany/Niedersachsen); 0651 (58e: intracutaneous injection); 5424 (58n: intracutaneous injection); 0853 (59e: intracutaneous injection).

Impfstoffe / Vaccines

Nach den ersten Isolierungen des Poliomyelitisvirus begann man bereits 1910 mit der Entwicklung von Impfstoffen (I.) zur aktiven Immunisierung. Am Anfang standen Tierversuche mit I., in denen das Virus durch Immunserum oder Wärme inaktiviert wurde. Erst wesentlich später wurden die heute üblichen Inaktivierungsmethoden mit Formaldehyd, UV-Strahlen

und kombinierten Verfahren entwickelt. Erst in den dreißiger Jahren wurden die ersten I. am Menschen erprobt, als man glaubte, genügend wirksame und sichere I. in der Hand zu haben. Fast gleichzeitig wurden die formaldehyd-inaktivierten Vakzine von BRODIE und die durch Ricinoleat chemisch virulenz-abgeschwächte Vakzine von KOLMER in Feldversuchen eingesetzt. Die Gründe für das Versagen dieser I. und die weitere zeitliche Weiterentwicklung der verschiedenen I. wurden bereits in der Einführung (s. S. 18, Abb. 7) eingehender analysiert. Als spezielle I. sind die Adsorbat- und Mehrfach-Vakzinen gesondert aufgeführt. Schon seit 1930 versucht man, das Prinzip der langsameren und damit wirksameren Antigenzufuhr durch Zusatz von Adsorbentien zu den I. auch bei der Poliomyelitis-Schutzimpfung anzuwenden; dieses Verfahren ist nur bei den zu injizierenden I. aus inaktiviertem Virus sinnvoll; es führte zu den grundlegenden Untersuchungen über die Wirkung des Antigendauerreizes. In jüngsten Arbeiten werden die Unterschiede verschiedener Poliomyelitisstämme in den Adsorptionsverhältnissen gegenüber Aluminiumhydroxyd geprüft, um sie für eine Stammdifferenzierung innerhalb der Typen auszunutzen. Seit 1957 versucht man, in bereits bekannte Injektionsimpfstoffe die Poliomyelitiskomponente aufzunehmen, um den Impfplan im Kindesalter durch möglichst komplexe Mehrfachimpfstoffe zu vereinfachen. Weitere gesondert aufgeführte Stichworte behandeln die Produktionsverfahren, die Haltbarkeit und die Prüfungsverfahren der verschiedenen I. Die Arbeiten über Unschädlichkeits- und Wirksamkeitsprüfungen sind seit 1953 zunehmend zahlreicher geworden, weil dem erhöhten Sicherheitsbedürfnis des modernen Menschen und dem Streben nach Perfektionismus entsprochen werden mußte.

s. a. Antigenität, nach Inaktivierung.
Inaktivierung des Virus.
Schutzimpfung, aktive Impfung, inaktivierte Impfstoffe.
Schutzimpfung, aktive Impfung, Lebendimpfstoffe.
Tierversuche, Impfstoffprüfung.

After the first isolations of the poliomyelitis virus, a start was made with the development of vaccines (V.) for active immunization as early as 1910. The initial animal experiments concerned V. in which the virus was inactivated with the aid of immune sera or heat. Only much later were the current methods of inactivation introduced which use formaldehyde, UV radiation and combinations of these processes. It was not until the thirties that the first trials were carried out with vaccines in man; it was then believed that sufficiently reliable and effective V. were available. Almost simultaneously, BRODIE's formaldehyde-inactivated V. and KOLMER's V. of chemically (ricinoleate) attenuated virulence were tried out in field trials. The reasons for the failure of these V. and the further development of V. were analysed in detail in the introduction (see page 35, fig. 7). Adsorbate and multiple vaccines are separately presented as special V. Since 1930, attempts have been made at using the principle of slower and therefore more effective antigen supply (by addition of adsorbents to the V.) in vaccination against poliomyelitis; this method is of value only when the V. injected consists of inactivated virus; these attempts led to the fundamental investigations into the action of the uninterrupted antigen

stimulus. In the most recent papers the differences between various poliomyelitis virus strains are discussed as tested on the basis of their adsorption to aluminum hydroxide in order to use these findings for strain differentiation within the types. Since 1957 attempts have been added to include the poliomyelitis components in known V. for injection in order to facilitate vaccination of children by the use of multiple V. of the highest possible complexity. Further separate titles deal with production methods, keeping capacity and preservation, and methods of examination. Papers on safety and potency have become more numerous since 1953, because investigators have to take into account the increased safety requirements in modern society and man's strivings for perfection.

cf. Animal experiments, testing of vaccines
Antigenicity, after inactivation
Inactivation of virus
Vaccination, active vaccination, inactivated vaccines
Vaccination, active vaccination, live vaccines

Allgemeines / General

0098 (10f: rabies vaccine); 5254 (12d); 3018 (22f); 0141 (27e); 2236 (31e: purification); 3591 (31i); 0785 (32e); 4682 (32d); 0744 (35e); 0747 (35e); 3270 (36f); 3592 (37e); 3322 (38e); 1481 (49e: tissue culture); 4026 (51e); 3376 (52e); 5227 (52e); 1553 (53e); 1750 (53e); 1952 (53e); 2461 (53e); 4488 (53e); 4507 (53e); 4576 (53f); 4721 (53e); 5229 (53f); 1442 (54s); 1467 (54e); 1471 (54e); 1825 (54i); 2622 (54e); 2623 (54e); 2626 (54s); 2630 (54e); 2814 (54d); 3037 (54e); 3078 (54e); 3128 (54e); 3996 (54e); 4022 (54f); 4023 (54e); 4062 (54e); 4531 (54f); 4591 (54e); 5265 (54e); 5286 (54e); 1817 (55i); 1818 (55f); 1846 (55e); 1856 (55d); 1880 (55s); 1889 (55s); 2036 (55d); 2151 (55h); 2539 (55d); 2627 (55s); 2636 (55f); 2643 (55s); 2980 (55f); 3076 (55e); 3119 (55f); 3143 (55s); 3952 (55p); 3975 (55e); 4038 (55e); 4268 (55e); 4595 (55e); 5178 (55f); 5180 (55f); 5232 (55d); 5273 (55i); 5283 (55s); 1522 (56e); 1819 (56d); 1831 (56d); 1833 (56d); 1997 (56d); 2183 (56e); 2188 (56s); 2309 (56u); 2310 (56e: «ideal»-vaccine); 2695 (56e); 4622 (56e); 4624 (56e); 4764 (56e); 5181 (56d); 5185 (56p); 5431 (56d); 0115 (57b); 1525 (57e); 1971 (57f); 2198 (57i); 2500 (57f); 4088 (57i); 4267 (57f); 4476 (57d: IV. intern. Conf. Geneva); 4948 (57h: IV. intern. Conf. Geneva); 5325 (57d); 5476 (57d); 0067 (58d); 0617 (58f); 0674 (58f); 0683 (58e); 1142 (58d); 1234 (58f); 1244 (58i); 1599 (58e); 1601 (58e); 2347 (58d); 4937 (58e); 5460 (58s); 0663 (59e); 0868 (59d); 1054 (59d); 1122 (59f); 1224 (59b); 1290 (59f); 2285 (59r: conference: Moscow); 2848 (59i: VI. europ. Symp.); 5403 (59d); 2611 (60i); 2699 (60d); 2776 (60e: 5th Conf. Copenhagen); 2785 (60f); 2868 (60d: VI. europ. Symp.); 2901 (60f); 3046 (60e); 3055 (60f); 3064 (60e); 3098 (60f); 3342 (60d); 3995 (60d); 4125 (60d); 4209 (60d); 4255 (60d); 5328 (60f); 5331 (60e); 2834 (61d); 2932 (61d); 3070 (61e); 3341 (61d); 3695 (61e); 4140 (61d); 4181 (61f: 5th Conf. Copenhagen); 4217 (61e); 4599 (61e); 4693 (61i); 4857 (61e); 5354 (61e); 5481 (61f).

Abgeschwächtes, lebendes Virus / Attenuated live virus

0888 (24e: monkeys); 0141 (27e); 4541 (27e: ricinoleate virus: monkey); 0887 (29e: monkeys); 3005 (34e: KOLMER-vaccine); 3891 (34e: KOLMER-vaccine); 0724 (35e: KOLMER-vaccine); 0725 (35e: KOLMER-vaccine); 0744 (35e: KOLMER-vaccine); 0751 (35e: KOLMER-vaccine); 2280 (35e); 3693 (35e: KOLMER-vaccine); 3878 (35e: KOLMER-vaccine); 3896 (35f: KOLMER-vaccine); 3898 (35e: KOLMER-vaccine); 4106 (35e: KOLMER-vaccine); 4318 (35d: KOLMER-vaccine); 0078 (36e: Na-ricinoleat and phenyl-quicksilver-nitrat); 0086 (36e: KOLMER-vaccine); 0731 (36e: KOLMER-vaccine); 0754 (36e: KOLMER-vaccine: warning); 4096 (36e: KOLMER-vaccine); 4776 (36f: KOLMER-vaccine); 5334 (37e: KOLMER-vaccine); 3295 (38e: KOLMER-vaccine); 3593 (38b); 0701 (48e: mice: under protection from immune mother); 1580 (51e: monkeys); 1581 (51e: monkeys); 3435 (51e); 0119 (52e); 2918 (52e); 4467 (52f: rabbit adapted strain); 1462 (53s); 1553 (53e); 1740 (53e); 1952 (53e); 2041 (53f: rabbit adapted strain); 2631 (53e: TN-strain KOPROWSKI); 4020 (53s); 4499 (53e); 4519 (53f); 1561 (54e); 1786 (54e); 2376 (54s); 2460 (54e); 2724 (54e); 2895 (54e); 2896 (54e); 3964 (54e: persistence of antibodies); 4045 (54e: segregation of avirulent variants); 4504 (54e); 4566 (54e: chick-embryo-adapted type 2 strain); 4585 (54e: rodent-adapted strain: chimpanzees); 4696 (54d); 0697 (55e); 0698 (55e); 1495 (55e); 1656 (55e); 1766 (55d); 1778 (55e); 1781 (55d); 1796 (55e); 1814 (55e); 1881 (55e); 1905 (55f: monkeys); 1924 (55e); 2153 (55e); 2239 (55s); 2240 (55s); 2257 (55e); 4036 (55e); 4607 (55e); 0673 (56e: chick-embryo-adapted MEF_1-strain); 1653 (56e); 1667 (56e); 1871 (56h: monkeys); 1954 (56e); 1962 (56d); 1979 (56e: infants under 6 month of age); 2047 (56e); 2097 (56e: dose: infection); 2173 (56e: adaptation of strain); 2180 (56e); 3118 (56s); 5186 (56p); 5241 (56e); 0387 (57e: SALK-vaccine); 0510 (57d); 0536 (57e); 0639 (57e); 0940 (57e); 0941 (57e); 0942 (57e); 0977 (57f); 0979 (57s); 1525 (57e); 1964 (57e); 2076 (57e: d-mutant); 2102 (57f); 2199 (57f); 2304 (57e: SM type 1); 2305 (57e: SM type 1 and TN type 2); 2317 (57e); 2332 (57e); 2595 (57e: naturally occuring strain); 2741 (57e); 3014 (57e: SABIN-vaccine); 3148 (57e); 3368 (57e); 3377 (57e); 4273 (57s: young children after SALK-vaccinated mothers); 0067 (58d); 0201 (58s: live vaccine: neonatal period and early infancy); 0246 (58d); 0356 (58e); 0357 (58e: antibody levels one year after live vaccination); 0521 (58e: antibody response: early infancy); 0538 (58e); 0637 (58h); 0638 (58h); 0686 (58s: Belgish Congo); 1004 (58e: indication); 1034 (58i: combination with inactivated vaccine); 1145 (58f); 1146 (58f); 1173 (58e); 1243 (58e: SALK-vaccine); 1325 (58s); 1590 (58e); 1600 (58e); 2334 (58e: SABIN-strains: virulence); 3383 (58e); 4178 (58d); 4248 (58r); 4934 (58e: virulence: plaque method); 4938 (58f: t-marker); 4961 (58e: d-marker); 0258 (59e); 0262 (59e); 0307 (59e: MS-marker); 0385 (59e); 0601 (59e); 0743 (59e); 0840 (59e); 0973 (59e); 0974 (59e); 0976 (59e); 0986 (59e); 0991 (59e); 0992 (59e); 1000 (59d); 1087 (59e: USSR); 1093 (59u: Hungary); 1157 (59e: England); 1163 (59e); 1164 (59e); 1165 (59e: USSR); 1166 (59e: Singapore); 1167 (59e: ČSR); 1195 (59e: Singapore); 1199 (59e); 1202 (59e: Southern Arizona); 1205 (59e: trivalent vaccine); 1225

(59e: newborns); 1226 (59e: Colombia); 1229 (59e); 1253 (59f); 1278 (59e: early infancy); 1282 (59e: monkey neurovirulence: t-marker); 1286 (59e: t- and d-marker); 1313 (59e: Cox-vaccine); 1314 (59r); 1322 (59e: SABIN-vaccine type 3: marker); 1344 (59f); 1350 (59f: viraemia); 1370 (59t: ČSR); 1373 (59e: virulence: 5-bromouracil and stable cell lines); 1391 (59d: Sweden); 1394 (59d: Missouri); 1403 (59d); 1404 (59e); 1422 (59e); 1428 (59d); 1430 (59e); 1431 (59e); 1987 (59e); 2132 (59e); 2133 (59e); 2134 (59e); 2270 (59i); 2291 (59e); 2292 (59s: Andes/Colombia); 2293 (59s: Managua/Nicaragua); 2300 (59r); 2367 (59r); 2368 (59r); 2369 (59r); 2447 (59d); 2521 (59s: Cuba); 2522 (59s: Cuba); 2978 (59d: poliomyelitis suum); 3082 (59e: Italy); 3156 (59e: virulence for Rhesus monkeys); 3157 (59e: spread: interference); 3158 (59e: antibody response: Cox-vaccine); 3159 (59e: pregnant women: Cox-vaccine); 3164 (59e: Sweden: CHAT-strain); 3167 (59e: Netherlands: SABIN-vaccine); 3170 (59e: Leopoldville/Congo); 3172 (59e: Medellin/Colombia); 3174 (59e: Mexico: SABIN-vaccine); 3177 (59e: Poland: CHAT-strain); 3181 (59e: Costa Rica); 3182 (59e: Cox-vaccine: Finland); 3184 (59e: Montevideo/Uruguay); 3205 (59e); 3208 (59e: monkey neurovirulence); 3210 (59e: markers); 3213 (59e: CHAT-strain); 3216 (59e: markers and neurovirulence); 3218 (59e: Cox-vaccine: infants under six month); 3220 (59e: Mexico City: SABIN-vaccine); 3222 (59e: USSR: SABIN-vaccine); 3223 (59e: USSR: SABIN-vaccine); 3226 (59e: USSR: SABIN-vaccine); 3227 (59e: SABIN type 3); 3231 (59e: CHAT-strain: Leopoldville/Congo); 3234 (59e: SABIN-vaccine: Esthonian and Lithuanian S. S. R.); 3235 (59e: SABIN-vaccine: ČSR); 3238 (59e: SABIN-vaccine: Mexico); 4087 (59i); 4251 (59r); 5375 (59e); 5457 (59s); 1177 (60d); 1362 (60e: USSR); 1367 (60d: USSR); 1401 (60u: USSR); 1416 (60d); 1424 (60e); 1432 (60e); 1433 (60e: Cox-vaccine); 1984 (60d: Cox-vaccine: Switzerland); 1985 (60d: contact); 1991 (60e: CHAT-strain: Poland); 1995 (60e: CHAT-strain: Congo); 2271 (60d); 2274 (60d); 2353 (60e); 2354 (60r); 2356 (60d); 2358 (60e); 2359 (60e); 2360 (60r); 2366 (60e: killed vaccine); 2370 (60e: concentration: bivalent cations); 2371 (60e); 2389 (60e: neuroactivity: markers); 2397 (60u: Hungary); 2401 (60d); 2406 (60e: meeting May 1960 Moscow); 2409 (60e: Nicaragua); 2436 (60e: CHAT-strain: Congo); 2437 (60e: t-marker: RNA); 2440 (60e: infectious RNA isolated from CHAT strain: serodifferentiation); 2450 (60e: Kenya); 2486 (60s); 2513 (60e: interference); 2525 (60e: excreted strains: markers: neurovirulence); 2532 (60d: Cox-vaccine: Berlin); 2559 (60e: USSR); 2560 (60s: Central America); 2563 (60e: Belgian Congo: CHAT-strain: stability); 2565 (60i); 2571 (60e: SABIN-type 3: contact infections); 2572 (60e: Cox-vaccine: Cuba); 2576 (60u: SABIN-vaccine and DPT); 2578 (60h); 2585 (60f: t-marker: neurovirulence); 2586 (60e: Miami); 2592 (60e: Cox-vaccine: Florida); 2612 (60e: USA-recommendations); 2696 (60d: planning: Austria); 2788 (60e: CHAT-strain: Congo); 2792 (60pl: CHAT-strain: Poland); 2903 (60e: antibody response in early life: immunologic tolerance); 2915 (60e: neurovirulence); 2922 (60r: d-marker); 2923 (60r); 2945 (60e: Mauritius); 2947 (60e); 2956 (60e: Philadelphia); 2971 (60e: doses); 2977 (60e: ČSR: SABIN-vaccine); 3022 (60e); 3026 (60f); 3043 (60e); 3044 (60e); 3045 (60i: interference: enteroviral infection);

3047 (60d: Cox-vaccine: Berlin); 3054 (60i); 3063 (60e); 3065 (60d: Florida 1960); 3198 (60f: ČSR); 3232 (60e: Colombia and Uruguay); 3243 (60e); 3248 (60e: Cox-vaccine); 3307 (60u); 3308 (60e); 3317 (60t: SABIN-vaccine); 3318 (60t: SABIN-vaccine: ČSR); 3327 (60r: color test); 3330 (60e); 3337 (60e); 3338 (60e: USSR); 3340 (60e); 3343 (60e: trivalent Cox-vaccine: cloistered community); 3388 (60e); 3391 (60e: ČSR); 3392 (60e: ČSR: spread of virus); 3450 (60e: ČSR); 3451 (60i: Cox-vaccine); 3456 (60e: Hungary); 3463 (60r); 3469 (60r: Latvian S. S. R.); 3472 (60r); 3473 (60r); 3476 (60r); 3480 (60r: trivalent vaccine); 3482 (60r: t-marker); 3486 (60r: storage: dragée-candy); 3488 (60r); 3490 (60r: type 1); 3974 (60pl: Poland); 3983 (60i); 3984 (60f: trivalent Cox-vaccine); 3985 (60e: SABIN-vaccine: newborn infants); 3995 (60d); 3999 (60d: Switzerland); 4074 (60u: Hungary); 4076 (60r); 4121 (60e: Germany); 4173 (60r: dissemination of vaccinal strains); 4192 (60e: South Africa); 4197 (60s: Cox-vaccine: Cuba); 4226 (60r: Moldavian S. S. R.); 4228 (60r); 4230 (60r: second vaccination); 4232 (60r: virus proliferation: intestinal tract); 4234 (60r: contact-infections); 4235 (60r: USSR); 4237 (60r: Byelorussian S. S. R.); 4239 (60r: pre-school age); 4242 (60r); 4244 (60r); 4253 (60r: Riga); 4256 (60r: Latvian S. S. R.); 4258 (60r); 4302 (60e: attenuation of BRUNHILDE strain: chick embryo); 4305 (60e: attenuation of BRUNHILDE strain: chick embryo); 4405 (60e: Philadelphia); 4570 (60e); 4572 (60e: recommendations to manufacture); 4573 (60e); 4575 (60e); 4578 (60d: + DPT-adsorbat); 4579 (60d: control of titres); 4727 (60e: SV 40); 4732 (60e); 4734 (60f: SABIN-vaccine: Mexico); 4860 (60s: Guatemala); 4874 (60e: ČSR); 4890 (60e: Latin-America and USA); 4893 (60e: USSR); 4895 (60e); 4896 (60e: Cox-vaccine: Berlin); 4903 (60e: maternal antibodies); 4908 (60e: trivalent vaccine); 4911 (60e: influence of age); 4913 (60e: dose and schedule: antibody response); 4916 (60e: dose and schedule: antibody response); 4920 (60e: Mexico); 4922 (60e: type 2); 4925 (60e: spread of virus: household contacts); 4927 (60e: spread of virus: household contacts); 4930 (60e: genetic stability: markers); 4954 (60e: elution marker); 4957 (60e: genetic markers); 4958 (60e: marker: neuropathogenicity for monkey); 4962 (60e: neurovirulence test: intramuscular inoculation of monkey); 4963 (60r); 4964 (60r); 4965 (60e: Cox-vaccine: Costa Rica: marker after human passage); 4967 (60e: stability of marker: human passage); 4969 (60e: Netherlands); 4974 (60e: Southern Louisiana: spread of virus); 4982 (60e: CHAT-strain: marker); 4984 (60e: spread: marker); 4985 (60e: Cox-vaccine: pregnant women and young infants); 4989 (60e: SABIN-strain type 3); 4990 (60e: USSR: trivalent SABIN-vaccine); 4994 (60e: Cox-vaccine: Israel); 4995 (60e: neonatal premature infants); 4998 (60e: full-term infants); 5001 (60e: newborn infants); 5004 (60e: newborn infants); 5006 (60e: Cox-vaccine: Cuba); 5009 (60e: Minnesota); 5011 (60e: Cox-vaccine: Minnesota); 5014 (60e: Cuba); 5018 (60e: Mexico); 5021 (60e: SABIN-vaccine: USSR); 5026 (60e: Southern Africa); 5032 (60e: ČSR); 5036 (60e: KOPROWSKI-vaccine: Poland); 5040 (60e: Cox-vaccine: Finland); 5043 (60e: Nicaragua); 5051 (60e: USSR); 5068 (60e: Dade County); 5077 (60e); 5282 (60e: USSR); 5285 (60e: ČSR); 5288 (60e: Hungary); 5295 (60e: antibody formation); 5298 (60e: antibody formation); 5301 (60e: virological

investigations); 5304 (60e: + BCG); 5307 (60e: + DPT-vaccine); 5310 (60e: neurovirulence: monkey); 5348 (60d); 5483 (60e: spread of virus); 0116 (61b: neurovirulence: marker); 2786 (61d: Cox-vaccine: Berlin); 2787 (61s: Philadelphia); 2883 (61d: Cox-vaccine: NE-Switzerland); 2890 (61h: SABIN-vaccine: Netherlands); 2919 (61d); 2929 (61u: + DPT); 3019 (61d: Cox-vaccine: Berlin); 3075 (61t: ČSR); 3149 (61e); 3191 (61f: Cox-vaccine: newborn infants); 3195 (61e: Cox-vaccine type 3); 3250 (61d); 3289 (61e); 3302 (61d: ČSR); 3303 (61d: Cox-vaccine: West Berlin 1960: marker); 3304 (61d: Switzerland); 3305 (61d: CHAT-strain: Switzerland); 3332 (61d: Atlanta/Georgia); 3333 (61e: SABIN-vaccine: Singapore); 3334 (61e: USSR); 3336 (61e: Hungary: virus excretion); 3339 (61e: pathogenicity for monkey: t-marker); 3360 (61e: Cincinnati: SABIN-vaccine); 3372 (61e: USA: program); 3389 (61e: Canada); 3390 (61e); 3448 (61e: New York); 3471 (61e: USSR); 3474 (61e); 3478 (61d: West-Berlin: Cox-vaccine); 3493 (61e: young infants); 3494 (61d); 3496 (61d: Germany); 3497 (61e: Cincinnati); 3500 (61e: type 3: spread of virus); 3989 (61d); 4063 (61e: Mauritius 1959); 4080 (61e: SABIN-vaccine: British trial); 4081 (61e); 4103 (61d: Europe); 4104 (61d); 4112 (61b: ČSR: SABIN-vaccine); 4115 (61e); 4116 (61d: Germany); 4117 (61e: Germany); 4119 (61d: Germany); 4120 (61e: South Africa); 4127 (61d: Berlin 1960); 4143 (61d: testing of vaccine); 4148 (61e: monkey neurovirulence test); 4179 (61d: Cox-vaccine: Berlin 1960); 4180 (61d: SABIN-vaccine: antibody: virus excretion); 4193 (61d: newborn and young infants); 4200 (61e: SABIN-vaccine: USSR); 4206 (61e: interference to wild virus); 4214 (61e: SABIN's strains: monkey); 4216 (61e: SABIN's strains: monkey: viraemia); 4227 (61f: trivalent Cox-vaccine); 4233 (61d: SABIN-vaccine); 4252 (61e: interference); 4259 (61e: changes after human passage); 4260 (61e: virus excretion: previous SALK-vaccination); 4261 (61e: changes after human passage); 4303 (61e: newborn); 4322 (61e: Britain); 4323 (61e); 4329 (61d: Austria: distribution); 4345 (61s: Uruguay); 4358 (61d: Germany); 4359 (61d: Germany); 4362 (61e: ČSR); 4363 (61e: USSR); 4598 (61e: USSR); 4625 (61e: after DPTP-vaccination); 4626 (61i: USSR); 4627 (61d); 4629 (61e: Cox-vaccine: community spread); 4632 (61e: after acquired immunity); 4639 (61d); 4648 (61e); 4649 (61e: + DPT-vaccination); 4650 (61e: KOPROWSKI-vaccine: Switzerland); 4651 (61e: SABIN-vaccine: ČSR); 4652 (61e: SABIN-vaccine: newborn infants); 4653 (61s: Cox-vaccine: Florida); 4654 (61s: Costa Rica); 4655 (61s: Costa Rica); 4656 (61e: serum inhibition: type 3: tissue culture); 4659 (61b: USSR); 4660 (61e: Cincinnati); 4661 (61i: Cox-vaccine: Rome); 4662 (61e: CHAT-strain: Congo); 4689 (61d: growth on continuous cell lines); 4711 (61o: Turkey); 4729 (61r: effect of chlorine as marker); 4731 (61r: + DPT-vaccination); 4735 (61f: safety and efficacy); 4736 (61e: trivalent Cox-vaccine); 4740 (61d: trivalent Cox-vaccine: Berlin); 4741 (61d: trivalent Cox-vaccine: Berlin); 4742 (61d: SABIN-vaccine: Germany); 4743 (61d: Cox-vaccination: marker); 4744 (61d: SABIN-vaccine: Germany); 4745 (61d: SABIN-vaccine: Germany); 4746 (61d: Cox-vaccine: Berlin); 4747 (61d: neuropathogenicity for monkey); 4748 (61d: Cox-vaccine: Berlin); 4856 (61e: ČSR); 4858 (61d: Germany); 4859 (61u: DPT-vaccination); 4897 (61e: monkey: virulence: sub-

cutaneous injection); 4959 (61f: age: susceptibility); 4968 (61e: Poland); 4971 (61e: neurovirulence); 4973 (61e: marker: human passage); 4975 (61e: USSR); 4976 (61e: neonates); 4977 (61e: intrafamiliar spread); 4983 (61e: Middle East); 4987 (61f: trivalent Cox-vaccine); 4988 (61f: trivalent Cox-vaccine); 4991 (61pl: KOPROWSKI-vaccine: Poland); 4992 (61pl: KOPROWSKI-vaccine: Poland); 4993 (61pl: KOPROWSKI-vaccine: Poland); 5059 (61d: Cox-vaccine: newborn); 5072 (61d: neuropathogenicity: monkey); 5078 (61e); 5122 (61e: new type 3 strain); 5176 (61pl: neuroallergic reaction); 5247 (61r: USSR); 5253 (61d: antibody formation); 5255 (61e: duration of antibodies); 5258 (61e: newborn); 5262 (61d); 5266 (61e: neurotropism in monkeys); 5270 (61e: marker); 5274 (61e: d-marker); 5277 (61e: Hungary); 5280 (61e: in sewage); 5314 (61e: Cox-vaccine: Switzerland); 5340 (61d); 5341 (61d); 5345 (61e: CHAT-strain: Poland); 5355 (61e); 5357 (61e: stability); 5361 (61d: SABIN-virus: HeLa-cells); 5362 (61e: Hungary); 5363 (61e: Sweden); 5366 (61e: Poland); 5372 (61e: Cox-vaccine); 5399 (61e: adsorption to $Al(OH)_3$: differentiation); 5401 (61d: adsorption to $Al(OH)_3$: differentiation); 5451 (61r: newborn period: SABIN-vaccine); 5466 (61d); 5473 (61e); 5480 (61pl: Poland); 5482 (61pl: KOPROWSKI-vaccine: Poland); 5484 (61e: interference); 5485 (61i: heterotypic reaction); 5486 (61i: antibody response); 5487 (61i: SABIN-vaccine: revaccination); 5492 (61e: aluminum marker); 5497 (61s: USSR); 5498 (61e: South Africa); 4875 (62d); 5020 (62d: Cox-vaccine: Berlin 1960); 5321 (62e: t-marker); 5339 (62d); 5350 (62e); 5369 (62d: d-marker); 5436 (62e: aluminum marker); 5496 (62d: Cox-vaccine: Berlin 1960).

Adsorbat-Impfstoffe / Adsorbat vaccines

0831 (30e: $Al(OH)_3$); 0004 (31e: aluminumhydroxyde); 0775 (31e); 2236 (31e: purification); 1078 (32e); 0815 (35e: animal experiments); 0933 (35e: aluminumhydroxyde: purification); 1085 (35e: sheep); 0019 (36e: aluminumhydroxyde); 0932 (36e: aluminum-gel); 2669 (39e); 4066 (42f: mice); 4171 (43e: «fortified» antigen: enteric toxin); 4720 (48e: mice); 0034 (50e: paraffin-oil, Mycobact. butyricum and Arlacel as adjuvans); 5329 (50e); 0037 (51e: mineraloil: Bayol F and Arlacel A); 0048 (51e: mineraloil); 0052 (51e: Bayol F and Arlacel A: hyperimmunization of monkeys); 3457 (51e: horse); 0119 (52e); 2601 (52e); 2892 (52e); 3141 (52e: monkey); 4464 (52e); 1740 (53e); 1769 (53e); 2632 (53e); 2963 (53e: monkey); 2964 (53e: monkey); 3136 (53e); 1795 (55d); 1797 (55d: animal experiments); 1868 (55i); 1913 (56d: German vaccine); 2135 (56s); 0309 (57e); 0636 (57s); 0067 (58d: aluminumhydroxyde: German vaccine); 1031 (58d: guinea pigs: antibody response); 1935 (58e: Al-phosphate); 0568 (59e); 0598 (59e); 1089 (59d: potency test); 1123 (59i: multiple antigens); 1132 (59d: German combined antigen); 1134 (59d: uninterrupted antigen stimulus); 1224 (59b); 1319 (59f: multiple antigens); 5402 (59d: $Al(OH)_3$); 2308 (60d: monkeys); 2351 (60d: combined antigens); 2370 (60e: concentration); 2394 (60e: combined antigens); 2790 (60i); 2937 (60i); 4219 (61d: $Al(OH)_3$); 4641 (61d); 5399 (61e: $Al(OH)_3$: intraserotypic differentiation); 5400 (61d: $Al(OH)_3$: intraserotypic differentiation); 5401 (61d: $Al(OH)_3$: intraserotypic differentiation).

Inaktiviertes Virus / Inactivated virus

Allgemeines / General

0421 (10d: carbolacid); 0096 (11d: carbolacid); 1435 (11d); 0831 (30e: adsorption: aluminumhydroxyd); 4550 (30s: phenol-inactivated); 0004 (31e: aluminumhydroxyd); 0775 (31e: adsorption: aluminumhydroxyd); 1038 (31d: phenol); 0225 (34e: Na-ricinoleat and chloroform); 0747 (35e: antigenicity); 2856 (35e: phenol); 4777 (35f: methylen blue + light); 0018 (36e: Na-ricinoleat); 0471 (36e); 1043 (37e: monkeys: ricinoleate vaccine); 0038 (43j: ultrasonic); 0036 (47e: ultrasonic); 4420 (48e); 3202 (51e: freeze-drying); 1740 (53e); 0591 (54e); 1561 (54e); 1781 (55d); 3124 (55h); 0942 (57e); 2191 (57e); 4178 (58d); 0431 (59e); 0661 (59d: requirements: Germany); 0867 (59e: Detroit 1958); 1135 (59d: testing of inactivated virus); 4739 (61d).

Formaldehyd / Formaldehyde

0101 (18e); 2855 (34e: BRODIE-vaccine); 4111 (34e: BRODIE-vaccine); 0470 (35e: BRODIE-vaccine); 0723 (35e: BRODIE-vaccine); 0768 (35e: BRODIE-vaccine); 0818 (35e: BRODIE-vaccine); 0913 (35e: BRODIE-vaccine); 2280 (35e); 3526 (35e: BRODIE-vaccine); 3594 (35e: BRODIE-vaccine); 4719 (35e); 0017 (36e); 0077 (36e: BRODIE-vaccine); 0471 (36e); 3379 (36e: BRODIE-vaccine); 4096 (36e: BRODIE-vaccine); 4571 (45e: Swiss-mice); 0042 (47e: uv-inactivated and active virus); 0372 (47e: animal experiments); 3155 (47e: cotton rats); 4308 (47e: experiments: mice); 2656 (48e: monkey); 4720 (48e: mice: Col. SK-virus); 1541 (51e: cotton rat); 1603 (52e: mice); 2030 (52e); 3140 (52e: chimpanzees); 3141 (52e: monkey); 3353 (52e); 0295 (53e: allergic encephalomyelitis of monkey); 1462 (53s); 1670 (53e); 1769 (53e); 2632 (53e); 3136 (53e); 3188 (53e); 3962 (53e); 3968 (53e); 4489 (53n); 4499 (53e); 0069 (54e); 0854 (54e); 1565 (54e); 1748 (54e); 1770 (54e); 2247 (54e: chimpanzees); 2459 (54e); 2534 (54d); 2615 (54e); 2814 (54d); 2893 (54e); 4034 (54n: Sweden); 4504 (54e); 4530 (54e); 5042 (54s); 0024 (55e); 0025 (55n); 0695 (55e); 0697 (55e); 0839 (55e: Denmark 1955); 1495 (55e); 1505 (55f: French vaccine); 1572 (55e: Cutter-disaster); 1575 (55e); 1610 (55e); 1617 (55e); 1618 (55e: history: USA); 1619 (55e); 1648 (55e); 1649 (55e: safety test); 1656 (55e); 1705 (55e); 1766 (55d); 1771 (55e); 1775 (55e); 1776 (55e); 1782 (55e: field trial USA 1954: FRANCIS-report); 1787 (55e); 1788 (55e); 1789 (55d); 1793 (55d); 1795 (55d); 1796 (55e); 1807 (55e: FRANCIS-report); 1816 (55e: program); 1854 (55d); 1861 (55f); 1873 (55f); 1895 (55e); 1905 (55f); 1908 (55d); 1915 (55e); 1977 (55e: field trial USA); 1978 (55e); 1994 (55e); 2082 (55e: Swedish vaccine); 2103 (55e); 2153 (55e); 2155 (55i: USA); 2156 (55e: minimum requirements); 2164 (55i); 2168 (55s); 2171 (55e); 2226 (55e); 2231 (55f: Canada); 2239 (55s); 2243 (55s); 2432 (55d); 2470 (55e: Denmark: intradermal); 2475 (55e); 2600 (55e); 2624 (55n); 2635 (55n); 2813 (55d: Behringwerk-vaccine); 2981 (55e); 2982 (55e: Denmark); 2983 (55e); 2984 (55e: Behringwerk-vaccine); 2986 (55f: Italy); 3068 (55d: testing); 3072 (55e: field trials: USA);

3077 (55e); 3079 (55e: FRANCIS-report); 3114 (55e); 3132 (55i); 3166 (55e); 3350 (55e); 3351 (55e); 3352 (55e); 3967 (55i); 4019 (55e); 4038 (55e: South Africa); 4142 (55e); 4176 (55i: USA 1954); 4588 (55e: FRANCIS-report); 4592 (55e: SCHEELE-report); 4603 (55e); 4606 (55n: Denmark); 4607 (55e); 4608 (55s: LEPINE-vaccine); 4620 (55f: 3. europ. Conf.); 5034 (55e); 5041 (55e: USA); 5060 (55e: distribution: Arkansas); 5061 (55e: Southern Alamada County); 5148 (55f); 5236 (55f: France); 5237 (55e: USA); 5257 (55e); 5261 (55n: FRANCIS-report); 5264 (55n); 5279 (55s: FRANCIS-report); 5330 (55e); 5395 (55d); 1445 (56e: 1955); 1465 (56i: Behringwerk-vaccine); 1521 (56e: South Africa-vaccine); 1522 (56e); 1527 (56i); 1551 (56e: USA); 1569 (56e); 1570 (56e); 1652 (56e: British vaccine); 1653 (56e); 1667 (56e); 1668 (56e); 1699 (56d); 1702 (56d); 1722 (56e: South Africa-vaccine); 1824 (56d: Behringwerk-vaccine); 1826 (56e); 1857 (56d); 1858 (56d: German vaccine); 1859 (56d); 1862 (56h); 1865 (56d); 1874 (56e); 1877 (56d); 1899 (56e: British vaccine); 1903 (56e); 1913 (56d: German vaccine); 1917 (56e: epidemic Hawaii 1955); 1919 (56e: antigenic potency of commercial vaccines); 1922 (56d: German requirements); 1927 (56e); 1931 (56d); 1953 (56d); 1956 (56e: Canada 1955); 1961 (56e: British Columbia); 1965 (56e: Central America); 2033 (56d); 2053 (56e); 2061 (56e: indication); 2093 (56e); 2099 (56e: New York); 2101 (56e: Delaware); 2114 (56e: safety test); 2135 (56s); 2159 (56e); 2161 (56e: England); 2162 (56e: England); 2163 (56e: South Africa); 2166 (56f); 2167 (56e: Missouri); 2169 (56s); 2170 (56f); 2172 (56f); 2176 (56d); 2177 (56e); 2178 (56e); 2179 (56h: Belgish vaccine); 2182 (56f: Canada); 2185 (56s); 2186 (56s); 2227 (56e); 2306 (56d); 2422 (56e: administration); 2426 (56d); 2441 (56d); 2442 (56d); 2471 (56e: Louisiana); 2474 (56e); 2476 (56f); 2477 (56e); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 2485 (56f: Belgium); 2489 (56f: Germany); 2501 (56f); 2549 (56d); 2551 (56d); 2554 (56d); 2637 (56d: FRANCIS-report); 2708 (56e: distribution in Ohio); 2803 (56e); 2970 (56e); 3017 (56n); 3069 (56d); 3101 (56e); 3115 (56s); 3130 (56s); 3131 (56f); 3400 (56e: Manitoba); 4025 (56e); 4097 (56e); 4169 (56e); 4619 (56e); 4621 (56f); 4757 (56e: virus content); 4760 (56e: control); 4770 (56d); 5048 (56e); 5187 (56p); 5211 (56e); 5235 (56f); 5240 (56e: USA); 5242 (56e: USA); 5243 (56f: young infants); 5275 (56e: Connecticut); 5276 (56e: booster dose); 5293 (56s: Puerto Rico); 5394 (56d); 5396 (56d); 5397 (56d); 5410 (56d: Switzerland); 5411 (56d: Denmark); 5412 (56e: British vaccine); 5423 (56e: reinoculations); 5432 (56d); 5433 (56d); 5434 (56d); 5474 (56d); 5475 (56d); 0305 (57e: safety testing in tissue culture); 0309 (57e); 0310 (57d); 0387 (57e: live vaccine); 0444 (57f: LEPINE-vaccine); 0495 (57d); 0505 (57e: partially inactivated virus: tissue culture); 0510 (57d); 0515 (57e: safety test); 0605 (57e: very young infants); 0639 (57e); 0640 (57b: French vaccine); 0669 (57e: inactivation by formaldehyde: theoretical aspects); 0671 (57e); 0672 (57f); 0762 (57f: SEITZ-filtration); 0763 (57e: + UV-inactivation); 0857 (57e); 0937 (57e); 0938 (57e: control); 0939 (57e); 1207 (57i: Verona); 1245 (57b); 1447 (57e: USA 1956); 1448 (57e: South Africa); 1460 (57h: Netherlands); 1479 (57e: British vaccine); 1482 (57b: Roumania); 1511 (57h: Netherlands); 1513 (57d: Switzerland); 1525 (57e); 1537 (57e: USA); 1543 (57e: USA); 1586 (57e: USA); 1945

(57e: antigenicity); 1963 (57d: Belgium); 1967 (57e: British vaccine); 2044 (57e: kinetics of inactivation); 2048 (57e); 2049 (57e: North Carolina); 2052 (57d); 2057 (57e: England); 2058 (57e); 2060 (57e: FRANCIS-report); 2063 (57e: kinetics of inactivation); 2075 (57e: USA 1956); 2089 (57d); 2094 (57e: 2. injection); 2095 (57e: Canadian vaccine); 2096 (57e: South Africa); 2105 (57e); 2117 (57d); 2123 (57e: Chicago 1956); 2124 (57f: Belgium); 2125 (57e: Canada); 2127 (57d: Coburg 1957); 2136 (57e: testing); 2137 (57e); 2139 (57e); 2196 (57e); 2277 (57e: American vaccine); 2278 (57e: British vaccine); 2313 (57e); 2315 (57e: Nebraska 1956); 2346 (57e: safety test); 2416 (57e); 2417 (57r); 2418 (57s); 2419 (57e); 2431 (57d); 2435 (57e: Israel); 2487 (57e: British vaccine); 2493 (57n: Sweden); 2499 (57f); 2505 (57t); 2506 (57e: British vaccine); 2512 (57e); 2518(57f); Switzerland); 2544 (57d: Germany); 2546 (57d: standards); 2548 (57d: safety test); 2564 (57d); 2683 (57d); 2753 (57e: British vaccine); 2938 (57e); 3012 (57e); 3013 (57e: FRANCIS-report); 3015 (57e: 3129 (57s); 3163 (57e: FRANCIS-report); 3175 (57d); 3257 (57e); 3945 (57f); 4263 (57e); 4264 (57e: England); 4273 (57s: pregnant women); 4944 (57f); 4946 (57e: British vaccine); 4947 (57d: Roumania); 5019 (57d: France); 5192 (57e); 5206 (57e); 5212 (57r: USSR); 5294 (57e: South Africa); 5319 (57e); 5327 (57e: FRANCIS-report); 5388 (57e: allergy to monkey protein); 5405 (57d); 5413 (57d: England); 5414 (57e: New Zealand); 5417 (57d: MAHONEY-strain); 5418 (57d: safety test: Germany); 5419 (57d: safety); 5422 (57d: USA); 5435 (57d); 5449 (57r: Scandinavian vaccine); 5470 (57e: formaldehyde content); 0067 (58d); 0113 (58e); 0201 (58s: pregnant women); 0204 (58e: Hungary: intracutaneous application); 0226 (58e: pregnant women and young infants); 0229 (58f: French vaccine); 0243 (58f: Belgium); 0246 (58d); 0249 (58d: Hungary); 0313 (58d: Germany/ Niedersachsen); 0384 (58e: Island); 0386 (58e: pregnant women); 0390 (58d: Germany/Niedersachsen); 0399 (58i: testing of formaldehyde); 0503 (58e: animal experiments: UV-vaccine); 0504 (58e: UV-inactivation); 0507 (58d: Belgish vaccine: Germany); 0509 (58d: antigenicity of different vaccines); 0553 (58s: Mexico); 0581 (58d: Switzerland); 0583 (58e: USA); 0585 (58d); 0586 (58d); 0589 (58d: Switzerland); 0603 (58e: British vaccine); 0604 (58e: British vaccine); 0610 (58e); 0614 (58e); 0616 (58h: Netherlands); 0646 (58e); 0650 (58e: degree and duration of virus excretion); 0651 (58e: application: antibody response); 0653 (58f: Switzerland); 0654 (58e: British-: SALK-vaccine); 0655 (58f: Belgish vaccine); 0656 (58f: Belgish and French vaccine: Luxemburg); 0657 (58f: Switzerland: SALK-vaccine); 0658 (58e: ČSR: Canadian vaccine); 0659 (58e: Hungary); 0660 (58f: Italian vaccine); 0677 (58e); 0684 (58e: intradermal and orally administration); 0760 (58e); 0842 (58e: ČSR 1957); 0847 (58e: ČSR 1957); 0850 (58e: potency); 0852 (58d); 0858 (58f: Spain); 0860 (58d: Switzerland 1957); 0862 (58u: Hungary 1957); 0864 (58e: Cutter-disaster: Idaho); 0890 (58d: Westfalen); 0949 (58f: control); 0957 (58e); 0970 (58e: kinetics of inactivation); 0990 (58f: Belgish vaccine); 1034 (58i: combination with live vaccine); 1145 (58f); 1146 (58f); 1173 (58e); 1197 (58e: Denmark); 1243 (58e: live vaccine); 1246 (58d: Switzerland); 1254 (58i); 1287 (58d: kinetics of inactivation: purified virus); 1305 (58s: kinetics of inactivation); 1342

(58e: USA); 1494 (58t: ČSR); 1503 (58f: Switzerland); 1533 (58e); 1534 (58e); 1535 (58e: British vaccine); 1538 (58e: British vaccine); 1584 (58e: antibody response); 1585 (58e: Cutter-disaster); 1588 (58e: Ontario); 1592 (58e); 2248 (58d); 2323 (58e: Minnesota 1955/56); 2324 (58f); 2395 (58i); 2520 (58e: British vaccine); 2843 (58d: Germany); 2928 (58i); 3383 (58e); 3465 (58he: Israel); 4086 (58d); 4271 (58d); 4277 (58he: Israel); 4288 (58i); 4667 (58e: allergic reactions); 5406 (58d: Germany); 5407 (58d: Germany); 5408 (58d: Germany); 5409 (58d); 5420 (58e); 5421 (58d); 5424 (58n); 5425 (58e: infants); 0066 (59e: Argentinien); 0361 (59e: early infancy); 0392 (59e: stability of potency); 0412 (59d: program: USA); 0559 (59e: CFT-antigen); 0560 (59e: filtration); 0568 (59e: type 1–problem); 0569 (59e: type 1–problem); 0597 (59e); 0662 (59e: Cutter-disaster: Idaho); 0835 (59e: Winnipeg); 0838 (59d); 0853 (59e); 0905 (59e: rapid immunization); 0965 (59e: persistence of antibodies); 0981 (59d: Switzerland); 0983 (59e: Manitoba 1958); 0987 (59e); 0993 (59e: USA); 0996 (59e: persistence of antibodies); 0997 (59d: Switzerland 1958); 1007 (59t: ČSR: intracutaneous application); 1009 (59e: British vaccine: booster dose); 1026 (59d); 1032 (59e: potency test); 1033 (59e: potency test: in vitro method: antibody combining capacity); 1089 (59d: potency test); 1091 (59e); 1121 (59f: French vaccine); 1133 (59e: Canada); 1144 (59e); 1147 (59t); 1149 (59f); 1150 (59f); 1151 (59f); 1155 (59f: Belgian vaccine); 1156 (59f: French vaccine); 1157 (59e: British vaccine); 1158 (59e: Hungarian vaccine); 1178 (59d); 1189 (59d: Belgian vaccine: Steiermark); 1214 (59e: antibody response: different ages); 1215 (59d); 1216 (59e: intradermal: Norway); 1220 (59e: reactions); 1280 (59e: detection and estimation of penicillin); 1291 (59e: Chicago 1956); 1301 (59f: French vaccine); 1302 (59d); 1310 (59d: purified virus); 1312 (59i); 1323 (59e: Netherlands); 1324 (59i: St. Gallen); 1326 (59s: Spain); 1327 (59s: Spain); 1328 (59e: USA); 1329 (59d: complication of CNS); 1330 (59i: Italy); 1331 (59f: Belgium); 1332 (59r: USSR); 1333 (59e: Southampton/England); 1341 (59f: France); 1370 (59t: ČSR); 1371 (59i: intradermal injection); 1376 (59e: safety test); 1378 (59he: antigenicity); 1387 (59d: Bulgarian); 1388 (59d: Denmark); 1389 (59d: Spain); 1390 (59d: Switzerland); 1403 (59d); 1404 (59e: British vaccine); 1406 (59i: Greece); 1411 (59e: purification of virus); 1414 (59f); 1423 (59e); 1637 (59r: USSR); 1658 (59i); 1659 (59r: formaldehyde testing); 1662 (59t: tissue culture); 1672 (59i: pregnancy); 1715 (59e: standardization); 1843 (59e: in cell cultures); 1937 (59n); 2132 (59e); 2134 (59e); 2258 (59i); 2260 (59i); 2261 (59f); 2268 (59f: Belgium); 2281 (59e: antigenicity: chick test); 2283 (59e: antigenicity: antibody combining test); 2294 (59r: biochemical control); 2301 (59r: USSR); 2391 (59e: USA); 2447 (59d); 2555 (59e: Southern Rhodesia); 2772 (59e: San Diego plan); 2930 (59i: + DPT); 2933 (59i); 2978 (59e: poliomyelitis suum); 3048 (59u); 3081 (59d: Austria); 3097 (59i: isolation of virus); 4068 (59e); 4079 (59i: Italy); 4089 (59e: quadruple antigen); 4124 (59i); 4276 (59e); 4286 (59e: Canada); 4289 (59e); 4970 (59e: Switzerland); 5249 (59r: USSR); 5256 (59d: 4. injection); 5375 (59e); 5389 (59d); 5404 (59d); 5453 (59d); 5467 (59d); 1177 (60d); 1352 (60d); 1989 (60e: animal experiments); 2341 (60e); 2342 (60e); 2343 (60e: standardization); 2352

(60e: concentration); 2357 (60e: Israel); 2363 (60e: Detroit 1958); 2375 (60d: antibody-persistence); 2387 (60e: New Jersey); 2392 (60e); 2397 (60u: Hungary); 2402 (60d: Switzerland); 2439 (60e: increased amounts of antigen); 2452 (60e: RNA: purified preparations); 2523 (60f: Belgium); 2524 (60i: Genua); 2529 (60f: chick test); 2558 (60e); 2561 (60f: antibody production); 2566 (60e: epidemic Iowa 1959); 2570 (60e: concentrated purified suspensions); 2575 60u: Hungary); 2610 (60d); 2700 (60i); 2774 (60i: CFT); 2789 (60i: antigenicity); 2790 (60i: adsorbed vaccine); 2791 (60e: antibody status four years after); 2872 (60e: Nairushire 1958); 2879 (60e: Southampton 1958/59); 2887 (60e: British vaccine); 2902 (60e: Israel); 2914 (60e: England and Wales 1958); 2937 (60i); 2945 (60e: Mauritius); 2951 (60d: Canada); 2955 (60e: Alaska/Bering Sea); 2957 (60d: Basel); 2960 (60e); 2973 (60e: New Haven/Conn.: antibody levels); 2974 (60e: Detroit and Wayne County 1958); 2975 (60e); 2976 (60e); 3023 (60e: England and Wales); 3033 (60d); 3050 (60f); 3053 (60f); 3058 (60i); 3061 (60t: ČSR); 3062 (60f); 3063 (60e); 3066 (60e: persistence of antibody); 3086 (60i: Rome); 3094 (60pl: complications); 3099 (60d); 3116 (60e: kinetics of inactivation); 3190 (60e: zone electrophoresis); 3196 (60e: newborns); 3198 (60f: ČSR); 3233 (60e: Alberta); 3237 (60e: vaccination status); 3240 (60e: neurological complication); 3241 (60f: precipitins: rabbit); 3242 (60e: Roumania); 3259 (60e: reactions); 3328 (60i: flocculation test); 3329 (60i: reactions); 3331 (60he: Israel); 3344 (60e: New York: immunization status); 3387 (60e: Canada); 3388 (60e); 3391 (60e: ČSR); 3393 (60i: Pisa/Italy); 3394 (60i); 3430 (60i: Naples); 3431 (60e: Tennessee); 3450 (60e: ČSR); 3452 (60b: Roumania); 3454 (60i: potency); 3456 (60e: Hungary); 3459 (60e: immunogenic potency); 3974 (60pl: Poland); 3981 (60e: Hungary); 3986 (60e: storage of Hungarian SALK-vaccine); 3995 (60d); 4074 (60u: Hungary); 4075 (60u: Hungary); 4082 (60u: neurologic complications); 4085 (60e: immunogenic potency); 4184 (60u: Hungary 1959); 4196 (60i); 4306 (60f); 4332 (60e); 4577 (60f: control); 4860 (60s: Guatemala); 4867 (60e: Canada); 4870 (60e: Denmark); 4874 (60e: ČSR); 4877 (60e: Israel); 4880 (60e: Norway); 4881 (60i: Italy); 4882 (60e: duration of antibody); 4885 (60e: duration of antibody); 4887 (60e: standardization); 4964 (60r); 5032 (60e: ČSR); 5317 (60e: neurological sequelae); 5458 (60d); 1850 (61f: Belgium); 2771 (61d: Trivirelon); 2919 (61d); 2939 (61e); 2953 (61e: persistence of antibody); 3075 (61t: ČSR); 3150 (61i: Rome); 3192 (61e: Seattle-King County); 3335 (61d: Hamburg); 3349 (61e: USA: lethality); 3355 (61e: antibody: N-Ireland); 3372 (61e: USA: program); 3386 (61e: incidence of virus); 3389 (61e: Canada); 3474 (61e: potency: USA); 3483 (61e); 3499 (61e: spread of virus); 3987 (61e: Middlesex); 3988 (61i: duration of antibody response); 3989 (61d); 4001 (61e: Arkansas 1959); 4002 (61e: Iowa 1959); 4003 (61e: Kansas City and Des Moines 1959); 4063 (61e: Mauritius); 4103 (61d: Europe); 4116 (61d: Germany); 4139 (61d); 4145 (61e: Houston area); 4150 (61e: Kansas City 1959); 4182 (61d: Neunkirchen 1960); 4183 (61d); 4191 (61e: N. Y. State); 4194 (61f: duration of antibody levels); 4203 (61e: Massachusetts 1959); 4204 (61e: purified and concentrated vaccine); 4212 (61d: minimum requirements: Germany); 4213 (61d: Duesseldorf); 4224 (61e: USA);

4225 (61f); 4236 (61e: young infants); 4238 (61d: Hungary); 4257 (61e: virus in pharyngeal secretions); 4260 (61e: spread of virus); 4323 (61e); 4346 (61e: United Kingdom); 4357 (61f: young infants); 4358 (61d: Germany); 4359 (61d: Germany); 4360 (61d: Switzerland); 4361 (61e: Canada); 4362 (61e: ČSR); 4415 (61e: Denmark); 4630 (61e: safety test); 4631 (61e: safety test for concentrated vaccine); 4633 (61e: North Carolina 1959); 4635 (61e: purified vaccine); 4640 (61i: young infants); 4645 (61e); 4646 (61f: Belgium); 4647 (61e: Hungary); 4661 (61i: Rome); 4664 (61e: preparation: ČSR); 4668 (61e: potency test); 4692 (61e); 4694 (61d: neuroallergic complication); 4695 (61e: New Jersey); 4733 (61r: antigenic activity); 4856 (61e: ČSR); 4879 (61d: allergy); 4892 (61i: early life); 4894 (61i: Di-toxoid); 4898 (61e: Germany); 4899 (61e: Rhode-Island); 4901 (61e: USA); 4986 (61i: Brescia); 5123 (61e: Finland); 5175 (61e: SALK-vaccine: Taiwan); 5177 (61e: potency test); 5316 (61e: Ireland); 5338 (61e: Connecticut); 5352 (61e: Netherlands); 5359 (61e: England and Wales); 5362 (61e: Hungary); 5363 (61e: Sweden); 5365 (61e: Finland); 5366 (61e: Poland); 5371 (61e: SV_{40}); 5480 (61pl: Poland); 4738 (62d: Middle Europe).

Immunserum / Immune serum

0095 (10d); 0104 (10d); 0106 (10e); 0373 (10f: monkeys); 1062 (10d: monkeys); 1380 (10d); 1435 (11d); 0142 (30e); 1185 (30e: monkeys); 0001 (31e: monkeys); 0007 (31e: monkeys); 1097 (31e: animal experiments); 0015 (32e: monkeys); 0791 (32e: monkeys); 1261 (32f: monkeys); 0146 (33e: monkeys); 0145 (34e: monkeys); 0016 (36e: monkeys); 1602 (51e: monkeys); 2816 (53d: gammaglobuline); 2740 (55e: activation); 0488 (59e: specifity).

Kombinierte Methoden / Combined methods

1602 (51e: monkeys: combined passive and active immunization); 0515 (57e: formaldehyde and UV-inactivation: safety test); 2070 (57e: UV and heat); 2193 (57f: formaldehyde and B-propiolactone); 2312 (57e: ionizing radiation and heat); 0504 (58e: formaldehyde and UV-irradiation); 0614 (58e); 1935 (58e: UV-irradiation and formaldehyde).

UV-Strahlen / UV-radiation

0473 (37e); 3890 (44e); 5271 (44e: mice); 4574 (45e: mice); 0042 (47e: formaldehyde and active virus); 3437 (50e); 1542 (51e: cotton rat); 4464 (52e: monkey); 1755 (54e); 2718 (54e); 1783 (55e); 1810 (55e); 1882 (56e: antibody response); 0763 (57e: + formalin-inactivation); 2190 (57e); 0503 (58e); 0504 (58e: formalin-inactivation); 0614 (58e); 0985 (59e: antibody response).

Wärme / Heat

0093 (10d); 0095 (10d); 0109 (10e); 0467 (10f: monkey experiments); 1380 (10d); 0359 (11f: monkey experiments); 0101 (18e); 0490 (18e:

monkey experiments); 0339 (30e: monkey experiments); 0453 (30e: monkey experiments); 0225 (34e); 2743 (51f); 1767 (55e: mouse experiments); 1810 (55e); 2326 (57e: immunologic types); 2780 (59i).

Haltbarkeit und Konservierung / Keeping capacity and preservation

0086 (36e: KOLMER-vaccine); 2247 (54e: chimpanzees); 1776 (55e: SALK-vaccine); 1780 (55e: temperature); 1828 (56e: merthiolate); 1919 (56e: SALK-vaccine); 2070 (57e: after UV- and heat-inactivation); 0851 (58e: duration: temperature); 0392 (59e: SALK-vaccine: stability and temperature); 1121 (59f: French vaccine); 1280 (59e: estimation of penicillin); 2374 (60f: thermo-inactivation); 2575 (60u: SALK-vaccine in Hungary: room temperature); 3473 (60r: candied live virus); 3486 (60r: live vaccine: dragée candy); 3986 (60e: Hungarian SALK-vaccine); 4893 (60e: SABIN-vaccine: in candy); 4329 (61d: SABIN-vaccine).

Mehrfach-Impfstoffe / Combined vaccines

0309 (57e); 1252 (57e: antibody response: animal experiments); 2090 (57e: diphtheria and poliomyelitis: animal experiments); 2194 (57e: vaccination program); 2332 (57e); 2338 (57i: + S. typhi-antigen: antibodies); 2348 (57e); 0618 (58f); 0619 (58e: combined antigens); 0950 (58f: combined antigens); 1142 (58d); 1172 (58e); 1519 (58e: antibody response); 2324 (58f); 2928 (58i); 5425 (58e: infants); 5426 (58d); 0209 (59e: vaccination program); 0211 (59e: vaccination program); 0222 (59e: vaccination program); 0600 (59e: Di-Tet-Tuss); 0989 (59e: Polio-Di-Tuss-Tet); 1021 (59d: Polio-Di-Tuss-Tet); 1088 (59e: vaccination program); 1123 (59i: animal experiments); 1132 (59d: Di-Tet-Polio); 1147 (59f); 1162 (59f); 1222 (59e: antibody response); 1223 (59d: antibody response); 1318 (59d); 1319 (59f); 1368 (59e: Canada); 1381 (59f); 1384 (59f: vaccination program); 1414 (59f); 1415 (59f); 1621 (59e); 2267 (59f); 2284 (59e); 2398 (59e: quadruple antigen); 2562 (59d); 2930 (59i: DPT-Polio); 4089 (59e: quadruple antigen); 4284 (59e); 4286 (59e: Canada); 4287 (59i); 1176 (60d); 1177 (60d); 1397 (60d: antibody response); 1405 (60d); 2350 (60d); 2351 (60d); 2394 (60d: antibody production); 2591 (60e: DPT-P); 2869 (60e: Compligen); 2933 (60i: DPT-Polio); 2940 (60i: DPT-Polio); 2943 (60f: DPT-Polio); 2948 (60e: DPT-Polio); 2951 (60d: Canada); 3053 (60f); 3063 (60e); 3088 (60f); 3090 (60f); 3239 (60f); 3319 (60t); 3428 (60i); 3453 (60r: pertussis-polio-vaccine); 3998 (60d); 4299 (60e); 4300 (60e); 4304 (60e); 4889 (60e: DPT-Polio-vaccine); 4966 (60r: DT-Polio-vaccine); 5458 (60d); 2771 (61d: Trivirelon); 2929 (61u: DPT and live vaccine); 3020 (61d: Quatro-Virelon); 3100 (61d); 3475 (61f: Polio- and TAB-vaccine); 3483 (61e: neonatal immunization); 4241 (61h); 4357 (61f); 4361 (61e: Canada); 4625 (61e: DPTP-vaccine and live vaccine); 4859 (61u: DPT- and live vaccine); 5145 (61d); 5351 (61d: Trivirelon: antibody response); 5355 (61e); 5466 (61d).

Produktionsverfahren / Production

0096 (11d: size of particles); 0695 (55e); 1610 (55e: SALK-vaccine); 1776 (55e); 1787 (55e); 1861 (55f); 1895 (55e: SALK-vaccine USA 1954); 1915 (55e: SALK-vaccine); 1978 (55e); 2156 (55e: USA); 2624 (55n: SALK-vaccine); 2986 (55f: Italy); 4606 (55n: SALK-vaccine: Denmark); 5034 (55e); 5236 (55f: France: SALK-vaccine); 5264 (55n: SALK-vaccine); 1456 (56i: β-propiolactone); 1521 (56e: South Africa-vaccine); 1569 (56e: SALK-vaccine); 1828 (56e: merthiolate); 1899 (56e: British vaccine); 1907 (56e: allergy); 1922 (56d: German requirements); 2181 (56f); 2182 (56f: Canada); 2441 (56d); 2476 (56f); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 2485 (56f: Belgian vaccine); 2489 (56f: Behring-factory/Germany); 2549 (56d); 4169 (56e: SALK-vaccine); 4760 (56e: SALK-vaccine); 0444 (57f: LEPINE-vaccine); 0495 (57d); 0536 (57e: live vaccine); 0671 (57e: SALK-vaccine: type 1); 0762 (57f: SEITZ-filtration); 0763 (57e: formalin-UV-vaccine); 0857 (57e); 0938 (57e: SALK-vaccine); 1448 (57e: South African vaccine: penicillin-content); 1479 (57e: British vaccine); 2014 (57e: purification); 2095 (57e: Canadian vaccine); 2313 (57e); 2689 (57d: concentration); 2753 (57e: British vaccine); 4947 (57d: SALK-vaccine: Roumania); 5449 (57r: Scandinavian vaccine); 0067 (58d); 0399 (58i: formaldehyde testing); 0614 (58e); 0619 (58e: quadruple vaccine); 0949 (58f: SALK-vaccine); 0957 (58e: SALK-vaccine: costs); 0990 (58f: SALK-vaccine: Belgium); 4221 (58e: SALK-vaccine: filtration); 4955 (58h: double filtration); 0066 (59d: Argentinien); 0560 (59e: SALK-vaccine: filtration); 1026 (59d); 1149 (59f); 1150 (59f); 1310 (59d: concentration of antigen); 1404 (59e: inactivated vaccine: England); 1427 (59e: action of insulin); 1659 (59r: content of free formaldehyde); 1662 (59t: tissue culture); 1715 (59e); 1717 (59e: high potency virus in FL cell cultures); 2285 (59r: conference: Moscow); 2301 (59r: USSR); 3222 (59e: USSR: SABIN-vaccine); 1398 (60e: penicillin content); 1433 (60e: COX-vaccine); 2352 (60e: concentration); 2370 (60e: concentration); 2384 (60d: tissue culture); 2452 (60e: concentration: RNA); 2457 (60e: monkey viruses); 2765 (60f); 2773 (60e: concentration); 2777 (60e: concentration); 2949 (60e: cell cultures activator); 3061 (60t: ČSR); 3063 (60e); 3242 (60e: Roumania: SALK-vaccine); 3476 (60r: pasty candies); 4572 (60e: live vaccine); 4573 (60e: live vaccine); 4727 (60e: SV 40); 5458 (60d); 3474 (61e: USA: live vaccine); 3990 (61e: tissue culture: trypsinization); 4115 (61e: live vaccine: Johannesburg); 4204 (61e: purification and concentration); 4664 (61e: SALK-vaccine: ČSR); 4690 (61e: prevention of adsorption on filter); 4726 (61e: simian foamy virus).

Prüfung / Examination

4066 (42f: mice); 4308 (47e: formolized vaccines); 1770 (54e: formaldehyde inactivation); 2460 (54e: live vaccine); 2718 (54e: rabbit test); 4034 (54n: SALK-vaccine: Sweden); 0839 (55e: Denmark 1955); 1610 (55e: SALK-vaccine); 1679 (55e: mouse test); 1766 (55d: Behringwerk-vaccine); 1787 (55e); 1795 (55d); 1818 (55f); 1854 (55d); 1861 (55f); 1895 (55e: SALK-vaccine in USA); 1915 (55e); 1978 (55e);

2156 (55c: USA); 2226 (55e); 2250 (55e: tissue culture); 2537 (55d); 2538 (55d); 2981 (55e); 3068 (55d); 4038 (55e: South African vaccine); 4592 (55e: SALK-vaccine); 4606 (55n: Denmark); 5264 (55n: SALK-vaccine); 0978 (56e: monkey test); 1521 (56e: South African vaccine); 1569 (56e: SALK); 1667 (56e); 1833 (56d); 1875 (56e: cotton rat); 1899 (56e: British vaccine); 1900 (56e: cortisone treated monkey); 1903 (56e: monkeys: cortisone-treatment and X-irradiation); 1911 (56e: statistical aspects of safety test); 1912 (56d: safety test); 1916 (56e: monkeys); 1918 (56d: German vaccine); 1919 (56e: commercial SALK-vaccines: guinea-pig test); 1922 (56d: German requirements); 2078 (56e: Cutter-vaccine); 2114 (56e); 2159 (56e: USA); 2162 (56e: England); 2179 (56h: Belgium); 2181 (56f); 2185 (56s); 2186 (56s); 2227 (56e); 2307 (56d: monkeys: cortisone); 2441 (56d); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 2485 (56f: Belgian vaccine); 2549 (56d); 2551 (56d); 2554 (56d: Germany); 4012 (56e: guinea-pig test: immunogenic capacity); 4025 (56e: SALK-vaccine); 4097 (56e: USA); 4169 (56e: SALK-vaccine); 4757 (56e: SALK-vaccine); 4760 (56e: SALK-vaccine: control); 5433 (56d: SALK-vaccine); 5474 (56d: SALK-vaccine); 5475 (56d: SALK-vaccine); 0444 (57f); 0505 (57e: partially inactivated SALK-vaccine: tissue culture); 0515 (57e: safety test); 0639 (57e); 0857 (57e); 0938 (57e: SALK-vaccine); 1479 (57e: British vaccine); 2052 (57d); 2064 (57e: guinea-pig test); 2087 (57e: mouse test); 2095 (57e: Canadian vaccine); 2124 (57f: Belgium); 2136 (57e: SALK-vaccine); 2195 (57f); 2278 (57e: British vaccine); 2346 (57e: SALK-vaccine: safety test); 2487 (57e: British vaccine); 2544 (57d); 2546 (57d: standards); 2548 (57d: SALK-vaccine); 2564 (57d); 2613 (57d); 2753 (57e: British vaccine); 3012 (57e: SALK-vaccine); 3368 (57e: live vaccine); 4263 (57e: ultra-centrifugation); 4264 (57e: British SALK-vaccine); 4946 (57e: British SALK-vaccine); 5418 (57d: SALK-vaccine: Germany); 5419 (57d: SALK-vaccine); 5470 (57e: SALK-vaccine: formaldehyde content); 0631 (58e: antibody response: guinea-pigs); 0761 (58e: antigenicity: chicken test); 0849 (58e: antigenicity: guinea-pigs); 0850 (58e: antigenicity: guinea-pigs); 0851 (58e: chicken test); 0949 (58f: SALK-vaccine); 0950 (58f: combined antigens); 0951 (58f: chicken test); 0990 (58f: Belgian SALK-vaccine); 1031 (58d: guinea-pig); 1535 (58e: British vaccine); 2111 (58e: guinea-pig test); 4934 (58e: virulence: plaque method); 4938 (58f: t-marker); 4961 (58e: attenuated strains: d-marker); 0186 (59d: potency test: SALK-vaccine); 0661 (59d: German requirements); 0662 (59e: Cutter-disaster: Idaho); 1026 (59d); 1032 (59e: antigenicity: guinea-pig test); 1033 (59e: potency test: antibody combining capacity); 1086 (59e: antigenicity: neutralizing-antibody-combining test = NAC); 1089 (59d: guinea pig test); 1135 (59d: testing of inactivated virus); 1149 (59f); 1150 (59f); 1151 (59f); 1178 (59d: formaldehyde inactivation and reactivation); 1279 (59e: chicken test); 1267 (59e: rat test); 1280 (59e: estimation of penicillin content); 1282 (59e: live vaccine: t-marker); 1303 (59e: chicken test); 1304 (59f: chicken test); 1309 (59d: chicken test: standardization); 1319 (59f: multiple antigens); 1322 (59e: SABIN-vaccine, type 3: marker); 1378 (59he: antigenicity); 1404 (59e); 1415 (59f: antigenicity: French vaccine); 1660 (59r: antibody response: rats); 1715 (59e-standardization); 2281 (59e: antigenicity: chick test); 2283 (59e: anti:

genicity: antibody combining test); 2285 (59r: conference: Moscow); 2294 (59r: formaldehyde); 2300 (59e: live vaccines); 2301 (59r: USSR); 3208 (59e: live vaccine: monkey neurovirulence); 3222 (59e: USSR: SABIN-vaccine); 5404 (59d: SALK-vaccine); 1398 (60e: determination of penicillin content); 1433 (60e: Cox-vaccine); 2274 (60d: live vaccine); 2296 (60e: monkeys: subcutaneous inoculation); 2316 (60f: antigenicity: immuno-inactivation [GARD]); 2343 (60e: SALK-vaccine: standardization); 2349 (60d); 2374 (60f: chicken test); 2378 (60e: antibody-combining test); 2389 (60e: attenuated strains: neuroactivity: markers); 2456 (60e: antibody response of roosters); 2457 (60e: monkeys viruses); 2525 (60e: excreted attenuated virus: markers); 2529 (60f: antigenicity: chick test); 2765 (60f); 2789 (60i: in vitro-titration of antigenic power); 2790 (60i: adsorbed vaccine); 2887 (60e: SALK-vaccine); 2911 (60e: antibody combining power test); 2915 (60e: live vaccines: neurovirulence); 2922 (60r: d-marker); 3063 (60e); 3454 (60i: SALK-vaccine: potency); 3459 (60e: SALK-vaccine: potency); 3473 (60r: live vaccine); 3476 (60r: USSR: live vaccine); 3482 (60r: t-marker: live vaccine); 4160 (60d); 4187 (60i: guinea-pigs and monkeys: cutaneous reactivity); 4304 (60e: combined vaccines); 4570 (60e: live vaccine); 4572 (60e: live vaccine); 4573 (60e: live vaccine); 4575 (60e: live vaccine); 4577 (60f: SALK-vaccine); 4579 (60d: live vaccine: titer); 4887 (60e: SALK-vaccine: potency); 4930 (60e: stability of attenuated strains: marker); 4954 (60e: attenuated strain: elution marker); 4957 (60e: live vaccine: genetic markers); 4958 (60e: SABIN-: Cox-strains: neuropathogenicity); 4960 (60e: simian virus); 4962 (60e: live vaccines: neurovirulence test); 4965 (60e: Cox-vaccine: marker after human passage); 4967 (60e: live vaccines: marker); 4982 (60e: CHAT-strain: marker); 5036 (60e: CHAT- and Fox-strain); 5310 (60e: SABIN-vaccine: neurovirulence in monkeys); 5458 (60d); 0116 (61b: live vaccine: marker: neurovirulence); 2771 (61d: Trivirelon); 2952 (61d: cell cultures: mixed infection); 3020 (61d: Quatro-Virelon); 3339 (61e: pathogenicity for monkey: t-marker); 3474 (61e: USA: live vaccine); 4115 (61e: live vaccine: South Africa); 4118 (61e: monkey kidney cells: tumor in hamster); 4143 (61d: live vaccine); 4148 (61e: monkey neurovirulence test: live vaccine); 4183 (61d: SALK-vaccine: chick test); 4205 (61e: virus B-infection of monkeys); 4212 (61d: requirements: Germany); 4214 (61e: SABIN's strains: pathogenicity for monkeys); 4216 (61e: SABIN's strains: viraemia in monkey); 4220 (61d: sterility); 4254 (61d: simian viruses); 4630 (61e: SALK-vaccine: safety test); 4631 (61e: concentrated SALK-vaccine: safety test); 4635 (61e: purified SALK-vaccine); 4664 (61e: SALK-vaccine: ČSR); 4729 (61r: attenuated virus: effect of chlorine); 4733 (61r: SALK-vaccine: antigenic activity); 4735 (61f: live vaccine); 4897 (61e: monkey: virulence: subcutaneous injection); 4971 (61e: neurovirulence test); 4973 (61e: SABIN-type 1 virus: marker after human passage); 5072 (61d: SABIN- and Cox-strain: neuropathogenicity for monkey); 5122 (61e: new type 3 strain (WM III): stability); 5177 (61e: SALK-vaccine); 5266 (61e: SABIN-vaccine: residual neurotropism in monkeys); 5270 (61e: SABIN-vaccine: marker); 5274 (61e: SABIN-vaccine: d-marker); 5370 (61e: D-antigen); 5371 (61e: SV 40: inactivation by formaldehyde); 5399 (61e: adsorption to $Al(OH)_3$: intratypic differentiation);

5400 (61d: adsorption to $Al(OH)_3$: intratypic differentiation); 5401 (61d: adsorption to $Al(OH)_3$: intratypic differentiation); 5492 (61e: aluminum marker); 5321 (62e: t-marker); 5369 (62e: d-marker); 5436 (62e: aluminum-marker).

Stammauswahl / Selection of strains

3136 (53e); 4488 (53e); 4519 (53f: live vaccine: rabbit-adapted virus); 0839 (55e: SALK-vaccine: Denmark: BRUNHILDE-strain); 1505 (55f: French vaccine); 1915 (55e); 2082 (55e: Swedish vaccine); 1445 (56e: SALK-vaccine 1955); 1521 (56e: South Africa-vaccine); 1569 (56e: SALK-vaccine: MAHONEY-strain); 1899 (56e: British vaccine); 2162 (56e: British vaccine); 2169 (56s); 2173 (56e: live vaccine); 2179 (56h: Belgian vaccine); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 4619 (56e); 0671 (57e: MAHONEY-: PARKER-strain); 1479 (57e: British vaccine); 1963 (57d: Belgian vaccine); 1972 (57e: British vaccine); 2095 (57e: Canadian vaccine); 2278 (57e: British vaccine); 2506 (57e: British vaccine); 4264 (57e: British vaccine); 4944 (57f: SALK-vaccine); 5417 (57e: SALK-vaccine: MAHONEY-strain); 0553 (58s: Mexico); 0583 (58e: type 1-problem); 0604 (58e: British vaccine); 0637 (58h: live vaccine); 0646 (58e: type 1); 0660 (58f: Italian vaccine); 0760 (58e: type 1-problem); 2520 (58e: British vaccine); 0568 (59e: type 1-problem); 0569 (59e: type 1-problem); 0601 (59e: live vaccine); 1278 (59e: live vaccine); 1300 (59e: live vaccine); 1301 (59f: French vaccine); 1373 (59e: live vaccine); 2301 (59r: USSR); 5389 (59d); 2274 (60d: live vaccine); 3242 (60e: SALK-vaccine: Roumania); 3474 (61e: USA: live vaccine: licensing); 5122 (61e: new type 3 attenuated strain [WM-III]).

Standards / Standards

1787 (55e); 2554 (56d); 2546 (57d); 2564 (57d); 0851 (58e); 1307 (58e: neutralization test); 0186 (59d: potency test); 1026 (59d); 1309 (59d: chicken test); 4570 (60e: live vaccine); 4577 (60e: normogram for antigenicity); 4887 (60e: SALK-vaccine: potency); 5458 (60e: SALK-vaccine); 3474 (61e: USA: live vaccine).

Unschädlichkeit / Safety

0101 (18e: monkeys: subcutaneous application); 4550 (30s: phenol-inactivated vaccine); 3005 (34e: KOLMER-vaccine); 0750 (35e); 0751 (35e: KOLMER-vaccine); 0913 (35e: BRODIE-vaccine); 3693 (35e: KOLMER-vaccine); 4719 (35e: formaldehyde-inactivated vaccine); 0078 (36e: KOLMER-vaccine); 0086 (36e: KOLMER-vaccine); 0471 (36e: monkeys); 0754 (36e: warning against live vaccine); 4096 (36e: KOLMER-vaccine); 0480 (37e); 3136 (53e); 1755 (54e: UV-vaccine); 1770 (54e); 2724 (54e); 0024 (55e); 0698 (55e: live vaccine); 0839 (55e: SALK-vaccine: Denmark); 1552 (55e: SALK-vaccine: Rh sensitivity); 1572 (55e: Cutter-disaster); 1610 (55e); 1649 (55e); 1766 (55d: Behringwerk-vaccine); 1771 (55e); 1787 (55e); 1788 (55e); 1790 (55e: serial urinary addis counts: monkey kidney tissue culture); 1795

(55d); 1809 (55e: penicillin content of SALK-vaccine: allergic patients); 1853 (55e); 1856 (55d); 1895 (55e); 1908 (55d); 1915 (55e); 1977 (55e: field trial USA 1954); 1978 (55e); 2156 (55e: Cutter-disaster); 2467 (55e); 3077 (55i: SALK-vaccine); 3350 (55e); 3351 (55e); 4592 (55e: SALK-vaccine: Cutter-disaster); 5237 (55e: SALK-vaccine); 5264 (55n: SALK-vaccine); 0978 (56e: monkey test); 1492 (56e: penicillin-allergy); 1521 (56e: South Africa-vaccine); 1569 (56e: SALK-vaccine); 1570 (56e: Cutter-disaster); 1667 (56e); 1668 (56e); 1699 (56d); 1702 (56d); 1819 (56d); 1824 (56d: Behringwerk-vaccine); 1858 (56d: German vaccine); 1874 (56e); 1882 (56e: UV-vaccine); 1899 (56e: British vaccine); 1900 (56e: monkey: cortisone: detection of live virus); 1903 (56e: monkey: cortisone: detection of live virus); 1907 (56e: allergy); 1911 (56e: safety test); 1912 (56d: safety test); 1913 (56d: German vaccine); 1922 (56d: German requirements); 1931 (56e); 1956 (56e: Canada 1955); 2053 (56e: SALK-vaccine); 2078 (56e: active virus in Cutter-vaccine); 2114 (56e); 2159 (56e: Cutter-disaster); 2162 (56e: British vaccine); 2163 (56e: South Africa-vaccine); 2179 (56h: Belgian vaccine); 2180 (56e: live vaccine); 2185 (56s); 2426 (56d); 2474 (56e); 2476 (56f); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 2551 (56d); 2554 (56d); 4097 (56e: SALK-vaccine); 4757 (56e: SALK-vaccine: live virus); 5235 (56f: SALK-vaccine); 5434 (56d: SALK-vaccine); 0305 (57e: tissue culture: SALK-vaccine); 0444 (57f: LEPINE-vaccine); 0515 (57e: safety test: tissue culture); 0536 (57e: live vaccines); 0669 (57e: kinetics of formaldehyde-inactivation); 0763 (57e: formalin-UV-vaccine); 0857 (57e); 0938 (57e: SALK-vaccine); 0939 (57e: SALK-vaccine); 0940 (57e: live vaccine); 0941 (57e: live vaccine); 0977 (57f: live vaccine); 1479 (57e: British vaccine); 1543 (57e); 1586 (57e); 1975 (57d); 2023 (57e: allergy against monkey kidney cell culture); 2052 (57d: Behringwerk-vaccine); 2075 (57e: USA 1956); 2089 (57d); 2117 (57d); 2136 (57e: British vaccine); 2195 (57f); 2304 (57e: SM type I); 2305 (57e: live vaccine: viraemia); 2313 (57e: SALK-vaccine); 2315 (57e: Nebraska 1957); 2346 (57e: SALK-vaccine); 2506 (57e: British vaccine); 2518 (57f: Switzerland); 2544 (57d); 2546 (57d); 2548 (57d); 2564 (57d); 2741 (57e: live vaccine); 2808 (57e: SALK-vaccine: pregnant women); 3163 (57e: FRANCIS-report); 4264 (57e: British SALK-vaccine); 5388 (57e: SALK-vaccine: allergy to monkey protein); 5419 (57d: SALK-vaccine); 5430 (57e: SALK-vaccine: monoarticular arthritis); 0067 (58d); 0227 (58e: SALK-vaccine: Idaho 1955); 0228 (58e: SALK-vaccine: Idaho 1956); 0246 (58d: live vaccine); 0356 (58e: live vaccine); 0390 (58d); 0553 (58s: Mexico); 0607 (58e: SALK-vaccine: cutaneous eruptions); 0608 (58e: SALK-vaccine: allergic reaction); 0610 (58e: SALK-vaccine); 0847 (58e: ČSR 1957); 0864 (58e: Cutter-disaster: Idaho); 0949 (58f: SALK-vaccine); 0990 (58f: Belgian SALK-vaccine); 1010 (58e: penicillin-allergy); 1239 (58i); 1241 (58i); 1589 (58e: penicillin-allergy); 1596 (58e: penicillin-allergy); 1597 (58e: allergic reactions); 1598 (58e: penicillin-allergy); 1704 (58e: penicillin-allergy); 2013 (58e: penicillin-allergy); 2324 (58f); 2395 (58i); 2517 (58n: penicillin-allergy); 2979 (58i); 4667 (58e: SALK-vaccine: allergic reactions); 5428 (58e: SALK-vaccine: nephritis); 0186 (59d); 0258 (59e: live vaccine); 0307 (59e: live vaccine: MS-marker); 0385 (59e: live vaccine); 0560 (59e: filtration); 0567 (59e: SALK-vaccine);

0601 (59e: live vaccine); 0661 (59d: requirements: Germany); 0662 (59e: SALK-vaccine: live virus); 0840 (59e: live vaccine); 0974 (59e: live vaccine); 0992 (59e: live vaccine); 0993 (59e: SALK-vaccine); 1021 (59d: Tetravaccine); 1026 (59d); 1087 (59e: live vaccine: USSR); 1091 (59e); 1121 (59f: French vaccine); 1128 (59e); 1132 (59d: combined antigen); 1147 (59f); 1149 (59f); 1150 (59f); 1151 (59f); 1165 (59e: live vaccine); 1167 (59e: live vaccine); 1194 (59e: penicillin-allergy); 1220 (59e: statistic of reactions); 1226 (59e: live vaccine); 1229 (59e: live vaccine: contacts); 1283 (59d: polyradiculitis); 1286 (59e: live vaccine); 1376 (59e: Canadian SALK-vaccine: safety test in tissue culture); 1404 (59e); 1626 (59e); 2134 (59e: live vaccine: contacts); 2292 (59s: live vaccine); 2293 (59s: live vaccine); 2300 (59r: live vaccine); 2301 (59r: USSR: SALK-vaccine); 2400 (59f: myalgies); 2413 (59i: SALK-vaccine: allergic manifestations); 2807 (59d: asthma); 3153 (59e: sensitivity to SALK-vaccine); 3158 (59e: Cox-vaccine); 3159 (59e: Cox-vaccine: pregnant women); 3208 (59e: live vaccine); 3216 (59e: live vaccine: neurovirulence after human passage); 3222 (59e: SABIN-vaccine); 3226 (59e: SABIN-vaccine: USSR); 3227 (59e: SABIN type 3); 3231 (59e: CHAT-strain: Leopoldville/Congo); 3235 (59e: SABIN-vaccine: ČSR); 4084 (59s: erythema multiforme); 4970 (59e: SALK-vaccine: Switzerland); 5389 (59d); 1362 (60e: live vaccine); 1367 (60d: live vaccine); 1433 (60e: Cox-vaccine); 1991 (60e: CHAT-strain: Poland); 1995 (60e: CHAT-strain: Congo); 2274 (60d: live vaccine); 2296 (60e: monkeys: subcutaneous route); 2384 (60d: tissue culture); 2399 (60d); 2402 (60d: Switzerland: SALK-vaccine); 2406 (60e: live vaccine); 2436 (60e: CHAT-strain: Congo); 2457 (60e: monkey viruses); 2525 (60e: live vaccine: excreted virus); 2526 (60e: sensitivity reaction to SALK-vaccine); 2532 (60d: Cox-vaccine/Berlin); 2571 (60e: SABIN-type 3); 2572 (60e: Cox-vaccine: Cuba); 2586 (60e: Cox-vaccine: Miami); 2591 (60e: DPT-Polio); 2788 (60e: CHAT-strain: Congo); 2909 (60i: acute haemorrhagic glomerulonephritis); 2959 (60i: tuberculosis); 2977 (60e: ČSR: SABIN-vaccine); 3047 (60d: Cox-vaccine: Berlin); 3063 (60e); 3090 (60f: combined vaccine); 3094 (60pl: SALK-vaccine); 3171 (60d: allergic reactions); 3193 (60i: WATERHOUSE-FRIDERICHSEN-syndrome); 3230 (60r: malignancy in continuous cell lines); 3232 (60e: Cox-vaccine: Colombia and Uruguay); 3248 (60e: Cox-vaccine); 3259 (60e: SALK-vaccine); 3329 (60i: SALK-vaccine: urticaria and relapses in whooping-cough); 3396 (60e: SALK-vaccine); 3449 (60r: latent virus in monkey); 3467 (60pl: SALK-vaccine); 3468 (60e: SALK-vaccine: exfoliative dermatitis); 3479 (60d: SALK-vaccine); 3983 (60i: live vaccine); 4082 (60u: SALK-vaccine: neurologic complications); 4121 (60e: SABIN-vaccine); 4160 (60d: SALK-vaccine); 4197 (60s: Cox-vaccine: Cuba); 4405 (60e: CHAT-strain); 4570 (60e: SABIN-vaccine); 4572 (60e: live vaccine); 4573 (60e: SABIN-vaccine); 4575 (60e: live vaccine); 4727 (60e: SV 40); 4895 (60e: live vaccine); 4896 (60e: Cox-vaccine: Berlin); 4920 (60e: SABIN-vaccine: Mexico); 4927 (60e: live vaccine: Southern Louisiana); 4930 (60e: stability of attenuated strains: marker); 4967 (60e: live vaccine: stability of marker); 4969 (60e: SABIN-vaccine: Netherlands); 4985 (60e: Cox-vaccine: teratogenic effects); 5018 (60e: SABIN-vaccine); 5051 (60e: SABIN-vaccine: USSR); 5068 (60e: live vaccine: Dade County); 5317

(60e: SALK-vaccine: neurological sequelae); 0116 (61b: live vaccine: neurovirulence: marker); 2770 (61d); 2786 (61d: Cox-vaccine: Berlin); 3019 (61d: Cox-vaccine: Berlin); 3304 (61d: live vaccine: Switzerland); 3305 (61d: CHAT-strain: Switzerland); 4118 (61e: monkey kidney cells: tumor in hamster); 4120 (61e: SABIN-vaccine: South Africa); 4127 (61d: Cox-vaccine: Berlin 1960); 4143 (61d: live vaccine); 4149 (61d: encephalitis after SALK-vaccination); 4205 (61e: safety test: virus B-infection of monkeys); 4212 (61d: SALK-vaccine: minimum requirements: Germany); 4214 (61e: SABIN's strains: pathogenicity for monkeys); 4254 (61d: simian viruses); 4345 (61s: Cox-vaccine); 4629 (61e: community spread: Cox-vaccine); 4630 (61e: safety test for SALK-vaccine); 4631 (61e: safety test for concentrated SALK-vaccine); 4635 (61e: purified SALK-vaccine); 4660 (61e: SABIN-vaccine: Cincinnati); 4662 (61e: KOPROWSKI-vaccine: Congo); 4694 (61d: SALK-vaccine: neuroallergic reactions); 4726 (61e: simian foamy virus); 4735 (61f: live vaccine); 4741 (61d: Cox-vaccine: Berlin); 4746 (61d: Cox-vaccine: Berlin); 4747 (61d: live vaccine: neuropathogenicity for monkey); 4858 (61d: SABIN-vaccine); 4879 (61d: SALK-vaccine: neuro-allergy); 4971 (61e: neuro virulence test); 5059 (61d: Cox-vaccine: newborn); 5072 (61d: attenuated strains: neuropathogenicity); 5122 (61e: new type 3 attenuated strain: stability); 5176 (61pl: live vaccine: neuroallergic reaction); 5262 (61d: SABIN-vaccine); 5345 (61e: CHAT-strain: Poland); 5357 (61e: SABIN-vaccine: stability); 5480 (61pl: live vaccine type 3: Poland); 5496 (62d: Cox-vaccine: Berlin 1960).

Wirksamkeit / Potency

3891 (34e: KOLMER-vaccine); 3896 (35f: KOLMER-vaccine); 4719 (35e: formaldehyde-inactivated vaccine); 4777 (35f: monkey: inactivated vaccine); 4776 (36f: KOLMER-vaccine); 1043 (37e: monkeys: ricinoleate vaccine); 3890 (44e: uv-inactivated vaccine); 4571 (45e: Swiss-mice); 4574 (45e: uv-inactivated vaccine); 3141 (52e: monkey); 3353 (52e: antigenicity after formaldehyde treatment); 3136 (53e: SALK-vaccine); 1565 (54e: SALK-vaccine: antibody response); 1755 (54e: UV-vaccine); 2459 (54e); 3964 (54e: live vaccine: persistence of antibodies); 4034 (54n: Swedish vaccine); 4530 (54e: SALK-vaccine: antibody formation); 0698 (55e: live vaccine); 0839 (55e: Danish vaccine); 1610 (55e); 1679 (55e: mouse test); 1705 (55d: USA); 1766 (55d: Behringwerk-vaccine); 1771 (55e); 1775 (55e); 1776 (55e); 1778 (55e: live vaccine); 1797 (55d: adsorbed vaccine: mouse protection test); 1807 (55e: FRANCIS-report); 1818 (55f); 1895 (55e); 1908 (55d); 1915 (55e); 1924 (55e: live vaccine: antibody response); 1977 (55e: field trial USA 1954); 1978 (55e); 2082 (55e: Swedish vaccine); 2813 (55d: Behringwerk-vaccine: antibody response); 2984 (55e: Behringwerk-vaccine: antibody response); 3068 (55d: SALK-vaccine); 4588 (55e: SALK-vaccine: FRANCIS-report); 5237 (55e: SALK-vaccine); 5264 (55n: SALK-vaccine); 1521 (56e: South African vaccine); 1569 (56e: SALK-vaccine); 1667 (56e); 1668 (56e); 1699 (56d); 1702 (56d); 1824 (56d: Behringwerk-vaccine: antibody response); 1831 (56d); 1875 (56e: cotton rat); 1879 (56e: infants and preschool children: SALK-vaccine); 1882 (56e: UV-vac-

cine); 1892 (56e: antibody response: simultaneous vaccination); 1899 (56e: British vaccine); 1913 (56d: German vaccine: antibody response); 1919 (56e: antigenic potency of commercial SALK-vaccine); 1922 (56d: German requirements); 1954 (56e: live vaccine); 2047 (56e: live vaccine); 2097 (56e: live vaccine); 2159 (56e); 2179 (56h: Belgian vaccine); 2185 (56s); 2186 (56s); 2426 (56d); 2476 (56f); 2480 (56e: Danish vaccine); 2481 (56e: British vaccine); 2554 (56d); 2637 (56d: FRANCIS-report); 4012 (56e: guinea-pig test: immunogenic capacity); 4025 (56e: British vaccine); 4760 (56e: SALK-vaccine: antigenicity tests); 5235 (56f: SALK-vaccine); 5475 (56d: SALK-vaccine); 0510 (57d: SALK-vaccine); 0671 (57e: type 1); 0762 (57f: SEITZ-filtration); 0763 (57e: formalin-UV-vaccine); 0857 (57e); 0938 (57e: SALK-vaccine); 0939 (57e: SALK-vaccine); 0940 (57e: live vaccine); 1479 (57e: British vaccine); 1543 (57e); 1586 (57e); 1945 (57e: antibody response); 1972 (57e: British vaccine); 2048 (57e: SALK-vaccine); 2070 (57e: uv- and heat inactivated vaccine: animal experiments); 2075 (57e: USA 1956); 2087 (57e: mouse test); 2089 (57d); 2136 (57e: British vaccine); 2139 (57e: SALK-vaccine: antibody response); 2313 (57e: SALK-vaccine); 2487 (57e: British vaccine); 2493 (57n: SALK-vaccine: guinea-pig test); 2547 (57d: FRANCIS-report); 2564 (57d); 3012 (57e: SALK-vaccine); 3014 (57e: SABIN-vaccine); 3163 (57e: FRANCIS-report); 4264 (57e: British SALK-vaccine); 4266 (57i); 4946 (57e: British SALK-vaccine); 5192 (57e: SALK-vaccine: severity of paralysis); 5327 (57e: FRANCIS-report); 0228 (58e); 0229 (58f: French vaccine); 0356 (58e: live vaccine); 0357 (58e: live vaccine: antibody response); 0390 (58d); 0503 (58e: animal experiments: formaldehyde-: UV-vaccine); 0504 (58e: formaldehyde- and UV-inactivation); 0508 (58d: antibody response); 0509 (58d: different SALK-vaccines); 0603 (58e: British vaccine: antibody response after revaccination); 0610 (58e: SALK-vaccine); 0614 (58e); 0646 (58e: MAHONEY-: BRUNENDERS-strain); 0849 (58e: antigenicity: guinea-pig test); 0850 (58e: potency test); 0851 (58e: chicken test); 0949 (58f: SALK-vaccine: testing); 0951 (58f: chicken test); 1935 (58e: antibody response: UV-formaldehyde-vaccine); 2324 (58f); 4955 (58h: SALK-vaccine: double infection); 0385 (59e: live vaccine: antibody response); 0559 (59e: complement fixing antigens); 0560 (59e: SALK-vaccine: filtration); 0568 (59e: type 1-problem); 0569 (59e: type 1-problem); 0597 (59e: antibody response); 0600 (59e: combined antigens); 0601 (59e: live vaccine); 0661 (59d: requirements: Germany); 0840 (59e: live vaccine); 0853 (59e: antibodies in children); 0968 (59e: disc-plate assay of antibodies); 0973 (59e: live vaccine); 0974 (59e: live vaccine); 0976 (59e: live vaccine: problems); 0992 (59e: live vaccines); 0996 (59e: SALK-vaccine); 1026 (59d); 1032 (59e: guinea-pig test); 1056 (59d: guinea-pigs); 1086 (59e: antigenicity: neutralizing-antibody-combining test = NAC); 1087 (59e: live vaccine: antibody response); 1089 (59d: guinea-pig test); 1091 (59e); 1121 (59f: French vaccine); 1123 (59i: multiple antigens: animal experiments); 1134 (59d: adsorbed vaccine); 1150 (59f); 1151 (59f); 1170 (59e: monkeys: antibody response); 1214 (59e: antibody response: age); 1279 (59f: chicken test); 1267 (59e: rat test); 1281 (59e: monkeys: virulence and immunogenicity); 1303 (59e: chicken test); 1304 (59f: chicken test); 1310 (59d: SALK-vaccine: purification);

1313 (59e: antibody response: Cox-vaccine); 1314 (59r: live vaccine); 1319 (59f: multiple antigens); 1320 (59f: revaccination); 1368 (59e: multiple antigens); 1404 (59e); 1415 (59f); 1660 (59r: rats: antibody response); 1715 (59e: standardization); 2281 (59e: chick test); 2283 (59e: tissue culture); 2301 (59r: USSR: SALK-vaccine); 2930 (59i: DPT-Polio); 3205 (59e: live vaccine); 3218 (59e: Cox-vaccine: infants under six months); 3231 (59e: CHAT-strain: Leopoldville/Congo); 4276 (59e: increased amounts of SALK-vaccine); 4284 (59e: quadruple antigen: antibody response); 4287 (59i: quadruple vaccine); 4970 (59e: SALK-vaccine: Switzerland); 1433 (60e: Cox-vaccine); 1990 (60e: SALK-vaccine: persistence of antibody); 1991 (60e: CHAT-strain: antibody response); 1995 (60e: CHAT-strain: antibody response); 2308 (60d: adsorbed vaccine); 2352 (60e: concentrated SALK-vaccine); 2357 (60e: Israel: SALK-vaccine); 2358 (60e: conversion rate: trivalent live vaccine); 2374 (60f: chicken test); 2378 (60e: antigenic potency: antibody-combining test); 2392 (60e: antibody response); 2439 (60e: SALK-vaccine: antibody response: increased amounts); 2529 (60f: chick test); 2575 (60u: SALK-vaccine in Hungary); 2592 (60e: Cox-vaccine: Florida); 2788 (60e: CHAT-strain: Congo); 2789 (60i: in vitro-titration of antigenic power); 2790 (60i: adsorbed vaccine); 2802 (60f: SALK-vaccine: antibody response); 2887 (60e: SALK-vaccine); 2911 (60e: antibody combining power test); 3045 (60i: live vaccine: interference with enteroviral infections); 3063 (60e); 3066 (60e: SALK-vaccine: persistence of antibody); 3196 (60e: SALK-vaccine: newborns); 3233 (60e: SALK-vaccine: Alberta); 3242 (60e: SALK-vaccine: Roumania); 3248 (60e: Cox-vaccine); 3388 (60e: SALK-vaccine); 3391 (60e: ČSR: live: SALK-vaccine); 3452 (60b: SALK-vaccine); 3453 (60r: pertussis-polio-vaccine); 3454 (60i: SALK-vaccine: guinea-pig test: chick test: antigen-antibody combining test); 3456 (60e: Hungary); 3459 (60e: content of antigen); 3473 (60r: live vaccine); 3480 (60r: antibody response: trivalent live vaccine); 3486 (60r: live vaccine: storage into dragée-candy); 3983 (60i: live vaccine); 3984 (60f: trivalent Cox-vaccine: antibody production); 3985 (60e: SABIN-vaccine: newborn infants); 4085 (60e: SALK-vaccine: immunogenic potency); 4121 (60e: SABIN-vaccine); 4299 (60e: combined vaccines); 4300 (60e: quadruple antigen: young infants); 4304 (60e: combined vaccines); 4405 (60e: CHAT-strain); 4570 (60e: SABIN-vaccine); 4572 (60e: live vaccine); 4573 (60e: SABIN-vaccine); 4577 (60e: SALK-vaccine); 4578 (60d: live vaccine and DPT-adsorbat); 4867 (60e: SALK-vaccine: Canada); 4874 (60e: SALK-vaccine: ČSR); 4877 (60e: SALK-vaccine: Israel); 4880 (60e: SALK-vaccine: Norway); 4881 (60i: SALK-vaccine: Italy); 4882 (60e: SALK-vaccine: duration of antibody); 4885 (60e: SALK-vaccine: duration of antibody); 4887 (60e: standardization of SALK-vaccine); 4889 (60e: DPT-polio-vaccine); 4893 (60e: live vaccine: USSR); 4895 (60e: live vaccine); 4908 (60e: trivalent live vaccine); 4911 (60e: live vaccine: influence of age); 4913 (60e: live vaccine: dose and schedule); 4916 (60e: live vaccine: dose and schedule); 4920 (60e: SABIN-vaccine: Mexico); 4922 (60e: interference); 4927 (60e: live vaccine: Southern Louisiana); 4964 (60r); 4965 (60e: Cox-vaccine: Costa Rica); 4966 (60r: DT-polio-vaccine); 4969 (60e: SABIN-vaccine: Netherlands); 4977 (60e: capacity of live vaccine to in-

fection); 4984 (60e: Cox-vaccine: Japan); 4985 (60e: Cox-vaccine: pregnant women and young infants); 4989 (60e: SABIN-strain type 3: persistence of antibodies); 4990 (60e: trivalent SABIN-vaccine); 4994 (60e: Cox-vaccine: Israel); 4998 (60e: full-term infants: live vaccine); 5001 (60e: SABIN-strain type 1: newborn infants); 5006 (60e: trivalent Cox-vaccine); 5009 (60e: trivalent live vaccine); 5011 (60e: Cox-vaccine); 5014 (60e: Cuba); 5018 (60e: SABIN-vaccine); 5021 (60e: SABIN-vaccine: USSR); 5032 (60e: ČSR); 5036 (60e: KOPROWSKI-vaccine); 5040 (60e: Cox-vaccine); 5043 (60e: live vaccine: Nicaragua); 5051 (60e: SABIN-vaccine: USSR); 5068 (60e: live vaccine: Dade County); 5292 (60e: SABIN-vaccine: Hungary: enterovirus isolation); 5295 (60e: live vaccine: antibody formation); 5298 (60e: live vaccine: antibody formation); 5458 (60d: SALK-vaccine); 2771 (61d: Trivirelon); 2787 (61s: live vaccine: Philadelphia); 2883 (61d: Cox-vaccine); 3019 (61d: Cox-vaccine: Berlin); 3333 (61e: SABIN-vaccine: Singapore); 3390 (61e: live vaccine); 3474 (61e: USA: SALK-vaccine); 3485 (61e: microprecipitin test); 3989 (61d: SALK- and SABIN-vaccine: antibody response); 4080 (61e: SABIN-vaccine: antibody response); 4127 (61d: Cox-vaccine: Berlin 1960); 4183 (61d: SALK-vaccine); 4204 (61e: purified SALK-vaccine); 4212 (61d: SALK-vaccine: minimum requirements: Germany); 4227 (61f: trivalent Cox-vaccine: antibody response); 4233 (61d: SABIN-vaccine: antibody response); 4236 (61e: SALK-vaccination: interference with maternal antibody); 4241 (61h: combined vaccine); 4303 (61e: newborns: trivalent live vaccine); 4635 (61e: purified SALK-vaccine); 4660 (61e: SABIN-vaccine: Cincinnati); 4662 (61e: KOPROWSKI-vaccine: Congo); 4668 (61e: SALK-vaccine: chick test); 4731 (61r: DPT- and live vaccine); 4733 (61r: SALK-vaccine: antigenic activity); 4735 (61f: live vaccine); 4736 (61e: trivalent Cox-vaccine); 4744 (61d: SABIN-vaccine: antibody response); 4745 (61d: SABIN-vaccine: Germany); 4748 (61d: Cox-vaccine: Berlin); 4858 (61d: SABIN-vaccine); 4859 (61u: DPT- and live vaccine); 4894 (61i: Di-toxoid and SALK-vaccine); 4968 (61e: Poland: live vaccine); 4976 (61e: live vaccine: neonates); 4986 (61i: SALK-vaccine: Brescia); 4987 (61f: trivalent Cox-vaccine); 4988 (61f: trivalent Cox-vaccine); 4993 (61pl: KOPROWSKI-vaccine: Poland); 5059 (61d: Cox-vaccine: newborn); 5123 (61c: SALK-vaccine: Finland); 5175 (61e: SALK-vaccine: Taiwan); 5177 (61e: SALK-vaccine); 5253 (61d: SABIN-vaccine); 5258 (61e: live vaccine: newborn); 5277 (61e: SABIN-vaccine: Hungary); 5314 (61e: Cox-vaccine: Switzerland); 5341 (61d: live vaccine); 5351 (61d: Trivirelon: antibody response); 5370 (61e: D-antigen); 5372 (61e: Cox-vaccine); 5451 (61r: SABIN-vaccine: newborn period); 5482 (61pl: KOPROWSKI-vaccine: type 1 and 3); 5486 (61e: SABIN-vaccine); 5020 (62d: Cox-vaccine: Berlin 1960);

Inaktivierung des Virus / Inactivation of virus

Hier sind nur diejenigen Publikationen über die verschiedenen Methoden der Inaktivierung (I.) des Poliomyelitisvirus erfaßt, die mit der Immunbiologie etwas zu tun haben, sei es, daß sie die Kinetik der I. als Grundlage

für die Herstellung von Impfstoffen aus inaktiviertem Virus behandeln, sei es, daß sie bei der I. durch Immunserum die Grundlage für die Wirksamkeit der passiven Serumprophylaxe und -therapie erhellen sollen, sei es, daß sie bei der I. durch Wärme die Grundlagen für die t-marker der Lebendimpfstoff-Stämme behandeln. Die häufigsten Verfahren der I. durch Formaldehyd, Immunserum, UV-Strahlen und Wärme habe ich gesondert gebracht. Selten angewandte oder kombinierte Verfahren der I. sowie Arbeiten allgemeinen Inhaltes habe ich unter «Allgemeines» an den Anfang gestellt.

s. a. Antigenität, nach Inaktivierung.
Impfstoffe, inaktiviertes Virus.

This section includes only such publications on various methods of inactivation (I.) of the poliomyelitis virus as have something to do with immune biology. This means they may either deal with the kinetics of I. as a principle in the production of vaccines from inactivated virus, or explain the principle of I. of immune serum as a principle in the efficacy of passive serum prophylaxis and therapy, or deal with I. by heat with reference to the principles of the t-marker of live vaccine strains. The most frequently used methods of I., by formaldehyde, immune serum, UV radiation and heat, were separately arranged. Seldom used or combined methods of I. and papers with a general subject were arranged under «general».

cf. Antigenicity, after inactivation
Vaccines, inactivated virus

Allgemeines / General

0373 (10f); 0096 (11d); 1045 (14e: phenol); 0279 (17e); 0831 (30e: aluminumhydroxyde); 5017 (30e); 0775 (31e: aluminumhydroxyde); 1038 (31d: phenol); 1078 (32e: adsorption); 0225 (34e: Na-ricinoleate and chloroform); 0736 (34e: endocrine principles); 0768 (35e: germicidally inactivation); 4777 (35f: methylen blue and light); 0018 (36e: Na-ricinoleate); 0019 (36e: aluminumhydroxyde); 0078 (36e: attenuation of virulence); 0086 (36e: attenuation of virulence); 0471 (36e); 2620 (39d: ultrasonic); 0038 (43j: ultrasonic); 1541 (51e); 3202 (51e: freeze drying); 0695 (55e); 1678 (55e: ionizing radiation); 4603 (55e); 4610 (55e); 1456 (56i: β-propiolactone); 1886 (56i: β-propiolactone); 2312 (57e: ionizing radiation: heat); 0189 (58f: high pression); 0631 (58e: antibody response: guinea-pigs); 1206 (58i: betapropiolate: antigenicity); 2781 (58i: tonsil extracts); 4178 (58d); 0525 (59e: specifity of antigen); 1306 (59s: irradiation with radium); 1393 (59d: formaldehyde: reversibility); 2373 (59e: phenol); 5402 (59d: $Al(OH)_3$); 2377 (60f: RNA: phenol); 2573 (60e: inhibitor from CNS); 4185 (61e: carbonyl compounds); 4668 (61e: gamma irradiation); 4739 (61d).

Fehlerquellen / Sources of error

0096 (11d: size of particles); 1772 (55d); 1699 (56d: formaldehyde); 1702 (56d: formaldehyde); 0938 (57e); 0864 (58e); 0838 (59d: formaldehyde: reactivation).

Formaldehyd / Formaldehyde

0101 (18e); 4111 (34e); 0470 (35e: BRODIE-vaccine); 0723 (35e: BRODIE-vaccine); 0768 (35e); 0913 (35e); 0017 (36e); 0077 (36e: BRODIE-vaccine); 0086 (36e: KOLMER-vaccine); 0042 (47e: monkey experiments); 0372 (47e); 4308 (47e); 4343 (48f); 1541 (51e); 3353 (52e); 0295 (53e: encephalomyelitis of monkey after vaccination); 1770 (54e); 2459 (54e); 0695 (55e); 0839 (55e: Denmark); 1606 (55e: CFT: specifity of types); 1610 (55e); 1766 (55d); 1776 (55e); 1779 (55d: antigenicity: pathogenicity); 1787 (55e); 1795 (55d); 2981 (55e); 4603 (55e); 1521 (56e: South Africa-vaccine); 1569 (56e); 1699 (56d); 1702 (56d); 1819 (56d); 1857 (56d); 1866 (56d: formaldehyde-laktose); 1888 (56i); 1911 (56e: safety test); 1912 (56d: safety test); 1931 (56d: safety test); 2114 (56e); 2135 (56s); 2174 (56e); 2481 (56e: British vaccine); 2551 (56d); 2803 (56e); 0305 (57e: safety testing: tissue culture); 0310 (57d); 0444 (57f: SALK: LEPINE); 0505 (57e); 0639 (57e); 0669 (57e); 0671 (57e); 0763 (57e: UV); 0857 (57e); 1337 (57e: kinetics); 1338 (57e: kinetics); 2044 (57e: kinetics); 2063 (57e: kinetics); 2193 (57f: + β-propiolactone); 2548 (57d: safety test); 2564 (57d); 2683 (57d); 2938 (57e); 3012 (57e); 0067 (58d); 0113 (58e: glycin); 0399 (58i: formaldehyde determination); 0503 (58e); 0504 (58e: UV-irradiation); 0556 (58d: haemaggregation); 0949 (58f); 0970 (58d: kinetics); 1125 (58e); 1126 (58e: temperature and pH); 1287 (58d: purified virus); 1305 (58s: kinetics); 0559 (59e: complementfixing antigens); 0560 (59e: filtration); 0838 (59d: reactivation); 0966 (59e: antigen: flocculation test); 1026 (59d); 1135 (59d: titration of inactivated virus); 1149 (59f); 1178 (59d: kinetics and reactivation); 1288 (59d: sedimentation); 1311 (59d: kinetics); 1393 (59d: reversibility); 1411 (59e); 1659 (59r: determination of free formaldehyde); 2294 (59r: biochemical control); 2377 (60f: RNA); 2570 (60e: concentrated purified suspensions); 2975 (60e: purified virus); 2976 (60e: review); 3116 (60e); 3190 (60e: zone electrophoresis); 4185 (61e: carbonyl compounds); 4635 (61e: purified virus); 4664 (61e); 4739 (61d); 5371 (61e: SV_{40}).

Immunserum / Immune serum

0095 (10d); 0098 (10f); 0099 (10f); 0100 (10f); 0106 (10e); 0373 (10f); 1060 (10e); 1062 (10d: serovaccine); 0090 (11e: convalescent serum); 1548 (12d); 0324 (13f); 0493 (25f); 1080 (29e: cataphoresis); 0175 (30e: horse serum); 0288 (30e); 0304 (30e); 1185 (30e); 2038 (30e); 0001 (31e: monkey: vaccination); 0002 (31e: horse serum); 0015 (32e: vaccine); 0016 (32e: vaccine); 1261 (32f); 1948 (32e); 0146 (33e); 0145 (34e: vaccine); 0735 (34e); 0746 (35e); 0020 (36e); 0827 (36e: therapy); 0667 (40e); 0125 (45e: mice serum); 0071 (48e: antivirus properties of human nasopharyngeal secretions); 0174 (48e:

neutralizationtest); 0072 (49e: human gammaglobuline); 2966 (53e); 2535 (54d: gammaglobuline); 1526 (56i: DULBECCO-KRECH-phenomen); 1664 (56e); 0540 (57e: determination of antibody titer); 0183 (58e: tissue culture); 0194 (58e: neutralizationtest); 0233 (58e: dissociation of virus from neutralizing antibody); 0971 (58e: mutation: resistance to neutralizing substances); 1477 (58e: model of virus antibody interaction); 1478 (58e: critical comparison of hypotheses); 1033 (59e: antibody combining capacity); 1208 (59e: stability of antigen-antibody complexes); 1221 (59e: inhibitor in certain horse sera); 2528 (59f); 2377 (60f: RNA); 4231 (60e: kinetic); 4864 (60e: reversibility); 3432 (61e: dissociation from antibody by fluorocarbon); 4210 (61e: reversibility); 4750 (61d: virus aggregation).

Kinetik / Kinetics

0471 (36e); 4343 (48f: formaldehyde); 1770 (54e: formaldehyde); 0695 (55e); 1610 (55e: formaldehyde); 1783 (55e: UV-irradiation); 1787 (55e); 2981 (55e: formaldehyde); 4603 (55e); 1857 (56d: formaldehyde); 1866 (56d: formaldehyde-laktose); 1911 (56e: formaldehyde: safety test); 1912 (56d: formaldehyde: safety test); 2803 (56e: formaldehyde); 0310 (57d); 0639 (57e); 0669 (57e: formaldehyde); 1337 (57e: formaldehyde); 1338 (57e: formaldehyde); 2044 (57e: formaldehyde); 2063 (57e: formaldehyde); 2190 (57e: UV-irradiation); 2564 (57d: formaldehyde); 2683 (57d: formaldehyde); 2938 (57e: formaldehyde); 0614 (58e); 0970 (58d: formaldehyde); 1126 (58e: formaldehyde); 1305 (58s: formaldehyde); 4178 (58d); 1026 (59d: formaldehyde); 1311 (59d: formaldehyde: protein of virus); 2373 (59e: phenol); 2297 (60e: thermal inactivation); 2570 (60e: formaldehyde: concentrated purified suspensions); 2975 (60e: formaldehyde: purified virus); 2976 (60e: formaldehyde); 3116 (60e); 4231 (60e: serum neutralization); 4864 (60e: serum: reversibility); 4635 (61e: formaldehyde: purified vaccine); 4739 (61d); 4749 (61d: heat); 4750 (61d: immune serum: virus aggregation).

UV-Strahlen / UV-radiation

0473 (37e); 5127 (37e); 4825 (42f); 3890 (44e); 5271 (44e); 4574 (45e); 0042 (47e: monkey experiments); 3437 (50e); 1542 (51e: electrons); 4464 (52e); 1755 (54e); 1783 (55e); 1882 (56e); 2174 (56e); 0763 (57e: formaldehyde); 2190 (57e); 0503 (58e); 0504 (58e: formaldehyde); 0525 (59e: specifity of antigen); 0985 (59e); 2377 (60f: RNA); 2455 (60e: RNA).

Wärme / Heat

0093 (10d); 0095 (10d); 0109 (10e); 0359 (11f); 0101 (18e); 0590 (18e); 0339 (30e); 0453 (30e); 5017 (30e); 0904 (33e: intracutan test); 0225 (34e); 2743 (51f); 2725 (54e: antigenicity); 1780 (55e); 1890 (56e: CFT: specifity of antigen); 2174 (56e); 2312 (57e: ionizing radiation); 2326 (57e: immunologic types); 2429 (57d); 0525 (59e: specifity of antigen); 1392 (59d); 1399 (59d); 2780 (59i); 2297 (60e); 2585 (60f: thermosensitivity: neurovirulence); 3027 (60e: RNA); 4077 (60e); 4749 (61d).

Monographien / Monographs

4979 (07d); 1019 (11d); 1435 (11d); 0613 (12e); 0443 (13e); 5398 (13e); 3915 (15d: trauma); 3921 (16d: trauma); 5311 (16e); 3770 (17f: serotherapy); 3018 (22f); 0551 (24f: serotherapy); 3785 (26f: serotherapy); 4677 (32e); 4671 (33d); 4699 (34d); 4782 (36f: serotherapy); 5128 (37f: serotherapy); 3446 (42d); 3908 (46e: bibliography 1789–1944); 3225 (50f); 5229 (53f); 2036 (55d); 2867 (55d); 2330 (56f); 5181 (56d); 0067 (58d); 4011 (58e); 5355 (61e: live vaccination).

Provokation / Provocation

Bei allen Virusinfektionen, die vorwiegend subklinisch oder latent verlaufen, können äußere Einflüsse, die die Resistenz des Makroorganismus herabsetzen bzw. seine Empfänglichkeit gegenüber dem Virus unspezifisch steigern, relativ leicht manifeste Erkrankungen provozieren. So ist auch bei der Poliomyelitis seit dem vorigen Jahrhundert bekannt, daß Traumen verschiedener Art lokale Manifestationen der Erkrankung hervorrufen können. Später wurden auch andere Formen der Provokation (P.) beschrieben; so wurde der Ausbruch der Poliomyelitis nach körperlicher Anstrengung, Ermüdung, Erkältung, Injektionen, Operationen und Cortisonzufuhr beobachtet. Alle diesbezüglichen Veröffentlichungen habe ich unter dem Stichwort «Stress-Situationen» zusammengefaßt. Nur die P. durch andere Infektionen, durch Schutzimpfungen und durch Tonsillektomien habe ich gesondert aufgeführt, weil sie wegen ihrer besonderen Bedeutung häufig bearbeitet wurden. Die vorwiegend negative Interferenz anderer Infektionskrankheiten mit der Poliomyelitis wurde schon lange beobachtet und kann als unspezifische Provokation aufgefaßt werden. Besonders ausgedehnt war die Diskussion über die unspezifische Provokation durch heterologe aktive Schutzimpfungen. Zunächst wurde wiederholt darauf hingewiesen, daß neurologische Komplikationen nach der Pockenschutzimpfung provozierte Poliomyelitiserkrankungen sein könnten; die Richtigkeit dieser Auffassung konnte bisher nicht bewiesen werden. Vor allem in den fünfziger Jahren entstand eine sehr umfangreiche Literatur über die P. durch die Schutzimpfung mit Diphtherie-Toxoid oder Mischimpfstoffen, die diese Komponente enthielten, nachdem in Australien und in England einschlägige Beobachtungen über gehäufte Poliomyelitiserkrankungen nach diesen Impfungen beobachtet worden waren; faßt man alle epidemiologisch verwertbaren Angaben zu dieser Streitfrage zusammen [5140 (62d)], so ist retrospektiv festzustellen, daß durch Injektionen von Diphtherie-Impfstoffen auffallend schwere Poliomyelitisinfektionen provoziert werden können, die durch eine charakteristische Inkubationszeit und durch eine Lokalisierung der Lähmung in der Nähe der Injektionsstelle gekennzeichnet sind. Nach homologen Impfungen ist eine spezifische Provokation möglich, die schon bei der ersten Impfphase 1935/36 und dann in den letzten Jahren anläßlich der Impfzwischenfälle nach Massenimpfungen besonders diskutiert wurde. Über lange Zeit wurde die provozierende Wirkung der Tonsillektomie umstritten. Heute kann als sicher gelten, daß ein operativer Eingriff im Rachenraum eine besonders schwere Verlaufsform der Poliomyelitis vom bulbären Paralysetyp provo-

zieren kann; dies ist pathogenetisch nicht verwunderlich, nachdem heute feststeht, daß die Tonsillen des Rachens sowohl bei der natürlichen Infektion wie bei der aktiven Immunisierung mit Lebendimpfstoffen Orte der Virusvermehrung und -abwehr sind. Alle genannten Formen der P. hat man im Tierversuch zumeist mit Erfolg nachahmen können.

s. a. Resistenz, Herabsetzung.
Resistenz, Tonsillen.
Resistenz, Wetter.
Schutzimpfung, aktive Impfung, Epidemie-Impfung.
Schutzimpfung, aktive Impfung, Impfschäden.
Schutzimpfung, aktive Impfung, Indikation.
Tierversuche, Resistenzversuche.

In all virus infections with a predominantly subclinical or latent course, external influences which reduce the resistance of the macro-organism or unspecifically raise its susceptibility to the virus, can relatively readily provoke manifest illness. In the case of poliomyelitis, too, it has been known since the previous century that injuries of various kinds can provoke local manifestations of the affection. Later, other forms of provocation (P.) have been described; observations were made on outbreaks of poliomyelitis following physical exertion, fatigue, cold, injections, operations, and cortisone administration. All relevant publications were collected under the title «stress situation». Only P. due to other infectious diseases, vaccination and tonsillectomy was separately arranged because it has been frequently discussed in view of its special significance. The mainly negative interference of other infectious diseases with poliomyelitis has long been known and can be regarded as unspecific provocation. A particularly lengthy discussion took place about unspecific provocation by heterologeous active immunization. It has been repeatedly pointed out that neurological complications following vaccination against smallpox can be provoked poliomyelitis; the correctness of this theory has not so far been demonstrated. Especially in the fifties a very voluminous literature arose on P. by vaccination with diphtheria toxoid or mixed vaccines containing these components, after definite observations on increased poliomyelitis incidence following these vaccinations had been made in Australia and England; summarizing all epidemiologically valid data on this question (5140 (62d)), it can be stated in retrospect that injections of diphtheria vaccines can provoke strikingly severe poliomyelitis infections, characterized by a characteristic incubation period and localization of paralyses in the vicinity of the site of injection. After homologous vaccination, specific P. is possible; this has been discussed even during the first period of vaccination (1935/1936) and, in recent years, on the occasion of incidents after mass vaccinations. The provocative effect of tonsillectomy has long been debated. Today it is considered certain that surgery on the pharyngeal cavity can provoke a particularly severe form of poliomyelitis of the bulbar paralysis type; pathogenically, this is not surprising since it has been recently established that the pharyngeal tonsils, both in natural infection and in active immunization with live vaccines, are sites of virus multiplication and virus defence. All the above-mentioned forms of P. have been successfully imitated in animal experiments.

cf. Animal experiments, experiments on resistance
Resistance, reduction
Resistance, tonsils
Resistance, weather
Vaccination, active vaccination, intraepidemic vaccination
Vaccination, active vaccination, untoward reactions to vaccination
Vaccination, active vaccination, indication

Allgemeines / General

4979 (07d); 0280 (17e); 2935 (23d); 4355 (31d); 4723 (36d); 2692 (39d); 2837 (40d); 2693 (41d); 3612 (44e: salt metabolism); 2898 (45d); 4839 (47e); 0220 (50e); 0221 (50e); 4383 (50e: hypothesis of autoinoculation); 0120 (52e); 2221 (52e); 1453 (53e); 2228 (53e: prophylaxis); 2853 (54f); 5024 (54f); 5025 (54d); 1656 (55e); 2242 (55s); 2867 (55d); 2989 (55f); 1823 (56d); 1898 (56e); 1997 (56d); 2968 (56d); 2969 (56d); 3036 (56d); 0967 (57d: protein and nucleic acid metabolism of nerve cells); 2054 (57d); 2120 (57d); 2220 (57h); 4011 (58e); 5378 (59i: primary tb); 2950 (60e); 3371 (60d); 3468 (60e: SALK-vaccine: exfoliative dermatitis); 3991 (60d); 4665 (60e); 3250 (61d).

Infektionskrankheiten / Infectious diseases

2146 (09i: measles); 0417 (11n: small pox); 0834 (11n: monkeys: vaccinia-virus); 0416 (12d: monkeys: small pox); 3906 (27d: malaria); 3907 (28f: malaria); 4380 (28e: measles); 0781 (31e: monkeys: vaccinia-virus); 3868 (32f: whooping cough); 2010 (33e: monkeys); 4162 (34d: enteritis); 3905 (36d: malarial therapy); 3904 (37i: malarial therapy); 2838 (38d); 2692 (39d); 2811 (39e: sparing effect of lymphocytic choriomeningitis); 2840 (39d); 3903 (39i: malarial therapy); 3446 (42d); 5213 (45d: pertussis); 5174 (49d); 0625 (50e); 0311 (51e: upper respiratory infection); 1980 (53f); 5052 (55f); 2552 (56d); 3036 (56d); 5197 (57i); 5201 (57i); 5297 (57d: mumps); 0190 (58e: monkeys: COXSACKIE infection); 2979 (58i); 1400 (59d); 3306 (59pl); 2959 (60i: tuberculosis); 5057 (61f: pneumopathy).

Heterologe Impfungen / Heterologeous vaccinations

3692 (09d: antirabic treatment); 0417 (11n: smallpox-vaccination); 0416 (12d: smallpox-vaccination: monkey experiment); 3659 (13e: antirabic vaccination); 3691 (16f: antirabic treatment); 2827 (21f: cholera-vaccine); 3522 (21f: cholera-vaccine); 4375 (26e: smallpox-vaccination); 3117 (28i: smallpox-vaccination); 3245 (28f: typhoid vaccination); 2800 (29d: smallpox-vaccination); 2917 (29d: smallpox-vaccination); 3183 (29i: smallpox-vaccination); 1183 (30h); 3462 (30d: smallpox-vaccination); 3514 (30f: smallpox-vaccination); 4042 (30e: smallpox-vaccination); 4141 (30e: smallpox-vaccination); 2676 (31d: smallpox-vaccination); 3296 (31f: smallpox-vaccination); 4328 (31f: smallpox-vaccination); 3687 (32n: smallpox-vaccination); 4722

(32n: smallpox-vaccination: postvaccinal encephalitis); 3255 (33i: smallpox-vaccination); 3686 (33d: smallpox-vaccination); 5318 (33e: smallpox-vaccination); 4315 (34d: smallpox-vaccination); 5105 (34s); 5106 (34e: monkey: paratyphoid-coli-filtrate); 2829 (35e); 4013 (35e); 5108 (35e: monkey: paratyphoid-coli-filtrate); 5121 (36e: monkey: paratyphoid-coli-filtrate); 2692 (39d: smallpox-vaccination); 3966 (39f: TAB-Di-vaccine); 2873 (40e: smallpox-vaccination); 3892 (40s: smallpox-vaccination); 4815 (40d: smallpox-vaccination); 3294 (43e); 5165 (44d: Di-vaccination); 3309 (47h: smallpox-vaccination); 4335 (48e: monkey: typhoid vaccine); 0360 (49e); 3169 (49d); 4432 (49t); 0196 (50e); 0213 (50e); 0214 (50e); 0215 (50e); 0216 (50e: antirabic vaccination); 0217 (50e: pertussis- and Di-vaccination); 0218 (50e); 0289 (50e); 0352 (50e); 0365 (50e); 1040 (50e); 1065 (50e); 1066 (50e); 1067 (50e); 1068 (50e); 1069 (50e); 1070 (50e); 1081 (50e); 1258 (50e: mouse experiments); 1609 (50e); 1695 (50h: smallpox-vaccination); 1718 (50d); 2655 (50e); 2691 (50e); 2747 (50e); 3359 (50e); 3374 (50e: DP-immunization); 4411 (50e); 4414 (50i); 4433 (50e: DP-inoculation); 4435 (50e); 5437 (50e); 0199 (51e: THEILER-virus); 0894 (51e: mouse test); 1434 (51e); 1436 (51e); 1508 (51n); 1546 (51e); 1719 (51e); 1720 (51d); 1721 (51e); 1726 (51e); 1727 (51e); 2130 (51e); 2209 (51e); 2801 (51d); 3093 (51d); 3160 (51e); 4385 (51d); 4413 (51e); 4439 (51e); 4479 (51i); 4724 (51n: vaccination); 4843 (51e); 4844 (51e); 5462 (51f: smallpox-vaccination); 0080 (52e: cholera-vaccination); 0120 (52e); 0176 (52e); 0177 (52e); 0856 (52e); 1137 (52e: animal experiments); 1437 (52e); 1454 (52e); 1545 (52e); 1568 (52e); 1644 (52e: animal experiments); 1725 (52e); 1729 (52e: catamnestic examination); 1950 (52e); 2150 (52e); 2234 (52e: monkeys); 2602 (52e); 2603 (52e); 2639 (52s); 2640 (52e); 2657 (52e: experimental approach); 2886 (52e); 4024 (52e); 4122 (52e); 4443 (52e); 4455 (52e); 4472 (52e); 4481 (52e); 4484 (52h); 4485 (52n); 4486 (52e); 4487 (52e); 4501 (52e: prophylaxis); 1439 (53f); 1453 (53e); 1514 (53f: pertussis-vaccine); 1554 (53e); 1555 (53e); 1733 (53e); 1734 (53e); 1756 (53i); 1947 (53d); 1980 (53f); 2015 (53e); 2016 (53e); 2019 (53e); 2020 (53e); 2021 (53e); 2027 (53e); 2815 (53d); 2818 (53d); 3366 (53f); 3401 (53e: DPT-immunization); 3976 (53i: DP-vaccine); 4108 (53e: DP: aged vaccines); 4497 (53e); 4508 (53s); 4583 (53e: interference by toxoid); 5468 (53f: Di-toxoid); 1502 (54e); 1758 (54i: animal experiments); 1803 (54e: monkeys); 2149 (54i); 2464 (54e); 2534 (54d); 4509 (54i); 4526 (54i); 4567 (54e: prophylaxis); 4568 (54i); 4584 (54e: Naja flava neurotoxoid); 5030 (54i); 5035 (54i: DP-vaccine: mice); 5046 (54i); 5048 (54f: prophylaxis); 0512 (55i: monkeys); 1575 (55e); 1641 (55e); 1759 (55i: animal experiments); 1777 (55d: animal experiments); 1928 (55s); 2252 (55e: monkeys); 2303 (55d: smallpox-vaccination); 2990 (55e); 4590 (55i); 4595 (55e); 4610 (55e); 5047 (55s: smallpox-vaccination); 1891 (56i: Di-vaccination); 1910 (56d: anamnestic serumreaction); 2165 (56f: smallpox-vaccination); 2314 (56e: Cynomolgus monkeys); 2337 (56e: DPT in a family); 2473 (56s); 2483 (56e); 2968 (56d); 3036 (56d); 4100 (56e); 4762 (56d: injections); 5275 (56: typhoid vaccination); 0309 (57e: vaccination program); 0396 (57e: smallpox vaccination); 1117 (57e); 1120 (57e: Di-prophylactics: guinea-pig); 1473 (57e); 2054 (57d); 2055 (57d: smallpox-

vaccination); 2118 (57i: animal experiments); 2276 (57e); 2543 (57d: smallpox-vaccination); 4050 (57t); 4943 (57e: smallpox-vaccination); 5201 (57i); 0171 (58d: DPT-vaccine); 0491 (58e); 1237 (58i); 1412 (58i: monkeys); 5387 (58e); 0562 (59e: England); 0563 (59e); 0564 (59e); 0565 (59e); 0836 (59e: statistical analysis); 1055 (59d: mouse experiments); 1400 (59d); 1402 (59d); 1386 (60d: Di-vaccination); 1408 (60d: mouse experiments); 2299 (60e); 3430 (60i); 3489 (60e: DP-vaccine); 4882 (60e: antibody titer); 4597 (61e); 4693 (61i); 5342 (61e); 5140 (62d: review); 5337 (62d: DPT-vaccination).

Homologe Impfungen / Homologous vaccinations

0750 (35e: USA); 0751 (35e: KOLMER-vaccine); 0077 (36e); 0078 (36e: KOLMER-vaccine: negative phase); 4385 (51d); 4515 (54e); 1787 (55e); 1788 (55e); 1807 (55e: FRANCIS-report); 1977 (55e: field trial USA 1954); 1978 (55e); 2470 (55e: intradermal route); 1874 (56e); 1917 (56e: epidemic Hawaii 1955); 2099 (56e: New York); 0511 (57d: Landry paralysis); 2057 (57e: England); 2075 (57e: USA 1956); 2123 (57e: Chicago 1956); 2276 (57e); 2277 (57e); 3163 (57e: FRANCIS-report); 0249 (58d: Hungary); 0398 (58e); 0413 (58r: USSR); 0610 (58e: USA); 0629 (58d); 0847 (58e: ČSR); 1276 (58f); 1321 (58s); 0330 (59d); 1055 (59d: mouse experiments); 1128 (59e); 1274 (59e); 1291 (59e: epidemic Chicago 1956); 1368 (59e: multiple antigen); 1402 (59d); 1407 (59e); 1957 (59i); 2260 (59i); 2588 (59d); 2910 (59e: negative phase); 4068 (59e); 4124 (59i); 5249 (59r: SALK-vaccine); 5377 (59i: convulsions); 1362 (60e: live vaccine); 1367 (60d: live vaccine); 1408 (60d: mouse experiments); 1689 (60d); 2399 (60d); 2404 (60d); 2405 (60d); 2524 (60i); 2847 (60e: polio-like illnesses); 2914 (60e); 3023 (60e: England and Wales); 3047 (60d: Cox-vaccine: Berlin); 3086 (60i: Rome); 3094 (60pl); 3467 (60pl: SALK-vaccine); 4195 (60e); 4896 (60e: Cox-vaccine: Berlin); 2770 (61d: SALK-vaccine); 2786 (61d: Cox-vaccine: Berlin); 3478 (61d: West-Berlin: Cox-vaccine); 3487 (61d); 4149 (61d: SALK-vaccine); 4252 (61e: live vaccine); 4741 (61d: Cox-vaccine: Berlin); 4746 (61d: Cox-vaccine: Berlin); 5262 (61d: SABIN-vaccine); 5342 (61e); 5496 (62d: Cox-vaccine: Berlin).

Tierversuche / Animal experiments

0834 (11n: monkeys: smallpox); 0416 (12d: monkeys: smallpox); 0781 (31e: monkeys: vaccinia-virus); 2010 (33e: monkeys: reinfection); 5106 (34e: monkey: paratyphoid-coli-filtrate); 4013 (35e: baby monkeys: vaccination); 5108 (35e: monkey: paratyphoid-coli-filtrate); 5121 (36e: monkey: paratyphoid-coli-filtrate); 3145 (37e: monkey: castration); 0091 (38e: tonsils); 2742 (38e: monkey: neurosurgical procedures); 5170 (40e: monkey: sterile inflammation); 0770 (43e: monkey: fatigue, chilling, and trauma); 0612 (45e: monkey: fatigue, chilling, and trauma); 4335 (48e: monkey: typhoid vaccination); 1258 (50e: bacterial vaccines: mice); 2211 (50e: mouse and hamster: cortisone); 0132 (51e: monkey: gammaglobuline prophylaxis); 0894 (51e: mice: heterologeous vaccination); 1608 (51e: monkey: tonsillectomy: bulbar paralysis); 2031 (51e: monkey: ACTH); 1137

(52e: Di-Pert-toxoid: mice); 1644 (52e: mice: allergens and antibiotics); 2234 (52e: monkeys: heterologeous vaccines); 2298 (52e: mice and hamsters: cortisone and ACTH); 2657 (52e: vaccination); 4382 (52e: monkey: tonsillectomy: gammaglobuline); 4444 (52e: Syrian hamster: cortisone); 4447 (52e: Syrian hamster: cortisone); 0292 (53e: monkeys: cortisone); 0298 (53e: Syrian hamster: cortisone); 1449 (53e: monkeys: tonsillectomy: gammaglobuline); 1747 (53e: Syrian hamster: cortisone); 3106 (53e: cortisone: Syrian hamster); 3107 (53e: cortisone); 4048 (53e: mice: fatigue); 4108 (53e: mice: DP-vaccine); 4583 (53e: monkey: interference by toxoid); 1694 (54e: hamster: hormone); 1758 (54i: mice: heterologeous vaccines); 1803 (54e: monkeys); 1960 (54e: hamster: cortisone); 3135 (54e: mice: hypophysectomy); 4099 (54e); 4584 (54e: monkey: Naja flava neurotoxoid); 0512 (55i: monkeys); 1759 (55i: Syrian hamster: heterologeous vaccines); 1777 (55d: monkeys); 2252 (55e: monkeys: injections: viraemia: invasiveness); 4604 (55i: mice: fatigue); 5309 (55i: mice: fatigue); 0978 (56e: cortisone: monkeys); 1696 (56e: Ateles niger: cortisone); 1842 (56e: Syrian hamster); 1900 (56e: monkeys: cortisone: safety test); 1903 (56e: monkeys: cortisone and X-radiation: safety test); 1916 (56e: monkeys: cortisone); 2307 (56d: monkeys: cortisone); 2314 (56e: Cynomolgus monkeys: diphtheria toxoid); 1117 (57e: heterologeous vaccination: mice); 1120 (57e: adsorbat toxoid: guinea-pigs); 2043 (57d: monkeys: cortisone and X-radiation); 2118 (57i: Di-pertussis-vaccine); 2733 (57e: stress: hamster); 0190 (58e: monkeys: COXSACKIE-infection); 1412 (58i: monkeys); 3505 (58e: monkey: neurotoxoid); 1055 (59d: mice: incubation period); 1992 (59f: mouse: hyperthermy); 2905 (59r: antibody response: cortisone); 2910 (59e: negative phase: Taiwan monkey); 5390 (59e); 1408 (60d: specific and nonspecific provocation: mice); 4146 (61e: monkey: neural block).

Tonsillektomie / Tonsillectomy

3112 (16e); 3934 (16e); 3702 (17e); 1047 (22d); 0092 (28e: bulbar paralysis); 0336 (29e); 0401 (29e: incubation-period); 3178 (32e); 0920 (35e); 0452 (37e); 0091 (38e: animal experiments); 0164 (38e: bulbar paralysis); 0433 (38e: bulbar paralysis); 0595 (38e); 2865 (38e: bulbar paralysis); 2646 (39e); 2692 (39d); 4093 (39e); 4177 (39e: bulbar paralysis); 3938 (40e); 0315 (41e); 0458 (41e); 0923 (41e); 2665 (41e); 3941 (41e); 0349 (42e); 0351 (42e); 3217 (42e); 3937 (42e); 3940 (42e); 4132 (42d); 5326 (42e); 0485 (43e: vitamin B); 3091 (43d: bulbar paralysis); 3935 (43e); 4137 (43e); 0008 (44e); 2625 (44e); 3936 (44e); 3939 (44s); 0486 (45e: bulbar paralysis); 3269 (45d); 3326 (45n); 0908 (46e); 0924 (46e); 0367 (47e: bulbar paralysis); 0626 (47e); 3256 (47e); 3954 (47n); 4839 (47e); 0350 (48e); 0527 (48e); 2831 (48e); 2832 (48e); 3105 (48e); 0529 (49e); 2833 (49e); 3214 (49e); 3261 (49e); 3262 (49e); 3953 (49s); 4049 (49e); 4364 (49e); 5174 (49d); 0236 (50e); 0238 (50e: bulbar paralysis); 1484 (50e); 1486 (50e); 1489 (50e); 1510 (50e); 2662 (50e); 3041 (50e); 3199 (50d); 3358 (50d); 3445 (50d); 4383 (50e); 5287 (50e); 0132 (51e: monkeys: gammaglobuline prophylaxis); 1438 (51e); 1491 (51e); 1509 (51e); 1608 (51e: bulbar paralysis: monkeys); 1723 (51e:

bulbar paralysis); 1724 (51e); 2806 (51i); 2830 (51e); 3093 (51d); 3265 (51e); 3266 (51e: bulbar paralysis); 0120 (52e); 0240 (52s); 0855 (52e); 1730 (52e: bulbar paralysis); 1731 (52e: bulbar paralysis); 2214 (52e); 4024 (52e); 4382 (52e: monkey: gammaglobuline); 4485 (52n); 4501 (52e: prophylaxis); 5472 (52f); 0129 (53e: bulbar paralysis); 1449 (53e: monkeys: gammaglobuline); 1559 (53e); 1736 (53e); 1739 (53e: bulbar paralysis); 1980 (53f); 1998 (53e); 2022 (53e); 2025 (53e: bulbar paralysis); 2228 (53e: prophylaxis); 2596 (53e); 3133 (53e); 3378 (53e); 4101 (53e); 5226 (53d); 0130 (54f); 1502 (54e); 1564 (54e); 1706 (54e); 1955 (54e: bulbar paralysis); 2000 (54e); 2009 (54e: bulbar paralysis); 3120 (54f); 3271 (54e); 4094 (54e); 4517 (54e); 4567 (54e: prophylaxis); 4568 (54i); 5027 (54e); 5029 (54e: prophylaxis); 5033 (54i: bulbar paralysis); 5048 (54f: prophylaxis); 0111 (55f); 0131 (55f); 1444 (55e); 1495 (55e); 1517 (55e); 1575 (55e); 1710 (55e); 1777 (55d: monkeys); 1811 (55e); 1925 (55e); 2011 (55d); 2990 (55e); 3111 (55e); 4590 (55i); 5053 (55i); 5146 (55d); 1475 (56i); 1480 (56e); 1499 (56n); 1823 (56d); 1867 (56d); 2314 (56e: Cynomolgus monkeys); 2478 (56s); 2552 (56d); 2969 (56d); 3036 (56d); 5245 (56n); 0967 (57d); 1115 (57e: bulbar paralysis); 1461 (57e); 1472 (57h: bulbar paralysis); 1473 (57e); 1523 (57d: bulbar paralysis); 2042 (57e); 2054 (57d); 2427 (57d); 2502 (57e); 4050 (57t); 5188 (57i); 5373 (57e); 0303 (58e); 0491 (58e); 0645 (58s); 1595 (58e); 2126 (58d); 2328 (58e: cranial nerve paralysis); 2345 (58e: cranial nerve paralysis: rural area); 5387 (58e); 1400 (59d); 2610 (60d); 3236 (60e); 3466 (60r); 4660 (61e: live vaccination); 5456 (61d).

Stress-Situation / Stress situation

3933 (96e: trauma); 3916 (97d: trauma); 3932 (98d: trauma); 3918 (00f: trauma); 3920 (00d: trauma); 3919 (01d: trauma); 3524 (02d: trauma); 3611 (04f: physical activity); 3917 (06e: trauma); 3931 (08d: trauma); 0442 (11f: trauma); 3930 (11d: trauma); 3929 (12d: trauma); 3659 (13e: bite of dog); 3927 (13d: trauma); 3928 (13d: trauma); 3915 (15d: trauma); 3921 (16d: trauma); 3922 (17e: trauma); 3923 (25i: trauma); 3924 (28h: trauma); 5000 (28d: injections); 3926 (31d: trauma); 4041 (32d: physical exertion); 2709 (35e: polar infall); 3529 (35d: prophylaxis); 2842 (36d: bite of dog); 3545 (36e: injections of neoarsphenamine); 3221 (37d); 3283 (37e: trauma); 0433 (38e: trauma); 2671 (38d: physical exertion); 2742 (38e: monkey: neurosurgical procedures); 2838 (38d); 2844 (38d: trauma); 4802 (38f: trauma); 2692 (39d: trauma, physical exertion); 2748 (39d: trauma); 2840 (39d); 3925 (39d: trauma); 4812 (40d); 5170 (40e: sterile inflammation); 2665 (41e); 3613 (41d: physical exertion); 3446 (42d); 3614 (42e: fatigue and chilling); 4131 (42d: prophylaxis); 0770 (43e: monkey: fatigue, chilling, and trauma); 3092 (43d); 4170 (43e); 0612 (45e: monkey: fatigue, chilling and trauma); 3326 (45n); 5213 (45d); 3309 (47h: trauma); 3491 (47e: physical activity); 4832 (47e: dental surgeon); 4839 (47e); 2653 (48e: physical and mental exertion); 2831 (48e: trauma); 0360 (49e: trauma); 0529 (49e: operations); 0876 (49e); 3169 (49d); 4432 (49t); 5174 (49d); 5220 (49e: prophylaxis); 5332 (49e: exercise); 0215 (50e); 0219 (50e: penicillin-injections);

0365 (50e: penicillin-injections); 0625 (50e: trauma); 1040 (50e); 1067 (50e); 1081 (50e); 2211 (50e: animal experiments: cortisone); 2638 (50e: physical activity); 2662 (50e: trauma); 2799 (50d); 3080 (50e: fatigue of travel); 3147 (50e); 3442 (50d); 3458 (50d); 4383 (50e); 5112 (50d); 1434 (51e); 1508 (51n: injections); 2031 (51e: ACTH); 2685 (51e); 2828 (51e: injections); 3093 (51d); 3161 (51e: physical activity); 3212 (51e: trauma); 3224 (51e: injections); 4057 (51e: appendectomy); 4843 (51e); 0120 (52e); 0176 (52e: penicillin-injections); 0177 (52e: penicillin-injections); 0855 (52e: operations on nose and throat); 0856 (52e: injections); 1545 (52e); 1568 (52e: injections); 1604 (52d: blood transfusion); 1644 (52e: allergens and antibiotics); 1950 (52e); 2212 (52e: dental extraction); 2214 (52e: operations on nose and throat); 2298 (52e: cortisone and ACTH); 2640 (52e: injection of medical substances); 2805 (52d); 2885 (52e); 3034 (52e); 3165 (52d); 3481 (52f: intramuscular injections); 4024 (52e); 4443 (52e: penicillin injections); 4444 (52e: cortisone); 4447 (52e: cortisone); 4451 (52d: prophylaxis); 4452 (52e); 4459 (52e); 4484 (52h); 4485 (52n); 4486 (52e: injections); 0292 (53e: monkey-infections: cortisone); 0298 (53e: Syrian-hamster-infection: cortisone); 1453 (53e); 1506 (53e: appendectomy); 1709 (53e: pollen extract); 1980 (53f); 2815 (53d); 2818 (53d); 3031 (53e: intramuscular injections); 3110 (53e: intramuscular injections); 3207 (53e: personality factors and fatigue); 4048 (53e: mice: fatigue); 4474 (53d); 4494 (53f); 1502 (54e); 1694 (54e: hamster); 1698 (54d: trauma); 1706 (54e); 1743 (54d); 1803 (54e: monkeys); 1960 (54e: hamster: cortisone); 2286 (54d); 2675 (54d: tropical warm air masses); 4099 (54e); 4562 (54e: penicillin injections); 5024 (54f); 5025 (54d); 5027 (54e); 5046 (54i); 5048 (54f: prophylaxis); 1796 (55e); 1928 (55s); 2011 (55d: localisation factor); 2252 (55e: monkeys: injections); 2705 (55e: cortisone: tissue culture); 2989 (55f); 2991 (55f); 2992 (55f: fatigue); 2993 (55f: lumbal punction); 2994 (55f); 3206 (55d: exercise and trauma); 4604 (55i: fatigue: mice); 5231 (55d: physical exertion); 5233 (55d: trauma); 5309 (55i: mice: fatigue); 0978 (56e: cortisone: monkeys); 1823 (56d); 1842 (56e: Syrian hamster); 1863 (56d); 1871 (56h: monkeys: cortisone); 1900 (56e: monkeys: cortisone); 1903 (56e: monkeys: cortisone); 1916 (56e: monkeys: cortisone); 2165 (56f: trauma); 2473 (56s); 2552 (56d); 2968 (56d); 2969 (56d); 3036 (56d); 4762 (56d: injections); 5246 (56e: physical exertion); 5275 (56e: i. m. injections); 0967 (57d); 2043 (57d: monkeys: cortisone and X-radiation); 2054 (57d); 2327 (57d); 2733 (57e: hamster); 5199 (57f); 5201 (57i); 0492 (58d); 2339 (58i: cortisone); 0566 (59e); 1400 (59d); 1636 (59r: rodent: cortisone); 2764 (59i); 2905 (59r: cortisone: antibody response); 1425 (60d); 3052 (60f); 4665 (60e); 3192 (61e); 4146 (61e).

Reinfektion / Reinfection

Here we have collected especially those papers reporting on secondary infection in animal experiments. In these experiments, immunity after the primary infection and its duration, then the dependence of reinfection on

the specificity of the virus type, and finally the control of human reinfection with a vaccination virus capable of multiplication was tested.

Hier sind vor allem diejenigen Veröffentlichungen zusammengefaßt, die über eine zweite Infektion im Tierversuch berichten. Dabei werden zunächst die Immunität nach der ersten Infektion und ihre Dauer, später die Abhängigkeit der Reinfektion von der Spezifität des Virustyps und schließlich das Angehen einer Reinfektion mit einem vermehrungsfähigen Impfvirus beim Menschen geprüft.

s. a. Immunität, nach natürlicher Exposition, Zweiterkrankung. Schutzimpfung, aktive Impfung, Lebendimpfstoffe. Tierversuche, Infektionsversuche.

cf. Animal experiments, infection experiments Immunity, after natural exposure, reinfection Vaccination, active vaccination, live vaccines

3567 (86i); 0093 (10d: monkeys: immunity); 0094 (10d: monkeys: immunity); 0095 (10d: monkeys: immunity); 0104 (10d); 0105 (10e); 0106 (10e: monkeys: immunity); 0108 (10e: monkeys: immunity); 0109 (10e: monkeys: immunity); 0377 (10d: monkeys); 0420 (10d: monkeys); 0422 (10d: monkeys: immunity); 0666 (10e); 0675 (10e); 0103 (11e: antibody titer); 0333 (11d); 1019 (11d); 4854 (11e: monkey); 0664 (12e); 0332 (13e); 0769 (15s); 3649 (15s); 0374 (16e: immunity); 0596 (16e); 3654 (16e); 3646 (17e); 3653 (18e); 0665 (19e); 0611 (23f); 0552 (30e: duration of immunity); 0005 (31e: monkeys: temperature reaction); 0832 (31e: monkeys); 4682 (32d); 0379 (33e: monkeys: specifity of strain); 0285 (34e); 0907 (34e); 2229 (34e); 3647 (34n); 3652 (34d); 0718 (35e); 0913 (35e: specifity of strain); 3651 (35s); 0738 (36e: monkeys: antibody response); 0829 (36e: monkeys: heterologeous strain); 0883 (36e: monkeys: antibody-titer); 3650 (36i); 3568 (36f); 4602 (36d); 0452 (37e); 0728 (37e: monkeys); 4294 (37e); 0166 (38e); 0337 (38e); 0705 (38e: monkeys); 2874 (38e: monkey); 3648 (38n); 4802 (38f); 3600 (39e: monkey); 4811 (39e: monkey: measles); 0156 (40e: monkeys: different strains); 3267 (40e); 0712 (41e: Rhesus monkeys); 2065 (41e: monkeys: immunity); 0140 (43e: Macaca mulatta); 0068 (44e: cotton rats); 0126 (45e: chimpanzees); 3228 (45e: monkey); 5289 (45e); 0409 (46e); 0197 (47e); 0369 (47e); 0711 (47e: chimpanzees); 3297 (47e); 2859 (48e: Macaca mulatta); 4834 (48e); 0929 (49e: specifity of strain); 0029 (50e: chimpanzees); 0195 (50e: antibody titer); 0236 (50e); 2739 (50e: chimpanzees); 2863 (50e); 0044 (51e: second attacks: virus type); 0110 (51n); 2670 (51e); 2995 (51e); 3460 (51t); 4417 (51e); 0080 (52e); 3006 (52e); 3140 (52e: chimpanzees); 3165 (52d); 2006 (54d); 2246 (54e: chimpanzees: neutralizing antibodies); 2286 (54d); 3122 (54e); 5027 (54e); 5031 (54i: hyperreactivity); 0697 (55e); 4019 (55e); 2108 (56e); 4759 (56f: antibody titer); 2067 (57e: antibody response); 2336 (57e); 0191 (58e); 0385 (59e: live vaccine); 1192 (59e: type 3: type 1); 1199 (59e: live vaccine); 2133 (59e: attenuated strains); 2302 (59r); 2971 (60e: antibody response); 4916 (60e: live vaccine).

Resistenz / Resistance

Unter dem Begriff Resistenz (R.) werden hier alle jene vorwiegend unspezifischen Vorgänge beschrieben, die die genetisch determinierte Empfänglichkeit des Makroorganismus gegenüber dem Poliomyelitisvirus erhöhen oder herabsetzen können. Leider sind Überschneidungen mit dem Begriff «Immunität» unvermeidlich, unter dem ich die im Laufe des Lebens erworbene Abwehrkraft gegenüber der Poliomyelitis verstehe, sofern sie durch die Einwirkungen von spezifischen und unspezifischen, natürlichen oder künstlichen Antigenreizen entsteht (s. S. 69). Die Veröffentlichungen über «Immunität» und «Resistenz» sind aus zwei Gründen heute noch nicht einwandfrei bibliographisch zu ordnen. Diese beiden Begriffe werden im internationalen Sprachgebrauch entweder in verschiedenen Definitionen benutzt, oder sie werden überhaupt nicht begrifflich getrennt und beliebig wechselweise gebraucht. Zum anderen steht für eine Reihe von Abwehrphänomenen sachlich noch nicht fest, ob es sich um Immunitäts- oder Resistenzmechanismen im oben definierten Sinne handelt. So ist beispielsweise noch nicht geklärt, ob nicht bei der Altersverteilung der Poliomyelitis neben der fraglos als Immunitätsphänomen anzusprechenden Antikörperverteilung noch unspezifische Abwehrmechanismen mitspielen, die dem Begriff «Resistenz» zuzuordnen wären. Dies gilt insbesondere für die Neugeborenen und Säuglinge, deren relative Unempfänglichkeit gegenüber der Poliomyelitis sicher nicht allein auf der passiven diaplazentaren Übernahme spezifischer Antikörper von der Mutter beruht. In dieser Definitionsschwierigkeit habe ich mir so geholfen, daß ich einerseits so weit wie möglich den Formulierungen der Autoren gefolgt bin, andererseits aber in Zweifelsfällen lieber eine Veröffentlichung unter beiden Hauptstichworten zitiert habe. Die zeitlichen Schwerpunkte der Forschungen über die R., die mit denen der aktiven und passiven Immunisierung interferieren, sind in der Einführung beschrieben (s. S. 20, Abb. 9). Zu der Unterteilung dieses Hauptstichwortes ist nur soviel zu sagen, daß unter «Herabsetzung» alle diejenigen Veröffentlichungen angeführt sind, die eine Störung des Abwehrgleichgewichtes gegenüber dem Poliomyelitisvirus verursachen; damit überschneidet sich dieser Teil mit einigen Unterteilungen des Hauptstichwortes «Provokation». Unter dem Stichwort «Wetter» habe ich auch einige Arbeiten über den Einfluß der Jahreszeit aufgenommen, wenn ausdrücklich über die Einwirkung typischer, jahreszeitlich bedingter Wetterlagen auf die R. berichtet wird; die große Zahl der Veröffentlichungen, die die Abhängigkeit der Poliomyelitis von der Jahreszeit behandeln, habe ich in diese Bibliographie nicht aufgenommen, weil es sich nicht um ein immunbiologisches sondern um ein epidemiologisches Phänomen handelt; nach unserem heutigen Wissen sind hier Eigenschaften des Virus und Expositionsfragen der Bevölkerung entscheidend.

s. a. Immunität, Altersverteilung.
Immunität, Unspezifität.
Provokation.
Serologie, Blutgruppen.
Tierversuche, Resistenzversuche.

We use the term «resistance» with reference to all those chiefly unspecific processes which can increase or reduce the genetically determined susceptibility of the macro-organism to poliomyelitis virus. Overlapping with the subject «immunity» is unfortunately not completely avoidable (cf. definition of «Immunity», page 70). For two reasons, publications on immunity and resistance cannot yet be bibliographically arranged in the correct manner. In international usage the two terms are either used under different definitions or they are simply not distinguished, and used alternately. On the other hand, for a number of defence phenomena it has not yet been established whether they entail resistance or immunity mechanisms in the above defined sense. For example, it has not yet been established whether, in age distribution, in addition to the antibody distribution undoubtedly to be regarded as immunity phenomenon, unspecific defence mechanisms are also involved, which would come under the heading «resistance». This holds true in particular for neonates and infants, whose relative insusceptibility to poliomyelitis is certainly not exclusively based on the passive diaplacental transmission of the mother's specific antibodies. I have overcome this difficulty of definition on the one hand, by following the formulations of the authors as much as possible, and on the other hand, in dubious cases, by quoting a publication under both main titles. The chronological highlights of research into R., which interfere with those into active and passive immunization, were described in the introduction (cf. page 36, fig. 9). As to the subdivision of this main title, it can be remarked that under «reduction», all publications are presented which deal with a disturbance of the defence equilibrium against the poliomyelitis virus; this means a measure of overlapping between this section and some sub-divisions of the main title «provocation». Under the title «weather» I collected some papers on the influence of seasons (if they reported expressly on the influence of typical seasonal weather conditions on R.); the majority of publications dealing with the correlation between poliomyelitis and seasons were not included in this bibliography, because they deal, not with an immune-biological but with an epidemiological phenomenon. According to our present knowledge, virus properties and questions of exposure of the population are decisive in this respect.

cf. Animal experiments, experiments on resistance
Immunity, age distribution
Immunity, nonspecifity
Provocation
Serology, blood groups

Allgemeines / General

0317 (10e); 0613 (12e); 0734 (13f); 0266 (16e: micrococcus); 0280 (17e); 2935 (23d); 3610 (27f: specific heredity); 0127 (28e: rural and urban areas); 1196 (29e); 1181 (31e: allergy); 4355 (31d); 0147 (32e); 0717 (32e); 1200 (32e); 1949 (32e: exposition); 4677 (32e); 4682 (32d); 0726 (33e); 0727 (33e: antibody: pregnancy and menstruation: inactivating power of normal human sera); 4123 (33d); 0725 (35e); 0930 (35e); 0903 (36e: monkey: climate); 0463 (36e: antibody response); 0753 (36e); 3516 (36e: diphtheria); 4723 (36d); 4725 (36d);

3145 (37e); 4295 (37d); 3215 (38d); 4805 (38e: blood groups); 0328 (39e: rural and urban areas); 2767 (39d); 2866 (39e: herpes antibody); 3515 (39e: diphtheria); 2693 (41d); 2711 (42e: antibody titers); 3446 (42d); 3879 (42e: autosomal recessive gene); 3881 (42f); 4131 (42d); 3612 (44e: salt metabolism); 0429 (47e); 1064 (47e); 0706 (49e); 0926 (49e); 0797 (50e: season); 2018 (50e: K and Na in serum); 0248 (51e: twin-family study); 2805 (52d); 5228 (52f); 2899 (53d); 5229 (53f); 1743 (54d); 2148 (54f); 2286 (54d); 2853 (54f); 2893 (54e); 4060 (54e); 5027 (54e); 5031 (54i: hyperreactivity); 5286 (54e); 0692 (55e); 0693 (55e); 0694 (55e); 1573 (55i: twins); 1575 (55e); 1640 (55e); 1928 (55s); 2251 (55e: laboratory animals: brown fat); 4038 (55e); 1650 (56e: hospital personnel); 1823 (56d); 1877 (56d); 3969 (56e); 4109 (56e); 0396 (57e: smallpox-vaccination); 0517 (57i: season); 1129 (57e: persistent and masced infections in tissue culture); 1191 (57e: recessive inheritance); 0681 (58f); 4011 (58e); 0432 (59e); 0592 (59d: hospital personnel); 1228 (59i); 1516 (59e: mortality of children); 2778 (60r: leucaemic cell line); 2950 (60e); 3371 (60d); 3957 (60e); 3991 (60d).

Altersverteilung / Age distribution

2916 (10d); 0443 (13e); 1707 (17e); 1549 (24d: Sweden); 0127 (28e: USA); 1042 (29d); 0455 (31e); 0928 (33e); 2936 (35d: early infancy); 0879 (36e: experimental animals); 0452 (37e); 0328 (39e: rural and urban areas); 2767 (39d); 0975 (41e); 1210 (42d); 0140 (43e: *Macaca mulatta*); 2898 (45d); 0429 (47e: USA); 2687 (47e: guinea-pigs); 0649 (48e); 0436 (49e: Eskimos/Canada); 0237 (50e); 3074 (50e); 3147 (50e); 3997 (50e: infants under 6 month); 2819 (51e: Buffalo); 3093 (51d); 5269 (51e); 2005 (52f); 2850 (52e: England and Wales); 1732 (53e: children under 6 month); 1744 (54e: season); 1745 (54d); 0694 (55e); 1547 (55e: infants under one year); 1638 (55i: Italy); 1641 (55e: Scotland); 1654 (55d: Germany); 1655 (55e: Greenland); 1762 (55e: USA); 1926 (55e: USA); 4037 (55e); 1845 (56e: USA); 0192 (57h: Belgium); 0517 (57i: season); 5300 (57e); 0187 (58e: Stockholm); 0193 (58e: Scotland); 0202 (58f: Belgish Congo); 0203 (58e: British Guiana); 0519 (58e: Hungary); 0678 (58i: Italy); 0679 (58e: New Zealand); 0682 (58i: Italy); 1035 (58i: Italy); 1188 (59d); 1219 (59e: Netherlands); 1516 (59e); 2849 (59e: England and Wales); 2580 (60e: Northern Israel).

Ernährung / Nutrition

0732 (43e: mice); 0068 (44e: cotton rat: inanition); 0765 (44e: mice: vitamin B_1 deficiency and inanition); 2668 (44e: mice: thiamine); 2750 (44e: mice: vitamin B_1 diet); 2593 (45e: cotton rats); 3955 (46e: cotton rat: inanition); 3956 (46e: mice); 1743 (54d); 1842 (56e: Syrian hamster).

Geschlechtsverteilung / Sex distribution

0443 (13e); 3201 (25e); 0928 (33e); 4703 (33u); 0911 (34d); 4701 (34d); 0920 (35e); 0452 (37e); 3877 (37e); 2767 (39d); 4823 (40e);

0923 (41e); 1210 (42d); 4170 (43e); 0068 (44e: cotton rat); 2593 (45e: cotton rats); 2898 (45d); 5213 (45d); 0484 (46e: cotton rat); 3955 (46e: cotton rat); 0649 (48e); 0237 (50e); 3074 (50e); 1607 (51e: England); 3093 (51d); 3123 (51e); 2005 (52f); 2850 (52e: England and Wales); 3006 (52e); 1745 (54d: Germany); 0694 (55e); 1547 (55e: infants under one year); 1641 (55e: Scotland); 1654 (55d: Germany); 1655 (55e: Greenland); 1762 (55e: USA); 5203 (56s); 5275 (56e: Connecticut); 5195 (57d); 5300 (57e); 0187 (58e: Stockholm); 0580 (58d: Switzerland); 1035 (58i: Italy); 1219 (59e: Netherlands); 2764 (59i: role of fatigue and trauma); 2849 (59e: England and Wales); 2580 (60e: Northern Israel); 3236 (60e).

Herabsetzung / Reduction

3933 (96e: trauma); 3916 (97d: trauma); 3932 (98d: trauma); 3918 (00f: trauma); 3920 (00d: trauma); 3919 (01d: trauma); 3524 (02d: trauma); 3611 (04f: physical activity); 3917 (06e: trauma); 3931 (08d: trauma); 2146 (09i: measles); 3692 (09d: antirabic treatment); 0417 (11n: smallpox-vaccination); 0442 (11f: trauma); 3930 (11d: trauma); 3929 (12d: trauma); 3659 (13e: bite of dog); 3927 (13d: trauma); 3928 (13d: trauma); 3915 (15d: trauma); 3112 (16e: tonsillectomy); 3691 (16f: antirabic treatment); 3921 (16d: trauma); 3934 (16e: tonsillectomy); 3702 (17e: tonsillectomy); 3922 (17e: trauma); 0133 (19e: monkeys: X-radiation); 2827 (21f: inoculation); 3522 (21f: cholera vaccination); 1047 (22d: tonsillectomy); 3923 (25i: trauma); 4375 (26e: smallpox-vaccination); 3245 (28f: typhoid vaccination); 3924 (28h: trauma); 5000 (28d: injections); 2917 (29d: smallpox-vaccination); 3183 (29i: smallpox-vaccination); 1183 (30h: heterologeous vaccination); 4042 (30e: smallpox-vaccination); 4141 (30e: smallpox-vaccination); 0781 (31e: monkeys: vaccinia virus); 1181 (31e: allergy); 2676 (31d: smallpox-vaccination); 3296 (31f: smallpox-vaccination); 3926 (31d: trauma); 4328 (31f: smallpox-vaccination); 3178 (32e: tonsillectomy); 3887 (32n: smallpox-vaccination); 4041 (32d: physical exertion); 4722 (32n: postvaccinal encephalitis); 5089 (32e: monkey: X-ray); 0150 (33e: monkeys: toxins of Enterobacteriaceae); 0811 (33e: mice: mucin); 0952 (33e: spleenectomy); 2010 (33e: monkeys: reinfection); 3255 (33i: smallpox-vaccination); 3686 (33d: smallpox-vaccination); 5318 (33e: smallpox-vaccination); 4315 (34d: smallpox-vaccination); 0920 (35e: tonsillectomy); 2829 (35e: vaccination); 3628 (35e: in laboratory animals); 4013 (35e: vaccination); 0821 (36e: mice: mucin); 0901 (36e: monkeys: castration: autarceologic susceptibility); 2842 (36d: bite of dog); 3545 (36e: Western Samoa: injections of neoarsphenamine); 4781 (36e: mice: thyroidectomy); 0452 (37e: tonsillectomy); 3283 (37e: trauma); 4796 (37e: X-rays); 0164 (38e: tonsillectomy); 0433 (38e: tonsillectomy: bulbar paralysis); 0595 (38e: tonsillectomy); 2671 (38d: physical exertion); 2742 (38e: monkey: neurosurgical procedures); 2838 (38d); 2844 (38d: trauma); 2865 (38e: tonsillectomy); 2692 (39d); 2748 (39d: trauma); 2840 (39d); 3925 (39d: trauma); 3966 (39f: TAB-Divaccine); 4093 (39e: tonsillectomy); 4177 (39e: tonsillectomy); 0329 (40e: endocrinology); 2837 (40d); 2873 (40d: smallpox-vaccination); 3892 (40s: smallpox-vaccination); 3938 (40e: tonsillectomy); 4815

(40d: smallpox-vaccination); 5170 (40e: monkey: sterile inflammation); 5171 (40f: mice: X-ray); 0315 (41e: tonsillectomy); 0458 (41e: tonsillectomy); 0923 (41e: tonsillectomy); 2618 (41d: weather); 2665 (41e); 2693 (41d); 3613 (41d: physical exertion); 3941 (41e: tonsillectomy); 3217 (42e: tonsillectomy); 3614 (42e: fatigue and chilling); 3937 (42e: tonsillectomy); 3940 (42e: tonsillectomy); 4131 (42d: prophylaxis); 5326 (42e: tonsillectomy); 0485 (43e: tonsillectomy); 0730 (43e: white rats: vitamin B_1-deficiency); 0770 (43e: monkeys: fatigue, chilling, and trauma); 3091 (43d: tonsillectomy); 3092 (43d); 3294 (43e: inoculations); 3935 (43e: tonsillectomy); 4137 (43e: tonsillectomy); 0068 (44e: cotton rat: rachitogenic diets and inanition); 0476 (44e: animal experiments: vitamin B); 2625 (44e: tonsillectomy); 3612 (44e: salt metabolism); 3936 (44e: tonsillectomy); 3939 (44s: tonsillectomy); 5165 (44d: Di-vaccination); 0486 (45e: tonsillectomy); 0612 (45e: monkeys: fatigue and chilling); 2898 (45d); 3269 (45d: tonsillectomy); 3326 (45n); 5213 (45d); 0484 (46e: animal experiments: vitamin); 0908 (46e: tonsillectomy); 0924 (46e: tonsillectomy); 0367 (47e: tonsillectomy: bulbar paralysis); 0370 (47e: pregnancy); 0626 (47e: tonsillectomy); 3256 (47e: tonsillectomy); 3309 (47h: smallpox-vaccination, trauma); 3491 (47e: physical activity); 3954 (47n: tonsillectomy); 4832 (47e: dental surgeon); 4839 (47e); 4972 (47e: cotton rat); 0057 (48e: *Macaca mulatta*: Desoxypyridoxin); 0061 (48e: Cynomolgus monkeys: tonsillectomy); 0160 (48e: monkeys: tonsillectomy: antibody response); 0527 (48e: tonsillectomy); 2653 (48e: physical and mental exertion); 2831 (48e: tonsillectomy and trauma); 2832 (48e: tonsillectomy); 3105 (48e: tonsillectomy); 3168 (48e: pregnancy); 4335 (48e: typhoid-vaccination: monkey); 0360 (49e: trauma); 0529 (49e: tonsillectomy); 0876 (49e); 2833 (49e: tonsillectomy); 3169 (49d); 3214 (49e: tonsillectomy); 3261 (49e: tonsillectomy); 3262 (49e: tonsillectomy); 3953 (49s: tonsillectomy); 4364 (49e: tonsillectomy); 4432 (49t); 5174 (49d); 5332 (49e: exercise); 0196 (50e: vaccinations); 0213 (50e: heterologeous vaccinations); 0215 (50e); 0216 (50e: antirabic vaccination); 0217 (50e: Pertussis- and Diphtheria-vaccination); 0218 (50e); 0219 (50e: penicillin-injection); 0221 (50e); 0238 (50e: tonsillectomy); 0289 (50e: vaccinations); 0352 (50e: vaccinations); 0365 (50e: vaccinations and penicillin-injections); 1040 (50e: heterologeous vaccinations); 1065 (50e: heterologeous vaccinations); 1066 (50e: heterologeous vaccinations); 1067 (50e: heterologeous vaccinations); 1068 (50e: heterologeous vaccinations); 1069 (50e: heterologeous vaccinations); 1070 (50e: heterologeous vaccinations); 1081 (50e: heterologeous vaccinations); 1258 (50e: heterologeous vaccinations); 1484 (50e: tonsillectomy); 1486 (50e: tonsillectomy); 1489 (50e: tonsillectomy); 1510 (50e: tonsillectomy); 1609 (50e: vaccinations); 1695 (50h: smallpox-vaccination); 1718 (50d: heterologeous vaccinations); 2235 (50e: mice: gestation); 2638 (50e: physical activity); 2655 (50e: inoculation); 2662 (50e: tonsillectomy and trauma); 2691 (50e: inoculation); 2721 (50e: mice: gestation); 2747 (50e: inoculations); 2799 (50d); 3041 (50e: tonsillectomy); 3080 (50e: fatigue of travel); 3199 (50d: tonsillectomy); 3358 (50d: tonsillectomy); 3359 (50e: immunization); 3374 (50e: immunization); 3445 (50d: tonsillectomy); 3458 (50d); 4383 (50e: auto-inoculation); 4411 (50e: immunization);

4414 (50i: immunization); 4433 (50e: DP-inoculation); 4435 (50e: antigen-injection); 5112 (50d); 5287 (50e: tonsillectomy); 5437 (50e: intracutaneous inoculation); 0087 (51d: trauma); 0199 (51c: THEILER-virus: heterologeous vaccinations); 0311 (51e: upper respiratory infection); 0894 (51e: mice: heterologeous vaccinations); 1434 (51e: injections); 1436 (51e: vaccinations); 1438 (51e: tonsillectomy); 1491 (51e: tonsillectomy); 1508 (51n: injections); 1509 (51e: tonsillectomy); 1546 (51e: heterologeous vaccinations); 1608 (51e: monkeys: tonsillectomy); 1719 (51e: heterologeous vaccinations); 1720 (51d: heterologeous vaccinations); 1721 (51e: heterologeous vaccinations); 1723 (51e: tonsillectomy); 1724 (51e: tonsillectomy); 1726 (51e: heterologeous vaccinations); 1727 (51e: heterologeous vaccinations); 2017 (51e: transport); 2028 (51e: monkeys: ACTH); 2031 (51e: monkeys: ACTH); 2209 (51e: heterologeous vaccinations); 2130 (51e: heterologeous vaccinations); 2801 (51d: inoculation); 2806 (51i: tonsillectomy); 2828 (51e: injections); 2830 (51e: tonsillectomy); 3123 (51e: menstruation); 3160 (51e: inoculations); 3161 (51e: physical activity); 3212 (51e: trauma); 3224 (51e: injections); 3265 (51e: tonsillectomy); 3266 (51e: tonsillectomy); 4057 (51e: appendectomy); 4385 (51d: vaccination); 4413 (51e: immunization); 4439 (51e: inoculation); 4479 (51i); 4724 (51n: vaccination); 4843 (51e); 4844 (51e); 5462 (51f: smallpox-vaccination); 0176 (52e: heterologeous vaccinations, penicillin-injections); 0177 (52e: parenteral inoculations); 0855 (52e: tonsillectomy); 0856 (52e: vaccinations and injections); 1137 (52e: mice: Di-Pert-toxoid); 1437 (52e: vaccinations); 1454 (52e); 1545 (52e: immunization and therapeutic procedures); 1568 (52e: vaccinations and injections); 1604 (52d: blood transfusion); 1644 (52e: allergens and antibiotics); 1725 (52e: heterologeous vaccinations); 1729 (52e: heterologeous vaccinations); 1730 (52e: tonsillectomy); 1731 (52e: tonsillectomy); 1950 (52e); 2150 (52e: heterologeous vaccinations); 2212 (52e: dental extraction); 2214 (52e: tonsillectomy); 2221 (52e); 2234 (52e: monkeys: heterologeous vaccines); 2298 (52e: cortisone and ACTH); 2602 (52e: prophylactic inoculations); 2603 (52e: prophylactic inoculations); 2639 (52s: inoculation); 2640 (52e: inoculation); 2657 (52e: inoculation: experimental approach); 2885 (52e); 2886 (52e: inoculations); 3165 (52d); 3481 (52f: intramuscular injections); 4024 (52e); 4122 (52e: immunization); 4382 (52e: tonsillectomy: gammaglobuline); 4443 (52e: injections); 4444 (52e: cortisone); 4451 (52e: prophylaxis); 4452 (52e); 4455 (52e: inoculation); 4459 (52e); 4472 (52e: DP-vaccination); 4481 (52e: inoculations); 4484 (52h); 4485 (52n); 4486 (52e); 4487 (52e); 4501 (52e: prophylaxis); 5472 (52f: tonsillectomy); 1439 (53f); 1449 (53e: tonsillectomy: gammaglobuline); 1453 (53e); 1506 (53e: appendectomy); 1514 (53f: pertussis-vaccination); 1554 (53e); 1555 (53e); 1559 (53e: tonsillectomy); 1709 (53e: pollen extract); 1733 (53e: heterologeous vaccination); 1734 (53e: heterologeous vaccination); 1736 (53d: tonsillectomy); 1739 (53e: tonsillectomy); 1747 (53e: Syrian hamster: cortisone); 1756 (53i: heterologeous vaccinations); 1980 (53f); 1998 (53e: tonsillectomy); 2015 (53e: heterologeous vaccinations); 2016 (53e: heterologeous vaccinations); 2019 (53e: heterologeous vaccinations); 2020 (53e: heterologeous vaccinations); 2021 (53e: heterologeous vaccinations);

2022 (53e: tonsillectomy); 2025 (53e: tonsillectomy); 2027 (53e: heterologeous vaccinations); 2228 (53e: prophylaxis); 2596 (53e: tonsillectomy); 2815 (53d); 2818 (53d); 3031 (53e: intramuscular injections); 3106 (53e: cortisone); 3107 (53e: cortisone); 3110 (53e: intramuscular injection); 3133 (53e: tonsillectomy); 3207 (53e: personality factors and fatigue); 3366 (53f); 3378 (53e: tonsillectomy); 3401 (53e: immunization); 3976 (53i: PD-vaccination); 4048 (53e: fatigue: mice); 4101 (53e: tonsillectomy); 4474 (53d); 4494 (53f); 4497 (53e: inoculations); 5226 (53d: tonsillectomy); 5468 (53f: Ditoxoid); 1502 (54e); 1564 (54e: tonsillectomy); 1698 (54d: trauma); 1706 (54e); 1743 (54d); 1745 (54d: prophylaxis); 1758 (54i: mice: heterologeous vaccines); 1803 (54e: monkeys); 1955 (54e: tonsillectomy); 1960 (54e: hamster: cortisone); 2000 (54e: tonsillectomy); 2009 (54e: tonsillectomy); 2149 (54i: heterologeous vaccinations); 2286 (54d); 2464 (54e: immunizing injections); 2534 (54d); 2675 (54d: tropical warm air masses); 3120 (54f: tonsillectomy); 3135 (54e: hypophysectomy); 3271 (54e: tonsillectomy); 4094 (54e: tonsillectomy); 4099 (54e); 4509 (54i: Di-vaccination); 4516 (54s: endocrine factor); 4526 (54i: DP-vaccination); 4562 (54e: penicillin-injections); 4567 (54e: prophylaxis); 4568 (54i); 5024 (54f); 5025 (54d); 5030 (54i: vaccinations); 5033 (54i: tonsillectomy); 5035 (54i: DP-vaccine: mice); 5046 (54i); 5048 (54f: prophylaxis); 0512 (55i: monkeys: heterologeous vaccinations); 1444 (55e: tonsillectomy); 1495 (55e); 1517 (55e: tonsillectomy); 1575 (55e); 1641 (55e: vaccinations); 1656 (55e); 1759 (55i: Syrian hamster: heterologeous vaccines); 1777 (55d: monkeys); 1811 (55e: tonsillectomy); 1925 (55e: tonsillectomy and pregnancy); 1928 (55s); 1981 (55d: pregnancy); 2011 (55d: vegetative irritation center: neural localization factor); 2242 (55s); 2251 (55e: laboratory animals: endocrine disturbances); 2252 (55e: monkeys: injections); 2303 (55d: smallpox-vaccination); 2867 (55d); 2989 (55f); 2990 (55e: prophylactic injections and tonsillectomy); 2991 (55f); 2992 (55f: fatigue); 2993 (55f: lumbal punction); 2994 (55f); 3111 (55e: tonsillectomy); 3206 (55d: exercise and trauma); 4590 (55i); 4595 (55e: vaccination); 4604 (55i: fatigue); 5047 (55s: smallpox vaccination); 5052 (55f: other infections); 5053 (55i: tonsillectomy); 5146 (55d: tonsillectomy); 5231 (55d: physical exertion); 5233 (55d: trauma); 5309 (55i: fatigue); 0978 (56e: monkeys: cortisone); 1475 (56i: tonsillectomy); 1480 (56e: tonsillectomy); 1499 (56n: tonsillectomy); 1823 (56d); 1842 (56e: Syrian hamster); 1863 (56d); 1867 (56d: tonsillectomy); 1871 (56h: monkeys: cortisone); 1891 (56i: Di-vaccination); 1900 (56e: monkeys: cortisone); 1903 (56e: monkeys: cortisone and X-rays); 1916 (56e: monkeys: cortisone); 2165 (56f: smallpox-vaccination and trauma); 2307 (56d: monkeys: cortisone); 2337 (56e: DPT-inoculation); 2473 (56s); 2478 (56s: tonsillectomy); 2483 (56e: prophylactic inoculations); 2552 (56d); 2968 (56d); 2969 (56d); 3036 (56d); 4762 (56d: injections); 4768 (56e: hamster: castration); 5245 (56n: tonsillectomy); 5246 (56e: physical exertion); 5275 (56e); 0967 (57d); 1115 (57e: tonsillectomy); 1117 (57e: mice: heterologeous vaccinations); 1120 (57e: guinea-pig: adsorbat-toxoid); 1461 (57e: tonsillectomy); 1472 (57h: tonsillectomy: bulbar paralysis); 1473 (57e: exogenic factors); 1523 (57d: tonsillectomy and bulbar paraly-

sis); 2042 (57e: tonsillectomy); 2043 (57d: monkeys: cortisone and X-rays); 2054 (57d); 2055 (57d: smallpox-vaccination); 2118 (57i: animal experiments: heterologeous vaccinations); 2220 (57h); 2276 (57e: inoculations); 2327 (57d); 2427 (57d: tonsillectomy); 2502 (57e: tonsillectomy); 2543 (57d: smallpox-vaccination); 2733 (57e: hamster: stress); 4050 (57t); 4943 (57e: smallpox-vaccination); 5188 (57i: tonsillectomy); 5197 (57i: infections); 5201 (57i); 0171 (58d: DPT-inoculation); 0190 (58e: monkeys: infection with COXSACKIE-virus); 0249 (58d: SALK-vaccine); 0303 (58e: tonsillectomy); 0629 (58d: homologous vaccination); 0645 (58s: tonsillectomy); 1237 (58i: heterologeous vaccination); 1276 (58f: homologous vaccination); 1595 (58e: tonsillectomy); 2328 (58e: tonsils: cranial nerve paralysis); 2339 (58i: cortisone); 2345 (58e: tonsillectomy status: rural area); 2979 (58i); 5387 (58e); 0562 (59e: heterologeous vaccinations); 0563 (59e: heterologeous vaccinations); 0564 (59e: heterologeous vaccinations); 0565 (59e: heterologeous vaccinations); 0566 (59e: penicillin); 0662 (59e: monkeys: cortisone); 0836 (59e: Di-Tuss-vaccination); 1055 (59d: vaccination: incubation period); 1291 (59e: SALK-vaccination); 1400 (59d); 1636 (59r: cortisone); 2588 (59d: SALK-vaccine); 2905 (59r: cortisone); 3306 (59pl: other infections); 1386 (60d: heterologeous vaccination); 1408 (60d: animal experiments: vaccinations); 1425 (60d: exogenic factors); 1689 (60d: homologous vaccinations); 2299 (60e: inoculations); 2399 (60d: SALK-vaccine); 2404 (60d: SALK-vaccine); 2405 (60d: SALK-vaccine); 2610 (60d: tonsillectomy); 3052 (60f); 3236 (60e: tonsillectomy); 3466 (60r: tonsillectomy); 2770 (61e: inoculations); 4149 (61d: homologous vaccination); 4202 (61e: traumatized tissue); 4741 (61d: live vaccination); 5342 (61e: vaccination and inoculation); 5140 (62d: Di-vaccination); 5337 (62d: DPT-vaccination).

Hormone / Hormones

0717 (32e); 1200 (32e); 0727 (33e: antibody: menstruation); 0736 (34e); 0741 (34e); 0742 (34e: monkeys); 0820 (35e: pregnancy); 3421 (35f); 3571 (35e: antibody: adrenal-ectomy); 3608 (35d); 0753 (36e); 4781 (36e: mice: castration); 3145 (37e); 0329 (40e: subclinical endocrinology); 3607 (40e); 3521 (41e); 3609 (41e: estrogen: monkey); 4170 (43e); 3326 (45n); 3958 (45e: estrogen: mice); 3137 (46e: mice); 3138 (46e: monkey); 0371 (47e: mice: autarceologic protection of estrogenic substance); 5117 (47e); 0215 (50e: negative phase: cortisone); 2211 (50e: animal experiments: cortisone); 2028 (51e: monkeys: ACTH); 2031 (51e: monkeys: ACTH); 2652 (51e: ACTH); 0292 (53e: monkeys-infection: cortisone); 0298 (53e: Syrian hamster: parenteral infection: cortisone); 1747 (53e: Syrian hamster: cortisone); 3106 (53e: cortisone: hamster); 3107 (53e: cortisone); 3399 (53e: cortisone: hamster); 1694 (54e: Syrian hamster: cortisone and other hormones); 1803 (54e: monkeys: cortisone); 1960 (54e: hamster: cortisone); 4516 (54s); 4582 (54e: monkey: cortisone); 1754 (55e: cortisone); 2249 (55e: Cynomolgus monkeys: cortisone); 2251 (55e: Syrian hamster: cortisone); 2705 (55e: cortisone: tissue culture); 5179 (55i: ACTH and cortisone); 0978 (56e: cortisone: monkeys: safety test); 1696 (56e: Ateles niger: cortisone); 1823 (56d: cortisone); 1842

(56e: Syrian hamster); 1916 (56e: monkeys: cortisone); 2307 (56e: monkeys: cortisone); 2473 (56s: cortisone); 4758 (56e: hamster: cortisone); 4768 (56e: hamster: cortisone: castration); 2733 (57e: hamster: cortisone); 5199 (57f); 2339 (58i: cortisone); 0662 (59e: cortisone: monkeys); 1938 (59i: cortisone therapy); 1939 (59i: cortisone therapy); 1424 (60e: cortisone: monkeys: viraemia after live vaccination); 2941 (60i: skin test: cortisone).

Konstitution und Vererbung / Constitution and heredity

3520 (12e: neuropathic constitution); 4917 (12e); 3615 (13d: siblings); 4372 (23d); 3610 (27f: specific heredity); 3563 (30e: allergy); 0702 (32e: blood groups); 4168 (32e); 5083 (32d); 3103 (33e); 3258 (33e); 0911 (34d: dactylograms and blood groups); 3549 (35d: dactylograms); 3608 (35d); 3145 (37e: endocrine differences); 3877 (37e); 4795 (37i); 3215 (38d); 3900 (38d: uniovular twins); 3902 (38n); 4154 (38d); 2767 (39d); 3901 (39d); 4156 (39e); 0329 (40e: subclinical endocrinology); 3607 (40e); 4134 (40d); 3521 (41e); 3880 (41e); 1210 (42d); 3010 (42e: familiar aggregation); 3446 (42d); 3879 (42e: autosomal recessive gene); 3092 (43d); 4170 (43e); 3326 (45n); 5478 (48d); 0248 (51e: twins); 2817 (51e); 3000 (51e: identical twins); 3093 (51d); 1980 (53f); 2818 (53d); 3187 (53e); 1983 (54i: twins); 4110 (54e); 5147 (54e); 1573 (55i: twins); 2466 (55e: eye and hair color); 3108 (55e: allergic constitution); 4761 (55e: identical twins); 1822 (56d: blood groups); 1823 (56d: genetic); 1191 (57e: recessive inheritance); 5190 (57e); 5199 (57f); 5252 (58d: psyche); 1400 (59d); 2390 (60i: twin-pairs); 2589 (60d: twin-pair); 4665 (60e).

Neugeborene / Newborn infants

3142 (10e: intra-uterine life); 3282 (18e); 3381 (29e); 0089 (30e: transmission of antibodies from mother); 4675 (32i); 4703 (33u); 3291 (34i); 4701 (34d); 29 36(35d); 2646 (39e); 3298 (39n); 3320 (39n); 4666 (40f); 4061 (42d); 1474 (43e); 3209 (44e); 0368 (47e: intrauterine infection); 0370 (47e); 4536 (47i); 0287 (48e); 4421 (48e); 4422 (48e); 2706 (50e: mice); 2897 (50e); 4053 (50d); 3102 (51e); 4054 (51d); 4418 (51s); 5221 (51d: embryopathy); 2215 (52e); 3073 (52e); 3113 (52e); 4441 (52e: congenital abnormalities); 4443 (52e); 4453 (52d: embryopathy); 5225 (52d); 1544 (53e: casuistic); 4071 (53e); 4558 (53e); 5224 (53d: embryopathy); 1566 (54e); 1567 (54e); 2006 (54d); 3071 (54e); 3144 (54e); 4095 (54e: intrauterine infection); 1490 (55f); 1574 (55e); 1578 (55e); 3461 (55i); 4102 (55e); 1829 (56e); 5272 (56e); 0496 (57d: foetus); 0530 (57e: transmission of antibody); 0531 (57e: transmission of antibody); 2344 (57e: viraemia); 2541 (57e); 0647 (58i: transmission of antibody); 0555 (59e); 5464 (59d); 4073 (60d); 5004 (60e: SABIN-vaccine); 4959 (61f: live vaccination).

Rasse / Race

5094 (33f: Switzerland); 0806 (36e: USA); 0452 (37e); 3877 (37e); 5117 (47e); 0649 (48e); 3003 (48e); 3004 (48e); 3442 (50d); 2817

(51e); 3219 (51e: Bantu: Europeans in South Africa); 4410 (51f: South Africa); 0120 (52e); 4110 (54e); 0693 (55e: underdeveloped areas); 2224 (55s); 2253 (55e: Louisiana: seroimmune patterns); 1845 (56e: South Louisiana); 1896 (56f: aborigines in Central Africa); 2066 (57e: antibody: Louisiana); 2123 (57e: Chicago epidemic 1956); 2484 (57p: Africans: Europeans); 2502 (57e: Africans: Europeans); 3067 (57e: Europeans and Maori: antibodies in New Zealand); 0533 (58e: tropical areas); 0534 (58e: tropical areas); 0679 (58e: New Zealand: Maori: Europeans); 1004 (58e: Africa); 1020 (58e: Maori and Europeans: antibody); 2262 (58f: antibodies: France: Vietnam); 1296 (59e: New Jersey 1958); 2555 (59e: Southern Rhodesia); 1395 (60e: Washington, D. C.); 2450 (60e: Kenya); 2973 (60e: New Haven/Conn.); 2974 (60e: Detroit 1958).

Schwangerschaft / Pregnancy

3246 (11f); 3253 (11f); 3670 (11e); 3675 (11f); 3569 (12s); 3356 (14d); 3674 (23e); 3667 (24e); 3381 (29e); 3669 (30d); 1084 (31e); 3016 (32e); 0727 (33e: antibody); 2822 (33e); 3260 (33f); 2852 (38d); 2767 (39d); 3673 (39e); 3943 (39d); 0522 (41e); 0923 (41e); 3668 (41e); 3950 (41e); 3162 (42d); 1474 (43e); 2617 (43n); 2835 (43e); 3672 (43e); 4170 (43e); 3011 (44e); 3671 (44e); 2825 (45e); 3326 (45n); 2821 (46e); 5383 (46n); 0368 (47e); 0370 (47e: abort); 2824 (47e); 3276 (47e); 5117 (47e); 0287 (48e); 2654 (48e); 3168 (48e); 4421 (48e); 4422 (48e); 2823 (49f); 3373 (49e); 5220 (49e); 0237 (50e); 2235 (50e: mouse experiments); 2662 (50e); 2706 (50e: mice); 2721 (50e: mice); 2881 (50d); 0088 (51f); 0122 (51e); 0123 (51f); 2131 (51e); 2210 (51e); 3093 (51d); 3123 (51e); 3944 (51f); 5143 (51d); 5221 (51d: mongolism); 0120 (52e); 2684 (52e); 3073 (52e); 4441 (52e); 4453 (52d: embryopathy); 5225 (52d); 5263 (52h); 1980 (53f); 2826 (53e); 3203 (53e); 3345 (53e); 5224 (53d: embryopathy); 1566 (54e); 1567 (54e); 1706 (54e); 3071 (54e); 3348 (54e); 4095 (54e: intrauterine infection); 1490 (55f); 1500 (55d); 1574 (55e); 1578 (55e); 1813 (55e); 1925 (55e); 1981 (55d); 2609 (55d); 2996 (55e); 2997 (55e); 3346 (55e); 3347 (55e); 1823 (56d); 1829 (56e); 2473 (56s); 2968 (56d); 2969 (56d); 5272 (56e); 0496 (57d: infection of foetus); 2045 (57e); 2054 (57d); 2279 (57e); 2327 (57d); 2344 (57e: viraemia in a newborn infant); 5189 (57e); 5195 (57d); 5199 (57f); 5210 (57e); 0185 (58e); 1028 (59e: Western Australia); 1400 (59d); 2579 (60f); 3387 (60e); 4665 (60e); 4083 (61e: acute bulbar paralysis); 4693 (61i).

Soziologie / Sociology

1707 (17e: rural and urban areas: USA); 1549 (24d: rural and urban areas: Sweden); 1042 (29d: rural and urban areas); 0340 (30e: antibodies: rural and urban areas); 0341 (30e: antibodies: rural and urban areas); 5336 (30e: rural and urban communities); 0328 (39e: rural and urban areas); 0706 (49e); 0721 (50e); 2621 (51e: antibody levels); 2819 (51e: Buffalo); 0700 (55e); 1651 (55f: antibodies in Uruguay); 1821 (55e: South Australia: antibodies: rural and urban areas); 1840 (55e: antibodies: Charleston/USA); 2224 (55s: underdeveloped

areas); 2253 (55e: Louisiana: seroimmune patterns); 1844 (56e: antibodies: North Ireland); 1902 (56e: antibodies: Brazil); 1965 (56e: antibodies: Central America); 0531 (57e: antibodies); 0573 (57f: France); 0593 (57e: neutralizing antibodies: number of children); 1973 (57f: rural and urban areas: Switzerland); 2056 (57d: antibodies: Basel); 2066 (57e: antibodies: Louisiana); 2104 (57e: antibodies: USA: Cairo); 2116 (57e: antibodies: North Ireland); 2123 (57e: Chicago epidemic 1956); 2335 (57e: antibodies: Charleston and Phoenix/USA); 2507 (57e: antibodies in Peru and Colombia); 0187 (58e: Stockholm); 0193 (58e: Scotland); 0231 (58f: France); 0535 (58d); 0580 (58d: Switzerland); 0599 (58e: neutralizing antibodies: number of children); 0682 (58i: Italy); 1006 (58f: antibodies: France); 1458 (58d: Germany: antibodies); 0870 (59d: Germany: «Siedlungsklassen»); 1219 (59e: rural and urban areas: Netherlands); 1622 (59f: antibodies: Paris); 2295 (60b: antibodies: Roumania: Bucarest: rural areas); 2580 (60e: Northern Israel); 2973 (60e: New Haven/Conn.: antibody levels); 2974 (60e: epidemic in Detroit 1958); 3096 (60d: Wien: antibody levels).

Tierversuche / Animal experiments

0414 (09d: monkeys); 0719 (09d); 0757 (09f: chimpanzees); 0109 (10e: different species of monkey); 0415 (10d: monkeys); 0422 (10d: monkeys); 0466 (10f: monkeys and rabbits); 0668 (10e: monkeys); 1049 (11e: rabbits); 0416 (12d: monkeys: smallpox-vaccination); 0880 (14e: monkeys: virulence); 1045 (14e: monkeys); 4926 (17s: monkey); 0133 (19e: monkeys: X-rays); 0135 (19e: monkeys: persistence of virus in nasopharynx); 1037 (20e: monkeys: intranasal); 1196 (29e: monkeys); 0142 (30e: rabbits); 0464 (30e: young rabbits); 0465 (30e); 0781 (31e: monkeys: vaccinia virus); 1946 (31e: monkeys); 3185 (31e: monkey); 0717 (32e); 1200 (32e: monkeys: hormones); 2201 (32e: normal antibodies); 5086 (32f: monkey: season); 5089 (32e: monkey: X-ray); 0150 (33e: monkey: toxins of enterobacteriaceae); 0810 (33e: monkey: agglutinin titer changes after infection); 0811 (33e: mice: mucin); 0952 (33e: guinea-pig: spleenectomy); 2010 (33e: monkeys: reinfection); 2794 (33e: monkey: titration of virus); 0741 (34e: monkeys: hormones); 5106 (34e: monkey: paratyphoid-coli-filtrate); 0755 (35e: *Ateles ater*); 0816 (35e: monkeys: infection through isolated intestinal loops); 3421 (35f: hormones); 3571 (35e: monkey: adrenalectomy); 3628 (35e); 3882 (35e: rodents: vitamin B and C); 4713 (35e: monkey: hyperpyrexia); 5108 (35e: monkey: paratyphoid-coli-filtrate); 0753 (36e: monkeys); 0805 (36e: monkeys: infection through isolated intestinal loops); 0821 (36e: mice: mucin); 0823 (36e: monkeys); 0830 (36e); 0878 (36e: monkeys); 0879 (36e: acquired resistance of growing animals); 0886 (36e: monkeys: prevention by intranasal irrigation with chemicals agents); 0901 (36e: monkeys: castration); 0903 (36e: monkeys: season); 1053 (36e: monkeys: blood-CNS barrier); 3420 (36e); 4781 (36e: mice: thyroidectomy and castration); 5121 (36e: monkey: paratyphoid-coli-filtrate); 0441 (37e: monkey: vitamine); 0481 (37e: monkeys: vitamin C); 3145 (37e: monkey: castration); 4298 (37e: monkey: role of the spleen); 4792 (37e: monkey: vitamin

C); 4796 (37e: X-rays); 4798 (37e: monkey: vitamin C); 0091 (38e: monkeys: infection of tonsils); 0155 (38e: monkeys: ergosterol and vitamin D); 2488 (38e: monkey: blood-CNS barrier); 2742 (38e: monkey: neurosurgical procedures); 5129 (38e: hedgehog and agouti); 0526 (39e: *Macacus cynomolgus*); 0528 (39e: Rhesus-monkeys: intraocular inoculation); 0740 (39e: monkeys); 4014 (39e: monkey); 0329 (40e: monkeys: autarceologic susceptibility); 0710 (40e: chimpanzees); 0927 (40e: monkeys); 3627 (40f: antibody); 3698 (40e: monkey: sparing effect: lymphocytic choriomeningitis); 3883 (40e: monkey: vitamin D); 5170 (40e: sterile inflammation of CNS: monkey); 5171 (40f: mice: X-ray); 0023 (41e: chimpanzees); 0159 (41e: monkeys: vitamin D); 0712 (41e: Rhesus-monkeys: reinfection); 0715 (41e: *Cercopithecus aethiops sabaeus*); 3609 (41e: monkey: estrogen); 0893 (42e: mice: thiamin); 0897 (42e: hamster); 3946 (42e: monkey: oral infection); 0128 (43e: mice: age); 0140 (43e: *Macaca mulatta*); 0708 (43e: monkeys: spontaneous infection); 0713 (43e: *Cebus capucina* and *Cercopithecus cephus*); 0714 (43e: Cynomolgus monkeys); 0730 (43e: white rats: vitamin B_1); 0732 (43e: mice: food intake); 0766 (43e: Cynomolgus monkeys); 0770 (43e: monkeys: fatigue, chilling and trauma); 0771 (43e: mice: vitamine); 0910 (43e: monkeys); 3696 (43e: monkey: TAB-vaccination); 4794 (43e: rodents); 0068 (44e: cotton rats: rachitogenic diets, inanition and sex); 0475 (44e: East African monkey); 0476 (44e: rats and mice: vitamin B); 0709 (44e: chimpanzees: spontaneous infection); 0733 (44e: Rhesus-monkeys: intranasal infection); 0764 (44e: monkeys: infection by inhalation); 0765 (44e: mice: vitamin B_1-deficiency and inanition); 2668 (44e: mice: diet); 2750 (44e: mice: vitamin B_1-diet); 3411 (44e: mice: pantothenic acid deficiency); 3885 (44e: mice: riboflavin); 0612 (45e: monkeys: fatigue, chilling and trauma); 0623 (45e: monkeys: accidental laboratory infection); 2593 (45e: cotton rats); 3958 (45e: mice: estrogen); 5135 (45e: monkey: thiamine deficiency); 5136 (45e: South African blackface monkey); 5380 (45e: mice: pyridoxine, inositol, and biotin); 5381 (45e: vervet monkey); 5382 (45f: rodents); 0484 (46e: cotton rats: vitamine and sex); 3137 (46e: mice: various hormones); 3138 (46e: monkey: estrogens); 3173 (46e: mice: temperature); 3189 (46e: mice: thiouracil); 3955 (46e: cotton rat: vitamin A, inanition, and sex); 3956 (46e: mice: vitamin B); 4838 (46e: monkey: folic acid); 5385 (46f: *Aethiops sabaeus*: LANSING strain); 0040 (47e: *Cercopithecus aethiops sabaeus*); 0326 (47e: infant monkeys); 0371 (47e: mice: estrogenic substance); 2007 (47e); 2673 (47e: cotton rat); 2687 (47e: guinea-pigs: relation to age); 4307 (47e: sensitazation in guinea-pigs); 4841 (47e: crossbred mice); 4842 (47e: flies); 4972 (47e: cotton rat); 0032 (48e: mice and cotton rats); 0057 (48e: *Macaca mulatta*); 0058 (48e: *Macaca irus* [Philippine Cynomolgus monkey]: high susceptibility against oral infection); 0059 (48e: *Macaca irus valida*, *Macaca irus mordax*, *Macaca philippinensis*: oral infection); 0060 (48e: different monkey species: intracerebral and oral infection); 0061 (48e: Cynomolgus monkeys: tonsillectomy); 0160 (48e: monkeys: tonsillectomy); 2717 (48e: mice: thyroxin); 4098 (48s: white rat: age); 4425 (48e: mice: oxythiamine); 4365 (49e: mice: nutrition); 4431 (49e: Syrian hamster); 0030 (50e: monkeys: cotton rats, mice); 1951 (50f: rabbits); 2211 (50e: mouse and hamster: cortisone); 2235

(50e: mice: gestation); 2706 (50e: mice: gestation); 2720 (50e: newborn mice: relative resistance); 2721 (50e: mice: gestation); 0132 (51e: monkeys: tonsillectomy); 1700 (51s: *Ateles neglectus*); 2028 (51e: monkeys: ACTH); 2031 (51e: monkeys: ACTH); 2652 (51e: mice: ACTH); 1643 (52e: bat); 2234 (52e: monkeys: heterologeous vaccines); 2298 (52e: mice and hamsters: cortisone and ACTH); 2729 (52e: testicular tissue from immune monkeys); 2730 (52e: suckling hamsters); 2797 (52e: monkey: COXSACKIE- and Polio-infection); 3179 (52e: mice: diets); 3364 (52e: monkey: hyaluronidase); 4113 (52e: Panamanian monkey); 4382 (52e: monkey: tonsillectomy); 4444 (52e: Syrian hamster: cortisone); 4447 (52e: Syrian hamster: cortisone); 4457 (52e: mice: methionine); 4458 (52e: mice: deficiencies of amino-acids); 4462 (52e: mice); 0292 (53e: Cynomolgus monkeys: cortisone); 1747 (53e: Syrian hamster: cortisone); 1749 (53e: monkeys: Newcastle-infection); 2731 (53e: mice: hyper- and hypothyroidism); 3106 (53e: hamster: cortisone); 3107 (53e: cortisone); 3399 (53e: Syrian hamster: cortisone); 4048 (53e: mice: fatigue); 4090 (53e: Rhesus-monkey: Naja toxoids); 4108 (53e: mice: DP-vaccine); 4471 (53e: suckling mice and monkey); 4502 (53e: monkey: glutamylcholine and vitamin B_1); 4510 (53e: low tryptophan diets); 4512 (53e: mixed infection: COXSACKIE-virus); 1694 (54e: Syrian hamster); 1701 (54s: *Ateles vellerosus*); 1758 (54i: mice: heterologeous vaccines); 1803 (54e: monkeys: injection and trauma); 1960 (54e: hamster: cortisone); 2245 (54e: Cynomolgus monkeys: invasiveness of strains); 2727 (54e: *Ateles* monkeys: type 2 and 3); 2894 (54e); 2946 (54e: monkey: Naja flava-toxoid); 3135 (54e: mice: hypophysectomy); 4099 (54e: provoking factors); 4582 (54e: monkey: cortisone); 5035 (54i: mice: DP-vaccine); 0512 (55i: monkeys: heterologeous vaccinations); 1759 (55i: Syrian hamster: heterologeous vaccines); 1777 (55d: monkeys: heterologeous vaccination and tonsillectomy); 1778 (55e: monkeys); 1905 (55f: monkeys: Central Africa); 2249 (55e: monkeys: in vivo- and in vitro-susceptibility); 4604 (55i: mice: fatigue); 5179 (55i: ACTH and cortisone); 5309 (55i: fatigue: mice); 1696 (56e: *Ateles niger*); 1842 (56e: Syrian hamster); 1916 (56e: monkeys: cortisone); 2307 (56d: monkeys: cortisone); 2314 (56e: Cynomolgus monkeys: diphtheria toxoid and tonsillectomy); 4758 (56e: hamster: cortisone); 4768 (56e: hamster: cortisone: castration); 4951 (56e: suckling hamster); 4952 (56e: cave bat); 0517 (57i: hamster: season); 1117 (57e: mice: heterologeous vaccinations); 2043 (57d: monkeys: cortisone and X-rays); 2733 (57e: hamster: cortisone and stress); 0190 (58e: monkeys: mixed infection with Polio- and COXSACKIE-virus); 0245 (58d: mice: after COXSACKIE-infection); 0308 (58e: mice: sparing effect of rabies virus); 0557 (58e: monkeys: contact transmission); 3505 (58e: monkey: neurotoxoid); 0662 (59e: monkeys: safety test); 1055 (59d: mice: vaccination in incubation period); 1716 (59e: young mice: COXSACKIE-infection); 1992 (59f: mouse: hyperthermy); 5390 (59e); 5391 (59e: type 1: adaptation to suckling mice); 4202 (61e: monkey: traumatized tissue); 4630 (61e: monkey: cortisone: safety test); 5447 (61e: monkey: intraspinally inoculation).

Tonsillen / Tonsils

1048 (11e); 4872 (11f: monkey); 3112 (16e); 3934 (16e); 3702 (17e); 4136 (17e); 0135 (19e: monkeys); 1047 (22d: tonsillectomy); 0092 (28e: bulbar paralysis after tonsillectomy); 0336 (29e); 0401 (29e: incubation period); 3078 (32e); 4705 (35e: virus content); 4712 (35e: virus content); 0164 (38e: bulbar paralysis); 2865 (38e: bulbar paralysis); 2646 (39e); 4093 (39e); 4164 (39d); 4177 (39e); 3938 (40e); 2665 (41e); 3941 (41e); 0349 (42e); 0351 (42e); 3217 (42e); 3937 (42e); 3940 (42e); 4132 (42d); 5326 (42e); 0485 (43e: vitamin B); 3091 (43d); 3935 (43e); 4137 (43e); 0008 (44e); 2625 (44e: bulbar paralysis); 3936 (44e); 3939 (44s); 0486 (45e: bulbar paralysis); 0621 (45e: occurence of virus in tonsils: interepidemic period); 3269 (45d); 3326 (45n); 0908 (46e: tonsillectomy); 0924 (46e: tonsillectomy); 0367 (47e: bulbar paralysis); 3256 (47e); 3954 (47n); 0061 (48e: Cynomolgus monkeys: tonsillectomy); 0160 (48e: monkeys); 0350 (48e); 0527 (48e: tonsillectomy); 2831 (48e); 2832 (48e); 3105 (48e); 0529 (49e: tonsillectomy); 2833 (49e); 3214 (49e); 3261 (49e); 3262 (49e); 3953 (49s); 4049 (49e); 4364 (49e); 5174 (49d); 0238 (50e); 1484 (50e); 1486 (50e); 1489 (50e); 1510 (50e); 2662 (50e); 3199 (50d); 3358 (50d); 3445 (50d); 5287 (50e); 0132 (51e: monkeys: gammaglobuline prophylaxis); 1438 (51e: tonsillectomy); 1491 (51e); 1509 (51e); 1608 (51e: bulbar paralysis after tonsillectomy: monkeys); 1723 (51e); 1724 (51e); 2806 (51i); 2830 (51e); 3265 (51e); 3266 (51e); 0120 (52e); 0240 (52s); 1730 (52e); 1731 (52e); 2214 (52e); 4485 (52n); 5472 (52f); 0129 (53e: bulbar paralysis); 1559 (53e); 1736 (53d); 1739 (53e); 1980 (53f); 1998 (53e); 2022 (53e); 2025 (53e); 2596 (53e); 3133 (53e); 3378 (53e); 4101 (53e); 5226 (53d); 0130 (54f); 1564 (54e); 1955 (54e); 2000 (54e); 2009 (54e); 3120 (54f); 3271 (54e); 3272 (54e: vomiting); 4094 (54e); 4517 (54e); 4567 (54e); 5033 (54i: bulbar paralysis); 0111 (55f); 0131 (55f); 1444 (55e: tonsillectomy); 1495 (55e); 1517 (55e); 1710 (55e); 1777 (55d: monkey experiments); 1811 (55e); 1925 (55e); 2990 (55e); 3111 (55e); 5053 (55i); 5146 (55d); 1480 (56e); 1499 (56n: bulbar paralysis); 1867 (56d); 2314 (56e: Cynomolgus monkeys); 2478 (56s); 2552 (56d); 5245 (56n); 1115 (57e: tonsillectomy: bulbar paralysis); 1461 (57e); 1472 (57h: bulbar paralysis); 1523 (57d); 2042 (57e); 2054 (57d); 2427 (57d); 2502 (57e); 5188 (57i); 5373 (57e); 0506 (58i: neutralizing power of tonsils); 1595 (58e); 2126 (58d); 2328 (58e: cranial nerve paralysis); 2345 (58e: tonsillectomy status: rural area); 2781 (58i: neutralizing effect of tonsil extracts); 0513 (59d: tonsillectomy: vaccination); 2610 (60d); 3236 (60e); 3466 (60r); 3192 (61e); 5456 (61d).

Vitamine / Vitamine

3882 (35e: vitamin B and C); 3884 (36e); 0441 (37e: monkeys); 4792 (37e: vitamin C: monkey); 4798 (37e: vitamin C: monkey); 0155 (38e: monkeys: vitamin D); 2860 (38e: vitamin C); 3293 (38e: vitamin B); 3660 (38d: vitamin B_1); 2861 (39e: vitamin C-therapy); 2862 (39e: vitamin C); 3883 (40e: vitamin D); 0159 (41e: monkeys: vitamin D); 3887 (41e: vitamin B); 0893 (42e: mice: thiamin-diet); 0485 (43e: tonsillectomy); 0730 (43e: white rats: vitamin B_1); 4170

(43e); 0068 (44e: cotton rats: rachitogenic diets); 0476 (44e: mice and rats: vitamin D); 0765 (44e: mice: vitamin B_1); 2668 (44e: mice: thiamine diet); 3411 (44e: mice: pantothenic acid deficiency); 3885 (44e: riboflavin); 3886 (44f: vitamin B); 3955 (46e: vitamin A); 3956 (46e: mice: vitamin B); 4365 (49e: mice: vitamin D); 4502 (53e: monkey: vitamin B_1); 5199 (57f).

Wetter / Weather

3871 (17e); 3876 (32f); 4017 (32e); 4018 (32e); 3875 (33f); 5099 (33d); 3001 (34e); 2709 (35e: polar infall); 4716 (35f); 4723 (36d); 3874 (38n); 4153 (38n); 4802 (38f); 3872 (40e); 2618 (41d); 4829 (41e); 4830 (41e); 3870 (42d); 3873 (43s); 2898 (45d); 3003 (48e); 4336 (48d); 3074 (50e); 3211 (50d); 4436 (50d: mice: virulence); 2820 (51e); 4454 (52e: humidity); 4478 (52e: Australia); 4498 (52e); 4461 (53e); 2675 (54d: tropical warm air masses); 4517 (54e); 4590 (55i); 5064 (55d); 5182 (56d); 5183 (56d); 5184 (56d); 3036 (56d); 3109 (56e: pollen: seasonal incidence); 5066 (56d); 5244 (56d); 5443 (56d); 4956 (57i); 5193 (57d); 5209 (57s); 5343 (57d); 5239 (58f); 2906 (59e); 2950 (60e); 3024 (60e); 3051 (60i); 3089 (60h); 4636 (61e: mucin); 4980 (61e: photoperiodicity); 4981 (61h: photoperiodicity).

Schutzimpfung / Vaccination

Die Bemühungen um verwertbare Methoden der aktiven und passiven Schutzimpfung (Sch.) begannen im Jahre 1910 kurz nach den ersten erfolgreichen Übertragungen des Virus auf Affen. Die Entwicklungstendenzen auf diesem Gebiet habe ich in der Einführung ausführlicher analysiert (s. S. 17ff., Abb. 7–9). Den sehr umfangreichen Stoff dieses Hauptstichwortes habe ich in die beiden großen Gruppen über die aktive und die passive Impfung gegliedert; nur zwei kleinere Themengruppen über die Immunisierungsverfahren, bei denen Prinzipien der aktiven und passiven Sch. kombiniert wurden, und über den Kostenaufwand der Sch. sind gesondert aufgeführt.

Die Veröffentlichungen über die *aktive Impfung* brachten zunächst um 1910 Ergebnisse aus Tierversuchen; später wurde über tierexperimentelle Immunisierungsergebnisse jeweils vor der Anwendung von neuen Impfstoffen am Menschen berichtet (vgl. S. 18, Abb. 7 und Abschnitt über «Tierversuche»). Unter dem Stichwort «Inaktivierte Impfstoffe» sind alle Arbeiten zusammengefaßt, bei denen Impfstoffe aus nicht mehr vermehrungsfähigem, durch chemische, physikalische oder immunologische Verfahren inaktiviertem Virus parenteral verwendet wurden. Unter «Lebendimpfstoffe» habe ich alle Veröffentlichungen gebracht, in denen über eine aktive Immunisierung mit noch vermehrungsfähigem Virus berichtet wird, das durch chemische Methoden in der Virulenz abgeschwächt sein sollte oder das durch geeignete Wirtspassage seiner Neuropathogenität für den Menschen beraubt wurde oder das in der Natur schon mit einer sehr niedrigen Pathogenität gefunden wurde. Der erste beim Menschen angewandte Lebendimpfstoff von KOLMER (1934) hatte eine zu hohe Restvirulenz, verursachte eine zu große Zahl von manifesten Erkrankungen

mit Lähmungen und mußte deshalb zurückgezogen werden; erst in den letzten drei Jahren stieg die Zahl der Veröffentlichungen über Lebendimpfstoffe so hoch an wie bei keinem anderen Thema der Poliomyelitis-Immunität, nachdem die großen erfolgreichen Feldversuche in vielen Teilen der Erde angelaufen waren. Von diesen drei Hauptthemen der aktiven Sch. sind noch kleinere Gruppen mit speziell interessierenden Themen abgeteilt. Unter dem Stichwort «Allergische Reaktionen» sind nicht nur Mitteilungen speziell über Überempfindlichkeitsreaktionen gegen inaktivierte Vakzinen (Affeneiweiß, Penicillin u. a.) aufgeführt, sondern es sind hier im weiteren Sinne auch Arbeiten über allergische Reaktionen auf eine Wiederzufuhr des Poliomyelitis-Antigens auf natürlichem Wege gesammelt, weil diese für die Grundlagen der Sch. und ihre Schädigungsmöglichkeiten wichtig sind. Unter dem Stichwort «Epidemie-Impfung» wird die Frage behandelt, ob man in den Beginn einer Epidemie hineinimpfen soll oder nicht; das Problem der Provokation einer schweren Verlaufsform bei mit Poliomyelitisvirus inkubierten Personen durch homologe Impfungen wird hier ebenso angesprochen wie die Frage, ob nicht Epidemie-Impfungen infolge organisatorischer Verzögerungen und wegen der bis zur Entstehung des Impfschutzes vergehenden Zeit meist zu spät kommen. Unter «Erfolgsstatistik» sind jene Veröffentlichungen zusammengefaßt, in denen der Erfolg der aktiven Sch. mit epidemiologisch-statistischen Methoden bearbeitet oder in denen die Zuverlässigkeit dieser Methoden diskutiert wurde; der Ort der Erhebungen ist fast allen Zitaten zur schnelleren Orientierung beigefügt. Die Stichworte «Impfplanung» und «Impfschäden» brauchen nicht besonders erläutert zu werden. Unter «Indikation» zur aktiven Sch. ist auch der Begriff «Kontraindikation» mit eingeschlossen; hier sind also nicht nur Veröffentlichungen zitiert, die etwa auf Grund niedriger Antikörperspiegel die Impfung bestimmter Altersklassen für besonders angezeigt halten, sondern es werden auch die Diskussionen darüber gebracht, ob bei bestimmten Krankheiten oder Krankheitsdispositionen eine aktive Sch. kontraindiziert ist. Unter dem Stichwort «Wiederholungsimpfungen» sind nicht alle Arbeiten aufgenommen, in denen routinemäßige, mehrfache Injektionen beschrieben werden, sondern hier habe ich mich auf jene Mitteilungen beschränkt, die ausdrücklich über die Notwendigkeit, Indikation und Wirkungsweise von Wiederholungs-Impfungen berichten.

Die Veröffentlichungen über *passive Impfung* konnten einfacher gegliedert werden. Unter «Allgemeines» sind wieder Arbeiten allgemeinen oder vergleichenden Inhalts, sowie Veröffentlichungen über selten angewendete, spezielle Verfahren zitiert. Die drei Hauptmethoden, die prophylaktische und therapeutische Anwendung von Gammaglobulin, Rekonvaleszentenserum und spezifischen Immunseren (s. S. 19, Abb. 8), sowie die Tierversuche zur passiven Immunisierung sind gesondert aufgeführt. Nur zu dem Stichwort «Rekonvaleszentenserum» ist eine Erläuterung erforderlich, weil dieser Begriff sehr weit gefaßt ist. Hier sind auch alle jene Arbeiten einbezogen worden, die über die Anwendung von Erwachsenenserum, Elternblut, Plasma, Bluttransfusion und ähnliches berichten, sofern der antikörperhaltige Anteil der Substanz als wirksames Prinzip gemeint ist.

s. a. Antikörper, Booster-Effekt.
Antikörper, nach Impfung.
Immunität, nach Schutzimpfung.
Impfmethoden.

Impfstoffe.
Provokation, homologe Impfungen.
Serumprophylaxe und -therapie.
Tierversuche, Immunisierung.
Übersichtsarbeiten, Schutzimpfung.
Vakzinetherapie.

Efforts to develop useful methods of active and passive vaccination (Va.) were started in 1910, shortly after the first successful transmissions of the virus to monkeys. A more detailed analysis of developmental trends in this area was presented in the introduction (see page 35, fig. 7–9). The great mass of material on this main title has been divided into the two great groups of active and passive vaccination; two small separate groups are presented, one on methods of immunization combining the principles of active and passive Va., and one on the cost of Va.
In 1910, the first publications on *active vaccination* presented results obtained in animal experiments; later, immunization results of animal experiments were always reported before the use of new vaccines in man (cf. page 18, fig. 7, and section «animal experiments»). Under the title «inactivated vaccines», all papers were collected which concerned the parenteral use of vaccines from viruses no longer capable of multiplication, inactivated by chemical, physical or immunological methods. Under «live vaccines» I collected all publications reporting on active immunization with virus still capable of multiplication, its virulence attenuated by chemical methods or deprived of its neuropathogenicity to man by suitable animal passages or found to have a low pathogenicity in its natural state. The first live vaccine used in man – that introduced by KOLMER (1934) – had a too high residual virulence, caused too many manifest illnesses with paralyses and had consequently to be withdrawn; only in the past three years did the number of publications on live vaccines rise to figures higher than those for any other subject concerning poliomyelitis immunity (since completion of the major successful field trials in many parts of the world). From these three main subjects of active Va., I separated smaller groups with subjects of special interest. Under the title «allergic reactions» I collected not only reports on hypersensitivity to inactivated vaccines (monkey protein, penicillin, etc.) but also papers on allergic reactions to further supply of the poliomyelitis antigen via the natural route, because these are of importance for the principles of Va. and its possible injurious effects. Under the title «intraepidemic vaccination», the question is treated as to whether vaccination should or should not be started at the beginning of an epidemic; the problem of provocation of a severe form in subjects incubated with poliomyelitis virus by homologous vaccinations, is discussed and also the question of whether epidemic vaccination is not too late in most cases as a result of delays in organization and the interval until immunization is effected. Under «statistical evaluation of effectiveness», all publications are presented which concern the elaboration of results of active Va. by epidemiological-statistical methods or in which the reliability of these methods is discussed; the location concerned is listed with nearly all references for rapid orientation. The titles «vaccination programme» and «untoward reactions to vaccination» require no elucidation. Under «indication» for active Va., is comprised «contraindication». Here not only are publications quoted that maintain that certain classes with low antibody

titres are specially suitable for vaccination, but there are also discussions of the possible contraindications to active Va. in the case of some diseases or predispositions to disease.
The title «revaccinations» does not cover all papers describing routine multiple injections but I have limited myself particularly to the necessity, indication and mechanism of action of repeated vaccination.
The publications on *passive Va.* could be arranged more simply. Under «general» I collected publications of general or comparative contents and those on special methods seldom used. The three main methods – the prophylactic and therapeutic use of γ-globulin, convalescent serum and specific immune sera (cf. page 19, fig. 8) and the animal experiments on passive immunization – were separatedly arranged. Only the title «convalescent serum» requires elucidation, because this term is used in a very wide sense. It includes all publications reporting on the use of adult serum, parental blood, plasma, blood transfusion, etc. in so far as the antibody-bearing part of the substance is meant to be an active principle.

cf. Animal experiments, immunization
Antibody, booster effect
Antibody, after vaccination
Immunity, after vaccination
Methods of vaccination
Provocation, homologous vaccinations
Reviews, vaccination
Serum prophylaxis and -treatment
Vaccine therapy
Vaccines

Allgemeines / General

5491 (11f); 0165 (37e); 0906 (48e); 5220 (49e); 4026 (51e); 4452 (52e); 5227 (52e); 4473 (53e); 5229 (53f); 5471 (53f); 2626 (54s); 4062 (54e); 4939 (54e); 5029 (54e); 5393 (54d); 4764 (56e).

Aktive Impfung / Active vaccination

Allgemeines / General

0094 (10d); 0095 (10d); 0107 (10e); 0419 (10d); 0421 (10d); 1379 (10d); 3888 (10r); 0359 (11f); 1019 (11d); 1435 (11d); 5254 (12d); 3018 (22f); 3591 (31i); 0435 (32e); 0785 (32e); 1200 (32e); 2026 (33e); 0428 (35e); 0744 (35e); 0747 (35e); 0914 (35e); 1023 (35e); 2280 (35e); 0020 (36e); 0084 (36e); 0426 (36e); 0468 (36e); 0469 (36e); 0752 (36e); 0830 (36e); 0918 (36d); 3270 (36f); 3603 (36e); 4725 (36d); 4778 (36f); 4790 (36d); 0480 (37e); 3592 (37e); 4006 (37e); 3322 (38e); 4886 (40f); 3186 (41e); 3446 (42d); 0372 (47e); 0649 (48e); 0706 (49e); 0929 (49e); 0632 (50e); 0353 (51e); 0290 (52e); 1728 (52e); 1950 (52e); 2892 (52e); 3376 (52e); 1553 (53e); 1556 (53e); 1675 (53e); 1740 (53e); 1750 (53e); 1799 (53e); 1952 (53e); 2461 (53e); 4507 (53e); 4576 (53f); 4721 (53e); 5461 (53e); 0010 (54e); 0013 (54s); 0591 (54e); 1442 (54s); 1467 (54e); 1471 (54e); 1498 (54f); 1561 (54e); 1683 (54e); 1688 (54d); 1706 (54e); 1753 (54e); 1825 (54i); 2615 (54e); 2622 (54e); 2623 (54e); 2630 (54e);

2853 (54f); 3037 (54e); 3078 (54e); 3128 (54e); 3996 (54e); 4022 (54f); 4023 (54e); 4504 (54e); 4515 (54e); 4531 (54f); 4591 (54e); 5037 (54s); 5042 (54s); 5265 (54e); 5286 (54e); 5349 (54e); 0697 (55e); 0700 (55e); 1483 (55e); 1485 (55e); 1495 (55e); 1505 (55f); 1633 (55d); 1656 (55e); 1710 (55e); 1754 (55e); 1761 (55d); 1763 (55d); 1764 (55d); 1779 (55d); 1781 (55d); 1796 (55e); 1800 (55i); 1817 (55i); 1818 (55f); 1846 (55e); 1853 (55e); 1854 (55d); 1856 (55d); 1873 (55f); 1880 (55s); 1889 (55s); 1894 (55e); 1909 (55e); 1920 (55s); 1928 (55s); 2012 (55e); 2036 (55d); 2151 (55h); 2152 (55f); 2153 (55e); 2154 (550); 2155 (55i); 2158 (55f); 2239 (55s); 2242 (55s); 2243 (55s); 2421 (55e); 2539 (55d); 2627 (55s); 2636 (55f); 2643 (55s); 2867 (55d); 2980 (55f); 3076 (55e); 3119 (55f); 3143 (55s); 3952 (55p); 3975 (55e); 4019 (55e); 4065 (55d); 4268 (55e); 4595 (55e); 4607 (55e); 5050 (55i); 5055 (55s); 5056 (55s); 5178 (55f); 5180 (55f); 5232 (55d: 3. internat. Conf. Rome); 5273 (55i); 5283 (55s); 0410 (56e); 0547 (56b); 1819 (56d); 1833 (56e); 1865 (56d); 1877 (56d); 1901 (56e); 1921 (56d); 1997 (56d); 2080 (56e); 2172 (56f); 2183 (56e); 2188 (56s); 2310 (56e: «ideal vaccine»); 2330 (56f); 2403 (56e); 2482 (56i); 2496 (56s); 2695 (56e); 3131 (56f); 4622 (56e); 4624 (56e); 5181 (56d); 5185 (56p); 5394 (56d); 5431 (56d); 5477 (56d); 0115 (57b); 0630 (57e); 0648 (57i); 0995 (57e); 1525 (57e); 1530 (57f); 1971 (57f); 2086 (57d); 2112 (57f); 2184 (57e); 2197 (57e); 2198 (57i); 2200 (57e); 2321 (57f); 2429 (57d); 2416 (57e: 4. internat. Conf. Geneva); 2417 (57r: 4. internat. Conf. Geneva); 2418 (57s: 4. internat. Conf. Geneva); 2419 (57e: 4. internat. Conf. Geneva); 2430 (57f: 4. internat. Conf. Geneva); 2500 (57f); 2504 (57i); 2505 (57t); 2515 (57h); 3382 (57d); 4088 (57i); 4267 (57f); 4476 (57d: 4. internat. Conf. Geneva); 4948 (57h: 4. internat. Conf. Geneva); 5325 (57d); 5476 (57d); 0067 (58d); 0247 (58e: international travel); 0301 (58d); 0302 (58d); 0532 (58f); 0554 (58f); 0606 (58e: SALK-vaccine: public acceptance in USA); 0617 (58f); 0618 (58f: combined antigens); 0620 (58f); 0629 (58d); 0676 (58d); 0677 (58e); 0683 (58e); 0687 (58s: Spain); 1142 (58d); 1234 (58f); 1244 (58i); 1459 (58d: program); 1599 (58e); 1601 (58e); 2115 (58f); 2347 (58d); 2348 (58e); 2410 (58p); 2928 (58i); 4011 (58e); 4937 (58e); 5313 (58i); 5460 (58e); 0432 (59e); 0523 (59e: public acceptance); 0868 (59d); 0994 (59d); 0999 (59d); 1005 (59e); 1054 (59d); 1122 (59f); 1211 (59d); 1224 (59b); 1228 (59i: nonspecifity); 1289 (59f); 1290 (59f); 1661 (59f); 1936 (59f); 1941 (59e: diagnostic); 2132 (59e); 2285 (59r: conference: Moscow); 2848 (59i: VI. europ. Symposium); 5375 (59e: 12th WHO assambly, Geneva); 5403 (59d); 2329 (60d); 2349 (60d); 2611 (60i); 2699 (60d); 2776 (60e: 5th Conf. Copenhagen); 2785 (60f); 2868 (60d: VI. europ. Symposium); 2901 (60f); 2947 (60e); 3033 (60d); 3046 (60e); 3055 (60f); 3062 (60f); 3063 (60e); 3064 (60e); 3098 (60f); 3342 (60d); 3388 (60e); 3419 (60i); 4125 (60d); 4209 (60d); 4255 (60d); 5328 (60f: 5. internat. Conf.); 5331 (60e: 5. internat. Conf.); 5469 (60d); 2834 (61d); 2932 (61d); 3070 (61e); 3151 (61d); 3341 (61d); 3695 (61e); 4181 (61f); 4217 (61e); 4240 (61d); 4599 (61e); 4627 (61d); 4641 (61d: dose and application); 4693 (61i); 4855 (61e); 4857 (61e); 5354 (61e); 5360 (61f: Switzerland); 5466 (61d); 5481 (61f); 5495 (61f).

Allergische Reaktionen / Allergic reactions

3563 (30e: susceptibility); 0005 (31e: monkeys: accelerated febrile reaction: reinoculation); 0457 (31e: monkeys: anaphylactic phenomena: revaccination); 1101 (31e: allergic skin test); 1181 (31e: susceptibility); 2207 (31e: local, specific immunreaction); 5442 (31e: intracutaneous test: convalescent children); 0703 (35e: KOLMER-vaccine: skin reaction); 5074 (47e: allergic encephalomyelitis: monkey); 5075 (47e: allergic encephalomyelitis: monkey); 0034 (50e: monkeys: immunization with virus and adjuvants); 0295 (53e: monkeys: allergic encephalomyelitis); 0022 (55s); 1809 (55e: penicillin); 3108 (55e: allergic constitution); 1492 (56e: penicillin); 1907 (56e: SALK-vaccine); 2166 (56f: SALK-vaccine); 0079 (57d: bronchial asthma of children); 0234 (57f: intradermal injection: sensibilization); 0608 (57e: children: SALK-vaccine); 1975 (57d: SALK-vaccine); 2023 (57e: asthma: protein of monkeys); 2050 (57e: SALK-vaccine: erythema multiforme); 2492 (57e: penicillin); 5388 (57e: SALK-vaccine: monkey protein); 0863 (58e: SALK-vaccine: severe allergic reaction); 1010 (58e: penicillin); 1589 (58e: penicillin); 1596 (58e: penicillin); 1597 (58e: penicillin); 1598 (58e: penicillin); 1704 (58e: penicillin); 2013 (58e: SALK-vaccine: penicillin); 2395 (58i: SALK-vaccine); 2517 (58n: penicillin); 4667 (58e: SALK-vaccine); 0254 (59d: SALK-vaccination: neuroallergic constitution); 0514 (59d: allergic constitution: immunization); 1175 (59e: SALK-vaccine); 1212 (59e: penicillin); 1220 (59e: SALK-vaccine); 1283 (59d: polyradiculitis: SALK-vaccination); 1329 (59d: SALK-vaccine: neurologic complications); 1402 (59d: SALK-vaccine); 1626 (59e: SALK-vaccine); 2290 (59i: reactions after vaccination); 2413 (59i: SALK-vaccine); 2399 (60d: SALK-vaccine: neuroallergic reactions); 2526 (60e: sensitivity reaction to SALK-vaccine); 3171 (60d: allergic death after SALK-vaccine); 3468 (60e: penicillin: SALK-vaccine); 3982 (60s: SALK-vaccine: intradermo-preinoculation); 4070 (60e: SALK-vaccine: allergic reactions); 4694 (61d: SALK-vaccine: neuroallergic complication); 4879 (61d: SALK-vaccine: neuroallergic complication).

Altersabhängigkeit / Dependence of age

1874 (56e); 1879 (56e); 1979 (56e: live vaccination: infants under six month of age); 0387 (57e: live vaccine: newborns and infants under six month); 0548 (57e: live vaccine: newborn and young infants); 0605 (57e: young infants); 0386 (58e); 0521 (58e: live vaccine: young infants); 0619 (58e: multiple antigen); 1152 (58d: duration of maternal antibodies: vaccination); 0361 (59e: SALK-vaccine: repeated vaccination of infants); 0570 (59e: age for primary immunization); 1225 (59e: live vaccine: neonatal period and early infancy); 2357 (60e: Israel); 2375 (60d: antibody-persistence: SALK-vaccine); 2392 (60e: SALK-vaccine: babies: antibody response); 5059 (61d: Cox-vaccine: newborn).

Epidemie-Impfung / Intraepidemic vaccination

0365 (50e); 4385 (51d); 1874 (56e); 1917 (56e: Hawaii 1955); 2101 (56e: Delaware); 2170 (56f); 0309 (57e: DPT-vaccination); 0639

(57e); 0939 (57c); 1207 (57i: Verona); 1586 (57e); 2075 (57e: USA 1956: 2095 (57e: Canada); 2096 (57e: South Africa); 2123 (57e: Chicago 1956); 2127 (57d: Coburg 1957); 0203 (58e: tropical poliomyelitis); 0204 (58e: Hungary); 0249 (58d: Hungary); 0413 (58r); 0491 (58e); 0538 (58e: live vaccine); 0586 (58d); 0610 (58e); 0629 (58d); 0686 (58s: live vaccine); 0852 (58d); 0969 (58d); 1254 (58i); 2324 (58f); 0212 (59e: vaccination program); 0867 (59e: Detroit 1958); 0905 (59e: rapid immunization); 1195 (59e: Singapore: live vaccine); 1226 (59e: Colombia: live vaccine); 1291 (59e: Chicago 1956); 1332 (59r: USSR); 1396 (59d); 1957 (59i); 2260 (59i); 2447 (59d); 4124 (59i); 1689 (60d); 2404 (60d); 2405 (60d); 2409 (60e: Nicaragua: live vaccine); 2439 (60e: with increased amounts of antigen); 2566 (60e: epidemic Iowa 1959); 2879 (60e: Southampton 1958/59); 3394 (60i); 3488 (60r: live vaccine); 4963 (60r: live vaccine: USSR); 3333 (61e: SABIN-vaccine: Singapore); 3487 (61d); 4213 (61d: SALK-vaccine: Duesseldorf); 4345 (61s: Cox-vaccine: Uruguay); 4645 (61e).

Erfolgsstatistik / Statistical evaluation of effectiveness

0076 (36e: BRODIE-vaccine: North Carolina and Virginia); 0078 (36e: KOLMER-vaccine); 3379 (36e: BRODIE-vaccine: field trial in USA); 0839 (55e: Denmark 1955); 1646 (55e); 1705 (55d: USA); 1782 (55e: USA 1954); 1802 (55e: USA/North Carolina); 1807 (55e: USA: FRANCIS-report); 1816 (55e: USA); 1977 (55e: USA 1954); 2600 (55e: FRANCIS-report); 3079 (55e: FRANCIS-report); 4142 (55e); 4588 (55e: FRANCIS-report); 5237 (55e: FRANCIS-report); 1470 (56h: USA 1954: statistical criticism); 1551 (56e: USA); 1570 (56e: USA); 1699 (56d: FRANCIS-report); 1702 (56d: FRANCIS-report); 1826 (56e: Massachusetts 1955); 1862 (56h); 1874 (56e); 1917 (56e: Hawaii 1955); 1953 (56d: USA 1954); 1956 (56e: Canada 1955); 1961 (56e: British Colombia); 2035 (56d: FRANCIS-report); 2093 (56e: Massachusetts 1955); 2099 (56e: New York); 2100 (56d: FRANCIS-report); 2167 (56e: Missouri); 2426 (56d); 2471 (56e: Louisiana); 2637 (56d: FRANCIS-report); 5211 (56e: SALK-vaccine: USA); 5235 (56f: SALK-vaccine); 5275 (56e: SALK-vaccine: Connecticut); 5293 (56s: SALK-vaccine: Puerto Rico); 0639 (57e); 0939 (57e: USA); 0942 (57e: USA); 1114 (57e: age distribution); 1116 (57e: age distribution: Canada 1956); 1447 (57e: USA); 1513 (57d: Switzerland); 1529 (57e: laboratory studies); 1537 (57e: USA); 1586 (57e: USA); 2049 (57e: North Carolina); 2057 (57e: England); 2075 (57e: USA 1956); 2095 (57e: Canada); 2123 (57e: Chicago 1956); 2125 (57e: Canada); 2137 (57e: SALK-vaccine: USA); 2196 (57e: Minnesota); 2315 (57e: Nebraska 1956); 2331 (57e: age distribution: British Colombia); 2431 (57d: Switzerland); 2499 (57f); 2505 (57t); 2506 (57e: United Kingdom); 2545 (57d); 2547 (57d: FRANCIS-report); 2753 (57e); 3013 (57e: FRANCIS-report); 3163 (57e: FRANCIS-report); 5327 (57e: FRANCIS-report); 5422 (57d: SALK-vaccine: USA); 0067 (58d); 0204 (58e: Hungary: SALK-vaccine); 0235 (58e); 0243 (58f: Belgium); 0507 (58d); 0538 (58e: live vaccine: Belgish Congo); 0553 (58s: Mexico); 0581 (58d: Switzerland); 0583 (58e: USA); 0589 (58d: Switzerland); 0610 (58e: USA); 0650 (58e: SALK-vaccine: degree and

duration of virus excretion); 0654 (58e); 0655 (58f: Belgium); 0658 (58e: ČSR); 0659 (58e: Hungary); 0677 (58e); 0686 (58s: Belgish Congo: live vaccine); 0688 (58f: Switzerland); 0691 (58e: Ontario/Canada); 0847 (58e: ČSR 1957); 0852 (58d); 0862 (58u: Hungary 1957); 1197 (58e: Denmark); 1503 (58f: Switzerland); 1540 (58e); 1588 (58e: Ontario); 2121 (58d: Switzerland); 2323 (58e: Minnesota 1955/56); 2420 (58e: Connecticut); 4277 (58e: SALK-vaccine: Israel); 0027 (59d: USA); 0462 (59e: USA); 0663 (59e: Israel); 0835 (59e: Winnipeg); 0867 (59e: Detroit 1958); 0960 (59d); 0964 (59e: Connecticut); 0981 (59d: Switzerland); 0983 (59e: Manitoba 1958); 0987 (59e: USA); 0991 (59e: live vaccine); 0993 (59e: USA 1957); 0997 (59d: Switzerland 1958); 1027 (59d: Germany); 1092 (59e: antibody response); 1133 (59e: Canada 1958); 1136 (59d: Germany 1958); 1147 (59f); 1155 (59f: Belgium 1958); 1156 (59f: France 1958); 1157 (59e: England 1958); 1158 (59e: Hungary 1958); 1159 (59f: Italy 1958); 1160 (59e: Norway 1958); 1161 (59d: Germany 1958); 1165 (59e: USSR: live vaccine); 1166 (59e: Singapore: live vaccine); 1167 (59e: ČSR: live vaccine); 1189 (59d: Steiermark 1958); 1195 (59e: Singapore: live vaccine); 1199 (59e: live vaccine); 1274 (59e: Canada); 1291 (59e: Chicago 1956); 1296 (59e: New Jersey 1958); 1312 (59i); 1323 (59e: Netherlands); 1328 (59e: USA); 1332 (59r: USSR); 1370 (59t: ČSR); 1623 (59b: Roumania); 1637 (59r: Cheliabinsk/USSR); 1937 (59n); 2261 (59f: Canada); 2263 (59e: method of calculation); 2268 (59f: Belgium); 2289 (59s: Buenos Aires); 2292 (59s: Andes/Colombia: live vaccine); 2293 (59s: Managua/Nicaragua: live vaccine); 2362 (59i: Rome); 2391 (59e: USA); 2447 (59d); 2555 (59e: Southern Rhodesia); 3081 (59d: Austria); 3234 (59e: SABIN-vaccine: Esthonian and Lithuanian S. S. R.); 3235 (59e: SABIN-vaccine: ČSR); 4286 (59e: SALK-vaccine: Canada); 5249 (59r: SALK-vaccine: USSR); 1362 (60e: USSR: live vaccination); 1367 (60 d: USSR: live vaccination); 1395 (60e: Washington, D. C.); 2273 (60d: Germany); 2341 (60e); 2342 (60e: Sweden); 2357 (60e: Israel: SALK-vaccine); 2359 (60e: live vaccine); 2363 (60e: Detroit 1958); 2387 (60e: New Jersey); 2397 (60u: Hungary); 2401 (60d: Switzerland: live vaccine); 2409 (60e: Managua/Nicaragua: live vaccine); 2450 (60e: Kenya: live vaccine); 2523 (60f: Belgium); 2524 (60i: Genua); 2559 (60e: USSR: live vaccine); 2566 (60e: epidemic Iowa 1959); 2699 (60d); 2872 (60e: Nairnshire 1958); 2914 (60e: England and Wales 1958); 2945 (60e: Mauritius); 2951 (60d: Canada); 2956 (60e: Philadelphia: live vaccine); 2957 (60d: Basel); 2974 (60e: epidemic Detroit 1958); 2977 (60e: ČSR: SABIN-vaccine); 3023 (60e: England and Wales); 3233 (60e: SALK-vaccine: Alberta); 3387 (60e: Canada); 3431 (60e: Tennessee); 3450 (60e: ČSR); 3974 (60pl: SALK-vaccine: Poland); 3981 (60e: SALK-vaccine: Hungary); 3993 (60d: SALK-vaccine: Germany); 4074 (60u: Hungary); 4075 (60u: SALK-vaccine: Hungary); 4121 (60e: Germany); 4126 (60e: SALK-vaccine: Denmark); 4184 (60u: SALK-vaccine: Hungary 1959); 4196 (60i); 4226 (60r: live vaccine: Moldavian S. S. R.); 4570 (60e: SABIN-vaccine); 4867 (60e: SALK-vaccine: Canada); 4874 (60e: SALK-vaccine: ČSR); 4877 (60e: SALK-vaccine: Israel); 4880 (60e: SALK-vaccine: Norway); 4893 (60e: live vaccine: USSR); 4920 (60e: SABIN-vaccine: Mexico); 4969 (60e: SABIN-vaccine: Netherlands); 5043 (60e: live vaccine: Nicaragua); 5051 (60e: SABIN-vaccine: USSR); 5282 (60e: SABIN-

vaccine: USSR); 5285 (60e: SABIN-vaccine: ČSR); 1850 (61f: Belgium); 2786 (61d: Cox-vaccine: Berlin); 2883 (61e: Cox-vaccine: NE-Switzerland); 3075 (61t: ČSR); 3192 (61e: Seattle-King County); 3333 (61e: SABIN-vaccine: Singapore); 3334 (61e: live vaccine: USSR); 3335 (61d: SALK-vaccine: Hamburg); 3349 (61e: SALK-vaccine: USA: lethality); 3471 (61e: USSR: live vaccine); 4001 (61e: SALK-vaccine: Arkansas 1959); 4002 (61e: SALK-vaccine: Iowa 1959); 4003 (61e: SALK-vaccine: Kansas City and Des Moines 1959); 4063 (61e: Mauritius 1959); 4103 (61d: Europe); 4116 (61d: Germany); 4139 (61d: SALK-vaccine); 4140 (61d); 4145 (61e: SALK-vaccine: Houston area); 4150 (61e: SALK-vaccine: Kansas City 1959); 4191 (61e: N. Y. State 1959: SALK-vaccine); 4203 (61e: SALK-vaccine: Massachusetts 1959); 4213 (61d: Duesseldorf); 4224 (61e: SALK-vaccine: USA); 4236 (61d: SALK-vaccine: Hungary); 4345 (61s: Cox-vaccine: Uruguay); 4360 (61d: SALK-vaccine: Switzerland); 4361 (61e: SALK-vaccine: Canada); 4362 (61e: ČSR); 4363 (61e: live vaccine: USSR); 4626 (61i: live vaccine: USSR); 4633 (61e: North Carolina 1959: SALK-vaccine); 4646 (61f: SALK-vaccine: Belgium); 4647 (61e: SALK-vaccine: Hungary); 4651 (61e: SABIN-vaccine: ČSR); 4655 (61s: live vaccine: Costa Rica); 4662 (61e: KOPROWSKI-vaccine: Congo); 4695 (61e: SALK-vaccine: New Jersey); 4741 (61e: Cox-vaccine: Berlin); 4742 (61d: SABIN-vaccine: Germany); 4745 (61d: SABIN-vaccine: Germany); 4858 (61d: SABIN-vaccine: Germany); 4899 (61e: SALK-vaccine: Rhode Island); 4901 (61e: SALK-vaccine: USA); 4968 (61e: live vaccine: Poland); 4975 (61e: SABIN-vaccine: USSR); 4986 (61i: SALK-vaccine: Brescia); 5314 (61e: COX-vaccine: Switzerland); 5316 (61e: SALK-vaccine: Ireland); 5338 (61e: SALK-vaccine: Connecticut); 5341 (61e: live vaccination); 5359 (61e: SALK-vaccine: England and Wales); 5480 (61pl: Poland); 4738 (62d: SALK-vaccine: Middle Europe).

Impfplanung / Vaccination programme

0428 (35e); 1558 (53e: USA); 0083 (54e: USA and Canada); 1471 (54e: Australia); 1748 (54e: USA); 1752 (54e: USA: participation in field trials); 1614 (55e: USA); 1639 (55e: Canada); 1649 (55e: safety of SALK-vaccine); 1785 (55e: USA 1954); 1788 (55e); 1789 (55d); 1793 (55d); 1801 (55e: USA); 1807 (55e: USA: FRANCIS-report); 1816 (55e: USA); 1908 (55d); 1978 (55e); 1994 (55e: USA); 2468 (55e); 2469 (55p); 2470 (55e: Denmark); 2472 (55f: France); 2539 (55d); 2694 (55e); 3077 (55e: British plans); 3352 (55e: SALK-vaccine: USA); 4606 (55n: SALK-vaccine: Denmark); 4617 (55s: Chile); 5060 (55e: Arkansas); 1455 (56e: Spain); 1466 (56h: Belgium); 1522 (56e); 1652 (56e: England); 1699 (56d); 1702 (56d); 1722 (56e: South Africa); 1878 (56d); 1918 (56d: antibodies); 1931 (56d); 1953 (56d: USA); 1961 (56e: British Colombia); 2061 (56e); 2099 (56e: New York); 2101 (56e: Delaware); 2161 (56e: England); 2163 (56e: South Africa); 2176 (56d: Germany); 2189 (56s: Brazil); 2227 (56e); 2422 (56e); 2444 (56f: Leopoldville/Congo); 2474 (56e); 2477 (56e: USA); 2480 (56e: Denmark); 2481 (56e: United Kingdom); 2485 (56f: Belgium); 2489 (56f: Germany); 2498 (56s: Brazil); 2503 (56s: Mexico); 2549 (56d: Germany); 2708 (56e: distribution in Ohio);

3121 (56f: antibody distribution); 3400 (56e: Manitoba: SALK-vaccine); 4619 (56e); 4754 (56f: Belgium); 5205 (56e: New Zealand); 5410 (56d: SALK-vaccine: Switzerland); 5434 (56d); 0309 (57e); 0548 (57e: SALK-vaccine-induced maternal antibodies: live vaccine in newborns and young infants); 0602 (57i: Italy: age and season); 0943 (57e: existing immunity of population); 1447 (57e: USA); 1448 (57e: South Africa); 1460 (57h: Netherlands); 1472 (57h: SALK-vaccine before tonsillectomy); 1482 (57b: Roumania); 1511 (57h: Netherlands); 1537 (57e: USA); 1543 (57e: USA); 1556 (57e: USA); 1587 (57e: Richland/Wash.); 1944 (57e: USA); 1966 (57d: antibodies in Germany); 2046 (57e: antibodies); 2048 (57e: SALK-vaccine); 2057 (57e: England); 2084 (57d: Germany); 2088 (57i: Italy); 2095 (57e: Canada); 2107 (57e); 2122 (57e: jet injector); 2194 (57e: multiple antigens); 2276 (57e: summer: provocation); 2278 (57e: British vaccine); 2332 (57e: combined approach of live vaccine and SALK-vaccine); 2433 (57d: USA); 2490 (57e: India); 2491 (57f: Belgium); 2493 (57n: Sweden); 2495 (57f: Algeria); 2500 (57f: France); 2502 (57e: South Africa); 2506 (57e: United Kingdom); 2508 (57t: Slovenia); 2510 (57b: Jugoslavia); 2516 (57d: Germany); 2518 (57f: Switzerland); 2545 (57d); 3163 (57e: USA: FRANCIS-report); 4278 (57e: India); 4280 (57s: Spain); 4281 (57s: Brazil); 4947 (57d: Roumania); 5294 (57e: South Africa); 5405 (57d: Germany: SALK-vaccine); 5414 (57e: SALK-vaccine: New Zealand); 5415 (57d); 5427 (57d); 5435 (57d: Germany); 0067 (58d); 0201 (58s: SALK-vaccination in pregnancy: live vaccination in neonatal period and early infancy); 0247 (58e: international travel); 0249 (58d: Hungary); 0313 (58d: Germany/Niedersachsen); 0394 (58e: USA); 0491 (58e: WHO); 0584 (58d: Germany); 0585 (58d: Germany); 0586 (58d: Germany); 0587 (58f); 0606 (58e: public's acceptance of SALK-vaccine: USA); 0615 (58e); 0616 (58h: Netherlands); 0620 (58f: propagandation: France); 0641 (58f); 0642 (58e); 0655 (58f: Belgium); 0656 (58f: Luxemburg); 0657 (58f: Switzerland); 0659 (58e: Hungary); 0680 (58f: France: antibody distribution); 0685 (58f: Belgium: antibody distribution); 0687 (58s: Spain); 0689 (58f: France); 0690 (58e: Germany); 0760 (58e); 0950 (58f: multiple antigen); 1034 (58i); 1127 (58f: SALK-vaccine: 4. injection); 1142 (58d); 1172 (58e: multiple antigens); 1173 (58e); 1174 (58e: Guatemala); 1241 (58i); 1246 (58d: Switzerland); 1247 (58o: Indonesia); 1250 (58h); 1251 (58f); 1254 (58i); 1342 (58e: Salt Lake City); 1385 (58e: Canada); 1459 (58d: Germany); 1519 (58e: multiple antigen); 1535 (58e: England); 1588 (58e: Ontario); 2248 (58d); 2311 (58e: California: reason for nonvaccination); 2520 (58e: Great Britain); 5407 (58d: SALK-vaccine: Germany); 5416 (58e: SALK-vaccine: England); 5426 (58d: combined antigens); 5463 (58d); 0066 (59d: Argentinien); 0112 (59e: England); 0208 (59e); 0209 (59e); 0210 (59e); 0211 (59e); 0212 (59e); 0222 (59e); 0261 (59e: France); 0300 (59d: Germany); 0412 (59d: USA); 0462 (59e: USA); 0523 (59e: public's acceptance: USA); 0561 (59e: England); 0570 (59e); 0600 (59e: combined antigens: Canada); 0965 (59e: SALK-vaccine: 4. injection); 0993 (59e: SALK-vaccine: USA bis 1957); 0994 (59d); 0999 (59d); 1005 (59e); 1027 (59d: Germany); 1028 (59e: pregnant women); 1088 (59e); 1147 (59f); 1162 (59f: multiple

antigens); 1168 (59e: infants under six month); 1198 (59f: Angola); 1223 (59d: multiple antigens); 1242 (59e: Kentucky); 1249 (59f); 1319 (59f: multiple antigens); 1368 (59e: Canada: multiple antigens); 1381 (59f); 1384 (59f); 1390 (59d: Switzerland: 4. injection of SALK- and live vaccination); 1414 (59f); 1420 (59e: participation in SALK-vaccination: USA 1954); 1423 (59e: USA); 1621 (59e: multiple antigen); 1672 (59i: pregnancy); 1957 (59i); 2264 (59f: Lebanon); 2267 (59f: combined antigens); 2282 (59e: British viewpoint); 2293 (59s: live vaccine: newborn infants in hospitals); 2361 (59i: Italy); 2391 (59e: USA); 2398 (59e: quadruple antigen); 2415 (59n: Norway); 2451 (59e: antibody distribution: serological monitoring system); 2530 (59f); 2533 (59d); 2590 (59e); 2772 (59e: San Diego plan); 3056 (59e); 3170 (59e: Congo: live vaccine); 3238 (59e: SABIN-vaccine: Mexico); 4079 (59i: Italy); 4285 (59e: India); 4286 (59e: Canada: combined antigens); 4900 (59e: India); 1176 (60d: multiple antigens); 1177 (60d); 1377 (60d: SALK-vaccine: 4. injection); 1405 (60d: multiple antigens); 1416 (60d); 2273 (60d: Germany); 2274 (60d: live vaccine: Germany); 2341 (60e); 2351 (60d: combined vaccines); 2354 (60r: live vaccine); 2364 (60e: Europeans in the tropics); 2365 (60e: Europeans in the tropics); 2366 (60e: live: killed vaccines); 2371 (60e: live vaccine); 2387 (60e: New Jersey: SALK-vaccine); 2388 (60e: Guatemala: antibody distribution); 2404 (60d); 2405 (60d); 2407 (60e: USA); 2436 (60e: vaccination with the CHAT-strain: Congo); 2556 (60e: tropical areas); 2560 (60s: live vaccine: Central America); 2574 (60i: SALK- and SABIN-vaccination); 2576 (60u: SABIN-vaccine and DPT); 2583 (60e: USA); 2584 (60e: USA); 2612 (60e: live vaccine); 2616 (60e: Indiana law); 2696 (60d: oral immunization: Austria); 2784 (60f); 2912 (60f: Belgium); 2923 (60r); 2943 (60f); 3049 (60f); 3051 (60i); 3057 (60f: Jugoslavia); 3063 (60e); 3152 (60f); 3237 (60e: vaccination status: USA); 3331 (60he: Israel); 3344 (60e: New York: immunization status); 3419 (60i); 3455 (60s: Portugal); 3456 (60e: Hungary); 3466 (60r: tonsillectomy); 3470 (60f); 3972 (60s: Brazil); 3977 (60e: Khartoum); 4192 (60e: South Africa); 4244 (60r: live vaccine); 4578 (60d: live vaccine and DPT-adsorbed vaccine); 4658 (60e: Egypt); 4860 (60s: Guatemala); 4870 (60e: Denmark); 4978 (60f: sanatorium); 5250 (60d: West-Berlin: Cox-vaccine); 5323 (60f); 5348 (60d); 2919 (61d); 2929 (61u); 3035 (61d: USA); 3100 (61d); 3191 (61f: mother and newborn infants); 3249 (61d); 3304 (61d: Switzerland); 3332 (61d: live vaccine: Atlanta/Georgia); 3360 (61e: SABIN-vaccine: Cincinnati); 3372 (61e: USA); 3389 (61e: Canada: live vaccine); 3448 (61e: New York: live vaccine); 3478 (61d: live vaccine); 3496 (61d: Germany); 3497 (61e: SABIN-vaccine: Cincinnati); 3987 (61e: Middlesex); 4103 (61d: Europe); 4104 (61d: live vaccine: Germany); 4115 (61e: South Africa: live vaccine); 4119 (61d: Germany); 4323 (61e); 4344 (61f: Greece); 4358 (61d: Germany); 4597 (61e); 4627 (61d: live vaccine); 4644 (61e: St. Vincent Island/West Indies); 4645 (61e); 4693 (61i); 4695 (61e: New Jersey); 4855 (61e); 4856 (61e: ČSR); 4857 (61e: armed forces in tropical areas); 4892 (61i: SALK-vaccine in the first 6 month of life); 4898 (61e: SALK-vaccination: Germany); 4983 (61e: Middle East); 5151 (61e: immune status); 5340 (61d); 5344 (61d); 5366 (61e: Poland); 5455 (61f); 5067 (62d: live vaccine:

Baden-Wuerttemberg); 5071 (62d: live vaccine: Baden-Wuerttemberg).

Impfschäden / Untoward reactions to vaccination

0457 (31e: monkeys: anaphylactic phenomena); 0744 (35e: KOLMER-vaccine); 0750 (35e: USA); 0076 (36e: BRODIE-vaccine); 0078 (36e: KOLMER-vaccine: negative phase); 0084 (36e: North Carolina 1935); 0086 (36e: KOLMER-vaccine-preparation method); 4096 (36e: KOLMER-vaccine); 5074 (47e: monkey: allergic encephalomyelitis); 5075 (47e: monkey: allergic encephalomyelitis); 0034 (50e: monkeys: encephalomyelitis after adjuvans vaccine); 1508 (51n); 0295 (53e: monkeys: allergic encephalomyelitis); 0118 (54e: warning: BRODIE-, KOLMER- and SALK-vaccine); 1565 (54e: penicillin-allergy); 1591 (54d: infection through injection); 1684 (54d: new type of syringe); 0024 (55e); 0512 (55i: animal experiments: heterologeous vaccinations); 1552 (55e: SALK-vaccine: Rh-sensitivity); 1572 (55e: Cutter-disaster); 1649 (55e); 1772 (55d); 1787 (55e: Cutter-disaster); 1790 (55e); 1807 (55e: FRANCIS-report); 1809 (55e: penicillin allergy); 1856 (55d); 1977 (55e: USA 1954); 2156 (55e: Cutter-disaster); 2467 (55e); 4592 (55e: SCHEELE-report); 0547 (56b); 1492 (56e: penicillin allergy); 1501 (56d: infection through injection); 1570 (56e: USA: Cutter-disaster); 1699 (56d); 1702 (56d: Cutter-disaster); 1857 (56d: Cutter-disaster); 1859 (56d: Cutter-disaster); 1907 (56e: allergy); 1953 (56d: Cutter-disaster); 1956 (56e: Canada 1955); 1997 (56d); 2099 (56e: New York); 2100 (56d: Cutter-disaster); 2159 (56e: Cutter-disaster); 2166 (56f: SALK-vaccine: allergy); 2227 (56e: Cutter-disaster); 2426 (56d); 2474 (56e); 2551 (56d); 3017 (56n: Cutter-disaster); 4097 (56e: SALK-vaccine); 5235 (56f: SALK-vaccine); 5448 (56d: monkey: perivenoese encephalomyelitis); 0511 (57d: Landry paralysis); 0608 (57e: allergic reactions: USA); 0639 (57e); 0939 (57e: USA 1956); 1586 (57e: USA); 1975 (57d); 2023 (57e: allergy against protein of monkey); 2050 (57e: SALK-vaccine: erythema multiforme); 2075 (57e: USA 1956); 2124 (57f: Belgium); 2492 (57e: penicillin); 2506 (57e: British vaccine); 2509 (57d: Germany); 2518 (57f: Switzerland); 5388 (57e: SALK-vaccine: allergy to monkey protein); 5430 (57e: SALK-vaccine: monoarticular arthritis); 0067 (58d); 0205 (58e: menstruation); 0227 (58e: SALK-vaccine with live virus: Idaho 1955); 0228 (58e: SALK-vaccine: Idaho 1956); 0249 (58d: Hungary); 0313 (58d: Germany); 0398 (58e); 0413 (58r: USSR); 0507 (58d: Germany); 0521 (58e: live vaccine); 0549 (58u: tuberculosis); 0550 (58e: electroencephalographic study); 0553 (58s: Mexico); 0583 (58e: USA); 0589 (58d: Switzerland); 0607 (58e: cutaneous eruptions after SALK-vaccine); 0610 (58e); 0655 (58f: Belgium); 0656 (58f: Luxemburg: allergic reactions); 0690 (58e: Germany); 0691 (58e: Canada); 0847 (58e: ČSR 1957); 0863 (58e: severe allergic reaction); 0864 (58e: Idaho 1955); 0890 (58d: Westfalen); 0969 (58d); 1010 (58e: penicillin allergy); 1153 (58e); 1235 (58i: children with heart disease); 1239 (58i); 1276 (58f); 1585 (58e: Cutter-disaster); 1589 (58e: penicillin allergy); 1596 (58e: penicillin allergy); 1597 (58e: SALK-vaccine: allergic reactions); 1598 (58e: penicillin allergy); 1704 (58e: penicillin allergy); 2013 (58e: peni-

cillin allergy); 2324 (58f); 2395 (58i); 2517 (58n: penicillin allergy); 2843 (58d); 2979 (58i); 4667 (58e: SALK-vaccine: allergic reactions); 5428 (58e: SALK-vaccine: nephritis); 0254 (59d: neuroallergic reactions); 0330 (59d: Landry paralysis); 0567 (59e: penicillin allergy); 0662 (59e: Cutter-disaster); 0840 (59e: live vaccine: neurotropism); 1021 (59d: tetravaccine); 1055 (59d: vaccination: incubation period); 1128 (59e: temporary paralysis); 1136 (59d: Germany 1958); 1156 (59f: France); 1161 (59d: Germany); 1175 (59e: temporary paralysis); 1189 (59d: Steiermark); 1194 (59e: penicillin allergy); 1212 (59e: penicillin allergy); 1215 (59d); 1220 (59e); 1229 (59e: live vaccine: spread of virus); 1278 (59e: live vaccine: infants); 1283 (59d: polyradiculitis); 1291 (59e: Chicago epidemic 1956: provocation); 1323 (59e: Netherlands); 1326 (59s: Spain); 1329 (59d: SALK-vaccine: CNS); 1402 (59d: Germany: SALK-vaccination); 1407 (59e: provocation); 1414 (59f); 1626 (59e); 1637 (59r: Cheliabinsk/USSR); 2258 (59i); 2260 (59i); 2290 (59i); 2400 (59f: myalgies); 2413 (59i: allergic manifestations: SALK-vaccine); 2807 (59d: SALK-vaccine: asthma bronchiale); 3153 (59e: SALK-vaccine); 4084 (59s: SALK-vaccine: erythema multiforme); 4970 (59e: SALK-vaccine: Switzerland); 5454 (59d); 1386 (60d); 1408 (60d: provocation: animal experiments); 1689 (60d: provocation); 2399 (60d: SALK-vaccine); 2402 (60d: Switzerland: SALK-vaccine); 2404 (60d: provocation); 2405 (60d: provocation); 2436 (60e: CHAT-strain: Congo); 2457 (60e: monkey viruses); 2526 (60e: sensitivity reaction to SALK-vaccine); 2532 (60d: Cox-vaccination: Berlin); 2909 (60i: acute haemorrhagic glomerulonephritis); 3047 (60d: Cox-vaccine: Berlin); 3094 (60pl: SALK-vaccine); 3171 (60d: death after SALK-vaccine); 3193 (60i: WATERHOUSE-FRIDERICHSEN syndrom); 3240 (60e: SALK-vaccine: meningoencephalomyelitis); 3259 (60e: SALK-vaccine); 3329 (60i: SALK-vaccine); 3396 (60e: SALK-vaccine); 3467 (60pl: SALK-vaccine); 3468 (60e: SALK-vaccine: exfoliative dermatitis); 3479 (60d: SALK-vaccine); 3982 (60s: SALK-vaccine: allergic reaction: intradermopreinoculation); 4070 (60e: SALK-vaccine: allergic reaction); 4082 (60u: SALK-vaccine: neurologic complications); 4195 (60e: SALK-vaccine); 4896 (60e: Cox-vaccine: Berlin); 4985 (60e: Cox-vaccine: teratogenic effects); 5317 (60e: SALK-vaccine: neurological sequelae); 2770 (61d: SALK-vaccine: CNS-damage); 2786 (61d: Cox-vaccine: Berlin); 3019 (61d: Cox-vaccine: Berlin); 4120 (61e: SABIN-vaccine: South Africa); 4149 (61d: SALK-vaccine); 4629 (61e: community spread: Cox-vaccine); 4694 (61d: SALK-vaccine: neuroallergic complication); 4879 (61d: SALK-vaccine: allergy); 5176 (61pl: live vaccine: neuroallergic reaction); 5262 (61d: SABIN-vaccine); 5496 (62d: Cox-vaccine: Berlin).

Inaktivierte Impfstoffe / Inactivated vaccines

0093 (10d); 0109 (10e: heat); 0373 (10f: monkeys); 1062 (10d: heat inactivated virus: monkeys); 0096 (11d: carbol-vaccine); 0101 (18e: formaldehyde and heat); 0590 (18e: monkeys); 4550 (30s: phenol-inactivated vaccine); 0146 (33e: seruminactivated virus); 0145 (34e: seruminactivated virus); 0225 (34e: monkeys); 2855 (34e: BRODIE-vaccine); 4111 (34e: BRODIE-vaccine); 0470 (35e: BRODIE-vaccine);

0723 (35e: BRODIE-vaccine); 0768 (35e: BRODIE-vaccine); 0818 (35e: BRODIE-vaccine); 0913 (35e: BRODIE-vaccine); 3526 (35e: BRODIE-vaccine); 3594 (35e: BRODIE-vaccine); 4719 (35e); 0017 (36e); 0018 (36e: monkeys: Na-ricinoleate vaccine); 0076 (36e: BRODIE-vaccine); 0077 (36e: BRODIE-vaccine); 0085 (36e: immunity); 0426 (36e: BRODIE-vaccine); 0427 (36e: BRODIE-vaccine-antibody response); 0471 (36e: monkeys); 3379 (36e: BRODIE-vaccine); 4096 (36e: BRODIE-vaccine); 0372 (47e: formaldehyde vaccine: animal experiments); 4308 (47e); 1531 (50e: antibody in faeces of vaccinated monkeys); 3437 (50e: uv-irradiated vaccine); 2030 (52e); 3141 (52e); 0012 (53f); 1462 (53s); 1558 (53e: SALK-vaccine); 1670 (53e); 1769 (53e); 3136 (53e); 3188 (53e); 3962 (53e); 3968 (53e); 4489 (53n); 4499 (53e); 0010 (54e); 0011 (54s); 0069 (54e); 0081 (54e); 0083 (54e); 0117 (54e: SALK-vaccine); 0591 (54e); 0854 (54e); 1565 (54e: antibodies); 1748 (54e: USA); 1755 (54e: UV-vaccine); 2459 (54e); 2534 (54d); 2814 (54d); 2893 (54e); 4034 (54n: Sweden); 4530 (54e: antibody formation); 0024 (55e); 0025 (55n); 0697 (55e); 0839 (55e: Denmark 1955); 1505 (55f: French vaccine); 1575 (55e); 1610 (55e); 1614 (55e: USA: distribution of vaccine); 1617 (55e); 1618 (55e: historical development of SALK-vaccine 1953–55); 1619 (55e); 1646 (55e: USA 1954); 1648 (55e); 1705 (55d: USA); 1766 (55d); 1768 (55d); 1771 (55e); 1773 (55d: antibodies); 1775 (55e: antibodies); 1776 (55e); 1782 (55e: USA); 1785 (55e: field trial: USA 1954); 1787 (55e); 1788 (55e); 1789 (55d); 1793 (55d); 1802 (55e); 1807 (55e: FRANCIS-report); 1816 (55e: USA); 1846 (55e); 1861 (55f); 1873 (55f); 1908 (55d); 1977 (55e: USA 1954); 1978 (55e); 1994 (55e); 2082 (55e: Swedish vaccine); 2103 (55e); 2152 (55f); 2155 (55i: USA); 2156 (55e: USA); 2160 (55e: USA); 2164 (55i); 2168 (55s); 2171 (55e); 2226 (55e); 2231 (55f: Canada); 2243 (55s); 2432 (55d); 2470 (55e: Denmark); 2472 (55f: France); 2475 (55e: antibody titer); 2600 (55e: FRANCIS-report); 2635 (55n); 2813 (55d: Behringwerk-vaccine); 2981 (55e: Sweden); 2982 (55e: Denmark); 2983 (55e); 2984 (55e: Germany); 3072 (55e); 3079 (55e: FRANCIS-report); 3114 (55e): 3132 (55i); 3166 (55e); 3350 (55e); 3351 (55e); 3352 (55e: USA); 3967 (55i); 4038 (55e: South African vaccine); 4142 (55e); 4176 (55i: USA 1954); 4588 (55e: FRANCIS-report); 4592 (55e: SCHEELE-report); 4606 (55n: Denmark); 4608 (55s); 4620 (55f: 3. europ. Conf.); 5034 (55e); 5041 (55e: USA); 5060 (55e: distribution: Arkansas); 5061 (55e: Southern Alameda County); 5148 (55f); 5236 (55f: France); 5237 (55e: FRANCIS-report); 5257 (55e: Mississippi); 5261 (55n: FRANCIS-report); 5279 (55s: FRANCIS-report); 5330 (55e); 5395 (55d); 0547 (56b); 1445 (56e: strains of different SALK-vaccines); 1465 (56i); 1470 (56h: USA 1954); 1521 (56e: South Africa-vaccine); 1522 (56e); 1527 (56i: antibody response); 1551 (56e: USA); 1569 (56e); 1570 (56e: USA); 1652 (56e: British vaccine); 1653 (56e); 1667 (56e); 1668 (56e); 1699 (56d); 1702 (56d); 1824 (56d); 1826 (56e: Massachusetts); 1831 (56d); 1851 (56e: antibodies against type 1); 1857 (56d); 1858 (56d: German vaccine); 1859 (56d); 1862 (56h); 1865 (56d); 1874 (56e); 1879 (56e: serologic response of infants and preschool children: SALK-vaccine); 1882 (56e: UV-vaccine: antibodies); 1913 (56d: German vaccine); 1917 (56e: Hawaii 1955); 1921 (56d: pathogenesis);

1927 (56e: antibody); 1931 (56d); 1953 (56d: USA); 1956 (56e: Canada); 1961 (56e); 1965 (56e: Central America); 1996 (56d: antibodies); 2033 (56d); 2053 (56e); 2061 (56e: antibodies: immunity); 2093 (56e: Massachusetts 1955); 2099 (56e: New York); 2100 (56d: FRANCIS-report); 2101 (56e: Delaware); 2135 (56s); 2159 (56e); 2161 (56e: England); 2162 (56e: England); 2163 (56e: South Africa); 2166 (56f); 2167 (56e: Missouri); 2169 (56s); 2170 (56f); 2176 (56d: Germany); 2177 (56e); 2178 (56e); 2182 (56f: Canada); 2227 (56e); 2309 (56u: live vaccination); 2426 (56d); 2441 (56d); 2471 (56e: Louisiana); 2477 (56e); 2480 (56e: Denmark); 2481 (56e: United Kingdom); 2482 (56i); 2489 (56f: Germany); 2501 (56f); 2549 (56d); 2551 (56d); 2637 (56d: FRANCIS-report); 2708 (56e: distribution in Ohio); 2970 (56e); 3017 (56n); 3069 (56d); 3101 (56e: excretion of virus: family contacts); 3115 (56s); 3130 (56s); 3400 (56e: Manitoba); 4025 (56e: Britain SALK-vaccine); 4097 (56e: safety); 4619 (56e); 4621 (56f); 5058 (56e); 5187 (56p); 5211 (56e: USA); 5235 (56f); 5240 (56e: USA); 5242 (56e: USA); 5243 (56e: young infants); 5275 (56e: Connecticut); 5276 (56e: booster dose); 5293 (56s: Puerto Rico); 5396 (56d); 5397 (56d); 5410 (56d: Switzerland); 5411 (56d: Denmark); 5412 (56e: British vaccine); 5423 (56e: reinoculations); 5432 (56d); 5433 (56d); 5434 (56d); 5474 (56d); 0309 (57e); 0310 (57d); 0387 (57e: live vaccine); 0495 (57d); 0510 (57d); 0548 (57e: pregnant women); 0605 (57e: early infancy); 0608 (57e: allergic reactions); 0636 (57s); 0639 (57e); 0640 (57b); 0672 (57f); 0763 (57e: formalin-UV-vaccine); 0857 (57e); 0937 (57e: SALK-vaccine: antibodies); 0939 (57e: SALK-vaccine); 0942 (57e); 0945 (57e: SALK-vaccine: antibodies); 1114 (57e: USA); 1116 (57e: Canada); 1207 (57i: Verona); 1245 (57b); 1447 (57e: USA); 1448 (57e: South Africa); 1460 (57h: Netherlands: vaccination program); 1511 (57h: Netherlands); 1513 (57d: Switzerland); 1537 (57e: USA); 1543 (57e: USA); 1586 (57e: USA); 1587 (57e: Richland/Wash.); 1944 (57e: program); 1945 (57e); 1963 (57d: Belgium); 1972 (57e: British vaccine); 2048 (57e); 2049 (57e: North Carolina); 2052 (57d); 2057 (57e: England); 2058 (57e: natural infections in immunized children); 2060 (57e: FRANCIS-report); 2075 (57e: USA 1956); 2088 (57i: Italy); 2089 (57d); 2095 (57e: Canada); 2096 (57e: South Africa); 2105 (57e); 2117 (57d); 2122 (57e: jet injector); 2123 (57e: Chicago 1956); 2124 (57f: Belgium); 2125 (57e: Canada); 2127 (57d: Coburg); 2137 (57e: USA); 2138 (57e: 4. internat. Conf. Geneva); 2139 (57e: antibody response); 2191 (57e); 2194 (57e: multiple antigens); 2196 (57e: Minnesota); 2277 (57e: American vaccine); 2278 (57e: British vaccine); 2313 (57e); 2315 (57e: Nebraska 1956); 2319 (57e: antibodies); 2331 (57e: British Colombia); 2333 (57d: Bern/Switzerland); 2348 (57e); 2416 (57e: 4. internat. Conf. Geneva); 2417 (57r: 4. internat. Conf. Geneva); 2418 (57s: 4. internat. Conf. Geneva); 2419 (57e: 4. internat. Conf. Geneva); 2430 (57f: 4. internat. Conf. Geneva); 2431 (57d: Switzerland); 2435 (57e: Israel); 2487 (57e: British vaccine); 2493 (57n: Sweden); 2494 (57s); 2495 (57f); 2499 (57f); 2505 (57t); 2506 (57e: United Kingdom); 2509 (57d: Germany); 2512 (57e); 2513 (57e: 3rd dose); 2518 (57f: Switzerland); 2547 (57d: FRANCIS-report); 2753 (57e); 2808 (57e: pregnant women); 3012 (57e); 3013 (57e: FRANCIS-report);

3015 (57e); 3129 (57s); 3163 (57e: FRANCIS-report); 3175 (57d); 3257 (57e); 3377 (57e: infection with live vaccine); 3380 (57e: infection with live vaccine); 3945 (57f); 4264 (57e: England); 4273 (57s: pregnant women); 4944 (57f); 4946 (57e: British vaccine); 4947 (57d: Roumania); 5019 (57d: France); 5192 (57e: severity of paralysis); 5206 (57e); 5212 (57r: USSR); 5294 (57e: South Africa); 5319 (57e); 5327 (57e: FRANCIS-report); 5388 (57e: allergy to monkey protein); 5413 (57d: England); 5414 (57d: New Zealand); 5422 (57d: USA); 0185 (58e: pregnant women); 0191 (58e: SALK-vaccine: immunity); 0201 (58s: pregnant women); 0204 (58e: Hungary); 0205 (58e: menstruation); 0227 (58e: SALK-vaccine with live virus: Idaho); 0228 (58e: SALK-vaccine: children); 0229 (58f: French vaccine: children); 0232 (58f: France); 0243 (58f: Belgium); 0244 (58d: antibody against different types); 0246 (58d: live vaccine); 0249 (58d: Hungary); 0313 (58d: Germany/Niedersachsen); 0384 (58e: antibody response); 0386 (58e: pregnancy and early infancy); 0390 (58d: SALK-vaccine); 0394 (58d: SALK-vaccine); 0398 (58e: neurological symptoms); 0413 (58r: USSR); 0492 (58d); 0494 (58e: South Rhodesia); 0507 (58d: Belgish vaccine/Germany); 0508 (58d: antibody response); 0509 (58d: vaccines of different origin); 0549 (58u: tuberculosis); 0550 (58e: EEG-study); 0553 (58s: Mexico); 0579 (58d: antibody response); 0581 (58d: Switzerland); 0583 (58e: USA); 0584 (58d: Germany); 0585 (58d: Germany); 0586 (58d); 0588 (58e: duration of protection); 0589 (58d: Switzerland); 0603 (58e: British vaccine); 0604 (58e: British vaccine); 0606 (58e: SALK-vaccine: USA: public's acceptance); 0607 (58e: cutaneous eruptions); 0610 (58e: USA); 0616 (58h: Netherlands); 0619 (58e: quadruple antigen); 0635 (58e); 0646 (58e); 0650 (58e: virus excretion); 0651 (58e); 0652 (58e: USA/Montana); 0653 (58f: Switzerland); 0654 (58e: England); 0655 (58f: Belgium); 0656 (58f: Luxemburg); 0657 (58f: Switzerland); 0658 (58e: ČSR); 0659 (58e: Hungary); 0660 (58f: Italy); 0674 (58f); 0677 (58e); 0684 (58e: antibody response: intradermal and oral administration); 0688 (58f: Switzerland); 0689 (58f: France); 0690 (58e: Germany); 0691 (58e: Canada); 0760 (58e); 0842 (58e: ČSR 1957); 0844 (58e: ČSR 1957); 0847 (58e: ČSR 1957); 0848 (58e: ČSR 1957); 0850 (58e: potency test); 0852 (58d); 0858 (58f: Spain); 0860 (58d: Switzerland 1957); 0861 (58i); 0862 (58u: Hungary 1957); 0863 (58e: severe allergic reactions); 0864 (58e: Cutter-disaster: Idaho 1955); 0890 (58d: Westfalen); 0950 (58f: multiple antigens); 0957 (58e); 0990 (58f: Belgish vaccine); 1010 (58e: penicillin allergy); 1034 (58i: combination with live vaccine); 1127 (58f: antibodies); 1143 (58i); 1145 (58f); 1146 (58f); 1148 (58f: antibody response); 1172 (58e: multiple antigens); 1173 (58e); 1197 (58e: Denmark); 1231 (58i: SCHICK-test); 1235 (58i: children with heart disease); 1236 (58f: booster injection); 1238 (58i: number of injections); 1240 (58e); 1241 (58i); 1243 (58e: live vaccine); 1246 (58d: Switzerland); 1247 (580: Indonesia); 1248 (58e: antibody response: infants); 1254 (58i); 1315 (58b: herpes immunity); 1342 (58e: Salt Lake City/USA); 1385 (58e: Canada: program); 1494 (58t: ČSR); 1503 (58f: Switzerland); 1519 (58e: multiple antigens); 1533 (58e); 1534 (58e); 1535 (58e: British vaccine); 1538 (58e: British vaccine); 1540 (58e); 1584 (58e: antibodies); 1588 (58e: Ontario); 1592 (58e); 1935 (58e:

UV-formaldehyde-vaccine); 2248 (58d); 2320 (58e: infections of household contacts); 2322 (58e: jet injection); 2323 (58e: Minnesota 1955/56); 2324 (58f); 2395 (58i); 2420 (58e: Connecticut); 2520 (58e: Great Britain); 2843 (58d: Germany); 3383 (58e); 3465 (58he: Israel); 4086 (58d); 4271 (58d); 4277 (58he: Israel); 4288 (58i); 5406 (58d: Germany); 5407 (58d: Germany); 5408 (58d: Germany); 5409 (58d); 5420 (58e); 5421 (58d); 5424 (58n: intracutaneous: subcutaneous injection); 5425 (58e: infants); 5463 (58e); 0300 (59d: Germany: program); 0330 (59d: Landry paralysis); 0361 (59e: early infancy); 0412 (59d: program: USA); 0430 (59e: antibody response: booster dose); 0431 (59e); 0462 (59e); 0490 (59d: antibodies); 0537 (58e: live vaccine); 0567 (59e); 0568 (59e); 0569 (59e); 0570 (59e: vaccination program); 0572 (59e: France); 0597 (59e); 0644 (59d); 0663 (59e: Israel: severe epidemic after SALK-vaccination); 0835 (59e: Winnipeg); 0853 (59e); 0866 (59e: antibody: virus excretion); 0867 (59e: Detroit 1958); 0905 (59e: rapid immunization); 0960 (59d); 0964 (59e: Connecticut); 0965 (59e: duration of antibody titers); 0981 (59d: Switzerland); 0983 (59e: Manitoba 1958); 0987 (59e: USA); 0989 (59e: multiple antigen); 0993 (59e: USA 1957); 0996 (59e: 4. dose); 0997 (59d: Switzerland 1958); 1007 (59t: ČSR: intracutaneous); 1008 (59e: children: booster dose); 1009 (59e: booster dose); 1021 (59d: tetravaccine); 1026 (59d); 1027 (59d: Germany); 1028 (59e: Western Australia: pregnancy); 1088 (59e: multiple antigens); 1091 (59e); 1092 (59e); 1121 (59f: France); 1122 (59f); 1130 (59e: early infancy); 1132 (59d: safety of combined antigens); 1133 (59e: Canada 1958); 1134 (59d: adsorbed vaccine); 1136 (59d: Germany 1958); 1144 (59e); 1147 (59f); 1155 (59f: Belgium); 1156 (59f: France); 1157 (59e: England); 1158 (59e: Hungary); 1159 (59f: Italy); 1160 (59e: Norway); 1161 (59e: Germany); 1162 (59f: multiple antigens); 1169 (59f); 1170 (59e: 3. dose); 1189 (59d: Steiermark); 1198 (59f: Angola); 1209 (59d); 1211 (59d); 1214 (59e: antibody: age); 1215 (59d); 1216 (59e: intradermal vaccination: antibody response); 1222 (59e: quadruple antigen); 1223 (59d: multiple antigens); 1242 (59e: Kentucky); 1274 (59e: Canada); 1284 (59e: natural immunity); 1285 (59e: natural immunity); 1289 (59f); 1291 (59e: epidemic Chicago 1956); 1296 (59e: New Jersey 1958); 1301 (59f: France); 1302 (59d); 1312 (59i); 1320 (50f: booster injections); 1323 (59e: Netherlands); 1324 (59i: St. Gallen); 1326 (59s: Spain); 1327 (59s: Spain); 1328 (59e: USA); 1329 (59d: complications of CNS); 1330 (59i: Italy); 1331 (59f: Belgium); 1332 (59r: USSR); 1333 (59e: Southampton/England); 1341 (59f: France); 1368 (59e: multiple antigens); 1370 (59t: ČSR); 1371 (59i: intradermal vaccination); 1382 (59f: antibody response); 1383 (59f: antibody response); 1387 (59d: Bulgarien); 1388 (59d: Denmark); 1389 (59d: Spain); 1390 (59d: Switzerland); 1396 (59d: intracutaneous vaccination); 1403 (59d); 1404 (59e: England); 1406 (59i: Greece); 1407 (59e); 1409 (59f); 1414 (59f); 1415 (59f); 1420 (59e: participation: field trials: USA 1954); 1423 (59e: participation: field trials: USA 1958); 1637 (59r: Cheliabinsk/USSR); 1658 (59i: antibodies); 1672 (59i: pregnancy); 1937 (59n); 1940 (59i: pregnancy); 2134 (59e: infection of contacts); 2258 (59i); 2260 (59i); 2261 (59f: Canada); 2268 (59f: Belgium); 2269 (59i: cutaneous reaction); 2289 (59s:

Buenos Aires); 2290 (59i: reactions); 2362 (59i: Rome); 2391 (59e: USA); 2413 (59i: allergic manifestations); 2415 (59n: Norway); 2555 (59e: Southern Rhodesia); 2588 (59d: Vorarlberg 1958); 2590 (59e: immunization program); 2772 (59e: San Diego plan); 2930 (59i: DPT-Polio); 2933 (59i); 3048 (59u: intracutaneous); 3081 (59d: Austria); 3097 (59i: isolation of virus); 4068 (59e); 4084 (59s: erythema multiforme); 4089 (59e: quadruple antigen); 4276 (59e: vaccine dose); 4284 (59e: quadruple antigen); 4286 (59e: Canada); 4287 (59i: quadruple vaccine); 4289 (59e); 4970 (59e: Switzerland); 5249 (59r: USSR); 5256 (59d: 4. injection); 5389 (59d); 5453 (59d); 5467 (59d); 1176 (60d: multiple antigens); 1346 (60d: antibody response); 1352 (60d: Germany); 1377 (60d: antibody response); 1395 (60e: Washington, D. C.); 1397 (60d: quadruple antigen); 1405 (60d: multiple antigen); 1419 (60e); 1990 (60e: 4. dose SALK-vaccine); 1993 (60e: virus dissemination); 2273 (60d: Germany); 2341 (60e); 2342 (60e: Sweden); 2350 (60d: Trivirelon); 2351 (60d: Trivirelon); 2352 (60e: after concentration); 2357 (60e: Israel); 2363 (60e: Detroit 1958); 2375 (60d: antibody-persistence); 2387 (60e: New Jersey); 2392 (60e: antibody response); 2394 (60e: combined antigens); 2396 (60e: gastrointestinal infection); 2397 (60u: Hungary); 2399 (60d: complications); 2402 (60d: Switzerland); 2404 (60d: provocation); 2405 (60d: provocation); 2407 (60e: USA: program); 2439 (60e: increased amounts of antigen); 2523 (60f: Belgium); 2524 (60i: Genua); 2558 (60e: virus excretion); 2566 (60e: epidemic Iowa 1959); 2583 (60e: USA: social position); 2584 (60e: USA: demographic factors); 2587 (60e: persistence of antibody); 2591 (60e: DPT-Polio); 2610 (60d); 2700 (60i); 2773 (60e: high titer virus-suspensions); 2774 (60i: CFT); 2791 (60e: antibody status: four years after); 2802 (60f: antibody response); 2869 (60e: Compligen); 2872 (60e: Nairnshire 1958); 2879 (60e: Southampton 1958/59); 2887 (60e: SALK-vaccine); 2902 (60e); 2914 (60e: England and Wales 1958); 2934 (60i: DPT-Polio); 2937 (60i); 2940 (60i: DPT-Polio); 2943 (60f: DPT-Polio); 2945 (60e: Mauritius); 2948 (60e: DPT-Polio); 2951 (60d: Canada); 2955 (60e: Alaska/Bering Sea); 2957 (60d: Basel); 2959 (60i: skin sensivity to tuberculine); 2960 (60e); 2973 (60e: New Haven/Conn.: antibody levels); 2974 (60e: Detroit and Wayne County 1958); 3023 (60e: England and Wales); 3050 (60f); 3053 (60f); 3058 (60i); 3062 (60f); 3066 (60e: persistence of antibody); 3086 (60i: Rome); 3090 (60f: combined vaccine); 3094 (60pl: complications); 3099 (60d: antibody levels); 3171 (60d: complications); 3196 (60e: newborns); 3198 (60f: ČSR); 3233 (60f: Alberta); 3237 (60e: USA: vaccination status); 3239 (60f: combined vaccination); 3240 (60e: neurological complication); 3242 (60e: Roumania); 3259 (60e: reactions); 3328 (60i: flocculation test); 3329 (60i: reactions); 3331 (60he: Israel); 3344 (60e: New York: immunization status); 3387 (60e: Canada); 3391 (60e: ČSR); 3393 (60i: Italy); 3394 (60i); 3430 (60i: Naples); 3431 (60e: Tennessee); 3450 (60e: ČSR); 3452 (60b: Roumania); 3453 (60r: pertussis-polio-vaccine); 3456 (60e: Hungary); 3467 (60pl); 3468 (60e: exfoliative dermatitis); 3479 (60d: complications); 3974 (60pl: Poland); 3981 (60e: Hungary); 3993 (60d: Germany); 4070 (60e: allergic reactions); 4074 (60u: Hungary); 4075 (60u: Hungary); 4082 (60u: neurologic complications); 4126

(60e: Denmark); 4184 (60u: Hungary 1959); 4189 (60i: tuberculosis); 4196 (60i); 4299 (60e: combined antigens); 4300 (60e: quadruple antigen); 4306 (60f); 4332 (60e); 4575 (60e: live vaccine); 4867 (60e: Canada); 4870 (60e: Denmark); 4874 (60e: ČSR); 4877 (60e: Israel); 4880 (60e: Norway); 4881 (60i: Italy); 4882 (60e: duration of antibody); 4885 (60e: duration of antibody); 4889 (60e: combined vaccines); 4964 (60r); 4966 (60r: DT-Polio-vaccine); 5032 (60e: ČSR); 5317 (60e: neurological sequelae); 5458 (60d); 5479 (60e); 1850 (61f: Belgium); 2561 (61f); 2770 (61d: CNS-damage); 2771 (61d: Trivirelon); 2939 (61e); 2953 (61e: persistence of antibody); 3020 (61d: Quatro-Virelon); 3150 (61i: Rome); 3192 (61e: Seattle-King County); 3335 (61d: Hamburg); 3349 (61e: USA: lethality); 3355 (61e: antibody: North Ireland); 3372 (61e: USA: program); 3386 (61e: incidence of virus); 3483 (61e: neonatal immunization); 3487 (61d); 3499 (61e: spread of virus); 3987 (61e: Middlesex); 3988 (61i: duration of antibody response); 3989 (61d: + SABIN-vaccination); 4001 (61e: Arkansas 1959); 4002 (61e: Iowa 1959); 4003 (61e: Kansas City and Des Moines); 4063 (61e: Mauritius); 4103 (61d: Europe); 4116 (61d: Germany); 4139 (61d); 4140 (61d); 4145 (61e: Houston area); 4149 (61d: postvaccinal encephalitis); 4150 (61d: Kansas City 1959); 4182 (61d: Neunkirchen); 4191 (61e: New York State 1959); 4194 (61f: duration of antibody titer); 4203 (61e: Massachusetts 1959); 4204 (61e: purified and concentrated vaccine); 4213 (61d: Duesseldorf); 4224 (61e: USA); 4225 (61f); 4236 (61e: young infants); 4238 (61d: Hungary); 4241 (61h: combined vaccine); 4257 (61e: antibody: prevalence of virus in pharyngeal secretions); 4260 (61e: spread of virus); 4323 (61e); 4344 (61f: Greece); 4346 (61e: United Kingdom); 4357 (61f: young infants); 4358 (61d: Germany); 4359 (61d: Germany); 4360 (61d: Switzerland); 4361 (61e: Canada); 4362 (61e: ČSR); 4415 (61e: Denmark); 4599 (61e); 4625 (61e: DPTP-vaccine); 4633 (61e: North Carolina 1959); 4635 (61e: purified vaccine); 4640 (61i: revaccination of young infants); 4646 (61f: Belgium); 4647 (61e: Hungary); 4692 (61e); 4694 (61d: neuroallergic complication); 4695 (61e: New Jersey); 4856 (61e: ČSR); 4879 (61d: neuroallergic complication); 4892 (61i: early life); 4894 (61i: Di-toxoid); 4898 (61e: Germany); 4899 (61e: Rhode Island); 4901 (61e: USA); 4902 (61e: cutaneous reaction); 4986 (61i: Brescia); 5123 (61e: Finland); 5150 (61d: pregnancy); 5316 (61e: Ireland); 5338 (61e: Connecticut); 5351 (61d: Trivirelon); 5352 (61e: Netherlands); 5359 (61e: England and Wales); 5362 (61e: Hungary); 5363 (61e: Sweden); 5365 (61e: Finland); 5366 (61e: Poland); 4738 (62d: Middle Europe).

Indikation / Indication

0353 (51e); 1632 (55e: distribution of antibodies); 1908 (55d: contraindications: SALK-vaccine); 2168 (55s: contraindications); 2469 (55p: Portugal); 2472 (55f: France); 2635 (55n); 2984 (55e: basic immunity); 1455 (56e: Spain); 1466 (56h: Belgium); 1892 (56e: tuberculosis of children); 1918 (56d: antibody titer); 2061 (56e); 2073 (56e: Australia and New Zealand); 2098 (56e: Liberia: antibodies); 2189 (56s: Brazil); 2482 (56i: Italy: antibodies); 2498 (56s:

Brazil); 5243 (56f: young infants); 0079 (57d: asthma bronchiale); 0192 (57h); 0309 (57e); 0575 (57f: antibodies of hospital personnel); 0602 (57i: Italy: age and season); 0943 (57e: existing immunity of population); 1336 (57r: USSR: epidemiology and prophylaxis); 1472 (57h: SALK-vaccination before tonsillectomy); 1482 (57b: Roumania); 1487 (57f: Tunis); 1523 (57d: tonsillectomy); 2052 (57d: Germany); 2490 (57e: India: age distribution); 2491 (57f: Belgium: age distribution); 2495 (57f: Algeria); 2508 (57t: Slovenia); 2510 (57b: Jugoslavia); 2519 (57f: diabetic children); 4278 (57e: India); 4280 (57s: Spain); 4281 (57s: Brazil); 0067 (58d); 0203 (58e: epidemic in British Guiana); 0491 (58e: WHO); 0533 (58e: Europeans in the tropics); 0534 (58e: tropics); 0549 (58u: primary tuberculosis of children); 0550 (58e: electroencephalographic study); 0576 (58i); 0584 (58d: Germany); 0585 (58d: Germany); 0587 (58f); 0641 (58f); 0642 (58e: age); 0680 (58f: distribution of antibody); 0685 (58f: Belgium: distribution of antibody); 1004 (58e: live vaccines); 1140 (58i: Naples: distribution of antibody); 1235 (58i: children with heart disease); 1459 (58d: Germany: program); 1874 (58e: contraindications: SALK-vaccine); 2324 (58f: contraindication); 5429 (58e: nephrosis); 0254 (59d: neuroallergic reactions); 0513 (59d: tonsillectomy); 0514 (59d: allergic children); 0985 (59e: uv-inactivated vaccine); 1198 (59f: Angola); 1275 (59i); 1334 (59e: Lebanon); 1335 (59i: Italy: age); 2264 (59f: Lebanon); 2266 (59e: St. Lucia); 2288 (59b: neutralizing antibodies in Bucarest); 2451 (59e: antibody distribution:serological monitoring system); 4900 (59e: India); 5377 (59i: convulsions); 5378 (59i: primary tuberculosis); 2364 (60e: Europeans in the tropics); 2365 (60e: Europeans in the tropics); 2611 (60i); 4896 (60e: contraindications: live vaccine); 2919 (61d); 3019 (61d: live vaccine); 4344 (61f: Greece); 4983 (61e: Middle East); 5150 (61d: pregnancy); 5456 (61d: tonsillectomy); 5071 (62d: live vaccination: Baden-Wuerttemberg).

Lebend-Impfstoffe / Live vaccines

0590 (18e: monkeys: after vaccination with heat inactivated vaccine); 0888 (24e: monkeys); 0887 (29e: monkeys); 3005 (34e: KOLMER-vaccine); 0724 (35e: KOLMER-vaccine); 0725 (35e: KOLMER-vaccine); 0751 (35e: KOLMER-vaccine); 3693 (35e: KOLMER-vaccine); 3878 (35e: KOLMER-vaccine); 3896 (35f: KOLMER-vaccine); 3898 (35e: KOLMER-vaccine); 4106 (35e: KOLMER-vaccine); 4318 (35d: KOLMER-vaccine); 0078 (36e: KOLMER-vaccine); 0086 (36e: KOLMER-vaccine); 0426 (36e: KOLMER-vaccine); 0427 (36e: KOLMER-vaccine: antibody response); 0731 (36e: KOLMER-vaccine); 0754 (36e: warning); 0915 (36e); 4096 (36e: KOLMER-vaccine); 4776 (36f: KOLMER-vaccine); 5334 (37e: KOLMER-vaccine); 3295 (38e: KOLMER-vaccine); 3593 (38b); 0371 (47e: immunization with active virus under autarceologic protection); 3435 (51e); 0119 (52e); 2918 (52e); 4467 (52f: rabbit adapted strain); 0012 (53f); 1462 (53s); 1952 (53e); 1982 (53d); 2041 (53f: rabbit adapted strain); 2631 (53e: TN-strain: KOPROWSKI); 4020 (53s); 4499 (53e); 4519 (53f: rabbit adapted virus); 0010 (54e); 0011 (54s); 0081 (54e); 0117 (54e); 1786 (54e); 2376 (54s); 2460 (54e); 2724 (54e); 2895 (54e); 2896 (54e); 3964 (54e: persistence of

antibodies); 4045 (54e: segregation of avirulent variants); 4585 (54e: chimpanzees); 4696 (54d); 0697 (55e); 0698 (55e); 1778 (55e); 1814 (55e); 1881 (55e); 1924 (55e: antibody response); 2240 (55s); 2257 (55e); 0547 (56b); 0673 (56e); 1653 (56e); 1667 (56e); 1871 (56h: monkeys); 1954 (56e: gammaglobuline); 1962 (56d); 1979 (56e: early infancy); 2047 (56e); 2097 (56e: dose); 2173 (56e: selection of strains); 2180 (56e: antibody and duration of virus excretion); 2309 (56u: after SALK-vaccination); 2482 (56i); 3118 (56s); 5186 (56s); 5241 (56e); 0387 (57e: early infancy: SALK-vaccine); 0531 (57e: early infancy); 0536 (57e); 0548 (57e: newborn after SALK-vaccination of mother); 0605 (57e: early infancy); 0639 (57e); 0648 (57i); 0940 (57e); 0941 (57e); 0942 (57e); 0977 (57f); 0979 (57s: Colombia); 1964 (57e); 2102 (57f); 2138 (57e: congr. in Geneva); 2199 (57f); 2304 (57e: SM type 1); 2305 (57e: SM type 1 and TN type 2); 2317 (57e); 2741 (57e); 3014 (57e: SABIN-vaccine); 3148 (57e); 3368 (57e); 3377 (57e: infection: antibody); 3380 (57e: infection: antibody); 4273 (57s: young children: SALK-vaccinated mothers); 0201 (58s: neonatal period and early infancy: after SALK-vaccination of mother); 0246 (58d); 0356 (58e); 0357 (58e: antibody response); 0521 (58e: early infancy: antibody response); 0532 (58f); 0537 (58e: after vaccination with inactivated vaccine); 0538 (58e: live vaccine: Belgish Congo); 0637 (58h: theoretical basis and selection of strains); 0638 (58h); 0677 (58e); 0686 (58s: Belgish Congo); 1004 (58e: indication: Africa); 1034 (58i: combination with inactivated vaccine); 1145 (58f); 1146 (58f); 1173 (58e); 1243 (58e: SALK-vaccine); 1325 (58s); 1590 (58e); 1593 (58e); 1594 (58e); 1600 (58e); 2334 (58e: SABIN-strains: virulence after passages in human tissue cultures); 3383 (58e); 4248 (58r); 0258 (59e: multiplication of virus); 0262 (59e); 0307 (59e: virulence of excreted strain); 0385 (59e); 0571 (59e: SALK-vaccine); 0743 (59e); 0840 (59e); 0973 (59e: USSR); 0974 (59e: Symposion Muenchen 1959); 0976 (59e: Conf. Washington 1959); 0986 (59e: persistence of antibodies); 0991 (59e); 0992 (59e); 1000 (59d); 1087 (59e: USSR); 1091 (59e); 1093 (59u: Hungary); 1157 (59e: England); 1163 (59e); 1164 (59e); 1165 (59e: USSR); 1166 (59e: Singapore); 1167 (59e: ČSR); 1195 (59e: Singapore); 1199 (59e); 1202 (59e: South Arizona); 1205 (59e: trivalent live vaccine: antibody response); 1209 (59d); 1211 (59d); 1225 (59e: newborns); 1226 (59e: Colombia); 1229 (59e); 1253 (59f); 1278 (59e: early infancy); 1286 (59e: safety); 1313 (59e: antibodies: Cox-vaccine); 1314 (59r); 1322 (59e: SABIN-vaccine, type 3); 1344 (59f); 1350 (59f); 1370 (59t: ČSR); 1391 (59d: Sweden); 1394 (59d: history); 1403 (59d); 1404 (59e); 1422 (59e); 1428 (59d); 1430 (59e); 1431 (59e); 1987 (59e); 2133 (59e); 2134 (59e: spread of virus: contacts); 2270 (59i); 2291 (59e); 2292 (59s: Andes/Colombia); 2293 (59s: Managua/Nicaragua); 2367 (59r); 2368 (59r); 2369 (59r); 2414 (59e: CFT); 2521 (59s: Cuba); 2522 (59s: Cuba); 3082 (59e: Italy); 3157 (59e: spread interference); 3158 (59e: Cox-vaccine); 3159 (59e: pregnant women: Cox-vaccine); 3164 (59e: Sweden: CHAT-strain); 3167 (59e: Netherlands: SABIN-vaccine); 3170 (59e: Leopoldville/Congo); 3172 (59e: Medellin/Colombia); 3174 (59e: Mexico: SABIN-vaccine); 3177 (59e: Poland: CHAT-strain); 3181 (59e: Costa Rica); 3182 (59e: Cox-vaccine: Finland); 3184 (59e: Montevideo/Uruguay); 3205 (59e);

3210 (59e: markers: excreted strains); 3213 (59e: CHAT-strain: familial spread); 3216 (59e: markers and monkey neurovirulence after human passage); 3218 (59e: Cox-vaccine: infants under six month); 3220 (59e: SABIN-vaccine: Mexico City); 3222 (59e: SABIN-vaccine: USSR); 3223 (59e: SABIN-vaccine: USSR); 3226 (59e: SABIN-vaccine: USSR); 3227 (59e: SABIN type 3); 3231 (59e: CHAT-strain: Leopoldville/Congo); 3234 (59e: SABIN-vaccine: Esthonian and Lithuanian S. S. R.); 3235 (59e: SABIN-vaccine: ČSR); 3238 (59e: SABIN-vaccine: Mexico); 4087 (59i); 4251 (59r); 5457 (59s); 1362 (60e: USSR); 1367 (60d: USSR); 1401 (60u: USSR); 1416 (60d); 1419 (60e); 1424 (60e: viraemia: monkeys); 1432 (60e); 1433 (60e: Cox-vaccine); 1984 (60d: Cox-vaccine: Switzerland); 1985 (60d: spread of virus); 1991 (60e: CHAT-strain: Poland); 1995 (60e: CHAT-strain: Congo); 2271 (60d); 2274 (60d: Germany); 2353 (60e: Colombia, Nicaragua, Costa Rica); 2354 (60r: USSR); 2356 (60d); 2358 (60e: trivalent); 2359 (60e); 2360 (60r); 2371 (60e); 2397 (60u: Hungary); 2401 (60d: Switzerland); 2406 (60e: meeting in Moscow, May 1960); 2409 (60e: Managua/Nicaragua); 2436 (60e: CHAT-strain: Congo); 2450 (60e: Kenya); 2486 (60s); 2513 (60e: Mexico: interference); 2525 (60e: excreted virus: neurovirulence); 2532 (60d: Cox-vaccination: Berlin); 2559 (60e: USSR); 2560 (60s: Central America); 2563 (60e: Belgian Congo: CHAT-strain: stability); 2565 (60i); 2571 (60e: SABIN-type 3: contact infections: Southern Louisiana); 2572 (60e: Cox-vaccine: Cuba); 2576 (60u: + DPT); 2578 (60h); 2586 (60e: Cox-vaccine: Miami); 2592 (60e: Cox-vaccine: Florida); 2612 (60e: USA-recommendations); 2696 (60d: program: Austria); 2788 (60e: CHAT-strain: Congo); 2792 (60pl: CHAT-strain: Poland); 2903 (60e: early life: immunologic tolerance); 2915 (60e: neurovirulence); 2922 (60r: d-marker); 2923 (60r); 2947 (60e); 2956 (60e: Philadelphia); 2977 (60e: ČSR); 3022 (60e); 3043 (60e); 3044 (60e); 3045 (60i: interference with enteroviral infections); 3047 (60d: Cox-vaccine: Berlin); 3054 (60i); 3065 (60d: Florida 1960); 3198 (60f: ČSR); 3232 (60e: Cox-vaccine: Colombia and Uruguay); 3243 (60e); 3248 (60e: Cox-vaccine); 3307 (60u); 3308 (60e); 3317 (60t: SABIN-vaccine); 3318 (60t: SABIN-vaccine: ČSR); 3327 (60r: color test: strains from vaccinated children); 3330 (60e); 3337 (60e); 3338 (60e: USSR); 3340 (60e); 3343 (60e: trivalent Cox-vaccine: cloistered community); 3391 (60e: ČSR); 3392 (60e: ČSR: spread of virus); 3450 (60e: ČSR); 3451 (60i: antibody: Cox-vaccine); 3463 (60r); 3469 (60r: Latvian S. S. R.); 3472 (60r); 3480 (60r: antibody response: trivalent vaccine); 3488 (60r: during outbreak); 3490 (60r: type 1); 3983 (60i); 3984 (60f: trivalent Cox-vaccine: antibody production); 3985 (60e: SABIN-vaccine: newborn infants); 3999 (60d: Switzerland); 4074 (60u: Hungary); 4076 (60r); 4121 (60e: Germany); 4173 (60r: dissemination of vaccinal strains); 4192 (60e: South Africa); 4197 (60s: Cox-vaccine: Cuba); 4226 (60r: Moldavian S. S. R.); 4228 (60r); 4230 (60r: second vaccination); 4232 (60r: virus profileration: intestinal tract); 4234 (60r: contact infections); 4235 (60r: USSR); 4237 (60r: Byelorussian S. S. R.); 4239 (60r: pre-school age); 4242 (60r); 4244 (60r); 4253 (60r: Riga); 4255 (60d); 4256 (60r: Latvian S. S. R.); 4258 (60r); 4405 (60e: Philadelphia); 4570 (60e); 4575 (60e); 4578 (60d: + DPT-adsorbed vaccine); 4732 (60e);

4734 (60f: infection with other enteroviruses); 4890 (60e: Latin-America and USA); 4893 (60e: USSR); 4895 (60e); 4896 (60e: Cox-vaccine: Berlin); 4903 (60e: maternal antibodies); 4908 (60e: susceptibility of infants); 4911 (60e: influence of age on susceptibility); 4913 (60e: dose and schedule: antibody response); 4916 (60e: dose and schedule: antibody response); 4920 (60e: SABIN-vaccine: Mexico); 4922 (60e: interference among enteroviruses); 4925 (60e: spread of virus: household contacts); 4927 (60e: spread of virus: household contacts); 4930 (60e: virus stability); 4957 (60e: genetic markers); 4963 (60r: USSR); 4964 (60r: USSR); 4965 (60e: Cox-vaccine: Costa Rica); 4967 (60r: stability of marker after human passage); 4969 (60e: Netherlands); 4974 (60e: spread of virus); 4977 (60e: intrafamilial spread); 4982 (60e: CHAT-strain: Swedish field trial); 4984 (60e: Japan); 4985 (60e: Cox-vaccine: pregnant women and young infants); 4989 (60e: persistence of antibodies); 4990 (60e: trivalent SABIN-vaccine: USSR); 4994(60e: Cox-vaccine: Israel); 4995 (60e: CHAT-strain: neonatal premature infants); 4998 (60e: CHAT-strain: full-term infants); 5001 (60e: SABIN-vaccine: newborn infants); 5004 (60e: SABIN-vaccine: newborn infants); 5006 (60e: Cox-vaccine: Cuba); 5009 (60e: trivalent live vaccine: Minnesota); 5011 (60e: Cox-vaccine: Minnesota: viraemia); 5014 (60e: Cuba); 5018 (60e: SABIN-vaccine: Mexico); 5021 (60e: SABIN-vaccine: USSR); 5026 (60e: Southern Africa); 5032 (60e: ČSR); 5036 (60e: KOPROWSKI-vaccine: Poland); 5040 (60e: Cox-vaccine: Sottunga Island/Finland); 5043 (60e: Nicaragua); 5051 (60e: USSR); 5068 (60e: Dade County); 5077 (60e); 5250 (60d: Cox-vaccine: West-Berlin); 5282 (60e: USSR); 5285 (60e: ČSR); 5288 (60e: Hungary); 5292 (60e: Hungary: enterovirus isolation); 5295 (60e: antibody formation); 5298 (60e: antibody formation); 5301 (60e: virological investigations); 5304 (60e: + BCG); 5307 (60e: + DPT-vaccine); 5348 (60d); 5483 (60e: spread of virus); 0116 (61b: neurovirulence: marker); 2786 (61d: Cox-vaccine: Berlin); 2787 (61s: Philadelphia); 2883 (61d: Cox-vaccine: NE-Switzerland); 2890 (61h: SABIN-vaccine: Netherlands); 2929 (61u: + DPT); 3019 (61d: Cox-vaccine: Berlin); 3075 (61t: ČSR); 3149 (61e); 3191 (61f: Cox-vaccine: newborn infants); 3195 (61e: Cox-vaccine type 3: duration of excretion and interference); 3250 (61d); 3289 (61e); 3302 (61d: ČSR); 3303 (61d: Cox-vaccine in West-Berlin: antibodies and marker); 3304 (61d: Switzerland); 3305 (61d: Switzerland: CHAT-strain); 3332 (61d: Atlanta/Georgia); 3333 (61e: SABIN-vaccine: Singapore); 3334 (61e: USSR); 3336 (61e: Hungary: virus excretion after SABIN-vaccine); 3339 (61e: pathogenicity for monkey: t-marker); 3360 (61e: SABIN-vaccine: Cincinnati); 3372 (61e: USA: program); 3389 (61e: Canada); 3390 (61e); 3448 (61e: New York); 3471 (61e: USSR); 3478 (61d: West-Berlin: Cox-vaccine); 3493 (61e: young infants); 3494 (61d); 3496 (61d: Germany); 3497 (61e: Cincinnati); 3500 (61e: type 3: spread of virus); 3989 (61d: after SALK-vaccination); 4063 (61e: Mauritius 1959); 4080 (61e: SABIN-vaccine: British trial); 4081 (61e); 4103 (61d: Europe); 4104 (61d: Germany); 4112 (61b: ČSR: SABIN-vaccine); 4115 (61e: South Africa); 4116 (61d: Germany); 4117 (61e: Germany); 4119 (61d: Germany); 4120 (61e: South Africa); 4127 (61d: trivalent Cox-vaccine: Berlin 1960); 4140 (61d); 4179

(61d: Cox-vaccine: Berlin 1960); 4180 (61d: SABIN-vaccine: antibody: virus excretion); 4193 (61d: virus excretion and antibody response: newborn and young infants); 4200 (61e: SABIN-vaccine: USSR); 4206 (61e: interference to wild virus); 4216 (61e: viraemia); 4227 (61f: trivalent Cox-vaccine: antibody response); 4233 (61d: SABIN-vaccine: antibody response); 4252 (61e: interference); 4259 (61e: changes in virus strains after human passage); 4260 (61e: virus excretion: previous SALK-vaccination); 4261 (61e: changes after human passage); 4303 (61e: newborns); 4322 (61e: adults: antibody response and virus excretion); 4323 (61e); 4329 (61d: organization); 4345 (61s: Uruguay); 4358 (61d: Germany); 4359 (61d: Germany); 4362 (61e: ČSR); 4363 (61e: USSR); 4598 (61e: USSR); 4599 (61e); 4625 (61e: after DPTP-vaccination); 4626 (61i: USSR); 4627 (61d); 4629 (61e: Cox-vaccine: community spread); 4632 (61e: after acquired immunity); 4639 (61d); 4648 (61e); 4649 (61e: DPT-vaccination); 4650 (61e: KOPROWSKI-vaccine: Switzerland); 4651 (61e: ČSR); 4652 (61e: newborn infants); 4653 (61s: Cox-vaccine: Florida); 4654 (61s: Costa Rica); 4655 (61s: Costa Rica); 4659 (61b: SABIN-vaccine: USSR); 4660 (61e: SABIN-vaccine: Cincinnati); 4661 (61i: Cox-vaccine: Rome); 4662 (61e: CHAT-strain: Congo); 4711 (61o: Turkey); 4731 (61r: + DPT-vaccine); 4736 (61e: trivalent Cox-vaccine); 4740 (61d: trivalent Cox-vaccine: Berlin); 4741 (61d: trivalent Cox-vaccine: Berlin); 4742 (61d: Germany); 4743 (61d: Cox-vaccination: marker); 4744 (61d: SABIN-vaccine: Germany); 4745 (61d: SABIN-vaccine: Germany); 4746 (61d: Cox-vaccine: Berlin); 4747 (61d: neuropathogenicity for monkey); 4748 (61d: Cox-vaccine Berlin); 4856 (61e: ČSR); 4858 (61d: Germany: SABIN-vaccine); 4859 (61u: + DPT-vaccination); 4959 (61f: age: susceptibility); 4968 (61e: Poland); 4973 (61e: marker: human passage); 4975 (61e: USSR); 4976 (61e: neonates); 4987 (61f: trivalent Cox-vaccine); 4988 (61f: trivalent Cox-vaccine); 4992 (61pl: KOPROWSKI-vaccine: Poland); 4993 (61pl: KOPROWSKI-vaccine: Poland); 5059 (61d: Cox-vaccine: newborn); 5078 (61e: eradication); 5122 (61e: new type 3 strain [WM III]: stability); 5150 (61d: pregnancy); 5162 (61e: virus in flies); 5176 (61pl: neuroallergic reaction: Poland); 5247 (61r: USSR); 5253 (61d: antibody formation and virus excretion); 5255 (61e: duration of antibodies); 5258 (61e: newborn); 5262 (61d); 5277 (61e: Hungary: isolation of enterovirus); 5280 (61e: examination of sewage); 5314 (61e: Cox-vaccine: Switzerland); 5340 (61d); 5341 (61d); 5345 (61e: Poland: CHAT-strain: spread of virus); 5355 (61e); 5357 (61e: stability of SABIN-vaccine); 5362 (61e: Hungary); 5363 (61e: Sweden); 5366 (61e: Poland); 5372 (61e: Cox-vaccine); 5451 (61r: newborn period); 5473 (61e); 5480 (61pl: Poland); 5482 (61pl: Poland); 5484 (61e: interference); 5485 (61i: heterotypic reaction); 5486 (61i: antibody response); 5487 (61i: revaccination); 5497 (61s: USSR); 5498 (61e: South Africa); 4875 (62d); 5020 (62d: Cox-vaccine: Berlin 1960: virus excretion and antibody response); 5339 (62d); 5350 (62e); 5496 (62d: Cox-vaccine: Berlin 1960).

Tierversuche / Animal experiments

0425 (09f: monkeys: rabies-vaccination); 0093 (10d: monkeys); 0098 (10f: monkeys); 0106 (10e: monkeys); 0107 (10c); 0109 (10c:

monkeys: heat inactivated vaccine); 0373 (10f: monkeys: inactivated vaccines); 0377 (10d: monkeys); 0419 (10d: monkeys); 0421 (10d: monkeys); 0422 (10d: monkeys); 0467 (10f: monkeys); 1060 (10e); 1062 (10d: monkeys: serovaccine and heat inactivated vaccine); 1380 (10d); 3200 (10e: monkey); 0359 (11f: monkeys: heat inactivated vaccine); 4863 (11e: monkey); 0097 (12d: monkeys); 1255 (12f: monkeys); 0374 (16e: monkeys); 1268 (17e: globoid bodies); 0101 (18e: Rhesus-monkeys: formaldehyde- and heat inactivated vaccine); 0590 (18e: monkeys: heat inactivated vaccine); 1036 (18e: rabbits); 3895 (18e: monkey); 5278 (18e: monkey); 0551 (24f); 0141 (27e: monkey); 4541 (27e: monkey: ricinoleate virus); 0887 (29e: monkeys); 3300 (29f: monkey); 0142 (30e: monkeys and rabbits); 0339 (30e: monkeys: heat inactivated virus); 0447 (30e: monkeys); 0831 (30e: adsorbed vaccines); 1079 (30e: monkeys: intradermal); 1185 (30e: simultaneous immunization); 1265 (30e: horse); 0001 (31e: monkeys: mixtures of virus and convalescent human serum); 0004 (31e: monkeys: aluminumhydroxyde vaccine); 0005 (31e: monkeys: live virus parenteral); 0006 (31e: horse); 0007 (31e: monkeys: mixtures of virus and convalescent human serum); 0408 (31e: monkeys: injection into the spleen); 0457 (31e: monkeys: anaphylactic reaction); 1038 (31e: monkeys: phenol vaccine); 1097 (31e); 1098 (31e); 1353 (31e: horse); 2206 (31e: monkeys: nasal live vaccination); 3247 (31f: horse and monkey); 0015 (32e: monkeys); 0558 (32e: monkeys: virulence of passage virus); 0791 (32e: monkeys); 1261 (32f: monkeys); 0146 (33e: monkeys: mixtures of virus and serum); 0812 (33e: monkeys); 1186 (33e: immune serum); 0145 (34e: monkeys: virus and serum); 0152 (34e: monkeys: active virus); 0200 (34e: refractor animals); 0225 (34e: monkeys); 0741 (34e: monkeys: live virus: hormonal factors); 2008 (34e: horse); 3005 (34e: monkey: KOLMER-vaccine); 3891 (34e: monkey: KOLMER-vaccine); 4111 (34e: BRODIE-vaccine: monkey); 0470 (35e: monkeys); 0704 (35e: KOLMER-vaccine: serological tests); 0723 (35e: BRODIE-vaccine); 0724 (35e: KOLMER-vaccine); 0768 (35e: BRODIE-vaccine); 0815 (35e: monkeys: adsorbed vaccines); 1023 (35e: monkeys); 1085 (35e: sheep); 2744 (35e: monkey); 2856 (35e: monkey: phenolized vaccine); 2857 (35e: monkey: living virus); 4719 (35e: monkey); 4777 (35f: monkey: methylen-blue-light-inactivated vaccine); 0016 (36e: monkeys: mixtures of virus and serum); 0017 (36e: monkeys: formaldehyde vaccine); 0018 (36e: monkeys: Na-ricinoleate vaccine); 0019 (36e: monkeys: aluminumhydroxyde); 0020 (36e: monkeys: antibody: immunity); 0077 (36e: Rhesus-monkeys: antibody response); 0086 (36e: KOLMER-vaccine: monkeys); 0471 (36e: monkeys: inactivated virus); 0731 (36e: KOLMER-vaccine); 0883 (36e: monkeys: antibody response); 0932 (36e); 3270 (36f); 4776 (36f: monkey: KOLMER-vaccine); 0474 (37e: horse); 1043 (37e: monkey: ricinoleate vaccine); 2754 (37e: monkey: intranasal route); 0705 (38e: monkey); 2659 (38e: monkey); 2745 (38e: monkey: intranasal route); 3204 (38e: monkey); 3551 (38e: horse); 2620 (39d: monkeys); 2669 (39e); 2858 (39e: monkey); 0156 (40e: monkeys: immunological differences of virus strains); 0157 (40e: monkeys: active virus: intracutaneous route); 2752 (40e: monkey: intracutaneous route); 2884 (40e: monkey: murine virus); 3286 (42f: mice); 4066 (42f: mice); 0038 (43j:

monkeys: sonic vaccine); 4171 (43e: horse); 3890 (44e: mice: uv-inactivated vaccine); 4571 (45e: Swiss mice); 4574 (45e: mice: uv-inactivated vaccine); 0036 (47e: monkeys: sonic vaccine); 0042 (47e: monkeys: active and inactivated virus); 0043 (47e: monkeys: antibody distribution); 0371 (47e: mice: immunization with active virus under autarceologic protection of estrogenic substances); 0372 (47e: formaldehyde vaccine: mice); 0891 (47e: protection tests); 3155 (47e: cotton rats); 4308 (47e: mice: formolized vaccines); 0032 (48e: mice and cotton rats); 0160 (48e: monkeys: oral immunization: antibody response); 0649 (48e); 0701 (48e: immunization under passive protection of immune mother); 2656 (48e: monkeys); 4310 (48e: rabbit); 4420 (48e: rabbit and mice); 4720 (48e: mice: Col. SK- and THEILER-virus); 0021 (49e: monkeys: active virus); 0073 (49e: monkeys: differentiation of virus types); 0774 (49e: mice: vaccination of mother); 4222 (49e: monkey); 4431 (49e: Syrian hamster); 5070 (49e: chimpanzees); 0029 (50e: chimpanzees); 0034 (50e: monkeys: antibody response: vaccine with adjuvants); 0065 (50e: mice: passive transfer of immunity from actively immunized mothers); 1531 (50e: monkeys: antibodies in faeces); 2619 (50e: monkeys); 4055 (50e: monkey: antibody response); 0046 (51e: monkeys: determination of virus types); 0047 (51e: monkeys: determination of virus types); 0048 (51e: monkeys: determination of virus types); 0052 (51e: monkeys: determination of virus types); 1541 (51e: cotton rats); 1542 (51e: cotton rats); 1580 (51e: monkeys: oral vaccination); 1581 (51e: monkeys: oral vaccination); 1602 (51e: monkeys: passive immunization); 2817 (51e: monkey); 3435 (51e: monkey); 1603 (52e: mice); 2030 (52e: chimpanzees); 2213 (52e: mice: rabies); 2730 (52e: chimpanzees: hamster adapted virus); 2880 (52e: monkey antibodies); 2882 (52e: chimpanzees); 3140 (52e: chimpanzees: duration of immunity); 3141 (52e: monkey); 3367 (52e: monkey); 4460 (52e); 4464 (52e: monkey: uv-irradiated adsorbed vaccine); 4493 (52i: mice: transmission of immunity); 0295 (53e: monkeys: allergic encephalomyelitis); 0297 (53e: monkeys: repeated ingestion of minute amounts of active virus); 1740 (53e); 2632 (53e: monkeys); 2804 (53e: mice: cross immunity: rabies); 4492 (53e: monkey: AK-strain); 2223 (54e: mice); 2246 (54e: chimpanzees); 2247 (54e: chimpanzees: vaccines of marginal antigenic potency); 2718 (54e: rabbit); 2894 (54e); 4045 (54e: monkey: avirulent variants); 4585 (54e: chimpanzees: live vaccine); 1679 (55e: mice protection test); 1767 (55e: mice); 1775 (55e: monkeys); 1797 (55d: adsorbed vaccine); 1805 (55f: donkey); 1881 (55e: chimpanzees: live vaccines); 1905 (55f: monkeys from Central Africa); 2256 (55e: chimpanzees); 1871 (56h: monkeys: live vaccine); 1875 (56e: cotton rat); 4025 (56e: mice and monkeys); 4770 (56d: mice); 5448 (56d: monkey: perivenoese encephalomyelitis); 0634 (57i: rabbits); 1252 (57e: multiple antigens: antibodies); 1520 (57r: rabbits: production of immune serum); 1943 (57e: chimpanzees); 2070 (57e: uv- and heat inactivated vaccine); 2087 (57e: mice: testing of vaccine); 2090 (57e: guinea-pigs: mixed antigens); 2595 (57e: attenuated strain); 0865 (58e: mice: COXSACKIE-virus); 0959 (58e: CFT); 1031 (58d: adsorbed vaccine: guinea-pigs); 3311 (58i: cattle); 0186 (59d: testing of vaccine); 0559 (59e: monkeys: complement-fixing antigen); 0866 (59e: monkeys: antibodies: virus excretion);

1055 (59d: mice: incubation period); 1056 (59d: antigen: antibody response); 1089 (59d: guinea-pigs: testing of vaccine); 1123 (59i: multiple antigens); 1134 (59d: adsorbed vaccines); 1281 (59e: monkeys); 1303 (59e: chicken); 1304 (59f: testing of vaccine); 1378 (59he: antigenicity of SALK-vaccine: guinea-pigs); 1660 (59r: rats); 2910 (59e: Taiwan monkey); 2978 (59d: poliomyelitis suum); 1408 (60d: provocation); 1989 (60e: Cynomolgus monkeys); 2308 (60d: adsorbed vaccine); 2456 (60e: roosters); 2941 (60i: guinea-pigs: skin test); 2944 (60e: monkey: antigenic structure of type 1); 3241 (60f: rabbit); 4187 (60i: cutaneous reactivity); 3020 (61d: Quatro-Virelon); 4897 (61e: monkey: attenuated strains: subcutaneous injection); 5145 (61d: combined antigens); 5493 (61r: production of diagnostic sera); 5499 (52e: guinea-pigs: CF-antibodies).

Wiederholungsimpfungen / Revaccinations

0003 (31e: monkeys); 0457 (31e: monkeys: anaphylactic reactions); 0152 (34e: monkeys); 0069 (54e); 1820 (55e: antibodies after 4. dose of SALK-vaccine); 2103 (55e: SALK-vaccine); 1874 (56e); 1879 (56e: antibodies); 1882 (56e: UV-vaccine: antibody response); 1892 (56e); 5276 (56e: SALK-vaccine); 5423 (56e: SALK-vaccine); 1945 (57e: SALK-vaccine); 2048 (57e: SALK-vaccine); 2094 (57e: 2. injection: SALK-vaccine); 2105 (57e: SALK-vaccine); 2139 (57e: SALK-vaccine: antibody response); 0191 (58e); 0228 (58e: SALK-vaccine: children); 0583 (58e); 0588 (58e); 0603 (58e: British vaccine); 1238 (58i); 1935 (58e: UV-formaldehyde-vaccine: antibody response); 0361 (59e: formaldehyde vaccine: infants); 1008 (59e); 1009 (59e); 1022 (59d); 1162 (59f: multiple antigens); 1170 (59e: 3. dose); 5256 (59d: SALK-vaccine); 1990 (60e: 4. dose: SALK-vaccine); 2513 (60e: live vaccine: interference); 2561 (60f: SALK-vaccine: booster effect); 5487 (61i: SABIN-vaccine).

Passive Impfung / Passive vaccination

Allgemeines / General

0107 (10e: serotherapy); 1379 (10d); 1019 (11d); 4390 (13e); 3792 (15f); 3278 (16e: autotherapy with spinal fluid); 3279 (16e: autotherapy with spinal fluid); 3280 (16e: autotherapy with spinal fluid); 3705 (16e: tetanus antitoxin); 3768 (16e); 3772 (16e); 3820 (16e); 3821 (16s); 1360 (17e); 1708 (17e); 3769 (17e); 3770 (17f); 3771 (17e); 3767 (18e); 3766 (21e); 3794 (21s); 3018 (22f); 3264 (23e); 3764 (24f); 3807 (24f); 3845 (24e); 3763 (26f); 3762 (27f); 3775 (27d); 3385 (28e); 3578 (28i); 3758 (28e); 3759 (28f); 3760 (28e); 3761 (28e); 3774 (28b); 3777 (29e); 1039 (30d: blood of adults and parents); 3723 (30f); 3755 (30f); 3757 (30s); 3798 (30i); 3808 (30f); 3694 (31e); 3749 (31f); 3750 (31e); 3751 (31f); 3752 (31f); 3753 (31f); 3790 (31e); 3805 (31f); 0435 (32e); 1016 (32e: therapy with milk as nonspecific protein); 3743 (32e); 3744 (32e); 4677 (32e); 1015 (33e: prophylaxis with blood of parents); 1018 (33e: blood); 2026 (33e); 3273 (33e); 3739 (33d); 3740 (33d); 3741 (33d); 3776 (33f); 3809 (33f); 3816 (33e); 3829 (33f); 3838 (33e); 4331 (33e);

4674 (33d); 5100 (33d); 5101 (33e); 0153 (34e: storage of serum); 0909 (34e); 3589 (34d: autocerebrospinal fluid treatment); 3732 (34d); 3733 (34i); 3734 (34i); 3735 (34d); 3736 (34i); 0745 (35e); 3729 (35b); 3799 (35e); 4317 (35e); 4320 (35e); 4321 (35d); 0752 (36e); 0830 (36e); 0918 (36d); 3603 (36e); 3819 (36d); 4290 (36f); 4291 (36d); 4723 (36d); 4725 (36d); 2841 (37d); 4006 (37e); 4795 (37i); 4797 (37e); 0168 (38e: prophylaxis); 3204 (38e); 3322 (38e); 4806 (38f); 0804 (39e: blood-CNS-barrier); 2766 (39d); 2769 (39d); 2840 (39d); 3267 (40e); 4886 (40f); 3823 (41b); 3446 (42d); 3881 (42f); 5164 (43f); 0451 (44e); 2898 (45d); 0876 (49e); 0929 (49e); 0632 (50e); 2032 (50e: blood plasma); 3375 (50e: storage of serum at 4° C); 3965 (51e); 0290 (52e); 1950 (52e); 2805 (52d); 3376 (52e); 1553 (53e); 1556 (53e); 1675 (53e); 1740 (53e); 4469 (53e: blood plasma therapy); 4507 (53e); 4511 (53e); 4721 (53e); 5222 (53d: «K 50»); 0013 (54s); 1498 (54f); 2853 (54f); 3037 (54e); 3996 (54e); 4022 (54f); 4023 (54e); 5042 (54s); 0699 (55e); 1483 (55e); 1485 (55e); 1505 (55f); 1633 (55d: Switzerland); 1754 (55e); 1761 (55d); 1800 (55i); 1818 (55f); 1880 (55s); 2239 (55s); 2241 (55s); 2867 (55d); 2980 (55f); 3952 (55p); 4610 (55e); 5050 (55i); 5055 (55s); 5178 (55f); 2496 (56s); 0185 (58e: passive transfer of antibodies from mother to infants); 0386 (58e: passive transfer of antibodies from mother to infants); 0683 (58e); 4011 (48e); 1030 (59d: woman's milk); 1672 (59i: passive transfer of antibodies from mother to infants); 4215 (61d: standardization).

Gammaglobulin / Gamma globuline

0451 (44e); 0286 (45e); 0072 (49e: monkeys: human gammaglobuline); 0871 (49e: prophylaxis); 0632 (50e); 0064 (51e: human gammaglobuline: mice protection test); 0132 (51e: monkeys: tonsillectomy); 1602 (51e: monkeys); 2715 (51e: mice protection test); 0173 (52e: Rhesus-monkeys: therapy and prophylaxis); 0178 (52e); 1642 (52e: mice protection test); 1645 (52e: antibody levels); 1986 (52s); 2004 (52e: monkeys); 2216 (52e: field trial USA); 2217 (52e: field trial USA); 2218 (52e: field trial USA); 2219 (52e); 2703 (52e: monkey); 3942 (52d); 4382 (52e: tonsillectomy); 5223 (52e); 5260 (52s); 0012 (53f); 0206 (53i); 0293 (53e: antibody response); 0406 (53e); 0445 (53e); 1441 (53e); 1449 (53e: tonsillectomy); 1462 (53s); 1463 (53e); 1469 (53d); 1476 (53e); 1507 (53e); 1557 (53e); 1611 (53e: Alabama 1953); 1612 (53e: North Carolina 1953); 1616 (53e: organization); 1669 (53e); 1671 (53e); 1673 (53e: organization); 1674 (53e: organization); 1735 (53e); 1737 (53e); 1738 (53e); 1799 (53e); 2001 (53e: antibody levels); 2003 (53e); 2024 (53e: USA-field trial); 2228 (53e); 2594 (53d); 2604 (53e); 2629 (53s); 2634 (53e); 2641 (53e); 2642 (53e); 2815 (53d); 2816 (53d: antibody titer); 2998 (53e); 3968 (53e); 4020 (53s); 4047 (53e: mice); 4490 (53e: USA); 4491 (53e: USA: plan for allocation); 4495 (53e: New York State plan); 4496 (53e); 4505 (53e); 4508 (53s: Mexico); 4513 (53i: antibodies in Italian gammaglobuline); 4514 (53s); 4556 (53d: Behringwerk-globuline); 4559 (53n: Swedish); 4563 (53s: Mexico); 4576 (53f); 5142 (53e); 5471 (53f); 0010 (54e); 0074 (54e); 0081 (54e); 0591 (54e); 1443 (54h); 1446 (54d); 1452 (54e); 1467 (54e); 1468

(54e); 1498 (54f); 1504 (54e); 1561 (54e); 1562 (54e); 1563 (54e: Illinois); 1688 (54d); 1697 (54d); 1706 (54e); 1741 (54d); 1742 (54d); 1743 (54d); 1746 (54f); 1748 (54e); 1757 (54d); 1774 (54e); 1812 (54e); 1825 (54i); 1942 (54d); 1976 (54e); 1999 (54e); 2275 (54e); 2463 (54e); 2535 (54d); 3038 (54e); 3125 (54h); 3176 (54d); 4030 (54i: antibody titer); 4058 (54e); 4504 (54e); 4515 (54e); 4520 (54h); 4531 (54f); 4532 (54e); 4533 (54e); 4534 (54e); 5027 (54e); 5039 (54e); 5141 (54f); 5173 (54e: field trial USA); 5349 (54e); 5490 (54e); 0699 (55e); 1483 (55e); 1571 (55e); 1577 (55e: antibody levels); 1628 (55e); 1710 (55e); 1779 (55d); 1796 (55e); 1798 (55d); 1804 (55d); 1805 (55f: immune serum of donkey); 1811 (55e: tonsillectomy); 1846 (55e); 1928 (55s); 2241 (55s); 4595 (55e); 4596 (55e: labor infection); 5045 (55n); 5054 (55e); 5232 (55d); 5283 (55s); 5459 (55d); 1849 (56e: antibody response); 1892 (56e: simultaneous vaccination); 1904 (56n); 1954 (56e: live vaccination); 2441 (56d); 2473 (56s); 2482 (56i); 4762 (56d); 5062 (56f: Saguenay region); 5202 (56e); 5203 (56s); 5306 (56i); 0609 (57f: prophylaxis: France); 0636 (57s); 1515 (57s: Argentinien); 2049 (57e: North Carolina); 2510 (57b: Jugoslavia); 5191 (57d); 5210 (57e); 5373 (57e: immune globuline); 0067 (58d); 0355 (58f); 0610 (58e: USA); 0306 (59u); 0644 (59d); 0835 (59e: prophylaxis against contact); 0869 (59d: prophylaxis); 0980 (59e); 1011 (59e); 1193 (59e: antibody levels); 1209 (59d); 2449 (60e: day nursery: virus excretion); 2557 (60r: antibody titer); 2779 (60e: digestive tract: chimpanzees); 3394 (60i); 3430 (60i); 4978 (60f); 5368 (60e: USSR).

Rekonvaleszentenserum / Convalescent serum

0106 (10e: antibody levels); 1256 (11f); 4862 (11e); 3290 (14f); 4392 (14f: intraspinal injection); 4399 (14f: intraspinal injection); 0402 (15f: therapy); 3722 (15s); 4931 (15f); 4932 (15f); 0263 (16e: therapy); 0264 (16e: therapy); 0374 (16e: monkeys); 0375 (16e: therapy); 0376 (16e: therapy); 0546 (16f: therapy); 2142 (16e); 3244 (16f); 3254 (16e); 3274 (16e: normal blood of adults); 3279 (16e); 3370 (16e: subdural); 3842 (16s); 3844 (16e: intraspinal); 0276 (17e); 0316 (17e: therapy); 1361 (17e); 3277 (17e); 0364 (18e: opsonic action); 1358 (18e); 0134 (19e: monkeys); 3288 (19e); 4398 (20e: intraspinal injection); 3299 (22e); 2935 (23d); 3846 (23e); 4372 (23d); 3845 (24e); 0318 (25e: therapy); 0319 (25e: therapy); 0320 (25e: therapy); 3201 (25e); 3802 (25e); 1714 (26e); 3301 (27e: collection and preparation of serum); 3323 (27e); 3324 (27e: collection of serum); 3325 (27e); 3542 (27f: autoblood); 4542 (27e); 4543 (27b); 4997 (27f); 0014 (28f: field trial 1925 in Sweden); 0136 (28e: sera of Rosenow and Pettit); 0323 (28e: therapy); 0729 (28e: therapy); 0798 (28e: therapy); 0799 (28e: therapy); 0800 (28e); 0802 (28e: preservation); 1363 (28e); 1364 (28pl); 2854 (28e); 3284 (28f); 3778 (28e: preparation of serum); 4999 (28f); 0873 (29e: therapy); 0874 (29e: therapy); 0875 (29e: therapy); 1041 (29e); 1071 (29e); 1074 (29e: complications); 1075 (29e: blood); 1077 (29e); 1095 (29e); 1096 (29e); 1266 (29e); 1365 (29e); 1366 (29s); 1417 (29d); 1550 (29d); 3002 (29e); 3007 (29e); 3146 (29e: determination of activity); 4348 (29e); 4349 (29e); 4545 (29e: organization); 4546 (29e); 4547

(29e); 4548 (29e); 0459 (30e); 0776 (30s); 0837 (30e: therapy); 1039 (30d); 1179 (30e); 1180 (30f); 1182 (30s); 1273 (30d); 3635 (30e: preparing of serum); 3700 (30f); 3719 (30e); 3720 (30h); 3721 (30f); 4035 (30e); 4351 (30e); 4352 (30f); 4356 (30h); 4549 (30e); 4551 (30d); 4552 (30e); 0002 (31e: horse immune serum); 0006 (31e: horse immune serum); 0007 (31e: monkeys); 0335 (31e); 0381 (31e); 0739 (31e: potency test); 0778 (31e: therapy); 0779 (31e: therapy); 0782 (31e: citratblood); 0783 (31e: preparation of human immune serum); 0784 (31e: dry storage of serum); 0954 (31t); 1082 (31e); 1083 (31e); 1084 (31e: pregnancy); 1099 (31e); 1100 (31e); 1103 (31e); 1105 (31e); 1106 (31e: blood of adults); 1107 (31h); 1110 (31f); 1124 (31d); 1154 (31e); 1171 (31d); 1201 (31h); 1354 (31e); 1355 (31e); 2225 (31f: blood); 3008 (31e); 3275 (31f); 3543 (31i: blood); 3583 (31e); 3639 (31f); 3640 (31e: depositories); 3717 (31e); 3718 (31i); 3754 (31f); 3780 (31f); 3824 (31h); 4040 (31d); 4163 (31d); 4326 (31e); 4327 (31e); 4347 (31h); 4354 (31f); 4355 (31d); 4554 (31e); 4681 (31f: France: organization); 4683 (31e); 5015 (31f); 5079 (31t); 5080 (31d); 5081 (31d); 0028 (32e); 0148 (32e); 0223 (32e: monkeys); 0325 (32e: therapy); 0449 (32e: therapy); 0545 (32e: therapy); 0786 (32e); 0787 (32e: therapy); 0788 (32e); 0789 (32e: therapy); 0790 (32e: therapy); 0792 (32e: therapy); 0793 (32e: examination of neutralizing effect); 0794 (32e: serum disease); 0819 (32e: specific reaction on streptococcus); 0882 (32e: antibody response); 0953 (32d); 1012 (32e); 1013 (32e); 1014 (32e); 1017 (32e); 1108 (32e); 1109 (32e); 1111 (32e); 1347 (32e); 1348 (32e); 1349 (32e); 3016 (32e); 3637 (32f); 3643 (32e); 3713 (32e); 3714 (32e); 3715 (32e); 3716 (32e); 3724 (32i); 3742 (32i); 3745 (32e); 3746 (32f: blood); 3747 (32e); 3748 (32e); 3781 (32d: procurement); 3817 (32e); 3825 (32e); 3831 (32e: blood); 3836 (32e); 3841 (32f: Canada: organization); 4005 (32d); 4064 (32f: monkey); 4324 (32d); 4325 (32i); 4678 (32d: Germany: organization); 4682 (32d); 4684 (32e); 4687 (32d); 4688 (32d); 5084 (32d); 5320 (32e); 0928 (33e: therapy); 0931 (33e: therapy); 0955 (33e); 0956 (33e: therapy); 1015 (33e); 1018 (33e); 1061 (33d: blood transfusion); 1186 (33e); 3292 (33e); 3527 (33d); 3532 (33d); 3535 (33d: parental blood); 3536 (33f: maternal blood); 3541 (33d); 3570 (33f); 3662 (33d: blood); 3710 (33d); 3711 (33d); 3712 (33d); 3737 (33s); 3738 (33d); 3773 (33u); 3776 (33f); 3791 (33e); 3796 (33f); 3797 (33d); 3828 (33i: blood); 3830 (33e); 3835 (33s); 3850 (33e: and blood); 3854 (33d); 3855 (33d); 3856 (33d); 3869 (33e); 4007 (33d); 4059 (33d); 4069 (33d); 4123 (33d); 4330 (33d); 4669 (33e); 4670 (33d: Germany: organization); 4671 (33d); 4672 (33e); 4673 (33e); 4680 (33d: Germany: organization); 4703 (33u); 5092 (33i); 5093 (33d); 5095 (33d); 5096 (33d); 0153 (34e: potency and changes with storage); 0594 (34e: therapy); 0822 (34e); 0909 (34e: adult blood transfusion); 0935 (34e: therapy); 0936 (34e: therapy); 1187 (34e: blood transfusion); 3104 (34e); 3530 (34d); 3531 (34f: blood transfusion); 3534 (34i); 3538 (34s: blood); 3540 (34f: blood transfusion); 3638 (34n: Denmark); 3706 (34d); 3707 (34f); 3708 (34d); 3709 (34s); 3731 (34f); 3800 (34d); 3801 (34e); 3837 (34e); 3840 (34e); 3852 (34n); 4091 (34d); 4175 (34d); 4313 (34d); 4314 (34e); 4315 (34d); 4698 (34d: Germany: organization); 4699 (34d); 4700 (34e);

4701 (34d); 4702 (34d); 4706 (34f); 4707 (34d); 4708 (34f: France: organization); 4709 (34e); 5105 (34s); 0722 (35e: therapy); 0758 (35e: blood of parents); 0772 (35e); 0773 (35e); 0814 (35e: antibody levels); 0914 (35e); 0916 (35e: therapy); 0917 (35e: therapy); 0919 (35e: therapy); 0920 (35e); 0922 (35e: therapy); 0930 (35e: blood); 1023 (35e: monkeys); 2272 (35e: monkeys); 2280 (35e); 3525 (35f); 3526 (35e); 3529 (35d); 3537 (35i: maternal blood); 3539 (35e: blood); 3665 (35d); 3684 (35f); 3725 (35n); 3730 (35s); 3839 (35d); 3843 (35n: intraspinal); 3866 (35d); 3867 (35f); 4319 (35n); 4714 (35d); 4716 (35f); 4717 (35d); 4775 (35n); 5107 (35e); 0020 (36e); 0463 (36e); 0468 (36e); 0478 (36e); 0824 (36e); 0825 (36e); 0827 (36e: therapy); 0828 (36e: therapy); 0912 (36e); 0915 (36e: blood transfusion); 0921 (36d: therapy); 3528 (36e: transfusion); 3636 (36e: standard serum); 3851 (36d); 3864 (36f); 3865 (36f); 4292 (36d); 4778 (36f); 4779 (36d); 4780 (36d); 4784 (36e); 4785 (36d); 4787 (36d); 4788 (36f: France: organization); 4790 (36d); 5120 (36d); 0162 (37n: therapy); 0252 (37d: therapy); 0483 (37e); 2677 (37d); 2678 (37d); 2679 (37d); 3221 (37d); 3575 (37e); 3592 (37e); 3634 (37d: procuring); 3664 (37e: parents blood); 3728 (37e); 3782 (37d: procurement); 3832 (37e); 3853 (37d); 3862 (37d); 3863 (37d); 4159 (37d); 4296 (37f); 4791 (37e); 4793 (37f: France: organization); 4799 (37t); 5124 (37d); 5125 (37d); 5128 (37f); 5131 (37f); 0168 (38e: therapy); 0169 (38e); 0251 (38d: therapy); 2838 (38d); 2839 (38d); 3580 (38e); 3849 (38e); 4151 (38f); 4152 (38d); 4157 (38f); 4172 (38d); 4800 (38d); 4803 (38f); 4807 (38d); 4808 (38f); 4809 (38f); 5153 (38d); 5392 (38e); 0358 (39e: antibody levels); 2763 (39d); 2769 (39d); 2836 (39d); 3727 (39e); 3803 (39h); 3834 (39e); 4164 (39d); 4165 (39d); 4166 (39d); 4814 (39e); 5154 (39d); 5155 (39e: blood-CNS-barrier); 5159 (39d); 5160 (39e: blood-CNS-barrier); 5161 (39s); 5172 (39t); 4130 (40i); 4812 (40d); 4817 (40d); 4818 (40t); 4819 (40t); 4823 (40e); 5169 (40e); 0158 (41e: mice); 3186 (41e); 3641 (41e: center in Chicago); 3726 (41e); 3833 (41e); 3847 (41e); 3860 (41e); 3861 (41e); 4822 (41d); 5168 (41e: protection test); 3512 (42e); 3784 (42e); 3857 (42f); 3858 (42d); 3859 (42e); 4132 (42d); 4265 (42e); 4824 (42d); 0070 (43e: mice protection test); 3783 (43s); 5166 (43d); 5167 (43d: blood and Homoseran); 3533 (44e: large dose of plasma); 0286 (45e); 5137 (45d: quantitative evaluation); 5214 (47d); 4342 (48d); 4833 (48d); 3492 (49d: blood); 4366 (49d: antibody content); 4430 (49d); 4434 (49e: plasma); 5114 (49d: plasma infusion); 5116 (49d); 5174 (49d); 0411 (50e: therapy with plasma of pregnant woman or of adults); 0625 (50e: therapy); 3409 (50d: blood of parents); 3413 (50d: blood of parents); 5110 (50r); 5112 (50d); 4412 (51e: LANSING antibody); 5260 (52s: total blood); 3447 (53d); 3176 (54d); 5196 (57d).

Spezifische Immunseren / Specific immune sera

0104 (10d: serotherapy); 0106 (10e: sheep serum); 0096 (11d: monkeys); 3588 (12e); 4389 (12f); 4395 (12e); 3519 (16e: diphtheria antiserum); 0260 (17e: ROSENOW-serum); 0267 (17e: ROSENOW-serum); 0268 (17e: horse serum: poliomyelitis-streptococcus); 0269 (17e: therapy); 0271 (17e: therapy); 0273 (17e); 0278 (17e: blood-

CNS-barrier); 0280 (17e); 0281 (17e: horse serum); 5267 (17e); 0102 (18f: serotherapy with horse immune serum); 0250 (18e: monkeys: ROSENOW-serum); 0343 (18e: horse immune serum); 0344 (18e: horse immune serum: polio-streptococcus); 0347 (18e: horse: streptococcus); 0348 (18e: ROSENOW-serum); 0366 (18e: NUZUM-horse serum); 0378 (18e); 0397 (18e: NUZUM-horse serum); 0446 (18f: NETTER-serum); 1356 (18e: ROSENOW-serum); 1359 (18e: NUZUM-serum); 3576 (18e: horse serum); 4933 (19e: ROSENOW-serum); 3765 (21f); 3814 (21e: horse serum); 3815 (21e: horse serum); 0438 (22f: PETTIT-serum); 3523 (22f: PETTIT-serum); 3813 (22e: horse serum); 0403 (23f: PETTIT-serum); 0404 (23f: PETTIT-serum); 0405 (23f); 3556 (23f); 0454 (24f: PETTIT-serum); 0551 (24f: PETTIT-serum); 3441 (24e: ROSENOW-serum); 3764 (24f); 3789 (24e: ROSENOW-serum); 5322 (24e: ROSENOW-serum); 0320 (25e: ROSENOW-serum); 0321 (25e: ROSENOW-serum); 0407 (25f: PETTIT-serum); 0493 (25f: PETTIT-serum from mutton); 3914 (25f: PETTIT-serum); 0253 (26f: PETTIT-serum); 3785 (26f); 4373 (26f: horse serum); 1711 (27e: ROSENOW-antistreptococcus serum); 3436 (27f: PETTIT-serum); 3788 (27e: ROSENOW-serum); 4376 (27f); 4543 (27b: PETTIT-serum); 4997 (27f: PETTIT-serum); 0136 (28e: sheep serum: ROSENOW- and PETTIT-sera); 0322 (28e: antistreptococcus-serum); 0801 (28e: ROSENOW-serum); 1364 (28pl); 3284 (28f: PETTIT-serum); 3321 (28f: PETTIT-serum); 4377 (28f); 4380 (28e: intraspinal injection); 5010 (28f: PETTIT-serum); 0439 (29e: concentrated horse immune serum); 1075 (29e: PETTIT-serum); 1266 (29f: PETTIT-serum); 1417 (29d: PETTIT-serum); 1550 (29d: PETTIT-serum); 3002 (29e: antistreptococcus horse serum); 3281 (29f); 3300 (29f: monkey-serum); 5005 (29f: monkey: immune serum); 0154 (30e: monkeys: horse serum); 1073 (30e: ROSENOW-serum); 1094 (30e: PETTIT-serum); 1179 (30e: LILLY-serum); 3688 (30f: PETTIT-serum); 3700 (30f); 3756 (30f: PETTIT-serum); 4352 (30f: PETTIT-serum); 0002 (31e: horse immune serum); 0006 (31e: horse immune serum); 0477 (31e: horse immune serum); 0777 (31e: horse immune serum); 0780 (31e: immune sera from goats and sheep); 0954 (31t: PETTIT-serum); 1097 (31e: animal experiments); 1098 (31e); 1099 (31e); 1353 (31e: horse serum); 1354 (31e); 2225 (31f: PETTIT-serum); 3247 (31f); 3275 (31f: PETTIT-serum); 3554 (31e: ROSENOW-serum); 3690 (31i: PETTIT-serum); 3818 (31e); 4163 (31d: PETTIT-serum); 4354 (31f: PETTIT-serum); 4355 (31d); 5015 (31f: PETTIT-serum); 5080 (31d); 0148 (32e: horse prophylaxis and therapy); 0198 (32e: goats and sheeps); 0449 (32e: therapy); 0786 (32e: horse immune serum: intraspinal application); 0788 (32e); 1012 (32e); 1017 (32e); 1024 (32d: PETTIT-serum); 1262 (32f: chimpanzees); 1348 (32e); 3552 (32f: PETTIT-serum, concentrated); 3724 (32i: PETTIT-serum); 3742 (32i: PETTIT-serum); 4325 (32i); 4676 (32f: PETTIT-serum); 4682 (32d); 4684 (32e); 4685 (32f: PETTIT-serum: intralumbal application); 5082 (32f: PETTIT-serum); 0149 (33e: monkeys: prophylactic and therapeutic value of horse immune serum); 0151 (33e: monkeys: horse serum); 0881 (33e: sheep serum); 1186 (33e); 3292 (33e: ROSENOW-serum); 3535 (33d); 3565 (33f); 3566 (33f); 3596 (33e: horse serum); 3796 (33f: PETTIT-serum); 3804 (33s); 3812 (33e); 4007 (33d: PETTIT-serum); 4671 (33d: PETTIT-serum); 5092 (33i);

5093 (33d); 0153 (34e: potency and changes with storage); 0200 (34e: horse serum); 2008 (34e: horse serum); 3518 (34s: diphtheria antiserum); 3534 (34i); 3701 (34f: plurality of strains); 3707 (34f: PETTIT-serum); 3793 (34e: ROSENOW-serum); 3801 (34e: horse serum); 3810 (34f: PETTIT-serum); 4091 (34d); 4706 (34f); 0722 (35e: therapy); 0925 (35e: animal experiments); 1023 (35e: horse serum: monkeys); 1085 (35e: sheep serum); 2272 (35e: monkeys: immune horse serum); 3555 (35e: sheep serum); 3661 (35e); 3779 (35f: PETTIT-serum); 3787 (35e: ROSENOW-serum); 3811 (35f: PETTIT-serum); 3827 (35e); 3897 (35f: PETTIT-serum); 4716 (35f: PETTIT-serum); 0020 (36e); 0479 (36e: PETTIT-horse serum); 3605 (36e: pathogenesis); 4782 (36f: PETTIT-serum); 5120 (36d); 0474 (37e: horse immune serum); 3877 (37e: ROSENOW-serum); 4297 (37f: PETTIT-serum); 5131 (37f: PETTIT-serum); 3551 (38e: horse serum); 3806 (38f: PETTIT-serum); 3899 (38f); 4157 (38f: PETTIT-serum); 4803 (38f); 4807 (38d); 4808 (38f); 4809 (38f); 5392 (38e: ROSENOW-serum); 0804 (39e: blood-CNS-barrier); 3826 (39e: ROSENOW-serum); 3517 (40i: diphtheria antitoxin); 3786 (40e: ROSENOW-serum); 4130 (40i); 2607 (43e: antistreptococcic serum); 3553 (43e: ROSENOW-serum); 5133 (44e: ROSENOW-serum); 0121 (45e: chimpanzees); 2845 (45e); 3457 (51e: horse serum); 0173 (52e: chimpanzees); 3367 (52e: monkey); 0009 (53e); 2732 (53e: monkey); 1805 (55f: donkey immune serum); 4590 (55i); 0516 (57e: animal experiments); 0331 (58e: animal experiments); 1345 (58e: monkeys: hyperimmune rabbit gammaglobuline); 1011 (59e: monkeys: serotherapy).

Tierversuche / Animal experiments

0098 (10f); 1060 (10e: monkeys); 0096 (11d: monkeys); 4862 (11e); 3822 (15e: monkey); 0376 (16e: monkeys: serotherapy); 0260 (17e: ROSENOW-serum); 0278 (17e: monkeys: blood-CNS-barrier); 0102 (18f: monkeys: horse immune serum); 0250 (18e: monkeys: ROSENOW-serum); 0343 (18e: monkeys: horse immune serum); 0344 (18e: monkeys: antistreptococcal horse serum); 0366 (18e: monkeys: antistreptococcal horse serum); 0378 (18e: blood-CNS-barrier); 0397 (18e: antistreptococcal serum: monkeys); 5278 (18e: monkey); 0134 (19e: monkey); 1037 (20e: monkeys: intranasal infection); 3264 (23e: monkey); 3845 (24e); 3775 (27d); 3002 (29e: monkey); 5005 (29f: monkey); 0154 (30e: monkey: horse serum); 0006 (31e: monkey: horse immune serum); 3247 (31f: monkey); 0198 (32e: monkey: immune sera from sheep and goats); 0223 (32e: monkey: convalescent serum); 1262 (32f: monkeys); 3683 (32e: guinea-pigs); 4064 (32f: monkey); 5085 (32e: guinea-pigs); 0149 (33e: monkeys: serotherapy and -prophylaxis); 0151 (33e: monkeys: horse serum); 0881 (33e: monkeys: sheep immune serum); 3701 (34f: monkey: PETTIT-serum); 1023 (35e: monkeys); 2272 (35e: monkeys); 4320 (35e: monkeys); 0020 (36e); 0821 (36e: mice); 0824 (36e); 0932 (36e); 3204 (38e: monkey); 2669 (39e); 2858 (39e: monkey); 2870 (39e: monkey); 0158 (41e: mice: convalescent serum); 0070 (43e: mice: human serum); 2607 (43e: monkeys: antistreptococcic serum); 0121 (45e: chimpanzees); 0125 (45e: mice); 4309 (47i: cats: con-

valescent serum); 0649 (48e); 0072 (49e: monkeys: gammaglobuline); 0774 (49e: mice: congenital immunity); 0065 (50e: mice: transfer of immunity from actively immunized mothers); 0064 (51e: mice: human serum); 0132 (51e: monkeys: tonsillectomy); 2715 (51e: suckling mice: protection test); 0173 (52e: monkeys: gammaglobuline); 1642 (52e: mice: human gammaglobuline); 2129 (52e: monkeys); 2703 (52e: monkey: gammaglobuline); 4382 (52e: monkey: tonsillectomy); 0009 (53e: chimpanzees: specific hyperimmune serum); 1449 (53e: monkeys: tonsillectomy: gammaglobuline); 2732 (53e: monkey); 3032 (53e: monkey: blood plasma-therapy); 4047 (53e: mice: gammaglobuline); 4469 (53e: monkey: plasma); 0699 (55e); 0516 (57e: mice: monkey serum); 0331 (58e: monkeys: rabbit immune serum); 1011 (59e: monkeys); 2779 (60e: chimpanzees: gammaglobuline); 2971 (60e: chimpanzees: virus excretion).

Kombinierte Verfahren / Combined methods

0095 (10d: active virus and immune serum); 1185 (30e: monkeys: simultaneous vaccination); 0007 (31e: monkeys: mixtures of active virus and convalescent serum); 0015 (32e: monkeys: mixtures of active virus and convalescent serum); 0791 (32e); 0701 (48e: mice: immunization with active virus under passive protection from immune mother); 1602 (51e: monkeys); 0698 (55e: live vaccine and convalescent serum); 1817 (55i); 1892 (56e: SALK-vaccine and gammaglobuline); 1954 (56e: live vaccine and gammaglobuline); 3963 (56e); 0548 (57e: SALK-vaccine-induced maternal antibodies in newborns: live vaccination); 0201 (58s: SALK-vaccine-induced maternal antibodies in newborns: live vaccination); 0537 (58e: live vaccine after SALK-vaccine); 4578 (60d: live vaccine and DPT-adsorbed vaccine); 5304 (60e: live vaccine and BCG); 5307 (60e: live vaccine and DPT); 5355 (61e: SABIN-vaccine: BCG and DPT).

Kosten / Costs

0074 (54e: gammaglobuline prophylaxis: field trial USA 1954); 1801 (55e: polio vaccine assistance act of 1955); 1816 (55e: SALK-vaccine: USA); 0066 (59d: Argentinien).

Serologie / Serology

Unter diesem Hauptstichwort habe ich einige Themen recht heterogenen Inhaltes zusammengefaßt, sofern sie mir für die Grundlagen und die praktische Anwendung der Serologie (S.) in der Immunitätsforschung der Poliomyelitis wichtig erschienen. Zu den grundlegenden Phänomenen gehört die «Antigen-Antikörper-Reaktion», ihre Kinetik und ihre serologische Bearbeitung mit modernen Methoden (Hämagglutination, fluoreszierende Antikörper u. ä.). Unter «Antigenität» sind nur diejenigen Publikationen genannt, die sich speziell und methodisch auf den serologischen Nachweis des Antigens und seiner Komponenten beziehen. Einige klinische Arbeiten sind unter dem Stichwort «Blutbild» zitiert, soweit

ihre Befunde als Ausdruck immunologischer Vorgänge interpretiert werden. Nachdem für einige Erreger epidemischer Krankheiten Antigengemeinschaften zu den Blutgruppen des Menschen nachgewiesen worden sind, interessiert auch die Beziehung der Poliomyelitis zu den Blutgruppen im immunbiologischen Sinne; deshalb habe ich unter dem Stichwort «Blutgruppen» Berichte über die Blutgruppenverteilung bei Poliomyelitiserkrankungen gesammelt. Es folgen die Arbeiten, die sich mit der speziellen Serologie der «Differenzierung der Typen» des Poliomyelitisvirus beschäftigen. Nur selten sind die Verschiebungen in der «Eiweißverteilung im Serum» während und nach der Infektion mit Poliomyelitisvirus experimentell untersucht worden. Der Wert der Serologie für die «Laboratoriumsdiagnostik» ist am Schluß dieses Hauptstichwortes gebracht; hier habe ich die Publikationen zitiert, die den praktischen Wert der im diagnostischen Laboratorium erhobenen serologischen Befunde behandeln.

s. a. Antikörper.
Antigenität.
Schutzimpfung, aktive Impfung, allergische Reaktionen.
Serologische Methodik.

Under this title I have collected subjects of truly heterogeneous content in so far as they seemed important for the principles and practical application of serology (S.) in the investigation of immunity to poliomyelitis. One of the basic phenomena is the antigen-antibody-reaction, its kinetics and serological study with modern methods (haemagglutination, fluorescent antibodies, etc.). Under «antigenicity» I mentioned only those publications which especially and methodically concern themselves with the serological demonstration of the antigen and its components. Some clinical papers are referred to under «blood count», in so far as their findings are interpreted as a manifestation of immunological processes. Because for some pathogens of epidemic diseases relations between antigens and human blood groups have been demonstrated, the correlation between poliomyelitis and blood groups is also interesting in the immune-biological sense; under the title «blood groups», therefore, reports on the blood groups distribution in poliomyelitis patients were collected. Then come the publications concerned with the special serology of the «differentiation of types» of the poliomyelitis virus. Changes in the «distribution of serum proteins» during and after infection with poliomyelitis virus have seldom been experimentally investigated. To conclude this section the value of serology for «laboratory diagnosis» is presented; here I have collected publications discussing the practical value of serological findings obtained in the diagnostic laboratory.

cf. Antibody
Antigenicity
Serological methods
Vaccination, active vaccination, allergic reactions

Allgemeines / General

0270 (17e: micrococci: immune reactions in rabbits); 0277 (17e: SCHICK-test); 0278 (17e: blood-CNS-barrier); 0364 (18e: opsonic

action on streptococci); 0137 (28e: streptococci); 0175 (30e: protective substances in immune serum); 0756 (35e: purification of neutralizing fraction: convalescent serum); 0933 (35e); 0452 (37e: SCHICK-test); 0667 (40e: absorption and elution of antibody with alumina gel); 3438 (41e); 0649 (48e); 0833 (49e: blood methylguanidine); 2018 (50e: K and Na in serum); 1532 (51e: serum alkaline phosphatase); 0291 (53e: levels of arginine, guanidoacetic acid, guanidine and methylguanidine); 4046 (53e: haemadsorption); 1792 (55e: physiological inhibitor of hyaluronidase after infection); 0984 (59e: British standard antisera); 1193 (59e: estimate of molecular equivalents of antibody); 1418 (59i: methods); 4000 (60d: serum encym-activity).

Antigen-Antikörper-Reaktion / Antigen-antibody-reaction

1058 (08e); 0270 (17e: poliomyelitis streptococci); 0273 (17e: poliomyelitis streptococci); 1357 (18e: CFT); 1712 (26e: skin reaction); 0460 (31e: skin reaction with streptococcal antigen); 0935 (34e); 0933 (35e); 0934 (35e); 2713 (49f: haemagglutination); 2759 (51f: haemagglutination); 2605 (54e: cutan test with streptococcal antigen); 1893 (55e: different methods of neutralization test); 1827 (56e: fluorescent antibodies); 1864 (56d: amounts of antigen: titer in neutralization test); 0520 (57i: fluorescent antibodies); 0540 (57e); 0972 (57e); 3398 (57e: fluorescent antibody); 4067 (57e: CFT); 5281 (57e: specific precipitates); 0183 (58e: tissue culture: adsorption); 0233 (58e: dissociation); 0556 (58d: method of haemaggregation); 0971 (58e: immune resistant mutants); 1477 (58e); 1478 (58e); 1086 (59e: neutralizing-antibody-combining test = NAC); 1208 (59e: stability: phase of immunity); 1308 (59i: intracutaneous test); 1374 (59e: C- and D-antigen: precipitation); 2269 (59i: cutaneous reaction); 5376 (59i: cutaneous reactivity); 2446 (60e: CFT); 2568 (60f: micro-flocculation-test); 2569 (60f: micro-flocculation-test); 2972 (60e: micromethod); 4231 (60e: serum neutralization: kinetic); 4737 (60i: intradermal test with SALK-vaccine); 3495 (61d: CFT: purified antigen); 3498 (61d: flocculating and nonflocculating antibodies); 4210 (61e: reversibility); 4656 (61e: serum inhibition: type 3: tissue culture); 4902 (61e: cutaneous reaction after SALK-vaccination); 5465 (61r: fluorescent antibodies).

Antigenität / Antigenicity

0272 (17e: CFT); 0347 (18e: streptococci); 0144 (31e: typing); 0379 (33e); 0822 (34e); 3701 (34f: PETTIT-serum); 4789 (36e); 0813 (37e); 3582 (37e); 0362 (39e); 0803 (39e); 3680 (41e: cotton rat strain); 0624 (42e); 0139 (43e: THEILER-virus); 3848 (43e); 3699 (44e: THEILER-virus); 5138 (45e); 4223 (49e); 5329 (50e); 0037 (51e: typing); 0063 (51e: infection titer); 1581 (51e: monkey: invasiveness of virus after oral administration); 1634 (51e: strain differentiation: neutralization test); 1703 (51e: after passage in animal experiments); 2716 (51e: CFT: LANSING strain); 4440 (51e: cellular pathogenicity); 4445 (51e: classification); 1603 (52e: type specifity in mousetest); 2129 (52e); 2601 (52e: CFT); 2701 (52e: CFT); 3180 (52e: tissue

culture); 4482 (52s: classification); 0299 (53e: MACK-virus); 1613 (53e: mousebrain: CFT); 2614 (53s); 2632 (53e); 3404 (53e); 4465 (53e: CFT); 4561 (53pl: strains in Poland); 2725 (54e: thermostability); 2726 (54e: CFT); 4518 (54f: strains in France); 4565 (54e: LANSING-: Col. SK-strain); 0696 (55e); 1606 (55e: formaldehyde inactivation: type specifity in CFT); 1615 (55e: type specifity); 1784 (55e: recombinants of type 1 and 2); 1810 (55e: heat and UV-radiation); 1883 (55i); 1666 (56f: types in France); 1687 (56e: tissue culture antigen: CFT); 1851 (56e: homogenicity of type 1); 1875 (56e: cotton rat test); 1890 (56e: heat inactivation: specifity: CFT); 1929 (56e: differentiation within type 2); 2423 (56e: MEF_1: soluble antigen); 2424 (56r: type 4); 5440 (56e: relationsship to canine hepatitis); 0539 (57f: fluorescent antibodies); 0961 (57e: CFT: tissue culture); 2064 (57e: guinea-pig test); 4067 (57e: CFT); 0188 (58e: CFT); 0400 (58e: tissue culture); 0631 (58e: antibody: guinea-pig); 0759 (58e: C- and D-antigen: tissue culture); 0761 (58e: chicken test); 0889 (58e: recombinants: CFT); 0951 (58f: chicken test); 0958 (58d: CFT); 1138 (58e: variation: specifity of type 1 and 2); 1206 (58i: inactivation with betapropiolate); 1218 (58e: titration: haemaggregation test); 1231 (58i: SCHICK-test); 2325 (58e: KB epithelial cells); 2453 (58e: sedimentation); 2454 (58e: homogenicity: precipitin test); 0488 (59e: specifity); 0966 (59e: flocculation test); 0988 (59e); 0989 (59e: multiple antigens); 1056 (59d: purification); 1086 (59e: titration: NAC-test); 1135 (59d: titration of inactivated antigens); 1141 (59b: specifity type 2 and 3); 1203 (59e: subtypes of type 1); 1204 (59e: subtypes of type 3); 1227 (59e: CFT: mouse adapted virus); 1372 (59f: Roumania); 1374 (59e: C- and D-antigen); 1411 (59e: purification of virus); 1627 (59e: D-C-antigen); 1351 (60d: titration: haemaggregation test); 1352 (60d); 2378 (60e: antibody-combining test); 2440 (60e: serodifferentiation within the same type); 2446 (60e: CFT); 2527 (60e: CFT); 2529 (60f: chick test); 2567 (60e: fluorocarbon treatment); 2782 (60e: N- and H-antigen); 4600 (60e: color test); 3484 (61e: microprecipitin test); 4229 (61e: common antigens: type 1 and 2); 4250 (61e: fluorescent antibody); 4691 (61r: noninfectious antigen); 4743 (61d: Cox-vaccine: marker); 5163 (61e: serodifferentiation); 5367 (61e: formalin treated antigen); 5370 (61e: D-antigen: potency of vaccine); 5438 (61e: intratype differences); 5489 (61f: tissue cultures: modification); 5452 (62e: C- and D-antigen: measurement).

Blutbild / Blood count

3200 (10e); 3252 (11f); 4915 (11e); 0613 (12e); 4394 (12e); 4408 (12f: monkey); 0443 (13e); 0124 (19e: monkeys: blood count after infection); 3201 (25e); 1052 (29d: lymphocytosis); 1550 (29d); 0464 (30e: young rabbits); 4555 (31e: monkey); 0928 (33e); 0749 (35n); 0930 (35e); 3550 (35d); 2846 (38f); 3267 (40e); 3251 (44e); 2898 (45d); 2028 (51e: monkeys: ACTH); 2031 (51e: monkeys: ACTH); 3006 (52e); 2220 (57h); 0383 (58d); 1295 (59d).

Blutgruppen / Blood groups

1260 (30f); 1270 (31f); 3546 (31f); 0450 (32e); 0702 (32e); 4168 (32e); 0726 (33e: neutralizing antibodies); 0727 (33e); 3547 (33d); 3710 (33d); 4674 (33d); 5097 (33d); 0735 (34e); 0909 (34e); 0911 (34d); 0922 (35e); 0930 (35e); 3548 (35d); 3549 (35d); 4775 (35n); 2810 (36e); 4723 (36d); 4295 (37d: resistance); 4805 (38e); 2768 (39d); 4824 (42d); 3092 (43d); 3544 (44s); 3093 (51d); 1552 (55e: Rh-antigen in SALK-vaccine); 1822 (56d); 1997 (56d: blood group substances in SALK-vaccine).

Differenzierung der Typen / Differentiation of types

0144 (31e); 0379 (33e); 0822 (34e); 0163 (37e: convalescent serum: other viruses); 0813 (37e); 0170 (38e: Sydney-: USA-type); 2690 (38e); 0362 (39e); 0803 (39e); 0156 (40e: crosstest in monkey and neutralization test); 0139 (43e: mice); 2660 (47e: from human blood); 0073 (49e: monkeys: immunity); 0179 (49e: reinfection by monkey); 0180 (49e: monkey); 2661 (49e: flocculation test); 2710 (49e); 4223 (49e); 0031 (50e); 0037 (51e: monkey: immunity); 0045 (51e); 0046 (51e: monkey: immunity); 0047 (51e: monkey: immunity); 0048 (51e: monkey: immunity); 0049 (51e); 0050 (51e); 0051 (51e); 0052 (51e); 0053 (51e); 0055 (51e: tissue culture); 1692 (52e: type specifity after infection); 2877 (52e); 1440 (53e); 2963 (53e: monkey); 2964 (53e: monkey); 3361 (53e); 0075 (54e: tissue culture); 0082 (54e: tissue culture); 2658 (54d); 2682 (54d); 2727 (54e: selective susceptibility of Ateles monkeys); 3028 (54e: standard serum); 0696 (55e); 1615 (55e: neutralization: CFT); 1631 (55e: typespecific rabbit serum); 1883 (55i); 1884 (55i: guinea-pig serum); 1923 (56e: antibodies after infection); 1929 (56e: subtypes of type 2); 2424 (56r: type 4); 4269 (57j: Japan); 0389 (58e: absorption: CFT); 1138 (58e: common antigen of type 1 and 2); 2325 (58e: KB epithelial cells); 1141 (59b: standard sera); 1203 (59e: subtypes of type 1); 1204 (59e: subtypes of type 3); 1300 (59e: variability); 1372 (59e: Roumania); 1352 (60d: Germany); 2355 (60e: specifity within type 1); 2379 (60e: base composition of RNA); 2408 (60e: CFT); 2446 (60e: CFT); 2920 (60r: color test); 2926 (60r: Odessa); 2944 (60e: antigenic structure of type 1); 4201 (61e); 4743 (61d: marker: Cox-vaccination).

Eiweißverteilung im Serum / Distribution of serum proteins

4015 (43e: horse immune serum); 0434 (46e: β-globuline); 3970 (49e); 1493 (50e); 2032 (50e); 0241 (51e: albumine decrease, α_1 and α_2-globuline increase); 4092 (52e); 0291 (53e: guanidine and arginine in serum); 3369 (53d: cerebrospinal fluid); 2287 (54d); 2606 (54i); 4030 (54i: gammaglobuline: antibody); 2109 (56e: antibody: monkey- and human immune serum); 5200 (57i); 0393 (58e: gammaglobuline: amniotic fluid); 0306 (59u: antibodies in gammaglobuline); 5347 (60e: newborn twins).

Laboratoriumsdiagnostik / Laboratory diagnosis

0099 (10f); 0100 (10f: antibody titer: abortive cases); 3200 (10e: fixations reaction); 0090 (11e: antibodies in neutralization test); 1057 (11d); 4394 (12e); 4397 (12d); 0266 (16e: opsonic titer against poliomyelitis streptococci); 0270 (17e: poliomyelitis streptococci); 0283 (17e: CFT); 1357 (18e: CFT); 4370 (22e: colloidal gold reaction); 4371 (23e: colloidal gold reaction); 1713 (26e: precipitation); 1051 (29e: blood sedimentation); 1052 (29d: blood count); 1044 (30e: colloidal gold test); 2072 (31e: colloidal gold test); 0707 (33e: skin test); 0904 (33e: intracutan test); 0224 (34e: EBERSON: colloidal test); 0749 (35n: blood count); 0933 (35e); 0872 (37e); 3557 (37e: cutaneous streptococcal antigen antibody reaction); 2793 (39e); 4135 (40e); 0975 (41e); 0895 (42e: mice: neutralization test); 2722 (47e: CFT); 4835 (48e: mice: interference test); 2713 (49f: haemagglutination); 4423 (49e: mice: interference test); 0056 (51e: CFT); 2621 (51e); 0290 (52e: streptococcal antigen); 1680 (52e: CFT); 1682 (52e: CFT); 2666 (52d); 2667 (52d); 2704 (52e: CFT); 2728 (52e); 2614 (53s); 4511 (53e); 4560 (53f); 5142 (53e); 1464 (54e: CFT); 1560 (54e); 1847 (54e: infection of children); 2147 (54e); 2682 (54d); 3961 (54e); 4522 (54d); 4569 (54e: CFT); 5230 (54n); 0696 (55e); 1605 (55e: domestic animals); 1781 (55d); 1794 (55e: CFT); 1815 (55i: skin reaction: animal experiments); 1848 (55e: CFT); 1869 (55f: CFT-micromethod); 1876 (55e: CFT); 1883 (55i); 2255 (55e: neutralization: CFT after infection); 2536 (55d: micro-CFT); 2540 (55d: micro-CFT); 2719 (55e: color test); 4032 (55s); 4609 (55n: CFT); 5446 (55s); 1665 (56e: flocculation test); 1808 (56d: CFT: contacts); 1830 (56d); 1834 (56e: epidemiological analysis); 1841 (56e: disc plate color test); 1849 (56e); 1852 (56d: CFT); 1855 (56d: CFT); 1930 (56f: neutralization test: plastic disc); 2181 (56f); 2425 (56d); 2550 (56d: micro-CFT); 3042 (56e); 4755 (56e); 4765 (56e); 4905 (56e); 5238 (56d: CFT); 0242 (57d: micro color test); 0498 (57d: neutralization test: CFT); 0577 (57i: neutralization test: CFT); 0859 (57e: CFT: neutralization test); 0944 (57e); 0947 (57e: CFT: neutralization test); 0948 (57e: precipitation: CFT); 0961 (57e: CFT); 1112 (57f); 1113 (57f); 1520 (57r: rabbit serum); 1529 (57e: virus excretion after vaccination); 2327 (57d: micro-CFT); 2688 (57d); 5308 (57d: CFT); 0171 (58d: CFT: inapparent cases); 0182 (58d: CFT with inactivated antigen); 0194 (58e: neutralization test); 0203 (58e: portable tissue culture laboratory in tropical areas); 0207 (58e); 0314 (58d); 0388 (58d: CFT); 0389 (58e: CFT); 0391 (58e: CFT); 0489 (58d: CFT); 0846 (58e: CFT); 0958 (58d: CFT); 1119 (58r: CFT); 1307 (58e: neutralization test: standard); 2121 (58d); 2347 (58d); 5248 (58d); 5312 (58e: enteroviruses); 0490 (59e: micro color test); 0541 (59f); 0542 (59f); 0592 (59d: CFT: hospital personnel); 0968 (59e: tissue culture: inhibition test); 0982 (59e: CFT); 0984 (59e: British standard serum: neutralization test); 1001 (59d); 1002 (59i); 1005 (59e: vaccination); 1033 (59e: vitro testing of antigenicity); 1063 (59d: CFT); 1090 (59d); 1092 (59e: HeLa cell culture); 1292 (59d: SALK-vaccination); 1369 (59e: flocculation test); 1375 (59e: neutralization by plaque test); 1418 (59i: neutralization test); 1429 (59e: flocculation test); 1941 (59e: after

vaccination); 2412 (59i: intradermal test); 2528 (59f: seroneutralization); 2581 (59f); 3085 (59e); 3087 (59d); 4274 (59f); 1421 (60f); 2381 (60f); 2382 (60f); 2408 (60e: typing of strains: CFT); 2527 (60e: CFT); 2531 (60d: CFT: neutralization); 2891 (60d); 2900 (60e); 2908 (60i: neutralizing antibodies: intradermoreaction); 2920 (60r: color test); 2925 (60r); 2926 (60r: virus isolation and typing); 2957 (60d); 2972 (60e: micromethod for determination of antibody); 3059 (60r: precipitation); 3194 (60i: virus neutralizing activity in stools); 4600 (60e: color test); 4243 (61f: CFT); 4250 (61e: virus identification: fluorescent antibody); 4634 (61f: CFT); 4637 (61d); 4657 (61e: CFT: nonspecifity); 4888 (61e: neutralization: gel diffusion method); 5353 (61b); 5488 (61i: CFT: neutralization test).

Serologische Methodik / Serological methods

Unter diesem Hauptstichwort sind diejenigen Veröffentlichungen aufgeführt, in denen serologische Methoden und ihre Modifikationen zum Nachweis spezifischer Antikörper gegen das Poliomyelitisvirus beschrieben, praktisch erprobt, kritisch diskutiert und verglichen werden. Serologische Methoden, die nur gelegentlich versucht und beschrieben wurden, und Arbeiten allgemeinen oder vergleichenden Inhalts habe ich unter «Allgemeines» zusammengefaßt. Die beiden ältesten und am häufigsten angewandten Methoden, die «Komplementbindung» und die «Neutralisation» von Virus durch spezifische Antikörper, sind gesondert aufgeführt. Die «Präzipitation», die vereinzelt seit den zwanziger Jahren versucht wurde, hat in jüngster Zeit mit der Entwicklung der modernen Nachweismethoden erneut Beachtung gefunden. Die jüngste und noch wenig praktisch verwendete serologische Methode ist die «Hämagglutination».

s. a. Antikörper, Nachweismethoden.
Antigenität.
Serologie.

This main title covers publications describing, testing, discussing, and comparing serological methods and their modifications for the demonstration of specific antibodies against the poliomyelitis virus. Serological methods only occasionally tried and described, and papers of general or comparative contents, were collected under «general». The two oldest and most frequently used methods the complement fixation and the neutralization of virus by specific antibodies – are presented separately. The «precipitation» test, occasionally studied since the twenties, has recently come to the fore again with the development of modern methods of demonstration. The most recent and not yet frequently used serological method is that of «haemagglutination».

cf. Antibody, methods
Antigenicity
Serology

Allgemeines / General

3200 (10e: fixations reaction); 0273 (17e: poliomyelitis streptococci: agglutinines and opsonines); 0277 (17e: SCHICK-test); 0344 poliomyelitis streptococci: agglutinines and opsonines); 0347 (18e: agglutination of streptococci); 0364 (18e: opsonines against streptococci); 3678 (18e: opsonic action); 4370 (22e: colloidal gold reaction); 4371 (23e: colloidal gold reaction); 1080 (29e: cataphoresis: electric surface charge of virus); 1044 (30e: colloidal gold test); 2204 (30e: colloidal gold test); 3560 (30e: colloidal gold test); 1101 (31e: allergic skin test); 2039 (31e: colloidal gold test); 2072 (31e: colloidal gold test); 3559 (31e: colloidal gold test); 0819 (32e: streptococci); 0707 (33e: skin test); 0904 (33e: intracutan test); 0224 (34e: EBERSON: colloidal gold test); 0703 (35e: skin test); 0704 (35e: colloidal gold test); 0748 (35e: colloidal gold test); 0756 (35e: purification of antibodies: adsorption); 4135 (40e); 0434 (46e: electrophoresis); 0833 (49e: methylguanidine); 0241 (51e: electrophoresis); 2614 (53s); 4046 (53e: haemadsorption); 4475 (53f: conglutination); 1631 (55e: typespecific rabbit serum); 1656 (55e); 1781 (55d); 1836 (55e: CFT: neutralization); 1837 (55e: CFT: neutralization); 1840 (55e: CFT: neutralization); 2340 (55i: neutralizing sera from rabbit); 1665 (56e: flocculation test); 1827 (56e: fluorescent antibodies); 1834 (56e: CFT: neutralization); 1841 (56e: disc color test); 1914 (56d: CFT: neutralization); 0234 (57f: sensibilization test); 0520 (57i: fluorescent antibodies: determination of antigen); 2059 (57e: CFT: neutralization); 2062 (57e: filterpaper disc test); 2092 (57e: filterpaper: tissue culture); 3398 (57e: fluorescent antibody); 0233 (58e: dissociation); 0556 (58d: haemaggregation); 0635 (58e: neutralization test: CFT); 0761 (58e: chicken test); 1218 (58e: haemaggregation); 5248 (58d); 0966 (59e: flocculation test); 0968 (59e: disc plate assay: tissue culture); 1086 (59e: neutralizing-antibody-combining test = NAC); 1092 (59e: antibody titration: HeLa cell culture); 1135 (59d: titration of inactivated virus); 1308 (59i: intracutan test); 1369 (59e: flocculation test); 1411 (59e); 1429 (59e: flocculation test); 2412 (59i: intradermal test); 2581 (59f); 4274 (59f); 4275 (59e: neutralizing substances in faeces); 1351 (60d: haemaggregation: titration of virus); 2316 (60f: neutralization: immunoinactivation [GARD]); 2378 (60e: antibody-combining test); 2440 (60e: serodifferentiation within the same type); 2911 (60e: antibody combining power test); 3328 (60i: flocculation test: other methods); 4302 (60e: interference test); 3498 (61e: flocculating and nonflocculating antibodies); 4144 (61e: virus in tissue culture: fluorescent antibody).

Hämagglutination / Haemagglutination

4424 (48f: sheep erythrocytes); 2713 (49f); 4369 (49f); 1620 (51e: Columbia SK-virus); 2759 (51f); 2666 (52d: Col.-SK-strain); 2667 (52d: parapoliomyelitis); 3960 (52d); 4564 (54e: JV-strain); 5268 (54e); 4766 (56e: flocculation by micro method); 4769 (56e); 2318 (58e); 4271 (58d).

Komplementbindung / Complement fixation

1058 (08e); 0270 (17e: poliomyelitis streptococci); 0272 (17e: antigen); 0273 (17e: poliomyelitis streptococci); 0283 (17e); 0344 (18e: poliomyelitis streptococci); 1357 (18e); 3644 (18e); 0737 (31e); 3645 (32f); 0704 (35e); 0748 (35e); 0933 (35e); 2793 (39e); 2722 (47e); 1497 (50e: antigen: mousebrain); 2598 (50d); 0056 (51e: neutralization test); 1582 (51e: neutralizing antibodies); 1686 (51e); 2716 (51e: antigen preparation); 3083 (51e: antigen: newborn mice); 0119 (52e); 1680 (52e); 1681 (52e); 1682 (52e: Kairo); 1692 (52e: type specifity); 2601 (52e); 2701 (52e: tissue culture: antigen); 2704 (52e); 2876 (52e); 2889 (52e); 1613 (53e: antigen: mousebrain); 1974 (53s); 2002 (53e: neutralization); 4465 (53e); 4470 (53e); 4511 (53e); 1464 (54e: diagnostic); 1560 (54e); 2726 (54e: multiple antigens); 3961 (54e); 4029 (54i); 4569 (54e); 5149 (54f: micromethod); 0696 (55e); 1606 (55e: antigen after formaldehyde inactivation: type specifity); 1615 (55e: neutralization); 1794 (55e); 1848 (55e: neutralization); 1869 (55f: micromethod); 1876 (55e); 2536 (55d: micro-CFT); 2540 (55d: micro-CFT); 4609 (55n); 1687 (56e: tissue culture antigen); 1808 (56d); 1852 (56d: neutralization); 1855 (56d: clinical diagnostic); 1890 (56e: heat inactivated antigen: specifity); 1929 (56e: homogenicity type 2); 1932 (56e); 2306 (56d); 2423 (56e: MEF_1: soluble antigen); 2425 (56d); 2445 (56i); 2550 (56d: micro-CFT); 3042 (56e); 4765 (56e: specifity); 4773 (56i); 5238 (56d); 0498 (57d: neutralization test); 0518 (57e: antigen); 0577 (57i: neutralization test); 0859 (57e: neutralization test); 0944 (57e); 0947 (57e: neutralization test); 0948 (57e: precipitation); 0961 (57e: antigen: tissue culture); 1520 (57r: rabbit serum); 2327 (57d: micro-CFT); 4067 (57e: typing of strains); 4774 (57d); 5308 (57d); 0171 (58d); 0182 (58d: inactivated antigen); 0184 (58e: noninfectious intracellular virus); 0188 (58e: antigenicity of different strains); 0203 (58e: epidemic in British Guiana); 0388 (58d); 0389 (58e: different antigens); 0391 (58e: different antigens); 0400 (58e: antigen components); 0489 (58d); 0502 (58e: antigen); 0508 (58d: neutralization test); 0759 (58e: C- and D-antigen: tissue culture); 0846 (58e); 0889 (58e: recombinants of types); 0958 (58d); 0959 (58e: vaccination); 1119 (58r); 1206 (58i: inactivated antigen); 0461 (59d); 0525 (59e: inactivated antigen); 0559 (59e: inactivated antigen: potency test); 0592 (59d); 0982 (59e: specifity); 1001 (59d); 1063 (59d: fluorescence); 1090 (59d); 1203 (59e: subtypes of type 1); 1204 (59e: subtypes of type 3); 1227 (59e: mouseadapted virus: antigen); 1292 (59e: SALK-vaccination); 2414 (59e: live vaccination); 3085 (59e); 2385 (60e: virus strains); 2386 (60d: antigens from HeLa cell cultures); 2408 (60e: typing of strains); 2446 (60e: differentiation of strains); 2527 (60e: neutralization); 2531 (60d: neutralization); 2567 (60e: fluorocarbon-treated cell culture antigen); 2569 (60f: micro flocculation test); 2774 (60i: during SALK-vaccination); 2782 (60e: N- and H-antigen); 2878 (60f); 2973 (60e: neutralization test); 3979 (60i); 3313 (61d: purified antigen); 3495 (61d: purified antigen); 4219 (61d: antigen: concentration with $Al(OH)_3$); 4229 (61e: common antigens: type 1 and 2); 4243 (61f); 4634 (61f: CFT); 4657 (61e: nonspecifity: enterovirus); 5152 (61e: preparation of antigen); 5367 (61e: formalin treated antigen).

Neutralisation / Neutralization

0099 (10f: monkey); 0100 (10f: monkey); 1060 (10e); 0090 (11e: monkey); 1057 (11d); 0613 (12e); 0324 (13f); 4387 (13f); 0278 (17e: cerebrospinal fluid); 0102 (18f: horse immune serum); 0366 (18e: monkey: antistreptococcal horse serum); 0378 (18e); 0397 (18e: antistreptococcal serum); 0089 (30e: monkey); 0154 (30e: horse immune serum); 0175 (30e: protein fractions of horse immune serum); 0288 (30e); 0340 (30e: monkey); 0341 (30e: monkey); 0354 (30e: monkey); 1079 (30e); 2038 (30e); 0002 (31e); 0003 (31e); 0006 (31e); 0144 (31e: typing); 0737 (31e); 0739 (31e: potency test of therapeutic serum); 0028 (32e: monkey); 0198 (32e: monkey); 0793 (32e: potency test of therapeutic serum); 0882 (32e); 1948 (32e); 0380 (33e); 0881 (33e: sheep immune serum); 0735 (34e); 0935 (34e); 0283 (35e: different antigens); 0746 (35e); 0748 (35e); 0814 (35e: convalescent and normal serum); 0817 (35e); 0933 (35e); 0016 (36e); 0877 (36e); 0163 (37e: convalescent serum: other viruses); 0813 (37e: typing of strains); 0872 (37e); 0170 (38e: typing); 0251 (38d: convalescent serum); 5130 (38e: monkey test); 0226 (39e); 0358 (39e: teststrain); 0362 (39e); 0528 (39e: monkey: intraocular injection); 0803 (39e: typing of strains); 0156 (40e: typing); 1835 (40e: animal experiments); 3682 (40e); 2663 (41e: mice protection test); 3680 (41e: cotton rat strain); 0624 (42e: strain specifity); 0885 (42e: mouse test: standardization); 0895 (42e: mouse test); 5076 (42e: mouse test); 0128 (43e: mice); 0138 (43e: mice); 0125 (45e: mice); 0622 (45e: mouse protection test); 5137 (45d: rodent test); 1259 (46e: mouse test); 4837 (46e: mouse test); 0039 (47e); 0041 (47e: mice); 0042 (47e: mice); 0884 (47e: mouse test); 0891 (47e: mouse test); 0033 (48e: mice); 0174 (48e: temperature); 1269 (48e: mouse test); 4420 (48e); 2710 (49e: differentiation of types); 0031 (50e: typing); 0037 (51e: typing); 0045 (51e); 0048 (51e: typing); 0049 (51e: typing); 0050 (51e: typing); 0051 (51e: typing); 0052 (51e: typing); 0053 (51e: typing); 0054 (51e); 0055 (51e: tissue culture); 0056 (51e: CFT); 0064 (51e: mice); 1582 (51e: CFT); 1634 (51e: differentiation of strains); 1692 (52e: type specifity); 2666 (52d: Col.-SK-strain); 2667 (52d: parapoliomyelitis); 2728 (52e: in mice); 2877 (52e); 3029 (52e: monkey testicular tissue); 3180 (52e: in tissue culture); 5333 (52e); 2002 (53e: CFT); 2966 (53e: tissue culture test); 2967 (53e: mouse protection test with small amount of blood); 4466 (53pl: mouse test); 0075 (54e: tissue culture); 0082 (54e: tissue culture); 1560 (54e); 1847 (54e); 2244 (54e: phenol red-color test); 2682 (54d: strain-typing); 2798 (54e: in mice); 2853 (54f: in mice); 3961 (54e); 4023 (54e: mouse test); 4537 (54e: tissue culture method); 4586 (54f: micromethod); 0696 (55e); 1605 (55e: domestic animals); 1615 (55e: CFT); 1630 (55e: amounts of virus); 1676 (55e: color test); 1677 (55e: color test); 1872 (55f); 1884 (55i: guinea-pig serum); 1893 (55e: different technics); 2719 (55e: color test); 4032 (55s); 1664 (56e); 1841 (56e: plate color test); 1864 (56d: amounts of antigen); 1923 (56e: heterotypic antibody after infection); 1929 (56e: homogenicity of type 2); 1930 (56f: plate technique); 1932 (56e); 2425 (56d); 3042 (56e); 4755 (56e); 4763 (56e: micromethod); 4765 (56e); 0242 (57d: micro color test); 0498 (57d: CFT); 0540 (57e:

immunoinactivation); 0577 (57i: CFT); 0859 (57e: CFT); 1520 (57e: rabbit serum); 2064 (57e: guinea-pig test); 2092 (57e: filterpaper: tissue culture); 2688 (57d); 0944 (57e); 0945 (57e); 0946 (57e: precipitation); 0947 (57e: CFT); 0181 (58e: HeLa cell culture); 0183 (58e: tissue culture); 0194 (58e: time and temperature); 0244 (58d); 0395 (58e); 0508 (58d: CFT); 0860 (58d: HeLa cells); 1307 (58e: standardization); 2318 (58e: haemagglutination); 2325 (58e: KB epithelial cells); 0490 (59d: micro color test); 0541 (59f); 0542 (59f); 0853 (59e); 0984 (59e: British standard serum); 0988 (59e: antigen); 1001 (59d); 1090 (59d); 1204 (59e: subtypes of type 3); 1217 (59e); 1221 (59e: inhibitor against type 1 in horse serum); 1230 (59e: non-infectious virus: blocking test); 1375 (59e: plaque test); 1418 (59i); 2448 (59j: intraspinal mouse test HeLa cell tissue culture); 2528 (59f); 3085 (59e); 3087 (59d); 1421 (60f: diagnostic); 1990 (60e: Colindale cytopathic test: Hampstead galaktose color test); 2316 (60f: immunoinactivation [GARD]); 2355 (60e: specifity within type 1); 2382 (60f); 2527 (60e: CFT); 2529 (60f); 2531 (60d: CFT); 2569 (60f: micro flocculation test); 2904 (60i: quantity of virus); 2908 (60i: intradermoreaction); 2920 (60r: color test); 2925 (60r: comperative study); 2927 (60i: intradermoreaction); 2942 (60i: intradermoreaction); 2972 (60e: micromethod); 2973 (60e: CFT); 3315 (60t); 3978 (60i); 4186 (60b: peritoneal test in mice); 4231 (60e: kinetic); 5346 (60e: paper disc method); 3312 (61d: zone phenomenon); 4208 (61e: modified color test); 4215 (61d: standardization of sera); 4218 (61d: serum avidity: virus aggregation); 4229 (61e: type specifity); 4246 (61f); 4247 (61f); 4663 (61e: different methods); 4728 (61i); 4888 (61e: gel diffusion method); 5163 (61e: serodifferentiation of epidemic strains).

Präzipitation / Precipitation

3677 (24e); 3676 (25e); 1713 (26e); 0137 (28e: streptococci); 0002 (31e); 0737 (31e); 0704 (35e); 0748 (35e); 0933 (35e); 2793 (39e); 2661 (49e: flocculation test: strain differentiation); 0670 (57e: agar diffusion test); 0946 (57e: neutralization); 0948 (57e: CFT); 5281 (57e); 0501 (58e: agar diffusion test); 2454 (58e: antigenic homogenicity); 1374 (59e: C- and D-antigen); 1627 (59e: C- and D-antigen); 2568 (60f: micro flocculation test: gel diffusion technique); 2569 (60f: micro flocculation test: gel diffusion technique); 3059 (60r); 3241 (60f: micromethod: rabbit: CFT); 3484 (61e: microtest); 3485 (61e: microtest); 4229 (61e: common antigens: type 1 and 2).

Serumprophylaxe und -therapie / Serum prophylaxis and treatment

Hier sind Veröffentlichungen vorwiegend klinischen und epidemiologischen Inhaltes zusammengefaßt, die über die Anwendung von antikörperhaltigen Flüssigkeiten zur Vorbeugung oder Behandlung der Poliomyelitis berichten (s. S. 19, Abb. 8). Prophylaxe und Therapie habe ich nicht

trennen können, weil bei vielen Mitteilungen wegen der pathogenetischen Eigenheiten der Poliomyelitis nicht entschieden werden kann, ob die passive Immunisierung noch vor dem Ausbruch der Erkrankung oder erst danach eingesetzt wurde, und weil häufig beide Anwendungsprinzipien in einer Veröffentlichung gemeinsam beschrieben werden. Dieses Hauptstichwort überschneidet sich häufig mit den zur passiven Schutzimpfung gebrachten Zitaten. Darüber hinaus werden die Veröffentlichungen folgenden Inhaltes ohne weitere Untergliederung gebracht: die Anwendung von Normalseren und unspezifischen Immunseren, die gegen andere Erreger gerichtet sind, sowie von Eigenblut- und Eigenliquorinjektionen, Berichte über die Grundlagen der Serumprophylaxe und -therapie, wie beispielsweise die Durchlässigkeit der Blutliquorschranke für die angewendeten Seren.

s. a. Antikörper, Globulin.
Schutzimpfung, passive Impfung.

This section presents publications of predominantly clinical and epidemiological contents, reporting on the use of antibody-bearing fluids in the prophylaxis and treatment of poliomyelitis (cf. page 36, fig. 8). Prophylaxis and treatment could not be separated, because in many reports, due to the pathogenic characteristics of poliomyelitis, it cannot be decided whether passive immunization was effected before or after the onset of the disease; also because both modes of application are frequently described in the same publication. This title shows frequent overlapping with references under passive immunization. Apart from this, publications were presented without further subdivision when dealing with the use of normal sera and unspecific immune sera directed against other pathogens, both in injections with the patient's own blood and those with the patient's own cerebrospinal fluid, reports on principles of serum prophylaxis and therapy (e. g. the permeability of the blood-CNS-barrier to the sera used).

cf. Antibody, globuline
Vaccination, passive vaccination

0104 (10d); 0106 (10e); 1379 (10d); 1256 (11f); 1435 (11d); 3588 (12e); 4389 (12f); 4395 (12e); 4390 (13e); 3290 (14f); 4392 (14f); 4399 (14f); 0402 (15f: convalescent serum); 3722 (15s); 3792 (15f); 3822 (15e); 4931 (15f); 4932 (15f); 0263 (16e: convalescent serum); 0264 (16e: convalescent serum); 0374 (16e: monkeys); 0375 (16e: convalescent serum); 0376 (16e); 0546 (16f); 2142 (16e); 3244 (16f); 3254 (16e); 3274 (16e: normal blood of adults); 3278 (16e: autotherapy with spinal fluid); 3279 (16e: autotherapy with spinal fluid); 3280 (16e: autotherapy with spinal fluid); 3370 (16e); 3519 (16e: diphtheria antiserum); 3705 (16e: tetanus antitoxin); 3768 (16e); 3772 (16e); 3820 (16e); 3821 (16s); 3842 (16s); 3844 (16e); 0260 (17e: animal experiments: ROSENOW-serum); 0267 (17e: ROSENOW-serum); 0268 (17e: antistreptococcal horse serum); 0269 (17e); 0271 (17e); 0276 (17e: convalescent serum); 0278 (17e); 0280 (17e); 0281 (17e); 0316 (17e: convalescent serum); 1360 (17e); 1361 (17e); 1708 (17e); 3277 (17e); 3769 (17e); 3770 (17f); 3771 (17e); 5267 (17e); 0102

(18f: horse serum); 0250 (18e: monkeys: ROSENOW-serum); 0343 (18e: monkeys: horse immune serum); 0344 (18e: monkeys: antistreptoccocal horse serum); 0348 (18e: ROSENOW-serum); 0366 (18e: monkeys: antistreptococcal horse serum); 0378 (18e); 0446 (18f: NETTER-serum); 1356 (18e); 1358 (18e); 1359 (18e: monkeys: horse serum); 3576 (18e: horse serum); 3767 (18e); 5278 (18e); 3288 (19e); 4398 (20e); 3765 (21f); 3766 (21e); 3794 (21s); 3814 (21e); 3815 (21e); 0438 (22f: PETTIT-serum); 3018 (22f); 3299 (22e); 3523 (22f: PETTIT-serum); 3813 (22e); 0403 (23f: PETTIT-serum); 0404 (23f); 0405 (23f); 3264 (23e); 3556 (23f); 3846 (23e); 4372 (23d); 0454 (24f: PETTIT-serum); 0551 (24f: PETTIT-serum); 3441 (24e: ROSENOW-serum); 3764 (24f); 3789 (24e); 3807 (24f); 3845 (24e); 3322 (24e); 0318 (25e: convalescent serum); 0319 (25e: convalescent serum); 0320 (25e: convalescent serum); 0321 (25e: ROSENOW-serum); 0407 (25f: PETTIT-serum); 0493 (25f: PETTIT's-mutton serum); 3201 (25e); 3802 (25e); 3914 (25f); 0253 (26f: PETTIT-serum); 1714 (26e); 3763 (26f); 3785 (26f); 4373 (26f); 1711 (27e: antistreptococcal serum); 3301 (27e: collection and preparation of serum); 3323 (27e); 3324 (27e: collection of serum); 3325 (27e); 3436 (27f: PETTIT-serum); 3542 (27f: autoblood); 3762 (27f); 3775 (27d); 3788 (27e); 4376 (27f); 4542 (27e); 4543 (27b); 4997 (27f); 0136 (28e: ROSENOW- and PETTIT-sera); 0322 (28e: antistreptococcal serum); 0323 (28e: convalescent serum); 0729 (28e: convalescent serum); 0798 (28e); 0799 (28e); 0800 (28e); 0802 (28e: production of serum); 1363 (28e); 1364 (28pl); 2854 (28e: convalescent serum); 3284 (28f); 3321 (28f: PETTIT-serum); 3385 (28e); 3578 (28i); 3758 (28e); 3759 (28f); 3760 (28e); 3761 (28e); 3774 (28b); 3778 (28e); 4377 (28f); 4380 (28e); 4999 (28f); 5010 (28f); 0439 (29e: concentrated horse immune serum); 0873 (29e: convalescent serum); 0874 (29e: convalescent serum); 0875 (29e: convalescent serum); 1041 (29e); 1071 (29e: technique); 1074 (29e: complications); 1075 (29e); 1077 (29e); 1095 (29e); 1096 (29e); 1266 (29f); 1365 (29e); 1366 (29s); 1417 (29d); 1550 (29d); 3007 (29e); 3281 (29f); 3777 (29e); 4348 (29e); 4349 (29e); 4545 (29e); 4546 (29e); 4547 (29e); 4548 (29e); 5005 (29f); 0154 (30e: monkeys: horse immune serum); 0341 (30e); 0459 (30e); 0776 (30s: protein therapy); 0837 (30e: convalescent serum); 1073 (30e: antistreptococcal serum); 1094 (30e); 1179 (30e); 1180 (30f); 1182 (30s); 1273 (30d); 3688 (30f: PETTIT-serum); 3700 (30f); 3719 (30e); 3720 (30h); 3721 (30f); 3723 (30f); 3755 (30f); 3756 (30f); 3757 (30s); 3798 (30i); 3808 (30f); 4035 (30e); 4351 (30e); 4352 (30f); 4356 (30h); 4549 (30e); 4551 (30d); 4552 (30e); 0335 (31e); 0381 (31e); 0739 (31e: potency test of serum); 0777 (31e: horse serum); 0778 (31e); 0779 (31e); 0780 (31e: goats- and sheep-serum); 0782 (31e: convalescent citratblood); 0783 (31e: production of serum); 0784 (31e: dry serum); 0954 (31t); 1082 (31e); 1083 (31e); 1084 (31e: pregnancy); 1097 (31e: animal experiments); 1098 (31e); 1099 (31e); 1100 (31e); 1103 (31e: technique); 1105 (31e); 1107 (31h); 1110 (31f); 1124 (31d); 1154 (31e); 1171 (31d); 1201 (31h); 1353 (31e: horse serum); 1354 (31e); 1355 (31e); 2225 (31f: convalescent blood and PETTIT-serum); 3008 (31e); 3247 (31f); 3275 (31f); 3543 (31i: blood); 3554 (31e: ROSENOW-serum); 3583 (31e); 3690 (31i: PETTIT-serum); 3694 (31e); 3717 (31e); 3718 (31i); 3749 (31f); 3750 (31e);

3751 (31f); 3752 (31f); 3753 (31f); 3754 (31f); 3780 (31f); 3790 (31e); 3805 (31f); 3818 (31e); 3824 (31h); 4040 (31d); 4163 (31d); 4326 (31e); 4327 (31e); 4347 (31h); 4354 (31f); 4355 (31d); 4554 (31e); 4681 (31f); 4683 (31e); 5015 (31f); 5079 (31t); 5080 (31d); 5081 (31d); 0147 (32e); 0148 (32e); 0198 (32e: monkeys: goat- and sheep-immune serum); 0223 (32e: monkeys: convalescent serum); 0325 (32e: convalescent serum); 0435 (32e); 0449 (32e); 0545 (32e: convalescent serum); 0786 (32e); 0787 (32e: convalescent serum); 0788 (32e); 0789 (32e: convalescent serum); 0790 (32e: convalescent serum); 0792 (32e: convalescent serum); 0793 (32e: potency test of serum); 0882 (32e: antibody response); 0953 (32d); 1012 (32e); 1013 (32e); 1014 (32e); 1016 (32e: protein therapy with milk); 1017 (32e); 1024 (32d: PETTIT-serum in adults); 1106 (32e: blood of adults); 1108 (32e); 1109 (32e); 1111 (32e); 1347 (32e); 1348 (32e); 1349 (32e); 3552 (32f: PETTIT-serum, concentrated); 3637 (32f); 3643 (32e); 3713 (32e); 3714 (32e); 3715 (32e); 3716 (32e); 3724 (32i); 3742 (32i); 3743 (32e); 3744 (32e); 3745 (32e); 3746 (32f); 3747 (32e); 3748 (32e); 3781 (32d); 3817 (32e); 3825 (32e); 3831 (32e); 3836 (32e); 3841 (32f); 4005 (32d); 4064 (32f: monkey); 4324 (32d); 4325 (32i); 4676 (32f); 4677 (32e); 4678 (32d); 4682 (32d); 4684 (32e); 4685 (32f); 4687 (32d); 4688 (32d); 5082 (32f); 5084 (32d); 5085 (32e); 5320 (32e); 0149 (33e: monkeys); 0151 (33e); 0900 (33e); 0928 (33e); 0931 (33e); 0955 (33e); 0956 (33e); 1015 (33e); 1018 (33e: blood); 1061 (33d: large amounts of blood); 1186 (33e); 3273 (33e); 3292 (33e); 3527 (33d); 3532 (33d); 3535 (33d: parental blood); 3536 (33f: maternal blood); 3541 (33d); 3565 (33f); 3566 (33f); 3570 (33f); 3662 (33d: blood); 3710 (33d); 3711 (33d); 3712 (33d); 3737 (33s); 3738 (33d); 3739 (33d); 3740 (33d); 3741 (33d); 3773 (33u); 3776 (33f); 3791 (33e); 3796 (33f); 3797 (33d); 3804 (33s); 3809 (33f); 3812 (33e); 3816 (33e); 3828 (33i); 3829 (33f); 3830 (33e); 3835 (33s); 3838 (33e); 3850 (33e); 3854 (33d); 3855 (33d); 3856 (33d); 3869 (33e); 4007 (33d); 4059 (33d); 4069 (33d); 4330 (33d); 4331 (33e); 4669 (33e); 4670 (33d); 4671 (33d); 4672 (33e); 4673 (33e); 4674 (33d); 4680 (33d); 4703 (33u); 5092 (33i); 5093 (33d); 5094 (33f); 5095 (33d); 5096 (33d); 5100 (33d); 5101 (33e); 0594 (34e: convalescent serum); 0822 (34e); 0909 (34e); 0935 (34e); 0936 (34e); 1187 (34e: blood transfusion from convalescents); 3104 (34e); 3518 (34s: diphtheria antiserum); 3530 (34d); 3531 (34f: blood transfusion); 3534 (34i); 3538 (34s: blood); 3540 (34f: blood transfusion); 3589 (34d: autocerebrospinal fluid treatment); 3638 (34n); 3701 (34f: PETTIT-serum); 3706 (34d); 3707 (34f); 3708 (34d); 3709 (34s); 3731 (34f); 3732 (34d); 3733 (34i); 3734 (34i); 3735 (34d); 3736 (34i); 3739 (34e); 3800 (34d); 3801 (34e); 3810 (34f); 3837 (34e); 3840 (34e); 3852 (34n); 4091 (34d); 4175 (34d); 4313 (34d); 4314 (34e); 4315 (34d); 4698 (34d); 4699 (34d); 4700 (34e); 4701 (34d); 4702 (34d); 4706 (34f); 4707 (34d); 4708 (34f); 4709 (34e); 5105 (34s); 0722 (35e); 0745 (35e); 0758 (35e: parental blood); 0772 (35e: convalescent serum); 0773 (35e: convalescent serum); 0814 (35e); 0914 (35e); 0916 (35e); 0917 (35e); 0919 (35e); 0920 (35e); 0922 (35e); 0925 (35e: animal experiments); 0930 (35e: blood transfusion); 1023 (35e: horse serum: monkeys); 3525 (35f); 3526 (35e); 3529 (35d); 3537 (35i: maternal blood);

3539 (35e: blood); 3555 (35e: sheep serum); 3665 (35d); 3725 (35n); 3729 (35b); 3730 (35s); 3779 (35f); 3787 (35e); 3799 (35e); 3811 (35f); 3827 (35e); 3839 (35d); 3843 (35n); 3866 (35d); 3867 (35f); 3897 (35f); 4317 (35e); 4319 (35n); 4320 (35e); 4321 (35d); 4714 (35d); 4716 (35f); 4717 (35d); 4775 (35n); 5107 (35e); 0463 (36e); 0478 (36e); 0479 (36e: PETTIT's horse serum); 0824 (36e); 0825 (36e); 0827 (36e); 0828 (36e); 0912 (36e); 0915 (36e); 0918 (36d); 0921 (36d); 3528 (35e: transfusion); 3605 (36e); 3819 (36d);3851 (36d); 3864 (36f); 3865 (36f); 4290 (36f); 4291 (36d); 4292 (36d); 4723 (36d); 4725 (36d); 4778 (36f); 4779 (36d); 4780 (36d); 4782 (36f); 4784 (36e); 4785 (36d); 4787 (36d); 4788 (36f); 4790 (36d); 5120 (36d); 0162 (37n: Sweden 1936); 0165 (37e); 0252 (37d: convalescent serum); 0474 (37e: horse hyperimmune serum); 0483 (37e: convalescent serum); 2677 (37d: convalescent serum); 2678 (37d: convalescent serum); 2679 (37d: convalescent serum); 2841 (37d); 3221 (37e); 3575 (37e); 3592 (37e); 3664 (37e: parents blood); 3728 (37e); 3782 (37d); 3832 (37e); 3853 (37d); 3862 (37d); 3863 (37d); 3877 (37e); 4159 (37d); 4296 (37f); 4297 (37f); 4791 (37e); 4793 (37f); 4795 (37i); 4790 (37t); 5124 (37d); 5125 (37d); 5128 (37f); 5131 (37f); 0168 (38d: convalescent serum); 0169 (38e); 0251 (38d: convalescent serum); 2838 (38d); 2839 (38d); 3322 (38e); 3806 (38f); 3849 (38e); 3899 (38f); 4151 (38f); 4152 (38d); 4157 (38f); 4158 (38i: autoliquortherapy); 4172 (38d); 4800 (38d); 4803 (38f); 4806 (38f); 4807 (38h); 4808 (38f); 4809 (38f); 5153 (38d); 5392 (38e); 0804 (39e: blood-CNS-barrier); 2763 (39d); 2769 (39d); 2836 (39d: convalescent serum); 2840 (39d); 3727 (39e); 3803 (39h); 3826 (39e); 3834 (39e); 4164 (39d); 4165 (39d); 4166 (39d); 4814 (39e); 5154 (39d); 5155 (39e); 5159 (39d); 5160 (39e); 5161 (39s); 5172 (39t); 3267 (40e); 3517 (40i: diphtheria antitoxin); 3786 (40e); 3795 (40f); 4130 (40i); 4812 (40d); 4817 (40d); 4818 (40t); 4819 (40t); 4823 (40e); 5169 (40e); 0158 (41e: mice: convalescent serum); 3186 (41e); 3641 (41e); 3726 (41e); 3823 (41b); 3833 (41e); 3847 (41e); 3860 (41e); 3861 (41e); 4822 (41d); 3446 (42d); 3512 (42e); 3784 (42e); 3857 (42f); 3858 (42d); 3859 (42e); 3881 (42f); 4132 (42d); 4265 (42e); 4823 (42d); 2607 (43e: antistreptococcic serum); 3553 (43e: ROSENOW-serum); 3783 (43s); 5164 (43f); 5166 (43d); 5167 (43d); 0451 (44e: gammaglobuline); 3533 (44e: large doses of plasma); 5133 (44e); 0286 (45e: gammaglobuline); 2845 (45e); 2898 (45d); 5137 (45d); 5214 (47d); 0649 (48e); 4342 (48d); 4833 (48d); 0876 (49e); 3492 (49d: blood of parents); 4430 (49d); 4434 (49e); 5114 (49d: plasma infusion); 5116 (49d); 5174 (49d); 0220 (50e); 0411 (50e: serum of pregnant women); 0625 (50e: human serum); 0632 (50e); 2799 (50d); 3375 (50e: storage of serum at 4° C); 3409 (50e: blood of parents); 3413 (50e: blood of parents); 5110 (50r); 5112 (50d); 1602 (51e: monkeys: gammaglobuline); 0173 (52e: monkeys: gammaglobuline); 0290 (52e); 1645 (52e: antibodies after gammaglobuline); 1986 (52s: gammaglobuline); 2004 (52e: monkeys); 2805 (52d); 3942 (52d: gammaglobuline); 4092 (52e); 5223 (52e); 5260 (52s); 0206 (53i: gammaglobuline); 0406 (53e: gammaglobuline); 1441 (53e: gammaglobuline); 1463 (53e); 1469 (53d: gammaglobuline); 1476 (53e: gammaglobuline); 1507 (53e: gammaglobuline); 1557 (53e: gammaglobuline); 1611 (53e: gammaglobuline); 1612

(53e: gammaglobuline); 1616 (53e: gammaglobuline: organization); 1669 (53e: gammaglobuline); 1671 (53e: gammaglobuline); 1673 (53e: gammaglobuline); 1674 (53e: gammaglobuline); 1735 (53e: gammaglobuline); 1737 (53e: gammaglobuline); 1738 (53e: gammaglobuline); 2003 (53e: gammaglobuline); 2024 (53e: gammaglobuline); 2629 (53s: gammaglobuline); 2634 (53e: gammaglobuline); 2641 (53e: gammaglobuline); 2642 (53e: gammaglobuline); 2998 (53e: gammaglobuline); 3032 (53e: monkey: blood plasma therapy); 3447 (53d); 4490 (53e: gammaglobuline); 4491 (53e: gammaglobuline); 4495 (53e: gammaglobuline); 4496 (53e: gammaglobuline); 4505 (53e: gammaglobuline); 4514 (53s: gammaglobuline); 4556 (53d: Behringwerk-gammaglobuline); 4559 (53n: Swedish gammaglobuline); 4563 (53s: gammaglobuline: Mexico); 4576 (53f: gammaglobuline); 5142 (53e); 5222 (53d); 1443 (54h: gammaglobuline); 1446 (54d: gammaglobuline); 1452 (54e: gammaglobuline); 1468 (54e: gammaglobuline); 1504 (54e: gammaglobuline); 1562 (54e: gammaglobuline); 1563 (54e: gammaglobuline); 1697 (54e: gammaglobuline); 1741 (54d: gammaglobuline); 1742 (54d: gammaglobuline); 1746 (54f: gammaglobuline); 1757 (54d: gammaglobuline); 1774 (54e: gammaglobuline); 1812 (54e: gammaglobuline); 1976 (54e: gammaglobuline); 1999 (54e: gammaglobuline); 2275 (54e: gammaglobuline); 2463 (54e: gammaglobuline); 3176 (54d); 4058 (54e: gammaglobuline); 4515 (54e: gammaglobuline); 4520 (54h: gammaglobuline); 4532 (54e: gammaglobuline); 4533 (54e: gammaglobuline); 4534 (54e: gammaglobuline); 5039 (54e); 5141 (54f); 5173 (54e); 5490 (54e); 0699 (55e); 1571 (55e: gammaglobuline); 1577 (55e: gammaglobuline); 1628 (55e: gammaglobuline); 1798 (55d: gammaglobuline); 1804 (55d: gammaglobuline); 1805 (55f: donkey immune serum); 2989 (55f); 4590 (55i); 4596 (55e: gammaglobuline: laboratory infection); 5045 (55n); 5054 (55e); 5459 (55d); 1904 (56n: gammaglobuline); 5062 (56f); 5202 (56e); 5203 (56s); 5306 (56i); 0516 (57e: animal experiments); 0636 (57s: gammaglobuline); 1515 (57s: Argentinien: gammaglobuline); 5191 (57d); 5196 (57d); 5210 (57e); 5373 (57e); 0355 (58f: gammaglobuline); 0980 (59e); 1011 (59e: monkey experiments); 1193 (59e); 1209 (59d: gammaglobuline); 4978 (60f).

Tierversuche / Animal experiments

In der Immunitätsforschung zur Poliomyelitis haben die Tierversuche (T.) immer eine große Rolle gespielt. Hier sind alle Arbeiten gesammelt, die über Methodik und Ergebnisse der T. berichten; die verwendeten Tierspezies sind in der Regel als Stichwort den Zitaten hinzugefügt. Mit «Infektionsversuchen» und mit der «Immunisierung» von Tieren begann die Erforschung der Ätiologie und Pathogenese der Poliomyelitis, und damit wurden die Grundlagen für die Immunitätsforschung gelegt. In «Resistenzversuchen» wurde die natürliche Empfänglichkeit der verschiedenen Tiere und ihre Beeinflussung durch äußere und innere Faktoren geprüft. Einen speziellen Wert gewannen die T. bei der Prüfung der am Menschen angewendeten Impfstoffe. Aus der Fülle dieser Arbeiten, die unter «Impfstoffprüfung» zusammengefaßt sind, habe ich eine spezielle

Gruppe abgesondert; seit der Einführung der Lebendimpfstoffe mußte die wichtige Frage tierexperimentell geprüft werden, ob die attenuierten Impfviren nach der Passage durch den Darm des Impflings an Pathogenität zugenommen haben. Diese Untersuchungen, die gemeinhin als Virulenztest bezeichnet und in der Regel am Affen durchgeführt werden, und ihre Beziehungen zu in vitro-Untersuchungen («marker») sind unter «Virulenztest bei nach Lebendimpfung ausgeschiedenen Stämmen» aufgeführt.

s. a. Antikörper, Tierversuche.
Immunität, nach Schutzimpfung, Tierversuche.
Impfstoffe, Prüfung.
Provokation, Tierversuche.
Resistenz, Tierversuche.
Schutzimpfung, aktive Impfung, Tierversuche.
Schutzimpfung, passive Impfung. Tierversuche.
Versuchstiere.

In the study of immunity to poliomyelitis, animal experiments (AE.) have always been very important. We have collected all reports on methods and results of AE.; the animal species used are as a rule added as titles. With «infection experiments» and «immunization» of animals, a start was made with the study of the aetiology and pathogenesis of poliomyelitis, and the principles of immunity research were thereby laid down. In «experiments on resistance», the natural susceptibility of various animals was tested, with reference to the influence of external and internal factors. AE. attained a special value in the testing of vaccines for human use. These papers are presented under «testing of vaccines», while a special group was separated concerning animal experiments on the question (important since the introduction of live vaccines) of whether attenuated vaccination viruses increase in pathogenicity following passage through the intestines of the inoculated animal. These studies, usually referred to as virulence testing and as a rule carried out in monkeys, and their relations to in-vitro investigations («marker»), are presented under «virulence test of strains excreted after live vaccination».

cf. Antibody, animal experiments
Experimental animals
Immunity, after vaccination, animal experiments
Provocation, animal experiments
Resistance, animal experiments
Vaccination, active vaccination, animal experiments
Vaccination, passive vaccination, animal experiments
Vaccines, examination

Allgemeines / General

5398 (13e); 5022 (15d); 2142 (16e); 0345 (18e: etiology: pleomorphic cocci); 0346 (18e: etiology: streptococci); 3994 (30d: pathogenesis); 0777 (31e: horse immune serum); 2237 (31e: virus antigenicity); 4945 (31e); 0028 (32e: monkeys: neutralization test); 2201 (32e: normal antibodies); 0817 (35e: monkeys: antibody response); 3571

(35e: antibody: monkey: adrenalectomy); 4723 (36d); 1835 (40e: comparison of neutralization test); 3439 (40e); 0128 (43e: mice: neutralization test); 0487 (45e: antibodies: dogs: epidemic); 0033 (48e: mice: neutralization test); 2796 (49e: monkey: local antibody formation: CNS); 1582 (51e: production of antigen); 2633 (51e: neutralization test of animal sera in Japan); 2685 (51e); 5228 (52f); 2962 (53e: normal antibody: monkey); 2853 (54f); 1605 (55e: antibodies: domestic animals); 1815 (55i: diagnostic skin reaction); 5178 (55f); 2173 (56e: cultivation of avirulent variants); 0865 (58e: mice: interference of Polio- and COXSACKIE-virus); 2457 (60e: monkey viruses); 5500 (62e: antibodies in cattle sera).

Immunisierung / Immunization

0425 (09f: monkeys: rabies vaccination); 0093 (10d: monkeys); 0098 (10f: Cynomolgus monkeys); 0106 (10e: monkeys, sheep); 0373 (10f: monkeys); 0419 (10d: monkeys); 0421 (10d: monkeys: carbol-vaccine); 0422 (10d: monkeys); 0467 (10f: monkeys); 1060 (10e: monkeys); 1062 (10d: monkeys: serovaccine and heat inactivated vaccine); 0096 (11d: monkeys); 0359 (11f: monkeys); 1019 (11d: monkeys); 4862 (11e); 4863 (11e); 0097 (12d: *Macacus*); 4395 (12e: horse); 3822 (15e: monkey: passive immunization); 0374 (16e: monkeys); 0376 (16e: monkeys: passive immunization); 3597 (16e: monkey); 0260 (17e: horse: pleomorphic streptococci); 0268 (17e: horse: pleomorphic streptococci); 0273 (17e: sheeps and rabbits: pleomorphic streptococci); 0275 (17e: monkeys: pleomorphic streptococci); 0281 (17e: monkeys: serumtherapy); 1268 (17e: globoid bodies); 0101 (18e: *Macacus rhesus*); 0102 (18f: horse); 0250 (18e: monkeys: ROSENOW-serum); 0343 (18e: horse); 0344 (18e: horse: pleomorphic streptococci); 0347 (18e: horse: pleomorphic streptococci); 0366 (18e: horse: pleomorphic streptococci); 0378 (18e: monkeys: passive immunization); 0397 (18e: monkeys: passive immunization); 0590 (18e: monkeys: heat inactivated vaccine); 1036 (18e: rabbits); 1359 (18e: passive immunization: monkeys with horse serum); 3576 (18e: horse); 3895 (18e: monkey); 5278 (18e: monkey); 0134 (19e: monkey: passive immunization); 3584 (19e: monkey: opsonins for streptococcus); 3264 (23e: monkey: passive immunization); 0551 (24f: production of serum); 0888 (24e: monkey: attenuated poliovirus); 0493 (25f: mutton: antiserum); 4373 (26f: horse: immune sera); 0141 (27e: monkeys); 1711 (27e: passive immunization: antistreptococcal serum); 4541 (27e: monkey: sodium ricinoleate virus); 0136 (28e: horses, sheeps); 0798 (28e: monkeys: passive immunization); 0887 (29e: monkeys); 1095 (29e: monkeys: passive immunization); 3002 (29e: monkey: passive immunization); 3300 (29f: monkey: production of immune serum); 5005 (29f: monkey); 0142 (30e: monkeys and rabbits); 0154 (30e: monkeys: passive immunization); 0175 (30e); 0339 (30e: monkeys: heat inactivated virus); 0447 (30e: monkeys); 1073 (30e: antistreptococcal serum); 1079 (30e: monkeys: intradermal); 1185 (30e: monkeys: simultaneous vaccination); 1265 (30e: horse); 2205 (30e: production of immune serum); 0002 (31e: horse); 0003 (31e: monkeys); 0004 (31e: monkeys); 0006 (31e: horse); 0007 (31e: monkeys); 0408 (31e: monkeys: spleen);

0457 (31e: monkeys: shock after revaccination); 0477 (31e: horse); 0737 (31e: monkeys); 0780 (31e: sheeps and goats); 1038 (31d: monkeys: phenolized vaccine); 1097 (31e: passive immunization); 1098 (31e); 2072 (31e: colloidal gold test: titration of immune sera); 2206 (31e: monkeys: nasal vaccination with live vaccine); 3247 (31f: horse and monkey); 4190 (31e: cross immunization: encephalomyelitis in horses); 0015 (32e: monkeys); 0148 (32e: horses); 0198 (32e: goats and sheep); 0223 (32e: monkeys: passive immunization); 0558 (32e); 0791 (32e: monkeys); 1261 (32f: monkeys); 1262 (32f: chimpanzees: antiserum); 3683 (32e: guinea-pigs: passive immunization); 4064 (32f: monkey: passive immunization); 0146 (33e: monkeys: virus and serum); 0149 (33e: monkeys: passive immunization); 0151 (33e: monkeys: passive immunization); 0812 (33e: monkeys); 0881 (33e: sheep: immune serum); 0145 (34e: monkeys: virus and serum); 0152 (34e: monkeys: active virus); 0200 (34e: nonsusceptibility); 0225 (34e: monkeys); 0735 (34e: monkeys: nonspecific immunization); 0741 (34e: monkeys: hormones); 2008 (34e: horses); 3005 (34e: monkey: KOLMER-vaccine); 3701 (34f: monkey: passive immunization); 4111 (34e: monkey); 0723 (35e: monkeys: BRODIE-vaccine); 0724 (35e: monkeys: KOLMER-vaccine); 0725 (35e: monkeys: KOLMER-vaccine); 0768 (35e: monkeys: BRODIE-vaccine); 0815 (35e: monkeys: adsorbed vaccine); 0818 (35e: monkeys: BRODIE-vaccine); 0925 (35e: monkeys: serumtherapy); 1023 (35e: monkeys); 1085 (35e: sheeps: adsorbed vaccine); 2272 (35e: immune serum: monkeys); 2856 (35e: monkey: phenolized vaccine); 2857 (35e: monkey: living virus); 3555 (35e: sheep); 3896 (35f: monkey: KOLMER-vaccine); 4318 (35d: monkey: KOLMER-vaccine); 4719 (35e: monkey); 4777 (35f: monkey: methylenblue-light-inactivated vaccine); 0016 (36e: monkeys); 0018 (36e: monkeys); 0019 (36e: monkeys); 0020 (36e: monkeys); 0077 (36e: Rhesus-monkeys: antibodies: formaldehyde inactivated vaccine); 0078 (36e: monkeys); 0086 (36e: monkeys: different vaccines of KOLMER); 0912 (36e: antibodies); 0932 (36e: monkeys); 0471 (36e: monkeys); 0731 (36e: monkeys: KOLMER-vaccine); 0824 (36e: monkeys: passive immunization); 3270 (36f); 4776 (36f: monkey: KOLMER-vaccine); 4782 (36f: production of serum); 4789 (36e: monkey); 0474 (37e: horses); 0482 (37e: monkeys: antibodies in nasal substances); 0813 (37e: monkeys: differentiation of strains); 1043 (37e: monkeys: ricinoleate vaccine); 2754 (37e: monkey: intranasal route); 3154 (37e: monkey: sparing effect of dog distemper); 2659 (38e: monkeys); 2745 (38e: monkey: intranasal route); 3204 (38e: monkey: passive immunization); 3322 (38e: monkey); 3551 (38e: horse); 2620 (39d: monkeys: ultrawaves inactivated virus); 2669 (39e: monkey and sheep); 2858 (39e: monkey); 2870 (39e: monkey: intraneural injection of serum); 0157 (40e: monkeys: active virus: intracutaneous administration); 2752 (40e: monkey: intracutaneous route); 0158 (41e: mice: passive immunization: convalescent serum); 3602 (41e: monkey); 2711 (42e: monkey); 3286 (42f: mice); 4066 (42f: mice); 0038 (43j: monkeys: ultrasound vaccine); 0070 (43e: mice: passive immunization); 2607 (43e: antistreptococcic serum); 4015 (43e: horse: globuline fraction in immunserum); 5271 (44e: UV-vaccine: mice); 0121 (45e: chimpanzees: passive immunization); 0125 (45e: mice:

serum protection test); 4571 (45e: Swiss mice); 4574 (45e: mice: uv-inactivated vaccine); 0036 (47e: monkeys: ultrasound vaccine); 0042 (47e: monkeys); 0043 (47e: monkeys); 0372 (47e: mice: formaldehyde vaccine); 0891 (47e: antibodies: domestic- and laboratory animals); 3155 (47e: cotton rats); 4308 (47e: mice: formolized vaccine); 5074 (47e: isoimmunization to CNS-tissue: monkey); 5075 (47e: isoimmunization to CNS-tissue: monkey); 0032 (48e: mice and cotton rats); 0701 (48e: mice); 2656 (48e: monkeys: formalin inactivated virus); 2859 (48e: *Macaca mulatta*); 4420 (48e: rabbit and mice); 4720 (48e: mice: Col.-SK- and THEILER-virus); 0021 (49e: *Macaca mulatta*); 0073 (49e: monkeys: differentiation of types); 0180 (49e: monkeys: determination of types); 0774 (49e: mice); 4222 (49e: monkey); 4368 (49e: monkey: antibody distribution); 4369 (49f: rabbit: immune sera); 4431 (49e: Syrian hamster); 5070 (49e: chimpanzees); 0029 (50e: chimpanzees); 0031 (50e: monkeys: typing); 0034 (50e: monkeys: vaccine with adjuvants); 0065 (50e: passive transfer of immunity from active immunized mother to young mice); 1531 (50e: monkeys: antibodies in faeces); 2619 (50e: monkeys: persistence of antibody); 2739 (50e: chimpanzees: inapparent infection); 4055 (50e: monkey: antibody response); 4438 (50e: monkey: cross protection test: Japanese B encephalitis); 0037 (51e: monkey: mineral-oil-vaccine); 0045 (51e: monkey: typing); 0046 (51e: monkey: typing); 0047 (51e: monkey: typing); 0048 (51e: monkey: typing); 0049 (51e: monkey: typing); 0050 (51e: monkey: typing); 0051 (51e: monkey: typing); 0052 (51e: monkey: typing); 0064 (51e: mice: passive immunization); 1541 (51e: cotton rats); 1542 (51e: cotton rats); 1580 (51e: monkeys: oral immunization); 1602 (51e: monkeys: active and passive immunization); 1686 (51e: rodents: CFT); 2817 (51e: monkey); 3435 (51e); 3457 (51e: horse); 0173 (52e: monkeys: passive immunization); 1603 (52e: mice: type specifity); 1642 (52e: mice: passive immunization with gammaglobuline); 2004 (52e: monkeys: passive immunization); 2030 (52e: formaldehyde-inactivated vaccine: chimpanzees); 2213 (52e: mice: cross-immunity: polio: rabies); 2703 (52e: monkey: passive protection: gammaglobuline); 2730 (52e: chimpanzees: hamster adapted strain); 2880 (52e: monkey: antibodies and immunity); 3140 (52e: chimpanzees: duration of immunity); 3141 (52e: monkey); 3367 (52e: monkey: production of immune serum); 4464 (52e: monkey: uv-irradiated adsorbed vaccine); 4493 (52i: mice: transmission of immunity); 0295 (53e: monkeys: allergic encephalomyelitis); 0297 (53e: monkeys: repeated oral administration of virulent virus); 2632 (53e: monkeys); 2732 (53e: monkey: passive immunization); 2804 (53e: mice: cross-immunity: rabies); 2963 (53e: monkey: typing of unknown strain); 2964 (53e: monkey: typing of unknown strain); 4047 (53e: mice: passive immunization); 4469 (53e: plasma: monkey); 4492 (53e: monkey: AK-strain); 5142 (53e); 0069 (54e: monkeys); 1561 (54e: monkeys); 2223 (54e: mice: collodion capsules); 2246 (54e: chimpanzees: antibodies); 2247 (54e: chimpanzees: vaccines of marginal antigenic potency); 2718 (54e: rabbit: immunserum); 3028 (54e: standard antiserum); 4585 (54e: chimpanzees: rodent adapted strain); 0697 (55e); 0699 (55e: passive immunization); 1610 (55e: monkeys); 1631 (55e: typespecific rabbit serum); 1767 (55e:

mice); 1773 (55d: rabbits: antibodies); 1775 (55e: monkeys); 1805 (55f: donkey); 1881 (55e: chimpanzees: live vaccine); 1884 (55i: guinea-pigs); 1905 (55f: monkey); 2157 (55e: monkey: antibody: immunity); 2239 (55s); 2241 (55s: passive immunization); 2256 (55e: chimpanzees); 2340 (55i: rabbit); 1871 (56h: monkeys: live vaccine); 1886 (56i: guinea-pig: β-propiolactone-inactivated virus); 1929 (56e: monkey: testing of antigenicity); 2306 (56d: antibodies); 4770 (56d: mice: formalin-inactivated virus); 5448 (56d: monkey: perivenoese encephalomyelitis); 0516 (57e: mice: passive immunization); 0634 (57i: rabbit: ultrasonic treatment of spleen); 1252 (57e: multiple antigens); 1520 (57r: rabbit: production of serum); 1943 (57e: chimpanzees); 2069 (57e: nonspecific immunization: hamster with Columbia SK-virus); 3368 (57e: monkey: live vaccine); 4904 (57s: hamster: Col.-SK-virus); 0331 (58e: rabbit); 0959 (58e: CFT); 1031 (58d: guinea-pig); 0559 (59e: monkeys: CFT-antigen); 1011 (59e: passive immunization); 1123 (59i: multiple antigens); 1134 (59d: adsorbed vaccine); 1141 (59b: standard sera); 1281 (59e: monkey); 2910 (59e: Taiwan monkey); 2978 (59d: poliomyelitis suum); 1408 (60d: mice: provocation); 1989 (60e: Cynomolgus monkeys); 2308 (60d: monkeys: adsorbed vaccine); 2567 (60e: antisera: guinea-pigs); 2779 (60e: passive immunization of chimpanzees: gammaglobuline); 2782 (60e: guinea-pigs: typespecific anti-N- and anti-H-indicator sera); 2941 (60i: guinea-pigs: skin test); 2944 (60e: monkey: antigenic structure of type 1); 2971 (60e: passive immunization of chimpanzees: virus excretion); 3241 (60f: rabbit: precipitins); 4211 (60e: rabbit and rooster); 3020 (61d: Quatro-Virelon); 5145 (61d: combined antigens); 5493 (61r: production of diagnostic sera); 5499 (62e: guinea-pigs: CF-antibodies).

Impfstoffprüfung / Testing of vaccines

0831 (30e: monkeys: adsorbed vaccines); 3552 (32f: concentrated immunserum); 3891 (34e: monkey: KOLMER-vaccine); 0086 (36e: monkey: KOLMER-vaccine); 3890 (44e: mice: uv-inactivated vaccine); 5271 (44e: UV-vaccine: mice); 4574 (45e: monkey: uv-inactivated vaccine); 2601 (52e: monkey: depot-adjuvant); 2918 (52e: monkey: live vaccine); 1755 (54e: UV-vaccine); 2460 (54e: monkeys: live vaccine); 4045 (54e: monkey: avirulent variants); 0839 (55e: monkeys and guinea-pigs); 1679 (55e: mouse protection test); 1776 (55e: monkey: duration); 1780 (55e: mice); 1787 (55e: monkeys); 1797 (55d: mice: adsorbed vaccine); 1895 (55e: monkey); 2537 (55d); 2538 (55d); 2740 (55e: mice: antigenicity test); 2981 (55e: guinea-pig potency test); 0978 (56e: monkey test with cortisone); 1521 (56e: monkey); 1875 (56e: cotton rat); 1900 (56e: monkey: cortisone); 1903 (56e: monkey: cortisone and X-rays); 1916 (56e: monkeys: cortisone); 1919 (56e: guinea-pig); 2078 (56e); 2185 (56s); 2186 (56s); 2307 (56d: monkeys: cortisone); 2481 (56e: monkeys); 2554 (56d); 4012 (56e: SALK-vaccine: guinea-pig: immunogenic capacity); 4025 (56e: British SALK-vaccine: mice and monkeys); 4757 (56e: monkey: SALK-vaccine); 4760 (56e: SALK-vaccine); 0857 (57e); 0938 (57e); 0940 (57e: monkey: live vaccine); 1252 (57e: multiple antigen); 1479 (57e: British vaccine); 1972 (57e: monkeys); 2064 (57e: guinea-pig test); 2070 (57e: uv-heat-inactivated

vaccine); 2087 (57e: mice); 2090 (57e: guinea-pig: diphtheria toxoid and polio antigen); 2493 (57n: guinea pigs); 2564 (57d); 2595 (57e: guinea-pigs: attenuated strain); 3368 (57e: monkey: live vaccine); 4946 (57e: British SALK-vaccine: antibody response of monkeys, guinea-pigs and cotton rats); 0503 (58e: guinea-pig: formaldehyde- and UV-vaccine); 0553 (58s: Mexico-vaccine: antibodies by Cynomolgus monkeys); 0631 (58e: guinea-pig: antibody response); 0849 (58e: guinea-pig); 0850 (58e: guinea-pig); 0851 (58e: chicken test); 0761 (58e: chicken test); 0951 (58f: antigenicity: chicken test); 1539 (58e); 2111 (58e: guinea pig test); 0186 (59d: potency test); 0662 (59e: monkeys); 1032 (59e: guinea-pigs); 1056 (59d: guinea-pigs 1150 (59f); 1170 (59e: monkeys); 1267 (59e: rat test); 1279 (59f: chicken test); 1303 (59e: chicken test); 1304 (59f); 1309 (59d: chicken test); 1378 (59he: guinea-pig test); 1660 (59r: rapid test with rats); 2281 (59e: antigenicity: chick test); 2300 (59r: monkeys: live vaccines); 3208 (59e: live vaccine: monkey neurovirulence); 3222 (59e: monkey: SABIN-vaccine); 1424 (60e: monkeys: viraemia after live vaccination); 1433 (60e: Cox-vaccine); 1989 (60e: Cynomolgus-monkeys: SALK-vaccine); 1991 (60e: monkeys: CHAT-strain); 2296 (60e: monkeys); 2374 (60f: chicken test); 2389 (60e: monkeys: live vaccine: neurovirulence); 2392 (60e: monkey- and chicken test); 2456 (60e: roosters); 2529 (60f: chicken test); 3230 (60r: malignancy in continuous cell lines); 3449 (60r: latent viruses in monkeys); 4085 (60e: immunogenic potency of SALK-vaccine: white rats); 4186 (60b: peritoneal test in mice); 4187 (60i: cutaneous reactivity); 4727 (60e: SV 40); 4887 (60e: monkey: standardization of SALK-vaccine) 4889 (60e monkey: combined vaccines); 4957 (60e: neuropathogenicity test: monkey); 4958 (60e: neuropathogenicity test: monkey) 4962 (60e: monkey: neurovirulence test: intramuscular inoculation); 4966 (60r: DT-polio-vaccine); 4967 (60e: live vaccines: marker: neurovirulence test); 4969 (60e: SABIN-vaccine: marker: neurovirulence test); 5036 (60e: monkey: CHAT- and FOX-strain); 5310 (60e: SABIN-vaccine: neurovirulence in monkeys); 4148 (61e: live vaccine: monkey neurovirulence test); 4183 (61d: SALK-vaccine: chicken test); 4205 (61e: monkey: virus B-infection); 4214 (61e: SABIN's strains: pathogenicity for monkeys); 4216 (61e: SABIN's strains: viraemia in monkeys); 4630 (61e: monkey: safety test for SALK-vaccine); 4631 (61e: monkey: safety test for concentrated SALK-vaccine); 4668 (61e: SALK-vaccine: potency test: chicks); 4726 (61e: simian foamy virus); 4733 (61r: SALK-vaccine: antigenic activity); 4747 (61d: live vaccine: neuropathogenicity for monkey); 4884 (61d: monkey); 4897 (61e: monkey: virulence of attenuated strains); 4971 (61e: monkey: neurovirulence test); 4973 (61e: SABIN-vaccine: marker after human passage); 5072 (61d: SABIN- and Cox-strains: neuropathogenicity for monkey); 5122 (61e: new type 3 attenuated strain: stability: monkey); 5145 (61d: combined antigens); 5266 (61e: SABIN-vaccine: neurotropism in monkeys).

Infektionsversuche / Infection experiments

0414 (09d: monkeys); 0418 (09d: monkeys and other animals); 0423 (09d: monkeys); 0424 (09f: chimpanzees); 0719 (09d); 0720

(09d: rabbits); 0757 (09f: chimpanzees); 2143 (09e: monkeys); 2144 (09e: monkeys); 2145 (09e: monkeys); 2233 (09d: monkeys); 4847 (09d: monkey); 0094 (10d: monkey); 0095 (10d: monkey); 0108 (10e: monkeys: reinfection); 0109 (10e: monkeys); 0317 (10e: monkeys: curse of infection); 0373 (10f: monkeys); 0377 (10d: monkeys); 0415 (10d: monkeys); 0420 (10d: monkeys); 0666 (10e: monkeys); 0668 (10e: monkeys); 0675 (10e: monkeys); 1059 (10e: monkeys); 1062 (10d: rabbits); 1257 (10f: monkeys: curse of infection); 1263 (10d: rabbit); 1264 (10d: rabbit); 1583 (10f: Cynomolgus monkey); 2644 (10d: monkeys); 2755 (10d: monkey); 2916 (10d); 3200 (10e: monkey); 3440 (10e); 3562 (10e); 4846 (10d); 4848 (10d: monkey); 4849 (10f: monkey); 4850 (10f: monkey); 4873 (10e: monkey); 4876 (10e: monkey); 0359 (11f: *Macacus cynomolgus*); 0834 (11n: monkey: vaccinia virus); 1048 (11e: tonsils: monkey); 1049 (11e: rabbit); 1050 (11e: monkey: infection from dust of sickroom); 1190 (11e: monkey); 1435 (11d); 3252 (11f: monkey); 3501 (11f: monkey); 4852 (11f: monkey); 4853 (11f: monkey); 4854 (11e: monkey); 4865 (11f: monkey); 4866 (11f: monkey: intranerval); 4868 (11e: fly); 4869 (11d: monkey); 4872 (11f: role of tonsils); 4914 (11e: monkey); 5491 (11f); 0097 (12d: Macacen: percutaneous infection with pox virus); 0416 (12d: monkeys: smallpox vaccination); 1255 (12f: monkeys); 1548 (12d: monkeys); 2203 (12e: monkeys: pathogenesis); 3406 (12e: monkey); 4393 (12f: guinea-pigs and rabbits); 4395 (12e: monkey); 4400 (12f: monkey); 4401 (12f: monkey); 4402 (12f: monkey); 4403 (12f: monkey); 4404 (12e: monkey); 4406 (12f: monkey); 4407 (12f); 4408 (12f: monkey: incubation period); 4409 (12d: monkey); 4871 (12d: monkey); 4909 (12e: monkey); 4918 (12e: monkey); 4919 (12e: monkey); 0332 (13e: monkey: virusexcretion); 0734 (13f); 3502 (13e: monkey); 4008 (13e: guinea-pigs); 4387 (13f: monkey); 4910 (13e: monkey); 0880 (14e: monkey: virulence of virus); 0898 (14e: monkeys: intraspinal); 0899 (14e: monkeys: viraemia); 1045 (14e: monkeys); 1046 (14e: monkeys: blood-CNS-barrier); 2735 (14e: monkey); 4388 (14e: monkey); 4391 (14d); 4923 (14d); 4924 (14f: transmission: *Stomoxys calcitrans);* 4929 (14d: monkey); 4928 (15e: monkey: transmission by *Lyperosia irritans*); 0255 (16e: monkeys and rabbits: cocci); 0256 (16e: monkeys and rabbits: streptococci); 0257 (16e: micrococci-etiology); 0265 (16e: micrococci-etiology); 0274 (16e: micrococci-etiology); 0437 (16e: cocci); 3597 (16e: monkey); 3631 (16e: rabbit); 3632 (16e: rabbit); 0282 (17e: cocci: etiology); 0284 (17e: cocci: etiology); 0440 (17e: monkey: pleomorphic cocci); 3285 (17e: monkey: etiology); 4926 (17s: monkey: different species); 0345 (18e: etiology: pleomorphic cocci); 0346 (18e: etiology: streptococci); 0363 (18e: monkey: globoid bodies); 1076 (18e: monkeys); 3618 (18e: small laboratory animals); 5278 (18e: monkeys); 0124 (19e: monkeys: blood count); 0135 (19e: monkey: persistence of virus in nasopharynx); 1037 (20e: monkeys: intranasal); 4538 (22e: rabbit and guinea-pig); 3630 (24e: rabbit); 4539 (24e: monkey virulence); 3506 (25d: spontaneous transmissibility); 4996 (25d: monkey: guinea-pig); 4540 (26i: rabbit); 0141 (27e: monkey: intracutaneous); 3323 (27e: monkey); 0801 (28e: streptococci); 4010 (28d); 4378 (28f: monkey); 4379 (28f: monkey); 4544 (28d: monkey); 5002 (28d:

monkey); 1072 (29e: streptococci); 1196 (29e: monkey: human resistance); 3263 (29e: monkey); 3629 (29e: rabbit); 3947 (29f: monkey); 5003 (29e: monkey); 0142 (30e: monkey and rabbit); 0464 (30e: young rabbits); 0466 (30e: rabbits); 1184 (30e); 1272 (30e: monkeys); 2141 (30e: monkeys); 3268 (30e: monkey: intratesticular route); 3951 (30d); 4350 (30f: monkey: mixed strains); 4552 (30e: monkey: virulence); 5007 (30f: monkey); 5008 (30e: monkey); 5012 (30i: monkey); 0005 (31e: monkey: reinfection); 0781 (31e: monkey: vaccinia virus); 0832 (31e: monkeys: reinfection); 1104 (31e: monkeys: influence of artificial fever); 1946 (31e: monkeys); 2208 (31e: monkeys); 3185 (31e: monkey); 4353 (31f); 4553 (31f: Cynomolgus: oral infection); 4555 (31e: monkey); 5013 (31f: monkey); 5016 (31f: monkey); 0223 (32e: monkey); 1271 (32e: monkey); 1948 (32e: monkey); 2238 (32e: monkey: etiology); 4031 (32d: monkey); 4682 (32d); 4684 (32e); 5085 (32e: guinea-pigs: toxic factor in stools and urines of patients); 5086 (32f: monkey: virulence: season); 5087 (32e: monkey: intestinal infection); 5088 (32e: monkey: oral infection); 5089 (32e: monkey: X-ray); 5090 (32e: guinea-pigs); 0150 (33e: monkeys: toxin of entero bacteria); 0808 (33e: monkey: incubation period); 0809 (33e: monkey: intranasal); 0810 (33e: monkey: bacterial agglutinines); 0811 (33e: mice: mucin); 0892 (33e: monkeys); 0952 (33e: guinea-pigs: extirpation of spleen); 2794 (33e: monkey: titration of virus); 2812 (33e: monkey); 3504 (33e: monkey); 3617 (33e: rodent); 4043 (33e: monkey); 4673 (33e: monkey: early involvement of CNS); 4674 (33d: rabbits); 4679 (33f: monkey: oral infection); 5098 (33e: mice); 0741 (34e: monkey: hormones); 0742 (34e: monkey: hormones); 0822 (34e: monkey: type of virus); 2008 (34e: monkey: horse hyperimmune serum); 3408 (34e: monkey); 3507 (34f: monkey); 3633 (34e: monkey); 4312 (34e: monkey); 4697 (34f: monkey); 4710 (34f: monkey); 4715 (34f: monkey); 5102 (34e: monkey: intestinal infection); 5103 (34f: monkey); 5104 (34e: monkey); 5106 (34e: monkey: paratyphoid-coli-filtrate); 0718 (35e: monkey: reinfection); 0745 (35e: monkey); 0755 (35e: *Ateles ater*); 0816 (35e: monkey: through isolated intestinal loops); 2744 (35e: monkey: pathogenesis); 3407 (35f: monkey); 3410 (35e: mice: adaptation of type 1); 3417 (35e); 3418 (35e); 3511 (35e: mice); 3513 (35d: monkey); 3882 (35e: vitamin B and C); 4013 (35e: baby monkeys: acceleration after vaccination); 4705 (35e: monkey: human spinal cords); 4712 (35e: monkey); 4713 (35e: monkey: hyperpyrexia); 4718 (35d: chimpanzees: spontane infection); 5108 (35e: monkey: paratyphoid-coli-filtrate); 0738 (36e: reinfection: monkey: antibody response); 0805 (36e: monkey: through isolated intestinal loops); 0821 (36e: mice: mucin); 0823 (36e: monkey: different application); 0829 (36e: monkey: reinfection); 0878 (36e: monkey: nasally instilled chemicals: protective action); 0886 (36e: monkey: chemoprophylaxis); 0901 (36e: monkey: castration); 0902 (36e: monkey); 1053 (36e: monkey: blood-CNS-barrier); 2672 (36e: monkey: intracutaneously); 3412 (36e: monkey); 3508 (36e: Marmoset monkey); 3509 (36f: mice); 4293 (36e: monkey); 4781 (36e: mice: thyroidectomy and castration); 4789 (36e: monkey); 4836 (36e: monkey: prevention); 5119 (36e: monkey); 5121 (36e: monkey: paratyphoid-coli-filtrate); 0441 (37e:

monkey: vitamine); 0728 (37e: monkey: reinfection); 2754 (37e: monkey: intranasal instillation of pituitrin S and adrephine); 2761 (37e: monkey: blood-CNS-barrier); 2762 (37e: monkey: blood-CNS-barrier); 3425 (37e: monkey); 3949 (37e: monkey); 4792 (37e: monkey: vitamin C); 4798 (37e: monkey: vitamin C); 5126 (37e); 0091 (38e: monkey: tonsillopharyngeal route); 0155 (38e: monkeys: ergosterol and vitamin D); 0170 (38e: calf and sheep); 0342 (38e: monkey: intranasal); 0705 (38e: reinfection: monkey); 2488 (38e: monkey: blood-CNS-barrier); 2742 (38e: monkey: pathogenesis); 2745 (38e: monkey: intranasal instillation of pituitrin S and adrephine); 2760 (38e: monkey: sparing effect of canine distemper); 2851 (38d: cattle); 2874 (38e: monkey: reinfection); 4804 (38d: cattle); 5129 (38e: hedgehog and agouti); 5130 (38e: monkey: intracerebral inoculation); 5156 (38d: blood-CNS-barrier: monkey); 0526 (39e: *Macacus cynomolgus*); 0740 (39e: monkey); 2645 (39e: eastern cotton rat); 2647 (39e: from cotton rat to white mouse); 2681 (39e: monkey: viraemia); 2766 (39d); 2811 (39e: monkey: sparing effect of lymphocytic choriomeningitis); 2861 (39e: monkey: vitamin C-therapy); 2862 (39e: monkey: vitamin C); 2875 (39e: monkey: pathogenesis); 3600 (39e: reinfection: monkey); 3621 (39e: cotton rat); 4167 (39e: monkey); 4810 (39e: monkey: olfactory nerve); 4811 (39e: monkey: reinfection: measles); 5155 (39e: blood-CNS-barrier: monkey); 5157 (39e: monkey); 5158 (39e: monkey); 5160 (39e: monkey: blood-CNS-barrier); 0157 (40e: monkey: intracutaneous route); 0172 (40e: *Sigmodon hispidus hispidus*); 0327 (40e: Cynomolgus monkey); 0329 (40e: monkey: estrogen substances); 0710 (40e: chimpanzees); 0927 (40e: monkeys); 2752 (40e: monkey: intracutaneous route); 2864 (40e: monkey: intraneural); 2884 (40e: cotton rats and white mice); 3590 (40e); 3619 (40e: *Sigmodon hispidus littoralis* rats); 3622 (40e: cotton rat); 3624 (40e: review); 3625 (40e: rodent); 3948 (40e: cotton rat and mice); 3959 (40e: cotton rat); 3698 (40e: monkey: lymphocytic choriomeningitis); 4009 (40e: cotton rat: spreading factor); 4133 (40e: monkey); 4813 (40f); 4816 (40e: monkey: cotton rat); 4820 (40e: rodents: nonspecific injections); 0023 (41e: chimpanzees); 0159 (41e: monkeys: vitamin D); 0712 (41e: Rhesus monkeys: reinfection); 0715 (41e: *Cercopithecus aethiops sabaeus*); 0767 (41e: monkeys: nonparalytic infection); 2065 (41e: monkey: reinfection); 2663 (41e: cotton rat and mice); 3229 (41e: monkey); 3365 (41e: cotton rat); 3503 (41e: monkey and guinea-pigs); 3616 (41e: cotton rat); 3620 (41e: cotton rat); 3623 (41e: wild rodent); 3697 (41e); 4016 (41d: ferret); 4033 (41e: monkey: spinal transection); 4128 (41f: mice); 4129 (41f: mice); 4821 (41e: intraneural spread: monkey); 4828 (41e: monkey: progression of virus in nerves); 5168 (41e: serum protection test); 0893 (42e: mice: thiamine diet); 0897 (42e: hamster); 3287 (42f: mice: LANSING strain); 3414 (42e: Cynomolgus monkey: oral infection); 3415 (42e: Rhesus monkey: intrasciatic inoculation); 3510 (42f: mice: LANSING strain); 3626 (42e); 3946 (42e: monkey); 4826 (42e: guinea-pigs); 4827 (42e: rodents: SK-virus); 0139 (43e: mice: THEILER-virus and mouseadapted LANSING strain); 0140 (43e: *Macaca mulatta*); 0713 (43e: *Cebus capucina* and *Cercopithecus cephus*); 0714 (43e: Cynomolgus monkey); 0730 (43e: white rats: vitamin B_1); 0732 (43e: mice: food

intake); 0766 (43e: Cynomolgus monkey: different routes of infection); 0910 (43e: monkey); 3423 (43e: monkey: inoculation of tooth pulp cavities); 3848 (43e: rodents); 4794 (43e: fetuses of rodents); 0733 (44e: Rhesus monkeys: intranasal infection); 0764 (44e: monkey: inhalation); 0765 (44e: mice: vitamin B_1 deficiency and inanition); 2750 (44e: mice: vitamin B_1 diet); 3411 (44e: mice: pantothenic acid deficiency); 4751 (44e: monkey); 5134 (44e: mice); 0126 (45e: chimpanzees: nonparalytic infection); 0621 (45e: monkeys); 0623 (45e: monkeys: accidental laboratory infection); 2738 (45e: interference); 3228 (45e: monkey); 3444 (45e: muskrats and other rodents); 5139 (45e: monkey: viraemia); 5379 (45e: monkey); 0484 (46e: cotton rats); 4838 (46e: monkey: folic acid); 5073 (46e: *Macaca mulatta*); 5384 (46f: mice: LANSING strain); 5385 (46f: *Aethiops sabaeus*: LANSING strain); 5386 (46e: monkey and chimpanzees); 0326 (47e: infant monkeys: oral infection); 0371 (47e: mice: estrogen substances); 0711 (47e: chimpanzees: reinfection); 2007 (47e); 2660 (47e: mice: human blood); 2673 (47e: cotton rat); 2686 (47e: sooty mangabeys [*Cercocebus fuliginosus*] and baboon [*Papio papio*]); 2687 (47e: guinea-pigs: relation to age); 2751 (47e: chimpanzees); 4307 (47e: sensitization in guinea-pigs); 4309 (47i: cats); 4311 (47f: *Cercopithecus aethiops sabaeus*); 4333 (47f: cotton rat); 4831 (47f: lemurs); 4839 (47e); 4840 (47e: monkey: virus levels in CNS); 4841 (47e: crossbred mice); 4842 (47e: flies); 4972 (47e: cotton rat); 0032 (48e: mice and cotton rats); 0057 (48e: *Macaca mulatta*); 0058 (48e: *Macaca irus*); 0059 (48e: *Macaca irus valida*: *Macaca irus mordax*: *Macaca philippinensis*); 0060 (48e: comparative susceptibility of Cynomolgus and other monkey species: oral and intracerebral infection); 0061 (48e: Cynomolgus monkeys after tonsillectomy); 0160 (48e: oral infection: antibody response); 0649 (48e); 2749 (48e: Cynomolgus); 2871 (48e: monkey: interference to murine polio-virus); 3894 (48e: monkey); 4098 (48s: white rat: age); 4105 (48f: rabbit); 4310 (48e: rats: intracerebral inoculation); 4334 (48e: monkey: purified virus); 4339 (48e: interference); 4342 (48d: interference); 4427 (48f: mice: LANSING strain); 4835 (48e: mice: interference test); 5069 (48e: adaptation to rodents); 5215 (48r: monkey); 5216 (48d: mice); 0072 (49e: monkey: gammaglobuline); 0073 (49e: monkey: differentiation of types); 0179 (49e: reinfection: virustype); 3992 (49e: monkey: mouseadapted virus); 4341 (49e: mice); 4367 (49e: suckling mice); 4423 (49e: mice: interference); 4426 (49e: rodents: Wallingford-strain); 4431 (49e: Syrian hamster); 5217 (49e: mice); 0029 (50e: chimpanzees); 0030 (50e: monkey, cotton rat, mouse: intracerebral injection); 1951 (50f: rabbit); 2211 (50e: mouse and hamster: cortisone); 2601 (50e: ACTH and cortisone); 2674 (50e: monkeys: dentinal tubules); 2720 (50e: newborn mice: relative resistance); 2756 (50e: monkey); 2757 (50e: monkey); 3197 (50f: rabbit); 3442 (50d); 3586 (50e: monkey: LANSING strain: Col.-SK-virus); 4386 (50e: monkey); 4437 (50e: monkey: transmission by mosquitoes); 0063 (51e: dissociation of titer of infectious and antigenic activity); 1532 (51e: monkey: serum alkaline phosphatase); 1536 (51e: mouse: increase in virulence); 1581 (51e: type of antigen: monkey); 1686 (51e: monkey: CFT); 1690 (51e: mice: interference with COXSACKIE-virus); 1700 (51s: *Ateles neglectus*); 2028

(51e: monkey: ACTH); 2031 (51e: monkey: ACTH); 2652 (51e: mice: ACTH); 2712 (51e: mice: intraspinal inoculation); 2714 (51e: mice: adaptation of Leon strain); 2715 (51e: suckling mice: intraperitoneal susceptibility); 2736 (51e: newborn mice: MEF_1-strain); 2737 (51e: Cynomolgus: pathogenesis); 0173 (52e: monkeys); 1137 (52e: provocation); 1450 (52e: mice); 1451 (52e: mice); 1643 (52e: bat); 1681 (52e: monkey: CFT); 2234 (52e: monkey: provocation: heterologeous vaccines); 2298 (52e: mice and hamsters: cortisone and ACTH); 2599 (52e: newborn mice); 2608 (52e: chick embryo); 2657 (52e: vaccination as provoking factor); 2702 (52e: monkey: viraemia); 2730 (52e: suckling hamsters); 2797 (52e: monkey: COXSACKIE and polio); 2876 (52e: newborn mouse); 2882 (52e: chimpanzees: antibodies and immunity); 2889 (52e: mice); 3139 (52e: monkey: pathogenicity after passage in human tissues); 3362 (52e: mice); 3364 (52e: monkey: hyaluronidase); 3424 (52e: chick embryo); 4113 (52e: Panamanian monkey); 4444 (52e: Syrian hamster: cortisone); 4446 (52e: cotton rats: virus titration); 4447 (52e: Syrian hamster: intraperitoneal infection: cortisone); 4450 (52e: cotton rats: pathogenesis); 4460 (52e: adaptation on mice); 4462 (52e: mice); 4463 (52e: mice: interference to COXSACKIE infection); 4477 (52d: mice: virus isolation); 4480 (52e: adaptation to rodents); 0009 (53e: chimpanzees after passive immunization); 0292 (53e: Cynomolgus monkey: intracardial infection: cortisone); 0294 (53e: monkeys and mice: benzimidazole); 0298 (53e: Syrian hamster: parenteral infection: cortisone); 1613 (53e: mice: production of antigen: CFT); 1747 (53e: Syrian hamster: cortisone); 1749 (53e: monkeys: Newcastle-infection); 1974 (53s: mice); 2002 (53e: chimpanzees: pathogenesis); 2731 (53e: mice); 3399 (53e: Syrian hamster: cortisone); 3405 (53e: oral: Cynomolgus monkeys); 3422 (53e: monkey: oral infection); 3443 (53e: mice: type 3); 4044 (53e: monkey); 4090 (53e: monkey: Naja toxoids); 4468 (53f: *Cercopithecus mona nigripes* and *Papio leucophaeus*); 4471 (53e: suckling mice and monkeys); 4500 (53e: benzimidazole); 4502 (53e: monkey: vitamin B_1); 4510 (53e: low tryptophan diets); 4511 (53e); 4512 (53e: interference: COXSACKIE-virus); 4519 (53f: rabbit-adapted virus for live vaccine); 4524 (53pl: monkey: pathogenesis); 4583 (53e: interference by toxoid: monkey); 1683 (54e: monkeys); 1694 (54e: Syrian hamster: hormones); 1701 (54s: *Ateles vellerosus*); 1803 (54e: monkeys: provocation); 2245 (54e: Cynomolgus monkeys: viraemia); 2460 (54e: monkeys: attenuated strains); 2723 (54e: adaptation to mice and cotton rats); 2727 (54e: Ateles monkeys); 2894 (54e: pathogenesis); 2946 (54e: monkey: Naja flava-toxoid); 3039 (54e: intratesticular inoculation); 3040 (54e: mice: intravenous); 3426 (54e: mice: adaptation of type 3); 3427 (54e: mice: type 1); 3433 (54e: mice: type 1 and 3); 4521 (54d: monkey: virus-isolation); 4527 (54i: mice); 4528 (54e: cave bat); 4529 (54e: monkey: interference with Col.-SK-virus); 4565 (54e: monkey: interference between LANSING- and Col.-SK-strain); 4580 (54e: monkey: noncytopathogenic variant); 4581 (54d: mice); 4582 (54e: monkey: brown fat); 4584 (54e: monkey: Naja flava neurotoxoid); 4587 (54e: Saukett strain: Syrian hamster); 4601 (54i: mice); 5031 (54i: monkey: hyperreactivity); 1647 (55e: chimpanzees: pathogenesis); 1777 (55d: monkeys: provocation);

1778 (55e: monkeys: live vaccine); 1792 (55e: monkeys: inhibitor of hyaluronidase); 1905 (55f: monkeys: Central Africa); 1924 (55e: chimpanzees: avirulent strains); 2249 (55e: monkey: in vivo-: in vitro-susceptibility); 2250 (55e: tissue culture); 2758 (55e: monkey: viraemia: lesions in the CNS); 3354 (55e: chick embryo); 4036 (55e: attenuated virus variants); 4593 (55e: fetal hamsters); 4595 (55e: wound tissue: Cynomolgus monkeys); 4612 (55e: Syrian hamster); 4613 (55e: mice: pentose nucleic acid); 4614 (55e: Syrian hamster); 4615 (55e: cave bat [*Myotus lucifugus*]); 4616 (55f: newborn mice); 4756 (55r: mice and cotton rat); 5302 (55e: mice); 5303 (55d: mice); 1696 (56e: *Ateles niger*); 1887 (56i: guinea-pig); 1914 (56d: monkey: antibody); 1916 (56e: monkey: provocation); 1921 (56d: monkey: pathogenesis); 2119 (56e: chimpanzees: virus distribution); 2314 (56e: Cynomolgus monkeys: virus distribution); 2424 (56r: type 4); 2809 (56e: mice: incubation period); 4161 (56e: monkey); 4752 (56i: rabbit); 4758 (56e: hamster: cortisone); 4768 (56e: hamster: cortisone: castration); 4770 (56e: mice: adaptation of type 1); 4906 (56i: hamster); 4940 (56e: interference: neurotoxoids); 4951 (56e: suckling hamster); 4952 (56e: cave bat); 4953 (56e: suckling hamster: infection by lactation); 5305 (56e: mice); 5444 (56e: mice and monkeys: helenine); 0941 (57e: monkeys: live vaccine); 1943 (57e: chimpanzees after immunization); 2043 (57d: Cynomolgus monkeys: cortisone and X-rays); 2068 (57e: monkeys: virus distribution); 2076 (57e: monkey: d-mutant); 2595 (57e: monkeys: attenuated strain); 2733 (57e: hamsters: cortisone and stress); 2795 (57e: mice: type 2); 4907 (57e: mice: interference to COXSACKIE-virus); 4941 (57e: adaptation of MAHONEY-strain to suckling mice); 4949 (57e: monkey); 0190 (58e: mixed infection with polio- and COXSACKIE-virus); 0308 (58e: mice: interference with rabies virus); 0331 (58e: Rhesus monkeys); 0557 (58e: monkeys: contact transmission); 1412 (58i: monkeys); 3505 (58e: monkey: neurotoxoid); 4935 (58e: interference: COXSACKIE-virus); 4936 (58e: interference: COXSACKIE-virus); 0866 (59e: monkeys: antibody: virus excretion); 1055 (59d: mice: vaccination during incubation period); 1413 (59i: rabbit); 1635 (59r: cotton rat: brain stem); 1636 (59r: cortisone); 1992 (59f: mouse: hyperthermy); 2438 (59e: Cynomolgus monkeys); 2910 (59e: Taiwan monkey); 3156 (59e: monkey: virulence of attenuated strains); 5390 (59e); 5391 (59e: type 1: suckling mice); 2437 (60e: mice: RNA: virulent attenuated virus); 2458 (60e: mice: antagonism between COXSACKIE virus and LANSING strain); 2573 (60e: monkeys: inhibitor from CNS); 2915 (60e: neurovirulence of attenuated virus: monkey); 2921 (60r: steppe lemming); 2950 (60e: monkey); 3095 (60f: mice: neurovirulence); 3371 (60d); 4302 (60e: monkey: egg-adapted virus); 3339 (61e: pathogenicity for monkey: t-marker); 4146 (61e: monkey: neural block); 4147 (61e: monkey: antibody); 4202 (61e: monkey: traumatized tissue); 4628 (61d: ultrastructure: CNS: monkey); 4630 (61e: monkey: intraspinal route); 4631 (61e: monkey: intraspinal route); 4636 (61e: mice: mucin); 5447 (61e: monkey: intraspinally inoculation).

Resistenzversuche / Experiments on resistance

0719 (09d); 0720 (09d: rabbit); 0109 (10e: different monkey species); 0097 (12d: Macacus monkeys); 0133 (19e: monkey: X-rays); 0142 (30e: rabbit); 0464 (30e: young rabbits); 0465 (30e: dogs, cats, guinea-pigs, mice a. o.); 1200 (32e: monkeys: hormones); 5086 (32f: monkey: season); 5089 (32e: monkey: X-rays); 0150 (33e: monkeys: toxin of enterobacteria); 0952 (33e: guinea-pigs: extirpation of spleen); 2010 (33e: monkeys: reinfection); 3587 (33e: inoculation with heterologeous antigens); 0742 (34e: monkeys: hormones); 0755 (35e: *Ateles ater*); 3421 (35f); 3628 (35e); 3882 (35e: vitamin B and C); 0753 (36e: monkeys); 0823 (36e: monkeys: different routes); 0878 (36e: monkeys); 0879 (36e: monkeys: age); 0883 (36e: monkeys: antibody titer); 0901 (36e: monkeys: castration); 0903 (36e: monkeys: season); 3420 (36e); 3509 (36f: mice irradiation); 4783 (36e); 0441 (37e: monkeys: vitamine); 0481 (37e: monkeys: vitamin C); 3145 (37e: monkey: castration); 3585 (37e: monkey: antiviral substances in nasal washings); 4298 (37e: monkey: role of the spleen); 4796 (37e: X-rays); 2760 (38e: monkey: sparing effect of canine distemper); 5129 (38e: hedgehog and agouti); 0526 (39e: *Macacus cynomolgus*); 0528 (39e: Rhesus monkeys: intraocular injection); 0803 (39e: monkeys: type of virus); 4014 (39e: monkey); 3627 (40f: antibodies); 3883 (40e: monkey: vitamin D); 5170 (40e: monkey: sterile inflammation of CNS); 5171 (40f: mice: X-ray); 0715 (41e: *Cercopithecus aethiops sabaeus*); 3609 (41e: monkey: estrogen); 4128 (41f: mice); 4129 (41f: mice); 0708 (43e: monkeys: spontaneous acquisition); 0713 (43e: *Cebus capucina* and *Cercopithecus cephus*); 0714 (43e: Cynomolgus monkeys); 0732 (43e: mice: food intake); 0766 (43e: Cynomolgus monkeys); 0770 (43e: monkeys: fatigue, chilling, trauma); 0771 (43e: mice: vitamine); 3696 (43e: monkey: TAB, vaccination); 4794 (43e: rodents); 0068 (44e: cotton rat: rachitogenic diet, inanition, sex); 0475 (44e: East African monkeys); 0476 (44e: rats and mice: vitamin B); 0709 (44e: chimpanzees: spontaneous infection); 0764 (44e: monkeys: inhalation); 0765 (44e: mice: vitamin B_1-deficiency and inanition); 2668 (44e: mice: thiamine diet); 3885 (44e: mice: riboflavin); 0612 (45e: monkeys: fatigue, chilling, trauma); 2593 (45e: cotton rats: inanition and sex); 3958 (45e: mice: estrogen); 5135 (45e: monkey: thiamine deficiency); 5136 (45e: Cercopithecus monkey); 5380 (45e: pyridoxine, inositol, and biotin); 5381 (45e: vervet monkey); 5382 (45f: certain rodents); 0484 (46e: cotton rats: vitamine and sex); 3137 (46e: mice: various hormones); 3138 (46e: monkey: estrogens); 3173 (46e: mice: temperature); 3189 (46e: mice: thiouracil); 3955 (46e: cotton rat: vitamin A, inanition and sex); 3956 (46e: mice: various dietary deficiencies); 4838 (46e: monkey: folic acid); 0040 (47e: *Cercopithecus aethiops sabaeus*); 0326 (47e: infant monkey: oral infection); 4311 (47f: *Cercopithecus aethiops sabaeus*); 0032 (48e: mice and cotton rat: age); 0057 (48e: *Macaca mulatta*: desoxypyridoxin); 0058 (48e: *Macaca irus* [Philippinen]: oral infection); 0059 (48e: Cynomolgus monkeys); 0060 (48e: different monkey-species: oral and intracerebral infection); 0061 (48e: Cynomolgus monkeys: tonsillectomy); 2717 (48e: mice: thyroxin); 4098 (48s: white rat: age); 4335 (48e: monkey: typhoid vaccination);

4425 (48e: mice: oxythiamine); 4365 (49e: mice: nutrition and vitamin D); 4431 (49e: Syrian hamster); 2211 (50e: mouse and hamster: cortisone); 2235 (50e: mouse: gestation); 2706 (50e: mice: gestation); 2720 (50e: newborn mice); 2721 (50e: mice: pregnancy); 4436 (50d: mice: seasonal relationship); 0132 (51e: monkeys: tonsillectomy); 0894 (51e: mice: heterologeous vaccinations); 1608 (51e: monkeys: tonsillectomy: bulbar paralysis); 2028 (51e: monkeys: ACTH); 2031 (51e: monkeys: ACTH); 2298 (52e: cortisone and ACTH); 2729 (52e: testicular tissue of immune monkeys); 3179 (52e: mice: amino acid unbalance); 4382 (52e: monkey: tonsillectomy); 4444 (52e: Syrian hamster: cortisone); 4447 (52e: Syrian hamster: cortisone); 4457 (52e: mice: methionine); 4458 (52e: mice: amino acid deficiencies); 4462 (52e: mice); 1449 (53e: monkeys: tonsillectomy: gammaglobuline); 2731 (53e: mice: hyper- and hypothyroidism); 3106 (53e: hamster: cortisone); 4048 (53e: mice: fatigue); 4468 (53f: *Cercopithecus mona nigripes* and *Papio leucophaeus*); 1960 (54e: hamster: cortisone); 2727 (54e: Ateles monkeys); 2946 (54e: monkey: Naja flava-toxoid); 5035 (54i: mice: DP-vaccination); 0512 (55i: heterologeous vaccinations); 2251 (55e: pathogenesis: endocrinological aspects); 2252 (55e: monkeys: provoking effect: injections); 4604 (55i: mice: fatigue); 5309 (55i: mice: fatigue); 1842 (56e: Syrian hamster: hormones); 2307 (56d: monkeys: cortisone); 2314 (56e: Cynomolgus monkeys: tonsillectomy and injections); 0517 (57i: hamster: season); 2118 (57i: heterologeous vaccinations); 2733 (57e: hamster: cortisone and stress); 0245 (58d: young mice: resistance against polio after infection with COXSACKIE B_1 virus); 1716 (59e: young mice: COXSACKIE infection); 2905 (59r: mice: cortisone); 2921 (60r: steppe lemming); 3371 (60d).

Virulenztest bei nach Lebendimpfung ausgeschiedenen Stämmen / Virulence test of strains excreted after live vaccination

0558 (32e: monkeys); 2724 (54e); 0698 (55e); 0673 (56e); 1871 (56h: monkeys); 0387 (57e); 0536 (57e); 0941 (57e: monkeys); 1964 (57e: monkeys); 2304 (57e: monkeys: SM type 1); 2305 (57e: monkeys: SM type 1 and TN type 2); 0537 (58e); 0638 (58h); 2334 (58e: monkeys: SABIN strains after passages in human tissue culture); 0385 (59e); 0601 (59e); 0840 (59e); 0991 (59e: monkeys); 1087 (59e: monkeys); 1199 (59e); 1202 (59e); 1282 (59e: T-marker); 1286 (59e: t- and d-marker); 1322 (59e: in vitro-markers); 1431 (59e); 3157 (59e); 3177 (59e); 3205 (59e); 3208 (59e); 3216 (59e); 3226 (59e: SABIN-vaccine: USSR); 3227 (59e: virulence for man); 1433 (60e: monkeys); 1991 (60e: monkeys: CHAT-strain); 2401 (60d: monkeys); 2525 (60e: markers); 3044 (60e); 3248 (60e); 3330 (60e); 4575 (60e); 4930 (60e: markers); 4967 (60e: marker); 4969 (60e: marker); 4974 (60e); 5040 (60e: Cox-vaccine); 3339 (61e: t-marker); 4259 (61e: SABIN type 2); 4261 (61e: SABIN type 1); 4743 (61d: Cox-vaccine: marker); 4973 (61e: marker); 5122 (61e: new type 3 strain [WM-III]); 5357 (61e: SABIN-vaccine).

Übersichtsarbeiten / Reviews

Hier werden Veröffentlichungen aufgeführt, die referierend über den jeweiligen Stand der Forschung und nicht über eigene experimentelle Arbeitsergebnisse berichten. Übersichten über die beiden großen Hauptthemen «Immunität» und «Schutzimpfung» habe ich gesondert angegeben.

s. a. Monographien.

Here we present publications reporting on the current state of research rather than on personal experimental findings. Reviews on the two main subjects «immunity» and «vaccination» are separatedly presented.

cf. Monographs

Allgemeines / General

4979 (07d); 0107 (10e); 0419 (10d); 2916 (10d); 3440 (10e); 4850 (10f: pathogenesis); 4851 (11e: pathogenesis); 0613 (12e); 4396 (12e: pathogenesis); 5254 (12d: prophylaxis); 4912 (13d: pathogenesis); 5398 (13e); 4391 (14d: pathogenesis); 4923 (14d); 5022 (15d); 2142 (16e); 5311 (16e); 4552 (30e); 0381 (31e); 1124 (31d: serumtherapy); 4163 (31d); 4355 (31d: pathogenesis); 4945 (31d); 0435 (32e); 1186 (33e); 4331 (33e: pathogenesis); 4316 (34d: pathogenesis); 0478 (36e: serumtherapy); 0826 (36e); 4723 (36d); 4786 (36i); 3215 (38d: pathogenesis); 4809 (38f); 2767 (39e: constitution); 3439 (40e); 4886 (40f); 5284 (41e: pathogenesis); 1210 (42d); 4751 (44e); 2898 (45d); 3908 (46e: bibliography 1789–1944); 1064 (47e); 4839 (47e); 0649 (48e); 3894 (48e: monkey: pathogenesis); 0926 (49e); 4364 (49e: tonsillectomy); 5115 (49d: pathogenesis); 0236 (50e); 3442 (50d); 5290 (50e: pathogenesis); 2685 (51e); 2129 (52e); 2221 (52e); 2805 (52d); 3034 (52e); 4442 (52e); 4452 (52e); 5228 (52f); 0012 (53f); 1736 (53d: tonsillectomy); 1982 (53d); 4494 (53f); 4560 (53f); 5142 (53e); 5229 (53f); 0010 (54e); 0013 (54s); 0117 (54e); 0239 (54s); 2853 (54f); 4522 (54d); 5029 (54e: prophylaxis); 0022 (55s); 0026 (55r); 0700 (55e); 2242 (55s: prophylaxis); 5178 (55f); 1823 (56d: resistance and provocation); 4109 (56e: pathogenesis); 5251 (56d: pathogenesis); 0531 (57e); 3009 (57e: pathogenesis); 0067 (58d); 0395 (58e); 0492 (58d); 4011 (58e); 5248 (58d: serology); 0541 (59f: serological diagnostic); 0542 (59f: serological diagnostic); 1090 (59d: diagnostic); 3371 (60d: pathogenesis); 5140 (62d: provocation: Di-vaccination).

Immunität / Immunity

0107 (10e); 1435 (11d); 0374 (16e); 3598 (17e); 3606 (18f); 4525 (30d); 1102 (31e); 0147 (32e); 0717 (32e); 0795 (32e); 4682 (32d); 2026 (33e); 0934 (35e); 0085 (36e); 0753 (36e: resistance); 0830 (36e); 4292 (36d); 3575 (37e); 4295 (37d); 2766 (39d); 3438 (41e); 4107 (41e); 4170 (43e: nonspecific immunity); 0706 (49e); 0929

(49e); 4222 (49e); 4340 (49f); 5439 (49f); 3225 (50f); 5290 (50e); 5291 (50e); 3434 (51f); 0178 (52e: passive immunization); 1728 (52e); 1950 (52e); 4459 (52e); 4483 (52f); 1740 (53e); 2899 (53d); 3416 (53d: pathogenesis); 4506 (53e); 2148 (54f); 2893 (54e); 2894 (54e); 5044 (54n: Sweden); 5286 (54e); 0697 (55e); 1970 (55d); 2239 (55s); 1898 (56e: pathogenesis); 5181 (56d); 0310 (57d); 2321 (57f); 0627 (58d); 0035 (59e: agammaglobulinaemia); 2133 (59e); 3957 (60e: resistance); 3991 (60d: pathogenesis); 4861 (60e).

Schutzimpfung / Vaccination

1379 (10d); 1380 (10d); 3888 (10r); 5254 (12d); 1708 (17e: serumtherapy); 3764 (24f: serotherapy); 3785 (26f: serotherapy); 0800 (28e: passive immunization); 3385 (28e: passive immunization); 3578 (28i); 3663 (28d); 3759 (28f: serotherapy); 3760 (28e: serotherapy); 3777 (29e); 3756 (30f: serotherapy); 4550 (30s); 0775 (31e); 3591 (31i); 3751 (31f: serotherapy); 3753 (31f: serotherapy); 3805 (31f: serotherapy); 0785 (32e); 0792 (32e: passive immunization); 3743 (32e: serotherapy); 2026 (33e); 3596 (33e); 3741 (33d: serotherapy); 3776 (33f); 3791 (33e: serotherapy); 3812 (33e: serotherapy); 3835 (33s: serotherapy); 3838 (33e: serotherapy); 0935 (34e: serumtherapy); 0936 (34e: serumtherapy); 3735 (34d: serotherapy); 0428 (35e); 0470 (35e: BRODIE-vaccine); 0744 (35e); 0747 (35e); 2280 (35e); 3525 (35f); 3661 (35e); 3779 (35f: PETTIT-serum); 3878 (35e: KOLMER-vaccine); 3898 (35e: KOLMER-vaccine); 4106 (35e: KOLMER-vaccine); 4318 (35d: KOLMER-vaccine); 0085 (36e); 0426 (36e: BRODIE- and KOLMER-vaccines); 0468 (36e); 0469 (36e); 0752 (36e); 0824 (36e: passive immunization); 0918 (36d); 3603 (36e); 3605 (36e); 3819 (36d: serotherapy); 4096 (36e: BRODIE- and KOLMER-vaccine); 4725 (36d); 4782 (36f: serotherapy); 4790 (36d); 0165 (37e); 0480 (37e); 3592 (37e); 4006 (37e); 4797 (37e); 5128 (37f: serotherapy); 5131 (37f: serotherapy); 5334 (37e); 3577 (38d); 3593 (38b: live vaccine); 3595 (40e); 3186 (41e); 3893 (43s); 0906 (48e); 0929 (49e); 4340 (49f); 5220 (49e); 0632 (50e); 2799 (50d); 3403 (50i); 0353 (51e); 4026 (51e); 4535 (51e); 4844 (51e: 2. internat. Conf.); 1950 (52e); 2005 (52f); 3376 (52e); 4442 (52e); 4449 (52e); 4452 (52e); 5227 (52e); 1462 (53s); 1463 (53e); 1553 (53e); 1556 (53e); 1675 (53e); 1740 (53e); 1750 (53e); 1769 (53e); 1799 (53e); 1947 (53d); 1952 (53e); 2461 (53e); 2594 (53d: gammaglobuline); 2604 (53e: gammaglobuline); 2815 (53d); 3188 (53e); 3968 (53e;) 4020 (53s); 4473 (53e); 4489 (53n); 4499 (53e); 4507 (53e); 4576 (53f); 4721 (53e); 5461 (53e); 5471 (53f); 0011 (54s); 0069 (54e); 0083 (54e); 0591 (54e); 0854 (54e); 1442 (54s); 1467 (54e); 1471 (54e); 1498 (54f); 1561 (54e); 1688 (54d); 1706 (54e); 1748 (54e); 1753 (54f); 1760 (54e); 1786 (54e: live vaccines); 1825 (54i); 1942 (54d); 2275 (54e: gammaglobuline); 2376 (54s: live vaccine); 2459 (54e: 3. internat. Conf. Rome); 2460 (54e: 3. internat. Conf. Rome); 2462 (54e); 2534 (54d); 2615 (54e); 2622 (54e); 2623 (54e); 2626 (54s); 2630 (54e); 2814 (54d); 2895 (54e: living vaccines); 2896 (54e); 3037 (54e); 3078 (54e); 3128 (54e); 3143 (54s); 3996 (54e); 4022 (54f); 4023 (54e); 4062 (54e); 4504 (54e); 4515 (54e); 4531 (54f); 4591 (54e); 4696 (54d: live vaccination); 4939 (54e); 5028

(54s); 5037 (54s); 5042 (54s); 5049 (54e); 5173 (54e: gammaglobuline); 5265 (54e); 5286 (54e); 5349 (54e); 5393 (54d); 0024 (55e); 0025 (55n); 1483 (55e); 1485 (55e); 1495 (55e); 1505 (55f); 1617 (55e); 1619 (55e); 1639 (55e: Canada); 1648 (55e); 1656 (55e); 1705 (55d); 1710 (55e); 1751 (55d); 1754 (55e); 1761 (55d); 1763 (55d); 1764 (55d); 1766 (55d); 1779 (55d); 1781 (55d); 1788 (55e); 1789 (55d); 1793 (55d); 1796 (55e); 1800 (55i); 1814 (55e: live vaccine); 1817 (55i); 1818 (55f); 1846 (55e); 1853 (55e); 1854 (55d); 1856 (55d); 1861 (55f); 1873 (55f); 1880 (55s); 1889 (55s); 1894 (55e); 1909 (55e); 1920 (55s); 1928 (55s); 1968 (55d); 2012 (55e); 2036 (55d); 2151 (55h); 2152 (55f); 2153 (55e); 2154 (55o); 2155 (55i); 2158 (55f); 2160 (55e); 2164 (55i); 2168 (55s); 2171 (55e); 2226 (55e); 2231 (55f); 2239 (55s); 2240 (55s); 2241 (55s: passive immunization); 2243 (55s); 2257 (55e: live vaccine); 2421 (55e); 2432 (55d); 2468 (55e); 2469 (55p); 2539 (55d); 2600 (55e: FRANCIS-report); 2624 (55n); 2627 (55s); 2635 (55n); 2636 (55f); 2643 (55s); 2867 (55d); 2980 (55f); 2983 (55e); 2999 (55e); 3072 (55e: field trials: USA); 3076 (55e); 3114 (55e); 3119 (55f); 3124 (55h); 3132 (55i); 3166 (55e); 3350 (55e: SALK-vaccine); 3351 (55e: SALK-vaccine); 3352 (55e: SALK-vaccine); 3952 (55p); 3967 (55i); 3975 (55e); 4019 (55e); 4038 (55e); 4065 (55d); 4176 (55i: field trial USA 1954); 4268 (55e); 4595 (55e); 4607 (55e); 4608 (55s); 4610 (55e); 4618 (55d); 4620 (55f: 3. Europ. Conf.); 5041 (55e); 5050 (55i); 5055 (55s); 5056 (55s); 5148 (55f); 5180 (55f); 5232 (55d: 3. internat. Conf. Rome); 5237 (55e: SALK-vaccine); 5257 (55e); 5261 (55n: FRANCIS-report); 5273 (55i); 5279 (55s: FRANCIS-report); 5283 (55s); 5395 (55d); 0410 (56e); 0547 (56b); 1522 (56e); 1551 (56e: USA); 1653 (56e); 1667 (56e); 1668 (56e); 1819 (56d); 1831 (56d); 1833 (56d); 1857 (56d); 1858 (56d); 1859 (56d); 1862 (56h); 1865 (56d); 1877 (56d); 1878 (56d: program of vaccination); 1901 (56e); 1931 (56d); 1953 (56d); 1962 (56d); 1997 (56d); 2033 (56d); 2035 (56d: FRANCIS-report); 2047 (56e: live vaccine); 2080 (56e); 2100 (56d: FRANCIS-report); 2159 (56e); 2166 (56f); 2169 (56s); 2170 (56f); 2172 (56f); 2176 (56d); 2177 (56e); 2178 (56e); 2181 (56f); 2182 (56f); 2183 (56e); 2188 (56s); 2189 (56s); 2227 (56e); 2309 (56u); 2310 (56e: «ideal»-vaccine); 2330 (56f); 2403 (56e); 2426 (56d); 2441 (56d); 2473 (56s); 2474 (56e); 2477 (56e); 2482 (56i); 2485 (56f); 2489 (56f); 2496 (56s); 2497 (56s); 2501 (56f); 2503 (56s); 2695 (56e); 2970 (56e: SALK-vaccine); 3017 (56n); 3069 (56d); 3115 (56s); 3118 (56s); 3130 (56s); 3131 (56f); 3963 (56e); 4279 (56i); 4621 (56f); 4622 (56e); 4624 (56e); 4754 (56f); 4764 (56e); 5058 (56e); 5065 (56i); 5181 (56d); 5185 (56p); 5186 (56p); 5187 (56p); 5235 (56f: SALK-vaccine); 5240 (56e: SALK-vaccine); 5241 (56e: live vaccine); 5242 (56e: SALK-vaccine); 5394 (56d); 5396 (56d); 5397 (56d); 5431 (56d); 5432 (56d); 5477 (56d); 0192 (57h); 0309 (57e); 0310 (57d); 0495 (57d); 0510 (57d); 0636 (57s); 0640 (57b); 0648 (57i); 0672 (57f); 0977 (57f: live vaccine); 0995 (57e); 1245 (57b); 1525 (57e); 1530 (57f); 1543 (57e); 1963 (57d); 1971 (57f); 2052 (57d); 2084 (57d); 2086 (57d); 2088 (57i); 2089 (57d); 2102 (57f: live vaccine); 2112 (57f); 2117 (57d); 2120 (57d); 2138 (57e: Congr. in Geneva); 2184 (57e); 2191 (57e); 2197 (57e); 2198 (57i); 2199 (57f: live vaccine); 2200 (57e); 2313 (57e); 2317 (57e: live vaccines); 2332

(57e); 2348 (57e); 2416 (57e: 4. internat. Conf. Geneva); 2417 (57r: 4. internat. Conf. Geneva); 2418 (57s: 4. internat. Conf. Geneva); 2419 (57e: 4. internat. Conf. Geneva); 2429 (57d); 2430 (57f: 4. internat. Conf. Geneva); 2431 (57d); 2433 (57d); 2494 (57s); 2495 (57f); 2500 (57f); 2502 (57e); 2504 (57i); 2505 (57t); 2512 (57e); 2515 (57h); 3012 (57e); 3013 (57e: FRANCIS-report); 3014 (57e: SABIN-vaccine); 3129 (57s); 3175 (57d); 3257 (57e: SALK-vaccine); 3368 (57e: live vaccine); 3382 (57d); 3945 (57f); 4088 (57i); 4266 (57i); 4267 (57f); 4476 (57d: 4. internat. Conf. Geneva); 4948 (57b: 4. internat. Conf. Geneva); 5019 (57d); 5206 (57e: SALK-vaccine); 5212 (57r: SALK-vaccine: USSR); 5319 (57e); 5325 (57d); 5415 (57d); 5435 (57d); 5476 (57d); 0235 (58e); 0301 (58d); 0302 (58d); 0356 (58e: live vaccine); 0394 (58e); 0509 (58d); 0532 (58f); 0554 (58f); 0584 (58d); 0586 (58d); 0587 (58f); 0610 (58e); 0615 (58e: program of vaccination); 0616 (58h: Netherlands); 0617 (58f); 0618 (58f: multiple antigens); 0620 (58f); 0629 (58d); 0674 (58f); 0676 (58d); 0677 (58e); 0683 (58e); 0687 (58s); 0689 (58f); 0690 (58e); 0760 (58e); 0852 (58d); 0861 (58i); 1034 (58i); 1142 (58d); 1145 (58f); 1146 (58f); 1234 (58f); 1244 (58i); 1246 (58d: Switzerland); 1250 (58h: program of vaccination); 1251 (58f: program of vaccination); 1254 (58i); 1325 (58s); 1488 (58f); 1533 (58e); 1534 (58e); 1538 (58e); 1540 (58e); 1590 (58e: live vaccination); 1592 (58e); 1593 (58e: live vaccination); 1594 (58e: live vaccination); 1599 (58e); 1600 (58e: live vaccination); 1601 (58e); 2115 (58f); 2121 (58d); 2248 (58d); 2324 (58f); 2347 (58d); 2928 (58i); 3383 (58e); 4086 (58d: SALK-vaccine); 4248 (58r: live vaccine); 4937 (58e: 4. internat. Conf. Geneva); 5313 (58i); 5409 (58d); 5421 (58d); 5460 (58e); 0431 (59e); 0432 (59e); 0462 (59e: USA); 0644 (59d); 0743 (59e: live vaccine); 0840 (59e: live vaccine); 0868 (59d); 0973 (59e: live vaccine); 0980 (59e: gammaglobuline); 0987 (59e: SALK-vaccine); 0994 (59d); 0999 (59d); 1000 (59d: live vaccine); 1005 (59e); 1054 (59d); 1088 (59e: program of vaccination); 1091 (59e); 1093 (59u: live vaccine); 1121 (59f: France); 1122 (59f); 1144 (59e); 1163 (59e: live vaccine); 1164 (59e: live vaccine); 1199 (59e: live vaccine); 1209 (59d); 1211 (59d); 1215 (59d); 1224 (59b); 1249 (59f: program of vaccination); 1253 (59f: live vaccine); 1289 (59f); 1290 (59f); 1301 (59f); 1302 (59d); 1341 (59f); 1394 (59d: live vaccine); 1403 (59d); 1404 (59e); 1409 (59f); 1414 (59f); 1422 (59e: live vaccine); 1428 (59d); 1430 (59e: live vaccine); 1661 (59f); 1936 (59f); 1987 (59e: live vaccine); 2132 (59e); 2133 (59e: live vaccine); 2134 (59e); 2267 (59f); 2270 (59i: live vaccine); 2285 (59r: conference: Moscow); 2291 (59e: live vaccine); 2367 (59r: live vaccine); 2368 (59r: live vaccine); 2369 (59r: live vaccine); 2415 (59n); 2447 (59d); 2521 (59s); 2533 (59d); 2848 (59i: VI. europ. Symposium); 3205 (59e); 4079 (59i); 4087 (59i: SABIN-vaccine); 4251 (59r: live vaccine); 4285 (59e); 5375 (59e: 12th WHO assembly, Geneva); 5389 (59d); 5403 (59d); 5453 (59d); 5457 (59s: live vaccine); 1176 (60d: multiple antigens); 1177 (60d); 1293 (60d); 1416 (60d: live vaccine); 1419 (60e); 1432 (60e: live vaccine); 1984 (60d: live vaccine); 2271 (60d: live vaccine); 2329 (60d); 2349 (60d); 2354 (60r: live vaccine); 2356 (60d: live vaccine); 2366 (60e); 2371 (60e: live vaccine); 2372 (60d); 2406 (60e: live vaccine); 2410 (60p); 2559 (60e: live vaccine: con-

ference: Moscow); 2578 (60h: live vaccine); 2611 (60i); 2612 (60e: US-recommendations: live vaccine); 2699 (60d); 2776 (60e: 5th Conf. Copenhagen); 2785 (60f); 2868 (60d: VI. europ. Symposium); 2901 (60f); 2923 (60r); 2947 (60e: live vaccine); 2960 (60e: SALK-vaccine); 3022 (60e: live vaccine); 3026 (60f: live vaccine); 3033 (60d); 3043 (60e: live vaccine); 3044 (60e: live vaccine); 3046 (60e); 3054 (60i: live vaccine); 3055 (60f); 3062 (60f); 3063 (60e); 3064 (60e); 3098 (60f); 3243 (60e: live vaccines); 3307 (60u: live vaccine); 3308 (60e: live vaccine); 3337 (60e: live vaccine); 3340 (60e: live vaccine); 3342 (60d); 3388 (60e); 3419 (60i); 3455 (60s); 3463 (60r); 3472 (60r: live vaccine); 3983 (60i: live vaccine); 3995 (60d); 4125 (60d); 4209 (60d); 4255 (60d); 4332 (60e); 4658 (60e); 4732 (60e: live vaccination); 5077 (60e: live vaccination); 5323 (60f); 5328 (60f: 5. internat. Conf.); 5331 (60e: 5. internat. Conf.); 5348 (60d); 5368 (60e: USSR); 5469 (60d); 2834 (61d); 2932 (61d); 3070 (61e); 3100 (61d); 3149 (61e: live vaccine); 3151 (61d); 3289 (61e: live vaccine); 3341 (61d); 3695 (61e); 4081 (61e: SABIN-vaccine); 4140 (61d); 4181 (61f: 5th Conf. Copenhagen); 4217 (61e); 4240 (61d); 4323 (61e); 4346 (61e: United Kingdom); 4358 (61d); 4599 (61e); 4627 (61d); 4639 (61d); 4641 (61d); 4645 (61e); 4648 (61e: live vaccination); 4659 (61b: SABIN-vaccine); 4661 (61i); 4693 (61i); 4855 (61e); 4857 (61e); 5078 (61e); 5144 (61e); 5354 (61e); 5355 (61e: live vaccine); 5356 (61i: 3rd internat. Symp.); 5360 (61f: Switzerland); 5362 (61e: Hungary); 5363 (61e: Sweden); 5466 (61d); 5473 (61e: live vaccine); 5481 (61f); 5495 (61f); 4875 (62d: live vaccination); 5339 (62d: live vaccine); 5350 (62e).

Vakzinetherapie / Vaccine therapy

Auch bei der Poliomyelitis hat man versucht, die bereits ausgebrochene Erkrankung durch eine Antigenzufuhr, also eine aktive Impfung, günstig zu beeinflussen. Soweit ich sehen kann, ist eine spezifische Vakzinetherapie (V.) bei der Poliomyelitis nicht versucht worden, wie sie bei einigen anderen Infektionskrankheiten zeitweise sehr geschätzt war. Die spezifische V. hat sich bei anderen Infektionen als gefährlich erwiesen, weil die zusätzliche Antigenbelastung zum Zusammenbruch der Abwehr des Makroorganismus führen kann, und ihr Wirkungsmechanismus ist nach klinischer Erfahrung vorwiegend unspezifisch. Dies mögen die Gründe dafür sein, daß bei der Poliomyelitis nur eine unspezifische V. mit heterologen Vakzinen oder fiebererzeugenden Antigenen gelegentlich versucht wurde. Im nachfolgenden habe ich auch die therapeutische Malariainfektion aufgeführt, soweit sie im akuten Erkrankungsstadium angewendet wurde, weil die Fiebertherapie mit Malariaparasiten ihrem Wesen nach auch eine V. ist.

s. a. Immunität, Unspezifität.

In poliomyelitis, too, attempts have been made at exerting a favourable influence on the disease after it has set in by antigen administration (i. e. active vaccination). So far as I can see, no specific vaccine therapy (V.) has been attempted in poliomyelitis, although these attempts have been con-

sidered very valuable at times in other infectious diseases. Specific V. proved to be dangerous in other infections because the additional antigen load can lead to a breakdown of the defence of the macro-organism, and its mechanism of action, clinical experience shows, is predominantly unspecific. This perhaps explains why in poliomyelitis only unspecific V. with heterologeous vaccines or pyretic antigens has sometimes been tried. Therapeutic malarial infection has also been presented in so far as used in the acute stage, because fever therapy with malarial parasites is essentially also vaccine therapy.

cf. Immunity, nonspecifity

0096 (11d: monkeys); 3889 (21e); 4374 (26i); 5091 (32d); 3658 (33u: antirabic vaccine); 3689 (33e: recovery after malarial paroxysm); 4704 (34u: antirabic vaccine); 0472 (35d: antirabic vaccine); 3655 (35s: antirabic vaccine); 3656 (35i: antirabic vaccine); 3657 (35d: antirabic vaccine); 4713 (35e: artificial hyperpyrexia: monkey); 2680 (37d: pyrifer); 4801 (37d: malaria therapy); 3910 (38d: pyrifer); 4158 (38i: autoliquortherapy); 3911 (39i: pyrotherapy); 4155 (39d: malaria therapy); 3703 (40s: tetanus toxin); 3704 (40s: tetanus toxin); 3909 (40d); 3913 (40i: diphtheria toxoid); 4817 (40d); 3783 (43s: tetanus toxin); 3912 (43e: pyrotherapy); 5218 (47d: pyrifer, vaccineurin); 5219 (48d: fever therapy); 5111 (49d: fever therapy); 5113 (49d: malaria therapy); 5109 (50d: pyrifer); 5143 (51d: bactifebrin); 0290 (52e); 5234 (55d: pyrifer).

Versuchstiere / Experimental animals

Hier sind alle Publikationen zusammengetragen, die Verwendbarkeit und Eignung von verschiedenen Tierspezies für experimentelle Zwecke beschreiben. Der jeweilige Verwendungszweck wurde in der Regel dem Zitat beigefügt. Die häufig verwendeten Versuchstiere, wie Affen, Goldhamster, Kaninchen, Mäuse, Meerschweinchen und Ratten, sind gesondert aufgeführt, während selten verwendete Tierarten und Mitteilungen allgemeinen und vergleichenden Inhaltes wieder unter «Allgemeines» zu finden sind.

s. a. Tierversuche.

This section presents all publications describing the use and suitability of various animal species for experiments. The exact purpose is, as a rule, also mentioned. Frequently used test animals such as monkeys, golden hamsters, rabbits, mice, guinea pigs, and rats, were separately collected; seldom used animal species and reports on general and comparative issues are again presented under «general».

cf. Animal experiments

Allgemeines / General

0418 (09d); 0719 (09d: infection experiments); 0106 (10e: sheep: immune serum); 0107 (10e: sheep, horse: immune serum); 2916 (10d); 4862 (11e); 4923 (14d); 5022 (15d); 0437 (16e: infection experiments with cocci); 0260 (17e: ROSENOW-serum); 0268 (17e: ROSENOW-serum); 0102 (18f: horse: immune serum); 0346 (18e: streptococcal etiology); 0347 (18e: streptococcal etiology); 0348 (18e: ROSENOW-serum); 3576 (18e: horse: serum production); 3618 (18e: small laboratory animals); 0493 (25f: mutton immune serum); 4373 (26f: horse: immune sera); 0136 (28e: horse, sheep: immune serum); 0801 (28e: streptococcal etiology); 4010 (28d); 0154 (30e: horse: immune serum); 0175 (30e: horse: immune serum); 0465 (30e: infection experiments); 1265 (30e: horse: immunization); 2205 (30e: production of immune serum); 3951 (30d: pathogenesis); 3994 (30d: pathogenesis); 0002 (31e: horse: immune serum); 0006 (31e: horse: immune serum); 0477 (31e: horse: immune serum); 0777 (31e: horse: immunization); 0780 (31e: goats and sheep: immunization); 4945 (31d); 0148 (32e: horse: serumprophylaxis and -therapy); 0198 (32e: goat and sheep: immune serum); 2201 (32e: normal antibodies); 0149 (33e: horse: immune serum); 0151 (33e: horse: immune serum); 0881 (33e: sheep: immune serum); 3617 (33e: transmission to rodents); 0153 (34e: horse: immune serum); 0200 (34e: serum of dog, sheep, goat, horse); 2008 (34e: horse: hyperimmune serum); 1085 (35e: sheep: production of serum); 3555 (35e: sheep: production of serum); 3628 (35e: resistance: laboratory animals); 4723 (36d); 4782 (36f: production of serum); 0474 (37e: horse: hyperimmunization); 4796 (37e: infection: X-rays); 0170 (38e: sheep: immune serum); 2851 (38d: infection: cattle); 3551 (38e: horse: production of serum); 4804 (38d: infection: cattle); 5129 (38e: hedgehog and agouti: resistance); 2669 (39e: immunization: sheep); 1835 (40e: comparison of neutralization tests); 2884 (40e: adaptation of virus); 3439 (40e); 3624 (40e: transmission: review); 3625 (40e: adaptation to rodent); 4813 (40f); 4820 (40e: rodents: nonspecific injections); 3623 (41e: adaptation to wild rodent); 3697 (41e); 4016 (41d: ferret: infection); 4794 (43e: adaptation of virus to rodents); 2738 (45e: rodent: interference); 3444 (45e: infection of muskrats and other rodents); 5137 (45d: neutralization test); 5382 (54f: sensitivity of certain rodents); 0891 (47e: antibodies by domestic and laboratory animals); 2007 (47e: infection experiments); 4309 (47i: susceptibility of cats); 4831 (47f: insusceptibility of lemurs); 4842 (47e: infection of flies); 0649 (48e); 5069 (48e: adaptation to rodents); 4426 (49e: WALLINGFORD-strain: rodents); 3442 (50d); 2633 (51e: antibody titers); 2685 (51e); 3457 (51e: horse: production of serum); 1643 (52e: infection: bat); 2608 (52e: infection of chicken embryo); 3424 (52e: infection of chicken embryo); 1740 (53e); 3107 (53e: cortisone: resistance); 3039 (54e: intratesticular inoculation); 4528 (54e: infection of cave bat (*Myotus lucifugus*)); 0697 (55e); 1805 (55f: immunization: donkey); 1815 (55i: diagnostic skin reaction); 4615 (55e: infection of cave bat); 4952 (56e: cave bat); 0851 (58e: chicken test); 0951 (58f: chicken test); 0959 (58e: vaccination: CFT); 1279 (59f: chicken test); 1303 (59e: chicken test); 1304 (59f: testing

of vaccine); 1309 (59d: testing of vaccine); 2281 (59e: chicken test: antigenicity of vaccines); 2374 (60f: antigenicity: chicken test); 2392 (60e: SALK-vaccine: potency test); 2456 (60e: antibody response: roosters); 2529 (60f: chicken test); 2921 (60r: sensitivity: steppe lemming); 3230 (60r: malignancy in continuous cell lines); 3371 (60d: pathogenesis); 4183 (61d: chicken test).

Affen / Monkeys

0414 (09d: infection experiments); 0418 (09d: infection experiments); 0423 (09d: infection experiments); 0424 (09f: infection experiments: chimpanzees); 0425 (09f); 0757 (09f: infection of chimpanzees); 2143 (09e: experiments for infection and viruspassage); 2144 (09e: experiments for infection and viruspassage); 2145 (09e: etiology); 2233 (09d: infection experiments); 4847 (09d: intraperitoneal infection); 0093 (10d: immunization); 0094 (10d: infection); 0095 (10d); 0098 (10f: immunization); 0099 (10f: immunization); 0100 (10f); 0104 (10d: antibodies after infection); 0108 (10e: reinfection); 0109 (10e: infection); 0317 (10e: infection route); 0373 (10f); 0377 (10d); 0415 (10d: infection experiments); 0419 (10d); 0420 (10d); 0421 (10d: immunization: carbol-vaccine); 0422 (10d: reinfection); 0466 (10f: immunity by reinfection); 0467 (10f: immunization); 0666 (10e: infection experiments); 0668 (10e: infection experiments); 0675 (10e: infection experiments); 1059 (10e: infection experiments); 1060 (10e: immunization); 1062 (10d: immunization); 1257 (10f: infection route); 1583 (10f: infection: M. cynomolgus); 2644 (10d: infection); 2755 (10d: pathogenesis); 3200 (10e: infection); 3440 (10e); 3562 (10e); 4848 (10d); 4849 (10f); 4850 (10f); 4873 (10e: pathogenesis); 4876 (10e: pathogenesis); 0090 (11e: neutralization test); 0096 (11d: immunization); 0359 (11f: Cynomolgus: infection experiment); 0834 (11n: mixed infection with vaccine-virus); 1048 (11e: infection); 1050 (11e: infection from dust of sickroom); 1190 (11e: infection route); 1435 (11d); 3252 (11f: infection); 3501 (11f); 4852 (11f: pathogenesis); 4853 (11f: pathogenesis); 4854 (11e: transmission); 4863 (11e); 4865 (11f); 4866 (11f: intranerval infection); 4868 (11e: contamination with infected fly); 4869 (11d); 4872 (11f: pathogenesis: tonsils); 4914 (11e); 5491 (11f: pathogenesis); 0097 (12d: Macacen: susceptibility); 0416 (12d: percutaneous infection: smallpox vaccination); 1255 (12f: infection, active immunization); 1548 (12d); 2203 (12e: distribution of virus: pathogenesis); 3406 (12e: infection); 4395 (12e: intracerebral infection); 4396 (12e: pathogenesis); 4400 (12f); 4401 (12f); 4402 (12f); 4403 (12f: intracerebral infection); 4404 (12e); 4406 (12f: pathogenesis); 4408 (12f); 4409 (12d); 4871 (12d: pathogenesis); 4909 (12e: transmission through *Stomoxys calcitrans*); 4918 (12e: transmission: *Musca domestica*); 4919 (12e: transmission: *Stomoxys calcitrans*); 0734 (13f); 3502 (13e); 4387 (13f); 4910 (13e: transmission through *Stomoxy calcitrans*); 4911 (13d); 0880 (14e: infection: virulence); 0898 (14e: intraspinal infection); 0899 (14e: viraemia); 1045 (14e: infection experiments); 1046 (14e: blood-CNS-barrier); 2735 (14e: pathogenesis); 4388 (14e); 4924 (14f: transmission: *Stomoxys calcitrans*); 4929 (14d); 3822 (15e: passive immunization); 4928 (15e: trans-

mission: *Lyperosia irritans*); 0255 (16e: etiology); 0256 (16e: etiology); 0257 (16e: etiology); 0265 (16e: etiology); 0374 (16e); 0376 (16e: serumtherapy); 3597 (16e: immunity); 0275 (17e: etiology); 0278 (17e: serumtherapy); 0281 (17e: serumtherapy); 0284 (17e: coccal etiology); 0440 (17e: infection experiments); 3285 (17e: etiology); 4926 (17s: susceptibility: different species); 0101 (18e: immunization); 0250 (18e: passive immunization: ROSENOW-serum); 0343 (18e: protection test with horse-serum); 0344 (18e: serum protection test); 0345 (18e: etiology: pleomorphic cocci); 0366 (18e: protection test with anticoccal horse serum); 0378 (18e: passive immunization: blood-CNS-barrier); 0397 (18e: serum protection tests); 0590 (18e: heat inactivated vaccine); 1076 (18e); 1359 (18e: passive immunization with horse serum); 3895 (18e: vaccination); 5278 (18e); 0124 (19e: infection: blood count); 0133 (19e: resistance: X-rays); 0134 (19e: passive immunization); 0135 (19e: nasopharynx); 3584 (19e: opsonins for streptococcus after infection); 1037 (20e: intranasal infection); 3264 (23e: serum treatment); 0888 (24e: live vaccine); 4539 (24e: virulence); 3506 (25d: spontaneous transmissibility); 4996 (25d); 0141 (27e: infection and immunization); 3323 (27e); 4541 (27e: immunization with ricinoleate virus); 0798 (28e: passive immunization); 4378 (28f: infection: virulence); 4379 (28f: pathogenesis); 4544 (28d); 5002 (28d: pathogenesis); 0887 (29e: active immunization); 1051 (29e: bloodsedimentation after infection); 1095 (29e: passive immunization); 1196 (29e: resistance); 3002 (29e: passive immunization); 3146 (29e: determination of activity of antiserum); 3263 (29e: infection); 3300 (29f: production of immune serum); 3947 (29f); 5003 (29e: pathogenesis); 5005 (29f: preparation of immune serum); 0089 (30e: neutralization test); 0142 (30e: infection and immunization); 0154 (30e: passive immunization); 0288 (30e: neutralization test); 0339 (30e: immunization with heat inactivated virus); 0340 (30e: neutralization test); 0341 (30e: neutralization test); 0354 (30e: neutralization test); 0447 (30e: different routes of immunization); 0831 (30e: adsorbed vaccines); 1073 (30e: serumtherapy); 1079 (30e: intradermal vaccination); 1184 (30e: infection routes); 1185 (30e: simultaneous vaccination); 1272 (30e: intracerebral infection); 2141 (30e); 3268 (30e: intratesticular infection); 4350 (30f: infection with mixed strains); 4552 (30e: virulence); 5007 (30f); 5008 (30e); 5012 (30i); 0001 (31e: vaccination: mixtures of virus and convalescent human serum); 0003 (31e: revaccinations: antibodies); 0004 (31e: aluminumhydroxyd-vaccine); 0005 (31e: accelerated febrile reaction: reinoculation); 0007 (31e: vaccination: mixtures of virus and convalescent human serum); 0408 (31e: active immunization: spleen injection); 0457 (31e: anaphylactic shock: revaccination); 0737 (31e); 0781 (31e: monkeys: simultaneous infection with vaccinia virus); 0832 (31e: reinfection); 1038 (31d: phenolized vaccine); 1104 (31e: influence of artificial fever: incubation period); 1946 (31e: infection and incubation period); 2206 (31e: nasal vaccination with live virus); 2208 (31e: intracerebral infection: virus distribution); 3185 (31e: missed and abortive infection); 3247 (31f: passive immunization); 4353 (31f: pathogenesis); 4553 (31f: oral infection); 4555 (31e: preparalytic stadium); 5013 (31f: pathogenesis); 5016 (31f: oral infection); 0015 (32e: vaccina-

tion: subinfectious, intracutaneous dose); 0198 (32e: passive immunization with goat- and sheep-immune serum); 0223 (32e: passive immunization with convalescent serum); 0558 (32e: virulence of passagevirus); 0791 (32e: immunity); 0896 (32e: herpes antibody); 1200 (32e: resistance); 1261 (32f: immunization); 1262 (32f: serumtherapy); 1271 (32e: intracerebral infection); 1948 (32e: etiology); 2201 (32e: normal antibodies); 2238 (32e: etiology); 4031 (32d: pathogenesis); 4064 (32f: passive immunization); 5086 (32f: susceptibility: season); 5087 (32e: intestinal infection); 5088 (32e: oral infection); 5089 (32e: resistance: X-ray); 0146 (33e: immunization); 0149 (33e: serumtherapy and -prophylaxis); 0150 (33e: infection experiments); 0151 (33e: passive immunization); 0379 (33e: neutralization experiments); 0808 (33e: virus during incubation period); 0809 (33e: intranasal infection); 0810 (33e: agglutinin titer changes after infection); 0812 (33e); 0892 (33e); 0900 (33e: neutralization test); 0955 (33e: neutralization test); 2010 (33e: provocation: reinfection); 2794 (33e: titration of virus); 2812 (33e: virus distribution: CNS); 3504 (33e); 4043 (33e: pathogenesis); 4673 (33e: early involvement of CNS after infection); 4679 (33f: oral infection); 5101 (33e: pathogenesis); 0145 (34e: immunization); 0152 (34e: immunization with active virus); 0225 (34e: immunization with different vaccines); 0735 (34e: nonspecific immunization); 0741 (34e: infection and vaccination: hormones); 0742 (34e: hormones); 0822 (34e: types of virus); 2008 (34e: passive immunization with horse immune serum); 3005 (34e: KOLMER-vaccine); 3408 (34e: infection); 3507 (34f); 3633 (34e); 3701 (34f: PETTIT-serum); 3891 (34e: KOLMER-vaccine); 4111 (34e: BRODIE-vaccine); 4312 (34e: pathogenesis); 4697 (34f: infection); 4710 (34f: incubation time); 4715 (34f: pathogenesis); 5102 (34e: intestinal infection); 5103 (34f); 5104 (34e: pathogenesis); 5106 (34e: paratyphoid-coli-filtrate: infection); 0718 (35e: reinfection); 0723 (35e); 0724 (35e); 0725 (35e); 0745 (35e: infection routes); 0755 (35e: resistance of *Ateles ater*); 0768 (35e: BRODIE-vaccine); 0815 (35e: adsorbed vaccine); 0816 (35e: infection through isolated intestinal loops); 0817 (35e: normal antibodies); 0818 (35e: BRODIE-vaccine); 0925 (35e: serumtherapy); 1023 (35e: immunization); 2272 (35e: prophylactic value of specific immune serum); 2744 (35e: pathogenesis); 2856 (35e: phenolized vaccine); 2857 (35e: intracutaneously immunization: living virus); 3407 (35f: infection); 3417 (35e); 3418 (35e); 3513 (35d); 3571 (35e: antibody: adrenalectomy); 3896 (35f: KOLMER-vaccine); 4013 (35e: infection); 4318 (35d: immunization: KOLMER-vaccine); 4705 (35e: infection with human spinal cords); 4712 (35e: infection); 4713 (35e: infection: hyperpyrexia); 4718 (35d: chimpanzees: spontane infection); 4719 (35e: immunization); 4777 (35f: immunization); 5108 (35e: paratyphoid-coli-filtrate: intracerebral infection); 0016 (36e: vaccination with mixtures of virus and serum); 0018 (36e: vaccination with Na-ricinoleate-vaccine); 0019 (36e: aluminumhydroxyd-vaccine); 0020 (36e: passive immunization); 0077 (36e: immunization); 0078 (36e: immunization); 0086 (36e: immunization); 0471 (36e: immunization); 0738 (36e: reinfection: antibodies); 0753 (36e: resistance); 0805 (36e: infection through isolated intestinal loops); 0823 (36e: infection experiments); 0824 (36e: passive immu-

nization); 0829 (36e: reinfection); 0877 (36e: neutralization test); 0878 (36e: prophylaxis with chemicals); 0879 (36e: resistance: age); 0883 (36e: immunity: antibody); 0886 (36e: chemoprophylaxis); 0901 (36e: castration: resistance); 0902 (36e); 0903 (36e: resistance: season); 0932 (36e: active and passive immunization); 1053 (36e: blood-CNS-barrier); 2672 (36e: intracutaneous infection); 3270 (36f); 3412 (36e); 3508 (36e: Marmoset monkey); 4293 (36e: pathogenesis); 4776 (36f: KOLMER-vaccine); 4783 (36e: nasal infection); 4789 (36e); 4836 (36e: prevention of intranasal infection); 5119 (36e); 5121 (36e: paratyphoid-coli-filtrate: infection); 0441 (37e: resistance: vitamine); 0481 (37e: resistance: vitamin C); 0482 (37e: antibody: nasal substances); 0728 (37e: reinfection); 0813 (37e: neutralization test: types of virus); 1043 (37e: immunization with ricinoleate-vaccine); 2754 (37e: infection and immunization: intranasal route); 2761 (37e: blood-CNS-barrier); 2762 (37e: blood-CNS-barrier); 3145 (37e: susceptibility: castration); 3154 (37e: sparing effect of dog distemper); 3425 (37e); 3585 (37e); 4298 (37e: pathogenesis: role of the spleen); 4792 (37e: infection: vitamin C); 4797 (37e); 4798 (37e: infection: vitamin C); 5126 (37e: infection); 0091 (38e: infection by the tonsillopharyngeal route); 0170 (38e: typing); 0342 (38e: intranasal infection); 0705 (38e: reinfection: specifity of strain); 2488 (38e: infection: CNS-barrier); 2659 (38e: immunization); 2690 (38e: differentiation of strain); 2742 (38e: pathogenesis); 2745 (38e: infection and immunization: intranasal route); 2760 (38e: canine distemper: poliomyelitis); 2874 (38e: reinfection); 3204 (38e: monkey: passive immunization); 3322 (38e: immunization); 3580 (38e); 5130 (38e: intracerebral inoculation); 5156 (38d: blood-CNS-barrier); 0526 (39e: M. cynomolgus: infection experiments); 0528 (39e: Rhesus-monkeys: intraocular infection); 0740 (39e: infection experiments); 0803 (39e: specifity of virustype); 2620 (39d: immunization); 2669 (39e: immunization); 2681 (39e: infection: viraemia); 2766 (39d: pathogenesis); 2811 (39e: sparing effect of lymphocytic choriomeningitis); 2858 (39e: humoral: tissue immunity); 2861 (39e: vitamin C-therapy); 2862 (39e: vitamin C); 2870 (39e: passive immunization); 2875 (39e: pathogenesis: lymphatic apparatus); 3600 (39e: reinfection); 4014 (39e: resistance); 4167 (39e); 4810 (39e: infection: olfactory nerve); 4811 (39e: reinfection: measles); 5155 (39e: blood-CNS-barrier); 5157 (39e: pathogenesis); 5158 (39e: pathogenesis); 5160 (39e: blood-CNS-barrier); 0156 (40e: immunological differentiation); 0157 (40e: infection and vaccination); 0327 (40e: infection); 0329 (40e: susceptibility: estrogen substances); 0710 (40e: chimpanzees: portals of entry of virus); 0927 (40e: spread of virus: infection by pharyngeal-intestinal route); 2752 (40e: infection and immunization: intracutaneous route); 2864 (40e: intraneural infection); 3590 (40e); 3698 (40e: sparing effect: lymphocytic choriomeningitis); 3883 (40e: vitamin D: susceptibility); 4133 (40e: pathogenesis); 4816 (40e: adaptation to cotton rat); 5170 (40e: resistance: sterile inflammation); 0023 (41e: chimpanzees: infection); 0159 (41e: infection: vitamin D); 0712 (41e: Rhesus-monkeys: reinfection); 0715 (41e: infection by oral and other routes); 0767 (41e: nonparalytic infection); 2065 (41e: antibodies: immunity); 3229 (41e: pathogenesis); 3503 (41e: transmission of murine strain);

3602 (41e: local immunity); 3609 (41e: susceptibility: estrogen); 4033 (41e: infection: spinal transaction); 4821 (41e: intraneural spread); 4828 (41e: progression of virus in nerves); 2711 (42e); 3414 (42e: oral infection); 3415 (42e: intrasciatic inoculation); 3626 (42e); 3946 (42e: oral infection); 0038 (43j: immunization with ultrasound vaccine); 0140 (43e: *Macaca mulatta*: infection); 0708 (43e: spontaneous acquisition of virus by Rhesus monkeys); 0713 (43e: susceptibility of *Cebus capucina* and *Cercopithecus cephus*); 0714 (43e: Cynomolgus monkey: resistance of CNS); 0766 (43e: Cynomolgus monkey: portal of entry); 0770 (43e: resistance: fatigue, chilling and trauma); 0910 (43e: susceptibility); 2607 (43e: antistreptococcal serum); 3423 (43e: inoculation of tooth pulp cavities); 3696 (43e: resistance: TAB-vaccination); 0475 (44e: susceptibility of East African monkeys); 0709 (44e: chimpanzees: spontaneous infection by accidental contagion); 0733 (44e: Rhesus monkeys: intranasal inoculation); 0764 (44e: Cynomolgus- and Rhesus monkeys: infection by inhalation); 4751 (44e: pathogenesis); 0121 (45e: chimpanzees: passive immunization); 0126 (45e: chimpanzees: nonparalytic infection); 0612 (45e: resistance: fatigue, chilling and trauma); 0621 (45e: infection experiments); 0623 (45e: accidental laboratory infection); 3228 (45e: nonparalytic infection); 5135 (45e: resistance: thiamine deficienc); 5136 (45e: South African black-face monkey); 5139 (45e: viraemia); 5379 (45e: intraspinal inoculation); 5381 (45e: susceptibility of vervet monkey); 3138 (46e: resistance: estrogens); 4836 (46e: folic acid: resistance); 5073 (46e: *Macaca mulatta*); 5385 (46f: *Aethiops sabaeus*: LANSING strain); 5386 (46e: pathogenesis); 0036 (47e: immunization with ultrasound vaccine); 0040 (47e: *Cercopithecus aethiops sabaeus*: resistance); 0042 (47e: immunization); 0043 (47e: immunization); 0326 (47e: oral infection of infant monkeys); 0711 (47e: chimpanzees: reinfection); 2686 (47e: susceptibility of *Cercocebus fuliginosus* and *Papio papio*); 2751 (47e: chimpanzees: pathogenesis); 4311 (47f: susceptibility of *Cercopithecus aethiops sabaeus*); 4839 (47e); 4840 (47e: virus levels in CNS); 5074 (47e: isoimmunization to CNS tissue); 5075 (47e: isoimmunization to CNS tissue); 0057 (48e: *Macaca mulatta*: resistance); 0058 (48e: *Macaca irus* [Philippinen]: susceptibility); 0059 (48e: *Macaca irus valida*, *Macaca irus mordax*, *Macaca philippinensis*: resistance); 0060 (48e: different species: resistance); 0061 (48e: Cynomolgus monkeys: resistance: tonsillectomy); 0160 (48e: infection: antibody response); 0649 (48e); 2656 (48e: immunization); 2749 (48e: oral infection); 2859 (48e: *Macaca mulatta*: reinfection); 2871 (48e: interference to murine virus); 3894 (48e: pathogenesis); 4334 (48e: infection with purified virus); 4335 (48e: increased susceptibility after typhoid vaccination); 5215 (48r); 0021 (49e: *Macaca mulatta*: active immunization); 0072 (49e: neutralization test); 0073 (49e: differentiation of types); 0179 (49e: reinfection: type of virus); 0180 (49e: differentiation of types); 2796 (49e: local antibody formation: CNS of convalescent); 3992 (49e: infection with mouseadapted virus); 4222 (49e: immunization); 4368 (49e: antibody distribution); 5070 (49e: chimpanzee); 0029 (50e: chimpanzees: infection); 0030 (50e); 0031 (50e: differentiation of types); 0034 (50e: immunization with adsorbed vaccines); 1531 (50e: antibodies in faeces after immunization); 2619 (50e:

persistence of antibody after immunization); 2674 (50e: infection: dentinal tubules); 2739 (50e: chimpanzees: immunity after inapparent infection); 2756 (50e: pathogenesis); 2757 (50e: pathogenesis); 3586 (50e: LANSING strain: Col.-SK-virus); 4055 (50e: antibody response); 4386 (50e); 4437 (50e: infection by mosquitoes); 4438 (50e: cross protection test: Japanese B encephalitis); 0037 (51e: use of adjuvants immunologic classification); 0045 (51e: immunologic classification); 0046 (51e: immunologic classification); 0047 (51e: immunologic classification); 0048 (51e: immunologic classification); 0049 (51e: immunologic classification); 0050 (51e: immunologic classification); 0051 (51e: immunologic classification); 0052 (51e: immunologic classification); 0132 (51e: tonsillectomy: gammaglobuline prophylaxis); 1532 (51e: serum alkaline phosphatase: infection); 1580 (51e: oral immunization); 1581 (51e: oral infection: differences in infectiousness of two related strains); 1602 (51e: gammaglobuline); 1608 (51e: bulbar paralysis: tonsillectomy); 1686 (51e: CFT after infection); 1700 (51s: *Ateles neglectus*: infection); 2028 (51e: resistance: ACTH); 2031 (51e: infection: ACTH); 2737 (51e: Cynomolgus: pathogenesis); 3435 (51e); 0173 (52e: chimpanzees); 1681 (52e: CFT after oral infection); 2004 (52e: Cynomolgus monkeys: passive immunization); 2030 (52e: chimpanzees: formaldehyde-inactivated vaccine); 2234 (52e: provocation with heterologeous vaccines); 2601 (52e); 2657 (52e: infection: vaccination); 2702 (52e: infection: viraemia); 2703 (52e: passive immunization: gammaglobuline); 2729 (52e: susceptibility of testicular tissue after immunization); 2730 (52e: virulence test); 2797 (52e: COXSACKIE-: polio infection); 2880 (52e: antibodies: immunity); 2882 (52e: antibodies: immunity); 2918 (52e: virulence: rodent-adapted strain); 3139 (52e: pathogenicity: passage in human tissues); 3140 (52e: chimpanzees: duration of immunity after vaccination); 3141 (52e: SALK-vaccine); 3364 (52e: intramuscular infection: hyaluronidase); 3367 (52e: production of immune serum); 4113 (52e: infection of *Cebus capucinus imitator* and *Alouatta palliata*); 4382 (52e: tonsillectomy: gammaglobuline); 4464 (52e: immunization); 0009 (53e: chimpanzees: passive immunization); 0292 (53e: Cynomolgus monkeys: intracardial infection: cortisone); 0294 (53e: infection: benzimidazole); 0295 (53e: vaccination: allergic encephalomyelitis); 0297 (53e: immunization: repeated ingestion of minute amounts of virus); 1449 (53e: tonsillectomy: gammaglobuline); 1749 (53e: nonspecific immunity after Newcastle-infection); 2002 (53e: chimpanzees: pathogenesis); 2632 (53e); 2732 (53e: passive immunization); 2962 (53e: normal antibody); 2963 (53e: typing of unknown strains); 2964 (53e: typing of unknown strains); 3361 (53e: classification of strains); 3404 (53e: antigenic typing); 3405 (53e: oral infection: Cynomolgus monkeys); 3422 (53e: oral infection: viraemia); 4044 (53e: pathogenesis); 4090 (53e: interference: Naja toxoids); 4468 (53f: susceptibility of *Cercopithecus mona nigripes* and *Papio leucophaeus*); 4469 (53f: plasma therapy); 4471 (53e: infection); 4492 (53e: immunization); 4500 (53e: infection: benzimidazole); 4502 (53e: infection: vitamin B_1); 4510 (53e: oral infection: low tryptophan diets); 4519 (53f: rabbit-adapted virus); 4524 (53pl: pathogenesis); 4561 (53pl: typing of strains); 4583 (53e: interference by toxoid); 0069 (54e: immunization); 1683 (54e: entry

and egress of infection); 1701 (54s: *Ateles vellerosus*); 1755 (54e: testing of uv-inactivated vaccine); 1803 (54e: infection and provocation); 2245 (54e: Cynomolgus monkeys: intravascular inoculation); 2246 (54e: chimpanzees: immunogenesis); 2247 (54e: chimpanzees: immunization); 2460 (54e: live vaccine); 2727 (54e: selective susceptibility of Ateles monkeys); 2894 (54e: immune barriers: pathogenesis); 2946 (54e: infection: Naja flava toxoid); 3028 (54e: preparation of standard antiserum); 4045 (54e: segregation of avirulent variants); 4521 (54d: virus isolation); 4529 (54e: interference with Col.-SK-virus); 4580 (54e: noncytopathogenic variant); 4582 (54e: brown fat in pathogenesis); 4584 (54e: interference: Naja flava neurotoxoid); 4585 (54e: chimpanzees: immunization with rodent-adapted strain); 5031 (54i: hyperactivity); 0512 (55i: M. cynomolgus: provocation: heterologeous vaccination); 0696 (55e: virus laboratory tests); 0839 (55e: safety test); 1552 (55e: Rh-sensibilization); 1610 (55e); 1647 (55e: pathogenesis: chimpanzees); 1775 (55e: antibody: immunity); 1776 (55e: testing of vaccines); 1777 (55d: infection and provocation); 1778 (55e: chimpanzees: avirulent strains); 1787 (55e: testing of vaccines); 1792 (55e: infection: physiological inhibitor of hyaluronidase); 1881 (55e: chimpanzees: live vaccine); 1895 (55e: SALK-vaccine: production and testing); 1905 (55f: Central African monkey: infection and immunization); 1924 (55e: chimpanzees: avirulent strains); 2157 (55e: antibody: immunity); 2249 (55e: in vivo-: in vitro-susceptibility); 2252 (55e: provoking effect: injections); 2256 (55e: chimpanzees: infection after immunization); 2758 (55e: viraemia: pathogenesis); 4036 (55e: attenuated virus variants); 4594 (55e: Cynomolgus: virus in wound tissue); 0978 (56e: safety test of inactivated vaccines); 1521 (56e: testing of vaccine); 1696 (56e: *Ateles niger*: infection); 1871 (56h: live vaccine); 1900 (56e: testing of vaccine); 1903 (56e: testing of vaccine); 1914 (56d: infection: antibody); 1916 (56e: testing of vaccine); 1919 (56e: testing of vaccine: guinea-pig test); 1921 (56d: pathogenesis); 1929 (56e: antigenicity test); 2078 (56e: testing of vaccine); 2109 (56e: antibody: β-globulinefraction); 2119 (56e: chimpanzees: virus distribution after infection); 2306 (56d: immunization SALK-vaccine: antibodies); 2307 (56d: susceptibility: cortisone); 2314 (56e: oral administration: virus distribution); 2424 (56r: type 4); 2481 (56e: safety test); 4161 (56e: pathogenesis); 4940 (56e: interference: neurotoxoids); 5444 (56e: infection: helenine); 5448 (56d: perivenoese encephalomyelitis after immunization); 0387 (57e: virulence test); 0536 (57e: virulence test); 0940 (57e: testing of live vaccines); 0941 (57e: testing of live vaccines); 1252 (57e: multiple antigen); 1479 (57e: testing of British vaccine); 1943 (57e: chimpanzees: immunization and infection); 1972 (57e: testing of vaccine); 2043 (57d: Cynomolgus monkeys: infection: cortisone and X-rays); 2068 (57e: virus distribution after infection); 2118 (57i: provocation: heterologeous vaccinations); 2595 (57e: neurotropism: naturally occuring attenuated strain); 3368 (57e: live vaccine: virulence test); 4946 (57e: antibody response: British SALK-vaccine); 4949 (57e: stomachal infection); 0190 (58e: mixed infection with polio- and COXSACKIE-virus); 0331 (58e: intraspinal infection: passive immunization); 0553 (58s: Cynomolgus monkeys: vaccination with SALK-vaccine: Mexico); 0557 (58e: contact transmission); 1345

(58e: passive immunization); 1412 (58i: infection: provocation); 1539 (58e: planning); 2334 (58e: virulence of SABIN-strains); 3505 (58e: neurotoxoid interference); 0385 (59e: virulence test); 0662 (59e: testing of vaccine); 0866 (59e: antibody: virus excretion after infection); 1011 (59e: serumtherapy); 1170 (59e: antibody response); 1281 (59e: immunization); 1282 (59e: virulence test); 1286 (59e: virulence test); 1344 (59f: virulence test); 2300 (59r: live vaccine); 2438 (59e: Cynomolgus: alimentary infection); 2910 (59e: antibody response: Taiwan monkey); 3156 (59e: virulence of attenuated strains); 3208 (59e: neurovirulence of live vaccine strains); 3216 (59e: neurovirulence test); 3222 (59e: control: SABIN-vaccine); 3227 (59e: neurotropism: virulence for man); 1424 (60e: live vaccination: viraemia); 1433 (60e: testing of Cox-vaccine); 1989 (60e: vaccination and infection); 1991 (60e: testing of vaccine); 2296 (60e: safety test); 2308 (60d: immunization: adsorbed vaccine); 2389 (60e: neurovirulence: attenuated strains); 2457 (60e: viruses carried by monkeys); 2525 (60e: neurovirulence test); 2573 (60e: inhibitor from CNS); 2779 (60e: chimpanzees: digestive tract: gammaglobuline); 2915 (60e: neurovirulence test); 2944 (60e: antigenic structure of type 1 strains); 2971 (60e: passive antibody: virus excretion); 3248 (60e: neurovirulence test); 3449 (60r: latent viruses); 4138 (60f: Congo: wild monkey: antibody distribution); 4187 (60i: cutaneous reactivity after immunization); 4302 (60e: infection with egg-adapted virus); 4727 (60e: SV 40); 4887 (60e: standardization of SALK-vaccine); 4930 (60e: neurovirulence test); 4957 (60e: neurovirulence test); 4958 (60e: neuropathogenicity: attenuated strains); 4960 (60e: Simian virus); 4962 (60e: neurovirulence test); 5036 (60e: neurovirulence test: CHAT- and FOX-strain); 5310 (60e: neurovirulence test); 3339 (61e: pathogenicity: t-marker); 4146 (61e: neural block: pathogenesis); 4147 (61e: viraemia: intramuscular injection: antibody); 4148 (61e: neurovirulence test: live vaccine); 4202 (61e: infection: traumatized tissue); 4205 (61e: safety test: virus B-infection); 4216 (61e: SABIN's strain: viraemia); 4628 (61d: ultrastructure of CNS after infection); 4630 (61e: safety test for SALK-vaccine); 4631 (61e: safety test for concentrated SALK-vaccine); 4726 (61e: Simian foamy virus); 4747 (61d: neuropathogenicity: live vaccine strains); 4884 (61d: enteritis-infection); 4897 (61e: virulence of attenuated strains: subcutaneous injection); 4971 (61e: neurovirulence test); 4973 (61e: neurovirulence test); 5072 (61d: neuropathogenicity test); 5122 (61e: neurovirulence test); 5266 (61e: residual neurotropism: live vaccines); 5357 (61e: neurovirulence test); 5447 (61e: technique of intraspinally inoculation).

Goldhamster / Syrian hamster

0897 (42c); 4431 (49e: susceptibility); 2211 (50e: cortisone); 2298 (52e: cortisone); 4444 (52e: infection: cortisone); 4447 (52e: intraperitoneal infection: cortisone); 0298 (53e: parenteral infection: cortisone); 1747 (53e: cortisone); 3106 (53e: infection: cortisone); 3399 (53e: infection: cortisone); 1694 (54e: hormones); 1960 (54e: cortisone); 4587 (54e: infection with Saukett strain); 1759 (55i: provocation with heterologeous vaccines); 2251 (55e: susceptibility);

4593 (55e: infection of fetal hamsters); 4612 (55e: infection); 4614 (55e: infection); 1842 (56e: cortisone); 4758 (56e: brown fat); 4768 (56e: castration: cortisone); 4906 (56i); 4951 (56e: suckling hamster); 4953 (56e: suckling hamster: infection by lactation); 0517 (57i: season: resistance); 2069 (57e: nonspecific immunization with Columbia-SK-virus); 2118 (57i: provocations with heterologeous vaccinations); 2733 (57e: infection: cortisone and stress); 4904 (57s: Col.-SK-virus).

Kaninchen / Rabbits

0719 (09d: infection experiments); 0720 (09d: infection experiments); 0466 (10f: infection); 1062 (10d: infection); 1263 (10d: infection); 1264 (10d: infection); 4846 (10d); 4848 (10d); 1049 (11e: infection); 4869 (11d); 4393 (12f: infection); 4407 (12f: infection); 0255 (16e: etiology); 0256 (16e: etiology); 0257 (16e: etiology); 0274 (16e: etiology); 3631 (16e); 3632 (16e); 0363 (18e: etiology); 1036 (18e: antiserum); 4538 (22e: infection); 3630 (24e: infection); 4540 (26i: infection); 3629 (29e: infection); 0142 (30e: infection and immunization: polio-virus or mixture of polio-vaccinia-virus); 0464 (30e: infection experiments); 4674 (33d: infection); 0200 (34e: antibody response); 4105 (48f); 4310 (48e: immunization); 4420 (48e: immune sera); 4369 (49f: immune sera); 1951 (50f: infection); 3197 (50f: infection); 2041 (53f: rabbit-adapted virus as live vaccine); 4519 (53f: virus-adaptation); 2718 (54e: immune serum); 1631 (55e: production of type specific antisera); 1773 (55d: antibody response); 2340 (55i: neutralizing sera); 1665 (56e: specific flocculation reaction); 4752 (56i: infection); 0634 (57i: immunization: treatment of spleen with ultrasound); 1520 (57r: production of serum); 0331 (58e: production of immune serum); 1345 (58e: hyperimmune gammaglobuline); 1141 (59b: production of reference sera); 1413 (59i: infection); 3241 (60f: precipitins); 4211 (60e: rapid production of antisera).

Mäuse / Mice

0465 (30e: infection); 0811 (33e: infection: mucin); 5098 (33e: pathogenesis); 3410 (35e: adaptation of type 1); 3511 (35e); 0821 (36e: infection: mucin); 3509 (36f: adaptation); 4781 (36e: infection after thyroidectomy and castration); 4783 (36e: nasal infection); 2647 (39e: infection from cotton rat); 1835 (40e: neutralization test); 2884 (40e: adaptation of virus); 3948 (40e); 5171 (40f: infection: X-ray); 0158 (41e: protection test with human convalescent serum); 2663 (41e); 4128 (41f: resistance); 4129 (41f: resistance); 5168 (41e: serumprotection test); 0885 (42e: neutralization test); 0893 (42e: resistance: thiamine intake); 0895 (42e: neutralization test); 3286 (42f: immunization); 3287 (42f); 3510 (42f: adaptation of LANSING strain); 4066 (42f: vaccination); 4827 (42e: infection with SK-virus); 5076 (42e: neutralization test); 0070 (43e: protection test with human convalescent serum); 0128 (43e: neutralization test); 0138 (43e: neutralization test); 0139 (43e: THEILER-virus: LANSING virus); 0732 (43e: food intake: resistance); 0771 (43e: vitamine); 3848

(43e: neutralization test); 0476 (44e: resistance: vitamin B); 0765 (44e: food intake: resistance); 2668 (44e: susceptibility: thiamine diet); 2750 (44e: resistance: vitamin B_1-diet); 3411 (44e: resistance: pantothenic acid deficiency); 3885 (44e: riboflavin: susceptibility); 3890 (44e: uv-inactivated vaccine); 5134 (44e: pathogenesis); 0125 (45e: serum protection test); 0622 (45e: neutralization test); 3958 (45e: resistance: estrogen); 4571 (45e: immunization); 4574 (45e: immunization with uv-inactivated vaccine); 5380 (45e: susceptibility: pyridoxine, inositol and biotin); 1259 (46e: neutralization test); 3137 (46e: resistance: various hormones); 3173 (46e: resistance: temperature); 3189 (46e: resistance: thiouracil); 3956 (46e: resistance: various dietary deficiencies); 4837 (46e: neutralization test); 5384 (46f: infection: LANSING strain); 0041 (47e: neutralization test); 0371 (47e: resistance: estrogen substances); 0372 (47e: immunization); 0884 (47e: neutralization test); 0891 (47e: neutralization test); 2660 (47e: infection from human blood); 4308 (47e: active immunization with formolized vaccine); 4841 (47e: susceptibility of crossbred mice); 0032 (48e: susceptibility); 0033 (48e: neutralization test); 0701 (48e: immunization under passive protection from immune mother); 1269 (48e: neutralization test); 2717 (48e: thyroxin: susceptibility); 4420 (48e: immunization); 4425 (48e: resistance: oxythiamine); 4427 (48f: pathogenicity of LANSING strain); 4720 (48e: immunization with Col.-SK- and THEILER-virus); 4835 (48e: interference test); 5216 (48d); 0774 (49e: congenital immunity); 4341 (49e: technique for transmission); 4365 (49e: resistance: nutrition); 4367 (49e: infection: suckling mice); 4423 (49e: interference: laboratory test); 5217 (49e); 0030 (50e); 0065 (50e: passive immunization of young mice from actively immunized mothers); 1497 (50e: antigen for CFT); 2211 (50e: cortisone); 2235 (50e: resistance: gestation); 2706 (50e: resistance: gestation); 2720 (50e: newborn mice: relative resistance); 2721 (50e: resistance: pregnancy); 4436 (50d: resistance: seasonal relationship); 0064 (51e: neutralization test and serum protection test); 0894 (51e: resistance: heterologeous vaccinations); 1536 (51e: increase in virulence after passage); 1686 (51e: antigen for CFT); 1690 (51e: interference with COXSACKIE-infection); 2652 (51e: ACTH: infection); 2712 (51e: intraspinal inoculation); 2714 51e: adaptation of LEON strain); 2715 (51e: suckling mice: intraperitoneal susceptibility); 2736 (51e: adaptation of LANSING-strain); 3083 (51e: adaptation of MEF_1 to newborn mice); 1137 (52e: provocation with heterologeous vaccines); 1450 (52e: infection); 1451 (52e: infection); 1603 (52e: immunization); 1642 (52e: passive protection test with gammaglobuline); 1644 (52e: provocation with allergens and antibiotics); 2213 (52e: cross-immunity: polio: rabies); 2298 (52e: infection: cortisone and ACTH); 2599 (52e: adaptation); 2657 (52e: infection: vaccination); 2728 (52e: antibody titration); 2876 (52e: newborn mice: infection); 2889 (52e: adaptation to newborn mice); 3179 (52e: resistance: amino acid unbalance); 3362 (52e: infection: statistical analysis); 4457 (52e: resistance: methionine); 4458 (52e: resistance: deficiencis of amino acids); 4460 (52e: adaptation); 4462 (52e: resistance); 4463 (52e: interference to COXSACKIE infection); 4477 (52d: virus isolation); 4493 (52i: transmission of immunity); 0294 (53e: infection: benzimidazole); 1613 (53e:

production of antigen for CFT); 1974 (53s: CFT-antigen); 2731 (53e: infection: hyper- and hypothyroidism); 2804 (53e: cross-immunity: rabies); 2966 (53e: protection test: tissue culture neutralization test); 2967 (53e: protection test with small amount of blood); 3443 (53e: infection with type 3); 4047 (53e: passive immunization: gammaglobuline); 4048 (53e: susceptibility: mice); 4466 (53pl: neutralization test); 4471 (53e: suckling mice: infection); 4500 (53e: infection: benzimidazole); 4510 (53e: infection: tryptophan); 4512 (53e: mixed infection: COXSACKIE virus); 1758 (54i: provocation with heterologeous vaccines); 2223 (54e: collodion capsules for immunization); 2723 (54e: adaptation of type 1 strains); 2798 (54e: neutralization test); 2853 (54f: protection test); 3040 (54e: intravenous infection); 3426 (54e: adaptation of type 3); 3427 (54e: infection with type 1); 3433 (54e: infection with type 1 and 3); 4527 (54i: infection doses: incubation period); 4581 (54d); 4601 (54i: infection); 5035 (54i: DP-vaccination: resistance); 0696 (55e: neutralization test); 1679 (55e: protection test); 1767 (55e: immunization with heat inactivated vaccine); 1780 (55e: testing of vaccine); 1797 (55d: testing of adsorbed vaccine); 2740 (55e: antigenicity test); 4604 (55i: resistance: fatigue); 4613 (55e: infection: PNA); 4616 (55f: infection of newborn mice); 4756 (55r: infection); 5302 (55e: intracerebral inoculation); 5303 (55d: infection); 5309 (55i: resistance: fatigue); 2173 (56e: adaptation of avirulent variants); 2424 (56r: type 4); 2809 (56e: infection: incubation period); 4770 (56d: adaptation of type 1: immunization); 5305 (56e: pathogenesis); 5444 (56e: infection: helenine); 0234 (57f: sensibilization); 0516 (57e: passive immunization with monkey immune serum); 2087 (57e: testing of vaccine); 2118 (57i: provocation: heterologeous vaccinations); 2688 (57d: neutralization test); 2795 (57e: virulence of type 2); 4907 (57e: interference: COXSACKIE-virus); 4941 (57e: adaptation of MAHONEY strain); 0245 (58d: polio-resistance after COXSACKIE-infection); 0308 (58e: infection: interference with rabies virus); 0865 (58e: interference: polio- and COXSACKIE-infection); 4935 (58e: interference: COXSACKIE-virus); 4936 (58e: interference: COXSACKIE-virus); 1055 (59d: vaccination during incubation period); 1636 (59r: cortisone and infection); 1716 (59e: interference with COXSACKIE-infection); 1992 (59f: infection: hyperthermy); 2905 (59r: antibody response: cortisone); 5391 (59e: adaptation of type 1: suckling mice); 1408 (60d: provocation); 2437 (60e: virulent and attenuated virus: RNA); 2458 (60e: antagonism between COXSACKIE virus and LANSING strain); 3095 (60f: neurovirulence: hyperthermy); 4186 (60b: peritoneal neutralization test); 4636 (61e: infection: mucin).

Meerschweinchen / Guinea pigs

4393 (12f: intraperitoneal infection); 4407 (12f: infection); 4008 (13e: infection); 4538 (22e: infection); 3506 (25d: spontaneous transmissibility); 4996 (25d); 0465 (30e: infection); 3683 (32e: passive immunization); 5085 (32e: specific toxic factor: stools and urines of patients); 5090 (32e: specific toxic factor: stools and urines of patients); 0952 (33e: infection: spleenectomization); 0200 (34e: antibody response); 3503 (41e: transmission of murine strain); 4826

(42e: infections with SK-virus); 4827 (42e: infections with SK-virus); 2687 (47e: susceptibility: relation to age); 4307 (47e: sensitization with Simian or rodent virus); 4339 (48e: infection: interference); 0839 (55e: testing of vaccine); 1884 (55i: testsera); 2981 (55e: potency test); 1886 (56i: testing of antigenicity); 1887 (56i: infection); 1919 (56e: testing of vaccine); 2306 (56d: immunization: SALK-vaccine: antibodies); 4012 (56e: immunogenic capacity test); 4760 (56e: SALK-vaccine: antigenicity test); 0234 (57f: sensibilization); 0857 (57e: testing of vaccine); 1252 (57e: multiple antigens); 2064 (57e: testing of antigenicity); 2090 (57e: testing of combined antigen); 2493 (57n: SALK-vaccine: effectiveness); 2595 (57e: antigenicity: attenuated strain); 4946 (57e: antibody response: British SALK-vaccine); 0503 (58e: potency test); 0631 (58e: antibody response); 0849 (58e: potency test); 0850 (58e: potency test); 1031 (58d: antibodies after adsorbed vaccine); 1032 (59e: testing of vaccine); 1056 (59d: antigenicity); 1089 (59d: testing of vaccine); 1134 (59d: testing of adsorbed vaccines); 1141 (59b: production of standard serum); 1378 (59he: testing of vaccine); 2567 (60e: antisera); 2782 (60e: preparation of type-specific anti-N- and anti-H-indicator sera); 2941 (60i: skin test after vaccination); 4187 (60i: cutaneous reactivity after immunization); 5499 (62e: CF-antibodies after inoculation).

Ratten / Rats

4407 (12f: infection); 3949 (37e: pathogenesis); 2645 (39e: eastern cotton rat); 3621 (39e: cotton rat); 0172 (40e: *Sigmodon hispidus hispidus*); 3618 (40e: *Sigmodon hispidus littoralis* rats); 3622 (40e: cotton rat); 3948 (40e: cotton rat); 3959 (40e: cotton rat: pathogenesis); 4009 (40e: cotton rat: spreading factor); 4816 (40e: adaptation to cotton rats); 2663 (41e: cotton rat); 3365 (41e: cotton rat); 3616 (41e: cotton rat); 3620 (41e: cotton rat); 3680 (41e: antigenicity of cotton rat strain); 3626 (42e); 0730 (43e: resistance: vitamin B_1); 0068 (44e: cotton rat: resistance); 0476 (44e: resistance: vitamin B); 2593 (45e: cotton rats: inanition and sex: resistance); 0484 (46e: resistance: cotton rat: vitamine and sex); 3955 (46e: cotton rat: vitamin A, inanition and sex); 2673 (47e: cotton rat); 2722 (47e: cotton rat: CF-antigen); 3155 (47e: cotton rats: immunization); 4333 (47f: susceptibility: cotton rat); 4972 (47e: acceleration of infection); 0032 (48e: cotton rat); 4098 (48s: age: susceptibility); 4310 (48e: infection); 0030 (50e: cotton rat); 0056 (51e: cotton rat: antigen for CFT); 1541 (51e: cotton rat: immunization); 1542 (51e: cotton rat: immunization); 1582 (51e: cotton rat: antigen for CFT); 2716 (51e: cotton rat: CF-antigen); 2601 (52e: cotton rat: CF-antigen); 4446 (52e: virus titration: cotton rats); 4450 (52e: pathogenesis: cotton rats); 2723 (54e: adaptation of type 1 strains); 4756 (55r: infection of cotton rats); 1875 (56e: testing of vaccine: cotton rat); 2424 (56r: type 4); 4946 (57e: antibody response: British SALK-vaccine); 1267 (59e: testing of vaccine); 1635 (59r: cotton rat: brain stem); 1636 (59r: cotton rat: cortisone); 1660 (59r: rapid determination of potency of vaccines); 4085 (60e: white rats: potency of SALK-vaccine).

AUTOREN-INDEX / INDEX OF AUTHORS

HERAUSGEBERARTIKEL / EDITORIAL

27, 45, 53, 66, 74, 81, 83, 117, 178, 196, 247, 271, 300, 301, 322, 406, 412, 426, 428, 445, 491, 531, 532, 561, 595, 603, 639, 642, 661, 663, 744, 746, 747, 754, 772, 775, 792, 795, 800, 824, 868, 957, 960, 973, 974, 976, 978, 1009, 1065, 1066, 1067, 1070, 1081, 1084, 1094, 1101, 1103, 1173, 1174, 1197, 1328, 1333, 1354, 1385, 1434, 1436, 1437, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1459, 1533, 1534, 1535, 1537, 1538, 1539, 1540, 1545, 1551, 1557, 1558, 1559, 1568, 1571, 1575, 1576, 1584, 1585, 1588, 1589, 1590, 1618, 1619, 1649, 1652, 1656, 1667, 1668, 1673, 1674, 1715, 1720, 1944, 1972, 1976, 1978, 1999, 2000, 2020, 2022, 2057, 2130, 2136, 2138, 2139, 2156, 2161, 2162, 2163, 2210, 2219, 2243, 2262, 2274, 2276, 2277, 2278, 2279, 2280, 2285, 2432, 2483, 2485, 2520, 2559, 2654, 2691, 2747, 2784, 2853, 2919, 2923, 3035, 3063, 3064, 3070, 3072, 3076, 3077, 3078, 3079, 3166, 3289, 3302, 3332, 3349, 3350, 3352, 3360, 3372, 3388, 3448, 3638, 3661, 3714, 3718, 3728, 3772, 3847, 4063, 4068, 4080, 4081, 4096, 4104, 4115, 4192, 4329, 4472, 4481, 4497, 4532, 4546, 4547, 4588, 4597, 4606, 4607, 4619, 4670, 4677, 4678, 4680, 4687, 4698, 4702, 4764, 4780, 4812, 4822, 4844, 4937, 5048, 5058, 5060, 5173, 5206, 5211, 5220, 5223, 5227, 5235, 5236, 5237, 5294, 5313, 5319, 5350, 5375, 5389, 5405, 5407, 5410, 5412, 5414, 5416, 5453, 5454, 5463, 5498

A

ABABEI, R. 1025
ABAD-GOMEZ, H. 1226, 2292, 3172
ABBE, D. 409
ABBOTT, M. 4501
ABEGG, W. 4824
ABELSON, N. M. 1552
ABINANTI, F. R. 4630, 4631
ÁBRAHÁM, E. 1340
ABRAMSON, H. 1544, 1547, 4486
ABRAMSON, H. A. 1709
ABRAMSON, H. L. 101, 176, 590, 3895
ABT, A. F. 236
ACCORTI, C. 2730
ACKERMANN, R. 2582
ACKERMANN, W. W. 395, 1129
ACOSTA, J. C. 2289
ACUÑA, M. 3842
ADAM, E. 843, 844, 847, 848, 1007, 3235, 3391
ADAM, J. 2380
ADAMOVÁ, V. 843, 844, 847, 848, 1007, 3235, 3391
ADAMS, J. M. 132, 1149, 4047, 4382
ADAMS, M. 112
ADAMSON, J. D. 436, 4265

Addair, J. 3879
Adler, M. 2251
Aderca, I. 2288, 2295, 2958, 3452, 4072, 4186
Adriaensens, J. 1350
Affeldt, J. E. 2032
Agate, G. H. 867, 2363, 2974
Ager, L. C. 3280
Agerholm, M. 1556, 1594
Agnese, G. 517, 634, 1330, 1891, 2074, 2789, 2904, 4728, 4956, 5441
Agol, V. I. 2922, 4691, 5274, 5369
d'Agostino, S. 1231, 1235, 1239, 1957, 2260, 2395, 2412, 2413, 2700, 2959, 2979, 4124, 5377, 5378
Ágoston, E. 5301
Ainbender, E. A. 4954
Ainslie, J. D. 1450, 1451, 1531, 1532, 1536, 1685, 2031
Aisenberg, M. S. 3423
Ajello, G. W. 4250
Akin, B. A. 2946, 3505, 4090, 4583, 4584, 4940
Alajouanine, 3245
Albano, A. 2565, 2689, 3082, 3395, 3430, 4087, 4753, 5485, 5486, 5487
Albrecht, J. 2698, 4637
Albrecht, R. M. 177, 2583, 2584, 3161, 4191
Alcocer, J. J. 2293, 2409, 5043
Alcock, A. J. W. 983, 2319, 3347
Alder, A. 3910
Aldershoff, H. 3513, 3514
Aleksandrova, V. P. 4239
Alekseyev, B. P. 4232
d'Alessandro, G. 1456, 1886, 2088, 3045
Alexa, I. 1276
Alexander, E. R. 4224
Alexander, H. E. 988, 1784, 2452
Alexander, M. 3478
Algora Nieto, M. 776
Alivisatos, G. P. 1843, 4344
Allaria, G. B. 3183
Allemand, H. 3544
Allen, F. M. 2223
Allen, J. E. 1452, 1706, 1710
Allen, W. A. 2407
De Almeida, R. 2410
Alonso, S. 5028
Alonso Jimeno, S. 13
Alsén, P. 3320
Alterthum 5000
Altevogt, R. 507, 890
Altman, J. S. 3641
Al'tshtein, A. D. 2925
Alvarez Alva, R. 2503, 5018
Alvarez-Amezquita, J. 2359, 2513
Alvarez, M. R., s. Ramos Alvarez, M.
Alves, M. W. 197
Aly, F. W. 3369
Ames, P. G. 1579, 1821, 1838
Ames, W. R. 2819
Ammon, H. 68
Amoss, H. L. 133, 135, 250, 278, 279, 280, 316, 378, 397, 880, 888, 898, 899, 1037, 1045, 1046, 1268, 1360, 2735, 3264, 3299, 3581, 3766, 3845, 3846, 4539, 4914
Amshel, J. 4177
Amyot, R. 2261
Anand, B. R. 4285
Anderlik, P. 5258, 5304
Anders, W. 870, 1027, 1136, 1232, 1457, 1458, 1822, 2273, 3993, 4103, 4738, 4898, 5195
Andersen, E. B. 1453
Anderson, C. P. 619, 1935
Anderson, D. M. 2865
Anderson, G. 238, 4441
Anderson, G. W. 238, 1454, 1546, 1955, 4441
Anderson, I. M. 4433
Anderson, J. A. 486, 774, 3137
Anderson, J. C. 2722, 3155
Anderson, J. F. 90, 3574, 4910, 4919
Anderson, O. 1994
Anderson, O. L. 1614, 1801, 1816
Anderson, T. 2506
Ando, K. 1613
Ando, O. 2448
Andrèn, G. 3687
Andreoni, G. 1312, 3097
Andrieu, G. 1146
Andzhaparidze, O. G. 2301, 4966, 5449
Angela, G. C. 576, 647, 660, 1143, 1983, 2198, 2848, 2992, 4266, 5031, 5065, 5188
Angel Aguilera, P. M. 4860

Angela-Artino, G. 4693
Angelillo, B. 2083
Anglin, C. S. 3402
Angolotti, E. 1455
Ansaldi, N. 3058, 3314, 3328
Anslow, R. O. 1686, 2736
Anz, W. 390, 2542
Appleyard, G. 2773
Aragona, F. 3193
Aráoz Alfaro, G. 3709, 3722, 3730
De Araújo Moraes, N. L. 3972
Arce 1182
Archetti, I. 1203, 1204, 1300, 2438, 4942
Arcuri, F. 1815, 4187, 4604
Arens, H. 5219
Ari, A. 2924
Arion, R. 3242, 4659
Aristoy, F. 858
Armijo, R. 5043, 5055
Armstrong, C. 172, 797, 1835, 2645, 2647, 2663, 2820, 3587, 3621, 3697, 3948, 3959, 4454, 4498, 4636, 4836
Armstrong, C. W. J. 1214, 2105
Armstrong, R. E. 305, 1375, 1376, 2297
Arns, W. 4381
Aronovitz, G. 593, 599
Aronson, S. M. 298, 1747, 2251, 3106, 3107, 3399, 4582, 4758
Arriagada, D. A. 22, 239
Arthuis, M. 542
Artusi 3591
Artzet, F. 2878
Asbach, M. 3942
Ashihara, Y. 2648, 4269
Ashmarina, E. E. 1165, 1401, 3234, 3471, 3490, 4893, 4975, 5021, 5282
Ashölter, C. 5221
Asmarina, E. E. s. Ashmarina, E. E.
Askani, H. 3863
Athenstaedt, F. 4172
Audebaud, G. 4052, 4468
Audeoud, H. 4685
Auerswald, W. 509, 1031, 1403, 1741, 1757, 1831, 2089, 2394, 3099, 3249, 4639
Aufranc, W. H. 1616
August, M. H. 4017
Auhagen, H. 5418
Auld, P. A. M. 3236
Auricchio, L. 4288
Austin, F. J. 161, 679, 3067
Avdeeva, L. I. 3486
Avella, A. 1235, 5377
Avila Cisneros, I. 2503
Aycock, W. L. 89, 127, 141, 147, 311, 325, 329, 336, 340, 349, 354, 371, 401, 427, 455, 522, 624, 799, 901, 1071, 1077, 1102, 1196, 2140, 2821, 3010, 3123, 3138, 3145, 3261, 3264, 3607, 3845, 3846, 3880, 3958, 4452, 4845, 5008
Ayer, W. D. 92, 3007
Aymard, B. 3053
Azmi, A. 4711

B

de Baan, P. 2713, 3586
Baastrup, S. 3799
Babonneix, L. 3247, 3610
Babonneix, M. L. 404
Bachmann, W. 2533
Bachtold, J. G. 47, 1792, 2078, 2157, 3405, 4757
Bacigalupi, J. C. 3184, 3232, 4345
Backett, E. M. 2116
Badiali, C. 682, 3310
Badillet, M. 355
Bäcker, F. 3171
Bäuerl, E. 1697
Bagliani, G. P. 4883
Bahlke, A. M. 286
Bailey, J. 4051
Bajda, L. 5257
Bakács, T. 2397, 3456
Baker, I. G. 370
Baker, M. E. 370
Bakina, M. N. 1165, 1401, 3234
Bakowska-Kenczewa, K. 4503
Balasubramanian, A. 1529
Balducci, D. 1868, 3454, 4270, 4773
Bamatter, F. 2419, 3269, 5057
Bancroft, P. M. 1029, 2077

Banerjea, J. C. 2829
Banker, D. D. 683
Bankhead, A. S. 962
Banks, H. S. 217, 1609, 2403, 4562
Banning, C. 1460
Balayan, M. S. 3059
Bános, S. 1958, 2411, 2575, 3986, 5258, 5304
Banu, E. I. 3823
Banzhaf, E. J. 6, 272, 281, 439
Barbieri, V. 2146
Barbour, O. 1018
Barcaroli, F. 5378
Barla-Szabo, J. 3655, 3656, 3657, 3658
Barley, N. H. 1128
Barnes, J. M. 2359, 2513
Barnett, E. J. 920
Barnett, E. V 905, 2439, 2949, 4276
Barnett, V. H. 4448
Barnum, G. L. 3533
Barojan, O. V. 413, 4173, 4188
Baron, H. 4213
Baron, S. 905, 2439, 2573, 2915, 2949, 3156, 4263, 4276, 4630, 4631, 4962, 4967
Baroyan, O. V. s. Barojan, O. V.
Barr, R. N. 992, 4629, 5009, 5011
Barrett, C. D., jr. 619, 989
Barrick, J. H. 965, 1519
Barski, G. 998, 1666, 1896, 1930, 4518, 4586
Barsky, P. 1461, 2184, 2541
Barsy, G. 4075, 4647
Bartalena, R. 4894
Bartel, G. 4271
Bartell, P. 1605
Barton, E. L. 195
Bascon 2823
Bascoulergue, P. 4052
Baskin, J. L. 2897
Basset, J. 189
Bastin, R. 587
Bates, T. 1574
Batson, R. 605, 965, 1005, 1172, 1519, 2191, 3431, 5425
Batt, B. E. A. 3784
Batten, F. E. 2142, 3142, 5311
Baudouin, A. 442
Baudraz, B. 1973, 2501
Bauer, F. C. 2123
Bauer, H. 387, 548, 992, 1313, 4273, 4629, 5009, 5011
Bauke, E. E. 5154
Baumann, Th. 1975, 2399
Baumeister, J. 1687, 1848, 4051
Bautista, G., jr. 1696, 2069, 4769, 4904, 5023
Bayarri, S. 5446
Bayer, H. 4581
Bazeley, P. L. 1565, 1770, 1771, 2227, 4887
Beale, A. J. 217, 1529, 2541, 4755, 5370, 5452, 5460
Beardmore, W. B. 515
Bearman, J. E. 5009, 5011
Beasley, A. R. 2705
Bécart, A. 3531
Becker, A. 513
Becker, H. 2916
Becker, J. 2006, 3862
Beckers, R. 1250, 3239
Beebe, A. R. 813, 3582
Beem, B. 4460
Behrend, R. C. 1863, 2682, 2799, 2867, 2991, 3036, 3093, 3169, 3206, 4436, 5024
Behrenroth, E. 2680, 3928
Béládi, I. 4642, 5301
Beladiez Navarro, J. M. 645
Belden, E. A. 2167
Belfus, F. H. 237
Belian, W. 1352, 2891, 3087, 4116, 4117, 4121, 4742
Beling, C. C. 3838
Beljajeva, A. P. 5215
Bell, E. J. 33, 71, 864, 1900
Bell, J. A. 1737, 4514
Bell, L. G. 873, 1365, 4348
Belyaev, A. L. 5493
Benavente, M. 1182, 3757
Benech, J. 438
Benedetto, A. 2908
Ben-Efraim, S. 1120
Beneke 4846
Benell, F. 2709
Benjamin, B. 1607, 1609, 3074
Bennett, B. L. 37, 48, 49, 52, 63, 1565, 1703, 1770, 1771, 3136, 3141, 3353, 5329
Benson, W. W. 1572
Bentegeat, J. 3864
Bentivoglio, G. C. 3255

Benyesh-Melnick, M. 1086, 1286, 2525, 3216, 3220, 4145
Bergamini, F. 2270, 2565, 3082, 4087, 5488
Berger, E. 490, 589, 1808, 1855, 2056, 2121, 2375, 2957, 3341, 5238
Berger, K. 1839
Berger, R. 2062
Bergquist, J. R. 1578
Berke, Z. 2924
Berkeley, W. H. 4118
Berkovich, S. 4203
Berman, P. H. 3390, 3985
Berni, A. 1275
Bernicchi, L. 5053
Bernkopf, H. 1765, 2128
Bernstein, H. G. G. 2845
Bertolini, A. 3184
Bertoye, A. 674, 2400
Bervoets, W. 202
Beske, F. 1705
Beswick, T. S. L. 1170, 1424, 1479, 2296, 2587, 2887, 4897, 4971, 5447
Bette, F. 2565, 3082, 4087
Beurlin, G. 3241
Beveridge, W. I. B. 1728
Bezer, A. E. 5074
Bezzubov, A. D. 3473
Bhagwat, S. M. 5063
Bhatt, P. N. 2037, 2253
Bhatt, P. R. 80
Bianchi, V. 2780
Bica, A. N. 1462, 2353, 4890
Bickel, J. E. 1463
Bieling, R. 2801, 4717, 5251, 5397
Bierly, M. Z. 1907
Bierly, Z. 1965
Biermann, A. H. 3209
Bigelow, G. H. 3643
Billich, R. 5221
Bing, R. 3852
Bingold, K. 1688
Bîrcă, A. 2288, 2295, 2958, 3452
Birk, W. 3221
Bittman, F. 3630
Bizzi, G. 3395
Bjerglund, R. 1453
Black, F. L. 1464, 1606, 1876, 3961
Blair, D. M. 494, 2555
Blanc, G. 1951, 2041, 3197, 4105, 4467, 4519
Blanchard, K. 3837
Blancher, G. 4225, 5495
Blanchet, G. 3134
Blatnik, D. 116, 5353
Blinnikov, K. S. 3449
Blixenkrone-Møller, N. 3549, 4319
Bloomfield, R. A. 2122
Blotevogel, H. 911
Blotevogel, W. 911
Bloxsom, A. 871
Blusson, J. 4518
Boak, R. A. 1449
Boand, A. V. 1303
Bocci, A. 3314
Boda, D. 4238
Bodian, D. 9, 23, 29, 30, 39, 40, 42, 44, 57, 59, 72, 121, 126, 173, 179, 180, 292, 293, 623, 709, 710, 712, 733, 938, 1602, 1647, 1803, 1915, 1916, 2004, 2012, 2119, 2232, 2245, 2252, 2751, 2864, 2894, 2971, 3009, 3037, 3228, 3229, 3590, 3602, 3894, 4014, 4033, 4133, 4146, 4147, 4167, 4323, 4426, 4449, 4506, 4821, 4828, 4840, 5070, 5151, 5157, 5240, 5331
Boek, W. E. 1423, 2584
Boemi, G. 4773
Boer, J. 4807
Bøe, J. 3954
Böttiger, M. 1125, 1391, 3164
van Bogaert, L. 1075, 2165, 3296, 4328
Boiko, V. M. 1401, 3488, 4893, 5021
DuBois, C. C. 3441
Boisen, M. 1807, 3163
Boissard, G. P. B. 635, 1369
Boissonnas, L. 4685
Bojko, V. M. s. Boiko, V. M.
Bolin, V. 774, 3137
Bolt, N. A. 3803
Bolzinger, R. 3568
Bommer, W. 1233, 1465, 1824, 1996
Bonafaccia, V. 1239, 2395
Bondarenko, O. M. 2302
Bondareva, N. V. 4237
Bonell, G. 3650
Bonetti, F. 497, 1512, 2340, 2445, 2985, 4753, 5259

Bonhoff, H. 4848
Bonifas, V. 501, 1973
Bonin, O. 186, 1026, 1833, 1922, 2185, 2186, 2554, 2564, 4143, 4212, 4215, 4220, 4750, 5458, 5477
De Bont, A. F. 500, 2428, 5296
Bordet, P. 1466
Bordt, D. E. 2869
Borelli, J. A. 3184
Borghans, J. G. A. 5208
Borghans-Delvaux, J. M. 5208
Borgiotti, R. 1672
Borgono, J. M. 5055
Borgström, C. A. 3901, 3902
Borman, G. S. 2915, 4118, 4962, 4967
Borrell 3868
Borremans 3296, 4328
Borrone, C. 5200
Bosch Marin, J. 677, 687, 1389
Bossert 5083
Botsztejn, A. 2898
Bottacin, L. 1002
Bottero 5471
Boué, A. 572, 3088
Bourne, I. H. J. 2021
Bousfield, G. 211, 615, 1554, 1727, 2019, 4435
Le Bouvier, G. L. 670, 946, 1374, 1627, 1810, 2104, 4470, 4569, 5281
Bower, A. G. 1509, 2032, 3533, 3668, 3727, 3817, 3997, 4434
Bower, B. D. 2299
Bowers, V. M., jr. 2826
Bowes, J. E. 1342
Boyd, I. A. 112
Boyd, T. E. 1740, 2153
Boyer, J. 2005
Boyer, P. A. 2869
Boyer, R. 2221
Bradford Hill, A. 213, 235, 1609, 2506, 2639, 2886
Bradley, J. 3219
Bradley, W. H. 654, 1157, 1467, 2462, 2506, 2662, 4461, 5359
Brahdy, M. B. 2017, 2822
Braileanu, A.-G. 5199
Braily, R. F. 2122
Brain, R. 3294
Braitenberg, H. 5225
Brancato, P. 1140, 2479, 2790 2937, 3045
Branchini, C. 1587
Brandwijk, A. C. 4241
Brátescu, A. 1550
Bratovanov, D. 1387
Braudo, J. L. 5387
Brauner, R. 5214
Bravo, H. 687
Brebner, W. B. 408, 457, 5320
Bredemann, W. 5143
Breen, G. E. 3074
Bregantseva, P. V. 4235
Breger 2676
Brehm, W. 2131
Brehme, T. 67, 1856, 1859, 1942, 3686, 4476, 5393, 5422, 5431
Breitzke, G. 4430
Bremer, A. 2759, 4369, 4424
Bremer, F. W. 1024
Brennan, J. C. 1286, 3208
Brenner, S. A. 4365
Brenner, W. 1947
Breton, A. 1251
Brewis, E. G. 583
Bridge, E. M. 409
Briggs, D. R. 434
Briggs, M. 357, 1844, 1964, 2175, 2304, 3355, 4259, 4260, 4261
Brink, V. 3592
Britten, S. A. 2463
Broadbent, B. 112
Brock, D. 228
Brockmann, H. 2763
Brodell, H. L. 607
Brodie, M. 7, 15, 28, 77, 143, 152, 153, 163, 470, 722, 723, 768, 817, 818, 872, 892, 913, 1185, 2794, 2812, 2855, 3322, 3511, 3526, 3580, 3594, 3628, 3633, 4111, 4705, 5104
Brodsky, W. A. 4092
Brody, J. 3181
Brody, J. A. 867, 993
Bronfenbrenner, J. 5168
Brooks, M. 2037
Brooks, N. J. 4170
Brooksaler, F. 2433
Brotzu 3591
Broughton-Alcock, W. 4408
Brown, A. 3860
Brown, C. M. 2506

Brown, C. P. 284
Brown, E. G. 1014
Brown, G. C. 125, 185, 294, 866, 884, 1240, 1252, 1343, 1628, 1685, 1820, 1879, 1892, 2031, 2094, 2254, 2363, 2475, 2791, 2948, 3038, 4500, 4882
Brown, L. V. 1603, 2772
Brown, M. 5144
Brown, R. A. 2109
Brown, R. P. 5316
Brown, W. G. 691
Brown, W. G. S. 288, 3178
Brownlee, K. A. 1646
Brucker, M. J. 1468
Brueckner, A. L. 1643, 1749, 4528, 4587, 4612, 4614, 4615, 4951, 4952, 4953
Brues, C. T. 4909
Brumfield, H. P. 4334
Brunel, D. 230, 2434
Brunner, F. 1798
Brunner, K. T. 1092, 1208, 1677
Brunner, L. T. 1903
Brunner, R. A. 1153, 3153
Brutsaert, P. 1003, 2158
Bubash, G. R. 5329
Bubel, H. C. 2157
Buccellato, G. 4536
Buchka, A. 2127
Buckley, S. 2650
Buckley, S. M. 1827, 3398
Bühlmann, A. 1469
Bürgin-Wolff, A. 2375, 2957, 3341
Buimovici, E. 1025, 1112, 1276
Bull, H. G. 3716
Bullock, L. T. 737, 2038, 2205
Bulychev, N. P. 2345, 3338, 4226, 5497
Buma, J. T. 1470
Bundesen, H. N. 2123
Burch, B. L. 905
Burhans, C. W. 3595
Burian, V. 3235, 3392
Burke, M. J. 2407
Burlingame, R. W. 3834
Burn, J. L. 4346
Burnet, F. M. 144, 226, 327, 526, 528, 927, 1095, 1471, 1609, 2655, 2866, 3558, 4442
Burns, C. 1598
Burns, J. S. D. 5437
Burt, A. M. 4888
Burney, L. E. 462, 743, 1422, 1430, 2612, 5479
Buser, F. 246, 579, 1985, 2271, 2356, 2401, 2932, 4193, 4650
Bustamante, M. E. 5018
Butchart, M. 5391
Buttle, G. A. H. 3135
Byatt, P. H. 3039
Bychowski, Z. 1364
Byrd, C. L., Jr. 2007, 2235, 4341

C

Cabasso, V. J. 1205, 1433, 1657, 2358, 2389, 3232, 3248, 3424, 4148, 4566, 4736, 5006
Cacallero, F. 506
Cackowskiej, G. 5482
Cadham, F. 874, 3859
Cadham, R. G. 835, 1774
Cagini, P. 5053
Cagliero, L. 3314
Cajal, N. 115, 2187, 2288, 2295, 2958, 2988, 3452, 4072, 4186, 4659
Calaresu, I. 2909
Calcarami, J. R. 5161
Calderin, A. M. 240
Calderón, C. 4508, 4563
Calomfiresco, R. 1025
Camacho Gamba, J. 979
Cambrelin, M. G. 111, 131
Camelin, A. 3966
Camerer, J. W. 2767
Cameron, A. T. 875
Cameron, C. M., jr. 1612, 1802
Campana, C. 4752
Campanella, F. 2565, 3082, 4087, 5487
Campbell, D. H. 804
Campbell, G. A. 4552
Campillo, S. 1986
Campos, O. P. 5047
Camus, J. 3556
Canalis, A. 1002
Cancevici, G. 2994
Cándano, A. 2503

Cândido de Oliveira, J. 3455
Canosa, C. 2168
Cantalini, C. 3329
Caputo, C. 2085
Carbonaro, O. 2320, 3499, 3500, 4257, 4289, 4897
Carcassonne, Y. 1498
Cardelle, G. 4197, 5014
Cardwell, W. 2335
Caritat, R. 3184
Carnes, H. E. 619, 1935
Carola, H. 4189
Caronia, G. 5050, 5356
Carp, R. I. 4957, 5321
Carpenter, C. M. 132, 1449, 4382
Carpenter, H. Ch. 758, 1015
Carpenter, J. G. 3787
Carré, M.-C. 2051
Carrell, R. C. 4042
Carriger, B. K. 523
Carroll, C. J. 185
Carteaud, J.-P. 1992
Carter, J. E. 331, 1011
Caruso, A. 2362
Carvalho de Sousa, J. 2383
Carvalho Loures, J. 1306
Carver, D. H. 650, 2322
Cary, W. 3940
Casals, J. 174, 1497, 1603, 1680, 1681, 1686, 1974, 2736, 2876, 2889, 3083
Casarosa, S. 3393, 3988
Casassa, A. 4157
Casaubón, A. 3651, 3842
Cascio, D. 833
Casey, A. E. 796
Casey, J. 5163
Cassano, A. 2774
Castellanos, A. 2522, 2572
Castelli, L. 3454
Castillo, C. 1496, 1651
Cathala, F. 3095
Cato, T. E. 2592, 4653
Caughey, J. E. 161, 679, 1020, 1495, 2113, 3067, 5205
Cavallero, F. 2781
Cavallo, G. 1526, 1527, 2306
Celers, J. 542, 544, 573, 574, 1006, 1169, 1316, 1622, 1624, 1933, 2499
Cellin, G. G. 3736
Cenci, V. P. 1016
de Cendoya, J. A. 3873
Cepleanu, M. 4186
Cerf, J. 2436, 2788, 3170
Cerruti, C. F. 3086, 3150
Červenka, J. 847, 1494
Cervini, E. 3097
Cervini, P. R. 3892
Chadwick, D. L. 2180
Chadwick, H. D. 773
Chadwick, W. L. 4454
Chahlke, H. D. 1897
Chalkina, O. M. 2354, 3222, 3226, 3338, 4226, 5497
Challut-Thal, F. 2577
Chamberlain, J. 3187
Chambers, J. V. 224
Chambers, V. C. 516, 1524, 3039
Chambron, J. 4138
Chaney, A. L. 2032
Chang, C. C. 1630
Chang, S. C. 4587, 4612, 4615, 4952, 4953
Chan-Tsing, S. 2920
Chapin, M. 1203, 1204, 2373
Chapman, J. M. 5039
Chapman, J. W. 985, 1882
Charbonneau, J. H. 4806
Chardonnet, Y. 2316, 2577
Charest, G. 2112
Charney, J. 518, 671, 2352, 2570, 4635
Chassagne, P. 3052, 5141
Chastel, C. 4634
Chatillon 2823
Checchi, A. 2422
Cheever, F. S. 1642, 2715
Cheney, C. W. H. 4370
Chernyshev, V. I. 4573
Chervinsky, P. 2050
Chesney, A. M. 316
Chieffi, A. 3903
Chin, T. D. Y. 2566, 4001, 4002, 4003, 4150
Chor, H. 952
Choremis, C. 2027
Chown, B. 873, 1365
Christensen, Ch. N. 1220
Christensen, O. 3326
Christie, A. 605, 965, 1172, 1519, 5425
Christie, A. B. 1595
Chudnoff, J. S. 1493, 2032

Chumakov, M. P. 1165, 1362, 1367, 1401, 2300, 2424, 3234, 3317, 3471, 3473, 3488, 4200, 4573, 4893, 4963, 4975, 5021, 5051, 5212, 5215, 5247, 5282
Chumakova, M. J. 1119, 2922, 4691, 5274, 5369
Chura, A. J. 5079
Church, R. E. 985, 1291, 1882, 1945
Churcher, G. M. 948, 966, 1369, 1665, 4766
Chwistecka W. 1520
Ciaccheri, G. 2979
Ciantini, F. 3534
Cibils Aguirre, R. 5161
Cinnerová, O. 1662, 3061, 3990, 4664
Cinque, T. 3329
Cioffari, M. S. 2150
Cislaghi, F. 3291
Ciucá, A. 3242
Clark, E. M. 64, 259, 1645, 2040, 2230, 2703, 2728, 2732, 3367, 3402, 3404, 3457
Clark, F. L. 1897
Clark, J. M. P. 2845
Clark, P. F. 103, 771, 880, 898, 899, 1045, 1048, 2203, 2668, 2711, 2731, 3179, 3406, 3411, 4457, 4458, 4510, 4838, 4868, 4918, 5087, 5135, 5170, 5380
Clarke, F. 1017, 3788, 3789
Clarke, F. B. 5322
Clarke, G. H. 409
Clarke, S. K. R. 537
Clausen, J. A. 1752
Claveaux, E. M. 3184, 3703, 3704, 3783
Clay, K. 1242
Clayton, L. B. 2592, 4653, 5068
Clément, R. 4886
Clemmer, D. I. 2571, 4927, 4974
Clifton, C. E. 224
Clyde, W. A. 1492
Cobb, S. W. 3203
Cocchi, R. 206
Cochran, K. W. 5444
Cockburn, W. C. 563, 2506
Cocozza, G. 5179
Coffee, A. T. 4417
Cohen, A. 4241
Cohen, B. J. 4957, 5122
Cohen, L. 718
Cohen, M. M. 1903
Cohen, M. S. 3678
Cohen, S. M. 199
Cohn, M. 1491
Coid, C. R. 1424, 1479, 2296, 4897, 5447
Col, Ch. 2579
Coleman, M. 4070
Colio, L. G. 1345
Colobert, L. 3475
Colonnello, F. 1938
Combe, P. 4978
Comby, J. 4776
Comes, R. 2338
Conlan, P. K. 1242
Conn, J. H. 3207
Connolly, J. H. 684, 1844, 1964, 2304, 4259, 4261
Constantinescu, N. M. 4186
Contamin, R. 1490
Contat, C. 4297
Contreras, G. 1691, 4903
Contreras da Silva, G. 4617
Conwell, D. P. 1845, 2066, 2067, 2253
Cook, G. T. 4692
Cook, S. R. 4528
Coonery, M. K. 4273
Cooney, M. K. 387, 548, 992, 4629, 5009, 5011
Cooper, E. D. 4120
Cooper, H. M. 176
Cooper, P. D. 4888
Copello, F. 5273
Copelman, L.-S. 5199
Coriell, L. L. 610, 1345, 1552, 1562, 1965, 2024, 2216, 2217, 2218, 4058, 5210
Corkin, D. L. 684
Cornefert, F. 998, 1930
Cornell, R. G. 1291, 3237
Cornely, D. 4995
Cornfeld, D. 2352, 4204
Cornfield, J. 1911
Corso, P. 2908
Corvazier, R. 4475
Cosco, N. P. 5151
Cossoy, S. 3651
Cote, G. 5062
Courtillie, P. 123

Courtois, G. 538, 686, 2436, 2788, 3170, 4662
Cowan, K. M. 518
Cowie, D. M. 909, 1106, 2856, 3831
Cowley, R. J. 3538
Cox, H. R. 471, 521, 673, 878, 879, 1205, 1433, 1553, 1786, 1952, 2358, 2389, 2608, 2730, 3232, 3248, 3424, 3984, 4148, 4566, 4696, 4736, 4783, 5006, 5372
Cozzolino, O. 3828
Craig, D. E. 294, 557, 866, 1892, 4500
Craighead, E. M. 4538
Craigie, J. 3605, 4797
Cramarossa, S. 1159
Cramblett, H. 4204
Cramblett, H. G. 4236
Cramer, R. 1997, 2453, 2454
Cramer, W. 1604
Crawford, J. G. 2911
Creighton, R. M. 983
Cremoncini, R. 4730
Crepea, S. B. 2023
Creutzfeldt, H. G. 3669, 4996
Van Creveld, S. 4948
Criley, B. R. 1345
Crimbithis, E. 575
Crosato, M. 3328
Crossley, M. I. 2592, 4653
Crovari, P. 1330, 2789, 2904, 4728, 4881, 5441
Crüsemann, R. 1292
Crüsemann-Hake, R. 508
Cruickshank, R. 1609
Cruz Hernandez, M. 2418
Csumakov, M. P. s. Chumakov, M. P.
Culbertson, C. G. 1679, 1780, 1828, 4310
Culp, C. F. 2387
Čumakov, M. P. s. Chumakov, M.P.
Cumberland, M. C. 139, 4840
Cumming, H. S. 4778
Cumming, J. G. 4383
Cundy, K. R. 2809
Cunning, D. S. 527, 529, 626, 908, 1489
Curatolo, D. 1312, 1335, 3097
Curcio, F. 4773
Curley, F. J. 371, 701, 3138
Cymbalista, S. 560
Czickeli, H. 5214, 5478

D

Dachy, A. 2912
Dadone, G. 1573, 3051
Daguet, G.-L. 1383, 2381, 2907, 4246, 4247
Dagulf, H. 2108
Dahm 720
Daire 680, 689
Dalldorf, G. 190, 199, 1690, 1919, 2760, 2811, 3154, 3698, 4367, 5138
Dalrymple-Champneys, W. 410
Damas, J.-P. 229, 1426, 2561
Damonte, R. A. 2289
Dane, D. S. 258, 356, 357, 1404, 1600, 1844, 1964, 1989, 2175, 2304, 2305, 3355, 3489, 4259, 4260, 4261, 4645
Danforth, D. N. 2826
Daniel, A. 4557
Dániel, M. 5277, 5280
Danielescu, G. 2295, 2958, 3452, 4072
Danulesco, V. 1255, 3501, 4393, 4400, 4402, 4403, 4405, 4407, 4872
Dardanoni, L. 3045
Darnton, M. 3359
Darré, H. 3721, 3754
Darter, R. W. 4633
Dauer, C. C. 62, 1926, 4039
Daunas, J. A. 979, 1325
Dave, K. H. 4763
Davide, H. 14
Davidenkova, E. F. 1087, 1314, 3226
Davidson, S. 3670
Davies, A. M. 2357, 4721
Davies, J. E. 835
Davies, M. 3465
Davies, W. L. 4458
Davis, D. C. 650, 2420
Davis, H. S. 2122
Davis, I. 3922
Davis, N. 1529, 4755

Davis, W. D. 5117
Davis, W. M. 3584
Davisson, E. O. 1828
Davoli, R. 2155, 4176
Day, P. A. 4257
Day, W. C. 1749
Dchang-Liä, G. 5361
Dean, D. J. 199
Deasy, L. C. 1752
Debré, R. 261, 573, 574, 1933, 3523, 5181, 5323
Debry, G. 641, 1139, 5239
Dechaume, J. 5007, 5013
Decroly 3918
Deeks, D. 3190
Defries, R. D. 2095
Deibel, R. 182
Dekegel, D. 2987, 4605, 5038
Dekking, F. 1131, 2578, 5364
De La Forest, G. 2102
Delaha, E. C. 4528
De Lange, C. 2936
Del Campo, A. 1207
Delery, F. M. 3343
Delherm 3247
Delville, J. P. 500, 2428, 5296
De Marco, S. 1207
Demme, H. 3951, 4031
Dennig, H. 3712, 5096
Dennis, J. 1429, 2385, 2446
Deparis, M. 587, 1488, 5229, 5335
Depoux, R. 4138, 5374
Derryberry, M. 523
Desbordes, J. 1151
v. Deschwanden, B. 2056
Descola, P. 4311, 4333
Despons, J. 130
Desproges-Gotteron, R. 1980
Dessy, G. 3578
Deutsch, J. V. 2741, 3015
Dewar, J. 2872
Diamond, E. L. 3163, 4142
Diana, M. G. 4196
Dick, G. W. A. 258, 356, 357, 432, 571, 684, 1404, 1541, 1542, 1600, 1844, 1964, 1989, 2304, 2305, 2506, 3355, 4259, 4260, 4261, 4645
Didier, J. 1213, 1487
Dienstl, U. 1031
Dimic, M. 4208
Dinckler, K. 3900
Dingemans, G. 2430
Diveley, R. L. 3002
Dixon, J. H. 2865
Dixon, J. P. 4454
Dixon, S. G. 343, 3576
Dizon, F. C. 1297
Doany, H. 3232, 4654, 4655
Dobrova, I. N. 1165, 1401, 3234, 3471, 3477, 4893, 4975, 5021, 5282
Dobrowolska, H. 1991, 2792, 3177, 3973, 5036, 5482
Dochez, A. R. 613, 3406
Dodero, J. 4710
Doeden, D. 3970
Dömök, I. 245, 865, 1716, 2458, 3336, 4891, 4907, 5277, 5280, 5292
Dönhardt 5232
Doleman, J. H. 859, 961
Donaldson, S. N. 209, 3489
Dong, L. 58, 714, 764, 766, 1608, 1683, 2737, 2749, 2756, 2757, 2758, 3422, 4044, 4386
Donle, W. 2675, 4336, 5064, 5244
Donskaya, L. V. 5390
Dooley, P. 794
Doraisingham, M. 1166, 1195
Dorfman, F. 732, 765, 893, 2750
Dorman, D. C. 2173, 2174, 3433, 4471
Dostal, V. 838, 1089, 1178, 1392, 1393, 1399, 1797, 2535, 2683, 2834, 4160, 4180, 5402
Dougherty, W. J. 1296, 2387, 4695
Douglas, A. M. 2113, 5205
Douglass, M. 2760, 3154
Doull, J. A. 3599
Dow, A. G. 3789
Dowe, J. B. 1486
Downie, A. W. 906
Downs, C. M. 4933
Downs, W. G. 4644
Doyle, H. S. 4805
Drabe, J. 5456
Draganesco, St. 1266, 3284
Drake, R. M. 856, 2634
Draper, G. 318, 613, 1082, 1361, 4156, 4168, 4394
Drees, O. 1056, 1287, 1288, 1310, 1864, 1866

Drescher, J. 556, 1135, 1218, 1351
Dřevo, M. 1662, 3061, 3990, 4664, 4690
Van Driel, C. B. 4241
Drinker, C. K. 2875
Drobyshevskaya, A. I. 1087, 2354, 3222, 3226, 3338, 4228, 5497
Drouhet, V. 541, 542, 543, 544, 573, 574, 1006, 1169, 1316, 1622, 1624, 1933
Drozdov, S. G. 1165, 1401, 3234, 3471, 4206, 4893, 4975, 5021, 5282
Duben, J. 4989
Dubes, G. R. 1203, 1204, 1281, 1300, 2373, 5324
Dublin, Th. D. 1785
Dubo, S. 4265
Dubois, M. 4372
Dubois, P. L. 4388
Dudgeon, J. A. 1485, 2059, 2506, 3144, 5049
Dührkop, A. 2011
Dufrane, N. 192, 2124
Duhamel 3688
Duhem, P. 4376, 4377
Duhig, J. V. 1186
Dulbecco, R. 1664, 2076
Dumitrescu, V. 1623
Dumoulin, J. 4620
Duncan, C. H. 3278
Duncan, D. 75, 82, 696, 3402, 5181
Duncan, I. B. R. 2847
Dundon, S. 289
Dunn, R. E. 1484
Dunoyer, F. 234
Dupertuis, C. W. 4156
Durand, P. 2933, 3691, 5382
Durich, J. 5105
Dutcher, R. M. 3424
Duttweiler, D. W. 303, 5373
Duvolon, S. 3510
Dwyer, J. M. 3666
D'yakova, V. S. 4226
Dzagurov, S. G. 2300, 3471, 3473, 3482, 4573, 4893, 4975, 5021, 5282

E

Eagles, G. H. 483
Earle, A. M. 2018
Eaton, R. M. 2032, 4434
Eberson, F. 250, 397, 812, 1948, 2039, 2072, 2238, 3504, 3559, 3560, 5290
Eckardt, F. 3100, 3151
Ecke, R. S. 3425, 5126
Eckert 333
Eckhardt, H. 3781, 3856, 4040, 4551, 4717
Eddy, B. E. 4118
Edipidis, T. 1843
Edlinger, E. 4178, 5361
Ege, N. 4208
Eggers, H. J. 2688, 3484, 3485,
Eggert, E. 4179, 5020
Ehrenberg, A. 2453, 2454
Ehrengut, W. 2055, 4943
Ehrich, C. 636
Ehrich, W. 5134
Ehrmantraut, W. R. 905
Eibl, H. 636
Eiger, M. S. 3390, 3985
Eik-Nes, K. 291
Eimind, K. 5245
Eissner, G. 1309, 2185, 2186, 2554, 4212, 4220, 5475
Ejov, N. N. 4226
Ekelund, H. 1431
Eklund, C. M. 228, 662, 864, 1900
Elbert, L. B. 3471, 4573, 5282
Elder, A. T. 4507
Eleff, M. G. 2322
Eley, R. C. 433, 1483, 3236
Elias, H. 1482
Elliot, G. R. F. 1961
Elliott, B. L. 1099
El-Messih, G. A. 4658
Elste, E. R. 1772
Elveback, L. 2393
Elvehjem, C. A. 771, 2668, 2731, 3411, 4457, 4458, 4510, 4838, 5380
Embil, J. 2358, 2486, 2521, 2522, 2572, 4197, 4736, 5006, 5014
Van den Ende, M. 1901, 2423, 2599
Enders, J. F. 55, 1481, 2701, 3139, 3957, 4465, 5178, 5181

Enders-Ruckle, G. 2770, 3019, 4127
Endo, M. 4518
Engelhard, W. E. 1029, 2077
Engelking, Ch. F. 1480
Engle, E. T. 717, 727, 736, 741, 1200, 2201, 2810
Engler, J. I. 1115
Enjalbert, L. 1213
Enomoto, C. 4269
Erb, I. H. 4805
Erb, W. 3916
Erber, B. 1261, 1262, 3552, 3701
Erickson, G. M. 2592, 4653, 5068
Eriksson, A. W. 3182, 5040
Escalada, J. G. 5028
vor dem Esche, P. 2086, 2351
Eschenbrenner, A. B. 5305
Eschenbrenner, J. W. 2832
Eshner, A. A. 105
EspadalerMedina, J.M. 1889, 4199
Étévé, J. 3510
Étienne, G. 253, 403, 405, 407, 438, 446, 454, 3281, 3565, 3566, 3762, 3763, 3804, 3807, 3810, 4997, 5010
Evang, K. 2159, 4624, 5424
Evans, C. A. 516, 1524, 2077, 2809, 2950, 3039, 4202, 4594
Evans, D. G. 568, 984, 1479
Evans, F. J. 2592, 4653
Evans, P. 1609
Exchaquet, L. 4296, 4803
Eyer, H. 510, 1699, 1702, 1819

F

Faber, H. K. 58, 714, 739, 764, 766, 808, 1608, 1683, 2737, 2749, 2756, 2757, 2758, 2833, 3160, 3186, 3422, 3946, 4043, 4044, 4386, 4672, 5101, 5276
Fabricant, N. D. 4364
Faerber, G. I. 2319
Faerber, K. P. 1132
Fagraeus, A. 4012
Fahey, J. J. 877
Fahey, M. F. 989, 4015
Fahraeus, J. 5118
Fairbrother, R. W. 154, 175, 288, 781, 1184, 1265, 1348, 1353, 3629, 4317, 5080
Falcoff, E. T. 5494
Falconnet, R. 3568
Falk, W. 1299, 2580, 4694, 4879
Fallon, R. J. 1832
Fanconi, G. 677, 852, 1779, 2805, 2898, 4132, 4385
Farina, R. 5494
Farisano, G. 2265
Farkas, E. 245
Farkas, G. 4082, 5317
Farmer, A. D. 4761
Faro, S. N. 1192, 1296
Farrell, L. N. 968, 1895, 5346
Favarel, R. 4831
Faxén, N. 1969
Fazekas, S. 1477, 1478
Feemster, R. F. 1826, 3123
Feig, M. 1476
Feiner, R. R. 4798, 4826
Felder, J. 1975
Feldman, E. V. 3226
Feldman, G. V. 3483, 4332
Feldman, M. Y. 1659, 2294
Feldman, Y. V. 4237
Felsenreich, G. 3081
Felton, H. M. 1965
Fendall, N. R. E. 533, 2450
Fenner, F. 1898
Fényves, A. 3242
Ferenbach, H. 4556
Ferencz 659
Fergus, J. W. 3218, 4985
Ferguson, A. J. 1479
Ferguson, J. K. W. 1368, 2951, 4286
Fernandez, U. 3569
Fernandez Moran, H. 1965
Fernandez Sanz, E. 3649
Ferola, R. 1241
Ferris, C. R. 1099
Ferro, A. 1002, 4942
Ferry, G. D. 5436
Fester, A. 4813
Festge, W. 5297
Feudell, P. 1981, 2609
Field, A. M. 1990
Field, C. M. B. 4259, 4260, 4261
Field, M. F. 2911
Filippi, P. 506, 1475, 2781

Finck, H. 5091
Findlay, G. M. 1258, 1609, 2298, 3110, 4837
Finger, H. 2952, 4218, 4254
Finkel, K. C. 1144
Finkelstein, M. H. 3561
Finland, M. 4249
Finlayson, M. H. 5136
Finucane, D. L. 1395
Fischer, A. E. 164, 315, 337, 452, 594, 825, 872
Fischer, G. 4724
Fischer, L. 3844
Fischer, R. 3645
v. Fischer, R. F. 5100
Fischer, W. P. M. 2570
Fishbein, M. 3908
Fishbein, W. I. 796
Fisher, A. 4444
Fisher, D. 2694
Fisher, O. D. 1964, 2304
Fisher, W. P. 671
Fisk, R. T. 358, 822, 2690, 4789
Fitzgerald, J. G. 5022
Flaccomio, R. 633, 1658, 1884, 1887
Flack, A. 538, 686, 1979
Flake, C. G. 433
Flandre, O. 230
Flaum, A. 1474
Flechsig, W. 1396
Fleer, G. P. 2300, 3471, 3476, 4893, 5021, 5282
Fleischhauer, G. 5020
Fleischner, E. C. 319
Fleming, D. S. 2323
Flesch, I. 5304
Fletcher, D. J. B. 1212
Fletcher, S. 2200
Flexner, S. 103, 106, 107, 108, 109, 135, 278, 280, 317, 374, 376, 378, 381, 415, 558, 666, 668, 675, 728, 729, 785, 791, 798, 802, 823, 832, 880, 888, 955, 1037, 1045, 1046, 1048, 1059, 1060, 1946, 2010, 2026, 2143, 2144, 2145, 2203, 2735, 2744, 2854, 3146, 3385, 3406, 3440, 3562, 3598, 3776, 3777, 3820, 3821, 4106, 4391, 4395, 4396, 4539, 4862, 4868
Flipse, M. E. 2586, 2592, 3065, 4653, 5068
Florentino, G. L. 55
Foà, A. 3690, 4325
Foard, F. T. 2049
Foerschler, W. 3839
Földes, P. 306, 1958, 2411, 2575, 3986, 5258, 5304
Fogel, A. 560
Fogh, J. 1783
Fog-Poulsen, M. 1655
Foley, A. R. 4700
Foley, G. E. 3958
Foli, A. 5306
Fomon, S. J. 4236
Footer, D. S. 1473
Forester, H. E. 993, 1291, 2075
Fornara, P. 5197
Fornosi, F. 1093, 5295
Forst, W. H. 4910
Fortong, G. 1329
Foster, C. 732, 765, 893, 2028, 2750, 3956, 4365, 4425, 5134
Foster, G. V. 3761
Foulkrod, C. 3674
Fowden, A. 1010
Fox, H. 4851
Fox, J. P. 191, 942, 1229, 1284, 1285, 1530, 1845, 1993, 2037, 2058, 2066, 2067, 2134, 2228, 2253, 2393, 2507, 2571, 4648, 4908, 4927, 4974, 5004, 5194
Fox, M. J. 237, 2824, 2825, 3187, 4095, 4834
Français, A. 3808
Francis, E. 4928
Francis, F. D. 665
Francis, Th., jr. 125, 557, 884, 1531, 1532, 1782, 1807, 1846, 1894, 1915, 1953, 1977, 2031, 2060, 2137, 3013, 3163, 3937, 5326, 5327, 5444
Franco, F. 1002, 4942
Franco, J. F. 4416, 5260
Franco, R. 13, 5028
Françon, F. 3795
Frank, W. P. 3251
Franke, F. 3932
Frankel, J. W. 2318
Frankl, J. 4271
Frantzen, A. 4720
Frappier, A. 643, 2734, 2775
Fraser, F. R. 899
Frauchiger, E. 2851, 4804

Freeman, M. 3558
Freeman, V. 4413
Freimüller, F. 5109
Fremel, F. 1523
French, J. D. 132, 1449, 4382
French, R. C. 305, 1375, 1376, 2297, 4211
Freese, A. E. 283
Freese, A. M. 284
Fresneau, M. 123, 3944
Freuchen, I. 2810
Freund, J. 34
Frey, W. 2844
Freyche, M. J. 694
Freydier, J. 2316, 2577
Friborg, C. R. 3830
Fribourg-Blanc 3245
Friedemann, U. 3741, 3797
Friedman, E. 4303
Friedman, R. M. 4962, 4967
Friedrich, J. 1824
Fries, J. H. 4070
Frisch, A. W. 4428
Friza, F. 2273, 4738
Frøseth, O. 1937
Frøvig, A. G. 368
Frohring, W. O. 476, 730
Froin, G. 3252
Frost, W. H. 90, 443, 3574, 4919
Frugoni, G. 3451, 4227, 4661
Fryda-Kaurimsky, Z. 5353
Fuchs, R. 5482
Fucinari, R. 484
Fugazzola, F. 3537
Fuite, K. 1472
Fujiwara, M. W. 4755
Furcolow, M. L. 4051
Furesz, J. 2456
Futer, D. 3926
Futer, D. S. 26, 3466

G

Gädeke, R. 4581, 5303
Gagarina, A. V. 2300, 3471, 4573, 4975, 5282
Gagé, M. 3134
Gaico, N. 3242
Gaignoux, Y. 3052
Gailonskaya, I. N. 4173, 4188
Gaisford, W. 361, 1008, 1088, 1130, 1248, 2939, 3483, 4332
Gajdusek, D. C. 962, 1518
Galdós, M. 3172
Gale, A. H. 1609
Gales, A. H. 2662
Gallagher, F. W. 4593
Galli, P. 3117
Gallia, F. 4419
Galloway, I. A. 4379
Galloway, T. C. 1517, 2025, 2042
Galmarini, A. G. 3873
Gamba, F. 2265
Gancevici, G. 3242
Ganduglia Pirovano, J. A. 1515, 3982
Gantes, R. 4903
Garaci, C. 5356
Garcia Sánchez, F. 4563
Gard, S. 310, 372, 540, 669, 695, 849, 850, 1305, 1337, 1391, 2044, 2159, 2355, 2563, 2938, 2981, 3017, 3116, 3164, 4012, 4169, 4268, 4308, 4603, 4760, 4802, 4982, 5044, 5181, 5331, 5363
Gardner, P. S. 3333, 4252, 4922
Garlick, C. H. 4421
Garofali, F. M. 3904
Garrett, A. 2469
Gaspar, I. 3729
Gasparini, V. 2265, 3394
Gasser, C. 1878
Gastinel, P. 234
Gattner, H. 5111
Gaudin, G. 2577, 4987, 4988
Gauer, L. W. 4089
Gaul, F. 2698
Gaustad, V. 2831
Gauthier 3245
Gautier, A. 1127, 5057
Gautier, P. 1514, 3881, 4352, 4385
Gaviria, D. 3172
Gavrilă, I. 2913
Gavrilov, V. I. 5270
Gavrilov, W. 4813
Gay, C. H. 3528
Gay, F. P. 2207, 3200
Gear, J. 995, 1004, 1521, 1522, 1525, 1950, 2484, 2512, 3219, 4262, 4410

GEAR, J. H. S. 693, 1722, 2159, 2224, 3004, 4056, 5026
GEATING, J. A. 331
GEBHARDT, L. P. 47, 149, 200, 224, 448, 477, 737, 808, 809, 886, 925, 1023, 1792, 2038, 2078, 2157, 2205, 2272, 3405, 3596, 4043
GÉDER, L. 5255, 5298
GEER, H. A. 4571
GEFFEN, D. 1609, 1733, 1734, 2160, 2416
GEFFEN, D. H. 352, 567, 1168, 1732, 1754
GEFFEN, T. J. 2914, 3023
GEIGER, J. C. 787, 3834
GELBER, J. 3306
VAN GELDEREN, H. H. 2220
GELFAND, H. M. 191, 1229, 1284, 1285, 1528, 1845, 1993, 2058, 2066, 2067, 2098, 2253, 2393, 2436, 2507, 2571, 2788, 3170, 4908, 4927, 4974, 5004, 5194, 5483
GELFAND, M. M. 2808, 5347
GENDON, Y. Z. s. GHENDON, Y. Z.
GENDRON, A. 1256
GENEVRAY, J. 4710
GEORGIADES, J. 1520, 1991, 4991, 4992, 4993, 5345
GERBAUT, P. 641, 1139, 1148, 1382, 3050
GERBAUX, J. 1316
GERBER, H. 101
GERBER, P. 2437, 5371
GEREST, F. 2823
GERFELDT, E. 2372
GERHARDT, L. P. 4757
GERHARDUS-CHIARI, E. 3099
GERLACH, F. 4366, 4544
GERLOFF, R. K. 228, 524, 652, 662, 864, 2414, 2954, 2955
GERMAN, W. J. 813, 2742, 3582
GERMER, W. D. 1177
GERNEZ-RIEUX, C. 232, 1936
GERSHOFF, S. N. 3179, 4457
GERVAIS, L. 2486, 2522, 2572, 4197, 5014
GERVOIS, M. 232, 1936
GERWE, E. G. 2281
GÉVAUDAN, P. 114
GHARPURE, P. V. 80, 4198, 4278, 4589, 4900, 5151, 5299
GHENDON, Y. Z. 1267, 1660, 2557, 3339, 4085, 4214, 4216, 4632, 5177
GHIO, T. 3394
GIACOMETTI, G. 5358
GIANNELLI, F. 2565, 3082, 4087, 5030, 5033
GIANOLI, A. C. 1513
GIBBELS, E. 2582, 4381
GIBBENS, ST. F. 2311
GIBBS, E. L. 550
GIBBS, F. A. 550
GIBBS, H. S. 5027
GIBSON, H. V. 2931
GIEDT, W. R. 1524
GIESELER, A. 5400
GIFFORD, H. 287
GILDEMEISTER, E. 2836
GILGENKRANTZ, S. 1382, 3050
GILL, D. G. 1611
GILLERT, K.-E. 171, 1346, 1377, 2425, 5467
GILLIAM, A. G. 76, 2646, 3379
GILLICK, E. E. 4093
GILMOUR, C. R. 875
GINEVRI, A. 2192, 4942, 4950
GINS, H. A. 4869
GINSBURG, N. N. 2367, 2925
GIONTA, D. 2390
GIORDANO, G. 2774
GIOVANARDI, A. 497, 1512, 1825, 2565, 2985, 3082, 3983, 4087, 4088, 5259
GIRARDI, A. J. 3961
GIRAUD, P. 114, 479
GIRDLESTONE, G. R. 1349, 1355
GISMONDI, A. 3517, 3798
GISPEN, R. 1511
GITLIN, D. 980
GIUFFRÈ, M. 4374
GIULIANI, G. 576, 647, 660, 1143
GIUSTI, M. 206
GLANZMANN, E. 3740, 4385
GLASER, G. H. 4905
GLASSER, M. A. 606
GLAZKOVA, G. S. 4239
GLESNE, L. R. B. 524
GLINSKAYA, E. V. s. GLYNSKAYA, E. V.
GLOVER, J. A. 1510
GLYNSKAYA, E. V. 3226, 4253, 4256
GODENNE, M. O. 4905

Godglück, G. 1408, 4884
Godtfredsen, A. 839, 2408, 3085
Goebel, F. 4163
Goerke, L. S. 1509, 1726
de Góes, P. 5186
Goetz, O. 388, 4209
Göggel, K. H. 4000
Goffart, P. 3470
Goffe, A. 4322
Goffe, A. P. 537, 1322, 2983, 4511, 4569
Gogstad, A. C. 1508
Golab, D. 838
Goldberg, E. L. 2123
Goldberg, H. P. 4429
Goldberg, M. E. 2226
Goldberg, S. 3748
Goldberg, S. A. 3511
Goldbloom, A. 7, 1185
Goldblum, H. 4714
Goldblum, N. 560, 857, 1378, 1682, 2357, 2370, 2902, 3195, 3196, 3331, 4277, 4303, 4448, 4877, 4994
Goldenberg, C., Jr. 3893
Goldman, C. 559, 967
Goldmann, K. 4718
Golenternek, D. 3668
Gollan, F. 2717
Golubyeva, L. P. 4235
Gomez, J. 1700
Gómez Malaret, S. 5203
Gómez Santos, F. 3174
Gonce, J. E., Jr. 1105, 1154
Gonella, C. 1507
González Avila, A. 2503
González Danrée, G. 3184
Gonzalez Escalada, J. 13
Gonzáles Fusté, F. 5315
González Martinez, A. 13, 5028
Gordon 3501
Gordon, F. B. 156, 339, 341, 453, 459, 464, 465, 487, 753, 815, 932, 1085, 2669, 2681, 2686, 3185, 3420, 3444, 3603, 4555
Gordon, J. E. 701, 3521
Gordon, J. N. 3396
Gordon, R. G. 4349
Gorev, N. E. 4230
Gorey, N. E. 1087
Gori, J. B. 2976
Goršúnova, L. P. 4756
Goryev, N. Y. 3223
Gorzkowsjkie, T. 5482
Gossler, U. 3906, 3907
Gotlieb, A. 3196
Gotlieb, T. 857
Gottberg, L. 2692
Gotti, D. 1506, 2222
Goube, P. 1505
Goulon, M. 2579
Gounelle, H. 1110
Graber, R. E. 1504
Gracoski, S. 4666
Graeber, F. O. 1572
Graevskaya, N. A. 5493
Graff, R. 5041
Graham, C. B., jr. 4202
Graham, D. G. 1895
Graham, S. 1420
Le Grand, E. 688, 981, 1211, 1503, 2402, 4360
Grandpierre 3810
Granicki, O. 3094
Graning, H. M. 2123
Grant, J. 1502, 2015
Grant, L. S. 582
Graser, F. 1329
Grasset, E. 501, 1971, 4385
Gravelle, C. R. 2566, 4001, 4002, 4150
Graves, G. W. 2209
Gray, A. L. 2474
Gray, H. 347
Gray, J. P. 787
Gray, N. 4652, 5001
Gray, P. G. 1555, 2016
de Grazia, G. 633, 1885
Green, R. H. 2972, 4977
Green, W. T. 907
Greenberg, B. G. 1802
Greenberg, L. G. 598
Greenberg, M. 176, 630, 1544, 1547, 1735, 1744, 1813, 2099, 2830, 3265, 3266, 4486, 5272
Greene, A. E. 1552, 1562, 4058
Greenspan, W. 2221
Gregg, N. C. 1629
Grégoire, J. 1301, 5455
Gretton-Watson, B. G. 1068
Greville, T. N. E. 2263
Grewar, D. 2046
Gries, G. 3369
Grieve, J. W. 3827

Griffith, A. 1175, 1626
Grillone, W. 576, 647, 660, 1143, 2933, 5031
Grinschgl, G. 1188, 1189
Grist, N. R. 193, 207, 2847, 2900, 4771
Groisman, G. M. 2354, 3338, 5497
Groot, H. 979
Grooten, O. 1260
Gross, D. 2011
Gross, M. 3740
Gross, P. A. M. 980
Gross, W. O. 969, 1501, 1591, 1684
Grossi, F. 3132
Grossiord, A. 1980, 5052
Grossman, L. H. 18, 19, 2745, 2754, 3508, 5119, 5129
Grossman, P. 1259, 1269
Grosso, E. 2565, 3082, 3983, 4087, 4189, 5485, 5486, 5487
Grossowicz, N. 2370
Grotten, O. 3546
Groulx, A. 2231
Groysman, G. M. 4226
Grubb, T. C. 3423
Grubbs, R. E. 5371
Grubmüller, J. 5233, 5252
Grüter, H. 5231
Grützner, L. 1377, 4740, 4878, 5020
Grumbach, A. 3634
Grumbach, R. 3053, 4357
Grund, G. 1500
di Gruttola, G. 5179
Gsell, O. 1390, 2431, 5256
Guassardo, G. 5012
Gubler, S. 3191, 4976
Gudnadóttir, M. 384
Guest, G. M. 159
Guevara, E. C. 4654, 4655
Guevara Rojas, A. 3238
Günther, O. 186, 1795, 1833, 1912, 2135, 2185, 2186, 2554, 3068, 3312, 4212, 4218, 4875, 5433, 5474
Guibert, A. 3966
Guilford, H. M. 1363
Guillain, G. 3611
Guilleman, P. 2197
Guilmet, C. 123, 3944
Gulevich, N. E. 2778
Gullo, A. 3045
Gundersen, T. 1499
Gunewardene, T. H. 3282
Gunn, W. 2695
Gutenbrunner, W. 1931
Guthrie, L. 3917
Gutiérrez Villegas, L. 553, 1986, 4563
Guttmann, L. 4330
Le Guyon, R. 3681, 4064

H

de Haas 616
Haas, R. 838, 949, 1089, 1149, 1178, 1392, 1393, 1399, 1526, 1527, 1766, 1797, 2159, 2306, 2534, 2535, 2538, 2544, 2548, 2551, 2643, 2683, 2765, 2816, 3995, 4160, 4180, 4739, 5344, 5395, 5399, 5400, 5401, 5402, 5466, 5476
Haas, V. H. 326, 1835
Habel, K. 1221, 1629, 1829, 2712, 2714, 2795, 2895, 4496, 5302
Haber, P. 3270, 3407, 3421
Habernoll, A. 2549
Hadden, S. B. 1153, 3153
Hadlow, W. J. 662, 1900
Hässig, A. 4772
Hässler, E. 1417, 3708
Hagen, F. 3500
Hagen, W. 5435
Hagens, S. J. 859, 961, 1429, 2385, 2446
Haguenau, J. 3542
Hahn, R. C. 3599
Haire, M. 4259
Halasz, S. 549
Haldeman, J. C. 1543
Hale, J. H. 1166, 1195, 1243, 3333, 4252, 4922
Halff, L. A. 1808
Hall, E. C. 2566, 4002
Hall, J. B. 1291
Hall, T. N. 3970
Hall, W. J. 1114, 1291, 1570, 2075
Hallauer, C. 1763, 5137
Hallervorden, J. 2185
Halliday, C. H. 975
Halonen, P. 982, 2567
Halperin, M. 1911
Halvarson, H. O. 4334

Halverson, W. L. 2634, 2828
Hamburger, F. 3535, 3660
Hamburger, J. 587
Hamel, C. 3637
Hamilton, H. L. 897
Hamilton, P. M. 3251
Hammel, B. 4581
Hammon, W. McD. 338, 632, 699, 706, 721, 885, 891, 895, 1562, 1642, 1669, 1870, 2003, 2024, 2110, 2216, 2217, 2218, 2241, 2641, 2642, 2715, 2998, 3030, 3965, 4009, 4027, 4058, 5076, 5210, 5312
Hammond, J. W. 4915
Hamparian, V. V. 389
Hampel, E. 3819
Hampil, B. 331, 1011
Hampton, J. W. F. 503, 504, 3190
Hannah, B. 691
Hannik, C. A. 1323, 5352
Hansen, K. 3093
Hansert, E. 628
Harding, E. B. 3362
Harding, H. B. 3362
Hardman, R. P. 4351, 4554
Hardy, A. V. 2592, 4653, 5068
Hare, J. D. 391, 559, 959, 967
Harford, C. G. 4048, 5168
Hargreaves, E. R. 2653
Harkins, H. N. 168, 463, 468, 877
Harmon, G. 1507
Harmon, P. H. 168, 339, 341, 453, 459, 463, 464, 465, 468, 707, 806, 877, 935, 936, 2761, 2835, 3185, 4555
v. Harnack, G. A. 2807
Harrington, A. B. 3212
Harris, C. H. S. 1853
Harrison, J. A. 667, 707, 756, 815, 933, 1085, 2669, 2793, 2870, 3882
Harrison, W. T. 3587, 4836
Hartman, H. J. 3747, 3790
Hartmann, H. 1377
Hartmann, O. 2818
Harvey, W. C. 3987
Hartviksen, K. 1160
Hartwich, P. 3409
Haseeb, M. A. 841, 3977
Haselbauer, P. 136
Hassan, M. M. 3977
Hastings, N. 68
Hatch, M. H. 4250
Hatem, J. 2264, 4195
Hatzky, K. 3547
Hauduroy, P. 2518, 4385
Haumeder, R. R. 3000
Havens, L. C. 3631, 3632
Havens, P. 2726
Hawke, W. A. 3860
Hayer, H. B. 129
Haynes, A. W. 2311
Haywood, H. B. 3659
Hazen, E. L. 447, 2206
Heal, F. C. 4805
Heald, J. A. 5490
Heaslip, W. G. 2860, 2874, 3515
Hecht, B. C. 1109
Heck, W. 3858
Hector, C. M. 3323
Hedeman, L. P. 3032, 4469
Heerup, H. 3725, 3843
Hegler, C. 4313
Heidema, S. T. 1183
Heinen, W. 5114
Heist, G. D. 363, 364, 3678
Hekker, A. C. 4241
Hektoen, L. 282, 3908
Held, J. P. 5052
Helms, K. 3887
Helms, K. T. 779, 923, 928
Helmschroth, R. 2763
Hemmes, G. D. 4484, 4520
Hemmes, G. S. 1742
Hemmes, J. H. 3024
Hempel, H. C. 585
Hemphill, F. M. 1807, 1953, 3163, 4142
Henderson, D. A. 3181
Hendric, K. H. 5008
Henckel, H. 5191
Henigst, W. 5194, 5337
Henle, W. 732, 765, 893, 2028, 2750, 3956, 4365, 4425
Henley, W. L. 2062
Henmi, M. 971
Henne, K. 2868, 3250
Henneberg, G. 556, 676, 1054, 1134, 1142, 1224, 1416, 2176, 2248, 2308, 2349, 3047, 4221, 4358, 4641, 4746, 4896, 5325, 5409, 5496
Hennessen, W. 1021, 1223, 1397, 1913, 2442, 2536, 2540, 2550, 3020, 3998, 4304, 5145, 5403

Hennessen, W. A. 4045
Henningsen, E. J. 483, 1388, 2470, 2635, 4415, 4823, 4870
Henriques, C. C. 4428
Henry, J. N. 3104
Hensel, A. E., Jr. 2590
Herberger, W. 1030
van Herick, W. 3623
Herken, H. 1699, 1702
Hernández Lira, P. 4563
Hernández Miyares, C. 4197, 5014
Herndon, C. N. 248
Herold, J. 3519
Herriott, R. M. 1541
Herrlich, A. 5150
Hertenstein, C. 508, 1001, 1292, 2386
Hertl, M. 644, 5191
Hervada, A. R. 2473
Herzog, E. G. 537
Herzog, F. 355
Herzog, M. 257
v. Hess, C. L. 346
Hess, E. R. 3512
Hess, J. 291
Hess, J. H. 2640, 3512, 4487
Hesselberg, C. 3793
Heymann, G. 2546
Heyne, D. 2268
Hicks, H. C. 3877
Hildebrand, M. 1291
Hildes, J. A. 1118, 2319, 3347
Hilding, A. C. 3105
Hill, A. B. s. Bradford Hill, A.
Hill, N. P. 5269
Hill, W. H. 4843
Hilleboe, H. E. 2477, 4495
Hilleman, M. R. 4635, 4727, 4960
Hillemann, M. R. 2352
Hingson, R. A. 2122, 2322
Hinrichs 5002
Hinrichs, R. 4694, 4879
Hinuma, Y. 3432
Hirayama, M. 2648, 4269
Hitce, J. M. 3722
Hobson, J. J. 2467
Hochenburger, E., jr. 2427
Hoder, F. 3735
Hodes, H. L. 2062, 4732, 4954
Hodes, R. 4099
Hodge, H. C. 3109
Hodgson, R. 1828
Hoeffler, H. 3712
Höchli, M. 79
Höpken, W. 312, 314, 390, 759, 1966, 2542, 3495
Höring, F. O. 627, 1699, 1702
Hoffert, W. R. 2592, 4653
Hofman, B. 638, 1317, 1862, 1871, 2595, 2666, 3361, 3429, 4046, 4241, 5208
Hofmann, W. 2851, 4804
Hofmeier, K. 3900, 4154
Hogben, G. H. 2449
Hohlbein, R. 2881
Holguin, A. H. 4908, 5004
Holkup, H. 5233
Hollander, D. H. 2650, 2967
Hollender, L. 4419
Hollinger, N. 721
Hollister, A. C., Jr. 1941, 2311, 3386
Holloway, A. 2701, 4465
Holt, L. B. 564, 836
Holtman, D. F. 3173, 3189, 4841
Holzmann, E. 4787
Hommes, A. 1311
Hook, A. E. 515, 763, 2803
Van Hoosier, G. L., Jr. 3156, 4205, 4630, 4631
Hopkey, I. A. 227, 228
Hopkins, F. R. B. 1826
Hopkinson, E. V. 2999
Horetzky, R. 3195
Hori, K. 2632, 4502
Horn, P. 122, 2996, 2997
Hornickel, K. 5343
Hornung 3669
Hornus, G. 3570, 4679, 4697, 5086 5103
Horodniceanu, F. 1025, 1112, 1113, 1141, 1372, 2994, 3242
Horsfall, F. L., Jr. 2776
Horstmann, D. M. 296, 326, 711, 991, 1202, 1282, 1640, 1663, 1806, 1834, 1836, 1837, 2002, 2133, 2388, 2638, 2702, 2739, 2741, 2973, 3015, 3157, 3377, 3380, 4037, 4174, 4916, 4965, 4977, 5162, 5379
Horstmann, P. 5383
Horvath, B. 1620
Horwitz, A. 4890, 5055

Horwitz, T. 3950
Hoshiwara, L. 4202, 4594
Hoskins, J. M. 4973
Hoskwith, B. 19, 5119
Hoskyns, B. L. 208
Hosley, R. J. 1303
Hotta, S. 516
Hottinger, A. 589, 4069
Hottinger, H. 4385
Hottle, G. A. 2915, 4630, 4631, 4962, 4967, 5371
Howard, C. W. 4918
Howard, E. M. 1258, 2298, 3135
Howard, R. E. 8
Howe, H. A. 23, 29, 39, 40 42, 59, 121, 126, 180, 295, 353, 623, 708, 709, 710, 712, 733, 926, 1541, 1542, 1634, 1670, 1943, 2030, 2246, 2247, 2256, 2461, 2751, 2864, 2880, 2892, 3140, 3228, 3229, 3425, 3590, 3602, 4014, 4033, 4133, 4167, 4821, 4828, 5070, 5126, 5157, 5158
Howell, F., Jr. 2592, 4653
Howell, K. 270
Howitt, B. F. 198, 223, 482, 780, 814, 881, 882, 1098, 2008, 2797, 3585, 3623, 3719, 4190, 5017
Hoyne, A. L. 2835, 2995
Hoyt, A. S. 822
Hsiang, C. M. 2601
Hsiung, G. D. 4961
Huang, N. 2352, 4204
Huber, E. G. 999
Huber, H. G. 2800, 3447, 4166
Huber, J. 3899
Huber, W. 1542
Hudemann, H. 4477
Hudson, C. C. 427
Hudson, F. I. 2101
Hudson, N. P. 167, 667, 742, 753, 793, 805, 807, 815, 816, 900, 1053, 1085, 2202, 2669, 2858, 3418, 3420, 3599, 3685, 4794
Huebner, R. J. 982, 2567
Hübner, E. 2917
Hünerbein, J. 302, 1858, 2084, 5415, 5417
Hürny, L. 4061
Hughes, S. 3056
Hullinghorst, R. L. 287
Hultin, J. V. 5151
Humke, W. 1500
Hummeler, K. 233, 389, 1979, 2782, 3432
Humuzache, E. 4666
Hunt, A. D., Jr. 1979
Hunter, J. S., Jr. 1566
Huntley, V. M. 1423
Huntoon, F. M. 4876
Hurst, E. W. 781, 1184, 1271, 1272
Husler, J. 4342
Husson, A. 1234
Hutchison, P. A. 4625
Huth 3920
Hyde, R. T. 5151
Hylton, R. 3802
Hyrenius, H. 1969

I

Iafusco, F. 2482
Iams, A. M. 3468
Ianconescu, M. 2288, 2295, 2958, 3452, 4072, 4186
Ianni, F. A. J. 2583, 2584
Iantaffi, C. 1231, 2295, 5378
Ibrahim, I. [illegible]
Ipsen, J. F. [illegible]
[illegible], J. T. [illegible]
[illegible], P. [illegible]
[illegible], F. [illegible]
[illegible], V. I. [illegible], 3206, [illegible], 4252, [illegible], [illegible], 5107
Von [illegible], B. [illegible]
Ingalls, [illegible] H. 511, [illegible]
Inglessi, E. 1406
Ingraham, H. S. 4093
Ingram, V. G. 4652
Inserillo, G. 1456, 1886, 1888
In't Veld, A. 5208
Ionesco-Mihaiesti, C. 1025, 1112, 1113, 1141, 1372, 2994, [illegible], [illegible], 4350, 4378
Ipsen, J. 1758, 5383
Isaacson, E. P. 4065
Isaacson, P. [illegible], [illegible]
[illegible], F. 1613
[illegible], C. [illegible]
Iwakura, N. [illegible]
[illegible]
[illegible]

J

Jaccard, G. 2518
Jaccottet, M. 4385, 4808
Jackson, A. V. 226, 526, 528, 927, 3558
Jackson, F. W. 3849, 4791, 5336
Jacob, W. 2054, 2327, 2540, 5343
Jacobs, J. P. 5346
Jacobs, M. 1507
Jacovides, G. 5428
Jahiel, R. 2251
Jahnes, W. G. 4934
Jamieson, W. A. 4310, 4420
Janbon, M. 230
Jancso, A. 3336, 5277, 5292
Janda, J. 3319
Janda, Z. 3391
Janeway, C. A. 980
Janeway, M. 863
Janik, F. 1001
Jánkevics, O. D. 1401
Jánossy, G. 5301
Janota, M. 985, 1755, 1882, 2070, 2718
Janowsky, C. C. 2787, 2956
Jantaffi, C. 2290, 2959
Jaworska-Romer, A. 5176
Jeandin, F. 3050
Jeavons, P. M. 2299
Jeffs, H. B. 3841
Jelìnek, J. 4989
Jellinger, K. 4149
Jemma, A. 4950
Jemma, G. 4540
Jemmer, A. 2192
Jenicke 3927
Jennens, M. G. 4569
Jennings, R. G. 248
Jensen, C. 483, 922, 2810, 3636, 4775, 5197
Jensen, O. 5151
Jensen, [illegible]
[illegible] 4741
[illegible]
[illegible], 2631, [illegible], 3435, [illegible]
[illegible]
Jiménez, R. M. 2522, 2572
Jitta, N. M. J. 3720
Joannon, P. 5335
Jobin, A. 3867
Jochheim, K.-A. 2347
John, H. 5182
Johns, A. W. 4422
Johnson, C. C. R. 75
Johnson, D. W. 1796
Johnson, E. A. 386, 387, 521, 548, 992, 4273, 4629
Johnson, G. E. 3104
Johnson, J. F. 2215
Johnson, K. W. 3345
Johnson, T. 850
Johnston, H. 3705
Johnston, P. B. 4726
Jones, E. E. 5346
Jones, E. S. 5135
Jones, J. H. 732, 765, 893, 2750, 3956, 4365, 4425
Jones, L. R. 3604
Joo, G. 3543
Joó, I. 2576, 4578, 4731, 4859, 5307
Joppich, G. 2769, 5174
Jordan, W. R. 3933
Joseph, K. 93, 95, 104, 1062, 2755
Jouve 479
De Juan, P. 2478
Juers, A. L. 4094
Jürgenssen, O. 2394
Juif, J.-G. 2166
Jung, M. 2508, 5353
Jungeblut, C. W. 5, 447, 481, 702, 717, 726, 727, 735, 736, 738, 741, 820, 904, 1044, 1104, 1200, 1620, 1696, 1877, 2069, 2141, 2201, 2204, 2206, 2207, 2208, 2666, 2687, 2727, 2738, 2861, 2871, 2881, 3268, 3397, 3503, 3516, 3571, 3608, 3699, 3992, 4046, 4207, 4353, 4445, 4564, 4769, 4797, 4798, 4826, 4904, 4945, 5022, 5039, 5127, 5132, 5442
J[illegible], F. L. [illegible], 3248, [illegible]
[illegible], 3373, 3241
[illegible]

K

Kabat, E. A. 5074
Kadish, A. H. 5430
Käckell, M. Y. 1910, 4774, 5351
Käppel, M. 2891
Kafantaris 5472
Kagan, J. R. 141, 1051
Kaiser, M. 3782
Kakusui, T. 5156
Kalčič, S. 2510, 4050
Kallner, G. 2435
Kalter, S. S. 1395, 4250
Kalwij, A. S. 1219, 3025, 5364
Kaminsky, J. 2046
Kamitsuka, P. 1203, 1204, 1929, 2068, 2438, 2944, 3028, 4161
Kanagaratnam, K. 1166, 1195
Kanazawa, K. 308
Kanchurin, A. K. 1635
Kanda, Y. 307
Kandel, A. 4500
Kanta, C. 4285
Kantor, L. 4926
Kantorovich, R. A. 2354, 3338, 4235, 5497
Kanzler, H. 5303
Kanzler, S. 4581, 5303
Kao, M.-I. 4114, 5175
Kaplan, A. S. 1691, 2249, 2707, 2725
Kaplan, L. 5189
Karasszon, D. 5310
Kardash, I. B. 4237
Karger, P. 4688
Karsten, F. 171
Kasahara, M. 38, 2620, 5156
Kåss, A. 3954
Kasymow, K. T. 2925
Kátay, A. 249, 4074, 5288
Kathay, A. 5362
Kato, Y. 2448, 4282
Katz, S. H. 2017
Kauders, O. 251, 3853, 4801
Kauffman, E. I. 4501
Kauffmann, F. 4720
Kaufman, R. E. 863
Kawakami, K. 2648, 4269
Kay, W. W. 763, 2190
Keeble, S. A. 4025
Kehrer, N. 484
Kékesi, F. 4082
Kelemen, G. 2929, 4578, 4649, 4731, 4859, 5307
Kelis, J. 4856
Kelleher, W. H. 220
Keller, C. J. 5166
Keller, W. 1000, 1176, 1318, 1766, 1773, 1852, 1918, 2126, 2538, 2544, 2548, 2551, 2562, 2667, 2813, 3442, 3529, 3710, 3711, 4131, 5394, 5426
Kelley, V. C. 434, 3970
Kellogg, W. H. 1041
Kelly, S. 1919
Kempf, J. E. 5155, 5160
Kempski, H. W. 1743, 4516
Kendall, E. J. C. 2587, 2887, 2953
Kendel, F. A. 3861
Kendrick, P. L. 1252, 2948
Kennedy, F. 1074
Kennedy, R. L. J. 1115
Kercher, E. F. 1567
Kernwein, G. 707
Kerr, M. R. 1641
Kersting, G. 1921, 2043, 2307, 2682, 5448
Kessel, J. F. 31, 46, 51, 140, 157, 358, 362, 621, 822, 1259, 1269, 1657, 2065, 2659, 2690, 2710, 2752, 2859, 2964, 3625, 4789, 5073
Kestermann, E. 3942
Ketler, A. 233, 3432
Kevy, S. V. 3236
Khanina, M. K. 4573
Kheit, S. L. 2557
Khesin, I. E. 4214, 4216
Khorazo, D. 1044
Khvatov, P. P. 4256
Khvatova, A. Y. 4256
Kibitkina, E. N. 4256
Kibler, M. 252
Kibrick, S. 4203
Kiekiela, M. 5176
Kikuth, W. 1764, 1766, 1865, 1982, 2426, 2538, 2544, 2551
Kilgariff, K. 450
Kima, T. 584, 585, 1654, 4117, 4359, 4745, 4858, 5025, 5262, 5434
Kimball, A. C. 992, 4629, 5009, 5011

King, E. Q. 742
Kinney, Ch. E. 350
Kinsman, D. 3431
Kirchmair, H. 3549, 4073
Kirillova, F. M. 5465
Kirk, B. E. 1303
Kirkwood, J. G. 2109
Kirn, A. 3475
Kirschstein, R. L. 2437, 2915, 3156, 4205, 4630, 4631, 4962, 4967
Kitaoka, M. 971, 2632, 2633, 3127, 4437, 4438, 4502, 4984
Kito, E. 291
Kjellén, L. 4765
Klaila, A. 4474
Klarenbeek, A. 4460, 4464, 4492
Klee, A. 3240
Klein, M. 1605
Klein, P. 1063, 2852
Klein, R. 1025, 1112, 1113, 1141, 1372, 2994, 3242
Klein, S. J. 132, 1449, 4047, 4382
Klein, S. W. 518
Kleinberg, S. 3950
Kleinman, H. 992, 2196, 2323, 4629, 5009, 5011
Kleinschmidt, E. E. 4501
Kleinschmidt, H. 677, 869, 994, 1402, 1405, 1425, 1428, 2489, 2766, 4065, 5406
Kleu, M. 4155
Klimt, C. R. 2218
Kling 4912
Kling, C. 324, 734, 3270, 3601, 4401, 4406, 4427, 4553, 4679, 4697, 4924, 5016, 5103, 5118
Kling, C. A. 4809
Klingler, E., Jr. 2373
Klöne, W. 2658, 5308, 5448
Klotz, A. W. 228
Klugh, G. F. 703, 751
Klyuchareva, T. E. 1087, 3222, 3226, 4228
Kmet, J. 2508
Knighton, J. E. 3689
Knoche, W. 3873
Knoepfelmacher, W. 2233
Knöpfli, R. 4193
Knothe, H. 2429
Knowelden, J. 213, 431, 562, 1592, 2506, 2753, 2990, 3333
Knox, A. W. 2706, 2721
Knox, J. C. 84
Koch, A. 1158
Koch, G. 2452, 4077, 4749
Koch, H. 5222
Koch, M. A. 2359, 2513
Kochs, H. 2532, 2786
Kodlin, D. 2087
Kodza, H. 2069
Koechlin, J. 4932
Koegel, O. 1324
Koehn, A. 4179
Koenig, S. 2452
Koeppe, H.-W. 5111
Kölbl, H. 3099
Körner, L. 1021, 1223, 2683, 3020, 5145, 5404
Környey, S. 4031
Kohl, H. 3909
Kohn, S. E. 4834
Kokko, U. P. 46, 51, 299, 2392, 2650, 2964, 2967, 4462
Kolesnikov, L. V. 4228
Koller, F. 4385
Koller, M. 5255, 5298
Koller, S. 2545, 2547, 2637
Kolmer, J. A. 20, 78, 86, 225, 283, 284, 363, 703, 704, 724, 725, 731, 748, 751, 912, 1043, 3005, 3204, 3617, 3878, 3891, 3894, 3896, 3898, 4318, 4719, 4796, 5334
Kolner, M. 2726
Kolochine, C. 1262
Komae, T. 2448
Komlos, L. 549
Kondo, H. 2448
Kono, R. 2648, 4269
Kool, S. M. 3024
Koomen, J. 4633
Kopeloff, N. 1104
Koprowski, H. 538, 601, 673, 686, 698, 940, 986, 1253, 1278, 1394, 1432, 1814, 1954, 1979, 1995, 2097, 2180, 2240, 2257, 2436, 2563, 2631, 2660, 2723, 2724, 2787, 2788, 2896, 2903, 2918, 2956, 3022, 3043, 3054, 3148, 3170, 3210, 3213, 3231, 3305, 3308, 3330, 3415, 3493, 3964, 4020, 4585, 4662, 4911, 4957, 4959, 4995, 4998, 5122, 5181, 5321
Kopyść, Z. 3467

KORNS, R. F. 177, 1782, 1807, 3163, 3224
KOROLEVA, G. A. 3230, 4893, 4990, 5021
KOSKOFF, Y. D. 4177
KOSMACHEVSKIY, V. V. 4239
KOSSMANN 5071
KOSSOVITCH, N. 1260
KOSTINA, K. A. 1165, 3234
KOSTRZEWSKI, J. 4968, 5480
KOVALEV, A. A. 4226
KOVALEVSKI, E. I. 3463
KOZAKEVICH, N. B. 1332
KOZDA, H. 4769
KRAFT, L. M. 296, 1678, 1836
KRAMÁR, E. 4701, 4703
KRAMER, B. 1013
KRAMER, S. D. 16, 17, 18, 19, 70, 89, 145, 146, 158, 325, 340, 354, 455, 716, 1071, 1077, 2646, 2745, 2754, 3008, 3365, 3508, 4571, 4673, 4684, 4712, 5007, 5119, 5129
KRAUS, N. 2380
KRAUS, P. 1854, 1970
KRAUS, R. 96, 419, 421, 1038, 3663, 3774, 3775, 3888, 4544, 4550, 4926
KRAUSE, F. 3462
KRAUSE, P. 719, 1263, 4674
KRAUSE, W. W. 2537
KRAUSLER, J. 4182
KRAUSPE 4010
KRECH, U. 1565, 1767, 1770, 1771, 1830, 1914, 2087, 2283, 2378, 2740, 3040, 3426, 3427, 4770, 4970
KREIBICH, H. 4053
KREPLER, P. 1410, 3096, 3175
KRET, A. 385, 638, 2314, 5208
KRIGSTEN, W. M. 168, 2761
KRILL, C. E. 351, 458, 5326
KRISTEV, T. 1387
KROATH, F. 5226
KROVETZ, L. J. 2323
KRUGMAN, S. 3390, 3985
KRUMBHAAR, G. D. 3348
KRUMBIEGEL, E. R. 2970
KRUMRICH, R. 3706, 3835
KRYL, R. 3319
KUBATSCH, J. 2679
KUBIE, L. S. 4326
KUBOTA, H. 2648
KUBOTA, T. 2448
KUBRYK, D. 1133, 1274, 3387
KÜNNE, B. 1047
KUITERT, J. H. 1468
KUKÁN, E. 4642, 5301
KUKAYN, R. A. 4256
KUKOWKA, A. 1090, 1161, 1962, 1963, 2036, 2117, 2286, 4119, 4618, 4947, 5019, 5413
KULESZA, A. 5480
KUMM, H. W. 591, 2129, 2630
KUNDRATITZ, K. 1968
KUNZ, C. 4182, 4149
KUPSKY, C. H. 2803
KURATSCH, J. 5124
KURNOSOVA, L. M. 1087, 2354, 3223, 3338, 4234, 4256, 4258, 5497
KUSKE, F. 5174
KUSLAP, T. R. 4893, 5021
KUUSI, T. K. 4613

L

LA BOCCETTA, A. C. 2625
LABZOFFSKY, N. A. 195, 691
LACAMBRE 680, 689, 1156
LACKMAN, D. 2414
LACORTE, J. G. 11, 1306, 2629, 3129
LAFONTAINE, A. 24[illegible], 4646
LAGERCRANTZ, P. [illegible], 3164
LAGONIGRO, F. [illegible]
LAGUNA, C. 132[illegible], [illegible]
LA[illegible]LE, O. 56, [illegible]
LA[illegible], J.-S. [illegible]
[illegible], W. [illegible]
LAIGNEL-LAVASTINE 3914
LAKE, B. M. 533
LAMBERT, S. M. 3545
LAMEDICA, G. 4883
LA[illegible], V. 1035
LA[illegible], K. 1923
LA[illegible], M. 762, 2124, [illegible]
[illegible], 4277, [illegible]
[illegible]

Landsteiner, K. 98, 359, 373, 423, 424, 425, 466, 467, 757, 1257, 2644, 4847, 4865, 4872
Lange, F. 1273
Langer, R. 3358
Langer, W. 3199
Langmuir, A. D. 939, 1114, 1291, 1570, 1586, 1617, 2159, 2341, 2391, 2421, 4039, 4855
Langstein, L. 953
Langworthy, H. G. 3938
Lapchine, L. 1213
Lapenta, D. 4927
Lapinleimu, K. 2071, 3969
Laquerrière 3247
Lareng, M. B. 1213
Larkin, M. 2174
Larkum, N. W. 1691
Larminie, H. E. 193, 207, 2900, 4771
Larnaudie, L. 4225
Larson, C. L. 524, 652, 1915, 2114
Larson, W. P. 4541
Larsson, K. 4229
Laruelle, L. 3247, 3752, 3796, 3809
Lascheid, W. P. 607
Lashkevich, V. A. 2300, 3471, 3486, 4573, 4893, 4975, 5021, 5282
Lassen, H. C. A. 25, 4101, 5181, 5383
Lato, M. 4590
Lauer, R. 1461
Laufer, I. 534
Laurence, G. D. 4569
Laurinsich, A. 2611
De Lavergne, E. 1139, 1382, 3050
Lavillaureix, J. 4616
Lavrova, I. K. 3230
Lawrenz, K.-H. 5234
Lawrence, N. 3155
Lea, A. J. 2466
Leake, J. P. 750, 826, 3374, 4545, [illegible]78
Lear[illegible], D. 3109
Lebeau, S. 4177
LeBlanc, D. J. 191, [illegible], [illegible], [illegible]85, 1845, [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible]
[illegible]
Lebourge, J. 5052
Lebrun, A. 1995, 2436, 2444, 2788, 3170, 4662
Lebrun, J. 539
Leclainche, X. 2802, 4306
Lederer, J. 2519
Ledinko, N. 184, 1230, 1580, 2621, 2657, 2729, 2965, 2966, 3180, 3363, 4440, 5333
Lee, L. H. 1166, 1195, 1665, 3333, 4252, 4766, 4922
Leeder, F. S. 4515
Leftwich, C. I. 5039
Legeżyński, S. 4466
Leiner, C. 377, 418, 420, 422, 1379
Leiner, K. 1019
Lelong, M. 3134
Lenahan, M. 1203, 1204, 1929. 2438, 2944
Lenahan, M. F. 1849
Lenard, A. 4414
Lenarsky, M. 2822
Lennartz, H. 499, 508, 1152, 1292, 1910, 1921, 2043, 2307, 2553, 2682, 3019, 3303, 4521, 4743, 4762, 4774, 4958, 5072, 5308
Lennette, E. H. 156, 167, 188, 742, 753, 793, 804, 805, 807, 816, 859, 944, 961, 1053, 1429, 1794, 1890, 1941, 2202, 2385, 2446, 2488, 2681, 2762, 2858, 3386, 3418, 3420, 3685, 4067, 4298, 4657
Lennon, G. T. 4542
Lensen, S. G. 3032, 4431, 4469
Lentz, M. 454
Lenz, M. 5089
Lenz, W. R. 2363, 2684
Leonardi, G. 3394
León Perazzo, D. 1515
Leong, K. W. 1166, 1195
Lepage, M. 2579
Lépine, P. 231, 587, 640, 672, 681, 977, 1121, 1150, 1236, 1245, 1289, 1290, 1301, 1341, 1414, 14[illegible], 165[illegible], 1666, 1746, 1817, 1818, 1866, 1930, 2102, 2148, 215[illegible], 2170, 2181, 2192, 2267, 2321, [illegible]4, 2330, 238[illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible], [illegible]

3134, 3434, 4022, 4267, 4340, 4456, 4483, 4518, 4531, 4553, 4586, 4621, 4777, 4944, 5016, 5164, 5419, 5420, 5439
Lépine, P. R. 4423, 4835
Lepow, M. L. 2558, 4652, 5001
Lerner, A. M. 4249
Leroy 2989
Leunda, J. J. 3184
Leuterer, W. 5146
Levaditi, C. 98, 99, 100, 304, 324, 359, 373, 424, 425, 466, 467, 734, 757, 1255, 1257, 1270, 1583, 3018, 3252, 3270, 3286, 3287, 3421, 3501, 3570, 3572, 3751, 3753, 4066, 4128, 4129, 4353, 4392, 4393, 4400, 4402, 4403, 4405, 4407, 4427, 4553, 4679, 4697, 4825, 4849, 4850, 4863, 4865, 4872, 4924, 5015, 5086, 5103, 5228, 5491
Levenbuk, I. S. 4214
Lévi, P. 609
Levine, L. 2090
Levine, M. I. 3103
Levine, S. 1765, 2357, 2389, 3195, 4277, 4303, 4656, 4994
Levinson, S. O. 612, 770, 790, 1108, 1755, 1882, 2718, 3437, 3512, 3614, 4412, 4574, 5271
Levy, D. 1299, 2580
Lévy, F.-M. 261
Levy, G. J. 169
Lewin, P. 612, 770
Lewis, B. H. 3259
Lewis, L. J. 37, 48, 49, 52, 1565, 1770, 1771, 3136, 3141, 3353, 5329
Lewis, P. A. 106, 108, 109, 317, 415, 675, 1059, 1060, 2143, 2144, 2145
Lhermitte, J. 3247
Li, C. P. 1373, 2712, 2714, 2798, 3410, 3443, 4095, 4205, 4934
Li, M.-S. 2873
Liao, S. J. 47
Lichstein, H. C. 3411, 3885, 4838, 5135, 5380
Lichtenstein, A. 784, 1171, 5084
Liebe, S. 330
Lieben, J. 1725
Liebesny, P. 4086
Lie-Khing-Ting 4078
von Liel, E. 489, 2610
Lievre, J. A. 3899
Likar, M. 1427
Lilley, A. B. 783
Lillie, R. D. 3948, 3959
Limper, M. 780, 1083
Lindahl, A. 4665
Lindahl, J. 5202
Lindemuth, A. 3931
Linden, H. 4682
Lindenmann, J. 4180
Lindgren, W. D. 5192
Lindholm, O. 4308
Lindner, W. 5297
Link, T. 921, 3866
Linneweh, F. 1768, 1793, 1908, 2543, 2551
Liotta, I. 3133
Lipman, W. H. 608
Lippert, A. 1293
Lippi, M. 648, 3451, 4227, 4661
Lipscomb, F. M. 3297
Lipson, H. A. 4018
Lipson, M. J. 650, 2322, 3101
Lipson Lepow, M. 2396
Lipton, I. 2995
Lipton, M. M. 34, 393, 530, 1297, 1298, 1676, 2719, 4275
Lisitsa, F. M. 3469
Lissac, J. 2579
Lissievici-Oprescu, E. 2187, 2988
Liszka, I. 4701, 4703
Litterer, W. 900
Litvak, A. 4371
Liu, O. C. 331, 1011
Llewelyn, J. 215
Locke, F. B. 177, 3161
Lockett, M. F. 3135
Loddo, B. 1413
Loeken, G. 3530
Loeschke, A. 3652, 5250
Loewe-Lyon, S. 2199
Loewenberg, E. 3640, 4788, 4793
Löffler, H. 242, 653, 657, 2333, 4772
Logan, J. S. 1990, 5029
Logan, W. P. D. 2850
Van Loghem, J. J. 3089, 4980, 4981
Lomer, T. A. 4035
Lo Monaco, G. B. 1206, 4730

Long, D. A. 1120
Long, P. H. 137, 1072, 1080
Longmore, J. B. 210
López Berrios, M. 2293, 2409
López Zanón, A. 2626
Lorenz, F. 2120
Lorenzen, J. 2517
Lorenzo, J. A. 3184
Loring, H. S. 2722, 3155
Lorrain, J. 641, 1139, 1148, 1382, 3050
Losonczy, Gy. 4238
Lossing, E. H. 1116, 1956, 2125
Loudon, I. S. L. 222
de Lourdes da Silva Ferreira, M. 1198
Louyot, P. 3810
Love, R. 3354
Lovtsevich, E. L. 4729
Low, R. J. 2573
Lowenberg, K. 909, 1106, 3831
Lozovskaya, L. S. 4733
Lubens, H. M. 3108
Lucas, W. P. 332, 3200, 3588, 4854
Lucchesi, P. F. 2625, 4314
Lucero, B. 5283
Ludin, F. 4489
Ludwig, E. H. 1562, 2110, 4027, 4058, 5312
Lukens, D. 518
Lulić, V. 5353
Lund, E. 181
Lundström, R. 4559, 5459
Lundt, P. V. 690, 5411
Luoto, L. 2325
Luria, S. A. 3673
Lush, D. 2866, 3558
Luthardt, Th. 2384
Luther, E. H. 336, 401, 799, 1071, 1077
Luz, C. 1366
Luz, L. A. 4386
Luzardo, O. 3184, 5203
Lwoff, A. 1992. 2585, 3095, 4938
Lwoff, M. 2585, 3095, 4938
Lychkovskaia, E. V. 2926
Lycke, E. 113, 850, 1125, 1126, 1337, 1338, 2044, 2063, 2111
Lynch, J. M. 905
Lyon, C. L. 920
Lyon, E. 1295
Lyskowzsew, M. M. 5249

M

Maass, G. 499, 1001, 1339, 1910, 2043, 4180, 4774, 4958, 5072, 5248, 5399, 5400, 5401
McAlister, J. 1989, 4259, 4260, 4261
McAllister, R. M. 1552, 1562, 4058, 5210
McAteer, R. F. 4899
McBride, O. W. 1115
McBride, W. D. 488, 1629, 2674
McCall, K. B. 4838, 5380
MacCallum, F. O. 35, 214, 1609, 2506
McCallum, J. L. 1531
McCarroll, J. R. 1663, 1834
Macciotta, G. 2504
McCloskey, B. P. 1040, 1721, 1729, 4024, 4439
McCloskey, L. W. 5312
Di Macco, G. 1244
McCollum, R. W. 1640, 4174
McConnell, A. A. 4443
McCord, W. J. 3347
MacCormack, J. D. 1853, 4019
McCormick, W. J. 485, 3293, 3886, 3935
McCredy, R. J. R. 1407
McDermott, W. 2660
McDougall, C. 790, 1108
McEachern, J. M. 873, 1365, 4348
MacFarlane, J. O. 1303, 1828
McFerran, J. B. 5500
McGee, E. L. 1954
MacGinty, A. 4903
McGoogan, L. S. 3016
MacGregor, I. W. 1438
Mac Gregor, L. G. 193, 207, 2900, 4771
McGugan, A. C. 4683
McGuire, J. C. 1242
Machlowitz, R. A. 671, 4635
McIntosh, E. G. S. 2900
McIntosh, J. 3502, 4375
MacIver, D. P. 4100
Mack, W. N. 891, 3365, 5326

McKay, A. L. 4351, 4554
MacKay, E. M. 755
Mackay, N. R. 1998
McKelvey, J. L. 386, 387, 521, 548, 3158, 3159, 3218, 4273, 4985
McKendry, J. B. J. 1645, 3402
McKenna, J. M. 2318
McKenzie, E. D. 3201
McKenzie, M. 873, 1365, 4548
McKeown, F. 1964, 2304, 4259, 4261
McKeown, S. B. 3122
McKhann, C. F. 1077, 4015
McKinley, E. B. 456, 2857, 4781
McKinley, J. C. 3694, 4541
McKinnon, N. E. 3832, 5336
McKinstry, D. 3890
McLachlan, I. M. 2879
McLaren, A. 1117, 4108
McLaughlin, J. 207, 2900
McLean, D. M. 4361
McLean, I. E. D. 4122
McLean, I. W., Jr. 505, 515, 614, 619, 761, 763, 989, 2190, 2803, 4300
McLeod, D .L. 1529
MacLeod, D. R. E. 1214, 1222, 1987, 4284, 4287, 4889
MacLeod, I. 5034
Mac Leod, R. C. 193
McLeod,W. J. 209, 1719, 1844, 4535
McMath, W. F. T. 555, 4102, 4596
MacMorine, H. G. 1895
McMullen 3746
Macnamara, J. 144, 917, 956, 1095, 1096, 1347, 3324, 3325, 3745, 3750, 3760
McNaught, R. C. 1608
McNaughton, G. A. 75, 1529
McQuarrie, I. 3970
Macrae, A. D. 1967, 1990, 2488
McRobert, G. R. 2365
Madden, W. J. 4834
Madsen, T. 2810, 3636
De Maeyer, E. 851, 951, 1279, 2374, 2523, 4277
Magee, M. C. 1544, 3265, 3266
Magliano, G. 2524, 2574
von Magnus, H. 60, 61, 160, 839, 2159, 2624, 3085, 4055, 4194, 4485, 4885, 5331, 5367, 5499
von Magnus, P. 839
Magoffin, R. L. 1941, 3386, 4657, 5192
Mai, H. 2839, 3848, 4321
Maister, M. 4610
Majima, E. 4949
Majori, L. 2265
Makarewicz, J. 4992
Malcolm, J. C. 5061
Malgras, J. 3241
Malolepszy, A. 3306
Malossi, M. 2606
Mamoen, R. 1247
Mancini, G. 3454
Mancini, L. 1308, 2908
Mandel, B. 183, 4201, 4210, 4231, 4864
Manes, J. F. 411
von Manger-Koenig, 2843, 5408
Mangold, G. 4451
Manicatide, M. 1266, 1550, 3284, 4543
Mannweiler, K. 2307, 4628, 4958, 5072
Manzi, F. 4568
Mar, G. I. 4237
Marberg, K. 2357, 3006, 4277
Marchal, J. 2577
Marchenko, A. T. 1267, 1660, 3339, 4216
De Marcillat, C. 3945
Marcovici, M. 1025, 1113, 1276, 2994
Mareš, I. 1662, 3061, 3990, 4664, 4690
Marfan, M. L. 3780
Margolis, J. 758
Marine, W. M. 2566, 4001, 4002, 4003, 4150
Marinesco, G. 1266, 3284, 4852, 4853, 4866
Marinoni, G. 2774
Marioni, R. 2362, 2390
Markham, F. S. 1205, 2358, 2623, 3232, 4736, 5006
Markovitz, J. 5429
Marks, H. H. 315
Marks, H. K. 1049
Markush, R. E. 2592, 4653, 5068
Marmann 4175
Maróczi, J. 2576, 2929, 4578, 4649, 4731, 4859, 5307
Maroteaux, P. 3152

Márquez Escobedo, M. 4563
Marraro, G. 2783
Marschenko, A. T. 5177
Marshall, A. L. 2616
Marshall, R. 3884
Marti, J. 2056
Martin, Ch. 542
Martin, G. K. 691
Martin, J. D. 2471
Martin, J. K. 365, 1609
Martin, J. P. 4331
Martin, L.-A. 1951, 2041, 3197, 4105, 4467, 4519
Martin, R. 229, 1426, 2561
Martin, W. J. 2849
Martingay 3246
Martinho da Rocha, J. 5185
Martini, R. 5183, 5193
Martins Da Silva, M. 201, 386, 387, 521, 548, 992, 1225, 1226, 1902, 2292, 2293, 2409, 2560, 3172, 3181, 4273, 4654, 4890, 5043
Mascola, A. D. 1640, 4174
Maslova, S. B. 5274
Mason, P. J. 5452
Massal, R. 4638
Masseo, G. 1238
Massot, M. 3321
Massucci, G. 2979
Mathers, G. 255, 266, 270, 274
Mathers, J. E. 4985
Mathew, A. G. 1028
Mathews, W. R. 3635
Mathey, W. E. 5009, 5011
Mathieu, J. 1382, 3050
Matjašič, M. 5353
Matsumiya, T. 2648, 4269
Matta, E. J., Jr. 5293
De Mattia, R. 2339, 2992, 4279, 4693, 5188
Mauler, R. 1021, 1223, 3020, 4304, 5145
Maurin, J. 189, 681, 1414, 3134
Mauvais, J.-B. 231
May, G. 4219
Mayer, C. 4315
Mayer, M. M. 400, 518, 525, 759
Mayerhofer, E. 4162
Mayes, O. 3174
Mayne, A. 3872
Mayor, H. D. 4144
Mayr, A. 2978
Mayrhofer, J. 5113
Mayser, H. 2509, 2516, 5067
Mazare, Y. 1490
Mazel, P. 3966
Mazur, B. 605, 1519
Mazzacuva, D. 4737
Meade, R. H. 3346
Meadors, G. F. 4845
Meals, R. W. 3727, 3817
Measroch, V. 3219
Mécs, I. 4642
Medalie, J. 2128
Medalie, M. 2502
Meenan, P. N. 10, 2622, 4272, 4473
Meer, U. 2531
Meersseman, F. 3966
Megevand, A. 579, 1147
Meier, P. 2195, 2346
Meinicke, E. 719, 1263, 1264
Melén, B. 187, 850, 853, 1032, 1033, 1125, 2063, 2064, 2493, 4765
Melick, D. W. 4505
Mellbye, F. 4880, 5261
Meller, H. K. 4083
Melnick, J. L. 54, 60, 61, 160, 203, 307, 326, 650, 711, 713, 947, 1086, 1286, 1464, 1577, 1580, 1581, 1606, 1615, 1663, 1682, 1691, 1834, 1840, 1841, 1929, 2029, 2255, 2335, 2336, 2420, 2451, 2525, 2621, 2657, 2685, 2707, 2725, 2729, 2739, 2741, 2863, 2882, 2965, 2966, 3015, 3042, 3044, 3180, 3208, 3216, 3220, 3363, 3377, 3961, 4028, 4145, 4440, 4448, 4537, 4611, 4623, 4644, 4842, 4930, 4961, 5069, 5139, 5142, 5333, 5379, 5381, 5386, 5436
Melnick, Th. 478
Melnotte, P. 641, 1139, 5239
Melnotte, P.-J. 5239
Meloni, G. A. 1815, 4601, 4604
Meltzer, S. J. 3279
Memmer, R. 1216, 1217
Mengano, G. 3724
Mengert, W. F. 3203
Menichini, G. 3976, 4526
Menk, W. 1124
Menninger, W. C. 3744

Mentha, G. 3121
Menzin, A. W. 2592, 3695, 4653, 5068
Mercado, A. 560, 1378, 2370
Mercier, P. 547, 575
Mérieux, Ch. 950, 1162, 1319, 1384, 1621
Merklen, F. P. 2115
Merrell, M. 128, 4446
Merrill, M. H. 2311
Merrill, R. E. 3431
Mesrobeanu, I. 3242, 3947, 4350, 4659
Messina, B. 3132
Messore, G. 4656
Le Mesurier, A. B. 4814
Meuli, H. 1633, 4291
Meyer 3275
Meyer, E. 3541, 3919
Meyer, J. 3241
Meyer, K. 736
Meyer, K. F. 2180, 3719
Meyer, M. A. 1153, 3153
Meyer, R. 2846, 3679, 3681, 3857, 4064, 4151, 4354
Meyer, W. J. 3344
Meyers, F. P. 65
Meylan, C. 1651
Michaels, R. H. 2359, 2513, 3985, 4660
Michaels, R. M. 3390
Michal, M. 965
Michelland, R. 2823
Michl, J. 1662, 3061, 3990, 4664
Miki, T. 4305
Milanovic, M. V. 5445
Miles, J. A. R. 161, 679, 1579, 1821, 1838, 2073, 3067, 3126
Miller, A. 1990, 2587, 2887, 2953
Miller, A. H. 855, 1724, 2214
Miller, C. A. 309, 1687, 1847, 1848, 1849, 2962, 2963, 3028
Miller, G. 857
Miller, M. J. 2098
Miller, N. F. 3667
Miller, R. C. 3834
Miller, S. 3726, 3833, 5169
Millikan, C. H. 1566
Mills, Ch. K. 1723
Mills, S. D. 2897
Milovanović, M. V. 4207
Milzer, A. 612, 770, 894, 1137, 1644, 1755, 1882, 2007, 2070, 2213, 2652, 2718, 2804, 3437, 3614, 4412, 4574, 5271
Minet, J. 3436
Mingrino, F. 5377
Minto, W. L. 4110
Minz, S. 4786
Miraglia del Giudice, M. 1940
Miralbell, M. 3518
Mirinova, L. L. 4893
Mirković, R. R. 4207, 5445
Mironova, L. L. 2921, 3471, 4573, 4975, 5021, 5282
Mirski, B. 5036
Mirsky, S. 4552
Misasi, M. 4158
Misgeld, F. J. 87, 5112, 5116
Mitamura, T. 4437
Mitchell, F. K. 2096
Mitnitskiy, D. M. 3861
Mittelbach, G. 1189
Mittelstrass, H. K. 628, 2384
Miura, T. 2632, 2633, 3127, 4502
Moese, J. 5216
Möllers, B. 4785
Moffatt, W. 1185
Mohr, H. 3929
Molina, A. M. 4601
Molitor, K. 656, 4054
Mollaret, P. 587, 2993
Molnár, E. 3336, 4891, 5277, 5292
Molner, J. G. 619, 867, 989, 1935, 2646, 2974
Moloney, P. J. 5470
Molron, J. H. 4565
Mommsen, H. 4800
Monaci, V. 497, 1512, 2340, 2445, 2565, 2985, 2986, 3082, 4087, 4753, 5259
Monakhova, O. I. 4237
Moncreiff, W. F. 665
Mongan, E. S. 398
Monro, I. C. 3080
Montagnon, B. 3475
Monteiro, E. 1306
Monteiro, E. S. 1166, 1195
Montoya, J. A. 2507, 3181, 4654, 4655
Montus, G. 3684, 4716
Moody, E. 3793
Moody, J. P. 436

Moore, F. 1911
Moore, F. J. 140, 621, 5073
Moore, H. F. 2379
Moore, M. 985
Moore, Th. 2229
Mooser, H. 4385
Morales, A. 3184
Morawitz, P. 4699
Moreau, P. 4211
Mores, A. 4799
Morgan, A. D. 910
Morgan, F. G. 1347, 3301, 3778
Morgan, I. M. 21, 29, 30, 41, 42, 43, 73, 180, 929, 2619, 2656, 4222, 4368, 5070, 5075
Morgan, W. T. J. 175, 1265, 1353
Mori, G. 1321
Mori, S. 206
Morin, G. 5013
Morioka, Y. 971
von Móritz, D. 472, 4704
Mormone, V. 2269, 2927, 2941, 3430, 5376
Moro, E. 1039
Moro, V. 3394
Moroianu, S. B. 1623
Morris, D. 4433
Morrissey, L. P. 195
Morrissey, R. A. 1291, 1882, 1945, 2070, 2718
Morrone, G. 2927, 2930, 2934, 2937, 4640, 4902
Morrow, J. R. 3673
Morse, J. L. 3575
Morwood, J. B. 4692
Morzycka, M. 4991, 4992
Moscovici, C. 2192, 4942
Moscovici, O. 3195, 4950
Moses, M. J. 1205, 2358, 4736, 5006
Moss, G. W. O. 1214, 1222, 2105, 4284, 4287
Mossman, W. G. 2072, 3504, 3559, 3560
Mountain, I. M. 1631, 1784
Mouriquand, G. 5007
Mouton, C. M. 3997
Moyer, A. W. 1205, 1433, 2109, 2358, 2389, 2608, 2730, 3232, 3248, 3424, 4148, 4736, 5006
Le Moyne, M.-T. 1382, 3050
Muckenfuss, R. S. 3439, 3682, 5130
Muench, H. 1812
Müller, E. 1057, 2969, 4871, 4929
Müller, F. 499, 958, 1063, 1152, 2531, 2553, 2771, 3342
Müller, H. 2693, 2837, 2838, 3458
Müller, R. 5097, 5218
Müller-Schmid, P. 4193
Mulligan, H. W. 2282
Munk, J. 1201, 4347
Munk, K. 1302, 2079
Munoz, J. 2591
von Muralt, G. 5059
Murano, G. 2928, 2940, 2943
Murphy, A. M. 1632, 2106
Murphy, L. C. 3375
Murphy, T. P., jr. 4512
Murray, R. 2343, 2392, 2915, 3156, 3474, 4572, 4962, 4967
Murray, S. E. 2081
Mussett, M. V. 4208
Mutsaars, W. 4369, 4424

N

Naftulin, H. 1882, 2070
Nagaki, D. 1577, 3961
Nagel, L. 983
Nagler, F. P. 305, 1375, 2159, 4867
Nagy, K. 5252
Nakano, M. 971
Nantel, A. 2743
Napier, J. A. 1807, 1953, 2791, 3163
Nardi, M. G. 2149
Naruszewicz, D. 1991, 2792, 3177
Nase, H. 3613
Nass, C. A. G. 1470
Nathanson, N. 1114, 1291, 1570, 1917, 2075, 2971, 4146, 4147
Navarro Viola, R. 4098
Neal, J. 1945, 2070
Neal, J. B. 828, 919, 3103, 4388
Neal, J. L. 2718
Nebiolo, A. 647, 861
von Neergaard, K. 3870
Neff, F. C. 1714
Nélis, P. 4343

Nelsen, D. J. 1954, 2180, 2631
Nelson, A. J. 1961, 2331
Nelson, C. S. 2708
Nelson, N. 429
Nelson, N. B. 907
Nelson, R. 1964, 2304, 3355, 4259, 4260, 4261
Nelson, R. B. 3345
Nelson, R. T. 357, 1989
Nelson, T. L. 673, 2180
Neret 3899
Nettelblad, Å. 2617
Netter, A. 99, 100, 263, 402, 546, 1100, 1180, 1256, 1358, 3244, 3253, 3290, 3570, 3572, 3639, 3675, 3700, 3759, 3792, 3865, 4387, 4389, 4392, 4399, 4681, 4931, 4932, 4999
Neudeck, W. 383
Neufeld, F. 1042, 4525
Neumann, P. 4787
Neupert, C. N. 4533
Neustaedter, M. 272, 281, 777, 1050, 1097, 1190, 1357, 3520, 3644, 4008, 4398, 4409, 4917
Neva, F. A. 1790, 2337
Neves da Silva, N. 4281
Nevin, M. 3630
Newcombe, J. 219
Nichol, M. 1707
Nicholls, A. G. 3583
Nichols, V. J. 2797
Nicholson, F. 1644, 2804
Nickel, A. C. 1711
Nicolaides, Ph. 2027
Nicolau, S. S. 1315, 4186, 4379
Niederman, J. C. 991, 1202, 2133, 2973, 3015, 3157, 3377, 4965
Nielsen, J. 694
Nielsen, O. J. 3648
Nieper, H. A. 4750
Nigro, N. 3058, 3314, 3328
Nihoul, E. 685, 2491, 3361, 4560, 4759
Ninane, G. 538, 686
Nisbeth, B. R. 5332
Nishizawa, Y. 4949
Noel, G. 4620
Noël, H. 5082
Noetel 3665
Di Nola, F. 2198, 2339, 2848, 2933, 2992, 5031
Nolan, J. P. 4623
Nomura, S. 971
Noordam, A. L. 1131, 2515
Norbury, F. G. 3715
Nordenskjöld, A. 162
Norman, A. 2455, 3027
Norn, M. 4319
Norton, J. W. R. 2049
Norton, T. W. 673, 986, 1954, 1979, 2180, 2563, 2631, 2660, 2723, 2724, 2918, 3213, 3435, 3964, 4585, 4957, 5122
Nosik, N. N. 1636, 2905
Nosov, S. D. 5368
Novák, A. 847, 1494
Núñez, J. 3181, 4654, 4655
Núñez Rivera, A. 4563
Nungester, W. J. 811, 5155
Nunziata, B. 2269, 2927, 2930, 2934, 2937, 2941, 2942, 4640, 4902, 5376
Nuzum, J. W. 257, 265, 268, 273, 344, 366, 1359, 3767, 3822
Nuzzolo, L. 2774

O

Ochsenius, K. 3855
Oclander, G. 5279
Oddo, F. G. 520, 633, 1418, 1456, 1658, 1883, 1884, 1885, 1886, 1887, 1888, 2338, 3978, 4030, 4513
Oehme, J. 1397, 2543
Ørskov 2480, 2982
Offutt, A. C. 2616
Oh, J. O. 4202
Ohara, T. 2448, 4935, 4936
Ohlbaum, A. 4903
Ohtomi, Y. 308
Oker-Blom, N. 1906, 1923, 3182, 4767, 5040, 5204, 5207
Okuno, Y. 4302, 4305
Olakowski, T. 1991, 2792, 3177
von Oldershausen, H. F. 3369
Olin, G. 187, 850, 853, 2044, 2082, 2342, 2493, 2651, 4012, 4034, 5118

Olitsky, P. K. 137, 174, 342, 471, 878, 879, 883, 1072, 1080, 1497, 1603, 1680, 1681, 1686, 2736, 2889, 3083, 3375, 3412, 3579, 3949, 4783, 4837
Oliveira de Ameida, J. 2259
Oliver, J. 134
Olivo, R. 4509
Olson, O. E. 3032, 4469
Onstott, R. H. 76, 3379
Oostenrijk, G. A. 5147
Oppenheimer, F. 1755, 1882, 2070, 2190, 4574, 5271
Oprescu, E. 115, 2288, 2295, 3452, 4072
Opton, E. M. 1577, 1841, 2388, 2972, 2973, 4977
Orel, H. 3739
Oren, J. 4899
Orio, J. 5374
Orlandelli, M. 3403
Ormiston, G. 4083, 4217
Ornelas Hernández, A. 4508, 4563
Orsi, E. V. 1433, 3232, 4656
Ortiz Mariotte, C. 4508, 4563
Orvis, H. A. 3818
Osgood, R. B. 332, 3588, 4854
Ostrovskiy, G. D. 4235
Ottati, F. C. 262
Oulmont, E. 442
Owen, T. K. 3073
Owen, W. B. 3653
Oyama, A. 2448, 4282, 4283
Ozere, R. L. 2371, 4643

P

Paccaud, M. F. 1127, 1870, 1872, 2034, 2568, 2569, 4193, 4274, 4976, 5057
Paccaud-Rümenapp, M. 5057
Pache, H. D. 3445
Pácsa, S. 2929, 4578, 4649, 4731 4859, 5307
Pätiälä, R. 5123
Paffenbarger, R. S., jr. 293, 1115, 1925, 2232, 5151
Pagano, J. S. 2787, 2903, 2956, 3213, 3493, 4995, 4998
Page, J. R. 3936
Pagoulatos, G. 1843
Pait, C. F. 31, 46, 51, 1259, 1269, 2710, 2859, 2964, 5073
Pakalnsh, N. P. 3469
Palacios, O. 4628
Pálffy, G. 4082
Pamment, H. G. 5392
Du Pan, R. M. 579, 1870, 1985, 2034, 3121, 3191, 4976, 5243
Papantonaki, J. 575
Papapanagiotou, J. 5152, 5367, 5499
Papazolu 5171
Paquet, P. 88
Pará, M. 1880, 5187
Paraschivesco, M. 3627, 5171
Pardee, A. B. 4450
Parfitt, E. M. 4569
Parish, H. J. 1091, 1609
Park, W. H. 6, 77, 145, 148, 439, 545, 723, 786, 788, 817, 828, 904, 914, 3103, 3273, 3526, 3594, 3743
Parker, G. C. 2745, 2754, 4673
Parker, H. L. 3283
Parker, L. 1369
Parker, W. L. 4625
Parkman, P. 593, 599
Parrott, R. H. 1395
Parry, W. H. 1626
Parsons, J. P. 909, 1106, 3831
Pascha, J. D. 3113
Pasta, C. 4865
Pastia, M. 359
Patella, V. 3567
Paterson, A. E. 931
Paterson, J. H. 1734
Patočka, F. 4016
Patrie, L. E. 1423
Pattison, E. W. 1826
Pattyn, S. R. 500, 2428, 5296
Paul, H. 1069, 4534
Paul, J. R. 36, 54, 379, 380, 382, 475, 692, 713, 715, 740, 803, 813, 991, 1202, 1561, 1837, 2029, 2061, 2133, 2159, 2310, 2366, 2465, 2649, 2672, 2741, 3015, 3034, 3042, 3157, 3377, 3573, 3582, 3996, 4021, 4026, 4223, 4448, 4599, 4611, 4925, 4965, 4977, 5162, 5181, 5331

Paul, W. D. 241, 4417
Pauli, P. 3734
Pauluzzi, S. 3454
Pautrizel, R. 4638
Pavia, R. A. 5312
Pavilanis, V. 12, 643, 2182, 2734, 2746, 2775, 2808, 4456, 5347
Pavillard, St. S. 1704
Pavlatou, M. 2697
Payan, L. 3321
Payne, A. M.-M. 566, 700, 943, 1307, 1516, 1601, 2080, 2242, 2317, 3149, 3243, 4060, 4735, 4895, 5181
Payot, F. 4385
Payzin, S. 1932, 2081
Paz De Almeida, A. 2189
Pazzaglia, A. 206
Peabody, F. W. 613, 3277, 4394
Peach, A. M. 82, 2059, 2464
Péan 3806
Peart, A. F. W. 436
Peat, A. A. 582
Pečenka, J. 842, 847
Peczenik, A. 303, 5373
Pedersen, P. M. 367, 3111
Pedrinazzi, M. F. B. 5197
Peele, T. 5158
Peelen, J. W. 3672
Peeples, W. J. 2615
Peers, J. H. 4816
Peiper, A. 4292
Peizer, L. R. 4201
Pellegrini, U. 4752, 5309
Pellissier, A. 4052, 4468
Pelner, L. 1194
Pelon, W. 2359, 2513, 4660
Peña, R. 4145
Pencik, A. S. 4076
Pendl, O. 4149
Penner, L. R. 4842
Pentsik, A. S. 3469
Penttinen, K. 5123, 5365
Perdue, T. R. 5061
Peremans, G. 611
Perez del Castillo, C. s. Castillo, C.
Pérez Gallardo, F. 1327
Perger, H. 3738
Perkins, F. T. 194, 361, 392, 570, 984, 1008, 1130, 1248, 1479, 2487, 2915, 2939, 3483, 4332, 4946
Perkins, J. E. 286
Pernice, A. 2783
Perreau, P. 123, 3944
Perria, M. 4187
Perrin, M. 5082
Perritt, R. A. 4042
Perry, W. L. M. 1899, 2159, 2506
Peŝek, J. 845
Pestel, M. 3120
Petersen, G. A. 2671
Petersen, H. 3874, 4153, 4829, 4830
Petersen, I. 839
Petersen, W. F. 2709, 3001, 3872
Peterson, L. J. 1572
Petrilla, A. 204, 862
Petrilli, F. L. 2789
Pette, H. 254, 514, 1699, 1702, 1789, 1921, 2043, 2052, 2307, 2799, 2814, 2840, 3165, 3215, 3446, 3416, 3819, 3994, 4031, 4059, 4355, 4723, 4747, 4958, 5002, 5072, 5115, 5427
Pettersson, A. 4401, 4406
Pettit, A. 102, 493, 1261, 1262, 3247, 3300, 3552, 3639, 3701, 3756, 3764, 3779, 3811, 4373, 4782, 5005, 5131
Petts, A. 1479
Petty, O. H. 3370
Pétursson, G. 384
Petzelt, K. 313, 1745, 1804
Petzetakis, M. 782, 2225
Pfaff, M. L. 2344
Pfaundler, M. 3577, 4004
Pfeister, K. 2723
Phélizot 3275, 4354
Phelps, K. R. 821
Phelps, W. M. 4669
Philbrook, F. R. 2093
Philip, R. N. 2414, 2955
Phillips, C. W., jr. 3113
Picard, H. 3506
Picciotto, L. 1940, 2479, 2790, 2930, 2937, 3459
Pickens, E. G. 662, 2325
Pickering, J. E. 4203
Piéchaud, F. 3864
Piedrahita, F. 1226, 2292, 3172
Piegler, I. 3314
Pierce, W. F. 2514
Piette, Y. 2165

Pignot, J. 3252, 4921
Piguet, Cl. 1973
Pille, E. R. 4733, 5438
Van Pilsum, J. 291
Pintér, M. 1340, 3384
Pinto, M. R. 32, 2614
Pinto, V. 2764
Pintus, L. 4187
Pirodda, E. 2806
Pirone, P. P. 4972
Pirosky, I. 2188
Piszczek, E. A. 3209
Pizarro, E. 1701
La Placa, M. 678, 682, 963, 1371, 1988, 3310, 3311, 3971, 5198
Placido Sousa, C. A. 194
Platou, E. S. 778, 3824
Player, G. S. 1564
Plotkin, S. A. 986, 1278, 1995, 2436, 2787, 2788, 2903, 2956, 3213, 3231, 3305, 3330, 3493, 4575, 4662, 4957, 4995, 4998, 5122
Plotz, H. 897, 3507
Plum, P. 749
Pockels, W. 5099
Podsedlovsky, T. S. 1165, 1401, 3234, 4893, 5021
Poetschke, G. 1823, 5251
Pötsch, F. 1410, 3096, 4183, 4627
Pötsch, S. 3081
Pohle, F. 5159
Pohlen, K. 3851, 4707
Pokorný, F. 3460
Polak, M. F. 3124, 3125
Polan, A. K. 2583, 2584
Polge, F. 1139, 1148, 1382, 3050
Polistina, G. 1983
Pollard, E. C. 1678, 2312
Pollard, M. 1582, 2601, 2704, 2716, 3202
Poletti, P. 5046
Pollock, T. M. 4322
Polson, A. 503, 504, 2453, 2454, 3190
Pomeroy, J. L. 3840
Ponce de León, A. 4563
Pond, W. L. 4458
Pondman, A. 1107
Pongratz, E. 501, 2568, 2569
Ponsford, J. 2173, 2174, 3433
Pontecorvo, M. 1123, 1254, 1940, 3428, 3459, 4030, 4513, 4892
Poos, R. S. 1917
Pope, A. S. 1826
Popesco, A. 1276
Popescu, G. 115, 1623
Popper, E. 423, 5254
Porez 3436, 5015
Porter, E. R. 3497
Portnoy, B. 2320, 4257
Posteraro, G. 602, 2479
Potash, L. 1229, 1284, 1285, 1993, 2571, 4927, 4974, 5483
Potter, F. C. 1214, 1222, 2105, 4284, 4287
Potter, M. M. 5151
Potthoff, C. J. 2315
Potts, C. S. 3381
Potts, L. W. 607
Poulsen, I. P. V. 3387
Pous Roca, R. 4563
Povalishina, T. P. 2921
Powell, H. M. 1679, 1780, 1828, 4310, 4420
Prasek, E. 2644
Přášilova, F. 3319
Prem, K. A. 386, 387, 521, 548, 3158, 3159, 3218, 4273, 4985
Pressman, J. J. 132, 1449, 4382
Preston, W. S., Jr. 5087
Previtali, G. 1012
Prevot, P. 3723
Price, D. E. 2406
Priddle, H. D. 2684
Prier, J. E. 5440
Prigge, R. 186, 1309, 2185, 2186, 2554, 2613
Prinzie, A. 192, 685, 762, 851, 951, 1279, 2092, 2124, 2374, 2377, 2491, 2519, 2523, 4577, 4754, 4955
Priolo, A. 1658
Procházka, J. 848, 4819, 5172
Proctor, R. 4644
Profeta, M. L. 5488
Profft, J. 1396
Prothro, W. B. 1343
Provvidenza, G. 2362
Pryor, H. B. 3258
Przesmycki, F. 1991, 2792, 3177, 4503, 4561, 4968, 5036
Püschel, E. 5224
Pugh, C. T. 1280
Pugh, I. 197

Pugh, R. C. B. 3144
Pumarola, A. 5315
Puntigam, F. 1839, 3479
Pursell, A. R. 2869
Pusic, G. 1800

Q

Quade, F. 4126
Quersin-Thiry, L. 685, 2491, 2987, 4605, 5038
Quigley, T. B. 285
Quinn, V. A. 1398
Quirce, J. M. 3181, 4654, 4655

R

Raad, G. R. A. 1579
Rabboni, G. 3733, 3742
Rabe, E. F. 50
Rabkina, S. A. 1637
Rabson, A. S. 1628, 1892, 3038
Rachid, K. 3536
Rademacher, I. 2891, 4121
Rader, D. 34, 1630
Radionova, R. N. 4234
Radkovský, J. 842, 843, 844, 847, 848, 3391, 4432
Radl, H. 1293, 2589
Radmayr, E. P. 2588
Raettig, H. 1055, 1408, 2329, 2404, 2699, 4140, 4255, 4741, 5140
Raffaelli, G. 3913
Raffel, S. 2722, 4135
Raffi, A. 4978
Ragazzini, F. 206
Raimondi, G. 2806
Raleigh, N. C. 2049
Ralph, N. M. 2300, 3471, 4573, 4893, 4975, 5021, 5266, 5282
Ramirez, M. 1701
Ramon, G. 554, 617, 618, 1122, 1409, 1873, 2152, 2785, 3062, 3119, 3131, 3366, 5468
Ramos-Álvarez, M. 2359, 2513, 3174, 3220, 3961, 4920, 5018
Van Ramshorst, J. D. 4241
Rangel Rivera, L. 3174
Rannon, L. 3196
Rantasalo, V. 5045
Rapin, M. 2579
Rapoport, M. 3664
Rapoport, S. 159
Rapoport, S. M. 5361
Rapp, H. J. 400, 518
Rasch, G. 4823
Raška, K. 4432
Rasmussen, A. F., Jr. 771, 2556, 2668, 2711, 2731, 3179, 3885, 4457, 4458, 4510, 5170
Raspi, M. 5092
Rast, J. 3191, 4976
Ratner, H. 4097, 5330
Ravazzoni, L. 2959
Ravenholt, R. T. 3192
Ravetta, M. 2774
Ravkina, L. I. 4573
Rávnay, M. 1340
Raybaud, C. 114
Raymond 3611
Read, A. E. 3071
Reading, E. H. 3890
Reagan, R. L. 897, 1643, 1749, 4528, 4587, 4612, 4614, 4615, 4951, 4952, 4953
Realmuto, A. 2361
Reames, H. R. 2488, 2762
Recht, P. 655, 677, 1155, 3026, 4576
Redman, W. M. 988, 1138, 1784
Readway, J. W. 3871
Reedy, J. J. 1191
Reeves, W. C. 891
Regan, C. 4371
Regan, J. C. 4370, 4371
Reger, M. 4164
Řehoř, J. 4818
Reichardt 4815
Reichert, R. 2320, 3499, 4257, 4289
Reid, A. F. 1477, 1478
Reid, D. B. W. 968, 2728, 2732, 5346
Reinhard, K. R. 2931, 2954, 2955
Reinhold, C. H. 216
Reiss, F. 5093

Remington, J. S. 4249
Remy, A. 3755
Renault, J. 3246
Rentsch, M. 5059
Rentschnick, P. 5148
Renz, M. 5137
Reploh, H. 507
Restle, H. 3020
Retan, G. M. 4326
Réthly, E. 3211
Réthy, L. 2576, 2929, 3090, 4578, 4649, 4731, 4859, 5307
Reti, L. 221, 1609
Reynolds, C. V. 84
Rey-Stocker, J. 4193
Rezácová, D. 3391
Rheinfurth, H. 2698, 4637
Rhim, J. S. 2359, 2513, 4660
Rhoads, C. P. 1, 2, 3, 4, 831, 887, 1072, 1079, 1080, 3146, 5003
Rhodes, A. J. 64, 75, 82, 259, 649, 691, 696, 1529, 1639, 1645, 1799, 2040, 2147, 2177, 2230, 2464, 2703, 2728, 2732, 3003, 3367, 3376, 3389, 3401, 3402, 3404, 3457, 4011, 4591, 4595, 4755, 4839, 4939, 5181, 5349
Rhomako, M. 5109
Ricci, G. 2164, 2700
Richardson, D. L. 1111
Richardson, S. M. 2956, 3330
Richling, E. 1189
Richmond, A. E. 4461
Ricken, D. 2771
Ridley, C. M. 1596
Riebler, R. 5196
Riethmüller, K. 2768
Riethmüller, M. 2768
Righetti, L. 3310
Rightsel, W. A. 505
Rigón, P. 5209
Riley, H. D. 1005, 2352, 4204
Riley, R. H. 4549
Rindge, M. E. 964, 1762, 2045, 5275, 5338
Rinehart, J. F. 3612
Riordan, J. T. 54, 1202, 1282, 2029, 2649, 3157, 3180, 4440, 4977, 5162, 5333
Van Riper, H. E. 854, 1064, 1648, 1748, 1874, 2178, 2468, 5242
Ristori, C. 5055
Ritchie, R. C. 2703, 2732
Ritossa, P. 4079
Ritzel, G. 490, 3305
Riva, V. 2091
Rivera, Z. B. F. 4860
Rivers, T. M. 85, 752, 934, 3046, 3188, 3438, 3561, 4062
Rizo, R. 1986
Rizza, O. 2774
Roane, Ph.-R., Jr. 525
Robbe-Fossat, 1666
Robbins, F. C. 55, 650, 1481, 1781, 2322, 2396, 2558, 3101, 3139, 4652, 5001, 5492
Robbins, P. S. 3850
Robert, L. 2085, 2091
Roberts, D. J. 5087
Roberts, E. C. 338, 2661
Roberts, E. R. 924
Roberts, J. T. C. S. 4558
Robertson, E. G. 526, 528
Robertson, H. E. 1677
Robertson, O. H. 134
Robertson, W. I. 4120
Robinson, H. E. 2760, 3154
Robinson, W. H. 5027
Robinson, I. A. 2300, 4573
Roca-Garcia, M. 673, 979, 1205, 1433, 2358, 2389, 2608, 3232, 3248, 3354, 4656, 4736, 5006
Rochaix, A. 3691
de Rodaniche, E. C. 2727, 4113
Rodkiewicz, T. 4992
Roeb, H. 5114
Roehm, H. 3693
Roemer, G. B. 2054, 5343
Römer, P. H. 93, 94, 95, 104, 414, 1062, 1380, 1435, 1548, 2755, 5398
Rønkjaer, M. 839
Roger, A. 1421, 1426, 2381, 2382, 2528, 2529, 4246, 4247
Roger, F. 1421, 1426, 2381, 2382, 2528, 2529, 3053, 4246, 4247
Rogers, N. G. 962, 1518
Rogova, V. M. 5266
Rohde, B. 1864, 4762, 5308
Rohde, W. 2441, 2447, 4522
Rohmer, P. 3275, 3707, 4354, 4706
Rohner, G. 498
Roi, G. 3911
Roizin, L. 3505

Roizman, B. 400, 518, 525, 759, 1717
Rolli, G. 4773
Romano, E. 399
Romanova, L. N. 5493
Romanzi, C. A. 1034, 4493, 4523, 4527
Rominger, E. 4779
Rondeau, J. L. 1955
Rondinini, B. 2606, 3461
van Rooyen, C. E. 649, 910, 2371, 4011
Rope, E. Z. 761
Roper, J. C. 3702, 3934
Rosa, A. 963, 1371, 1988, 3971, 4509
Rosada, R. D. 3953
Rosen, L. 982, 3031, 3481
Rosenau, M. J. 3631, 3632, 4909, 4914
Rosenbaum, H. E. 4048
Rosenberg, L. C. 3295
Rosengard, D. E. 1826
Rosenow, E. C. 256, 260, 267, 275, 290, 345, 346, 347, 348, 437, 440, 460, 801, 819, 1073, 1356, 1711, 1712, 1713, 2605, 2607, 3553, 3557, 3597, 3676, 3758, 3786, 3814, 3815, 3826, 5133
Rosenstock, I. M. 523
Rosenthal, G. 3540
Rosiano 3284
Roşianu, N. 4543
Rosin, S. 3251
Ross, W. G. 195
Rossetti, A. 1237
Rossi, E. 5059
Rossi, L. 4675
Rossi Belgrano, C. 3873
Rossier, A. 4225
Rossier, R. 2957
Rossotti, C. 5358
Roth, G. H. 3840
Rottmann, A. 1867
Rouchy, R. 123, 3944
Roudný, J. 842, 847, 1370
Rous, P. 134
Rouse, S. A. 2315
Routh, J. I. 241
Rouves 2823
Rowan, D. F. 191
Rowan, J. J., Jr. 3288
Rowe, R. E. 1343
Rowlett, D. B. 1587
Rozee, K. R. 4643, 5163
Rozina, E. E. 4214, 4216
Rubin, M. I. 930
Rubinstein, H. M. 5151
Rucker, J. B., Jr. 343, 3576
De Rudder, B. 2551, 2618, 2671, 4005
Rudnai, O. 519, 3981, 4075, 4184, 4238, 4647
Rueck, G. A. 3274
Ruegsegger, J. M. 1205, 2358, 3343, 4736, 5006
Rüstow, H. 2055
Ruhl, H. 3943
Ruhräh, J. 4327
Ruiz Moreno, G. 2497
Rule, A. M. 20, 225, 703, 704, 748, 751, 3005, 3617, 4719, 4796
Rusch, F. 2598
Rusche, F. 4029
Ruschi, A. 3393, 3988, 4894
Ruschmann, E. 838, 1178, 1311, 1392, 1399, 4160
Rusescu, A. 1550
Russell, K. 604, 1479
Russell, W. R. 360, 1419, 1593, 1599, 2506, 2885, 3491, 4459, 5181
Russo, A. 1237
Russo, G. 633, 1638
Rustigian, R. 2726
Rutstein, D. D. 3257
Ruys, A. Ch. 1219, 5364
Rykushina, B. P. 4235
Rybkina, N. M. 2368

S

Saavedra, A. 1321
Sabin, A. B. 91, 159, 297, 334, 342, 536, 697, 767, 840, 878, 879, 883, 903, 904, 941, 1078, 1163, 1199, 1680, 1681, 1692, 1693, 1750, 1753, 1778, 1881, 1924, 2047, 2132, 2159, 2236, 2239, 2291, 2359, 2376, 2460, 2513, 2604,

2720, 2796, 2817, 2862, 3014, 3118, 3205, 3307, 3337, 3368, 3383, 3390, 3412, 3414, 3415, 3484, 3485, 3949, 3985, 4036, 4045, 4109, 4423, 4504, 4570, 4580, 4598, 4660, 4732, 4734, 4751, 4783, 5078, 5181, 5241, 5265, 5331, 5473
Sachs, D. 4051
Sachtleben, P. 461, 592
Sack, H. 492
Sacks, M. 2599
Saddington, R. S. 5088
Sadler, W. P. 1578
Sadowski, R. 2664
Saenz, A. C. 2388
Sáenz Briones, V. 3184
Sá-Fleitas, M. J. 326, 2673
Saggese, M. 4479
Sagin, J. F. 2570
Saguier, J. C. 5161
Saïd, G. 544, 1006, 1622, 1624
Saiman, T. E. 4270
Salan, I. 4790
Salanier, J. G. M. 3770
Salanier, M. 546, 4932
Salchow, U. A. 3335
Salenstedt, R. 850, 1032, 2064
Sales-Vázquez, R. S. 1920, 1928, 4199, 4280, 5056
Salfeld, H. 4295
Salis, M. 2909
Salk, J. E. 24, 37, 48, 49, 52, 63, 69, 588, 597, 937, 945, 987, 996, 1565, 1569, 1610, 1703, 1769, 1770, 1771, 1775, 1776, 1790, 1851, 1915, 1927, 2048, 2053, 2103, 2244, 2459, 2877, 2893, 2960, 2976, 3012, 3029, 3066, 3114, 3115, 3136, 3141, 3143, 3353, 3962, 4482, 4499, 4530, 5329, 5421, 5423
Salmon, S. 3194
Salmonsen, E. M. 3908
Salvaggio, L. 2565, 3082, 3395, 3430, 4087, 5485, 5486, 5487
Salveraglio, F. J. 3184
Salvioli, G. 677, 1228, 4130, 4309, 5462
Salzberg, R. 2957
Sampaio, A. 3952
Samuel, J. 1597
Sanakoyeva, I.I. 4632
Sanches, A. 2259
Sanchis-Bayarri Vaillant, V. 3980, 4032, 4245
De Sanctis, A. N. 331
De Sanctis-Monaldi, T. 3451, 4661
Sanders, B. E. 1011
Sanders, F. K. 2169
Sanders, M. 2884, 2946, 3503, 3505, 4090, 4583, 4584, 4826, 4940
Sandler, F. 238, 4441
Sangster, E. 4337
Sanna, A. 512, 1758, 1759, 1791, 2083, 2118, 4906, 5035
Santamaura, S. 1658
Santopadre, G. 3393, 3988, 4894
Santos, F. G. 4920
Sanz, E. F. 769
Sapin-Jaloustre, H. 444
Šapiro, A. M. 5110
Saralegui, J. 3184
Sarber, R. W. 515
Sarno, D. 3923
Sartorius, F. 4744, 5253
Sarvan, M. 3057
Saslaw, S. 5461
Sather, G. E. 721, 1562, 1642, 2715, 3030, 4028, 4058, 5312
Satta, E. 1756
Saucier, J. 469, 3525
Sauer, L. W. 2398, 2603
Saunders, A. 4390
Saunders, J. 4622
Sauthoff, R. 628, 1773, 1797, 1860, 2384, 2442, 2813, 3967
Sautter, V. 2193, 2529
Savelyeva-Vassilieva, E. A. 1314
Sawers, W. C. 170
Sazanova, V. D. 1637
Scafi, M. 1308, 2908
Scalais, M. 1331
Scarabicchi, S. 5200, 5201
Scarborough, H. 2364
Schaaf, H. A. 1201, 4347
Schaapman-Tilma, B. 4241
Schabel, F. M., Jr. 796, 2686
Schad, N. 1698
Schaefer, J. 3373

Schaeffer, K. 1965
Schaeffer, M. 145, 146, 151, 2798, 3439, 3443, 3410, 3682, 4095, 5130
Schär, M. 246, 580, 581, 997, 1246, 2273, 2401, 2402, 3304, 3305, 3999, 4650, 4738, 5360
Schaffer, F. L. 518, 1411, 2379, 2975, 5281
Schatz, D. L. 2171
Schaudig, E. 2350
Scheele, L. A. 1787, 1788, 4592
Scheid, W. 2582, 4381
Schellenberg, W. 3162
Schellenberger, A. 461, 592
Schenck, D. M. 1643
Schieble, J. H. 1628, 3038
Schier, R. 4181
Schiff, F. 3548
Schindl, K. 2696
Schinzel, A. 5339
Schlaepfer, J. 2568, 2569
Schlesmann, C. 4725
Schlossberger, H. 921, 3706, 3835, 3866, 4717, 5081
Schmelcher, R. 1386
Schmid, E. 4152
Schmidt, J. 4125, 5348
Schmidt, K. 3313
Schmidt, N. 3362
Schmidt, N. J. 188, 859, 961, 1429, 1794, 1890, 1941, 2385, 2446, 3386, 4067, 4657
Schmidt, W. A. K. 3495
Schmitt, H. 3921
Schmutz, E. 1270
Schneider, N. J. 2592, 4653
Schneider, W. 2952, 4215, 4220, 4254
Schneweis, K. E. 1745
Schönberg, F. 4581, 5303
Scholer, H. 3382
Scholz, F. 2610
Schonne, E. 2377
Schottmüller, E. 1061, 3532, 4324
Schottmüller, H. 4397
Schreck, K. 3550
Schrickx, A. M. 1131
Schroeder, C. R. 755
Schuchardt, L. F. 2591
v. Schulthess, G. 1736
Schultz, E. W. 149, 200, 224, 435, 448, 477, 737, 809, 830, 886, 925, 1023, 2038, 2205, 2272, 3263, 3596, 3609, 4135
Schultz, P. 505
Schulz, H. W. 4436
Schulze, H. 4213
Schuman, L. M. 1563, 2196, 2323, 2602
Schuster, H.-F. 2287
Schwab, J. L. 4794
Schwartz, A. B. 1708
Schwartz, D. 1006
Schwartz, R. P. 3109
Schwartzer, K. 4294
Schwarz, E. G. 1181, 3563
Schwarz, H. 3254
Schwarz, L. 88
Schweier, P. 489
Schweinsberg, H. 2683, 2816
Schwentker, F. F. 3561
Schwerdt, C. E. 30, 518, 1411, 1541, 1542, 2014, 2379, 3155, 4446, 4450, 5281
Scobey, R. R. 118
Scozzarella, E. 2361
Scrimshaw, N. S. 2556
Scroggie, A. 4903
Scsekocsihina, E. A. 5270
Seal, J. R. 4983
Seal, S. C. 396, 4198
Seanor, H. E. 2344
Sebastiani, A. 648, 3451, 4227, 4661
Seckinger, D. L. 2600
Sedallian, P. 5007, 5013
Seddon, H. J. 2506
Sée, P. 3247
Seebauer, F. 3099
Seelemann, K. 1132
Segagni, E. 3058, 3314, 3328
Sehring, M. 625
Seibert, R. H. 4039
Seichter, H. 2054, 2540
Seidenfeld, M. A. 1752
Seiffert, G. 1699, 1702, 3494, 3496, 5340, 5341
Seiler, L. 4833
Selivanov, Y. M. 4237
Sella, F. 2986, 3060
Sellers, M. I. 2556
Selzer, G. 502, 503, 889, 1227, 2423, 2527, 2599, 4229, 4941, 5391

Semashko, A. M. 1277
Semenitz, E. 2598, 4029
Semenov, B. F. 5489
Semkow, R. 4503, 4561
Semple, A. B. 1626
Sennett, L. 2825
Serfling, R. E. 3237, 4899
Sergiesco, D. 1025, 1112, 1113, 1141, 1372, 3242
Serter, A. 5464
Servant, P. 3475
Setälä, A. 3276
Severin, G. 3298
Seyal 3688
Seydell, E. M. 3112, 3217, 3941, 4136
Seymour, B. 5388
Sfart, T. 1482
Sganga, C. 4590
Sgîndăr, P. 1623
Shand, F. L. 4322, 4668
Shannon, J. A. 1787, 1915, 2114
Shapiro, A. M. s. Šapiro, A. M.
Sharapov, B. I. 4226
Sharp, E. 1203, 1204
Sharp, G. R. 2601
Sharpless, G. R. 1542
Sha-Shi-Nan 5156
Shaughnessy, H. J. 339, 341, 453, 459, 464, 465, 985, 1291, 1755, 1882, 1945, 2070, 2718, 3128, 3185, 4555
Shaw, E. B. 319, 323, 450, 480, 625, 780, 837, 876, 915, 1083, 3373, 4709
Shaw, M. B. 227
Sheffield, F. W. 966, 1665, 4766
Shelokov, A. 1829, 3102, 4655, 5302
Shepard, A. C. 2387
Sheppard, P. A. E. 664, 3654, 4914, 4915
Sheremet'yeva, L. G. 4237
Sherman, I. 1187, 3527
Sherman, I. L. 3237
Sherwood, N. P. 4933
Shiao, L.-C. 4114, 5175
Shimada, F. T. 259, 1895, 2703, 2732, 3367, 3402, 3404, 3457
Shippen, L. P. 5291
Shirman, G. A. 1165, 3234, 3471, 4206, 4893, 5021, 5282, 5484
Shirreff, W. T. 4035
Shlyakhov, Y. N. 4226
Shmeleva, G. A. 3473, 3482, 4573
Shoji, J. 2511
Shope, R. E. 1915
Shoyer, M. 3539
Shu, H. L. 4219
Shwartzman, G. 298, 1694, 1747, 1842, 1960, 2211, 2251, 3106, 3107, 3399, 4444, 4447, 4582, 4758
Sigard, J. A. 3542
Siedler, H. D. 1395
Siecal, Sh. 1809
Siegel, B. V. 4613
Siegel, M. 1735, 1744, 1813, 3265, 3266, 5272
Siegert, R. 2303, 2770, 4127
Siegl, J. 918, 2678, 3176, 3732, 3800, 5120, 5153
Sigel, M. M. 2028, 2592, 2705, 4653
Siggia, S. 2764
Siguier, F. 587
Sigurdsson, B. 384
Silanos, G. 4737
Da Silva, N. C. 3130
Silverberg, R. J. 58, 714, 764, 766, 1608, 2737, 2749, 2756, 2757, 2795, 3422, 3946, 4044, 4386, 5302
Silverman, A. C. 335, 827, 1949
Silverstein, C. M. 5117
Silverthorne, N. 75, 3402, 3860
Simchowitz, H. 1052
Simmons, J. M., Jr. 3168
Sims Roberts, J. T. C. 4071
Sinatra, A. 2338
Sindram, I. S. 5263
Singleton, J. D. 4137
Sinyak. K. M. 3471, 4893, 5021, 5282
Sirken, M. G. 2263
Sirman, G. A. 1401
Sittig, O. 2852
Sjoding, J. 1811
Skaar, A. E. 238, 1546, 4441
Skalska, P. 3196
Skinhøj, E. 4384
Škovránek, V. 658, 842, 847, 1167, 1370, 2977, 3075, 3198, 3235, 3318, 3450, 4112, 4362, 4651, 4874, 5032, 5285

Skřidlovská, E. 4989
Skvortsov, V. V. 1336
Slater, E. A. 4334
Sleigh, J. 218
Slome, R. 2526
Slonim, D. 1662, 3061, 3990, 4664, 4690
Smadel, J. E. 1915, 2313
Smellie, J. M. 3812
Smillie, J. G. 3997
Smillie, R. A. 436
Smillie, W. G. 1076
Smith, D. C. 1343, 1879
Smith, E. C. 1011, 1077
Smith, H. T. 796
Smith, J. L. 132, 1449, 4382
Smith, L. W. 702
Smith, S. C. 2731, 4458
Smith, W. 966, 1369, 1609, 1665, 3498, 4766
Smith, W. F. 3968
Smith, W. M. 3039
Smorodintsev, A. A. 1087, 2354, 3222, 3223, 3226, 3334, 3338, 3340, 3472, 4228, 4242, 4244, 4248, 4251, 5051, 5497
Snell, B. 4270
Snow, D. J. R. 1579, 2212, 3259, 4478
Snyder, L. H. 3879
Sobel, A. E. 5119
Soergel, M. 2944
Soergel, M. E. 4150
Sohier, R. 2316, 2472, 2577, 2581, 4987, 4988, 5328, 5481
Sokolova, I. S. 1401, 3471, 4893, 5021, 5282
Solis-Cohen, M. 363, 364
Solomon, C. I. 325
Solomon, H. E. 176
Solórzano, R. 1226, 2292
Soloviev, V. D. 2301, 2360, 2417, 2778, 4085, 5489
De Somer, O. 4577
De Somer, P. 192, 685, 762, 851, 951, 990, 1022, 1145, 1279, 1304, 1320, 2092, 2124, 2179, 2374, 2377, 2476, 2491, 2523, 4277, 4754, 4955, 5180
Somerville, R. G. 207, 2900
Sophian, A. 375
Sorel, R. 1249
Soret, M. G. 2946, 3505, 4090, 4583, 4584, 4940
Soto, C. M. 930
Soule, E. H. 2897
Soulé, J.-L. 544, 573, 574, 1622, 1624, 1933
Soule, M. H. 456, 5155, 5160
Soulé, S. L. 1006
Soulier, J.-P. 355
Sourander, B. 4722
Sourander, P. 2334
Southby, R. 916
Southcott, R. V. 1739, 3271, 3272
Sovina, J. 847
Spaar, J. W. 2185
Spalatin, J. 5353
Spalding, J. M. K. 1419
Spann, W. 5066
Spears, G. 679, 2113, 3067, 5205
Speers, J. F. 2566, 4002
Spence, L. 4644
Spicer, C. C. 2906, 2914
Spicer, C. R. 3791
Spigland, I. 2359, 2513, 2902, 4660
Spiller, W. G. 3813
Spishakoff, N. M. 3668
Spolverini, L. 4795
Spooner, E. T. C. 2506
Spooner, E. T. G. 2159
Spring, W. J. 2141
Sproule, B. J. 3233
Sprunt, K. 988, 1138, 1784
Squeri, L. 2783
Stackiw, W. 983, 1118, 1529, 2319, 4625, 4755
Staffieri, F. P. 2869
Stalker, M. R. 3836
Stańczyk, R. 1991, 2792, 3177, 5036
Stanesco, V. 1583, 4849
Stanley, N. F. 2173, 2174, 3433, 4023, 4463, 4471
Stanley, P. 3511
Stansbury, J. R. 3256
Starbuck Maxwell, E. 622
Starfinger, K. 3915
Stark, L. 4905
Starke, G. 3989, 4233, 4579, 4689, 5253
Stebbins, E. L. 4093
Stebbins, M. R. 1657, 3424, 4431, 4566
Stefan, J. 3413

Stefanopoulo, G. J. 551, 3510, 5385
Steigman, A. J. 299, 334, 393, 530, 1297, 1298, 1676, 2719, 2796, 4092, 4275, 4423, 4462
Steinbach, M. M. 3571
Steiner, G. 3011
Steklova, P. M. 4226
de Stella, M. 4676
Stender, A. 2677, 2841
Stephens, R. N. 4092
Sternberg, J. 2808, 5347
Stevens, H. W. 3643
Stevens, K. M. 972, 1193
Stevenson, C. S. 2684
Stevenson, W. J. 205
Stewart, C. A. 778, 3824
Stewart, F. W. 136, 137, 729, 887, 2854, 3385, 5003
Stiefler, G. 4007
Still, G. F. 552
Stillerman, M. 164, 315, 337, 452, 872
Stillmunkès, A. 4708, 5128
Stimpert, F. D. 157, 358, 362, 2065, 2190, 2659, 2690, 2752, 3625, 4789
Stimson, A. M. 3618
Stimson, P. M. 2215
Stoian, I. 3242
Stoitzner-Fiala, Y. 3099
Stokes, J., Jr. 451, 758, 986, 1015, 1278, 1954, 1979, 2024, 2028, 2216, 2217, 2218, 2332, 3213, 3330, 3664, 3963
Stokes, L. J. 1579, 1821, 1838
Stone, R. L. 1828
Stone, S. 3912
Stones, P. B. 5354
Stookey, P. F. 1099
Stoppani, A. 4986
Stovall, W. D. 3713
Strandström, H. 1906, 1923, 3182, 5040, 5204, 5207
Strangmann, E. 4134
Strauss, I. 4873, 4876
Strean, G. J. 2808, 5347
Strickland, A. G. R. 1664
Ströder, J. 1824
Ström, J. 1904, 5202
Stroud, G. M. 607
Stroup, A. 438, 3765
Stuart, J. 3203
Stuart-Harris, C. H. 537, 2506, 2753, 3227, 4019, 4857
Stulberg, C. S. 4334
Stumpf, P. K. 1532
Stur, D. 970
Su Chan-Tsing 3327, 4600
Sucher, O. 535
Sudre, R. 4608
Sugg, H. R. 321
Sujoy, E. 3544
Sulkin, S. E. 3975, 4512
Sunada, K. 227, 228
Sureau, P. 1625
Sutherland, I. N. 2506, 4455, 5246, 5342
Šutova, T. A. 5215
Sutton, N. H. 3869
Svedmyr, A. 2701 4012, 4465, 4609, 4765, 5230
Svendsen, K. 110
Swaminathan, C. S. 4480, 4763, 5268
Swan, C. 3626
Swan, H. P. 4517
Swarts, C. L. 1567
Sweet, B. H. 4727, 4960
Syverton, J. T. 386, 1092, 1677, 1902, 1903, 2674
Szaflarski, J. 4466
Szeri, I. 306, 1958, 2411, 2575, 3048, 3986, 5258, 5304
Szersnovicz, F. 4638
Szöllösy, E. 4642, 5301
Szokolova, I. S. s. Sokolova, I. S.

T

Taillens, J. 3731, 3829, 5094
Takacs, W. S. 155, 476, 730, 3616, 3619, 3620, 3622, 3680, 4335, 4820, 4972
Takahashi, M. 4305
Takemori, N. 971
Takemoto, K. K. 1221
Tamalet, J. 114
Tamplin, E. C. 1510, 3041, 4049
Tangheroni, W. 3976, 4526
Tanner, W. A. 3357
Taranova, G. P. 3480, 4990, 5451

Tasman, A. 4241
Tassovatz 3275, 4354
Tatsumi, M. 2648
Taube, E. 3464
Taylor, A. R. 505, 515, 614, 763, 1935, 2190
Taylor, E. 279, 2319, 5267
Taylor, E. M. 5470
Taylor, E. S. 3168
Taylor, E. W. 596, 3646
Taylor, H. D. 124, 133
Taylor, I. 565, 1607
Taylor, J. A. 1961
Taylor-Robinson, D. 2773, 2777
Taytsch, Z. 4503, 4561
Tebbutt, A. H. 928
Teelock, B. 2945
Teichholz, M. 3130
Tenke, U. 3925
Tenney, H. K. 165
Teodoru, C. V. 1694, 1842, 2251, 2733, 4768
Terburgh, J. T. 4356
Terni, M. 2780, 3194
Terragna, A. 1939, 2933
Terrell, C. O. 1179
Terrien, E. 4290
Testa, I. 3967
Tesdal, M. 3647
Teyscl, O. 954
De Teyssieu, M. 2827, 3522
Thalhimer, W. 790, 1108
Thaning, A. 417
Thayer, J. R. 2597
Theiler, M. 4107
Thelander, H. E. 319, 323, 450, 625, 780, 837, 876, 1083, 3258, 4709
Thélin, F. 1514
Thenebe, C. L. 325, 1016
Thieffry, S. 542, 2172, 2499, 3225, 5181
Thiele, G. H. 3554
Thiem 3524
Thiodet, J. 2495
Thivolet, J. 4987, 4988
Thompson, C. 1280
Thompson, R. 65, 142, 3268, 4945
Thompson, R. L. 2857, 4781
Thompson, R. Q. 1280
Thomsen 834, 4923
Thomsen, O. 97, 416
Thomson, D. 1760, 4558
Thomson, J. E. 2490
Thomson, J. E. M. 2505
Thomson, W. O. 1212
Thomssen, R. 838, 1089, 1178, 1392, 1393, 1399, 3991, 4160, 4180, 5399, 5400, 5401
Thooris, G. 3031, 3481
Thro, W. C. 1050, 1190, 4409
Thrupp, L. D. 394, 993, 1291, 1395, 2075
Timasheff, S. N. 2109
Timm, E. A. 505, 619, 761, 763, 989, 1935, 2803
Timmers, W. C. 3021
Tinel, J. 3675
Tinn, C. A. 4832
Tipton, V. C. 4901
Tischer, L. A. 3696
Tiscornia, J. V. 3892
Tiso, E. 5179
Tobin, J. O'H. 194, 430, 569, 646, 760, 1092, 1479, 1875, 1903, 1990, 2296, 2457, 2487, 2587, 2753, 2887, 2953, 4208, 4897
Töndury, G. 496, 4453
Török, G. 3589
Tolbert, O. 5324
Tolchinsky, E. 1807, 3163
Tolczynski, B. 2596
Tolskaya, E. A. 3230, 3471, 4893, 4990, 5021, 5282
Tomatis, L. 5065
Tomcsik, J. 1718, 4385
Tomellini, R. 1891, 2443
Van Tongeren, H. A. E. 3021, 4337
Toomey, J. A. 150, 155, 166, 351, 441, 458, 473, 474, 476, 705, 730, 745, 810, 821, 829, 902, 3408, 3417, 3551, 3555, 3564, 3600, 3616, 3619, 3620, 3622, 3624, 3680, 3683, 3696, 3883, 4006, 4013, 4015, 4017, 4018, 4171, 4293, 4312, 4316, 4335, 4686, 4810, 4811, 4820, 4972, 5085, 5090, 5102, 5106, 5108, 5121, 5284, 5326
Top, F. H. 1730, 2328, 2345, 2665
Torian, O. N. 449
Torres Umaña, C. 4418
Tosi, H. C. 3184, 3232

Touraine 1256
Tournier, P. 1992, 3095
Towne, E. B. 256, 275, 346, 437, 440
Townsend-Coles, W. F. 3110
Toyoshima, K. 4305
Tracy, S. 1732, 1734
Trask, J. D. 379, 380, 382, 715, 740, 803, 813, 2672, 2742, 3573, 3582
Traub, E. 1699, 1702
Trethowan, W. H. 4404
Treynor, J. V. 5287
Trocellier, L. 1006
Truckenbrodt, H. 3487
Trueta, J. 4099
Trüb, C. L. P. 2054
Trumpp 3615
Tsauzner, G. M. 1637
Tschumakow, M. P. s. Chumakov, M. P.
Tschuschner, A. 1400
Tsen, E. T. H. 1036
Tsypkin, L. B. 4573
Türk, E. 5165, 5167
Tufanov, A. V. 4573
Tulinius, S. 2470, 2635
Tumilowicz, J. J. 2782
Tuminello, D. 5054
Tunbridge, R. E. 2845
Tuncmann, Z. M. 2154
Tunnicliff, R. 266
Tupa, A. 3947, 4350, 4378, 4715
Tupin, M. 1661
Turletti, G. 4693
Turnbull, H. M. 3502, 4375
Turner, D. 965, 5425
Turner, R. 2492, 2947, 4038
Turner, Th. B. 138, 622, 2650, 2967
Tuthill, J. H. 2049
Tyrrell, D. 4025
Tyrrell, D. A. J. 4270
Tytell, A. A. 2352, 2570, 4635
Tzamouranis, N. 575

U

Udall, V. 4973
Uehlinger, E. 511
Ullrich, O. 4123
Ulrich, H. 269
Ulstrup, J. C. 1216, 1217, 2415
Underwood, G. E. 4185
Ungeheuer, H. 5066
Untracht, S. 4667
Urbach, H. 5318
Urteaga, B. O. 4084
Ushcherenko, N. I. 2926
Uspensky, U. S. 1165, 3234, 4893, 5021
Utz, J. P. 1395

V

Váczi, L. 5255, 5298
Vaisman, A. 234, 4427
Valenciano, L. 3303, 4958, 5072
van Valkenburg, C. T. 3924
Vallbona, C. 2168
Valle, J. R. 2498
Vallejo Nájera, A. 3737
Vallette 3275, 4354
Vanadzin, B. 1826
Vandeputte, M. 202
Vanderboom, K. 894, 1755, 2718
Vaněcková, N. 3391, 3392
Vanegas Amado, H. 979
Vanini, G. C. 512, 1412, 1758, 1759, 4906, 5035
Vannugli, R. 3419
Vaptzarov, I. 1387
Vardala, M. 1843
Vargas Méndez, O. 3181, 4654
Vasiliev, K. G. 2354, 3226, 3338, 4253, 4256, 5497
Vasilieva, K. A. 1165, 1401, 3234, 4893, 5021
Vasilieva, V. I. 3453, 4964
Vass, E. 549
Vasziljeva, K. A. s. Vasilieva, K. A.
Vaughan, H. F. 2665
Vazquez, H. J. 3939
Vázquez Gamboa, R. 4098
Veeneklaas, G. M. H. 2220
Velasco Blanco, L. 3794
Velde, G. 2842
Veldee, M. V. 3351

Venturi, G. 5306
Venturi, R. 678
Veomett, R. C. 3027
Vercruysse, J. A. 3586
Verdejo Viras, G. 5457
Verhas, J. 2968
Verjaal, A. 1695, 3309
Verlinde, J. D. 385, 637, 638, 1164, 1294, 1777, 1871, 2151, 2234, 2314, 2595, 2713, 2890, 3167, 3361, 3364, 3371, 3586, 4046, 4337, 4460, 4464, 4492, 4494, 4529, 4565, 4969, 5208, 5357
Versé, H. 4381
Verwey, W. F. 2591
Vesenjak-Hirjan, J. 5353
Vest, M. 1855
Viborel, L. 620
Vieira Roche, R. 2259
Vieuchange, J. 3509, 4311, 4333, 5384, 5385
Vigh, Gy. 4238
Vignec, A. J. 740, 803
Viklicky, J. 3642
Vilches, A. M. 2496, 5042
Villemin-Clog, L. 3805
Vilner, L. M. 3473
Vincent, P. 1934, 2400
Violet, P. 4987, 4988
Violle, H. 3684, 4716
Virat, J. 229, 231, 681, 4243, 4634
Vitali-Mazza, L. 1412
Viteri, M. 5037
Vivell, O. 182, 495, 586, 1000, 1852, 2033, 2100, 2126, 2551, 2667, 2984, 3033, 3960, 4139, 4476, 5396, 5432, 5469
Vlès, F. 3875, 3876
Vogel, M. L. 2009
Vogt, A. 5057
Vogt, D. 2350
Vogt, M. 1664, 2076
Vogt, W. 242, 653, 2333
Voiculesco, R. 2994
Voight, R. B. 1807, 3163
Voigt, J. C. 3889
Voigt, L. 3492
Vojtová, H. 3235, 3392
Vollum, R. L. 2887
Volpato, C. 577, 2445, 2565, 3082, 3979, 4087, 4753
Vonka, V. 843, 844, 846, 847, 1007, 3235, 3315, 3391, 4663, 4989
Voroshilova, M. K. 1165, 1401, 2300, 3230, 3234, 3316, 3471, 3480, 4893, 4913, 4975, 4990, 5021, 5215, 5282, 5451
Voss, G. 4041
Votiakov, V. I. 2354, 3226, 3338, 4237, 5497
Vought, R. L. 630
De Vries, J. A. 4241
Vysoká, B. 3319

W

Wagstaff, H. 212
Wagstaff, J. 212
Waisman, H. A. 771, 2668, 2824, 3411, 3885, 5135, 5380
Wakefield, A. L. 3671
Walentynocicz-Stańczyk, R. 4524
Walker, P. J. 4784
Wallich 3542
Wallis, C. 4512, 5436
Walshe, F. M. R. 3816, 4320
Walter, E. 3930
Waltner, K. 2309, 3662, 3773
Walton, M. 1840, 2335, 2336, 4611
Ward, E. N. 1565, 1771, 2244, 3029, 3136
Warren, J. 391, 559, 959, 967, 3390, 3985
Ward, R. 34, 119, 159, 326, 767, 1208, 1630, 2275, 2594, 3147, 3414, 3415, 5069, 5379, 5381
Warren, M. D. 4057
Warren, R. J. 4652, 5001
van Wart, R. 4789
Wasbotten, P. M. 877
Washburn, A. M. 4001
Watkins, J. T. 3201
Watson, G. I. 4488
Watson, G. S. 1477, 1478
Weaver, H. M. 68, 484 1671, 1675, 2593, 3011, 3955, 4490, 4491, 4811, 5121
Weaver, R. W. 4510

Weber, B. 2552
Weber, G. 1699, 1702, 1857, 2035
Weber, R. 4152
Wecker, E. 2440, 2563
Weed, S. D. 4185
Wehr, R. E. 3497, 4660
Wehrle, P. F. 593, 599, 1562, 1650, 2024, 2218, 2320, 3499, 3500, 4058, 4257, 4289, 5210
Weichsel, M. 4295
Weigand, H. 190
Weihl, C. 2352, 4204
Weil, A. 5098
Weill, 5007
Weinstein, L. 2009, 3102, 3123, 3346, 5300
Weinstein, N. 2009
Weiser, K. 1808
Weisflog, G. 1861, 1870, 5243
Weiss, C. 2183
Weiss, G. 120
Weiss, M. A. 894
Weissfeiler, J. 5077, 5355
Weissman, D. 4201
Welke, C. 3989
Welke, G. 4233, 4579, 4689
Weller, T. H. 55, 1481, 1560, 3139
Wells, A. V. 2266
Wells, C. W. 264
Wenner, H. A. 50, 1203, 1204, 1281, 1300, 1653, 1847, 1929, 2068, 2076, 2250, 2438, 2944, 2962, 2963, 3028, 3163, 3357, 4161, 5217, 5286
Werner, M. 4796
Wernstedt, W. 328, 1549, 4338, 4401, 4406
Wesselhoeft, C. 3214, 3292
Wesslén, T. 631, 853, 1431, 2044, 2334, 2651, 3084, 4012
West, E. J. 1111
Westman, A. 1969
Weston, J. 1203, 1204
Westphal, K. 3854
Westwood, J. C. N. 2773, 2777
De Wever, A. 1850, 2268, 4646
van der Wey, A. P. 5263
Weyer, E. R. 6, 439, 896, 2237
Whalen, J. P. 4257
Whalen, J. W. 2869
Wheeler, G. W. 256, 275, 345, 437, 3597
Whitney, E. 5138
Wicht, J. F. 5136
Wickman, I. 4979
Widiez, A. 3610
Wieland, E. 4091, 5125
Wiener, A. 859
Wiesener, H. 3019
Wiesmann, E. 860, 1761, 1984, 2883, 5059, 5314
v. Wiesner, R. 377, 418, 420, 422, 1019, 1379
Wijffels, J. C. M. 2220
Wilcox, W. C. 47, 1792, 2157
Wild, Cl. 1973
Wildführ, G. 4477, 5184
Willcocks, W. J. 923
Willemin, L. 1270, 3275, 4353, 4354
Willemin-Clog, L. 3749
Willi, H. 4159
Williams, A. W. 3285
Williams, E. C. P. 2670
Williams, H. C. M. 2879
Willy, R. G. 268, 344
Wilmer, B. H. 4623
Wilner, B. I. 619, 989
Wilson 114
Wilson, A. B. K. 4264
Wilson, A. N. 1524
Wilson, D. 1964, 2304
Wilson, D. C. 1427
Wilson, G. S. 1909, 2506
Wilson, J. C. 2963, 3028, 4784
Wilson, J. L. 1731, 2194
Wilson, R. J. 600, 1214, 1222, 4284, 4287, 4299, 4889
Wilson, S. A. K. 3267, 4380
Wilson, V. O. 1115, 1925
Wilt, J. C. 436, 983, 1118, 2046, 2319, 4625
Wilterdink, J. B. 385, 638, 1164, 1317, 2595, 2890, 3021, 3167, 3429, 4969, 5357
Wilzbach, C. A. 4411
Wimberly, I. L. 5436
Wimphen, A. 1980
Winborn, C. D. 3256
Windorfer, A. 629, 1210, 1689, 2405, 2551, 2815, 3487, 4165, 4240, 5443
Wingate, M. B. 4083
Winkelstein, W., Jr. 1420

Winkler, K. C. 3024
Winnicka, W. 3049
Winslow, K. 320
Winsor, Ch. P. 2650
Winsser, J. 297, 1693, 2259, 2344, 4045, 4337
Winter, M. M. 4971
Winters, M. 449
Wior, H. 5036, 5366
Wirth, J. 1869, 5149
Wishart, D. E. S. 3262
Wishart, F. O. 2348
Wisner, B. 1276, 1372, 3242, 3593, 3947, 4350, 4378
Witherbee, W. D. 133
Witkop-Oosténryk, G. A. 5190
Witkowska, H. 3467
Wittek, A. 5095
Wöckel, W. 330, 1283
Wohlrab, R. 244, 390, 1959, 1966, 2542, 3495, 4748
Wolf, A. 4827, 5074
Wolf, A. M. 985, 1882, 2070, 2718, 4412
Wolf, H. F. 4713
Wolf, W. 4053
Wolfer, L. 3905
Wollstein, M. 1058
Wolman, I. J. 758, 1015
Wood, E. M. 516
Wood, W. 259, 436, 696, 1645, 1895, 2481, 2703, 2732, 2753, 3402, 3404, 4025, 5181
Woodie, J. D. 47
Woods, W. A. 2396, 2558, 3101, 5492
Woolcott, J. F. 1579
Woolpert, O. C. 2870, 3882, 4794
Wrange, G. 187, 850, 1125, 2063, 2064
Wray, S. 3833, 5169
Wright, C. C. 3400
Wright, G. A. 3073
Wright, J. H. 4538
Wulff, F. 4153
Wyler, R. 2314
Wyllie, J. 5289
Wyman, L. 2090
Wyman, M. G. 5192

Y

Yakunin, Yu. A. 3466
Yamada, N. 578, 2888, 2961
Yamamura, T. 4305
Yancey, F. S. 4951, 4953
Yang, C.-S. 2910, 4114, 5175
Yankauer, A., Jr. 4429
Yankevich, O. D. 1165, 3234, 4893, 5021
Yarosh, W. 1376, 4211
Yarrow, A. 2449
Yekutiel, M. 2128
Yekutiel, P. 2357, 4277
Yergeau, F. 3606
Yetts, R. 361, 392, 1008, 1130, 1248, 1479, 2939
Yoffa, A. 3922
Yoffey, J. M. 2875
Yohn, D. S. 4027, 5312
Yoshioka, I. 1282, 3157, 5162
Young, D. C. 2684
Young, D. G. 3233
Young, G. A. 3717
Young, L. E. 128, 138, 139, 622
Young, R. D. 4118
Youngner, J. S. 37, 48, 49, 52, 1565, 1770, 1771, 1851, 1893, 2001, 2244, 2326, 3029, 3136, 3141, 3353, 5329
Yow, M. 4145
Yudelman, H. 2526

Z

Zabin, E. 1691
Žáček, K. 651, 843, 844, 846, 847, 1007, 1167, 3235, 3315, 3319, 3391, 3392, 3450, 4651, 4663
Žáčková, Z. 846
Zaleska, A. 5036
Zaleska, H. 5480
Zamfiresco, M. 1112, 1372, 3242
Zamora Tiffón, M. 2494
Zappert, J. 1019, 4671
Zardini, V. 2258
Závadová, H. 846

Zechnich, R. 593, 599
Zeitlenok, N. A. 2368, 2369, 4729
Zellweger, H. 369, 1334, 2264, 2898, 3091, 3092, 4132, 5213
Zenke, U. 2748
Zepp, H. D. 2062, 4954
Zerboni, R. 3393, 3988, 4894
Zhdanov, V. M. 2406, 4363, 4626, 5051
Zhevandrova, V. I. 4893, 4990, 5021
Zhilova, G. P. 2354, 3223, 3338, 4234, 4235, 4258, 5497
Zhukova, E. K. 3466
Zikowsky, J. 4817
Zimák, J. 4818
Zimmerman, M. C. 2013
Zimmermann, R. 3356
Zingher, A. 276, 277, 3768, 3769, 3771, 4388
Zink, A. O. 1751
Zischinsky, H. 1209, 1215, 4149
Zourbas, J. 543, 1381, 2802, 4306
Zubova, Z. F. 4966
Zulian, G. 3394
Zuschek, F. 2318
Zwartouw, H. T. 2773, 2777

STICHWORT-INDEX
REFERENCE WORD INDEX

A

Aaland Islands 47, 50, 51, 61, 75
Abgeschwächtes, lebendes Virus (s. a. Lebend-Impfstoffe) **96**
aborigines 47, 50, 139
abort 139
abortive cases 59, 61, 73, 74, 182, 215
absorption of antibodies 46, 179, 181
Abwasser 100, 167
ACTH 125, 126, 128, 135, 137, 142, 180, 202, 203, 206, 219, 223
active vaccination (s. a. immunization, vaccination) **147**
adaptation 42, 96, 180, 200, 203, 204, 213, 217, 222, 223, 224, 225
adjuvants 54, 79, 100, 149, 155, 169, 196, 197, 219
adrenalectomy 67, 137, 140, 194, 216
adsorbat vaccines 43, 53, 55, 56, 67, 69, 88, 90, 93, 98, **100**, 101, 105, 110, 114, 115, 116, 126, 136, 154, 160, 168, 169, 170, 195, 196, 197, 215, 216, 218, 221, 224, 225
adsorption 108, 110, 111, 118, 179, 184
Ägypten 47, 50, 60, 74, 154
Ätiologie 193, 199, 200, 213, 214, 215, 216, 222
Affen 48, 50, 52–56, 59, 60, 63–69, 73, 74, 77, 79, 88–93, 96, 97, 99, 100, 101, 103, 106, 107, 109, 110, 112, 114, 119, 120, 123, 124, 125, 127, 129, 133–138, 140–143, 149, 155, 156, 157, 163, 164, 167–177, 179, 180, 181, 186, 188–207, 212, **214**
Africa 69, 73
agammaglobulinemia 55, 62, 208
agar diffusion test 66, 187
age distribution, antibody **47**, 62
age distribution, immunity (s. a. dependence of age) **72**, 77, 83, 86, 87
age distribution, resistance **132**, 217, 225
aged vaccines 124
agglutination 63
agglutinines 91, 200, 216
agouti 141, 201, 205, 213
AK-strain 89, 90, 169, 196
Aktive Schutzimpfung (s. a. immunization, vaccination) **147**
Akureyri-fever 91
Alabama 171
Alaska 57, 63, 75, 76, 77, 81, 105, 161
Alaskan Eskimos 47, 48, 50, 52, 60, 62, 72, 74, 76, 132
Alberta 85, 105, 116, 151, 161
albumine 181
Algeria 153, 163
alimentary infection 62, 69, 221
allergens 126, 128, 135, 223
allergic reactions (s. a. neuroallergic reactions) 63, 100, 103, 104, 106, 108, 112, 113, 131, 133, 138, **149**, 155, 156, 158, 159, 161, 163, 184, 196, 219
$Al(OH)_3$ 43, 67, 88, 93, 100, 101, 110, 111, 118, 168, 185, 215, 216

Alouatta palliata 219
α-globuline 181
Altersabhängigkeit, Schutzimpfung **149**
Altersverteilung, Antikörper **47**, 62
Altersverteilung, Immunität **72**, 77, 83, 86, 87
Altersverteilung, Resistenz **132**, 217, 225
aluminumhydroxyde s. $Al(OH)_3$
aluminum marker 111
aluminum-phosphate 100
Amazon basin 48, 51, 62
Amnionflüssigkeit 46, 49, 50, 55, 62, 77, 80, 181
amniotic fluids 46, 49, 50, 55, 62, 77, 80, 181
Amsterdam 76
anamnestic serumreaction 54, 91, 124
anaphylactic reaction 149, 155, 168, 170, 215
Andaman Islands 51, 52, 63, 77
Angola 72, 154, 160, 163
animal experiments 49, 55, 56, 64, 65, **67**, 76, 80, **88**, 93, 100, 101, 103, 104, 106, 107, 115, 124, **125**, 128, 134, 137, **140**, 156, 157, **167**, 175, **176**, 179, 182, 186, 188, 189, 190, **192**
antibiotics 126, 128, 135, 223
antibody **44**, 137, 157, 158, 159, 181, 182, 193, 194, 197, 204, 216, 217
antibody, after natural exposure **59**, **73**, 78
antibody, after vaccination **53**, **79**, 168, 218, 219, 222
antibody-combining-test 43, 44, 64, 104, 109, 110, 115, 116, 120, 179, 180, 184
antibody distribution s. distribution of antibodies
antibody in faeces 46
antigen-antibody-reaction 46, **179**, 182
Antigendauerreiz 43, 100
antigenic variation 44
antigenicity **41**, 55, 65, 79, 100, 103, 104, 105, 109, 110, 114, 115, 118, 119, 120, 170, **179**, 181, 182, 193, 197, 198, 214, 220, 224, 225
Antikörper **44**, 137, 157, 158, 159, 181, 182, 193, 194, 197, 204, 216, 217
Antikörper im Stuhl 46
Antikörper nach Impfung **53**, **79**, 168, 218, 219, 222
Antikörper, nach natürlicher Exposition **59**, **73**, 78
Antikörperverteilung 54, 60, 68, 72, 79, 89, 139, 140, 153, 154, 163, 169, 196, 218
antirabic treatment s. rabies vaccination
antistreptococcal serum s. ROSENOW-serum, streptococci
appendectomy 128, 135
Argentine 52, 63, 77, 104, 108, 153, 172, 177, 192
arginine 179, 181
Arizona 62, 96, 164
Arkansas 85, 87, 102, 105, 152, 157, 162
Arlacel 100
Armenian S.S.R. 48, 51, 62, 76
artificial fever (s. a. hyperpyrexia, hyperthermy, pyrifer) 200, 215
asthma 113, 149, 156, 163
Ateles ater 140, 200, 205, 216
Ateles monkey 181, 203, 206, 220
Ateles neglectus 142, 202, 219
Ateles niger 126, 137, 142, 204, 220
Ateles vellerosus 142, 203, 220
Atlanta 154
attenuated live virus (s. a. live vaccines) 90, **96**, 109, 110, 129, 169, 170, 194, 198, 204, 220, 221
Augenfarbe 138
Australia 47, 50, 51, 60, 73, 74, 75, 139, 144, 152, 160, 162
Austria 48, 52, 63, 76, 84, 97, 99, 104, 151, 154, 161, 165
autarceologic susceptibility 133, 137, 141, 163, 169
auto-antibody 63, 76
autoblood 172, 189
autosomal recessive gene 132, 138
autotherapy 123, 134, 170, **171**, 188, 191, 212
avidity 46, 66, 75, 80, 187
avirulent variant 68, 90, 92, 96, 164, 194, 197, 204, 220, 224

B

baboon s. *Papio*
bactifebrin 212
Baltimore 47, 50, 74
Bantu 47, 50, 139
Basel 85, 161
basic immunity 162
bat 142, 203, 204, 213
Baumwollratte 49, 65, 67, 68, 89, 90, 92, 101, 106, 109, 114, 129, 132, 133, 134, 141, 144, 169, 179, 180, 186, 196, 197, 198, 201–205, 217, 222, 225
Bayern 47, 51, 61, 75
Bayol F 100
BCG-vaccination 91, 99, 166, 177
Behringwerk-globuline 171, 192
Behringwerk-vaccine 54, 79, 101, 102, 108, 111, 112, 114, 157
Belfast 63, 76
Belgish vaccine 55, 80, 102, 103, 104, 108, 111, 112, 115, 159
Belgium 47, 48, 50, 51, 55, 60–62, 72, 74–76, 78, 79, 84–87, 102–106, 108, 109, 132, 150–155, 158–163
benzimidazole 203, 219, 223, 224
Berlin 58, 59, 62, 76, 82, 83, 85–88, 97–100, 113, 114, 117, 125, 152, 154, 156, 165–167
β-globuline 50, 181, 220
β-propiolactone 43, 106, 107, 118, 119, 180, 197
bibliography 121, 207
biotin 141, 205, 223
Bisamratte 202, 213
bite of dog 127, 133
bivalent cations 43, 97
blackface monkey 141, 218
blocking test 187
blood-CNS-barrier 66, 67, 140, 141, 171, 174, 176, 178, 191, 199, 200, 201, 214, 215, 217
blood count **180**, 182, 199, 215
blood groups 59, 65, 132, 138, **181**
blood of adults 170, 172, 173, 188, 190, 191
blood of parents 170, 174, 190, 191
blood plasma (s. a. plasma infusion) 171, 177, 191, 192
blood sedimentation 182, 215
blood transfusion 128, 135, 173, 174, 190, 191
Blutbild **180**, 182, 199, 215
Blutgruppen 59, 65, 132, 138, **181**
Blutliquorschranke 66, 67, 140, 141, 171, 174, 176, 178, 191, 199, 200, 201, 214, 215, 217
Blutplasma (s. a. plasma infusion) 171, 177, 191, 192
Blutsenkung 182, 215
Bluttransfusion 128, 135, 173, 174, 190, 191
Bologna 47, 48, 51, 52, 61, 62, 63, 75, 76
Bombay 50, 60, 74
booster effect **48**, 54, 55, 56, 79, 80, 102, 104, 158, 159, 160, 170
braunes Fett 132, 203, 220, 222
Brazil 48, 51, 61, 62, 72, 75, 76, 140, 152, 153, 154, 162, 163
Brazzaville 47, 50, 60, 74
Brescia 106, 117, 152, 162
British Colombia 83, 84, 86, 102, 150
British Guiana 48, 51, 62, 72, 75, 76, 132, 163, 185
British vaccine 49, 55, 79, 80, 102, 103, 104, 105, 108, 109, 111, 112, 115, 119, 153, 155, 157, 158, 159, 170, 197, 198, 220, 225
BRODIE-Vakzine 17, 35, 52, 53, 54, 67, 73, 78, 79, 83, 87, 88, 92, 93, 101, 111, 119, 150, 155, 156, 157, 168, 195, 208, 216
brown fat 132, 203, 220, 222
BRUNENDER-strain 98, 111, 115
Brunhilde-Stamm 98, 111, 115
Bucarest 47, 48, 50, 51, 61, 62, 75, 76, 140, 163
Buenos Aires 84, 151, 161
Buffalo 72, 132, 139
bulbar paralysis 125, 126, 127, 133, 134, 136, 139, 143, 206, 219
Bulgarian 104, 160
B-virus infection 110, 114, 198, 221
Byelorussian S.S.R. 85, 98, 165

C

Cairo 47, 50, 51, 60, 61, 75, 140, 185
calf 201
California 153
Canada 44, 47, 50, 57, 60, 62, 72, 74, 83–87, 99, 101–108, 112, 116, 132, 150–155, 157–162, 166, 173, 209
Canadian vaccine 93, 103, 108, 109, 111, 113
canine hepatitis 42, 91, 180
canine distemper virus s. distemper virus
C-Antigen 42, 43, 46, 179, 180, 185, 187
Cape Verde Islands 48, 52, 62, 76
carbol-vaccine 93, 101, 156, 194, 214
carbonyl compounds 118, 119
cardial infection s. intracardial infection
Caribbean Islands 48, 51, 62, 76
castration 125, 133, 136, 137, 138, 140, 142, 200, 204, 205, 217, 222
cat 176, 202, 205
catamnestic examination 124
cataphoresis (s. a. electrophoresis) 119, 184
cattle 69, 76, 90, 169, 201, 213
cattle serum 66, 69, 194
cave bat 142, 204, 213
Cebus capucina 141, 201, 205, 218, 219
cell cultures (s. a. tissue culture) 56, 110
cellular immunity (s. a. local immunity) **73**
Central Africa 51, 54, 61, 68, 75, 90, 139, 142, 169, 204, 220
Central America 57, 61, 74, 79, 97, 102, 140, 154, 158, 165
Cercopithecus aethiops sabaeus 141, 201, 202, 205, 218
Cercopithecus cephus 141, 201, 205, 218
Cercopithecus mona nigripes 203, 206, 219
Cercopithecus pygerythrus 141, 205, 218
cerebrale immunity s. intracerebrale immunity
cerebrale injection s. intracerebrale injection
cerebrospinal fluid 46, 59, 67, 74, 170, 171, 181, 186, 188, 190, 191, 212
Cerocebus fuliginosus 202, 218
Charleston 75, 139, 140
CHAT-strain 52, 56, 57, 58, 81, 82, 83, 84, 97, 98, 99, 100, 110, 113, 114, 116, 154, 156, 164, 165, 166, 167, 197, 206, 221
chemoprophylaxis 217
Chicago 47, 72, 83, 84, 86, 103, 104, 125, 139, 140, 150, 151, 156, 158, 160, 174
chicken 90, 170, 203, 204, 213
chicken test 42, 43, 44, 49, 55, 64, 69, 104, 105, 109, 110, 111, 115, 116, 117, 184, 198, 213, 214
Chile 47, 50, 61, 75, 152
chilling 125, 127, 134, 141, 205, 218
chimpanzees 49, 52–55, 59, 60, 61, 68, 69, 74, 77, 87, 89, 90, 92, 96, 101, 107, 129, 140, 141, 164, 169, 172, 175–177, 195–205, 214, 216–221
China 50, 59, 73
chlorine 110
chloroform-vaccine 101, 118
cholera vaccination 123, 124, 133
Cincinnati 58, 83, 86, 99, 114, 117, 154, 166, 167
citratblood 173, 189
classification of virus strains (s. a. typing of virus strains, differentiation of types) 42, 68, 89, 179, 180, 219
Cleveland 72
climate 131
CNS (s. a. blood-CNS-barrier) 59, 74, 89, 104, 118, 141, 156, 162, 194, 200, 202, 204, 216, 218, 221
coli agglutinins 59, 73, 90
Colindale cytopathic test 187
collection of convalescent serum 172, 173, 174, 189
colloidal gold test 54, 59, 63, 182, 184, 195
Colombia 47, 48, 51, 56, 61, 62, 75, 76, 81, 84, 87, 97, 98, 113, 140, 150, 151, 164, 165

color test (s. a. micro color test, phenol red color test) 98, 165, 180–183, 186, 187
colostrum 60
Columbia SK-Virus 42, 60, 64, 65, 66, 69, 74, 77, 78, 89, 90, 91, 101, 169, 180, 184, 186, 196, 197, 201–203, 219, 220, 222, 223, 225
combined antigen 69, 76, 80, 90, 100, 107, 109, 113, 115, 148, 162, 170, 198, 225
combined methods of vaccination 78, 81, 96, 103, **106**, 153, **177**
combined vaccines 42, 43, 49, 56, 57, 58, 81, 82, **107**, 110, 116, 117, 162, 198
common antigens 66, 180, 181, 185, 187, 197
complement fixation test (s. a. micro-CFT) 42–44, 47, 50, 52–57, 59–63, **64**, 65–69, 72, 74–77, 79–81, 89–91, 104, 105, 115, 119, 120, 161, 164, 169, 170, 179–184, **185**, 186, 187, 196, 197, 202, 203, 213, 219, 223–225
complication of vaccination s. untoward reactions to vaccination, provocation
Compligen 57, 81, 107, 161
concentrated SALK-vaccine (s. a. purified SALK-vaccine) 56, 81, 106, 110, 114, 116, 120, 162
concentration of antigen (s. a. purification of antigen) 43, 66, 97, 100, 105, 108, 185
Conference s. Europäische Konferenz, Europäisches Symposium, Internationale Konferenz, Symposium
Conference Washington 1959 164
congenital abnormalities s. embryopathy
congenital immunity 68, 177, 223
conglutination 42, 64, 184
Congo 47, 48, 51, 52, 56, 58, 61, 62, 63, 69, 75, 76, 81, 83, 84, 86, 87, 88, 96, 97, 99, 113, 114, 116, 117, 132, 150, 151, 152, 154, 156, 164, 165, 167, 221
Connecticut 61, 75, 76, 81, 83, 86, 87, 102, 105, 106, 133, 139, 140, 150, 151, 152, 158, 160, 162
constitution **138**, 207
contacts 60, 61, 62, 63, 69, 73, 74, 75, 78, 84, 87, 97, 98, 113, 142, 158, 160, 164, 166, 172, 182
continuous cell lines 99, 198
contraindication of vaccination (s. a. indication) 162, 163
convalescent serum (s. a. collection of c., production of c.) 59, 60, 65, 67, 74, 119, 168, **172**, 176, 177, 179, 181, 186, 188–191, 195, 215, 216, 222
convulsions 125, 163
cortisone 55, 56, 69, 90, 109, 112, 125, 126, 128, 135, 136, 137, 138, 142, 197, 202, 203, 204, 206, 213, 219, 220, 221, 222, 223, 224
Costa Rica 48, 51, 57, 58, 62, 76, 82, 83, 86, 88, 97, 98, 99, 116, 152, 164, 165, 166, 167
costs of vaccination 108, **177**
cotton rat 49, 65, 67, 68, 89, 90, 92, 101, 106, 109, 114, 129, 132, 133, 134, 141, 144, 169, 179, 180, 186, 196, 197, 198, 201–205, 217, 222, 225
COXSACKIE-virus 60, 62, 68, 69, 73, 74, 76, 90, 91, 123, 126, 137, 142, 169, 194, 202, 203, 204, 206, 219, 220, 223, 224
Cox-vaccine 49, 56, 57, 58, 59, 80, 81, 82, 83, 85, 86, 87, 88, 97, 98, 99, 100, 108, 110, 113, 114, 116, 117, 125, 149, 150, 152, 154, 156, 164, 165, 166, 167, 180, 181, 198, 206, 221
cranial nerve paralysis 127, 136, 143
Croatia 63, 77
cross immunity 68, 89, 91, 169, 181, 195, 196, 223, 224
ČSR 48, 50, 51, 52, 55, 56, 57, 58, 59, 62, 63, 74, 77, 80, 81, 82, 83, 84, 85, 86, 87, 92, 93, 96, 97, 98, 99, 103, 104, 105, 106, 110, 112, 113, 116, 117, 125, 151, 152, 154, 155, 159, 160, 161, 162, 164, 165, 166, 167
Cuba 48, 51, 56, 57, 58, 62, 76, 80, 81, 82, 97, 98, 113, 117, 164, 165, 166
Curaçao 63, 76

cutaneous injection s. intracutaneous injection
cutaneous reaction s. skin reaction
cutaneous reactivity 78, 83, 90, 110, 159, 161, 179, 182, 183, 187, 194, 198
cutan test s. skin reaction
Cutter disaster 80, 101, 103, 104, 109, 111, 112, 155, 156, 159
Cynomolgus monkey (s. a. *Macacus cynomolgus*) 56, 59, 62, 67, 68, 69, 90, 124, 126, 127, 134, 137, 141, 142, 143, 170, 194, 197, 198, 199, 200, 202, 203, 204, 218

D

dactylograms 138
Dade County 85, 98, 113, 117, 166
Dänemark 53, 54, 58, 79, 83, 84, 85, 86, 92, 93, 101, 102, 103, 105, 106, 107, 109, 111, 119, 150, 151, 152, 154, 157, 158, 159, 162, 173
Dakar 48, 51, 62, 76
Danish vaccine 55, 79, 102, 108, 109, 111, 112, 114, 115
D-Antigen 42, 43, 46, 110, 117, 179, 180, 185, 187
Dauer der Immunität 80, 82, 129, 159, 169, 196, 197, 219
Dauer der Virusausscheidung (s. a. Virusausscheidung) 103, 166
Delaware 102, 149, 152, 158
delayed second inoculation 55
Denmark 53, 54, 58, 79, 83, 84, 85, 86, 92, 93, 101, 102, 103, 105, 106, 107, 109, 111, 119, 150, 151, 152, 154, 157, 158, 159, 162, 173
dental surgeon 127, 128, 134, 135
dentinal tubule 202, 219
dependence of age, vaccination **149**
depot 197
dermatitis exfoliativa 113, 123, 156, 161
Des Moines 85, 86, 105, 152, 162
desoxypyridoxin 134, 205
Detroit 72, 84, 85, 86, 87, 101, 105, 139, 140, 150, 151, 160, 161
Deutschland 44, 47, 48, 51, 52, 55, 58, 61–63, 72, 75, 76, 80–88, 93, 98, 101–104, 106, 110, 113, 114, 117, 132, 133, 140, 151–156, 158–160, 163, 165, 167, 173, 181
diabetes 163
diagnostic sera 69
diaplacental transmission of antibodies (s. a. maternal antibodies, transmission of immunity) **49**, 63, 76, 138, 169, 177
differentiation of types (s. a. classification, Klassifizierung, typing of virus strains) 42, 100, 169, 180, **181**, 185, 186, 187, 195, 202, 217, 218
diphtheria 73, 78, 91, 107, 131, 132
diphtheria antiserum 188, 190
diphtheria antitoxin 47, 174, 176, 191
diphtheria toxoid 83, 90, 106, 117, 136, 142, 162, 198, 212
disc plate assay 64, 66, 115, 182, 184
dissociation of antigen-antibody complexes (s. a. antigen-antibody-reaction) 179, 184
distemper virus 89, 91, 195, 201, 205, 217
distribution of antibodies 54, 60, 68, 72, 79, 89, 139, 140, 153, 154, 163, 169, 196, 218
distribution of serum proteins **181**
distribution of virus 204, 215
Di-vaccination 56, 58, 91, 124, 125, 133, 134, 136, 137, 207
d-marker 96, 97, 100, 109, 110, 111, 165, 206
d-mutant 96, 204
dog 194, 205, 213, 217
dog serum 59
domestic animals 182, 194, 196, 213
donkey 50, 68, 90, 169, 172, 176, 192, 197, 213
dosage 57, 78, 82, 96, 98, 116, 148, 161, 166
DPTP-vaccine 49, 56, 57, 58, 69, 81, 82, 83, 97, 98, 99, 104, 107, 113, 116, 117, 125, 126, 135, 136, 137, 142, 149, 154, 161, 162, 165, 166, 167, 177, 198, 206, 224
dragée candy 98, 107, 108, 116
drinking water 73

Druck 118
dry serum 189
DULBECCO-KRECH-phenomen 120
duration of antibody titres 49, **52**, 57, 58, 74, 83, 100, 105, 116, 149, 162
duration of immunity 80, 82, 129, 159, 169, 196, 197, 219
duration of virus excretion (s. a. virus excretion) 103, 166
dust of sickroom (s. a. spontaneous infection) 199, 214

E

early infancy 55, 56, 57, 58, 62, 76, 78, 80, 81, 82, 93, 96, 97, 102, 104, 106, 132, 149, 153, 158, 159, 160, 164, 165
East African monkey 141, 205, 218
EBERSON-test 182, 184
ECHO-virus 62, 76, 91
Ecuador 48, 51, 62, 76
EEG 155, 159
effectiveness of vaccines s. potency
efficacy of vaccines s. potency
Egypt 47, 50, 60, 74, 154
Eigenblut 172, 189
eindimensionale Ordnung 4
Einführung **1**
Eingeborene 47, 50, 139
Eiweißverteilung im Serum **181**
electroencephalography s. EEG
electrophoresis 54, 105, 119, 184
Elternblut 170, 174, 190, 191
elution marker 98, 110
elution of antibodies 46, 179
embryopathy 138, 139
Empfindlichkeit 100, 149, 166, 167, 181, 195, 202, 203, 204, 213–221, 223–225
encephalitis (s. a. Japanese B.-encephalitis) 59, 73, 90, 114
encephalomyelitis (s. a. perivenöse encephalomyelitis) 88, 90, 101, 119, 149, 155, 169, 195, 196, 219
encym activity 179
endocrine gland 88, 118, 133
endocrinology 133, 136, 137, 138, 206
England (s. a. Great Britain, United Kingdom) 47, 50, 60, 61, 75, 83–87, 96, 102, 103, 105, 106, 109, 125, 132, 133, 150–153, 158–161, 164
enteritis 123, 221
enteric toxin 100
enteroviruses 65, 85, 97, 116, 117, 165, 166, 182, 185
Entstehung der Antikörper **50**
Entwicklungsländer 47, 50, 60, 73, 77, 139
Epidemie-Impfung **149**, 165
epidemiological statistical evidence of immunity **77**, **83**
epidemiology 60, 72, 74, 84
eradication 88, 167
Erbrechen 143
Erfolgsstatistik, aktive Impfung **150**
ergosterol 141, 200
Erkältung 125, 127, 134, 141, 205, 218
Ermüdung 125, 126, 127, 128, 133, 134, 136, 141, 142, 205, 206, 218, 224
Ernährung (s. a. Hunger, pantothenic acid deficiency) **132**, 141, 206, 223
Erwachsenenblut 170, 172, 173, 188, 190, 191
erythema multiforme 113, 149, 155, 156, 161
erythrocytes 64, 184
Eskimos 47, 48, 50, 52, 60, 62, 72, 74, 76, 132
Esel 50, 68, 90, 169, 172, 176, 192, 197, 213
Esthonian S.S.R. 48, 52, 62, 76, 84, 87, 97, 151, 165
estrogen 137, 141, 169, 201, 202, 205, 217, 218, 223
etiology 193, 199, 200, 213, 214, 215, 216, 222
Europäische Konferenz (3.) 102, 157
Europäisches Symposium (VI.) 78, 95, 148
examination of vaccines (s. a. potency of vaccines, safety of vaccines, testing of vaccines) **108**

exercise 127, 128, 136
exogenic factors 136, 137
experimental animals (s. a. animal experiments) 132, **212**
exposition 71, 131
eye color 138

F

faeces 46, 50, 54, 62, 63, 68, 76, 89, 157, 169, 184, 196, 218
Familienerkrankungen 62, 63, 76
family outbreak 62, 63, 76
Farbtest (s. a. micro color test, phenol red color test) 98, 165, 180–183, 186, 187
fatigue 125, 126, 127, 128, 133, 134, 136, 141, 142, 205, 206, 218, 224
feces s. faeces
Fehlerquellen, Inaktivierung des Virus **119**
Feldversuch 81, 83, 99, 101, 112, 114, 125, 150, 152, 157, 160, 166, 171, 172, 177, 209
ferret 201, 213
fetus 202, 222
Feuchtigkeit 144
fever therapy = Fiebertherapie s. artificial fever, hyperpyrexia, hyperthermy, pyrifer
field trial 81, 83, 99, 101, 112, 114, 125, 150, 152, 157, 160, 166, 171, 172, 177, 209
filter paper disc test 63, 184, 187
filtration 104, 108, 112, 115, 119
Fingerabdruck 138
Finland 47, 48, 50, 51, 52, 56, 58, 61, 63, 75, 77, 81, 82, 83, 97, 98, 106, 117, 162, 164, 166
Fledermaus 142, 203, 204, 213
Fliege 141, 167, 199, 202, 213, 214
flocculation (s. a. micro flocculation test) 42, 43, 44, 56, 57, 58, 62, 63, 64, 66, 81, 105, 119, 161, 179, 180, 181, 182, 184, 187, 222
Florida 57, 58, 81, 83, 85, 97, 98, 99, 116, 165, 167
fluorescent antibody 42, 43, 44, 63, 64, 179, 180, 183, 184, 185
fluorocarbon 120, 180, 185
fly 141, 167, 199, 202, 213, 214
folic acid 141, 202, 205, 218
Folsäure 141, 202, 205, 218
food intake 141, 201, 222, 223
formaldehyde, inactivation of virus 43, 44, 54, 55, 79, 80, 89, 93, **101**, 103, 104, 106, 108, 110, 114, 115, 118, **119**, 120, 156–158, 160, 168, 180, 185, 195–197, 219, 223
fortified antigen 42, 100
Fox-strain 82, 110, 198, 221
France 44, 47, 48, 50, 51, 52, 60, 61, 62, 63, 72, 74, 75, 76, 77, 84, 102, 103, 107, 139, 140, 151, 152, 153, 156, 157, 159, 160, 162, 172, 173, 174, 180, 210
FRANCIS-report 54, 55, 80, 83, 84, 86, 87, 101, 102, 103, 112, 114, 115, 125, 150, 152, 153, 155, 157, 158, 159, 209, 210
freeze drying vaccine 101, 118
French Oceania 47, 50, 61, 75
French vaccine 55, 56, 80, 93, 101, 103, 104, 107, 109, 111, 113, 115, 157, 159
Frettchen 201, 213
Frühe Kindheit 55, 56, 57, 58, 62, 78, 80, 81, 82, 93, 96, 97, 102, 104, 106, 132, 149, 153, 158, 159, 160, 164, 165
Frühgeburten 57, 82, 166

G

gamma globuline (s. a. hyperimmune gamma globuline) 54, 59, 60, 65, 66, 74, 83, 106, 120, 125–127, 135, 143, 164, **171**, 177, 181, 191, 192, 196, 197, 202, 206, 208–210, 219, 221–224
gamma-irradiation 118
gealterte Vakzinen 124
Gefriertrocknung 101, 118
gel diffusion method 66, 183, 187
Gemeinsame Antigene 66, 180, 181, 185, 187, 197
genetic marker 110, 166
Geneva 47, 50, 51, 61, 75

Genua 47, 49, 51, 72, 75, 85, 105, 151, 161
geographical distribution of antibodies **50**, 59
geography 74
Georgia 47, 50, 60, 73, 74, 99, 154, 166
Gereinigte SALK-vaccine (s. a. concentrated SALK-vaccine) 58, 82, 106, 108, 110, 114, 115, 117, 119, 120, 162
German vaccine (s. a. Behringwerk-vaccine) 54, 79, 100, 102, 109, 112, 115, 157
Germany 44, 47, 48, 51, 52, 55, 58, 61–63, 72, 75, 76, 80–88, 93, 98, 101–104, 106, 110, 113, 114, 117, 132, 133, 140, 151–156, 158–160, 163, 165, 167, 173, 181
germicidally inactivation 118
Geschlechtsverteilung **132**, 141, 205, 225
gestation 89, 134, 142, 206, 223
Gewebeimmunität s. local immunity
Gewebekultur 42, 44, 46, 63–66, 73, 80, 95, 99, 102, 104, 108, 109, 111–114, 116, 119, 120, 128, 132, 137, 179–182, 185–187, 204, 224
Glasgow 51, 61, 75
globuline (s. a. α-globuline, β-globuline, gamma globuline) **50**, 67, 89, 195
glycin 119
goats 53, 67, 195
goat serum 65, 175, 176, 189, 190, 213, 216
Goldhamster (s. a. Hamster) 67, 68, 69, 77, 78, 89, 90, 91, 110, 114, 125, 126, 128, 132, 135–138, 141, 142, 169, 196, 202, 203, 204, 206, **221**
Goldsolreaktion 54, 59, 63, 182, 184, 195
Great Britain (s. a. England, United Kingdom) 47, 50, 60, 74, 99, 153, 160
Greece 48, 51, 62, 76, 104, 154, 160, 162, 163
Greenland 48, 52, 63, 72, 73, 77, 132, 133
Griechenland 48, 51, 62, 76, 104, 154, 160, 162, 163
Grönland 48, 52, 63, 72, 73, 77, 132, 133
Guam 47, 50, 60, 74
guanidine 179, 181
Guatemala 48, 52, 62, 63, 76, 98, 105, 153, 154
guinea pigs 55, 66, 68, 69, 89, 90, 92, 100, 109, 110, 118, 124, 126, 132, 136, 141, 170, 176, 181, 186, 195, 197–202, 204, 205, **224**
guinea pig test 43, 44, 66, 109, 115, 116, 180, 187, 197, 198, 220

H

Haarfarbe 138
haemadsorption 179, 184
haemagglutination 60, **64**, 66, 179, 182, **184**, 187
haemaggregation test 42, 43, 64, 66, 119, 179, 180, 184
Hahn 69, 81, 90, 110, 170, 197, 198, 214
Haifa 72
hair color 138
Haltbarkeit des Antikörper-Titers 49, **52**, 57, 58, 74, 83, 100, 105, 116, 149, 162
Haltbarkeit von Impfstoffen **107**
Hamburg 47, 51, 61, 75, 85, 105, 152, 162
Hammel 175, 189, 194, 213
Hampstead galaktose color test 187
hamster (s. a. Goldhamster, Syrian hamster) 197, 201, 203, 204, 206, 222
Handbuch **3**
H-Antigen 43, 65, 90, 180, 185, 197, 225
Haustiere 182, 194, 196, 213
Hautreaktivität 78, 83, 90, 110, 159, 161, 179, 182, 183, 187, 194, 198
Hauttest 43, 54, 56, 62, 63, 64, 66, 68, 69, 71, 73, 74, 79, 80, 90, 120, 138, 149, 170, 182, 184, 197
Hawaii 83, 102, 125, 149, 150, 157

heat inactivation 43, 44, 46, 64, 67, 88, 90, 93, **106**, 107, 118, **120**, 156, 163, 180, 185, 194, 215, 224
hedgehog 141, 201, 205, 213
HeLa cell cultures 43, 64, 66, 100, 182, 184, 185, 187
helenine 204, 220, 224
Helsinki 47, 50, 60, 75
Herabsetzung der Resistenz **133**
heredity 131, **138**
herpes 42, 65, 67, 78, 90, 91, 132, 159, 216
Herstellung von Rekonvaleszenten-serum 172, 173, 189
heterologeous vaccinations **123**, 125, 126, 133–137, 142, 155, 203, 205, 206, 219, 220, 222, 223, 224
heterotypic antibodies 52, 59, 61, 74, 75, 77, 83, 100, 186
high pression 118
Höhlenfledermaus 142, 204, 213
Holland 48, 51, 52, 56, 62, 63, 72, 76, 81, 84–87, 97, 98, 99, 102, 104, 106, 113, 116, **132**, **133**, 140, 151, 153, 156, 158, 159, 162, 164, 166, 210
homogenicity of types 69, 180, 185, 186, 187
homologous vaccinations, provocation **125**, 137
Homoseran 174
homotypic antibodies 52
hormones 67, 72, 88, 126, **137**, 140, 141, 168, 195, 200, 203, 205, 206, 216, 221, 223
horse 48, 50, 52, 53, 67, 68, 79, 88, 89, 100, 168, 169, 194, 195, 196
horse serum (s. a. ROSENOW-serum) 65, 66, 67, 69, 88, 119, 120, 173–176, 181, 186–189, 190, 191, 193, 200, 213, 215, 216
hospital personnel 61, 62, 64, 75, 132, 163, 182
Houston 85, 152, 162
human passage of live vaccines 98, 99, 100, 110, 113, 164, 167
humidity 144
humorale immunity 73
Hund 194, 205, 213, 217
Hundebiß 127, 133
Hunde Hepatitis 42, 91, 180
Hundeserum 59
Hungarian vaccine 104, 105
Hungary 47, 48, 50, 51, 52, 58, 61, 62, 63, 72, 74–77, 81, 83–87, 93, 96–100, 103, 105, 106, 107, 116, 117, 125, 132, 150–153, 155, 159–162, 164, 165, 166, 211
Hunger 132, 134, 141, 202, 205, 225
hyaluronidase 142, 179, 203, 204, 219, 220
hyperimmune gamma globuline 176
hyperimmunization of animals 100, 176, 177
hyperpyrexia (s. a. artificial fever, hyperthermy, künstliches Fieber, pyrifer) 212, 216
hyperreactivity 49, 73, 129, 132, 203, 220
hyperthermy (s. a. artificial fever, hyperpyrexia, künstliches Fieber, pyrifer) 126, 140, 142, 200, 204, 224
hypophysectomy 126, 136, 142
hypothesis 66, 123

I

Idaho 80, 103, 109, 112, 155, 159
ideal vaccine 95, 148, 209
Igel 141, 201, 205, 213
Illinois 172
immune serum (s. a. NETTER-, NUZUM-, PETTIT-, ROSENOW-serum) 65, 79, 88, 90, **106**, 172, **174**, 177, 179, 196, 213, 222
immune serum, inactivation of virus **119**
immunity 59, 60, 61, 62, 67, **69**, 129, 157, 158, 179, 181, **207**, 215, 216, 217, 219, 220
immunity and antibodies **53**, 78, 88, 89, 90
immunization s. vaccination
immunization, animal experiments 134, 135, **194**, 213, 215, 216
immuno-inactivation (GARD) 56, 63, 66, 81, 110, 184, 187

immunological types 59, 107, 120
immunologic tolerance 97, 165
Immunserum (s. a. NETTER-, NUZUM-, PETTIT-, ROSENOW-serum) 65, 79, 88, 90, **106**, 172, **174**, 177, 179, 196, 213, 222
Impfbeteiligung 154, 160
Impfmethoden **91**
Impfpistole 55, 80, 92, 153, 158, 160
Impfplanung 82, 98, 99, 101, 104, 105, 107, 116, 124, 148, 150, **152**, 158–161, 163, 165, 166, 171, 209, 210, 221
Impfschäden (s. a. Cutter disaster, neurological complication, provocation) 105, **155**, 172, 189
Impfstoffe (s. a. BRODIE-, COX-, KOLMER-, KOPROWSKI-, LEPINE-, SABIN-, SALK-, sero-, sonic-, UV-vaccine) **93**
Impfstoffprüfung (s. a. Unschädlichkeit von Impfstoffen, Wirksamkeit von Impfstoffen) 43, 68, 69, 99, 101, 103, **197**
inactivated vaccines (s. a. BRODIE-, COX-, LEPINE-, SALK-, sero-, sonic-, UV-vaccine) **156**
inactivation, antigenicity **43**
inactivation of virus (s. a. formaldehyde, gamma-irradiation, heat, phenol, Röntgenbestrahlung, serum, temperature, UV-irradiation, Wärme, X-irradiation) **101**, **117**
inanition 132, 134, 141, 202, 205, 225
inapparent infections 57, 61, 64, 73, 81, 182, 196
incubation period 126, 137, 142, 143, 156, 170, 199, 200, 204, 215, 216, 224
India 48, 49, 50, 51, 52, 60, 61, 63, 72, 74, 75, 77, 153, 154, 163
Indiana 154
indication of active vaccination 48, 76, 96, 102, **162**, 164
Indonesia 48, 52, 63, 76, 153, 159
infection experiments **198**, 214, 215, 222
infectious diseases, provocation **123**
inhalation 202, 205, 218
injections 127, 128, 133–137, 142, 206, 220
innersekretorische Drüsen (s. a. endocrinology) 88, 118, 133
inositol 141, 205, 223
insulin 108
interference 49, 57, 59, 69, 81, 89, 91, 97, 99, 100, 116, 117, 124, 126, 165, 166, 167, 170, 194, 202, 203, 204, 213, 218, 219, 220, 221, 223, 224, 225
interference test 43, 182, 184, 202, 223
International Conference (2.) 208
Internationale Konferenz (3.) Rom 148, 208, 209
Internationale Konferenz (4.) Genf 78, 95, 148, 158, 164, 209, 210
Internationale Konferenz (5.) Kopenhagen 78, 95, 148, 211
Internationale Konferenz Moskau 95, 97, 108, 110, 148, 165, 210, 211
intestinal infection 200, 217
intracardial infection 203, 219
intracerebrale immunity 54, 68
intracerebrale injection 68, 201, 202, 205, 214, 215, 216, 224
intracutaneous injection 49, 53, 55, 56, 67, 76, 80, 84, 89, **92**, 93, 103, 104, 135, 160, 168, 195, 201, 216, 217
intracutan test s. skin test
intradermal injection 101, 103, 125, 149, 159, 215
intradermal test s. skin reaction
intraepidemic vaccination **149**, 165
intralumbal application 175
intramuscular injection **93**, 98, 198, 219, 221
intranasale immunization 54, 92, 195
intranasale infection 67, 88, 89, 141, 168, 176, 195, 199, 201, 202, 215–217, 222
intranervale infection 199, 201, 214, 217
intraneural spread 201, 218
intraocular injection 65, 141, 186, 205, 217
intraperitoneale infection 203, 214, 221, 223, 224
intrasciatic infection 201, 218

intraspinal injection of serum 172, 174, 175
intraspinally inoculation 142, 199, 203, 204, 214, 218, 220, 221, 223
intratesticular infection 200, 203, 213, 215, 216
intratypic differentiation 43, 110, 111
intrauterine infection 139
intrauterine life 138
intravenous infection 203, 220, 224
introduction **24**
invasiveness 126, 179
ionizing radiation 43, 44, 106, 118, 120
Iowa 85, 86, 105, 150, 152, 161, 162
Island 47, 51, 61, 75, 103
isoimmunization 89, 218
isolated intestinal loops 67, 140, 216
Israel 47, 48, 50, 51, 52, 56, 57, 60, 61, 62, 73, 74, 75, 76, 81, 82, 84, 85, 87, 98, 103, 104, 105, 116, 117, 132, 133, 140, 149, 151, 154, 158, 160, 161, 162, 166
Italian vaccine 55, 80, 103, 111
Italy 47, 48, 50, 51, 60, 61, 62, 73, 74, 75, 76, 80, 82, 84, 85, 87, 97, 101, 104, 105, 107, 116, 132, 133, 140, 151, 153, 154, 158, 159, 160, 161, 162, 163, 164

J

Jahreszeit 72, 76, 77, 132, 140, 142, 144, 153, 163, 200, 205, 206, 216, 217, 222, 223
Jahreszeitliche Verteilung der Antikörper 46, 60, 62
Jamaica 51, 72, 75
Japan 44, 47, 48, 50, 51, 52, 57, 60, 61, 62, 63, 68, 72, 74, 75, 76, 77, 82, 117, 166, 181, 194
Japanese B-encephalitis 91, 196, 219
jet injection 55, 80, 92, 153, 158, 160
Johannesburg 108
Jugoslavia 153, 154, 163, 172
JV-strain 184

K

Kaninchen 53, 55, 67, 68, 69, 81, 88, 89, 90, 93, 96, 105, 108, 140, 141, 163, 168, 169, 176, 177, 178, 180, 181, 182, 184, 185, 187, 194, 196, 197, 199, 200, 202–205, **222**
Kansas City 85, 86, 88, 105, 112, 162
Kapuzinerartige Affen s. *Cebus*
Kastration 125, 133, 136, 137, 138, 140, 142, 200, 204, 205, 217, 222
Kataphorese (s. a. electrophoresis) 119, 184
Katze 176, 202, 205
KB epithelial cells 180, 181, 187
keeping capacity of vaccines **107**
Kentucky 154, 160
Kenya 85, 97, 139, 151, 165
Keuchhusten 113, 123, 124
kinetics of inactivation of virus 66, 103, 105, 112, 119, **120**, 179, 187
Klammeraffen s. *Ateles*
Klassifizierung von Virusstämmen (s. a. typing of virus strains, differentiation of types) 42, 68, 89, 179, 180, 219
Klima 131
KOLMER-Vakzine 17, 35, 52, 54, 67, 78, 79, 83, 88, 89, 93, 96, 107, 110, 114, 119, 125, 149, 150, 155, 163, 168, 195, 197, 208, 216, 217
Kolostrum 60
Kombinierte Antigene 69, 76, 80, 90, 100, 107, 109, 113, 115, 148, 162, 170, 198, 225
Kombinierte Impfstoffe 42, 43, 49, 56, 57, 58, 81, 82, **107**, 110, 116, 117, 162, 198
Kombinierte Verfahren der Schutzimpfung 78, 81, 96, 103, **106**, 153, **177**
Komplementbindungsreaktion (s. a. micro-CFT) 42–44, 47, 50, 52–57, 59–63, **64**, 65–69, 72, 74–77, 79–81, 89–91, 104, 105, 115, 119, 120, 161, 164, 169, 170, 179–184, **185**, 186, 187, 196, 197, 202, 203, 213, 219, 223–225
Komplikationen der Schutzimpfung s. Impfschäden, Provokation

Konferenz s. Europäische Konferenz, Europäisches Symposium, Internationale Konferenz, Symposium
Konkurrenz der Antigene 43
Konservierung von Impfstoffen **107**
Konstitution **138**, 207
Kontaktpersonen 60, 61, 62, 63, 73, 74, 75, 78, 84, 87, 97, 98, 113, 142, 158, 160, 164, 166, 172, 182
Kontraindikation (s. a. indication of active vaccination) 162, 163
Konzentrierung von Antigen (s. a. Reinigung von Antigen) 43, 66, 97, 100, 105, 108, 185
KOPROWSKI-vaccine 53, 54, 57, 58, 59, 79, 82, 83, 86, 88, 93, 96, 98, 99, 100, 114, 117, 152, 163, 166, 167
Kosten der Schutzimpfung 108, **177**
Krankenhauspersonal 61, 62, 64, 75, 132, 163, 182
Kreuzimmunität 68, 89, 91, 169, 181, 195, 196, 223, 224
Kroatien 63, 77
Küken 90, 170, 203, 204, 213
Küken Test 42, 43, 44, 49, 55, 64, 69, 104, 105, 109, 110, 111, 115, 116, 117, 184, 198, 213, 214
künstliches Fieber (s. a. hyperpyrexia, hyperthermy, pyrifer, pyrotherapy) 200, 215

L

laboratorial diagnosis 83, **182**
laboratory animals 136, 196, 199
laboratory infection 192, 202, 218
lactation 204, 222
Lähmungsrate, nach Schutzimpfung **86**
Ländliche Gebiete 72, 73, 131, 132, 137, 139, 140, 143
Lagerung 98, 105, 116, 171, 173, 176, 191
Landry paralysis 125, 155, 156, 160
LANSING-Stamm 42, 47, 54, 59, 60, 66, 74, 89, 91, 141, 179, 180, 201, 202, 203, 204, 218, 219, 222, 223, 224
latent infection 63, 73, 77, 198, 221
Latvia 72, 85, 87, 98, 165
Lebend-Impfstoffe 49, 52–59, 61, 68, 73, 77–84, 86, 87, 88, 90, 93, 102, 108, 110–117, 120, 125, 127, 129, 137, 138, 149–156, 158, 159, 160, 162, **163**, 169, 172, 177, 185, 195, 197, 198, 203, 204, 208–211, 215, 220–222
Leibesübung 127, 128, 136
lemurs 202, 213
Leon strain 203, 223
Leopoldville 48, 51, 56, 61, 62, 75, 76, 81, 84, 97, 113, 116, 152, 164, 165
LEPINE-vaccine 55, 80, 102, 108, 112, 119
lethality after vaccination **87**, 105
Lettland 72, 85, 87, 98, 165
leucaemic cell line 73, 132
Libanon 72, 77, 154, 163
Liberia 47, 50, 51, 59, 61, 73, 74, 75, 162
licensing of vaccines 111
light 118, 168, 195
Ligurien 47, 61, 75
LILLY-serum 175
Liquor 46, 59, 67, 74, 170, 171, 181, 186, 188, 190, 191, 212
Literatur-Dokumentation **7**
literature documentation **28**
Literaturquellen **8**
literature statistic **35**
Literatur-Statistik **17**
Lithuanian S.S.R. 48, 52, 62, 76, 84, 87, 97, 151, 165
live vaccines 49, 52–59, 61, 68, 73, 77–84, 86, 87, 88, 90, 93, 102, 108, 110–117, 120, 125, 127, 129, 137, 138, 149–156, 158, 159, 160, 162, **163**, 169, 172, 177, 185, 195, 197, 198, 203, 204, 208–211, 215, 220–222
Lizenzierung von Impfstoffen 111
local formation of antibodies 59, 74, 194, 218
local immunity 72, 194, 218
localisation factors 128
Lösliches Antigen 64, 180, 185
London 47, 51, 61, 75

Louisiana 47, 50, 51, 57, 61, 72, 75, 82, 83, 86, 87, 98, 102, 113, 116, 139, 140, 150, 158, 165
louping ill 59, 90
lumbal punction 128, 136
Luxemburg 84, 103, 153, 155, 159
lymphatic apparatus 217
lymphocytic choriomeningitis 91, 123, 141, 201, 217
lymphocytosis 180
Lyperosia irritans 199, 215

M

Macacus 194, 205, 214
Macacus cynomolgus (s. a. Cynomolgus monkey) 141, 201, 205, 214, 217, 219, 220, 221
Macacus irus 141, 202, 205, 218
Macacus irus mordax 141, 202, 218
Macacus irus valida 141, 202, 218
Macacus mulatta 73, 77, 129, 132, 134, 141, 196, 201, 202, 205, 218
Macacus philippinensis 141, 202, 218
Macacus rhesus s. Rhesus-monkey
MACK-Virus 44, 91, 180
Madagascar 48, 51, 62, 76
Mäuse 49, 54, 65–69, 73, 79, 89–92, 96, 100, 106, 107, 108, 119, 124–126, 134–137, 139, 140, 142, 144, 168–170, 174, 176, 177, 181, 182, 185, 191, 194–198, 200–206, **222**
Mäuseschutztest 65, 66, 67, 108, 114, 115, 169, 171, 174, 177, 186, 187, 196, 197, 222–224
MAHONEY-strain 103, 111, 115, 204, 224
malaria 90, 91, 123, 212
malignancy in continuous cell lines 113, 198, 214
Mangaben s. *Cerocebus*
Manitoba 47, 51, 61, 62, 75, 84, 86, 87, 102, 104, 151, 153, 158, 160
manual 25
Maori 51, 62, 76, 139
marker (s. a. aluminum-, d-, elution-, genetic-, MS-, t-marker) 98, 99, 100, 110, 113, 114, 165, 166, 167, 180, 181, 198, 206
marmoset monkey 200, 217
Marokko 47, 50, 60, 74
Masern 123, 129, 133, 201, 217
masked infection 46, 73, 132
Massachusetts 58, 63, 77, 83, 85, 86, 105, 150, 152, 157, 158, 162
maternal antibodies (s. a. diaplacental transmission of antibodies, transmission of immunity) 52, 55, 63, 76, 98, 117, 149, 153, 166, 177
maternal blood 173, 174, 190
maturation of antibodies 50
maturation of immunity 72
Mauritius 85, 87, 88, 97, 99, 105, 151, 152, 161, 162, 166
measles 123, 129, 133, 201, 217
Meerkatzen s. *Cercopithecus*, vervet monkey
Meerkatzenartige Affen s. *Ateles*, *Cerocebus*, *Macacus*
Meerschweinchen 55, 66, 68, 69, 89, 90, 92, 100, 109, 110, 118, 124, 126, 132, 136, 141, 170, 176, 181 186, 195, 197–202, 204, 205, **224**
Meerschweinchentest 43, 44, 66, 109, 115, 116, 180, 187, 197, 198, 220
MEF_1-strain 42, 64, 96, 180, 185, 203, 223
mehrdimensionale Einordnung 12
Mehrfachimpfstoffe 42, 43, 49, 56, 57, 58, 81, 82, **107**, 110, 116, 117, 162, 198
Melbourne 47, 50, 59, 75
meningoencephalomyelitis 156
menstruation 59, 73, 131, 135, 137, 155, 159
mental exertion 127, 134
merthiolate 43, 107, 108
methionine 142, 206, 223
methods of antibody detection **63**
methods of vaccination **91**
methylen blue 101, 118, 168, 195
methylguanidine 179, 184
Mexico 47, 48, 50, 51, 52, 55, 56, 57, 58, 60, 62, 63, 69, 74, 76, 77, 81, 82, 84, 85, 87, 97, 98, 103, 111,

112, 116, 150, 152, 154, 155, 159, 164, 165, 166, 171, 192, 198, 220
Miami 81, 97, 113, 165
mice 49, 54, 65–69, 73, 79, 89–92, 96, 100, 106, 107, 108, 119, 124–126, 134–137, 139, 140, 142, 144, 168–170, 174, 176, 177, 181, 182, 185, 191, 194–198, 200–206, **222**
Michigan 50, 60, 75
micro-CFT 60, 61, 64, 75, 182, 185
micrococcus (s. a. streptococci) 73, 131, 178
micro color test 66, 182, 186, 187
micro flocculation test 57, 63, 64, 66, 76, 179, 184, 185, 187
micromethod of FARRELL 64
micro neutralization test 66, 186, 187
micro precipitin test 43, 58, 63, 66, 77, 82, 117, 180
Middle East 163
Middlesex 154, 162
milk 68
milktherapie 170
Milz 55, 67, 69, 92, 140, 168, 194, 197, 200, 205, 215, 222
Milzexstirpation 133, 140, 224
mineraloil 100, 196
minimum requirements s. requirements
Minnesota 58, 82, 84, 86, 98, 104, 150, 151, 158, 160, 166
Mißbildungen 138
Mississippi 157
Missouri 83, 97, 102, 150, 158
Mittlerer Osten 163
mixed infection 142
Moldavian S.S.R. 85, 98, 151, 165
molecular equivalent of antibody 179
mongolism 139
monkeys 48, 50, 52–56, 59, 60, 63–69, 73, 74, 77, 79, 88–93, 96, 97, 99, 100, 101, 103, 106, 107, 109, 110, 112, 114, 119, 120, 123, 124, 125, 127, 129, 133–138, 140–143, 149, 155, 156, 157, 163, 164, 167–177, 179, 180, 181, 186, 188–207, 212, **214**
monoarticular arthritis 112, 155
monographs **121**
Montana 48, 51, 159
Montevideo 62, 84, 97, 164
morbidity 47, **87**
Morocco 47, 50, 60, 74
mortality 132
Moskau 95
mosquito 202, 219
mother, active immunization 49
mother's milk 171
mouse protection test 65, 66, 67, 108, 114, 115, 169, 171, 174, 177, 186, 187, 196, 197, 222–224
MS-marker 96, 112
mucin 133, 140, 144, 200, 204, 222, 224
München 85
Mütterliche Antikörper (s. a. diaplacental transmission of antibodies, Übertragung der Immunität) 52, 55, 63, 76, 98, 117, 149, 153, 166, 177
Mütterliches Blut 173, 174, 190
multiple antigens 42, 43, 49, 52, 55, 56, 80, 100, 109, 115, 116, 125, 149, 153, 154, 158, 159, 160, 169, 170, 180, 185, 197, 210, 220, 225
Mumps 123
murine virus 89, 91, 168, 202, 217, 218, 224
Musca domestica → fly, Fliege
muscle weakness 62, 76
Muskelschwäche 62, 76
muskrats 202, 213
mutation 120
Mutter, aktive Immunisierung 49
Muttermilch 171
mutton 175, 189, 194, 213
myalgies 113, 156
Mycobact. butyricum 100
Myotus lucifugus 204, 213

N

Nabelschnur 76
Nachweismethoden von Antikörpern **63**
NAC-Test 43, 44, 64, 104, 109, 110, 115, 116, 120, 179, 180, 184
Nager 128, 141

Nahrungsaufnahme 141, 201, 222, 223
Nairnshire 105, 151, 161
Naja flava neurotoxoid 91, 124, 126, 142, 203, 206, 220
N-Antigen 43, 65, 90, 180, 185, 197, 225
Naples 47, 48, 51, 61, 62, 75, 76, 105, 161, 163
Na-ricinoleated vaccine s. ricinoleated vaccine
nasale infection s. intranasale infection
nasale immunization s. intranasale immunization
nasopharyngeal secretions 59, 74, 195
natives 47, 50, 139
natural exposure, immunity **73**
natural immunity 49
Neapel 47, 48, 51, 61, 62, 75, 76, 105, 161, 163
Nebraska 48, 51, 61, 62, 75, 76, 84, 87, 103, 112, 150, 158
negative phase 125, 126, 137, 155
neonatal immunity and immunization (s. a. newborn infants) 46–49, 51, 52, 55–59, 62, 69, 71, 72, 75–78, 80–83, 96–100, 105, 107, 114, 116, 117, 142, 149, 153, 162, 164
nephritis 112, 113, 156
nephrosis 163
nervale infection s. intranervale infection
Netherlands 48, 51, 52, 56, 62, 63, 72, 76, 81, 84–87, 97, 98, 99, 102, 104, 106, 113, 116, 132, 133, 140, 151, 153, 156, 158, 159, 162, 164, 166, 210
NETTER-serum 175, 189
Neugeborene **138**, 139, 153, 161, 164, 167, 177, 181
Neugeborenen-Immunität und -Impfung 46–49, 51, 52, 55–59, 62, 69, 71, 72, 75–78, 80–83, 96–100, 105, 107, 114, 116, 117, 142, 149, 153, 162, 164
neural block 204, 221
neural localization factor 136
neural spread s. intraneural spread
neuroallergic reaction 100, 106, 114, 149, 156, 163, 167
neurological complication 105, 113, 114, 149, 156, 159, 160, 161, 162
neuropathic constitution 138
neuropathogenicity test s. neurovirulence test
neurosurgical procedures 125, 127, 133, 141
neurotoxoid (s. a. Naja flava neurotoxoid) 126, 142, 204, 220, 221
neurotropism 100, 110, 156, 198, 220, 221
neurovirulence test (s. a. virulence test of strains excreted after live vaccination) 97–100, 110, 113, 114, 120, 165, 166–168, 198, 203, 204, 216, 219–221, 223
Neuseeland 47, 48, 50, 51, 60, 61, 62, 72, 73, 75, 76, 77, 103, 132, 139, 153, 159, 162
neutralization 42, 47, 54, 55, 56, 59, 63, 64, 72, 75, 79, 81, 120, 181, 182, 183, 184
neutralization test (s. a. micro neutralization test) 42, 47, 60, 61, 62, **65**, 68, 80, 89, 111, 120, 179, 181, 182, 185, **186**, 187, 193, 194, 213, 215, 216, 217, 218, 222, 223
newborn infants (s. a. neonatal immunity and immunization) **138**, 139, 153, 161, 164, 167, 177, 181
Newcastle virus 68, 91, 142, 203, 219
Newfoundland 52, 63, 77
New Guinea 48, 52, 63, 76
New Haven 52, 57, 63, 76, 81, 105, 139, 140
New Jersey 84, 86, 105, 106, 139, 151, 152, 154, 160, 161, 162
New Orleans 47, 51, 61, 75
New South Wales 72
New York 75, 77, 83, 85, 86, 99, 102, 105, 125, 150, 152, 155, 158, 161, 162, 166, 171
New Zealand 47, 48, 50, 51, 60, 61, 62, 72, 73, 75, 76, 77, 103, 132, 139, 153, 159, 162
Nicaragua 48, 52, 56, 58, 63, 76, 82, 84, 85, 87, 97, 98, 117, 150, 151, 164, 165, 166

Niedersachsen 47, 48, 51, 52, 61, 62, 75, 76, 84, 93, 103, 153, 159
nonspecific provocation 126
nonspecifity 65, 69, 73, 88, **90**, 148, 183, 185, 195, 197, 207, 216, 219, 222
normal antibodies 194, 216, 219
normal serum 186
North Carolina 50, 60, 74, 78, 83, 85, 86, 91, 103, 106, 150, 152, 155, 158, 162, 171
Northern Ireland 47, 48, 50, 51, 58, 61, 62, 75, 76, 82, 86, 105, 140, 152, 162
Norway 51, 56, 62, 76, 80, 84, 85, 86, 87, 93, 104, 105, 116, 151, 154, 160, 161, 162
nuclein acid metabolism (s. a. RNA) 123, 204
nutrition (s. a. inanition, pantothenic acid deficiency) **132**, 141, 206, 223
NUZUM-serum 65, 175

O

obsistin 69
ocular injection s. intraocular injection
Österreich 48, 52, 63, 76, 84, 97, 99, 104, 151, 154, 161, 165
Östrogene 137, 141, 169, 201, 202, 205, 217, 218, 223
Ohio 102, 152, 158
olfactory nerve 201, 217
Ontario 84, 86, 104, 151, 153, 159
operations 127, 128
opsonines 59, 63, 67, 73, 172, 178, 182, 184, 194, 215
oral vaccination (s. a. Cox-, KOPROWSKI-, SABIN-vaccine) 49, 78, 80, **93**, 154, 159, 169, 179, 196, 219
oral infection 59, 68, 89, 103, 200, 202, 203, 205, 215, 216, 218, 219, **220**
organization 192
origin of antibodies **50**
oxythiamine 206, 223

P

Padua 76
Palermo 47, 61, 75
Panamanian monkey 142, 203
pantothenic acid deficiency 141, 144, 202, 223
paper disc method 66, 187
Papio leucophaeus 203, 206, 219
Papio papio 202, 218
Papuans 48, 52, 63, 76
paraffin oil 100
paralysis rate after vaccination **86**
parapoliomyelitis 60, 64, 65, 184, 186
paratyphoid-coli-filtrate 124, 125, 140, 200, 216, 217
Paris 47, 51, 52, 61, 62, 63, 75, 76, 140
PARKER-strain 111
Partikelgröße 108, 119
participation in vaccination 154, 160
Passage von Lebendimpfstoff durch den Menschen 98, 99, 100, 110, 113, 164, 167
passive transfer of antibody 54, 171, 223
passive vaccination 36, 46, 54, 67, 68, **170**, 194, 195, 196, 197, 203, 208, 209, 214, 215, 216, 217, 218, 220, 221, 223, 224
pathogenesis 55, 72, 157, 176, 193, 199, 200, 201, 203, 204, 206, 207, 208, 213, 214–225
pathogenicity 42, 99, 114, 119, 179, 203, 204, 219
pathogenicity test s. neurovirulence test
Paviane s. *Papio*
penicillin 104, 107–110, 112, 113, 137, 149, 155, 156, 159
penicillin injections 127, 128, 134, 135, 136

percutaneous infection 199, 214
peritoneale infection s. intraperitoneale infection
perivenöse Encephalomyelitis 55, 90, 155, 169, 197, 220
persistence of antibodies 49, 54, 56, 57, 58, 76, 79, 81, 82, 96, 104, 105, 114, 116, 117, 140, 161, 162, 163, 164, 166, 196, 219
personality factors 128, 136
pertussis s. whooping cough
Pertussis-Polio-vaccine 57, 81, 135, 161
Peru 47, 51, 61, 75, 140
PETTIT-Serum 42, 65, 67, 172, 175, 176, 179, 189, 190, 191, 208, 216
Pferde 48, 50, 52, 53, 67, 68, 79, 88, 89, 100, 168, 169, 194, 195, 196
Pferdeserum (s. a. ROSENOW-serum) 65, 66, 67, 69, 88, 119, 120, 173–176, 181, 186–189, 190, 191, 193, 200, 213, 215, 216
phenol inactivation 118, 120, 156
phenol red-color test 42, 43, 66
phenol-vaccine 88, 101, 111, 168, 195, 215, 216
Philadelphia 48, 52, 57, 58, 77, 82, 85, 87, 97, 98, 99, 117, 151, 165, 166
Philippines 50, 59, 74
Phoenix 75, 140
phosphatase 179, 202, 219
photoperiodicity 144
pH-Wert 119
physical activity 127, 128, 133–136
Pinseläffchen s. marmoset monkey
pituitrin S 201
Planung von Impfungen s. Impfplanung
plaque test 66, 96, 109, 182, 187
plasma infusion (s. a. blood plasma, Blutplasma) 174, 177, 196, 219
plastic panels 66, 182
pleomorphic streptococcus 53, 63, 193, 194, 199, 215
Pocken 123, 125
Pockenschutzimpfung 78, 91, 123, 124, 125, **132**, 133, 134, 135, 136, 137, 140, 199, 214
Poland 44, 47, 48, 50, 52, 56, 57, 58, 59, 60, 63, 74, 76, 77, 81, 82, 83, 85, 86, 87, 88, 97, 98, 100, 105, 113, 114, 117, 151, 152, 154, 161, 162, 164, 165, 166, 167, 180
polar infall 127, 144
Polarluft-Einbruch 127, 144
Polen 44, 47, 48, 50, 52, 56, 57, 58, 59, 60, 63, 74, 76, 77, 81, 82, 83, 85, 86, 87, 88, 97, 98, 100, 105, 113, 114, 117, 151, 152, 154, 161, 162, 164, 165, 166, 167, 180
poliomyelitis suum 60, 90, 91, 97, 104, 170, 197
pollen extract 128, 135, 144
polyradiculoneuritis 62, 76, 91, 113, 149, 156
Port Gentil/Gabon 48, 51, 62, 76
Porto Rico 50, 59, 73, 83, 87, 102, 150, 158
Portugal 154, 162
postvaccinal encephalitis 124, 133, 162
potency of vaccines 55, 80, 90, 99, 100, 102, 104–106, 110, 111, **114**, 115, 159, 169, 180, 185, 186, 189, 190, 198, 214, 225
pox virus 199
precipitation (s. a. micro precipitin test) 42, 43, 54, 59, 61, 64, **66**, 67, 179, 180, 182, 183, 185, **187**
precipitin 90, 105, 179, 197, 222
pregnancy 49, 55–59, 62, 65, 73–75, 79–82, 93, 97, 98, 103, 104, 112, 113, 117, 131, 134, 136, 137, **139**, 153, 154, 158–160, 162, 163, 167, 173, 189, 191
premature neonatals infants 57, 82, 166
preparalytic stadium 215
preparation s. production
pre-school age 98, 157, 165
preservation of vaccines **107**
production of convalescent serum 172, 173, 189
production of immune sera 67, 88, 90, 189, 194, 195, 196, 197, 213, 215, 219, 222
production of vaccines **108**, 155, 220
program of vaccination 82, 98, 99, 101, 104, 105, 107, 116, 124, 148, 150, **152**, 158–161, 163, 165, 166, 171, 209, 210, 221

propagandation 153
prophylaxis 123, 124, 125, 126, 127, 128, 134, 135, 136, 163, 170, 171, 172, 175, 200, 207, 217, 219
protein metabolism 123
protein therapy 170, 189, 190
provocation **121**, 126, 142, 153, 156, 161, 170, 197, 203, 204, 206, 207, 216, 219, 220, 221, 222, 223, 224
Prüfung von Impfstoffen (s. a. Impfstoffprüfung, Unschädlichkeit, Wirksamkeit) **108**
psyche 138
public acceptance 148, 153, 159
Puerto Rico s. Porto Rico
punched cards 31
purification of antibody 46, 59, 179, 184
purification of antigen (s. a. concentration of antigen) 42, 43, 65, 95, 100, 103, 104, 105, 179, 180, 185
purified SALK-vaccine (s. a. concentrated SALK-vaccine) 58, 82, 106, 108, 110, 114, 115, 117, 119, 120, 162
pyridoxine 141, 205, 223
pyrifer (s. a. artificial fever, hyperpyrexia, hyperthermy) 212
pyrotherapy s. pyrifer

Q

quadruple antigen 49, 56, 78, 80, 81, 104, 107, 108, 116, 154, 159, 160, 161, 162
Quatro-virelon 58, 69, 107, 110, 162, 170, 197

R

rabbits 53, 55, 67, 68, 69, 81, 88, 89, 90, 93, 96, 105, 108, 140, 141, 163, 168, 169, 176, 177, 178, 180, 181, 182, 184, 185, 187, 194, 196, 197, 199, 200, 202–205, **222**
rabies 89, 169, 196, 204, 223, 224
rabies vaccination 54, 68, 74, 91, 95, 123, 124, 133, 134, 142, 167, 194, 212
race **138**
rachitogenic diet 134, 141, 144, 205
radium-irradiation 118
Randlochkarten 11
rapid immunization 56, 80, 92, 93, 104, 150, 160
Rasse **138**
rats (s. a. Baumwollratte, cotton rat) 90, 116, 134, 141, 143, 144, 170, 205, **225**
rat test 43, 109, 115, 198
reactivation 109, 118, 119, 120, 179
recessive inheritance 132, 138
recombination 44
reduction of resistance **133**
Referaten-Zeitschriften 9
refractory animals 67
Reifung von Antikörpern 50
Reifung der Immunität 72
reinfection 48, 49, 53, 59, 60, 67, 74, 75, **77**, 84, 85, 88, 125, **128**, 129, 133, 140, 141, 181, 199–202, 205, 214–218
Reinigung von Antigen (s. a. Konzentrierung von Antigen) 42, 43, 65, 95, 100, 103, 104, 105, 179, 180, 185
Reinigung von Antikörpern 46, 59, 179, 184
reinoculation s. revaccination
Reise 128, 134
Rekonvaleszentenserum (s. a. Sammlung von R., Herstellung von R.) 59, 60, 65, 67, 74, 119, 168, **172**, 176, 177, 179, 181, 186, 188–191, 195, 215, 216, 222
requirements 101, 102, 105, 108, 109, 110, 112, 113, 114, 115, 117
resistance 20, 36, 56, 67, 81, 120, **130**, 181, 200, 202, **205**, 206, 207, 208, 213–219, 222–225
respiratory infection 135
revaccination 59, 60, 68, 78, 80, 83, 86, 89, 93, 98, 100, 102, 115, 116, 149, 158, 162, 167, 169, **170**, 195, 215

reversibility s. reactivation
reviews **207**
rezessive Vererbung 132, 138
Rh-Antigen 42, 111, 181
Rhesus monkey 67, 77, 97, 129, 141, 142, 168, 171, 194, 195, 201, 202, 204, 205, 217, 218
Rhode Island 86, 106, 152, 162
Rhodesia 48, 52, 63, 76, 84, 87, 104, 139, 151, 159, 161
Rh-sensitivity 54, 155, 220
riboflavin 141, 144, 205, 223
ricinoleated vaccine 67, 88, 89, 92, 93, 96, 101, 114, 118, 157, 168, 194, 195, 215, 216, 217
Riga 57, 81, 98, 165
Rind 69, 76, 90, 169, 201, 213
Rinder-Serum 66, 69, 194
Rio de Janeiro 51
RNA 44, 97, 105, 108, 118, 119, 120, 181, 224
rodent 128, 141
Röntgen-Bestrahlung 109, 126, 128, 133, 134, 136, 137, 140–142, 197, 204, 205, 213, 215, 216, 220, 222
Rom 58, 83, 84, 85, 99, 105, 106, 125, 151, 161, 162, 167
rooster 69, 81, 90, 110, 170, 197, 198, 214
ROSENOW-Serum (s. a. Pferdeserum, horse serum) 46, 64, 65, 67, 172, 174, 175, 176, 188, 189, 191, 194, 213, 215
Roumania 48, 52, 57, 62, 63, 72, 73, 76, 81, 84, 102, 103, 105, 108, 111, 116, 140, 151, 153, 159, 161, 163, 180, 181
rural areas 72, 73, 131, 132, 137, 139, 140, 143

S

SABIN-strains 52, 198, 206, 221
SABIN-vaccine 49, 53, 55–59, 78, 80–83, 85–88, 96–100, 108–110, 114–117, 125, 138, 150–152, 154, 156, 162, 164–167, 170, 177, 198, 206, 209, 211, 221
safety of vaccines 99, 101, 102–104, 106, 109, 110, **111**, 112–114, 119, 120, 126, 137, 142, 152, 158, 164, 198, 220, 221
sagoo s. *Cebus*
saliva 59, 74
SALK-vaccine 49, 52–58, 62, 64–66, 68, 69, 73, 75, 78–88, 90, 92, 93, 96, 99, 103, 107–116, 119, 123, 137, 148–157, 160, 161, 163, 164, 170, 177, 179, 181, 182, 185, 197, 198, 209–211, 214, 219, 220, 221, 225
Salt Lake City 153, 159
salt metabolism 132, 134
Sammlung von Rekonvaleszentenserum 172, 173, 174, 189
San Diego 154, 161
San Francisco 47, 50, 60, 74
Sardinia 47, 51, 61, 75
Saudi Arabia 47, 51, 61, 75
Saukett strain 203, 221
Schafe 53, 54, 64, 67, 88, 100, 168, 184, 194, 195, 201
Schafserum 65, 67, 174, 175, 176, 186, 189, 190, 191, 213, 216
schedule of vaccination s. program of vaccination
SCHEELE-report 102, 155, 157
SCHICK-test 73, 91, 159, 178, 179, 180, 184
Schilddrüse 133, 140–142, 200, 205, 206, 222–224
Schimpansen 49, 52–55, 59, 60, 61, 68, 69, 74, 77, 87, 89, 90, 92, 96, 101, 107, 129, 140, 141, 164, 169, 172, 175–177, 195–205, 214, 216–221
Schnell-Immunisierung 56, 80, 92, 93, 104, 150, 160
Schock 195, 215
Schottland 47, 48, 51, 61, 62, 72, 75, 132, 133, 140
Schutzimpfung **78**, 135, **144**, 168, 182, 185, **208**, 219, 220, 221, 223, 225
Schutzimpfung der Mutter 89, 96, 169, 223
Schwangerschaft 49, 55–59, 62, 65, 73–75, 79–82, 93, 97, 98, 103, 104,

112, 113, 117, 131, 134, 136, 137, **139**, 153, 154, 158–160, 162, 163, 167, 173, 189, 191
Schweden 47, 50, 51, 55, 61, 72, 74, 75, 77, 79, 84, 97, 100, 101, 103, 106, 132, 139, 151, 153, 157, 158, 161, 164, 166, 172, 191, 192, 208, 211
Schweiz 47, 50, 51, 55, 58, 61, 62, 72, 75, 76, 79, 80–88, 97–100, 102–106, 112–114, 116, 117, 133, 138, 140, 148, 150–155, 158, 159, 161, 165–167, 171, 210, 211
Scotland 47, 48, 51, 61, 62, 72, 75, 132, 133, 140
season 72, 76, 77, 132, 140, 142, 144, 153, 163, 200, 205, 206, 216, 217, 222, 223
seasonal distribution of antobidies 46, 60, 62
Seattle King County 85, 152, 162
second attacks 48, 49, 53, 59, 60, 67, 74, 75, **77**, 84, 85, 88, 125, **128**, 129, 133, 140, 141, 181, 199–202, 205, 214–218
second injection 79, 103, 165
sedimentation 119, 180
Seelische Belastung 127, 134
SEITZ-filtration 102, 108, 115
selection of strains for vaccines **111**
sensibilization 93, 184, 224, 225
sensitivity s. susceptibility
Serbia 48, 52, 63, 77
serodifferentiation 43, 64, 66, 97, 168, 180, 184, 187
serological methods **183**
serology **177**
serotherapy s. serumtreatment
serovaccine 119, 168, 194
serum disease 173
serum inactivation 43, 156
serum production s. production of immune sera
serum prophylaxis 19, 36, 46, **187**, 213, 216
serum treatment 36, 46, 59, 121, 170, 174, 175, 176, **187**, 194, 195, 207, 208, 213, 215, 216, 221
sewage 100, 167
sex distribution **132**, 141, 205, 225
sheep 53, 54, 64, 67, 88, 100, 168, 184, 194, 195, 201
sheep serum 65, 67, 174, 175, 176, 186, 189, 190, 191, 213, 216
shock 195, 215
siblings s. twins
Siedlungsklassen 62, 140
Sigmodon hispidus hispidus 201, 225
Sigmodon hispidus littoralis 201, 225
simian foamy virus 108, 110, 114, 198, 221
simultaneous vaccination 54, 79, 115, 168, 172, 177, 194
Singapore 84, 85, 96, 99, 117, 150, 151, 152, 164, 166
size of particles 108, 119
skin reaction 56, 57, 58, 62, 63, 64, 66, 68, 73, 83, 90, 110, 159, 161, 170, 179, 182, 183, 187, 194, 213, 221
skin test 43, 54, 56, 62, 63, 64, 66, 68, 69, 71, 73, 74, 79, 80, 90, 120, 138, 149, 170, 182, 184, 197
SK-virus s. Columbia SK-virus
Slowenia 48, 51, 62, 153, 163
smallpox 123, 125
smallpox vaccination 78, 91, 123, 124, 125, 132, 133, 134, 135, 136, 137, 140, 199, 214
SM type I-strain 55, 79, 96, 112, 164, 206
sociology 48, 60, 62, 75, 76, **139**, 161
soluble antigen 63, 180, 185
sonic vaccine 89, 101, 118, 169, 195, 196, 217
sources of error, inactivation of virus **119**
sources of literature **30**
South Africa 47, 48, 50, 51, 52, 59, 60, 61, 63, 73, 74, 75, 77, 83, 98, 99, 100, 102, 103, 110, 114, 139, 150, 152, 153, 154, 156, 158, 159, 166, 167
South Africa vaccine 54, 79, 102, 108, 109, 111, 112, 114, 119, 157
Southampton 85, 104, 105, 150, 160, 161
Southern Alamada County 83, 86, 102, 157
Soziologie 48, 60, 62, 74, 75, 76, **139**, 161
Spain 48, 52, 63, 72, 77, 103, 104, 148, 152, 153, 156, 159, 160, 162, 163

sparing effect 91, 141, 142, 195, 201, 205, 217
specific immune sera (s. a. immune serum, NETTER-, NUZUM-, PETTIT-, ROSENOW-serum) **174**
specifity 43, 44, 46, 53, 59, 64, 65, 67, 69, 75, 106, 118, 129, 180, 185, 187
specifity of types **77**, 119, **217**
Speichel 59, 74
spleen 55, 67, 69, 92, 140, 168, 194, 197, 200, 205, 215, 222
spleenectomy 133, 140, 224
spontaneous infection 141, 199, 200, 204, 214, 215, 218, 220, 224
spread of virus after live vaccination 58, 82, 85, 97, 98, 99, 100, 105, 106, 114, 156, 162, 164, **165**, 166, 167, 217
stability of antigen 43, 97, 98
stability of antigen-antibody complexes 179
stability of live vaccines 100, 113, 114, 165, 166, 167, 198
stable cell lines 97
Stadtgebiet 72, 73, 131, 132, 139, 140
Stammauswahl für Impfstoffe **111**
standard antisera 46, 54, 66, 67, 68, 69, 81, 90, 171, 174, 179, 181, 182, 187, 196, 197, 220, 222, 225
standardization 186, 187
standards of vaccines 57, 65, 66, 82, 103, 104, 105, 109, 110, **111**, 116, 198, 221
statistical evaluation of effectiveness, active vaccination **150**
Staub (s. a. spontaneous infection) 199, 214
Staupe 89, 91, 195, 201, 205, 217
Steiermark 86
steppe lemming 204, 206, 214
sterile inflammation 125, 127, 134, 141, 217
St. Lucia 51, 62, 76, 163
Stockholm 48, 61, 72, 75, 132, 133, 140
Stomoxys calcitrans 199, 214
storage 98, 105, 116, 171, 173, 176, 191
streptococci (s. a. pleomorphic streptococci) 42, 59, 60, 63, 64, 66, 67, 73, 90, 91, 173, 174, 175, 179, 182, 184, 185, 186, 187, 193, 194, 199, 200, 213, 218
stress situation 126, **127**, 137, 142, 204, 206, 222
Streuung von Virus nach Lebendimpfung 58, 82, 85, 97, 98, 99, 100, 105, 106, 114, 156, 162, 164, 165, 166, 167
Stuhl 46, 50, 54, 62, 63, 68, 76, 89, 157, 169, 184, 196, 218
S. typhi antigen 107
subclinical infection 60, 67, 68, 73
subcutaneous injection 55, 69, 80, 90, **92**, **93**, 100, 110, 111, 160, 170, 221
subtropical areas 59
subtypes 180, 181, 184, 185, 187
suckling mice 202, 203, 204, 206, 223, 224
Sudan 51, 62
Süd Afrika 47, 48, 50, 51, 52, 59, 60, 61, 63, 73, 74, 75, 77, 83, 98, 99, 100, 102, 103, 110, 114, 139, 150, 152, 153, 154, 156, 158, 159, 166, 167
Süd Afrika Vakzine 54, 79, 102, 108, 109, 111, 112, 114, 119, 157
susceptibility 100, 149, 166, 167, 181, 195, 202, 203, 204, 213–221, 223–225
SV_{40} 98, 106, 108, 110, 113, 119, 198, 221
Sweden 47, 50, 51, 55, 61, 72, 74, 75, 77, 79, 84, 97, 100, 101, 103, 106, 132, 139, 151, 153, 157, 158, 161, 164, 166, 172, 191, 192, 208, 211
Swedish vaccine 54, 68, 79, 92, 101, 103, 108, 111, 114, 157
Swiss mice 68, 89, 101, 114, 169, 196
Switzerland 47, 50, 51, 55, 58, 61, 62, 72, 75, 76, 79, 80–88, 97–100, 102–106, 112–114, 116, 117, 133, 138, 140, 148, 150–155, 158, 159, 161, 165–167, 171, 210, 211
Symposium München 1959 164, 210, 211

syphilis reaction 63
Syrian hamster (s. a. hamster) 67, 68, 69, 77, 78, 89, 90, 91, 110, 114, 125, 126, 128, 132, 135–138, 141, 142, 169, 196, 202, 203, 204, 206, **221**

T

TAB-vaccine 90, 91, 107, 124, 133, 141, 205, 218
Tahiti 47, 50, 60, 72, 74
Taipei area 48, 52, 63, 76
Taiwan 58, 83, 106, 117
Taiwan monkey 69, 90, 126, 170, 197, 204, 221
tears fluid 59, 74
temperature inactivation 119, 120
Tennessee 47, 59, 85, 86, 105, 151, 161
teratogenic effects 113, 156
Teschen disease 60, 90, 91, 93, 97, 104, 170, 197
testicular infection s. intratypic differentiation
testicular tissue 65, 89, 142, 186, 206, 219
testing of vaccines (s. a. potency of vaccines, safety of vaccines) 43, 68, 69, 99, 101, 103, **197**, 214, 220, 221, 224, 225
tetanus antitoxin 170, 188, 212
tetravaccine 43, 113, 156, 160
THEILER-Virus 42, 67, 89, 91, 124, 135, 169, 179, 196, 201, 222, 223
thermostability 42, 180
thiamine 132, 141, 143, 144, 201, 205, 218, 222, 223
thiouracil 141, 205, 223
thyroidectomy 133, 140, 200, 222
thyroidism 142, 206, 224
thyroxin 141, 205, 223
Tierversuche 49, 55, 56, 64, 65, **67**, 76, 80, **88**, 93, 100, 101, 103, 104, 106, 107, 115, 124, **125**, 128, 134, 137, **140**, 156, 157, **167**, 175, **176**, 179, 182, 186, 188, 189, 190, **192**
tissue culture 42, 44, 46, 63–66, 73, 80, 95, 99, 102, 104, 108, 109, 111–114, 116, 119, 120, 128, 132, 137, 179–182, 185–187, 204, 224
tissue immunity s. local immunity
t-marker 96, 97, 98, 99, 100, 109, 110, 111, 166, 204, 206, 221
TN-strain 54, 55, 79, 93, 96, 163, 164, 206
Tokyo 47, 61, 75
Tollwut 89, 169, 196, 204, 223, 224
Tollwut-Impfung 54, 68, 74, 91, 95, 123, 124, 133, 134, 142, 167, 194, 212
tonsillectomy 50, 125, **126**, 133, 134, 135, 136, 137, 141, 142, 143, 153, 154, 163, 171, 172, 177, 202, 205, 206, 207, 218, 219
tonsils 46, 50, 118, 125, 137, 141, **143**, 199, 214, 217
tooth pulp cavity 202, 218
toxines 133, 140, 200, 205
Tränenflüssigkeit 59, 74
transmission of immunity (s. a. diaplacental transmission of antibodies, maternal antibodies, passive transfer of antibodies) 78, 138, 169, 177, 196, 223
transmission of virus s. spontaneous infection
transport 135
trauma 121, 125, 127, 128, 133, 134, 135, 136, 141, 142, 205, 218
traumatized tissue 137, 142, 204, 220, 221
travel 128, 134
Trinkwasser 73
triple antigen 58, 82
trivalent live vaccine 56, 57, 58, 80, 81, 82, 83, 96, 98, 99, 100, 116, 117, 164, 165, 166, 167
Trivirelon 58, 82, 83, 105, 110, 117, 161, 162
Trockenblut 189
Trockenserum 189
tropical areas 50, 59, 72, 74, 139, 150, 154, 163, 182
tropical warm air masses 128, 136, 144
Tropische Warmluft 128, 136, 144
trypsinization 108
tryptophan 142, 203, 219, 224
tuberculine 161

tuberculosis 57, 62, 76, 81, 113, 123, 155, 159, 162, 163
Türkei 47, 48, 51, 52, 61, 63, 75, 76, 99, 167
tumor virus 110, 114
Tunis 51, 61, 72, 163
Turin 51, 62, 76
Turkey 47, 48, 51, 52, 61, 63, 75, 76, 99, 167
twins 49, 50, 72, 77, 132, 138, 181
type dependence of immunity **90**
type specifity 54, 60, 61, 63, 64, 74, 75, 77, 89, 91, 180, 181, 184, 185, 186, 187, 196
typhoid vaccination (s. a. TAB-vaccine) 123, 124, 125, 133, 134, 218
typing of virus strains (s. a. classification of virus strains, differentiation of types) 42, **44**, 65, 77, 79, 89–91, 99, 100, 129, 179, 183, 185, 186, 196, 216, 217, 219

U

Überanstrengung 127, 128, 133–136
Überempfindlichkeit 49, 73, 129, 132, 203, 220
Übersichtsarbeiten **207**
Übertragung der Immunität (s. a. diaplacental transmission of antibodies, mütterliche Antikörper) 78, 138, 169, 177, 196, 223
ultracentrifugation 109
ultrasound vaccine s. sonic vaccine
umbilical cord 76
under-developed areas 47, 50, 60, 73, 77, 139
Ungarische Vakzine 104, 105
Ungarn 47, 48, 50, 51, 52, 58, 61, 62, 63, 72, 74–77, 81, 83–87, 93, 96–100, 103, 105, 106, 107, 116, 117, 125, 132, 150–153, 155, 159–162, 164, 165, 166, 211
unidimensional classification 26
uninterrupted antigen stimulus 43, 100
United Kingdom (s. a. England, Great Britain) 84, 86, 106, 150, 152, 153, 158, 162, 211
Unschädlichkeit von Impfstoffen 99, 101, 102–104, 106, 109, 110, **111**, 112–114, 119, 120, 126, 137, 142, 152, 158, 164, 198, 220, 221
Unspezifität 65, 69, 73, 88, **90**, 148, 183, 185, 195, 197, 207, 216, 219, 222
untoward reactions to vaccination (s. a. Cutter disaster, neurological complication, provocation) 105, **155**, 172, 189
urban areas 72, 73, 131, 132, 139, 140
urine 63, 77
urticaria 113
Uruguay 47, 48, 50, 51, 58, 60, 62, 74, 76, 82, 84, 85, 88, 97, 98, 99, 113, 139, 150, 152, 164, 165, 167
USA 50, 51, 52, 59, 60, 61, 72, 74, 75, 77, 78, 83, 84, 86, 87, 98, 99, 101, 102, 103, 104, 105, 106, 107, 109, 110, 111, 112, 114, 115, 117, 125, 132, 133, 138, 139, 140, 148, 150, 151, 152, 153, 154, 155, 157, 158, 161, 162, 166, 171, 172, 177, 209, 210
USSR 48, 52, 56, 57, 58, 63, 76, 77, 78, 81, 82, 84, 85, 86, 87, 88, 96, 97, 98, 99, 100, 103, 104, 108, 110, 111, 113, 116, 117, 125, 150, 151, 152, 155, 156, 159, 160, 161, 163, 164, 165, 166, 167, 172, 206, 210, 211
uterine infection 139
UV radiation, inactivation 43, 55, 106, 107, 119, **120**, 157, 180, 195
UV-vaccine 49, 52, 54, 56, 68, 79, 80, 89, 90, 101, 102, **106**, 108, 111, 112, 114, 115, 119, 157, 158, 160, 163, 169, 170, 195–198, 220, 223

V

vaccination **78**, 135, **144**, 168, 182, 185, **208**, 219, 220, 221, 223, 225
vaccination of mother 89, 96, 169, 223
vaccination programme s. program of vaccination
vaccines (s. a. BRODIE-, COX-, KOLMER-, KOPROWSKI-, LEPINE-,

SABIN-, SALK-, sero-, sonic-, UV-vaccine) **93**
vaccine therapy **211**
vaccineurin 212
vaccinia virus 123, 125, 133, 140, 199, 200, 214, 222
Vakzinetherapie **211**
Valencia 48, 52, 63, 76, 77
variability of antigen 44, 180, 181
vegetative irritation center 136
Vererbung 131, **138**
Verletztes Gewebe s. Wundgewebe
Versuchstiere (s. a. Tierversuche) 132, **212**
vervet monkey s. *Cercopithecus pygerythrus*
Vierfach-Impfstoff 49, 56, 78, 80, 81, 104, 107, 108, 116, 154, 159, 160, 161, 162
Vietnam 48, 51, 62, 76, 139
viremia 60, 68, 69, 74, 90, 97, 99, 110, 112, 126, 138, 139, 165, 166, 167, 198, 199, 201, 202, 203, 204, 214, 217, 218, 219, 220, 221
Virginia 150
virulence 43, 44, 73, 96, 97, 99, 109, 115, 118, 140, 144, 164, 199, 200, 202, 204, 206, 214, 215, 224
virulence test of strains excreted after live vaccination **206**
Virus-Ausscheidung 56, 57, 61, 69, 75, 77, 78, 81, 82, 87, 90, 99, 113, 151, 158, 159, 160, 161, 164, 165, 167, 169, 172, 177, 182, 197, 199, 221
virus B-infection 110, 114, 198, 221
virus aggregation 66, 120, 187
virus excretion 56, 57, 61, 69, 75, 77, 78, 81, 82, 87, 90, 99, 113, 151, 158, 159, 160, 161, 164, 165, 167, 169, 172, 177, 182, 197, 199, 221
vitamin A 144, 205, 225
vitamin B 126, 132, 134, 140, 141, 142, 143, 144, 200, 202, 203, 205, 219, 223, 225
vitamin C 140, 141, 143, 200, 201, 205, 217
vitamin D 141, 143, 144, 201, 205, 206, 217
vitamine, resistance **143**, 200, 205, 217, 222, 225
vomiting 143
Vorschulalter 98, 157, 165

W

Wärme-Inaktivierung 43, 44, 46, 64, 67, 88, 90, 93, **106**, 107, 118, **120**, 156, 163, 180, 185, 194, 215, 224
Wallingford strain 202, 213
Washington 48, 62, 84, 86, 139, 151
WATERHOUSE-FRIDERICHSEN-syndrome 113, 156
Wayne County 105, 161
weather (s. a. polarinfall, tropical warm air masses) 134, **144**
Wertigkeit von Impfstoffen s. Wirksamkeit von Impfstoffen
Westafrica 47, 59, 74
Westfalen 48, 55, 62, 80, 84, 103, 155, 159
West Indies 48, 52, 63, 77
Wetter (s. a. Polarluft-Einbruch, tropische Warmluft) 134, **144**
WHO assembly (12.) Geneva 148, 210
whooping-cough 113, 123, 124
Wiederholungsimpfung 59, 60, 68, 78, 80, 83, 86, 89, 93, 98, 100, 102, 115, 116, 149, 158, 162, 167, 169, **170**, 195, 215
Wien 48, 51, 52, 62, 63, 76, 140
Winnipeg 72, 77, 84, 86, 104, 151, 160
Wirksamkeit von Impfstoffen 55, 80, 90, 99, 100, 102, 104–106, **110**, 111, **114**, 115, 159, 169, 180, 185, 186, 189, 190, 198, 214, 225
WM III-strain 110, 111, 167, 206
wound tissue s. traumatized tissue
Wundgewebe 137, 142, 204, 220, 221

X

X-irradiation 109, 126, 128, 133, 134, 136, 137, 140–142, 197, 204, 205, 213, 215, 216, 220, 222

Y

Y-SK-virus 60, 74, 91

Z

Zahnoperation 127, 128, 134, 135
Zellkulturen s. Gewebekultur
Zentral Afrika 51, 54, 61, 68, 75, 90, 139, 142, 169, 204, 220
Zentral Amerika 57, 61, 74, 79, 97, 102, 140, 154, 158, 165
Ziegen 53, 67, 195
Ziegenserum 65, 175, 176, 189, 190, 213, 216
Zitratblut 173, 189
ZNS (s. a. Blutliquorschranke) 59, 74, 89, 104, 118, 141, 156, 162, 194, 200, 202, 204, 216, 218, 221
zone phenomenon 66, 187
Zweiterkrankung 48, 49, 53, 59, 60, 67, 74, 75, **77**, 84, 85, 88, 125, **128**, 129, 133, 140, 141, 181, 199–202, 205, 214–218
Zweite Injektion 79, 103, 165
Zweiwertige Kationen 43, 97
Zwillinge 49, 50, 72, 77, 132, 138, 181